Use these links to rapidly review the document
TABLE OF CONTENTS
TABLE OF CONTENTS

Table of Contents

As filed with the Securities and Exchange Commission on September 12, 2014.

Registration No. 333-            


SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM F-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933



ISRAEL CHEMICALS LTD.
(Exact Name of Registrant as Specified in Its Charter)

Israel
(State or Other Jurisdiction of
Incorporation or Organization)
  2870
(Primary Standard Industrial
Classification Code Number)
  Not Applicable
(I.R.S. Employer
Identification Number)

Israel Chemicals Ltd.
Millennium Tower
23 Aranha Street
P.O. Box 20245
Tel Aviv, 61202 Israel
(972-3) 684-4400

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)



Avi Doitchman and Lisa Haimovitz
Israel Chemicals Ltd.
Millennium Tower
23 Aranha Street
P.O. Box 20245
Tel Aviv, 61202 Israel
(972-3) 684-4400
  ICL North America Inc.
Attention: General Counsel
622 Emerson Road, Suite 500
St. Louis, Missouri 63141
(314) 983-7500

(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)



Copies to:

Michael P. Kaplan
Davis Polk & Wardwell LLP
450 Lexington Avenue
New York, New York 10017
(212) 450-4000

 

Adam M. Klein
Goldfarb Seligman & Co.
98 Yigal Alon Street
Tel Aviv, 6789141 Israel
(972-3) 608-9999

 

Leslie N. Silverman
Cleary Gottlieb Steen &
Hamilton LLP
One Liberty Plaza
New York, New York 10006
(212) 225-2000

 

Adva Bitan
Gross, Kleinhendler, Hodak,
Halevy, Greenberg and Co.
One Azrieli Center
Round Building
Tel Aviv, 6701101 Israel
(972-3) 607-9999

Approximate date of commencement of proposed sale to the public:
As soon as practicable after the effective date of this Registration Statement.

          If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.     o

          If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.     o

          If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.     o

          If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.     o



CALCULATION OF REGISTRATION FEE

               
 
Title Of Each Class Of Securities
To Be Registered

  Amount To
Be Registered (1)

  Proposed
Maximum
Offering
Price Per
Share (2) (3)

  Proposed Maximum
Aggregate Offering
Price (1) (2)

  Amount Of
Registration Fee

 

Ordinary Shares, par value NIS 1.00 per share

  68,200,000   $7.66   $522,412,000   $67,286.67

 

(1)
Includes 6,200,000 shares that the underwriters have the option to purchase from the selling shareholder.

(2)
Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(c) under the Securities Act of 1933, as amended, based upon the average of the high and low price of the ordinary shares as provided by the Tel Aviv Stock Exchange on September 8, 2014 and converted into U.S. dollars based on the exchange rate reported by the Bank of Israel on such date, which was NIS 3.6000 = $1.00.

(3)
Rounded up to the nearest cent.

           The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

   


Table of Contents

PROSPECTUS (Subject to Completion)
Dated September 12, 2014

The information in this prospectus is not complete and may be changed. Neither we nor the forward counterparties or selling shareholder, as applicable, may sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and neither we nor the forward counterparties or selling shareholder, as applicable, is soliciting offers to buy these securities in any state where the offer or sale is not permitted.

ISRAEL CHEMICALS LTD.

62,000,000 Ordinary Shares

$          per share



This is an initial public offering in the United States of ordinary shares of Israel Chemicals Ltd.

Our controlling shareholder, Israel Corporation Ltd. ("Israel Corporation"), is selling 36,207,128 of our ordinary shares. In addition, Israel Corporation expects to enter into forward sale agreements with Morgan Stanley & Co. LLC and Goldman, Sachs & Co., or one of their respective affiliates, which we refer to in such capacities as the forward counterparties, pursuant to which Israel Corporation will sell, and the forward counterparties will purchase, up to 36,207,128 ordinary shares, subject to the terms and conditions of the forward sale agreements. Upon entry into the forward sale agreements, the forward counterparties expect to sell 25,792,872 of our ordinary shares under this prospectus through the underwriters named in this prospectus to hedge their positions under these forward sale agreements, and Israel Corporation will make available to the forward counterparties the ordinary shares to be sold by them under this prospectus. We refer in this prospectus to the combined offering of an aggregate amount of 62,000,000 of our ordinary shares, comprised of the sale by Israel Corporation of 36,207,128 of our ordinary shares and the expected sale by the forward counterparties of 25,792,872 of our ordinary shares, as the offering. See "Underwriting" for more details.

We will not receive any proceeds from the sale of the ordinary shares by the underwriters, whether in connection with the forward sale agreements or the sale of ordinary shares by Israel Corporation directly to the underwriters, including any proceeds from any exercise by the underwriters of their option to purchase additional shares described below. Israel Corporation will receive proceeds from its sale of the ordinary shares directly to the underwriters and will receive proceeds from the forward counterparties if it enters into the forward sale agreements.

Our ordinary shares are listed on the Tel Aviv Stock Exchange (the "TASE") under the symbol "ICL." On September 11, 2014, the last reported sale price of our ordinary shares on the TASE was NIS 26.90, or $7.41, per share (based on the exchange rate reported by the Bank of Israel on such date, which was NIS 3.6280 per $1.00). The price per share in this offering will be determined by reference to the closing price of the ordinary shares on the last TASE trading date prior to the pricing date.



We have been approved to list the ordinary shares on the New York Stock Exchange (the "NYSE") under the symbol "ICL."



Investing in the ordinary shares involves risks. See "Risk Factors" beginning on page 20 of this prospectus.



 
 
Price to
Public
 
Underwriting
Discounts and
Commissions(1)
 
Proceeds to
forward
counterparties
 
Proceeds to
Israel
Corporation

Per Share

  $        $            $            $         

Total

  $                     $                     $                     $                  

(1)
Israel Corporation has agreed to reimburse the underwriters for certain expenses in connection with this offering. See "Underwriting."

Israel Corporation has granted the underwriters the right to purchase an additional 6,200,000 ordinary shares.

Neither the Securities and Exchange Commission ("SEC") nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The underwriters expect to deliver the ordinary shares to purchasers on or about                       , 2014.



Morgan Stanley   Barclays
Deutsche Bank Securities   Goldman, Sachs & Co.
BMO Capital Markets

                           , 2014



TABLE OF CONTENTS

 
 
Page

Presentation of Financial and Other Information

  ii

Glossary of Selected Terms

  iii

Prospectus Summary

  1

Summary Historical Consolidated Financial Data

  17

Risk Factors

  20

Special Note Regarding Forward-Looking Statements

  38

Price Range of Our Ordinary Shares

  39

Use of Proceeds

  40

Dividend Policy

  41

Capitalization

  42

Dilution

  43

Selected Consolidated Financial Data

  44

Management's Discussion and Analysis of Financial Condition and Results of Operations

  46

Business

  94

Management

  181

Certain Relationships and Related Party Transactions

  198

Principal and Selling Shareholders

  201

Description of Share Capital

  204

Shares Eligible for Future Sale

  210

Tax Considerations

  212

Underwriting

  221

Conflicts of Interest

  225

Expenses Related to the Offering

  227

Legal Matters

  228

Experts

  228

Enforcement of Judgments

  229

Where You Can Find More Information

  230

Index to Consolidated Financial Statements

  F-1



        Until                        , 2014 (25 days after commencement of this offering), all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.



        In this prospectus, unless otherwise indicated or the context otherwise requires, all references to "ICL," the "Group," the "Company," "we," "our," "ours," "us" or similar terms refer to Israel Chemicals Ltd., together with its consolidated subsidiaries. When we refer to our "parent company" or to "Israel Corporation," we refer to our controlling shareholder, Israel Corporation. Unless otherwise indicated or the context otherwise requires, references in this prospectus to "NIS" are to the legal currency of Israel, "U.S. dollars," "$" or "dollars" are to United States dollars, "euro" or "€" are to the Euro, the legal currency of certain countries of the European Union, and "British pound" or "£" are to the legal currency of the United Kingdom.

        Neither we nor the underwriters have authorized anyone to provide you with information different from that contained in this prospectus or in any free writing prospectus that we file with the SEC. Neither we nor the underwriters take any responsibility for, or can provide any assurance as to the reliability of, any information other than the information in this prospectus, any amendment or supplement to this prospectus or any free writing prospectus that we file with the SEC. The forward counterparties and Israel Corporation, as applicable, are offering to sell, and seeking offers to buy, ordinary shares only in jurisdictions where such offers and sales are permitted. You should assume that the information appearing in this prospectus is accurate only as of the date of this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date.

        We have not taken any action to permit a public offering of the ordinary shares outside the United States or to permit the possession or distribution of this prospectus outside the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about and observe any restrictions relating to the offering of the ordinary shares and the distribution of this prospectus outside the United States.

i



PRESENTATION OF FINANCIAL AND OTHER INFORMATION

        We maintain our financial books and records in U.S. dollars. Our consolidated income statement data for each of the years ended December 31, 2013, 2012 and 2011 and our consolidated balance sheet data as of December 31, 2013 and 2012, included in this prospectus, have been prepared in accordance with the international financial reporting standards ("IFRS"), as issued by the international accounting standards board ("IASB"). None of the financial information in this prospectus has been prepared in accordance with accounting principles generally accepted in the United States.

        Market data and certain industry data used in this prospectus were obtained from internal reports and studies, where appropriate, as well as estimates, market research, publicly available information and industry publications, including publications, reports or releases of the International Monetary Fund ("IMF"), the U.S. Census Bureau, the Food and Agriculture Organization of the United Nations ("FAO"), the International Fertilizers Association ("IFA"), the United States Department of Agriculture (the "USDA") and the United States Geological Survey. Industry publications generally state that the information they include has been obtained from sources believed to be reliable, but that the accuracy and completeness of such information is not guaranteed. Similarly, internal reports and studies, estimates and market research, which we believe to be reliable and accurately extracted by us for use in this prospectus, have not been independently verified. However, we believe such data is accurate and agree that we are responsible for the accurate extraction of such information from such sources and its correct reproduction in this prospectus. There is only a limited amount of independent data available about certain aspects of our industry, market and competitive position. As a result, certain data and information about our market rankings in certain product areas are based on our good faith estimates, which are derived from our review of internal data and information, information that we obtain from customers, and other third party sources. We believe these internal surveys and management estimates are reliable; however, no independent sources have verified such surveys and estimates.

        This prospectus contains translations of certain NIS amounts into U.S. dollars at specified rates solely for your convenience. These translations should not be construed as representations by us that the NIS amounts actually represent such U.S. dollar amounts or could, at this time, be converted into U.S. dollars at the rate indicated. Unless otherwise indicated, we have translated NIS amounts into U.S. dollars at an exchange rate of NIS 3.471 to $1.00, the daily representative exchange rate reported by the Bank of Israel for December 31, 2013, and euro amounts into U.S. dollars at an exchange rate of €0.7257 to $1.00, the noon buying rate in New York for cable transfers payable in euros as reported by the U.S. Board of Governors of the Federal Reserve System for December 31, 2013.

        We own or have rights to trademarks or trade names that we use in conjunction with the operation of our business. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the ® or ™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent of the law, our rights or the rights of the applicable licensor to these trademarks and trade names. In this prospectus, we also refer to product names, trademarks, trade names and service marks that are the property of other companies. Each of the trademarks, trade names or service marks of other companies appearing in this prospectus belongs to its owners. Our use or display of other companies' product names, trademarks, trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, the product, trademark, trade name or service mark owner, unless we otherwise indicate.

ii


Table of Contents


GLOSSARY OF SELECTED TERMS

        The following is a glossary of selected terms used in this prospectus.

Bromine

  A chemical element used as a basis for a wide variety of uses and compounds, and mainly as a component in flame retardants or fire prevention substances. Unless otherwise stated, the term "bromine" refers to elemental bromine.

CFR

 

Cost and freight. In a CFR transaction, the prices of goods to the customer includes, in addition to FOB expenses, marine shipping costs and all other costs that arise after the goods leave the seller's factory gates and up to the destination port.

Cleveland Potash

 

Cleveland Potash Ltd., a United Kingdom company included in our Fertilizers segment.

CPI

 

The Consumer Price Index, as published by the Israeli Central Bureau of Statistics.

Dead Sea Bromine Company

 

Dead Sea Bromine Company Ltd., included in our Industrial Products segment.

Dead Sea Magnesium

 

Dead Sea Magnesium Ltd.

Dead Sea Works

 

Dead Sea Works Ltd., included in our Fertilizers segment.

EPA

 

U.S. Environmental Protection Agency.

FAO

 

The Food and Agriculture Organization of the United Nations, an international food organization.

FOB

 

Free on board expenses are expenses for overland transportation, loading costs and other costs, up to and including the port of origin. In an FOB transaction, the seller pays the FOB expenses and the buyer pays the other costs from the port of origin onwards.

Iberpotash

 

Iberpotash S.A., a Spanish company included in our Fertilizers segment.

IFA

 

The International Fertilizers Association, an international association of fertilizers manufacturers.

ILA

 

Israel Lands Administration.

IMF

 

International Monetary Fund.

K

 

The element potassium, one of the three main plant nutrients.

N

 

The element nitrogen, one of the three main plant nutrients.

NYSE

 

The New York Stock Exchange.

P

 

The element phosphorus, one of the three main plant nutrients, which is also used as a raw material in industry.

Phosphate

 

Phosphate rock that contains the element phosphorus. Its concentration is measured in units of P 2 O 5 .

iii


Table of Contents

Polymer

 

A chemical compound containing a long chain of repeating units linked by a chemical bond and created by polymerization.

Polysulphate

 

The commercial name for the mineral polyhalite, composed of potash, sulfur, calcium and magnesium, used in its natural form as fertilizer for organic agriculture.

Potash

 

Potassium chloride (KCl), used as a plant's main source of potassium.

Potash Corporation of Saskatchewan

 

Potash Corporation of Saskatchewan Inc., a Canadian company, the largest potash producer in the world, which owns 13.84% of our outstanding ordinary shares.

REACH

 

Registration, Evaluation and Authorization of Chemicals, a framework within the European Union.

Rotem

 

Rotem Amfert Negev Ltd., included in our Fertilizers segment.

Salt

 

Unless otherwise specified, sodium chloride (NaCl).

Soluble NPK

 

Soluble fertilizer containing the three basic elements for plant development (nitrogen, phosphorus and potash).

Tami

 

Tami (IMI) Research and Development Institute Ltd., the central research institute of ICL, included in our Industrial Products segment.

TASE

 

Tel Aviv Stock Exchange, Ltd.

USDA

 

United States Department of Agriculture.

iv


Table of Contents



PROSPECTUS SUMMARY

         This summary highlights information contained elsewhere in this prospectus and does not contain all of the information you should consider before investing in our ordinary shares. You should read this entire prospectus carefully, including the section entitled "Risk Factors" and the financial statements and the related notes included elsewhere in this prospectus, before you decide to invest in our ordinary shares.


Company Overview

        We are a leading specialty minerals company that operates a unique, integrated business model. We extract raw materials and utilize sophisticated processing and product formulation technologies to add value to customers in three attractive end-markets: agriculture, food and engineered materials. These three end-markets constitute over 90% of our revenue. Our operations are organized into three segments: (1) Fertilizers, which operates the raw material extraction for us and markets potash, phosphates and specialty fertilizers; (2) Industrial Products, which primarily extracts bromine from the Dead Sea and produces and markets bromine and phosphorus compounds for the electronics, construction, oil and gas drilling and automotive industries and (3) Performance Products, which mainly produces, markets and sells a broad range of downstream phosphate-based food additives and industrial intermediates.

        Our principal assets include:

    Access to one of the world's richest, longest-life and lowest-cost sources of potash and bromine (the Dead Sea)

    Access to potash mines in the United Kingdom and Spain

    Bromine compounds processing facilities located in Israel, the Netherlands and China

    A unique integrated phosphate value chain, from phosphate rock mines in the Negev Desert in Israel to our value-added products in Israel, Europe, the United States, Brazil and China

    An extensive global logistics and distribution network with operations in over 30 countries

    A focused and highly experienced group of technical experts developing production processes, new applications, formulations and products for our three key end-markets: agriculture, food and engineered materials

        For the year ended December 31, 2013, we generated total sales of $6.3 billion, operating income of $1.1 billion, net income of $820.2 million and Adjusted EBITDA of $1.6 billion. Our Fertilizers segment sold 4.7 million tons of potash to external customers, 0.9 million tons of phosphate rock and 1.7 million tons of phosphate fertilizers, generating sales of $3.4 billion, operating income of $821.1 million and Adjusted EBITDA of $1.1 billion. Our Industrial Products segment generated sales of $1.3 billion, operating income of $114.5 million and Adjusted EBITDA of $224.7 million. Our Performance Products segment generated sales of $1.5 billion, operating income of $195.8 million and Adjusted EBITDA of $242.4 million. See "—Summary Historical Consolidated Financial Data" for a definition of Adjusted EBITDA and a reconciliation to the comparable IFRS measure.

 

1


Table of Contents

 
   
2013 Revenue Contribution by Segment   2013 Adjusted EBITDA Contribution by Segment (1)


GRAPHIC

 


GRAPHIC

Total: $6.3 billion

 

Total: $1.6 billion


(1)    Excludes Adjusted EBITDA attributable to Other and eliminations. Does not sum to 100% due to rounding.

 

 
   
2013 Revenue Contribution by End-Market   2013 Adjusted EBITDA Contribution by End-Market


GRAPHIC

 


GRAPHIC


Our Industry

        The majority of our businesses compete in the global fertilizer and specialty chemicals industries.

    Fertilizers

        Fertilizers serve an important role in global agriculture by providing vital nutrients that help increase both the yield and the quality of crops. We supply two of the three essential nutrients—potassium, phosphorous and nitrogen—required for plant growth. There are no known substitutes for these nutrients. Although these nutrients are naturally found in soil, they are depleted over time by farming, which leads to declining crop yields and land productivity. To replenish these nutrients, farmers must apply fertilizers. The demand for fertilizers is volatile and seasonal, and pricing decreased in 2013; however, since the beginning of 2014, there have been price increases in some of the fertilizer products, particularly phosphate fertilizers. In our estimation, the policy of most countries is to ensure an orderly supply of high-quality food to their residents, including by encouraging agricultural production, which should preserve the long-term growth trend of fertilizer consumption.

        Potash, the salt form of potassium, helps regulate a plant's physiological functions and improves plant durability, providing crops with protection from drought, disease, parasites and cold weather. Unlike

 

2


Table of Contents

phosphate and nitrogen, potash does not require additional chemical conversion to be used as a fertilizer and is mined either from conventional underground mines or, less frequently, from surface or sub-surface brines, such as our operations in the Dead Sea. According to estimates from the United States Geological Survey, six countries accounted for approximately 87% of the world's aggregate potash production and the top seven producers operated approximately 78% of world production in 2013. Worldwide sales of potash recovered in 2013, as compared to 2012, although at a lower rate than expected at the beginning of 2013, due to a number of principal reasons: an erosion of 18% in the exchange rate of the Indian rupee against the U.S. dollar between January and November 2013, a fall in the prices of agricultural commodities in the fourth quarter of 2013 and the announcement of Uralkali , the Russian potash producer, in July 2013 of its exit from the joint potash marketing company with Belaruskali and a change in its selling strategy and transition to a policy favoring quantity over price while taking advantage of the company's full production capacity. This announcement triggered a fall in potash prices in the markets and also caused a postponement in potash purchases by customers due to their expectation of further price declines. In the fourth quarter of 2013, the demand for potash stabilized, and in the first half of 2014, there was further improvement, and prices, particularly of granulated potash, continued to rise, mainly in Europe and the United States. Global potash demand for agricultural uses is projected to grow at an average annual rate of 3% from 2013 through 2018 according to the IFA.

        Phosphate, a salt of phosphoric acid, is essential to plant root development and is required for photosynthesis, seed germination and efficient usage of water. Phosphate fertilizers are produced from phosphate rock, sulfuric acid and ammonia. The principal phosphate fertilizer producing regions are those with plentiful supplies of high quality, low-cost phosphate rock. The vast majority of the world's phosphate rock production in 2013 was in China, the United States, Morocco and Russia. Global phosphoric acid demand for all uses is forecast to grow at an annual rate of 2% through 2018 according to the IFA. Worldwide demand and prices for phosphate fertilizers were weak during all of 2013, mainly as a result of low demand in India and postponement of purchases throughout the world. Towards the end of 2013, phosphate prices started to rise moderately and continued to climb in the first quarter of 2014 due to strong demand in South America, commencement of preparation of the North American buyers for the upcoming season and return to the market of other buyers that had postponed purchases based on an expectation of continued price declines. At the beginning of the second quarter of 2014, there was a trend of declining prices, which reversed during the quarter.

        Barriers to adding new potash and phosphate production are significant. Adding new capacity requires long lead time and billions of dollars of capital per operation. In potash, economically recoverable deposits are scarce, typically deep in the earth and geographically concentrated. We believe that current potash market prices do not support the development of new (greenfield) mines. In phosphates, the need for economic access to multiple raw material feedstocks (phosphate rock, sulfuric acid and ammonia) combined with complex downstream production processes also act as significant barriers to entry.

        The specialty fertilizers market is growing faster than the conventional fertilizers market. Specialty fertilizers are often used for specialty crops (such as greenhouses and horticulture) but are rapidly expanding into usage for larger specialty field crops. Farmers are looking for fertilizers that are customized to meet the needs of specific crops and climates, to maximize yield and quality. Specialty fertilizers, such as controlled release fertilizers (which allow for the release of nutrients over time), slow release fertilizers (which allow for a very slow release of nutrients), liquid fertilizers (integrated in irrigation systems) and soluble fertilizers (integrated in drip irrigation systems and foliar spraying), ensure the timely and proportionate release of nutrients, thus not only significantly reducing their environmental impact but also providing highly efficient fertilization for a wide range of agricultural crops, including fruits, vegetables and high-value perennial crops. Increasing consumer demand for healthier food is expected to drive the growth of the specialty agriculture end-market, including specialty fertilizers.

 

3


Table of Contents

    Specialty Phosphates

        Phosphate is also used in a broad range of downstream products in the food, electronics, energy and construction industries. These phosphate derivatives deliver additional and attractive margins. Main usage areas are: (1) food additives for improved texture and stability of processed foods such as meat, bakery, dairy and beverage products and (2) technical phosphates for usage in road surfaces, oil and paint additives, flame retardants and fire extinguishing. Demand for phosphate-based products is driven by global economic growth and improved living conditions. As global population grows, living standards improve and consumers demand more sophisticated food products, demand for phosphate-based products increases.

    Bromine

        The largest commercial use of bromine is brominated flame retardants, which accounts for approximately 40% of current demand for bromine. Flame retardants help materials such as plastic enclosures for consumer electronics, printed circuit boards, insulation materials for construction, furniture, automobiles, and textiles meet fire-safety requirements. The flame retardant market has contracted in the past few years. On the other hand, alternative uses of bromine have grown considerably, with bromine now used in a number of newer applications, including water purification, shale gas fracking, oil and gas drilling and other industrial uses. Many new applications are under development by us and our competitors.

        Bromine is found naturally in seawater, underground brine deposits and other water reservoirs, such as the Dead Sea, and is extracted by evaporation. The Dead Sea is the world's premier source of bromine, with concentration levels significantly higher than in regular seawater, and it accounts for about half of the global supply. Because it has the highest concentration of bromine, the Dead Sea is the most economical supply source as the least amount of water must be extracted and evaporated to generate bromine.

        The bromine industry is highly concentrated, with three companies accounting for approximately 80% of worldwide capacity in 2013 (us, Albemarle Corporation ("Albemarle") and Chemtura Corporation ("Chemtura")). Barriers to entry are significant, primarily due to the lack of economically feasible bromine supplies, and the requirement for a dedicated, complex and sophisticated global supply chain, such as the need for isotanks to transport bromine. We estimate that approximately 70% of global elemental bromine production is consumed internally, as there is a very small market for merchant bromine. As such, bromine production requires downstream compound production facilities.


Highly Integrated and Synergistic Value Chain

GRAPHIC

 

4


Table of Contents

        Over 90% of our revenue is derived from three highly attractive end-markets: agriculture, food and engineered materials.

    Agriculture

        Global fertilizer demand is driven by grain demand and prices, which are primarily driven by population growth and dietary changes in the developing world:

    Population and Income Growth.   Historically, growth in world fertilizer consumption has been closely correlated with growth in world population, which is expected to increase by over 1.0 billion to reach 8.3 billion by 2030, according to the U.S. Census Bureau. Currently, developed countries use fertilizer more intensively than developing countries and therefore produce crops at much higher yields. Economic growth in emerging markets is increasing food demand and thus fertilizer use. Populations in emerging markets are also shifting to more protein-rich diets as incomes increase, with such increased consumption requiring more grain for animal feed. According to the IMF, income per capita in developing countries is expected to grow by 6.0% annually up to 2018.

    Declining Arable Land per Capita.   As the world's population grows, mainly in cities, farmland per capita decreases and more food production is required from each acre of farmland. This, in turn, requires increased yield on existing farms. According to data from the Food and Agriculture Organization of the United Nations ("FAO"), the amount of arable land per capita is expected to decrease from 0.218 hectares per person to 0.197 hectares per person between 2012 and 2030. Significant amounts of new arable land are only available in limited quantities, mainly in Brazil. Therefore, the only viable path to increase crop production is through the yield increase in existing farms in developing countries, mainly in China, India, Russia, Africa and Central America. We believe fertilizers (especially more potash and phosphates) together with water availability and better seeds are the main route to higher yields.

    Low Grain Stock-to-Use.   The pressure on food demand is expected to continue to result in relatively low historical levels of the grain stock-to-use ratio (a metric indicating the level of carryover stock), as illustrated by the chart below. The grain stock-to-use ratio was approximately 20.8% for the 2013/2014 season, which represented an increase from a low of 16.6% for the 2006/2007 season but a decrease as compared to the high of 28.9% for the 2000/2001 season, according to data from the United States Department of Agriculture (the "USDA"). Based on a report published by the USDA in July 2014, an increase is expected in the grain stock-to-use ratio to approximately 21.3% at the end of the 2014/2015 season. A decline in the grain stock-to-use ratios generally indicates that grain prices will increase (due to limited stockpiles and tighter grain supply). This generally is a positive development for fertilizers, as higher grain prices support more fertilizer use.

 

5


Table of Contents

GRAPHIC

    Food

        Consumer demand for different food products in developed countries has changed dramatically over the last several decades, driven by increased per capita incomes, demographic shifts and lifestyle changes. Longer working hours, changing family structures, increased awareness of nutrition and health issues and access to a broader variety of food products result in growing demand for sophisticated, higher-quality products with longer shelf-lives such as convenience food and processed food products.

        This changing demand includes greater demand for processed food products with enhanced nutritional value and balance and with improved flavor, texture and appearance. An increasingly longer supply chain and consumer awareness of waste of foods also drives the demand for longer shelf-life and food stability. These secular trends act as long-term drivers of demand for food additives such as phosphate derivatives, phosphate-based formulations and hygiene products for the processed meat, bakery, dairy and beverages industries.

    Engineered Materials

        Demand for engineered materials, which include bromine-, phosphorus-and phosphate-based products, is driven by increased construction, and greater demand for energy, potable water and pharmaceutical products. Increased standards of living also increase regulation and growing environmental awareness. These trends result in greater demand for flame retardants, bromine- and chlorine-based biocides for water purification and waste water treatment and bromine-, magnesia- and potassium chloride-based intermediates for the pharmaceutical industry.

        Additionally, growth in oil and gas exploration is expected to continue to drive demand for bromine-based completion fluids and for bromine-based biocides used for fracking. Worldwide annual average oil rig count has been growing at a compounded annual growth rate of 4.0%, from 2,395 in 2004 to 3,412 in 2013.

 

6


Table of Contents


Our Competitive Strengths

        We attribute our success to the following strengths:

    Unique portfolio of mineral assets.   We benefit from our access to resource-rich, long-life and low-cost raw materials, mainly potash and bromine. Our access to these resources is based upon exclusive concessions and licenses from the State of Israel, and leases and concessions from local governments in the United Kingdom and Spain. Access to these assets provides us with a consistent, reliable supply of raw materials, allowing us to produce our products on a large scale and in a cost-effective manner.

    Dead Sea in Israel:   Our potash and bromine production facilities at the Dead Sea enjoy low production costs due to the high concentration and virtually unlimited supply of minerals contained in the Dead Sea. Extraction of potash and bromine occurs via solar evaporation, a low-cost process, as compared to mining potash from underground deposits or extracting bromine from less concentrated sources, which are more energy intensive. The hot and dry climate of the Dead Sea allows us to store at a low cost, very large amounts of potash (exceeding one full year of production) outdoors. This storage capacity enables us to operate worldwide potash facilities at full production capacity despite periodic fluctuations in demand. In addition, we benefit from the geographic proximity of our facilities in Israel to seaports and from Israel's geographic positioning vis-à-vis our main geographical markets (especially the fast growing markets of India, China and Brazil), reducing transportation and logistics costs. While we benefit from these advantages, we expect to incur significant infrastructure-related costs to fully harvest salt from Pond 5 at our Dead Sea complex, which is our central evaporation pond, to avoid the need to continue to raise the water level in the pond. In addition, while the supply in the Dead Sea is virtually unlimited, our access to this supply of potash and bromine is subject to permitting and concession rights in Israel, the need to construct a new pumping station and the potential obligation to pay higher taxes and royalties. See "Risk Factors—Risks Related to Our Business."

    United Kingdom and Spain assets:   In addition to our operations in Israel, we mine potash in the United Kingdom and Spain. Access to these assets provides us with production and logistics flexibility, geographical proximity to European clients, business diversification and additional reserves for future growth.

    Our integrated phosphate value chain:   Due to our access to the phosphate rock in the Negev Desert, we are the only sizeable backward integrated phosphate player. We mine and process phosphate rock from three open-pit mines under mining concessions with the State of Israel. Approximately three-quarters of the phosphate rock produced is used internally to manufacture phosphate fertilizers and phosphoric acid, with the balance sold to external producers. See "Risk Factors—Risks Related to Our Business—Our mining operations are dependent on concessions, licenses and permits granted to us by the respective governments in the countries where they are located."

 

7


Table of Contents


    Diversification into higher value-added specialty products leveraging our integrated business model.   Our integrated production processes are based on a synergistic value chain that allows us to both efficiently convert raw materials into value-added downstream products and utilize by-products. For example, in phosphates we utilize our backward integration to produce higher-margin specialty phosphates used in food ingredients and engineered materials applications. Our food ingredients provide solutions for improved texture and shelf-life for meat, dairy and bakery products. In addition, as a by-product of our potash production at the Dead Sea, we generate brines with the highest bromine concentration globally. Our bromine-based products serve the electronics, construction, oil and gas and other industries. Our potash mine in the United Kingdom also contains another mineral (polysulphate) which can be mined using the same infrastructure and addresses unmet emerging mineral needs of farmers.

    Leading positions in markets with high barriers to entry.   We are a global leader in many of the key markets in which we operate, including potash, phosphorus and potassium ("PK") fertilizers, specialty fertilizers and phosphates, elemental bromine and phosphate-based food additives. We believe we are generally ranked among the top three leaders in our markets, as shown in the table below:

Product
  Rank   End-markets

Potash

  #2 in Western Europe and
#6 Worldwide
  Agriculture

PK fertilizers

  #1 in Western Europe   Agriculture

Specialty fertilizers

  #1 Worldwide in MAP/MKP
soluble fertilizers,
#2 (tied) in Europe in
controlled-release fertilizers and
#1 in the United States
in controlled-release
fertilizers
  Agriculture

Phosphate-based food additives

  Top 3 Worldwide   Food

Specialty phosphates

  Top 2 Worldwide   Food / Engineered Materials

Elemental bromine

  #1 Worldwide   Engineered Materials

Phosphorus-based flame retardants

  #1 Worldwide   Engineered Materials

Forest fire retardants

  #1 Worldwide   Engineered Materials

      Most of our businesses rely on natural resources that are scarce and concentrated in the hands of a few market participants, making it difficult for new competitors to enter our businesses. Our exclusive concessions, intellectual property and proprietary technologies, world-wide marketing and distribution network and high industry start-up costs for new market entrants further add significant barriers to entry.

    Strategically located production and logistics assets.   We benefit from the proximity of our facilities, both in Israel and Europe, to developed economies (Western Europe) and emerging markets (such as China, India and Brazil). For example, in Israel, we ship from two seaports: the Port of Ashdod (with access to Europe and South America) and the Port of Eilat (with access to Asia, Africa and Oceania). Access to these two ports provides us with two distinctive advantages versus our competitors: (1) we have lower plant gate-to-port costs and ocean freight costs, which lowers our overall cost structure and (2) we have faster time to markets due to our proximity to end-markets, allowing us to opportunistically fill short lead-time orders, strengthening our position with our customers. In addition, we are the sole producer with the ability to transport potash and phosphates

 

8


Table of Contents

      from the same port (which we do in Israel). Our sales are balanced between emerging markets (approximately 40% of 2013 sales) and developed economies (approximately 60% of 2013 sales).

    Significant operating cash flow generation and return on capital.   Our businesses have historically generated significant amounts of operating cash flow, having generated $1.7 billion and $1.1 billion of operating cash flow in 2012 and 2013, respectively. We are able to generate significant levels of operating cash flow due to the size and scale of our business and our relatively high margins. These cash flows have enabled us to produce high returns on capital, appropriately maintain and expand our production facilities and take advantage of acquisition opportunities. In addition, since 2007, we have had a policy of paying a quarterly dividend of up to 70% of our net income. This policy has resulted in a strong dividend yield of 8% (equal to the total dividend per share in NIS distributed from net income in 2013, including a special one-time $500 million dividend, divided by the average price per share on the TASE during 2013).

    Highly knowledgeable people and culture of collaboration and determination.   Our operations are managed by an international management team with extensive industry experience. We develop leaders with strong experience in their fields and the culture to drive change and innovation in our Company. We also bring in leaders from outside the Company to supplement our expertise. We focus on nurturing and empowering talent through a global platform of qualification, collaboration and communication that reinforces innovation.


Our Strategy

        Our "2020—Next Step Forward" corporate strategy is targeted to fulfill essential needs in our three core markets. We have developed a strategic plan based on three value-creation pillars: (1)  Efficiency: improve existing operations; (2)  Growth : organic and external expansion of our value chain from specialty minerals into the agriculture, food and engineered materials markets; and (3)  Enablers : create one global ICL, strengthen innovation, provide an empowering environment to our people and align management with our stakeholders to support our growth and efficiency goals. We intend to implement this strategy while maintaining our strong financial position and our current dividend policy of distributing up to 70% of our net income.

        Our key strategic initiatives include:

    Continuously improve the cost position of our distinctive mineral asset base.   We have identified, and have started implementing cost reduction initiatives in our potash and phosphate operations. At our facility in Spain, we are consolidating our activities from two facilities into one facility while maintaining our production capacity. This will help us lower our fixed costs of production. At Cleveland Potash Ltd. ("Cleveland Potash") in the United Kingdom, we are upgrading our production facilities to improve utilization rates, which will significantly reduce fixed costs per ton. Finally, at the Dead Sea in Israel, we are increasing the potential production capacity of our potash processing plants, and implementing process efficiencies to improve our utilization rates. In phosphates, we intend to transform our cost base by implementing an efficiency plan at our Rotem site, including headcount reductions that are currently being implemented and process improvements to increase utilization rates. Regarding the plan for efficiency and integration of the global processes into our Company, as well as the plan for reducing the production cost of our specialty minerals pursuant to the strategic plan described below, we estimate that these activities, the execution of which we have already started, will give rise to savings by the end of 2016 in the amount of approximately $350 million annually compared with 2013. Our estimate is based on projections made by our management and subjective assessments that are based on the experience we have accumulated and on actual process improvements. While the cost savings and efficiencies to be generated by our strategic plan described above are presented with numerical specificity, and we believe such targets to be reasonable as of the date of this prospectus, the manner of implementation of the strategic plan and its impact may be different, possibly even significantly

 

9


Table of Contents

      different, than that forecasted. This may result from various factors, including the situation prevailing in the market, competition, regulation and the risk factors characterizing our activities. Accordingly, our actual results may differ from these targets and the differences may be material and adverse, particularly if actual events adversely differ from one or more of our key assumptions. We caution investors not to place undue reliance on any of these assumptions and targets. See "Special Note Regarding Forward-Looking Statements" for additional information regarding these forward-looking statements and "Risk Factors."

    Streamline and integrate our global processes.   We have also identified several areas of efficiency improvements such as procurement, pricing, energy, research and development ("R&D") and other shared services. For example, in procurement we are optimizing expenditures by consolidating our purchasing activities on a global basis. In energy, we are improving technical systems to optimize usage and are building a cogeneration power plant based on natural gas (dual-fuel) in order to achieve energy self-sufficiency in Israel by 2016.

    Expand our production capabilities and reserves base.   We plan to increase our potash production capability to approximately 6 million tons per year by 2018. This will be achieved through debottlenecking in Spain and improved utilization rates in Israel and the United Kingdom. At Cleveland Potash, we are extending the mining area to provide additional reserves and to increase our low-cost polysulphate production, a new fertilizer targeting low sulfur soils. In addition, we are evaluating further capacity increases in our current potash assets and at other potential potash locations. In phosphate, we are increasing our production in Rotem by approximately 15% by improving utilization rates. In addition, we are seeking governmental and municipal approvals for a new mining site—Barir field—in the Negev Desert in Israel, which, if granted, will provide further cost savings and increased scale through a focused investment program. See "Risk Factors—Risks Related to Our Business—Our mining operations are dependent on concessions, licenses and permits granted to us by the respective governments in the countries where they are located." Separately, we are assessing additional phosphate reserves in emerging markets with an intention to develop a full phosphate franchise in key regions in the world. Consistent with this strategy, we are in active discussions concerning phosphate franchises in key emerging markets. As of the date of this prospectus, we are negotiating with a third party for the engagement in joint ventures for current and future activities relating to the mining and sale of phosphate rock in emerging markets as well as for the production, marketing and distribution of downstream products of phosphate rock in the aforementioned markets. As of the date of this prospectus, the negotiations have not yet ripened into in-principle commercial agreements and the parties have not yet reached essential agreement regarding the structure of the transaction and the consideration to be paid by the Company, and therefore definitive agreements have yet to be signed and there is no certainty that these negotiations will ultimately result in definitive binding agreements or that such transactions will be consummated. If the negotiations ripen into definitive agreements, the Company estimates that the consideration it pays will be hundreds of millions of dollars.

    Expand market demand for our products.   In potash, we will increase our investment in educating emerging market farmers on the economic benefits of applying the optimal levels of potash. In particular, we are focusing on India and Africa due to our current position in these markets, our proximity to them and the currently low application of potash in these markets. This demand creation is intended to secure above-average sales growth in potash for us. We intend to continue driving demand growth for bromine through the development of new products and new applications by increasing our R&D spending, utilizing our industry knowledge, collaborating with others and by advocating for fire safety and mercury control regulations in emerging markets.

    Grow our value-added downstream products.   As part of our growth strategy we intend to use our strong cash flow to further grow our specialty and value-added products organically and through acquisitions. This will allow us to drive strong growth in our businesses and continue to evolve from

 

10


Table of Contents

      a product-based to a market-focused organization. In the fast growing and high return-on-assets specialty fertilizers business, we are improving our core technologies and expanding our geographical footprint in liquid fertilizers, advanced coated fertilizers and soluble fertilizers. In food, we intend to expand our existing phosphate-based texture and stability solutions to emerging markets. In addition, we are constantly collaborating with our customers to develop new formulations. The next phase of this strategy is to leverage our expertise and technology platform to provide enhanced texture and stability solutions beyond additives based solely on phosphates, including through acquisitions, strategic partnerships and joint ventures. Finally, in engineered materials, we intend to utilize our expertise and technology in developing bromine and phosphate-based solutions for industrial applications. With respect to our activities that do not constitute our core businesses, we are examining various possibilities in connection with the continued integration of such activities in our Company and are preparing to divest activities that are not synergetic with our activities. As of the date of this prospectus, we are taking various measures to execute these activities in a monetary scope estimated by us in the range of $300 million to $500 million, including by means of contacting potential purchasers and/or requesting to receive offers. However, binding agreements have not yet been signed and, accordingly, there is no certainty that binding agreements will be signed or that one or more of these transactions will be completed. Our goal is to generate over 10% of sales from new product introduction in our specialty businesses (outside potash and commodity phosphates) by 2018.

    Further develop and enhance our "One ICL" culture and empower our people.   In order to achieve our strategies and continue to carry out our evolution from a natural resources company to an essential needs company, we believe we must continue to enable our people to thrive within our organization and are implementing our "One ICL" strategy. Under our "One ICL" strategy, we are working to harmonize our systems (for example, by moving to a single global enterprise resource planning system) and processes and better share best practices across our Company to ensure that we provide the best services within our end-markets and avoid product or divisional silos. We will continue to identify and reward top performing employees and will move them to the right locations within the organization where they can be most effective, while incentivizing them through compensation and performance assessments to help us achieve our goals.


Recent Developments

        We continue to actively work to implement our strategic plan as described above, but, as we do so, we are undergoing a review of our plans in Israel to address the following recent developments in Israel:

    On May 19, 2014, we received the partial award of an arbitration panel, the main points of which are as follows: (i) our subsidiary, Dead Sea Works Ltd. ("Dead Sea Works"), has to pay royalties to the State of Israel on the sale of downstream products manufactured by subsidiaries that are controlled by us that have production plants both in and outside the Dead Sea area, including outside Israel; (ii) the royalties shall be paid according to the value of the downstream products, which will be set according to the formula described in Section 15(a)(2) of the Concession Deed (the sale price of the downstream product to unrelated third parties minus the deductions set forth in sub-sections (I), (II) and (III) of that section); and (iii) with respect to metal magnesium, it was decided that the State of Israel and Dead Sea Works should exhaust their discussions on the subject of the royalties to be paid by Dead Sea Works on this material and, if no agreement is reached, the subject will be returned to arbitration. The arbitrators' award was given with respect to fundamental determinations with respect to the liability to pay royalties on downstream products and does not include any reference to the financial calculations arising out of the award. The financial calculation will be resolved during the next phase of the arbitration. In the second quarter of 2014, we recorded a provision in the amount of approximately $135 million due to the implementation of the partial arbitration award for the years 2000 through 2013 (representing $149 million for royalties for such years plus $31 million for interest (in financing expenses), net of tax of $45 million). In addition, as

 

11


Table of Contents

      a result of the arbitrators' decision, the current expense in the first half of 2014 in respect of royalties increased by approximately $6 million. The arbitrators' award is partial and the financial calculations as to the method of implementation of the award have yet to be determined by the arbitrators. Therefore, our estimation is based on various assumptions regarding the manner of calculating the royalties pursuant to the partial arbitration award and reflects our best estimate of the expenditure that will be required to settle the liability as of June 30, 2014. The final amount that will be determined by the arbitrators at the end of the second stage of the arbitration after the arbitration panel determines the financial calculations as noted above may differ, including materially, from this provision amount. In the second stage of the arbitration, which will deal with determination of the amounts of the royalties, we intend to claim that the correct amount of the royalties is significantly lower than the amount stated. In 2013, our subsidiary, Dead Sea Works, paid royalties to the State of Israel on sales of bromine in the amount of approximately $10.3 million. According to the assumptions on the basis of which the provision was made, as mentioned above, Dead Sea Works would have been required to pay additional royalties in 2013 in the amount of approximately $11.4 million (before tax) on downstream products. The amount of royalties to be paid in the future for the aforementioned downstream products will be derived from, among other things, the quantities sold, market prices and the mix of products and therefore may differ from the amounts which would have been paid for the year 2013, as mentioned above. Together with our financial and legal advisors, we are reviewing the arbitration panel's award and its implications.

    A committee formed by the Israeli finance minister (the "Sheshinski Committee") to evaluate the appropriate policy of the State of Israel in respect of royalties to be paid for use of natural resources announced on May 18, 2014 draft recommendations (the "Committee's Interim Recommendations") for public comment that would set (i) a unified royalty rate of 5% from the sales ex plant (compared to the current phosphate royalty rate of 2% ex mine and the potash royalty rate of 5% on the first 1.5 million tons sold and 10% on any additional quantities sold; the bromine royalty rate would remain unchanged at the current 5%); and (ii) a new "natural resources tax," which would be in addition to the regular Israeli corporate income tax (see "Tax Considerations" for a discussion of the Israeli corporate tax rate), on the operating profit of each company that exploits natural resources in Israel at the suggested rate of 42%, which would apply to all operating profits after the deduction of an amount equal to an 11% return on the book value (after depreciation) of such company's fixed assets. On July 17, 2014, we submitted our response, in writing, to the Committee's Interim Recommendations and on August 4, 2014, we orally presented our position to the Sheshinski Committee and pointed out errors and that the Sheshinski Committee's model was inconsistent with principles and targets established by it, will have negative consequences and is unconstitutional. See "Business—Mineral Extraction and Mining Operations—Concessions and Mining Royalties."

    We intend, with the assistance of our legal advisors, to take all necessary legal actions in order to protect our rights.

        On August 6, 2014, our Board of Directors discussed the impact of the Committee's Interim Recommendations and the partial arbitration award in the royalties arbitration (the "Royalties Arbitration"), as well as the need to implement cost-cutting and efficiency plans, and its main resolutions are as follows:

    We estimate, based on our 2013 prices and cost structure and an effective corporate tax rate of 26.5%, and assuming that the Committee's Interim Recommendations were applied with respect to our bromine and bromine compounds subsidiaries on a consolidated basis, that the incremental after-tax cost to us of the Committee's Interim Recommendations, together with the impact of the Royalties Arbitration, would be approximately $160 million per year. The actual cost for the applicable years could differ based on market pricing, our cost structure, the corporate tax rate, the

 

12


Table of Contents

      final methodology for calculation of the tax rate, changes in the committee's final recommendations as compared to the current recommendations and the final outcome of the Royalties Arbitration. The recommendations of the Sheshinski Committee remain subject to a public review process, and once any final recommendations are produced by the Sheshinski Committee, these recommendations will require approval by the Israeli cabinet and the Knesset before implementation. The recommendations described above could change materially at any point during this process and are not binding upon us until enacted into law. Any new unified royalty rate or new taxes with respect to Dead Sea Works are not expected to become effective until 2017, although taxes applicable to phosphate and bromine operations could be implemented sooner.

    To continue to freeze our investments in Israel, as incorporated in our long-term plan, and to re-evaluate the attractiveness of each investment, separately. As of the date of this prospectus and so long as the Committee's Interim Recommendations are expected to be implemented, we have decided to (a) cancel investments that were previously approved by us prior to the date of announcement of the Committee's Interim Recommendations, and (b) cease approving further investments, in an aggregate amount of approximately $750 million. We are continuing to evaluate the impact of implementation of the Committee's Interim Recommendations and the Royalties Arbitration on additional investment plans, in the amount of approximately $1 billion.

    To continue to evaluate the implementation of cost-cutting initiatives and the possibility for their acceleration.

    To continue to act to execute our strategy of expanding our operations in more attractive geographic areas, and to the extent required, to reallocate spending that had previously been planned for Israel into projects or acquisitions in these other markets.

    To evaluate the economic profitability of continuing to produce certain products, including metal magnesium, bromine compounds and certain phosphate downstream products. The economic profitability review will consider the option of discontinuing certain products and/or to endeavor to reduce the production costs in connection with these products, including by means of potential collaborations.

        Further to the Board of Directors' resolution on the evaluation of the economic profitability of continuing to produce certain products, including metal magnesium, bromine compounds and certain phosphate downstream products, on August 27, 2014, our Board of Directors decided as follows:

    Our Board of Directors instructed our management team to develop and implement an efficiency plan designed to significantly improve the profitability of Bromine Compounds Ltd. ("Bromine Compounds"), which is in our Industrial Products segment. Our Board of Directors has determined that this plan is required due to the continuing erosion of profits on bromine compounds as a result of a decline in demand for flame retardants, low structural growth of the world market, a drop in prices and strengthening of the shekel, compounded by the significant recent developments related to the partial arbitration decision with respect to royalties on sales of downstream products, including bromine compounds and the possibility that the Sheshinski Committee's Interim Recommendations will be adopted and enacted into legislation. Our management team is making preparations to formulate a plan, as stated, which it expects will include the reduction of labor and other costs in Bromine Compounds. No assurances can be provided that we will be able to formulate such a plan or that such a plan can be implemented successfully, as a result of various factors, including the situation of the market, competition, regulation, labor relations and/or any of the risk factors associated with the operation of our Company as set forth in this prospectus. In addition, our Company could be adversely affected as a result of such plan, including through potential labor unrest.

    Our Board of Directors instructed our management team to make preparations for the closure of our magnesium plant at the Dead Sea, commencing January 1, 2017, unless the discussions with the

 

13


Table of Contents

      State of Israel regarding the tax and royalties issues will support the continuation of the activities of the magnesium plant. Our management team has been instructed to support all existing and future customer orders and commitments in order to avoid any interruptions until the final closure of the plant. The main economic justification for continuation of the activities of the magnesium plant at the Dead Sea stems from the plant's synergies with our other facilities in Sodom, which provide it with, and receive from it, raw materials (the "Synergies"). The net value of the Synergies has declined due to the increase in the tax burden on production from natural resources in Israel that have already been implemented, and will further decline if the Sheshinski Committee's Interim Recommendations are enacted into law. As result of the abovementioned tax burden, we have halted all investments in the magnesium plant (other than investments required by law). In 2013, our total sales of magnesium were approximately $115 million and the gross profit of the magnesium company in 2013 was approximately $1 million, the net book value of the assets of the magnesium company as of June 30, 2014 was approximately $35 million and the depreciation expense in 2013 was approximately $6 million.


Our History

        We were established in 1968 as a government owned and operated company in Israel and operate today as a limited liability company under the laws of Israel. In 1975, the shares of various development companies (including, among others, Dead Sea Works, the companies today consolidated as Rotem Amfert Negev Ltd. ("Rotem"), the bromine companies and Tami (IMI) Research and Development Institute Ltd. ("Tami")) were transferred to us. In 1992, following a decision by the Israeli government to privatize our Company, Israel published its tender prospectus, and the shares of ICL were listed on the TASE. Prior to our public share issuance, we issued to Israel a special state share (the "Special State Share") in our Company and our main Israeli subsidiaries. See "Description of Share Capital—The Special State Share."

        In 1995, Israel sold its controlling interest in us (representing approximately 24.9% of our shares) to Israel Corporation, which was controlled at that time by the Eisenberg family. A majority of the ordinary shares held by Israel were sold during the following years. In 2000, Israel ceased to be an interest holder in terms of holding any ordinary shares in us, but it retained the Special State Share. In 1999, the Ofer Group acquired the Eisenberg family's shares in Israel Corporation. Immediately prior to this offering, Israel Corporation holds approximately 52.38% of our outstanding ordinary shares. With respect to any ordinary shares Israel Corporation sells directly to the underwriters, it will cease to have voting rights. With respect to any ordinary shares subject to the forward sale agreements, and made available to the forward counterparties under these agreements, Israel Corporation will cease to have voting rights with respect to these ordinary shares and will, at the relevant settlement dates, regain voting rights with respect to all or a portion of the ordinary shares it makes available to the forward counterparties under these agreements if it elects cash settlement or net physical settlement.


Other Information

        Our legal and commercial name is Israel Chemicals Ltd. Our registered office and principal place of business is located at Millennium Tower, 23 Aranha Street, P.O. Box 20245, Tel Aviv 61202, Israel. The telephone number at our registered office is +972-3-684-4400. Our website address is www.icl-group.com. The reference to our website is intended to be an inactive textual reference and the information on, or accessible through, our website is not intended to be part of this prospectus.

 

14


Table of Contents

 


THE OFFERING

The offering

  This is a combined offering of an aggregate amount of 62,000,000 of our ordinary shares, comprised of the sale by Israel Corporation of 36,207,128 of our ordinary shares and the expected sale by the forward counterparties of 25,792,872 of our ordinary shares to hedge their positions under the forward sale agreements described below.

 

Our controlling shareholder, Israel Corporation, expects to enter into forward sale agreements with the forward counterparties pursuant to which Israel Corporation will sell, and the forward counterparties will purchase, up to 36,207,128 ordinary shares, subject to the terms and conditions of the forward sale agreements.

 

The forward counterparties expect to sell 25,792,872 of our ordinary shares under this prospectus through the underwriters named in this prospectus to hedge their positions under these forward sale agreements. Israel Corporation will make available to the forward counterparties the ordinary shares to be sold by them under this prospectus.

Ordinary shares issued and outstanding as of the date of this prospectus (excluding shares held by us or our subsidiaries)

 

1,270,425,548 ordinary shares.

Option to purchase additional shares

 

Israel Corporation has granted the underwriters the right to purchase an additional 6,200,000 ordinary shares.

Use of proceeds

 

We will not receive any proceeds from the sale of the ordinary shares by the underwriters, whether in connection with the forward sale agreements or the sale of ordinary shares by Israel Corporation directly to the underwriters, including any proceeds from any exercise by the underwriters of their option to purchase additional shares. Israel Corporation will receive proceeds from its sale of the ordinary shares directly to the underwriters and will receive proceeds from the forward counterparties if it enters into the forward sale agreements.

Dividend policy

 

Our Board of Directors has adopted a dividend policy to pay quarterly dividends of up to 70% of our net income. Any dividends must be declared by our Board of Directors, which will take into account various factors including our profits, our investment plan, our financial status and additional factors they deem appropriate. Dividend payments are not guaranteed and our Board of Directors may decide, in its absolute discretion, at any time and for any reason, not to pay dividends. See "Dividend Policy." On August 6, 2014, we declared a $47 million dividend, which will be paid on September 17, 2014 with an ex-dividend date of September 4, 2014.

Risk factors

 

See "Risk Factors" for a discussion of risks you should consider before deciding to invest in our ordinary shares.

Proposed NYSE trading symbol

 

"ICL."

 

15


Table of Contents

Conflicts of Interest

 

Some of our ordinary shares will be sold by the underwriters in connection with the forward sale agreements. Because each of Morgan Stanley & Co. LLC and Goldman, Sachs & Co. is acting as an underwriter for the offering and will receive in its (or its respective affiliate's) capacity as a forward counterparty at least 5% of the proceeds of this offering, a conflict of interest under Financial Industry Regulatory Authority ("FINRA") Rule 5121 is deemed to exist. As required by FINRA Rule 5121, Barclays Capital Inc. has agreed to act as "qualified independent underwriter" for this offering and has participated in the preparation of, and has exercised the usual standards of "due diligence" in respect of, this prospectus. See "Underwriting—Conflicts of Interest."

        Unless we specifically state otherwise, references in this prospectus to the amount of our ordinary shares issued and outstanding and the percentage ownership of our shareholders as of the date of this prospectus exclude shares held by us or our subsidiaries and the information in this prospectus does not take into account:

    the sale of up to 6,200,000 ordinary shares that the underwriters have the option to purchase from Israel Corporation;

    11,993,400 ordinary shares issuable upon the exercise of options outstanding as of June 30, 2014 under our incentive compensation plans at a weighted average exercise price of NIS 42.6585 per share (see "Management—Incentive Compensation Plans" for more information about our outstanding option plans); and

    up to 4,384,540 shares issuable upon exercise of options and up to 1,025,449 restricted shares that may be granted under our new equity compensation plan approved by our Board of Directors on August 6, 2014 (and subject to shareholder approval in the case of the grants to our Chief Executive Officer).

 

16


Table of Contents

 


SUMMARY HISTORICAL CONSOLIDATED FINANCIAL DATA

        The following tables present our summary consolidated financial data for each of the periods indicated. You should read this information in conjunction with "Presentation of Financial and Other Information," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our audited financial statements, including the notes thereto, included elsewhere in this prospectus.

        We have derived our summary consolidated income statement data for the six months ended June 30, 2014 and 2013 and the years ended December 31, 2013, 2012 and 2011 and our summary consolidated statements of financial position data as of June 30, 2014 and December 31, 2013 and 2012 from our financial statements included elsewhere in this prospectus, which have been prepared in accordance with IFRS, as issued by the IASB. We have derived our summary consolidated income statement data for the years ended December 31, 2010 and 2009 and our summary consolidated statements of financial position data as of December 31, 2011, 2010 and 2009 from our consolidated financial statements, which are not included herein.

 
  Six Months Ended
June 30,
  For the Years Ended December 31,  
 
  2014   2013   2013   2012   2011   2010   2009  
 
   
   
  (in thousands of U.S. dollars, except for share data)
 

Income Statement Data:

                                           

Sales

  $ 3,148,217   $ 3,410,507   $ 6,271,542   $ 6,471,433   $ 6,868,550   $ 5,571,976   $ 4,356,053  

Cost of sales

    2,042,867     2,033,647     3,861,572     3,760,235     3,767,962     3,185,609     2,579,057  

Gross profit

    1,105,350     1,376,860     2,409,970     2,711,198     3,100,588     2,386,367     1,776,996  

Selling, transportation and marketing expenses

    429,077     433,759     850,325     797,291     861,976     774,147     550,136  

General and administrative expenses

    148,847     138,786     281,491     248,782     265,142     235,095     186,351  

Research and development expenses, net

    44,207     41,369     82,870     74,099     70,126     61,948     51,635  

Other expenses

    170,586     8,901     110,194     61,085     29,929     7,741     94,144  

Other income

    (8,366 )   (1,858 )   (16,276 )   (23,691 )   (4,660 )   (11,218 )   (3,604 )

Operating income

    320,999     755,903     1,101,366     1,553,632     1,878,075     1,318,654     898,334  

Finance expenses, net

    69,377     17,877     26,855     60,894     77,812     60,187     1,477  

Share in earnings of equity accounted investees

    11,743     7,412     25,685     26,555     34,265     31,729     43,695  

Income before income taxes

    263,365     745,438     1,100,196     1,519,293     1,834,528     1,290,196     940,552  

Income taxes

    63,305     123,128     280,023     217,561     333,470     261,579     166,238  

Net income attributable to the shareholders of the Company

    198,502     621,521     818,573     1,300,076     1,498,151     1,024,740     770,420  

Net income attributable to non-controlling interests

    1,558     789     1,600     1,656     2,907     3,877     3,894  

Earnings per share:

                                           

Basic earnings per share

  $ 0.156   $ 0.489   $ 0.644   $ 1.024   $ 1.182   $ 0.810   $ 0.610  

Diluted earnings per share

  $ 0.156   $ 0.489   $ 0.644   $ 1.024   $ 1.177   $ 0.806   $ 0.608  

Weighted average number of ordinary shares outstanding:

                                           

Basic

    1,270,431     1,270,397     1,270,414     1,270,009     1,267,699     1,264,425     1,262,991  

Diluted

    1,270,431     1,270,397     1,270,414     1,270,117     1,272,945     1,271,598     1,266,398  

Cash Flow Data:

   
 
   
 
   
 
   
 
   
 
   
 
   
 
 

Net cash provided by operating activities

  $ 286,806   $ 616,826   $ 1,126,909   $ 1,727,218   $ 1,358,744   $ 1,565,958   $ 1,225,442  

Net cash used in investing activities

    (506,559 )   (390,931 )   (839,332 )   (740,709 )   (625,529 )   (679,052 )   (463,768 )

Net cash provided by (used in) financing activities

    209,989     (190,497 )   (309,990 )   (1,018,624 )   (833,666 )   (725,088 )   (726,686 )

 

17


Table of Contents

 

 
  As of
June 30,
  As of December 31,  
 
  2014   2013   2012   2011   2010   2009  
 
  (in thousands of U.S. dollars)
   
 

Balance Sheet Data:

                                     

Cash and cash equivalents

  $ 177,777   $ 188,340   $ 206,067   $ 238,141   $ 354,654   $ 198,787  

Property, plant and equipment

    3,917,512     3,686,240     3,097,385     2,615,420     2,182,647     2,087,444  

Total assets

    8,436,149     7,973,485     7,344,911     6,963,674     6,184,818     5,702,616  

Short-term credit and current portion of long-term debt

    858,671     718,284     552,062     361,578     47,804     81,663  

Long-term debt

    1,782,082     1,243,638     916,594     847,006     844,168     555,204  

Debentures

    275,000     67,000     228,708     485,470     528,728     503,794  

Total equity

    3,155,832     3,678,674     3,388,264     3,090,251     2,644,390     2,794,849  

 

 
  Six Months
Ended June 30,
  Year Ended December 31,  
 
  2014   2013   2013   2012   2011   2010   2009  
 
  (in thousands of U.S. dollars)
 

Other Data:

   
 
   
 
   
 
   
 
   
 
   
 
   
 
 

Adjusted EBITDA (1)

    $682,230   $ 926,454   $ 1,568,492   $ 1,945,042   $ 2,225,058   $ 1,610,590   $ 1,255,946  

(1)
We disclose in this prospectus a financial measure titled Adjusted EBITDA. We use Adjusted EBITDA to facilitate operating performance comparisons from period to period. Adjusted EBITDA is defined as our income to Company shareholders plus depreciation and amortization plus financing expenses, net and taxes on income plus items we view as unusual.

We believe Adjusted EBITDA facilitates company-to-company operating performance comparisons by backing out potential differences caused by variations such as capital structures (affecting financing expenses, net), taxation (affecting taxes on income) and the age and book depreciation of facilities and equipment (affecting relative depreciation and amortization), which may vary for different companies for reasons unrelated to operating performance. Adjusted EBITDA is a non-IFRS measure for reporting our total Company performance. Our management believes, however, that disclosure of Adjusted EBITDA provides useful information to investors, financial analysts and the public in their evaluation of our operating performance. Adjusted EBITDA should not be considered as the sole measure of our performance and should not be considered in isolation from, or as a substitute for, operating income or other statement of operations or cash flow data prepared in accordance with IFRS as a measure of our profitability or liquidity. Adjusted EBITDA does not take into account our debt service requirements and other commitments, including capital expenditures, and, accordingly, is not necessarily indicative of amounts that may be available for discretionary uses. In addition, Adjusted EBITDA, as presented in this prospectus, may not be comparable to similary titled measures reported by other companies due to differences in the way that these measures are calculated.

 

18


Table of Contents

    The table below reconciles Adjusted EBITDA to the IFRS measure, income to Company shareholders:


 
  Six Months
Ended June 30,
  Year Ended December 31,  
 
  2014   2013   2013   2012   2011   2010   2009  
 
   
   
  (in thousands of U.S. dollars)
 

Income to Company shareholders

    198,502     621,521     818,573     1,300,076     1,498,151     1,024,740     770,420  

Depreciation and amortization

    177,346     163,928     347,741     322,511     315,625     254,081     229,311  

Finance expenses, net

    69,377     17,877     26,855     60,894     77,812     60,187     1,477  

Taxes on income

    63,305     123,128     280,023     217,561     333,470     261,579     166,238  

Unusual items, net (a)

    173,700         95,300     44,000         10,000     88,500  
                               

Adjusted EBITDA

  $ 682,230   $ 926,454   $ 1,568,492   $ 1,945,042   $ 2,225,058   $ 1,610,590   $ 1,255,946  

(a)
Unusual expense in the first half of 2014 consists mainly of approximately $23 million of costs caused by the strike at our Rotem subsidiary and approximately $149 million in respect of a provision relating to prior periods due to the partial arbitration award in the Royalties Arbitration (before interest expenses and the tax impact). Unusual expense in 2013 includes $60 million of early retirement expense at our Rotem subsidiary in Israel from an early retirement program and a $25 million increase in a waste removal provision and $10 million asset write-down in our Industrial Products segment. Unusual expense in 2012 includes $33 million of early retirement expense at Rotem and $22 million of early retirement expense in our Industrial Products segment, offset by $11 million of unusual income due to a VAT refund. Unusual expense in 2010 includes an expense relating to a malfunction at our sulfuric acid plant. Unusual expense in 2009 includes an early retirement expense and an expense relating to a plant shutdown in our Performance Products segment.

        The following table reconciles Adjusted EBITDA for the year ended December 31, 2013 for each of our operating segments to operating income, which is the most similar IFRS measure:

 
  Fertilizers   Industrial
Products
  Performance
Products
  Other   Eliminations (a)  
 
  (in thousands of U.S. dollars)
 

Operating income

    821,071     114,525     195,797     (16,574 )   10,632  

Depreciation and amortization

    218,428     75,071     46,580     6,323     1,339  

Unusual items, net (b)

    60,200     35,100              

Adjusted EBITDA

    1,099,699     224,696     242,377     (10,251 )   11,971  

(a)
Represents elimination of intercompany transactions, and share in earnings of equity accounted investees.

(b)
Unusual expense in our Fertilizers segment includes an early retirement expense at Rotem. Unusual expense in our Industrial Products segment includes a $25 million increase in a waste removal provision and $10 million asset write-down.

 

19


Table of Contents


RISK FACTORS

         Our business, financial condition and results of operations could be materially and adversely affected if any of the risks described below occur. As a result, the market price of our ordinary shares could decline, and you could lose all or part of your investment. This prospectus also contains forward-looking statements that involve risks and uncertainties. See "Special Note Regarding Forward-Looking Statements." Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors, including the risks facing our Company or investments in the Middle East and Europe described below and elsewhere in this prospectus.


Risks Related to Our Business

Our mining operations are dependent on concessions, licenses and permits granted to us by the respective governments in the countries where they are located.

        Our mining business depends on concessions granted to us by the respective governments in the countries in which our mining operations are located. Loss or impairment of these concessions could materially and adversely affect our business, financial condition and results of operations.

        We extract potash and sodium chloride in Israel, Spain and the United Kingdom and bromine, magnesium and certain other minerals in Israel pursuant to concessions and licenses in those countries. In Israel, the concession granted by the government to utilize the resources of the Dead Sea ends on March 31, 2030. As consideration, we pay royalties to the Israeli government. In Spain, the government granted our Fertilizers segment mining rights based on legislation from 1973. Some of these licenses are valid until 2037 and the rest are valid until 2067. In exchange for these licenses, we pay royalties to the Spanish government. In the United Kingdom, the mining concession of Cleveland Potash is based on approximately 114 mining leases and concessions for extracting various minerals, in addition to numerous easements and rights of way from private land owners and rights to mine in the North Sea granted by the United Kingdom. The terms of all of these leases, concessions, easements and rights of way extend for periods ranging from 2015 to 2038. See "Business—Mineral Extraction and Mining Operations—Concessions and Mining Rights."

        Furthermore, we mine phosphate rock from phosphate deposits in the Negev Desert in accordance with three concessions from the State of Israel valid up to the end of 2021. In exchange for these concessions, we are required to pay royalties to the Israeli government.

        In addition to our existing phosphate mines in the Negev Desert, which we estimate have up to approximately eight years of remaining reserve life for phosphate rock and phosphoric acid production, our plan for mining phosphates in Barir field (South Zohar) in the Negev is in the planning approval stages, and it has not yet been decided whether to file the plan with the proper authorities. Residents of the surrounding towns and villages and the Bedouin settlement in the area have objected to the filing of the plan and continuation of the related planning stages, due to the fear of environmental and health dangers they contend will be caused as a result of operation of the mine. While we believe the mining activities in Barir field do not involve any risks to the environment or to people, others may reach contrary conclusions. After an expert appointed by the Israeli Ministry of the Prime Minister expressed his opinion that there is no health hazard in the Barir field, the Israeli Ministry of Health appointed an expert on its behalf to examine the matter before the Israeli Ministry of Health formulates an opinion. On April 3, 2014, we learned that the Israeli Ministry of Health had received the opinion of its expert and, after reading the opinion, the Israeli Ministry of Health decided to oppose mining, including exploratory mining, in the Barir field. We disagree with the Israeli Ministry of Health's interpretation of this opinion. Based on our understanding of this opinion, we believe this opinion does not contradict our position that the mining activities in Barir field do not involve any risks to the environment or to people. The residents of nearby towns are continuing to object to advancement of the mining plan and even to mining tests. Non-receipt of approval to mine in the Barir field will significantly harm our future mining reserves in the medium and

20


Table of Contents

long term. If we fail to receive such approval and cannot find alternative sources of phosphates, our business, financial condition and results of operations may be materially and adversely affected.

        Our ability to operate and/or expand our production and operating facilities is dependent on our receipt of, and compliance with, permits issued by governmental authorities, including authorities in Israel, Spain and the United Kingdom. A decision by a government authority to deny any of our permits applications may impair our business and operations.

        In addition, existing permits are subject to challenges with respect to their validity, revocation, modification and non-renewal. Any successful challenges with respect to the validity of our permits or the revocation, modification or non-renewal of our permits could materially adversely impact our operations and financial condition. In addition, a failure to comply with the terms of our permits could result in payment of substantial fines and subject us to criminal sanctions.

The locations of some of our mines and facilities expose us to various natural disasters.

        We are exposed to natural disasters, such as flooding and earthquakes, that may cause material damage to our business.

        In Israel, some of our plants are located on the African-Syrian Rift, a seismically active area. In recent years sinkholes and underground cavities have been discovered in the area of the Dead Sea, which could cause harm to our plants. In the area of Sodom, where many of our plants are located, there are occasional flash floods in the stream-beds. While we have insurance coverage that covers these types of damage, subject to payment of deductibles, the insurance may not be sufficient to cover all of these damages.

        In addition, we have underground mines in the United Kingdom and Spain. Water leakages into these mines might cause disruptions to mining or loss of the mine. We do not have property insurance for the underground property of our mine in the United Kingdom.

The accumulation of salt at the bottom of Pond 5, the central evaporation pond in our solar evaporation pond system used to extract minerals from the Dead Sea, requires the water level of the pond to be constantly raised in order to maintain the production capacity of our fertilizers.

        As part of the evaporation process, salt in Pond 5 at the Dead Sea (which is the main evaporation pond in our system of solar ponds) is sinking at the rate of about 20 million tons per year. Sinking of the salt causes a reduction of the brine volume in the pond. Our production process requires that a fixed brine volume be preserved in the pond. For this purpose, the water level of the pond is raised by approximately 20 centimeters annually. Failure to raise the water level by this amount will cause a reduction in our production capacity. However, raising the water level of the pond above a certain level is likely to cause structural damage to the foundations and the hotel buildings situated close to the water's edge and to other infrastructure on the western shoreline of Pond 5.

        We are currently working with the Israeli government to develop various temporary defenses and a permanent solution, which consists of full harvesting of the salt in such a manner that raising the water level in Pond 5 will not be necessary after completion of the harvesting. The temporary defenses are supposed to provide protection pending the implementation of a permanent solution, which is supposed to provide protection until the end of the current concession period in 2030. According to the Dead Sea Protection Company, the total cost of the salt harvesting is estimated, as of October 2010, to be an undiscounted amount of NIS 7 billion (a discounted amount of NIS 3.8 billion). The Israeli government will bear up to 20% of the cost of the salt harvesting. The Israeli government's maximum commitment (20% of NIS 3.8 billion, the discounted amount) is linked to the CPI and bears interest at the rate of 7%. See "Business—Mineral Extraction and Mining Operations" for more information about these temporary defenses and the proposed permanent solution. There is no assurance that the temporary defenses or the permanent solution will be fully implemented or, if implemented, that they will prevent damage to the

21


Table of Contents

surrounding infrastructure or our operations at Pond 5. The failure to develop a solution or any such damage could materially and adversely affect our business, financial condition and results of operations.

A new pumping station will be required due to the receding water level of the Dead Sea.

        As part of our production process in Israel, we pump water from the Dead Sea through a special pumping station and deliver it to the salt and carnallite ponds. Due to the receding water level of the Dead Sea, the water line is receding from the current pumping station and construction of a new pumping station is necessary. Construction of the new station depends on, among other things, receipt of statutory approvals. We have set up a designated team to advance the required processes and to monitor the various developments that could impact receipt of the statutory approvals. A failure to construct the new pumping station on time may impair our ability to pump the required amount of raw material from the Dead Sea.

        In addition, as the water level of the Dead Sea recedes, we may be pressured to reduce our usage of minerals from the Dead Sea, which could have a material and adverse impact on our business, financial condition and results of operations.

Any disruption in the transportation services we use to ship our products could have a material adverse effect on our business, financial condition and results of operations.

        Approximately one-half of our net sales are sales of bulk products characterized by large quantities. Most of this production quantity is shipped from two seaports in Israel from dedicated facilities. It is not possible to ship large quantities in bulk from other facilities. Any significant disruption with regard to the seaport facilities, including due to strikes by port workers or regulatory restrictions, could delay or prevent exports of our products to our customers overseas, which could materially and adversely affect our business, financial condition and results of operations.

As a multinational company, we are exposed to fluctuations in currency exchange rates.

        Our multinational activities expose us to the impact of currency exchange rate fluctuations. Our financial statements are prepared in U.S. dollars. Our sales are made in a variety of currencies, primarily in U.S. dollars and euros. The portion of our sales made in currencies other than the U.S. dollar exposes us to fluctuations in the exchange rates of these currencies against the U.S. dollar. The functional currency of most of our foreign subsidiaries outside Israel and the United States is the local currency; therefore, the revenue and expenses of these companies in the local non-U.S. dollar currency do not represent exposure. On the other hand, revenues and expenses of these companies denominated in U.S. dollars expose these companies to fluctuations in currency exchange rates of the U.S. dollar against their functional currencies.

        A portion of our expenses in Israel are incurred and paid in NIS. Therefore, we are exposed to strengthening of the currency exchange rate of the NIS relative to the U.S. dollar (i.e., an appreciation of the NIS). Our strategy is to partially hedge against the exposure described above according to market conditions and projections regarding developments in currency exchange rates. See "Management's Discussion and Analysis of Financial Condition and Results of Operations—Quantitative and Qualitative Disclosures About Market Risk—Exchange Rate Risk."

Because some of our liabilities bear interest at variable rates, we are subject to the risk of interest rate increases.

        A portion of our liabilities bear interest at variable rates. We are exposed to the cash flow risk stemming from an increase in interest rates, which would increase our financing expenses and adversely affect our results. See "Management's Discussion and Analysis of Financial Condition and Results of Operations—Quantitative and Qualitative Disclosures About Market Risk—Interest Rate Risk."

22


Table of Contents

We are subject to risks associated with our international sales and operations, which could negatively affect our sales to customers in foreign countries as well as our operations and assets in foreign countries. Some of these factors may also make it less attractive to distribute cash generated by our operations outside Israel to our shareholders, to use cash generated by our operations in one country to fund our operations or repayments of indebtedness in another country or to support other corporate purposes.

        In 2013, we derived approximately 95% of our sales from customers located outside Israel. As a result, we are subject to numerous risks and uncertainties relating to international sales and operations, including:

        The occurrence of any of the above in the countries in which we operate or elsewhere could jeopardize or limit our ability to transact business there and could adversely affect our revenue and operating results and the value of our assets located outside Israel.

        In addition, tax regulations, currency exchange controls and other restrictions may also make it economically unattractive to utilize cash generated by our operations in one country to fund our operations or repayments of indebtedness in another country or to support other corporate purposes.

Some of our employees have pension and health insurance arrangements that are our responsibility.

        Some of our employees in Israel and overseas have pension and health insurance arrangements that are our responsibility. Against some of these liabilities, we have monetary reserves that are invested in financial assets. See note 21 to our audited financial statements for information about our employee benefits liabilities and composition of plan assets. Changes in life expectancy, changes in the capital market or changes in other parameters by which undertakings to employees and retirees are calculated, and statutory amendments could increase our net liability for these arrangements.

We could be adversely affected by price increases or shortages with respect to our principal raw materials.

        We use water, energy and various raw materials as inputs and we could be affected by higher costs or shortages of these materials.

        Our phosphate facilities use large quantities of water purchased from the Mekorot Company, Israel's national water company, at prices set by the government. If these prices rise significantly, our costs will rise as well. In our plants in Sodom, we obtain water from an independent system that is not part of the national water system. A shortage of water in the water sources in proximity to the plants would force our Fertilizers segment to seek water sources located further away at higher cost.

        Our plants consume large amounts of energy. Significant price increases for energy, or energy shortages, in Israel would affect production costs and/or quantities. The production processes and facilities at our magnesium plant require a continuous supply of electricity. While our magnesium plant has two power supply sources—our power station in Sodom and the national electricity network—there is no assurance that power supply from these two sources could not both be damaged. Prolonged damage to the regular supply of electricity may damage the plants and the environment. In addition, the current supply of

23


Table of Contents

gas to our subsidiaries in Israel is dependent on a single supplier and also on a single gas pipeline with limited transmission capacity. While our plants are prepared for the use of alternative energy (fuel oil and/or diesel), an increase in our energy costs, or energy shortages could materially and adversely affect our business, financial condition and results of operations.

        In addition, an increase in price or shortage of raw materials, such as sulfur (which we purchase from a third party) could reduce our margins and adversely impact our results of operations and our business.

        We can provide no assurance that we will be able to pass through increased costs relating to water, energy or other raw materials, such as sulfur, that we must source from third parties. Our inability to efficiently and effectively pass through cost increases could adversely affect our margins. In addition, shortages in our principal raw materials may disrupt production and adversely affect the performance of our business.

The construction of a canal connecting the Red Sea to the Dead Sea could negatively impact the production of our plants.

        A draft of the final World Bank report evaluating the feasibility of a canal from the Red Sea to the Dead Sea in order to address the shrinking of the Dead Sea was recently published and Israel, the Palestinian Authority and Jordan have signed an agreement to implement a similar but much smaller project involving construction of a pipeline from the Red Sea. The objective of the canal is to desalinate water for countries in the region (mainly Jordan), stabilize the level of the Dead Sea and contribute to regional peace. Such a canal would likely change the composition of the Dead Sea, which could negatively impact the production of our plants.

We are subject to the risk of labor disputes, slowdowns and strikes.

        From time to time we experience labor disputes, slowdowns and strikes. For example, we recently underwent a strike at our Rotem subsidiary in Israel. We may face additional labor disputes in the future, particularly if we seek to reduce costs or shut down certain plants or assets as part of our review of our plans in Israel, as described under "Prospectus Summary—Recent Developments," or other initiatives. For example, we are aware that unionized employees at certain of our facilities object to some of our existing cost cutting initiatives and are seeking to challenge such initiatives. Most of our employees are subject to collective bargaining agreements. Lengthy slowdowns or strikes at any of our plants could disrupt production and prevent delivery of products that had already been ordered, and it takes time to return to full capacity production in all facilities. If labor disputes, slowdowns or strikes occur, we could incur significant shutdown and related costs, which could adversely impact our operating results and affect our ability to fully implement future operational changes to enhance our efficiency. Moreover, due to the interdependency of our plants, slowdowns or strikes in any one of our plants could have a material impact on us. See "Business—Employees."

Our operations and sales are subject to the volatility of market supply and demand and we face significant competition from some of the world's largest chemical companies.

        In addition to seasonal and cyclical variations (mainly in our Fertilizers segment), some of our businesses are characterized by fluctuations caused, in part, by factors on the supply side, such as entry into the market of new manufacturers and products and expansion of the production capacity of existing manufacturers, as well as changes on the demand side. Some of our products are commodities that are available from multiple sources. Our competitors include some of the world's largest chemical companies. Some of these companies are state-owned or government-subsidized. The primary competitive factor with respect to our products is price. Our prices for our products are impacted by the prices prevailing in the market. At the end of July 2013, Uralkali announced that it was discontinuing its joint marketing with Belaruskali (Uralkali and Belaruskali are the leading potash producers in Russia and Belarus). In addition,

24


Table of Contents

it was reported in the media that Uralkali would implement a new policy in potash sales of preferring quantity over price. We believe this announcement led to a fall in potash prices. Additional competitive factors include product quality, customer service and technical assistance. If we are unable to compete effectively with these companies, our results of operations would almost certainly be adversely affected.

A committee established by the Israeli finance minister is currently considering higher taxes and royalties on our operations.

        The Israeli Minister of Finance, Mr. Yair Lapid, has established a public committee, headed by Prof. Eytan Sheshinski, for examination of the policy with respect to the royalties received by the State of Israel from private entities, including us, for use of national natural resources such as potash and phosphate. The committee is required, among other things, to examine the royalties policy from a broad perspective, while making reference to the impacts on the present agreements between the various parties engaged in these matters and the State of Israel. A similar committee established in 2011 for the oil and gas industries concluded that the tax and royalty rates should be increased significantly. If the committee determines that the taxes and royalties we pay should be increased and the Israeli government agrees, it could have a material adverse effect on us. On November 4, 2013, we submitted our position in writing to the committee. Our request, dated December 3, 2013, to exclude this matter from the committee's jurisdiction was denied by the Minister of Treasury. On May 18, 2014, the committee released its draft recommendations for public comment. The principal draft recommendations are as follows:

On July 17, 2014, we submitted our response, in writing, to the Committee's Interim Recommendations, and on August 4, 2014, we orally presented our position to the Sheshinski Committee. See "Prospectus Summary—Recent Developments" and "Business—Mineral Extraction and Mining Operations—Concessions and Mining Royalties." We intend, with the assistance of our legal advisors, to take all necessary legal actions in order to protect our rights. On August 6, 2014, our Board of Directors discussed the impact of the Committee's Interim Recommendations and the Royalties Arbitration, as well as the need to implement cost-cutting and efficiency plans, and resolved to take certain actions described in "Prospectus Summary—Recent Developments."

25


Table of Contents

        For information regarding Dead Sea Works's commencement of an arbitration proceeding in connection with what we view as the Israeli government's breach of our concession agreement with respect to the Dead Sea due to its convening of this committee, see note 23 to our audited financial statements. On March 27, 2014, the Israeli Ministry of Finance notified Dead Sea Works that it has rejected its request to appoint an arbitrator on behalf of the State of Israel. The Israeli Ministry of Finance contends that the establishment of the committee falls with the State of Israel's administrative authorities and does not constitute a disagreement or dispute between the parties according to the concession agreement. The State of Israel further argues that an arbitration panel is not the appropriate forum for challenging the establishment of the committee and its work and that the establishment of the committee does not fall under the relevant clause in respect of which the parties may turn to arbitration. On April 30, 2014, Dead Sea Works filed a request in the Jerusalem District Court that such court order the appointment of an arbitrator on behalf of the State of Israel for the purpose of managing the arbitration process between Dead Sea Works and the State of Israel in accordance with the binding arbitration arrangements between the parties. A court hearing was held on July 10, 2014 but the Court's decision has not yet been received. See "Business—Legal Proceedings—Dead Sea Works Proceedings."

Inaccuracies in our estimates of mineral reserves and resource deposits could result in lower than expected sales and higher than expected costs.

        We base our mineral reserve and resource estimates on engineering, economic and geological data assembled and analyzed by our engineers and geologists, which are reviewed by outside firms. However, reserve estimates are necessarily imprecise and depend to some extent on statistical inferences drawn from available drilling data, which may prove unreliable. There are numerous uncertainties inherent in estimating quantities and qualities of reserves and non-reserve deposits and costs to mine recoverable reserves, including many factors beyond our control. Estimates of economically recoverable commercial reserves necessarily depend on a number of factors and assumptions, all of which may vary considerably from actual results, such as:

        Any inaccuracy in our estimates related to our mineral reserves and non-reserve mineral deposits could result in lower than expected sales and higher than expected costs.

We intend to expand our business through acquisitions and various initiatives to increase production and reduce costs at our existing operations. This could result in a diversion of resources and extra expenses, a disruption of our business and an adverse effect on our financial condition and results of operations.

        One of the components of our strategy is to pursue acquisitions of businesses or to enter into joint ventures. The negotiation process with respect to potential acquisitions or joint ventures, as well as the integration of acquired or jointly developed businesses, will require management to invest time and resources, in addition to the necessary financial investments. There is no guarantee that the acquired businesses or joint ventures will be successfully integrated with our products and operations and we may not realize the intended benefits of the acquisition or joint venture.

        Future acquisitions could result in:

26


Table of Contents

        If future acquisitions disrupt our operations, our business may be materially and adversely affected.

        In addition, we are working on a number of initiatives to improve our existing operations, including initiatives to increase production in Spain and Israel and reduce operating costs at our facilities. These initiatives may cost more or take longer than we anticipate and we may not be able to achieve our goals. If we cannot do so, our competitive position could be adversely affected. See "Prospectus Summary—Our Strategy—Continuously improve the cost position of our distinctive mineral asset base" and "—Streamline and integrate our global processes."

Our tax liabilities may be higher than expected.

        We are subject to taxes in many jurisdictions, and discretion is required in determination of the provisions for our tax liability. Similarly, we are subject to examination by tax authorities in many different jurisdictions. As part of these examinations, the relevant tax authorities may disagree with the amount of taxable income, as stated, deriving from our inter-company agreements and may also dispute our interpretation of the applicable tax legislation. For example, the tax authorities in Israel issued an assessment to us demanding that we pay additional tax in the amount of approximately $230 million in respect of the years 2009 to 2011. See note 20 to our audited financial statements. Even though we believe our estimates are reasonable, the final outcome of these examinations and any related legal proceedings may be different than the provisions that we record in respect of our tax liability and may have a significant impact on our results of operations. No tax expenses were included in our financial statements in connection with this assessment.


Risks Related to Our Industry

Our operations and sales are subject to a crisis in the financial markets.

        We are a multinational company and our financial results are affected by global economic trends, the changes in terms of trade and financing, and fluctuations of currency exchange rates. A crisis in the financial markets could cause a reduction in the international sources of credit available for the purpose of financing commercial operations. The impact of such a crisis might be expressed in terms of availability of credit to us and our customers, and of the price of credit. In addition, the volatility and uncertainty in the European Union affect our activities in this market.

Sales of our fertilizer products are subject to the condition of the agricultural industry.

        Most of our fertilizer products are sold to producers of agricultural products. Fertilizer sales may be adversely impacted as a result of a decline in agricultural produce prices or the availability of credit, or other events that cause farmers to plant less and consequently reduce their use of fertilizers. For example, periods of high demand, increasing profits and high capacity utilization tend to lead to new investment in crops and increased production. This growth increases supply until the market is over-saturated, leading to declining prices and declining capacity utilization until the cycle repeats. As a result, the prices and volumes of fertilizer products have been volatile. This price and volume volatility may cause our results of operations to fluctuate and potentially deteriorate. The price at which we sell our fertilizer products and our sales volumes could fall in the event of industry oversupply conditions, which could have a material adverse effect on our business, financial condition and results of operations. In contrast, high prices may lead our customers to delay purchasing decisions in anticipation of future lower prices, thereby decreasing

27


Table of Contents

our sales volumes. These phenomena could materially and adversely affect our business, financial condition and results of operations.

        In addition, government policies, and specifically, subsidy levels, may affect the amount of agricultural crops and, as a result, sales of our fertilizer products. Generally, reductions in agricultural subsidies or increases in subsidies to local fertilizer manufacturers in a country where we sell our products are likely to have a negative impact on our fertilizer business.

        Finally, the agricultural industry is strongly affected by local weather conditions. Conditions such as heavy storms, long periods of drought, floods, or extreme seasonal temperatures are likely to affect the local crop's quality and yield and cause a reduction in the use of fertilizers. Loss of sales in an agricultural season in a target country as a result of weather-related events can cause a loss of sales for the whole year.

Sales of our industrial products are affected by various factors that are not within our control, including developments in the electronics markets and legislative changes impacting the use of our products.

        Our industrial products accounted for 20.7% of our sales (before set-offs of inter-segment sales) in 2013. Our sales of these products are dependent on various factors outside our control. For instance, a large proportion of our industrial products are sold for use as flame retardants. This area is subject to government regulation around the world, which can restrict certain uses of flame retardants. In addition, various "green" organizations have been increasing their pressure to reduce the use of bromine-based flame retardants, and various countries are assessing possible limitations on the use of bromine-based flame retardants. The European Union has already banned the bromine-based flame retardant DECA for use in electrical and electronic applications, and it is likely that DECA will be prohibited for all uses in the European Union in 2017 at the earliest. See "Business—Regulatory and Environmental, Health and Safety Matters." Sale of completion fluids depends on the extent of operations in the oil drilling market, mainly in deep drillings in the high seas, which in turn is dependent on fuel prices, and on the decisions of oil companies regarding rates of production and areas of production of oil and gas.

        In addition, a large portion of our industrial products are used as inputs for end-products. For example, a significant portion of our flame retardants are added to plastic components in electronic devices, including personal computers and televisions. The slowdown of the global economy in recent years as well as the increasing use of smart phones and tablets as opposed to personal computers have led to a decline in the demand for personal computers, which in turn has caused a decline in the demand for bromine-based flame retardants sold by our Industrial Products segment. Beginning in late 2012, there was also a slump in demand for bromine-based flame retardants for construction. Our strategy is to attempt to increase the demand through development of new products and new applications, by introducing bromine products such as flame retardants into new geographic areas where they are not currently used or to develop their use as part of new applications. A failure to increase demand for our bromine-based products could have a material adverse effect on our business, financial condition and results of operations.

Sales of our performance products are affected by various factors that are outside our control, including a recession or slowdown in the world economy as well as an increase in the euro exchange rate vis-à-vis the U.S. dollar.

        Sales of our performance products are affected by various factors that are outside our control, including general economic conditions in the markets where we operate. For example, our sales may be affected by the slow economic recovery or any reversal thereof in Europe. We have significant manufacturing operations in Europe and a large portion of our European sales are in euros, whereas some of our competitors are manufacturers outside Europe whose operational currency is the U.S. dollar. As a result, the revaluation of the euro exchange rate vis-à-vis the U.S. dollar increases the competitive advantage of these competitors.

28


Table of Contents

As an industrial chemicals company, we are subject to various legislative and licensing restrictions in Israel and throughout the world in the areas of environmental protection and safety. Related compliance costs and hazards inherent to the nature of our business may have a negative effect on our results of operations.

        Because we are active in the field of industrial chemicals, we are significantly affected by legal rulings and licensing authorities in the areas of environmental protection and safety. In recent years, there has been a significant increase in the stringency and enforcement of legislative directives and regulatory requirements in these areas, in Israel and throughout the world, and the cost of compliance has risen significantly. Additionally, legislative changes throughout the world may prohibit or restrict use of our products, due to environmental protection, health or safety considerations. Standards that will be adopted in the future are likely to affect us and change our methods of operation. Furthermore, some of our licenses, including business licenses and mining licenses, are for fixed periods and must be renewed from time to time. Renewal of the licenses is not certain and the renewal may be made contingent on additional conditions. See "Business—Regulatory and Environmental, Health and Safety Matters."

        In addition, although we take precautions to enhance the safety of our operations and minimize the risk of disruptions, we are subject to hazards inherent in chemical manufacturing and the related storage and transportation of raw materials, products and wastes. These hazards include explosions, fires, mechanical failures, remediation complications, chemical spills and discharges or releases of toxic or hazardous substances. These and other hazards are also inherent in our mining operations, particularly underground mining. These hazards can cause personal injury and loss of life, severe damage to or destruction of property and equipment and environmental damage, and may result in suspension of operations and the imposition of civil or criminal penalties. In addition, our manufacturing facilities contain sophisticated manufacturing equipment. In the event of a major disruption in the operations of any of this equipment, we may not be able to resume manufacturing operations for an extended period of time. The occurrence of material operating problems at our facilities, including, but not limited to, the events described above, may have a material adverse effect on us, during and after the period of such operational difficulties, as we are dependent on the continued operation of our production facilities and we may become subject to substantial liabilities related to these circumstances.

Due to the nature of our Company, we are exposed to administrative and legal proceedings, both civil and criminal, including as a result of alleged environmental contamination caused by certain of our facilities.

        From time to time we are exposed to administrative and legal proceedings, both civil and criminal, including as a result of alleged environmental contamination caused by certain of our facilities. In addition, from time to time examinations and investigations are conducted by enforcement authorities in and outside Israel. See "Business—Legal Proceedings."

        Furthermore, we are from time to time exposed to claims alleging physical or property damage, which may cause us financial harm. In addition, some of the manufacturing or marketing activities (and sometimes transportation and storage as well) entail safety risks that we attempt to minimize but are not able to eliminate. In various countries, including Israel and the United States, legislation exists that can impose liability on us irrespective of our actual intent or negligence. Other laws place responsibility on defendants jointly and severally, and sometimes retroactively, and therefore can cause us to be liable for activities done jointly with others and at times by others. We may also be found liable for claims related to land that we mined or activities that we conducted within our premises, after such activities have ceased.

        In addition, over the past several years, there has been an increase in the filing of claims together with a request for their certification as class actions. Due to the nature of class actions, these claims may be for very high amounts and the costs of defending against such actions may be significant even if the claims are without merit. In addition, our insurance policies include coverage limitations, are restricted to certain causes of action and may not cover claims relating to certain types of damages. In August 2013, a request was filed in the District Court of Tel Aviv for certification of a claim as a class action against us, Israel Corporation, PotashCorp Cooperative Agricultural Society Ltd., the members of our Board of Directors

29


Table of Contents

and our Chief Executive Officer. The aggregate amount of the damages claimed is NIS 2.75 billion or NIS 3.28 billion (depending on the share price used to calculate the alleged damages). We have not made a provision for this claim in our audited financial statements. See note 23 to our audited financial statements and "Business—Legal Proceedings—Securities Law Proceedings" for additional information.

We are exposed to the risk of third-party and product liability claims.

        We are also exposed to risk of liability related to damage caused to third parties by our operations or by our products. For example, we are subject to a number of claims alleging bodily injury as a result of discharges to the Kishon River and of various pollutants in the vicinity of our Neot Hovav plants. We are also subject to claims alleging liability for the impacts from the rising water level at one of our evaporation ponds at the Dead Sea. See note 23(C) to our audited financial statements. We have third-party liability insurance for damages caused by our operations and for product liability. However, there is no certainty that this insurance will fully cover all damage for such liability. Likewise, sale of faulty products by us might give rise to recall of products by us or by our customers that used the products.

Our insurance policies may not be sufficient to cover all actual losses that we may incur in the future.

        We maintain property, environmental, business interruption and casualty insurance policies, but we are not fully insured against all potential hazards and risks incident to our business. We are subject to various self-retentions and deductibles under these insurance policies. As a result of market conditions, our loss experience and other factors, our premiums, self-retentions and deductibles for insurance policies can increase substantially and, in some instances, certain insurance may become unavailable or available only for reduced amounts of coverage. In addition, significantly increased costs could lead us to decide to reduce, or possibly eliminate, coverage. As a result, a disruption of operations at one of our key facilities or a significant casualty could have a material adverse effect on our financial condition and results of operations.


Risks Related to Our Operations in Israel

Due to our location in Israel, our operations may be subject to war or acts of terror.

        War or acts of terror in the locations where we operate are likely to negatively impact us. This impact may manifest itself in production delays, distribution delays, loss of property, injury to employees, and appreciation of insurance premiums. In addition, our plants are more likely to be targets of terrorist acts due to the chemicals they store. We do not have property insurance against war or acts of terror, other than compensation from the State of Israel pursuant to Israeli law, which covers only physical property damage, without accounting for reinstatement values.

        Since the construction of our initial facilities in the 1950s, we have never experienced material business interruptions as a result of war or acts of terror (including the recent conflict between Israel and Hamas in Gaza), but we can provide no assurance that we will not be subject to any such interruptions in the future.

        Our computer network and production technologies constitute a basic platform for operational continuity and are also potential targets for acts of terror. Potential cyber threats can cause damage to systems, data loss, software vulnerability and external and internal access to sensitive and confidential information. We have implemented a plan for safeguarding and backing up the information systems. The activities include: separation of the information networks from the computerized process systems, physical safeguarding of the computer rooms and terminals and training of employees. However, there is no assurance that our plan will successfully accomplish its goals.

30


Table of Contents

We conduct operations in Israel and therefore our business, financial condition and results of operations may be materially and adversely affected by political, economic and military instability in Israel and its region.

        Our headquarters, some of our operations, and some of our mining facilities are located in central Israel and many of our key employees, directors and officers are residents of Israel. Accordingly, political, economic and military conditions in Israel and the surrounding region may directly affect our business. Since the establishment of Israel in 1948, a number of armed conflicts have taken place between Israel and its Arab neighbors, Hamas (an Islamist militia and political group in the Gaza Strip) and Hezbollah (an Islamist militia and political group in Lebanon). Any hostilities involving Israel or the interruption or curtailment of trade within Israel or between Israel and its trading partners could materially and adversely affect our business, financial condition and results of operations and could make it more difficult for us to raise capital (although the recent conflict between Israel and Hamas in Gaza has not had a material effect on our business, financial condition or results of operations). Recent political uprisings, social unrest and violence in various countries in the Middle East and North Africa, including Israel's neighbors Egypt and Syria, are affecting the political stability of those countries. This instability may lead to deterioration of the political relationships that exist between Israel and these countries and have raised concerns regarding security in the region and the potential for armed conflict. In addition, Iran has threatened to attack Israel and is widely believed to be developing nuclear weapons. Iran is also believed to have a strong influence among parties hostile to Israel in areas that neighbor Israel, such as the Syrian government, Hamas in Gaza and Hezbollah in Lebanon. Any armed conflicts, terrorist activities or political instability in the region could materially and adversely affect our business, financial condition and results of operations. In addition, the political and security situation in Israel may result in parties with whom we have agreements involving performance in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant to force majeure provisions in such agreements.

Our operations may be disrupted as a result of the obligation of Israeli citizens to perform military service.

        Many Israeli citizens are obligated to perform one month, and in some cases more, of annual military reserve duty until they reach the age of 45 (or older, for reservists with certain occupations) and, in the event of a military conflict, may be called to active duty. In response to terrorist activity, there have been periods of significant call-ups of military reservists. It is possible that there will be military reserve duty call-ups in the future. Our operations could be disrupted by such call-ups (although we did not have material disruptions from the recent call-ups of military reservists relating to the conflict with Hamas in Gaza).

It may be difficult to enforce a U.S. judgment against us and our directors and executive officers named in this prospectus, in Israel or the United States, or to serve process on our directors and executive officers.

        We are incorporated under Israeli law. Many of our directors and executive officers listed in this prospectus reside outside the United States, and most of our assets are located outside the United States. Therefore, a judgment obtained against us or many of our directors and executive officers in the United States, including one based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the United States and may not be enforced by an Israeli court. It also may be difficult for you to effect service of process on these persons in the United States or to assert U.S. securities law claims in original actions instituted in Israel. See "Enforcement of Judgments."

Your rights and responsibilities as a shareholder will be governed by Israeli law which may differ in some respects from the rights and responsibilities of shareholders of U.S. companies.

        We are incorporated under Israeli law. The rights and responsibilities of the holders of our ordinary shares are governed by our Articles of Association and Israeli law. These rights and responsibilities differ in some respects from the rights and responsibilities of shareholders in typical U.S. corporations. In particular, a shareholder of an Israeli company has a duty to act in good faith toward the company and

31


Table of Contents

other shareholders and to refrain from abusing its power in the company, including, among other things, in voting at the general meeting of shareholders on matters such as amendments to a company's articles of association, increases in a company's authorized share capital, mergers and acquisitions and interested party transactions requiring shareholder approval. In addition, a shareholder who knows that it possesses the power to determine the outcome of a shareholder vote or to appoint or prevent the appointment of a director or executive officer in the company has a duty of fairness toward the company. There is limited case law available to assist us in understanding the implications of these provisions that govern shareholders' actions. These provisions may be interpreted to impose additional obligations and liabilities on holders of our ordinary shares that are not typically imposed on shareholders of U.S. corporations.


Risks Related to Our Ordinary Shares and the Offering

We are controlled by one of our shareholders. This shareholder may make decisions with which other shareholders may disagree.

        Immediately prior to this offering, Israel Corporation holds approximately 52.38% of our outstanding ordinary shares. With respect to any ordinary shares Israel Corporation sells directly to the underwriters, it will cease to have voting rights. With respect to any ordinary shares subject to the forward sale agreements, and made available to the forward counterparties under these agreements, Israel Corporation will cease to have voting rights with respect to these ordinary shares and will, at the relevant settlement dates, regain voting rights with respect to all or a portion of the ordinary shares it makes available to the forward counterparties under these agreements if it elects cash settlement or net physical settlement. Following this offering, Israel Corporation will still have voting control over 46.68% of our ordinary shares.

        The interests of Israel Corporation may differ from your interests. Israel Corporation exercises control over our operations and business strategy and has sufficient voting power to control many matters requiring approval by our shareholders, including:

        In addition, this concentration of ownership may delay, prevent or deter a change in control, or deprive you of a possible premium for your ordinary shares as part of a sale of our Company. Israel Corporation could also sell its stake and transfer control to another party without your consent.

The existence of a Special State Share gives Israel veto power over transfers of certain assets and shares above certain thresholds, and may have an anti-takeover effect.

        Israel holds a Special State Share in our Company and in some of our Israeli subsidiaries. The Special State Share entitles Israel, among other things, to restrict the transfer of certain assets and some acquisitions of shares by any person that would become a holder of specified amounts of our share capital. See "Description of Share Capital—The Special State Share" for a further discussion of these restrictions. Because the Special State Share restricts the ability of a shareholder to gain control of our Company, the existence of the Special State Share may have an anti-takeover effect and therefore depress the price of our ordinary shares.

32


Table of Contents

The market price of our ordinary shares is subject to fluctuation, which could result in substantial losses for our investors.

        The stock market in general, and the market price of our ordinary shares in particular, is subject to fluctuation, and changes in our share price may be unrelated to our operating performance. The market price of our ordinary shares on the TASE has fluctuated in the past, and we expect it will continue to do so. The market price of our ordinary shares is and will be subject to a number of factors, including:

        These factors and any corresponding price fluctuations may materially and adversely affect the market price of our ordinary shares and result in substantial losses for our investors.

There has been no prior public market in the United States for our ordinary shares, and an active trading market in the United States may not develop.

        Prior to this offering, there has been no public market in the United States for our ordinary shares. An active trading market in the United States may not develop following completion of this offering or, if developed, may not be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce the fair market value of your shares.

If equity research analysts issue unfavorable commentary or downgrade our ordinary shares, the price of our ordinary shares could decline.

        The trading market for our ordinary shares will rely in part on the research and reports that equity research analysts publish about us and our business. The price of our ordinary shares could decline if one or more securities analysts downgrade our ordinary shares or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business.

You may be diluted by the future issuance of additional ordinary shares in connection with our incentive plans, acquisitions or otherwise.

        We have approximately 190 million ordinary shares authorized but unissued. We may choose to raise substantial equity capital in the future: (1) to acquire or invest in businesses, products or technologies and other strategic relationships and (2) to finance unanticipated working capital requirements and respond to competitive pressures. The issuance of any additional ordinary shares in the future, or any securities that are exercisable for or convertible into our ordinary shares, will have a dilutive effect on our shareholders since by raising additional funds by issuing equity or convertible debt securities, we will reduce the percentage ownership of our then-existing shareholders, and these securities may have rights, preferences or privileges senior to those of our existing shareholders. In addition, 11,993,400 options for our ordinary shares were outstanding as of June 30, 2014. See "Management—Incentive Compensation Plans." Any ordinary shares that we issue, including under any options plans, would dilute the percentage ownership held by the investors who purchase ordinary shares in this offering.

33


Table of Contents

If our existing shareholders sell additional ordinary shares, or if these shares are sold by others, either on the TASE or the NYSE, after this offering, or if the forward counterparties or their affiliates sell additional ordinary shares to adjust their respective hedge positions during the terms of the forward sale agreements, the market price of our ordinary shares could decline.

        The sale of substantial amounts of our ordinary shares in the public market, or the perception that such sales could occur, could harm the prevailing market price of our ordinary shares on the TASE or the NYSE. These sales, or the perception that these sales could occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. We have a total of 1,295,015,589 ordinary shares outstanding. All of our outstanding shares will be freely tradable without restriction or further registration under the Securities Act, except that any shares held by our affiliates, including Israel Corporation, may be sold only in compliance with the limitations described in "Shares Eligible for Future Sale."

        We, our directors and officers, and Israel Corporation will sign lock-up agreements with the underwriters that will, subject to certain exceptions, including with respect to sales by pledgees under margin loans, restrict the sale of ordinary shares held by them for 180 days following the date of this prospectus. Upon the expiration of the lock-up agreements, all of such shares will be eligible for resale in a public market, subject, in the case of shares held by our affiliates, to volume, manner of sale and other limitations under Rule 144. Morgan Stanley & Co. LLC may, in its sole discretion, release all or any portion of the shares subject to lock-up agreements. See "Underwriting" for a description of these lock-up agreements.

        As of September 10, 2014, Israel Corporation has pledged approximately 372 million ordinary shares, or approximately 55.9% of the total ordinary shares it holds, to secure certain liabilities, almost entirely comprised of margin loans with an aggregate outstanding principal amount of $1.034 billion. As of that date, the ordinary shares pledged by Israel Corporation represent approximately 29.3% of the total ordinary shares outstanding and was in an amount equal to approximately 87% of ordinary shares held by non-affiliates. Each margin loan requires Israel Corporation to pledge additional ordinary shares or cash collateral if certain loan-to-value ratios are greater than the maximum ratios agreed upon with the lender of the applicable margin loan. In accordance with the loan-to-value ratios, based on the aggregate principal amount of loans outstanding as of September 10, 2014, Israel Corporation would be required to pledge additional ordinary shares or cash collateral if the price of our ordinary shares were to decline to prices ranging from $4.39 to $6.24, with the weighted average trigger price being approximately $5.84. See "Price Range of Our Ordinary Shares" for more information about the historical price ranges of our ordinary shares. One or more of the margin loans also contain provisions that, subject to their terms, effectively require prepayment if certain events or circumstances occur, including any that have a material adverse effect on Israel Corporation, Israel Corporation ceasing to control us, a decline in the price of our ordinary shares below a specified level, Israel Corporation's failure to comply with specified financial ratios or a requirement of prepayment is triggered under any other material indebtedness. The only liabilities of Israel Corporation that are secured by ordinary shares, and that are not margin loans, relate to cross-currency interest rate swaps. At June 30, 2014, Israel Corporation had, on an unconsolidated basis, approximately $2.424 billion of total indebtedness, of which approximately 43% is comprised of the margin loan indebtedness described above. If Israel Corporation fails to pledge additional ordinary shares or cash collateral when it is required to do so or otherwise fails to comply with the respective terms of the margin loans and the lender accelerates payment of all amounts outstanding under these loans as a result of this non-compliance, then the lender could sell the ordinary shares pledged thereunder. In addition, certain lenders under the margin loans may elect at any time to hedge their exposure to the ordinary shares in transactions that could directly or indirectly impact the price of ordinary shares.

        Pursuant to the terms of its lock-up agreement, Israel Corporation may during the lock-up period (1) pledge additional ordinary shares under its existing margin loans and cross-currency interest rate swaps, whether required to do so to comply with the respective terms of the margin loans or otherwise, and

34


Table of Contents

(2) enter into new pledge agreements and pledge additional shares to finance existing margin loan indebtedness, so long as in any such case the aggregate principal amount of debt under its margin loans would not be greater (after giving effect to the financing or additional pledge) than $1.14 billion. The lock-up agreement does not otherwise impose any limitations on the terms of any such financing arrangements or on Israel Corporation's ability to renegotiate any of the terms of its existing margin loan arrangements or cross-currency interest rate swaps.

        As described under "Prospectus Summary—The Offering," Israel Corporation expects to enter into forward sale agreements pursuant to which it will agree to sell, and the forward counterparties will agree to purchase from Israel Corporation, up to 36,207,128 ordinary shares, subject to the terms and conditions of the forward sale agreements. Israel Corporation will have the right to elect cash settlement or net physical settlement under the forward sale agreements in lieu of delivering all the ordinary shares. To the extent Israel Corporation elects cash settlement or net physical settlement under the forward sale agreements, the forward counterparties will return to Israel Corporation all or a portion of the ordinary shares it previously made available to the forward counterparties. Subsequent to the sale of the ordinary shares covered by this prospectus to establish their respective initial hedge positions in respect of the forward sale agreements, the forward counterparties or their affiliates may make additional sales and purchases of ordinary shares to adjust their respective hedge positions during the terms of the forward sale agreements. Neither we, Israel Corporation nor the forward counterparties make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of the ordinary shares, but any selling activities could depress the price of our ordinary shares. In addition, neither we, Israel Corporation nor the forward counterparties make any representation that the forward counterparties or any of their affiliates will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice.

        We intend to file one or more registration statements on Form S-8 under the Securities Act to register our ordinary shares or securities convertible into or exchangeable for our ordinary shares issued pursuant to our equity incentive plans. The ordinary shares registered under such registration statements will be available for sale in the open market. We expect that the initial registration statement on Form S-8 will cover approximately 16.5 million ordinary shares.

        As restrictions on resale end, the market price of our ordinary shares could drop significantly if the holders of these restricted shares sell them or are perceived by the market as intending to sell them. These factors could also make it more difficult for us to raise additional funds through future offerings of our ordinary shares or other securities.

We may not be able to fulfill our dividend policy in the future.

        Our Board of Directors has adopted a dividend policy to pay quarterly dividends of up to 70% of our net income. Any dividends must be declared by our Board of Directors, which will take into account various factors including our profits, our investment plan, our financial status and additional factors they deem appropriate. Dividend payments are not guaranteed and our Board of Directors may decide, in its absolute discretion, at any time and for any reason, not to pay dividends, to reduce the amount of dividends paid, to pay dividends on an ad-hoc basis or to adopt a share buyback program.

Our ordinary shares will be traded on different markets and this may result in price variations.

        Our ordinary shares have traded on the TASE since 1992 and will be listed on the NYSE following this offering. Trading in our ordinary shares on these markets will be made in different currencies (U.S. dollars on the NYSE and NIS on the TASE) and take place at different times (resulting from different time zones, different trading days and different public holidays in the United States and Israel). The trading prices of our ordinary shares on these two markets may differ due to these and other factors. Any decrease in the price of our ordinary shares on one of these markets could cause a decrease in the trading price of our ordinary shares on the other market.

35


Table of Contents

We will incur additional costs as a result of this offering, and our management will be required to devote substantial time to new compliance initiatives as well as to compliance with ongoing U.S. and Israeli reporting requirements.

        As a public company in the United States, we will incur additional significant accounting, legal and other expenses that we did not incur before the offering of our ordinary shares on the NYSE, including costs associated with complying with the requirements under Section 404 and other provisions of the Sarbanes-Oxley Act of 2002 (the "Sarbanes-Oxley Act"). We expect these rules and regulations to increase our legal and financial compliance costs and to make some activities more time consuming and costly. The implementation and testing of new compliance processes and systems may require us to hire outside consultants and incur other significant costs. In addition, any future changes in the laws and regulations affecting public companies in the United States and Israel, including Section 404 and other provisions of the Sarbanes-Oxley Act, the rules and regulations adopted by the SEC and the NYSE, as well as applicable Israeli reporting requirements, for so long as they apply to us, could result in increased costs to us as we respond to such changes.

As a foreign private issuer, we are permitted to follow certain home country corporate governance practices instead of applicable SEC and NYSE requirements, which may result in less protection than is afforded to investors under rules applicable to domestic issuers.

        As a foreign private issuer, we will be permitted to follow certain home country corporate governance practices instead of those otherwise required by the NYSE for domestic issuers. For instance, we may follow home country practices in Israel with respect to, among other things, composition and function of the audit and finance committee and other committees of our Board of Directors and certain general corporate governance matters. In addition, in certain instances we will follow our home country law, instead of NYSE rules applicable to domestic issuers, which require that we obtain shareholder approval for certain dilutive events, such as an issuance that will result in a change of control of our Company, certain transactions other than a public offering involving issuances of a 20% or more interest in our Company and certain acquisitions of the stock or assets of another company. Following our home country corporate governance practices as opposed to the requirements that would otherwise apply to a U.S. company listed on the NYSE may provide less protection than is afforded to investors under the NYSE rules applicable to domestic issuers.

        In addition, as a foreign private issuer, we will be exempt from the rules and regulations under the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"), related to the furnishing and content of proxy statements and the requirements of Regulation FD (Fair Disclosure), and our directors, officers and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions of Section 16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as domestic companies whose securities are registered under the Exchange Act.

You will incur immediate and substantial dilution in the net tangible book value of the ordinary shares you purchase.

        The assumed initial public offering price of $7.41 per ordinary share (which was the last reported sale price of our ordinary shares on the TASE on September 11, 2014, based on the exchange rate reported by the Bank of Israel on such date) will be substantially higher than the net tangible book value of our outstanding ordinary shares as of June 30, 2014. Accordingly, if you purchase our ordinary shares at the assumed initial public offering price, you will incur immediate and substantial dilution (based on such assumed price) of $5.61 per ordinary share.

36


Table of Contents

We have a history of quarterly fluctuations in our results of operations due to the seasonal nature of the demand for some of our products. We expect these fluctuations to continue. Fluctuations in our results of operations may disappoint investors and result in a decline in our share price.

        We have experienced, and expect to continue to experience, fluctuations in our quarterly results of operations. Our sales have historically been stronger in the second and third quarters of each year. This is due to the mix of products we sell in those quarters, as well as the mix of sales in different countries. If, for any reason, our revenues in the second and third quarters are below seasonal norms, we may not be able to recover these sales in subsequent quarters and our annual results of operations may not meet expectations. If this occurs, the market price of our ordinary shares could decline.

Although we do not expect to be a passive foreign investment company, or a PFIC, for U.S. federal income tax purposes in the foreseeable future, no assurance can be given in that regard, and if we were a PFIC for any taxable year, certain adverse U.S. federal income tax consequences could apply to U.S. investors.

        In general, a non-U.S. corporation will be a PFIC for any taxable year if either (i) at least 75% of its gross income is "passive income" or (ii) at least 50% of the average quarterly value of its assets consists of assets that produce, or are held for the production of, passive income. Passive income generally includes dividends, interest, rents, royalties and gains from transactions in commodities (other than certain active business gains from the sales of commodities). Based on the manner in which we operate our business, we do not expect to be a PFIC for our current taxable year or in the foreseeable future. However, because PFIC status depends on the composition and character of a company's income and assets and the value of its assets from time to time, there can be no assurance that we will not be a PFIC for any taxable year. If we were a PFIC for any taxable year during which a U.S. investor owned our ordinary shares, such U.S. investor may be subject to certain adverse U.S. federal income tax consequences, including increased tax liability on gains from dispositions of the ordinary shares and certain excess distributions, and a requirement to file annual reports with the U.S. Internal Revenue Service. U.S. investors should note that we do not intend to provide shareholders with the information that would enable them to make a qualifying electing fund ("QEF") election, which, if available, would result in alternative treatment (which alternative treatment could, in certain circumstances, mitigate the adverse tax consequences of owning shares in a PFIC). See "Tax Considerations—Material U.S. Federal Income Tax Considerations for U.S. Holders—Passive Foreign Investment Company Rules."

37


Table of Contents


SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

        This prospectus contains statements that constitute "forward-looking statements," many of which can be identified by the use of forward-looking words such as "anticipate," "believe," "could," "expect," "should," "plan," "intend," "estimate" and "potential," among others.

        Forward-looking statements appear in a number of places in this prospectus and include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those identified in "Risk Factors" in this prospectus. These risks and uncertainties include factors relating to:

        Forward-looking statements speak only as of the date they are made, and we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.

38


Table of Contents


PRICE RANGE OF OUR ORDINARY SHARES

        Our ordinary shares have traded on the TASE under the symbol "ICL" since 1992. As of June 30, 2014 the Company had 1,295,015,589 ordinary shares issued and outstanding, par value NIS 1 per share. No new shares will be issued in connection with this prospectus. See "Description of Share Capital" for a detailed description of the rights attached to the shares.

        The following table shows the annual, quarterly and monthly ranges of the high and low per share sales price for our ordinary shares as reported by the TASE in NIS and U.S. dollars. U.S. dollar per ordinary share amounts are calculated using the U.S. dollar representative rate of exchange on the date to which the high or low market price is applicable, as reported by the Bank of Israel.

 
  NIS Price Per
Ordinary Share
  U.S. Dollar
Price Per
Ordinary Share
 
 
  High   Low   High   Low  

Annual:

                         

2013

    51.75     24.48     13.87     6.74  

2012

    50.10     38.22     12.94     9.85  

2011

    64.78     33.91     17.93     8.99  

2010

    62.70     40.19     17.43     10.78  

2009

    55.44     25.45     14.67     6.55  

Quarterly:

                         

Third Quarter 2014 (through September 11, 2014)

    29.60     26.45     8.64     7.29  

Second Quarter 2014

    31.80     28.90     9.20     8.41  

First Quarter 2014

    31.97     27.01     9.21     7.71  

Fourth Quarter 2013

    31.35     28.03     8.84     7.95  

Third Quarter 2013

    36.55     24.48     10.07     6.74  

Second Quarter 2013

    49.16     35.70     13.54     9.90  

First Quarter 2013

    51.75     44.91     13.87     11.85  

Fourth Quarter 2012

    50.10     44.59     12.94     11.94  

Third Quarter 2012

    48.64     41.93     12.20     10.72  

Second Quarter 2012

    43.76     38.22     11.75     9.85  

First Quarter 2012

    44.40     38.64     11.92     10.27  

Most Recent Six Months:

                         

September 2014 (through September 11, 2014)

    28.24     26.45     7.89     7.29  

August 2014

    28.65     26.95     8.20     7.54  

July 2014

    29.60     27.67     8.64     8.09  

June 2014

    30.66     28.90     8.86     8.41  

May 2014

    31.80     29.96     9.20     8.69  

April 2014

    31.47     29.76     9.07     8.53  

March 2014

    31.97     28.95     9.21     8.29  

39


Table of Contents


USE OF PROCEEDS

        We will not receive any proceeds from the sale of the ordinary shares by the underwriters, whether in connection with the forward sale agreements or the sale of ordinary shares by Israel Corporation directly to the underwriters, including any proceeds from any exercise by the underwriters of their option to purchase additional shares. Israel Corporation will receive proceeds from its sale of the ordinary shares directly to the underwriters and will receive proceeds from the forward counterparties if it enters into the forward sale agreements.

40


Table of Contents


DIVIDEND POLICY

        Our Board of Directors approved the payment of a quarterly dividend at a rate of up to 70% of our net income on March 27, 2007, and reapproved that policy on May 24, 2010 and August 6, 2013. Any dividends must be declared by our Board of Directors, which will take into account various factors including, inter alia, our profits, our investment plan, our financial position, the progress relating to our strategy plan, the conditions prevailing in the market and additional factors they deem appropriate. Dividend payments are not guaranteed and our Board of Directors may decide, in its absolute discretion, at any time and for any reason, not to pay dividends. Any dividends declared on our ordinary shares will be declared and paid in U.S. dollars. Dividends paid to shareholders who hold their shares through TASE Clearing House nominees are generally converted into NIS on the basis of the representative exchange rate prevailing on the day prior to the ex-dividend date of the dividend.

        The terms of certain of our existing indebtedness require us to maintain a minimum level of shareholders' equity, which could restrict our ability to pay dividends in the future. See note 17(D) to our audited financial statements for additional information regarding covenants in our loan agreements and their impact on our ability to pay dividends.

        In addition, the distribution of dividends is limited by Israeli law, which permits the distribution of dividends only out of distributable profits and only if there is no reasonable concern that such distribution will prevent us from meeting our existing and future obligations when they become due. See "Description of Share Capital—Our Ordinary Shares—Dividends and Liquidation Rights." Generally, dividends paid by an Israeli company are subject to an Israeli withholding tax, except for dividends paid to an Israeli company. For a discussion of certain tax considerations affecting dividend payments, see "Tax Considerations."

        The following table sets forth the cash dividends we have paid on our ordinary shares since January 1, 2009.

Year Ended December 31,
  Dividend per Ordinary Share
(in U.S. dollars)
  Aggregate Dividends
(in thousands of U.S. dollars)
 

2009

    0.44     549,037  

2010

    0.79     998,251  

2011

    0.88     1,131,033  

2012

    0.80     1,019,222  

2013

    0.50     634,388  

2014 (through September 12)

    0.53     673,325 (1)

(1)
Represents a special one-time dividend of $500 million declared on February 11, 2014, which was paid on March 26, 2014, with an ex-dividend date of March 12, 2014, an $83 million divided declared on March 18, 2014, which was paid on May 27, 2014, with an ex-dividend date of May 13, 2014, a $91.5 million dividend declared on May 14, 2014, which was paid on June 25, 2014, with an ex-dividend date of June 10, 2014, and a $47 million dividend declared on August 6, 2014, which will be paid on September 17, 2014, with an ex-dividend date of September 4, 2014.

41


Table of Contents


CAPITALIZATION

        The following table sets forth our consolidated capitalization as of June 30, 2014, derived from our unaudited condensed consolidated interim financial statements prepared in accordance with IFRS, as issued by the IASB.

        This table should be read in conjunction with, and is qualified in its entirety by reference to "Selected Consolidated Financial Data," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our audited financial statements and the related notes included elsewhere in this prospectus.

 
  As of June 30, 2014  
 
  (in thousands of U.S.
dollars)

 

Long-term indebtedness, excluding current portion:

       

Loans from banks and others

  $ 1,782,082  

Debentures

    275,000  
       

Total long-term indebtedness, excluding current portion

    2,057,082  

Equity:

       

Share capital (Ordinary shares, NIS 1 par value, 1,484,999,999 shares authorized, 1,295,015,589 shares issued and outstanding; Special State Share, NIS 1 par value, 1 share authorized, 1 share issued and outstanding) (1)

    542,853  

Share premium

    133,633  

Capital reserves (1)

    80,301  

Retained earnings (2)

    2,632,915  

Treasury shares

    (260,113 )
       

Total equity attributable to the shareholders of the Company

    3,129,589  

Non-controlling interests

    26,243  
       

Total equity

    3,155,832  
       

Total capitalization (3)

  $ 5,212,914  
       
       

(1)
On August 6, 2014, our Board of Directors approved an issuance of up to approximately 4,384,540 non-marketable options, for no consideration, exercisable for approximately 4,384,540 of our ordinary shares, and up to approximately 1,025,449 restricted shares, to approximately 450 of our officers and senior employees.

(2)
On August 6, 2014, we declared a $47 million dividend to be paid on September 17, 2014, with an ex-dividend date of September 4, 2014.

(3)
Total capitalization equals total long-term indebtedness, excluding current portion, plus total equity.

42


Table of Contents


DILUTION

        If you invest in our ordinary shares in this offering, your investment will be immediately diluted to the extent of the difference between the initial public offering price per ordinary share and the net tangible book value per ordinary share. Dilution results from the fact that the per share offering price of the ordinary shares is substantially in excess of the net tangible book value per share attributable to the ordinary shares.

        Our net tangible book value of as of June 30, 2014 was $2,331.1 million, or $1.80 per ordinary share. Net tangible book value per share is determined by dividing our tangible net worth—i.e., total assets, less intangible assets, minus total liabilities—by the aggregate number of ordinary shares outstanding. As we will not receive any of the proceeds of this offering, our net tangible book value will not be affected by the offering. The offering of the ordinary shares at an assumed initial public offering price of $7.41 per share (the last reported sale price of our ordinary shares on the TASE on September 11, 2014, based on the exchange rate reported by the Bank of Israel on such date) represents an immediate dilution to new investors of $5.61 per share. The following table illustrates this per share dilution:

Assumed initial public offering price

  $ 7.41  

Net tangible book value per share as of June 30, 2014

    1.80  
       

Dilution per share to new investors

  $ 5.61  
       
       

        Dilution is determined by subtracting net tangible book value per share after the offering from the initial public offering price per share.

        Israel Corporation and our officers and directors have only purchased a limited number of ordinary shares in the five years prior to the date of this prospectus, including purchases by Israel Corporation of shares from our former chief executive officer, shares acquired upon option exercise and a small number of purchases by officers or directors on the TASE. The prices paid in these transactions were in most cases at or above the current market price of our ordinary shares and the price anticipated to be paid in the offering, and do not reflect any substantial disparity to the price of the ordinary shares offered hereby.

43


Table of Contents


SELECTED CONSOLIDATED FINANCIAL DATA

        The following tables present our selected consolidated financial data for each of the periods indicated. You should read this information in conjunction with "Presentation of Financial and Other Information," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our audited financial statements, including the notes thereto, included elsewhere in this prospectus.

        We have derived our selected consolidated income statement data for the six months ended June 30, 2014 and 2013 and the years ended December 31, 2013, 2012 and 2011 and our selected consolidated statements of financial position data as of June 30, 2014 and December 31, 2013 and 2012 from our financial statements included elsewhere in this prospectus, which have been prepared in accordance with IFRS, as issued by the IASB. We have derived our selected consolidated income statement data for the years ended December 31, 2010 and 2009 and our selected consolidated statements of financial position data as of December 31, 2011, 2010 and 2009 from our consolidated financial statements, which are not included herein.

 
  Six Months Ended
June 30,
  For the Years Ended December 31,  
 
  2014   2013   2013   2012   2011   2010   2009  
 
  (in thousands of U.S. dollars, except for share data)
 

Income Statement Data:

                                           

Sales

  $ 3,148,217   $ 3,410,507   $ 6,271,542   $ 6,471,433   $ 6,868,550   $ 5,571,976   $ 4,356,053  

Cost of sales

    2,042,867     2,033,647     3,861,572     3,760,235     3,767,962     3,185,609     2,579,057  

Gross profit

    1,105,350     1,376,860     2,409,970     2,711,198     3,100,588     2,386,367     1,776,996  

Selling, transportation and marketing expenses

    429,077     433,759     850,325     797,291     861,976     774,147     550,136  

General and administrative expenses

    148,847     138,786     281,491     248,782     265,142     235,095     186,351  

Research and development expenses, net

    44,207     41,369     82,870     74,099     70,126     61,948     51,635  

Other expenses

    170,586     8,901     110,194     61,085     29,929     7,741     94,144  

Other income

    (8,366 )   (1,858 )   (16,276 )   (23,691 )   (4,660 )   (11,218 )   (3,604 )

Operating income

    320,999     755,903     1,101,366     1,553,632     1,878,075     1,318,654     898,334  

Finance expenses, net

    69,377     17,877     26,855     60,894     77,812     60,187     1,477  

Share in earnings of equity accounted investees

    11,743     7,412     25,685     26,555     34,265     31,729     43,695  

Income before income taxes

    263,365     745,438     1,100,196     1,519,293     1,834,528     1,290,196     940,552  

Income taxes

    63,305     123,128     280,023     217,561     333,470     261,579     166,238  

Net income attributable to the shareholders of the Company

    198,502     621,521     818,573     1,300,076     1,498,151     1,024,740     770,420  

Net income attributable to non-controlling interests

    1,558     789     1,600     1,656     2,907     3,877     3,894  

Earnings per share:

                                           

Basic earnings per share

  $ 0.156   $ 0.489   $ 0.644   $ 1.024   $ 1.182   $ 0.810   $ 0.610  

Diluted earnings per share

  $ 0.156   $ 0.489   $ 0.644   $ 1.024   $ 1.177   $ 0.806   $ 0.608  

Weighted average number of ordinary shares outstanding:

                                           

Basic

    1,270,431     1,270,397     1,270,414     1,270,009     1,267,699     1,264,425     1,262,991  

Diluted

    1,270,431     1,270,397     1,270,414     1,270,117     1,272,945     1,271,598     1,266,398  

44


Table of Contents


 
   
  As of December 31,  
 
  As of
June 30,
2014
  2013   2012   2011   2010   2009  
 
  (in thousands of U.S. dollars, except for share data)
 

Balance Sheet Data:

                                     

Cash and cash equivalents

  $ 177,777   $ 188,340   $ 206,067   $ 238,141   $ 354,654   $ 198,787  

Total current assets

    3,186,977     3,041,640     3,063,065     3,207,255     3,004,085     2,652,707  

Property, plant and equipment

    3,917,512     3,686,240     3,097,385     2,615,420     2,182,647     2,087,444  

Total assets

    8,436,149     7,973,485     7,344,911     6,963,674     6,184,818     5,702,616  

Short-term credit and current portion of long-term debt

    858,671     718,284     552,062     361,578     47,804     81,663  

Long-term debt

    1,782,082     1,243,638     916,594     847,006     844,168     555,204  

Debentures

    275,000     67,000     228,708     485,470     528,728     503,794  

Total equity

    3,155,832     3,678,674     3,388,264     3,090,251     2,644,390     2,794,849  

45


Table of Contents


MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

         The following Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") should be read together with "Selected Consolidated Financial Data" and our audited financial statements and the related notes appearing elsewhere in this prospectus. Our audited financial statements have been prepared in accordance with IFRS, as issued by the IASB. Except where otherwise specifically indicated, all amounts in this MD&A are expressed in United States dollars.

         This discussion contains forward-looking statements that are subject to known and unknown risks and uncertainties. See "Special Note Regarding Forward-Looking Statements." Actual results and the timing of events may differ significantly from those expressed or implied in such forward-looking statements due to a number of factors, including those set forth in the section entitled "Risk Factors" and elsewhere in this prospectus.


Principal Factors Affecting Our Results of Operations and Financial Condition

        We are a multinational company, the financial results of which are affected by the demand for basic agricultural products, global economic trends, changes in terms of trade and financing, and fluctuations in currency exchange rates. Together with and as part of our business strategy, we are taking steps to adapt our marketing and production policies to global market conditions. We are also focusing on improving our cash flows and diversifying our financing sources, and we are committed to taking continuous actions to improve efficiency and reduce costs.

        We are an Israeli corporation, and we have significant production facilities in Israel. Accordingly, we are affected by the political, economic and security conditions prevalent in Israel. See "Risk Factors—Risks Related to Our Operations in Israel—We conduct operations in Israel and therefore our business, financial condition and results of operations may be materially and adversely affected by political, economic and military instability in Israel and its region." In particular, we have been adversely affected by several recent developments in Israel that could lead to materially higher costs and lower profitability and cash generation. See "Prospectus Summary—Recent Developments."

        In 2013, approximately 51% of our sales revenue was derived from production activities taking place outside Israel and approximately 11% of the cost of sales of products produced outside Israel was attributable to raw materials supplied from Israel. In the first half of 2014, approximately 54% of our sales revenue was derived from production activities taking place outside Israel and approximately 9% of the cost of sales of products produced outside Israel was attributable to raw materials supplied from Israel.

        Our sales are affected by pricing for our products and the quantities we sell. In the second half of 2013 and the first half of 2014, prices for certain of our key products were lower, but this was partially offset by higher quantities sold. Our margins were adversely affected by the lower prices.

        Energy expenses accounted for approximately 7% of our total operating costs in 2013 and in the first half of 2014. Of these energy expenses, the cost of oil and oil products, electricity and natural gas represented approximately 14% ($52 million), 48% ($182 million) and 25% ($95 million), respectively, in 2013. Energy costs decreased in the first half of 2014 compared with the first half of 2013 due to the supply of gas from the Tamar field, which led to savings as a result of the switch from use of expensive fuels, and from the undertaking to purchase electricity from OPC Rotem Lt. at a lower cost compared with the price of electricity purchased from the Israeli Electric Company. We expect that with the gradual increase in the use of natural gas, energy expenses as a percentage of total operating costs will decline and the mix of these costs will change.

        In 2012, our gas supplier in Israel, the Yam Tethys partnership, announced that it was being forced to reduce the quantities of gas it supplied because of the dilution of the gas in its well. The rate of the decline in the supply of gas from Yam Tethys, compared with the potential use in 2012, amounted to approximately

46


Table of Contents

53%. On April 1, 2013, the supply of gas from the Tamar Field commenced as a substitute for the quantity supplied by the Yam Tethys partnership. Supply of the gas from the Tamar Field fulfills all of our gas needs for the facilities for which we have completed conversions. Increased use of natural gas in our facilities is expected to significantly reduce emissions of pollutants in the area surrounding our facilities, improve the quality of the output, reduce maintenance expenses and lead to a significant monetary savings due to the transition from the use of more expensive fuels.

        In 2012, 2013 and the first half of 2014, our marine transportation expenses amounted to approximately 7% of our total operating costs. In 2013 and the first half of 2014, our shipping costs amounted to approximately $384 million and approximately $191 million, respectively. In recent years, bulk shipping prices have been extremely volatile. After several years of falling marine bulk transportation prices, transportation prices began to increase beginning in the middle of 2013. Marine bulk transportation prices reached a record high in the last three years and stood at 2,337 points on the Baltic Dry Index ("BDI") in the middle of December 2013. The BDI is an index used to measure the average price to ship raw materials around the world by sea. Beginning in the first quarter of 2014, prices fell, and the average BDI for the second quarter was 976 points, approximately 47% less than the average BDI for the fourth quarter of 2013. Compared with the second quarter of 2013, however, the price level is still somewhat higher. The index for the second quarter of 2014 is 10% higher than its average level in the second quarter of 2013. The average BDI for the fourth quarter of 2013 was 1,858 points, constituting an increase of about 100% compared with the corresponding quarter in 2012. In 2012, the average BDI was 923 points compared to an average of 1,547 points in 2011, representing a decrease of 40%.

        Our financial statements are prepared in U.S. dollars. Most of our sales are in U.S. dollars, even though a portion of our sales is in other currencies, mainly euros. Part of our operating expenses in Israel are denominated in NIS; therefore, devaluation of the average NIS exchange rate against the U.S. dollar has a positive impact on our profitability, while appreciation has the opposite effect. Devaluation of the average exchange rate of the euro against the U.S. dollar has a negative impact on our profitability, while appreciation has the opposite impact. On the other hand, devaluation of the euro against the U.S. dollar improves the competitive ability of our subsidiaries whose functional currency is the euro, compared with competitors whose functional currency is the U.S. dollar.

        We hedge against our exposure to the risks described above, particularly our exposure to the cost of sales and operating expenses denominated in NIS, other currencies that are not the functional currency of our subsidiaries, marine transportation prices and energy prices. Since most of these hedging transactions are treated as economic (non-accounting) hedges, they are not reflected in our operating costs but instead recorded as finance income or expenses in our statements of income. Our management determines the extent of our hedging activities based on their estimation of our cost of sales and operating expenses, as well as their expectations of developments in the markets in which we operate. See "—Quantitative and Qualitative Disclosures About Market Risk—Risk Management."

        There is a relationship among the amount of available arable land, the amount of food needed for the population and the use of fertilizers. Natural population growth, changes in food consumption habits (a shift to richer nutrition, largely based on animal protein, which increases grain consumption) resulting from the rising standard of living, mainly in developing countries, and environmental-quality considerations along with the aspirations of certain advanced economies to reduce dependence on oil imports, which have strengthened the trend of shifting to production of fuel from agricultural products (bio-fuels), affect the increase in global consumption of grains (cereals, rice, soybean, corn, etc.). These trends led to significantly lower grain inventories a few years ago and, consequently, higher prices of agricultural produce, increased planting of grain crops worldwide and higher yield per unit of agricultural land, mainly through the increased application of fertilizers. In 2013, there was an increase in cheap alternative energy sources, such as the production of shale gas in the United States. The impact of these

47


Table of Contents

alternative energy sources on overall energy prices could also impact the economic viability of the production of bio-fuels and the rate of growth of their use. Production of ethanol from corn in 2013 was somewhat higher than in 2012. Nonetheless, in light of the pressure on the U.S. government to reduce the required level of ethanol production (the required use levels of bio-fuels in the United States, Europe and Brazil are defined by law), moderation of fuel prices, the decline in fuel consumption in the United States and the decision of the U.S. Environmental Protection Agency ("EPA") not to increase the percentage of ethanol in gasoline (the blending rate) from 10% to 15%, no increase in the demand for corn on the part of the ethanol industry is expected in 2014 in the United States, which is the main market for these fuels.

        Following the stable prices in the first half of 2013, there was a moderate decline in the prices of most grains, due to an expectation of a large harvest and an increase in the planting areas, mainly of corn in the United States. In January 2014, after corn prices fell to their lowest level since August 2010 the downward trend reversed and grain prices rose through the end of May 2014. However, following USDA publications predicting an increase in the harvests, particularly of corn and wheat, a significant decline set in with respect to prices of most grains and as of the end of the second quarter of 2014, grain prices have returned to their levels at the beginning of the year—and are even lower for some of the grains. Wheat prices in 2013 fell more moderately from their record levels in 2012. However, due to an increase in the demand for wheat imports in China and a fear of damage to the harvests in South America, along with dry weather conditions in the main growing regions in the United States, wheat prices returned to a moderate climb in the first quarter of 2014; however, as noted, in May 2014 they resumed their descent. Soybean prices began to fall in the second half of last year, however more moderately than corn. Similar to the trends characterizing corn and wheat prices, soybean prices also rose in the first half of 2014, mainly due to the fear of harm to the harvests in South America as a result of dry weather conditions together with strong demand in the United States and China. Nonetheless, in May, this trend also reversed, due to an expectation of an increase in planted areas and large harvests in the United States. On the other hand, rice maintained relatively stable prices since the beginning of 2012.

        Based on a report published by the USDA in July 2014, an increase is expected in the ratio of the inventories of grains to annual consumption, up to 21.3% at the end of the agricultural 2014/2015 year, compared with an expectation of 20.81% at the end of the 2013/2014 agricultural year, and compared with 19.91% in the prior agricultural year and 20.42% in the 2011/2012 agricultural year. Most of the increase in the 2013/2014 agricultural year stems from an increase in the inventory of corn.

        In the short term, the demand for fertilizers is volatile and seasonal and is affected by factors such as the weather in the world's central agricultural growing regions, fluctuations in the scope of the planting of the main crops, agricultural input costs, agricultural product prices and developments in biotechnology. Some of these factors are influenced by subsidies and credit lines granted to farmers or to producers of agricultural inputs in various countries, and by environmental regulation. Changes in currency exchange rates, legislation and international trade policy also affect the supply, demand and level of consumption of fertilizers worldwide. Notwithstanding the volatility that may be caused in the short term as a result of these factors, we estimate that the policy of most countries in the world is to ensure an orderly supply of high-quality food to their residents, including by encouraging agricultural production, which should preserve the long-term growth trend of fertilizer consumption.

        Worldwide sales of potash recovered in 2013, compared with 2012, although at a lower rate than expected at the beginning of the year. According to IFA estimates, global potash sales in 2013 amounted to approximately 55.3 million tons, compared with 51.7 million tons in 2012, an increase of 7%. Worldwide potash sales in the first half of 2013 were greater than in the prior year. However, the second half of 2013 ushered in a number of challenges that unfavorably impacted demand, including an erosion of 18% in the exchange rate of the Indian rupee against the U.S. dollar between January and November 2013 (which impacted the demand for imports from India, one of the world's largest importers of potash) and the decline in the prices of agricultural commodities in the fourth quarter of 2013. In addition, in July 2013, the Russian potash producer Uralkali announced its exit from its joint potash marketing company with

48


Table of Contents

Belaruskali (BPC) and its decision to change its marketing strategy from preferring price to preferring quantity. This announcement triggered uncertainty with respect to potash prices and, as a result, led to a halt in demand for potash in the third quarter of 2013. The demand for potash stabilized in the fourth quarter of 2013 and further improved in the first half of 2014.

        In the beginning of 2013, our Fertilizers segment signed three-year framework contracts with a number of customers in China for the sale of 3.3 million tons of potash. The sale prices in accordance with these agreements will be determined in negotiations between the parties from time to time. As part of these agreements, in January and February of 2014, our Fertilizers segment signed agreements for the supply of potash in the first half of 2014 in a scope substantially similar to the contracts signed with its customers for the first half of 2013. The contracts were signed at a price of $305 per ton CFR, which was $95 per ton CFR less than the contracts signed in 2013. During the second half of 2013, a number of sale transactions to customers in China were executed based on the current spot rate. The imports into China in the first half of 2014 were 3.9 million tons, an increase of approximately 6% compared with the first half of 2013.

        In the Indian market, a change in the subsidy policies for fertilizers and the devaluation of the local currency against the U.S. dollar gave rise to a significant increase in the retail price of potash and phosphates to farmers and a drop in demand in 2013. Imports of potash into India fell from 4.5 million tons in 2011 to 3.4 million tons in 2012 and to 3.1 million tons in 2013. In the first quarter of 2014, the potash manufacturers signed contracts for the agricultural year beginning on April 1, 2014 and ending on March 31, 2015 at a price that embodies a decline of $105 per ton compared with the price closed in the prior supply contracts in India in the beginning of 2013. In the period between April 2014 and the date of this prospectus, our Fertilizers segment agreed with its customers in India to supply potash for the 2014/2015 agricultural year in an aggregate quantity of approximately 825 thousand tons (including optional quantities). The selling price agreed to is about the same as the price set in transactions with other producers supplying potash to the Indian market. The imports into India in the first half of 2014 increased by 29% compared to the first half of 2013 and stood at 1.5 million tons.

        Imports of potash into Brazil in 2013 reached about 7.6 million tons, reflecting an increase of about 3.8% over 2012, which was a record year for potash imports. The strong demand for potash continued in the first half of 2014, where the total imports in the first half of 2014 were about 4.6 million tons reflecting an increase of approximately 27% compared with the corresponding period in 2013.

        The worldwide demand for phosphate fertilizers was weak during all of 2013, mainly as a result of low demand in India and postponement of purchases throughout the world. A number of countries relied mainly on inventories accumulated as of the end of 2012. Global consumption of phosphate fertilizers in 2013 was approximately 40.9 million tons of P 2 O 5 , according to IFA estimates. The decline stemmed from a sharp drop in demand in India and a more moderate decline in North America, mainly in the United States, which was partly offset by increased consumption in Latin America, Europe and East Asia.

        In 2012, there was an erosion of potash prices. In 2013, there was surplus potash production capacity, mainly due to an increase in the production capacity of various potash producers, particularly in Canada and Russia. At the end of July 2013, the Russian potash manufacturer Uralkali announced its exit from the potash marketing company that is jointly owned by it and Belaruskali (BPC), through which the two manufacturers, Uralkali and Belaruskali, exported their output. Concurrent with the exit announcement, Uralkali also gave notice of a change in its selling strategy and transition to a policy favoring quantity over price while taking advantage of the company's production capacity. This announcement triggered a fall in potash prices in the markets and also caused a postponement of potash acquisitions by customers with an expectation of additional price declines. During the fourth quarter of 2013, prices stabilized and demand revived, returning to its regular level. During the first half of 2014, the price of potash began to slowly increase in the spot markets—Brazil, Europe and the United States—mainly due to the tight supply of granular potash compared to demand.

49


Table of Contents

        2013 was characterized by a decline in the phosphate fertilizer trade along with an erosion of the prices of phosphate fertilizers. The phosphate market was adversely affected by the decline in purchases made by the main importer, India, mainly due to a cut in the subsidies for these products and the depreciation of the exchange rate of the Indian currency against the U.S. dollar. Towards the end of the year, a certain recovery was felt and the prices started to rise moderately due to good demand in South America, commencement of preparations of the North American buyers for the upcoming season and return to the market of other buyers that had postponed purchases based on an expectation of continued price declines. The first quarter of 2014 was characterized by stable prices and good demand in South America, primarily Brazil. During the second quarter of 2014, the demand increased, particularly in Brazil and the United States, which gave rise to an increase in the prices of phosphate fertilizers. On the other hand, in India the first quarter of the year was characterized by weak demand mainly as a result of the seasonal factor. In the second quarter of the year, there was an increase in the quantities imported to India compared with the first part of the year, although the level remained below the expectation for this market, in light of the low imports last year, owing to the lateness of the monsoon rains.

        In the specialty fertilizers products market, the decline in raw material prices affected the average selling prices in 2013. However, the decline in the selling prices, which took place mostly in the fourth quarter of 2013, was at a lower rate than the decline in the raw materials prices.

        Set forth below are the average annual prices per metric ton of potash, phosphate rock and bromine for the last five years.

 
  Average Annual Price ($ per metric ton)  
 
  2013   2012   2011   2010   2009  

Potash

                               

FOB Vancouver

  $ 380   $ 459   $ 436   $ 331   $ 628  

FOB Middle East

    389     461     431     352     626  

FOB Baltic

    375     449     421     328     626  

Phosphate Rock

                               

FOB Morocco

    145     185     185     123     120  

CFR India

    162     200     201     147     140  

Bromine

    2,726     2,860     3,495     2,665     1,820  

        The operations of our Industrial Products segment are largely affected by the level of activities in the electronics, construction, automotive, oil drilling, furniture, pharmaceuticals, agriculture, textile and water treatment markets. Pressure is increasingly being exerted by "green" organizations in the area of environmental protection to reduce the use of bromine-based flame retardants. On the other hand, additional and new uses for bromine and its related compounds are being developed, along with regulation in various countries leading to increased use of bromine and bromine compounds. The economic slowdown in the world over the past several years, which continued in 2013, triggered a slowdown in the demand for electronic products and in the construction area. This trend, along with the decline in sales of personal computers due to increased use of tablets and smartphones, caused a decline in the demand for flame retardants, mainly bromine based, for the electronics and construction sectors. There was a certain improvement in demand for bromine-based flame retardants during the second quarter of 2014 for some of the uses in the electronics sector.

        In 2013 and the first half of 2014, elemental bromine prices were relatively stable in the United States and China, whereas there were price declines in Europe and India. In the first half of 2014, the demand continued to be strong in the market for clear brine fluids for oil and gas drilling completions due to the relatively high number of drillings in the Gulf of Mexico.

50


Table of Contents

        In 2013, the market for biocides for treatment of swimming pools was impacted by falling prices as a result of a strategy by our competitors to increase their market share. In the beginning of 2013, the U.S. Department of Commerce decided to impose anti-dumping taxes on manufacturers of chlorine-based biocides from China, at the rate of about 30% to 38%. In the beginning of 2014, the anti-dumping taxes on the Chinese were increased by approximately 20%, and at the beginning of April 2014, the U.S. Department of Commerce gave notice of the imposition of anti-dumping taxes on Japanese manufacturers at a rate of 59% to 109%. The anti-dumping tax on biocides in the U.S. market will permit us to obtain a better position in the market even though this impact had not yet been expressed due to the fact that most of the transactions in this market are based on annual contracts. Demand for bromine-based biocides used for water treatment continued to be strong in the first half of 2014. The market for de-icing salts was characterized by high demand in 2013 and in the first half of 2014. The market for organic bromides for neutralizing mercury (Merquel products) remained unchanged in 2013 and was characterized by an increase in demand in the first half of 2014 due to cold weather conditions and high gas prices.

        The development of technology that allows the production of shale gas and its application in the United States presents business opportunities, including an increase in demand for bromine-based biocides.

        Most of our Performance Products segment's products are affected by the global economic situation, competition in the target markets, price fluctuations in the fertilizer market, which affect the price and availability of the main raw materials of our Performance Products segment, and fluctuation in energy prices, which mainly affect production costs of thermal phosphoric acid. In addition, some of our Performance Products segment's target markets are characterized by seasonality, mainly in the area of wildfire flame retardants. All of these market conditions create a competitive market for our Performance Products segment's products.

        During 2013, demand for our products increased despite the uncertain economic atmosphere in the global markets. However, although demand increased in 2013, customers and competitors continued to exercise pressure to lower prices of phosphorous-based products. In addition, the expected restriction on the use of phosphate salts in dishwasher detergent (STPP) will create further pressure on prices of phosphorus-based products in Europe. The atmosphere of uncertainty in the United States resulted in lower growth rates in this market and caused a slow recovery of the market. Our Performance Products segment began preparations for the expected increase in demand for low-sodium foods in the United States and has launched a food strategy to meet the demand for healthy and nutritious ingredients.

        In the second quarter of 2014, the demand for downstream phosphate-based products in the European and U.S. markets declined compared with the corresponding period last year. Furthermore, the behavior of our competitors, who implemented a sales strategy that gives preference to market share over prices, continued to have an impact in the second quarter of 2014. Although there was only a moderate increase in our prices, the quantities sold by us suffered a significant decline in demand, mainly in North America. This decline stems from the increased competition. In addition, the results in the second quarter of 2014 were impacted by a low seasonal demand in the area of forest fire retardants in the western part of the United States, along with a shutdown of a P2S5 plant. The P2S5 activities are expected to recover in the second half of 2014. Our recent acquisition of the Germany-based Hagesud Group in January 2014 continued to contribute to the improvement in our Performance Products segment's results while, on the other hand, in the second quarter of 2014, the specialty food products area was impacted by the crisis in the Ukraine.

51


Table of Contents


Expected Expenses for Compensation Plans

        Subsequent to the end of the second quarter of 2014, our Board of Directors approved the issuance of up to approximately 4,384,540 non-marketable options exercisable for approximately 4,384,540 of our ordinary shares, and up to approximately 1,025,449 restricted shares, to approximately 450 of our officers and senior employees (the "2014 Equity Compensation Plan"). The issuance includes 367,294 options and 85,907 restricted shares to our CEO, which is subject to approval by the general meeting of our shareholders scheduled for October 20, 2014. For a description of the 2014 Equity Compensation Plan, see "Management—Incentive Compensation Plans—The 2014 Equity Compensation Plan."

        The fair value of the 2014 Equity Compensation Plan (including both the non-marketable options and restricted shares) is approximately $16.8 million. The date of approval of the issuance to our CEO by the general meeting of our shareholders will be considered the grant date, and the fair value of the CEO's 2014 Equity Compensation Plan will be re-measured upon such approval. The fair value will be expensed over the vesting periods (for a description of the vesting periods, see "Management—Incentive Compensation Plans—The 2014 Equity Compensation Plan"). The expected expense for the periods ended December 31, 2014, December 31, 2015, December 31, 2016, December 31, 2017 and December 31, 2018, is approximately $2.1 million, $5.4 million, $5.2 million, $2.9 million and $1.2 million, respectively.

        In addition, our Board of Directors approved a long-term remuneration plan for approximately 11,800 of our non-management employees who are not included in the new equity compensation plan in the aggregate scope of up to approximately $17 million (the "2014 Long-Term Incentive Plan"). Pursuant to the 2014 Long-Term Incentive Plan, the cash payment to each employee, if any, will be based on our three-year cumulative net profit from 2015 to 2017. The fair value of the liability must be calculated at each reporting date and up to December 31, 2017. Any changes in fair value will be recognized in profit or loss for the applicable period. The range of the possible aggregate expense is between zero and approximately $17 million beginning with the third quarter of 2014 through the fourth quarter of 2017, depending upon the extent to which we expect to meet the approved net profit objectives for the years 2015 through 2017.


Results of Operations

        We have based the following discussion on our financial statements. You should read the following discussion together with our financial statements. The discussion that follows is qualified in its entirety by reference to our financial statements.

52


Table of Contents


Six Months Ended June 30, 2014 Compared to Six Months Ended June 30, 2013

        Set forth below are our results of operations for the six months ended June 30, 2014 and 2013.

 
  Six Months
Ended
June 30,
   
 
 
  % Increase
(Decrease)
 
 
  2014   2013  
 
  (in millions of
U.S. dollars)

   
 

Sales

    3,148     3,411     (7.7 )

Cost of sales

    2,043     2,034     0.4  
               

Gross profit

    1,105     1,377     (19.8 )

Selling, transportation and marketing expenses

    429     434     (1.2 )

General and administrative expenses

    149     139     7.2  

Research and development expenses, net

    44     41     7.3  

Other expenses

    171     9     1,800  

Other income

    (8 )   (2 )   300  
               

Operating income

    321     756     (57.5 )
               

Finance expenses

    92     65     41.5  

Finance income

    (22 )   (47 )   (53.2 )
               

Finance expenses, net

    69     18     283.3  
               

Share in earnings of equity accounted investees

    12     7     71.4  
               

Income before taxes on income

    263     745     (64.7 )

Taxes on income

    63     123     (48.8 )
               

Income for the period

    200     622     (67.8 )
               
               

Attributable to:

                   

Shareholders of the Company

    199     622     (68.0 )

Non-controlling interests

    1.6     0.8     100  
               

Income for the period

    200     622     (67.8 )
               
               

    Sales

        Our sales in the six months ended June 30, 2014 amounted to approximately $3,148 million, compared with approximately $3,411 million in the six months ended June 30, 2013. This decrease is due mainly to a decrease in selling prices, which led to a decrease in total sales of approximately $380 million. This decrease was partly offset by an increase in quantities sold, including the first time consolidation of the financial statements of companies acquired during 2013 and in the six months ended June 30, 2014, which led to an increase in sales of approximately $60 million, and a change in currency exchange rates, in the amount of approximately $57 million.

53


Table of Contents

        Below is a geographical breakdown of our sales according to customer location:

 
  Six Months
Ended
June 30,
 
 
  2014   2013  
 
  (in millions of
U.S. dollars)

 

Israel

    155     170  

North America

    641     593  

South America

    271     408  

Europe

    1,320     1,298  

Asia

    668     865  

Rest of the world

    93     77  
           

Total

    3,148     3,411  
           
           

        The sales breakdown indicates an increase in sales in Europe, stemming primarily from an increase in quantities of fertilizers sold, the impact of the acquisition of Knapsack and Hagesud in our Performance Products segment, and an increase in sales in North America, as a result of an increase in quantities sold of clear brine fluids, biocides for treatment of water, as well as magnesium chloride and fertilizers. On the other hand, there was a decrease in the sales in Asia mainly due to a decrease in the selling prices of potash and a decrease in the quantities of potash sold in Asia, except for China. The decline in South America stems mainly from a decline in quantities sold and selling prices of fertilizers and potash sold, compared with the corresponding period in 2013. The decline in the fertilizer quantities in South America derives mainly from the impact of the strike at our Rotem subsidiary.

    Cost of sales

        Our cost of sales in the six months ended June 30, 2014 amounted to approximately $2,043 million compared with approximately $2,034 million in the six months ended June 30, 2013, an increase of approximately $9 million. The increase in cost of sales derives, primarily, from an increase in quantities sold, including the first time consolidation of results of companies acquired during 2013 and in the six months ended June 30, 2014, in the amount of approximately $38 million, the impact of the change in currency exchange rates, in the amount of approximately $64 million, the impact of the strike at our Rotem subsidiary, in the amount of approximately $23 million, and an increase in royalties in the six months ended June 30, 2014 due to the partial arbitration decision regarding this matter, in the amount of approximately $6 million. This increase was partly offset by a decline in raw material and energy prices, in the amount of approximately $56 million, a decrease in royalties and selling commissions mainly due to the drop in total sales, in the amount of approximately $37 million, and a decrease in other operating expenses, in the amount of approximately $29 million, resulting mostly from a decrease in salary expenses as a result of retirement of employees at our Rotem subsidiary.

    Gross profit

        Our gross profit amounted to approximately $1,105 million in the six months ended June 30, 2014, compared with gross profit of approximately $1,377 million in the six months ended June 30, 2013, a decrease of approximately $272 million. The gross profit margin as a percentage of sales was approximately 35.1% in the six months ended June 30, 2014, compared with approximately 40.4% in the six months ended June 30, 2013.

    Selling and marketing expenses

        Our selling and marketing expenses amounted to approximately $429 million in the six months ended June 30, 2014, compared with approximately $434 million in the six months ended June 30, 2013. Selling and marketing expenses mainly include costs with respect to marine shipping, overland shipping, selling

54


Table of Contents

commissions and employee salaries. The decrease in expenses is mainly from the impact of a change in the mix of the market destinations and products sold and shipped in the first half of 2014, in the amount of approximately $13 million. This decrease was partly offset as a result of the first time consolidation of companies acquired during 2013 and in the six months ended June 30, 2014, in the amount of approximately $5 million, along with the impact of changes in exchange rates, in the amount of approximately $3 million.

    General and administrative expenses

        Our general and administrative expenses amounted to approximately $149 million in the six months ended June 30, 2014, compared with approximately $139 million in the six months ended June 30, 2013. General and administrative expenses mainly include salary expenses. The salaries in Israel are paid in NIS, whereas the salaries in Europe are paid in euros. The increase stems mainly from the impact of currency exchange rates as a result of the strengthening of the average value of the NIS and the euro against the U.S. dollar during the six months ended June 30, 2014, as well as from the first-time consolidation of companies acquired during 2013 and in the six months ended June 30, 2014.

    Research and development expenses

        Our research and development expenses amounted to approximately $44 million in the six months ended June 30, 2014, an increase of approximately $3 million compared with the six months ended June 30, 2013.

    Other expenses

        Other expenses, net, amounted to approximately $162 million, an increase of about $155 million compared with the corresponding period in 2013. The increase in other expenses stems mainly from an unusual expense, in the amount of approximately $149 million (before interest expenses and the tax impact) relating to prior periods, due to the arbitration decision regarding royalties.

    Operating income

        Our operating income amounted to approximately $321 million in the six months ended June 30, 2014, a decrease of approximately $435 million compared with the six months ended June 30, 2013. Our operating margin (the ratio of operating income to sales) was approximately 10.2% in the six months ended June 30, 2014, compared with approximately 22.2% in the six months ended June 30, 2013. Operating income after eliminating unusual items, primarily a provision in respect of prior periods stemming from the arbitration decision regarding royalties and costs in connection with the strike at our Rotem subsidiary, amounted to approximately $495 million, a decrease of $261 million compared with the corresponding period in 2013. Our operating margin based on adjusted operating income was approximately 15.7% compared with approximately 22.2% in the corresponding period in 2013.

    Financing expenses, net

        Our net financing expenses amounted to approximately $69 million in the six months ended June 30, 2014, compared with net financing expenses of approximately $18 million in the six months ended June 30, 2013. The financing expenses include unusual expenses, in the amount of approximately $32 million, mainly in connection with the arbitration decision dated May 19, 2014 regarding royalties, where after elimination of unusual expenses, the financing expenses amounted to approximately $37 million, an increase of approximately $19 million compared with the corresponding period in 2013. The increase derives mainly from an increase in interest expense, in the amount of approximately $9 million, a decrease in financing income in the six months ended June 30, 2014 due to a change in the fair value of financial derivatives and revaluation of net short-term financial liabilities, in the amount of approximately $12 million, and an increase in interest expense with respect to provisions for employee benefits, in the amount of approximately $2 million. On the other hand, there was a decrease in financing expenses with respect to the impact of exchange rate differences on provisions for employee benefits, in the amount of

55


Table of Contents

approximately $4 million, as a result of the appreciation of the NIS against the U.S. dollar at the period-end date, at the rate of approximately 1% in the six months ended June 30, 2014, compared with an appreciation, at the rate of approximately 3.1%, in the six months ended June 30, 2013.

    Tax expenses

        Our tax expenses amounted to approximately $63 million in the six months ended June 30, 2014, compared with tax expenses of approximately $123 million in the six months ended June 30, 2013. The tax rate on the pre-tax income was approximately 24.0% in the six months ended June 30, 2014 compared to approximately 16.5% in the six months ended June 30, 2013. The increase in the effective tax rate in the six months ended June 30, 2014 stems, mainly, from an unusual tax expense as a result of an assessment agreement with respect to certain subsidiaries in Europe in an amount of approximately $51 million, which was partially offset by tax income derived from an additional deduction for tax purposes in respect of investments made by a subsidiary in Europe, in the amount of approximately $24 million. The increase in the effective tax rate was also due to an increase in the Companies Tax rate in Israel to 26.5%. On the other hand, the difference in the tax rates in connection with recognition of a deferred tax asset with respect to the provision for arbitration reduced the tax rate.

    Net income

        The income attributable to the Company's shareholders amounted to approximately $199 million in the six months ended June 30, 2014, compared with approximately $622 million in the six months ended June 30, 2013, a decrease of approximately $423 million.


Year Ended December 31, 2013 Compared to Year Ended December 31, 2012

        Set forth below are our results of operations for the years ended December 31, 2013 and 2012.

 
  For the
Years Ended
December 31,
   
 
 
  % Increase
(Decrease)
 
 
  2013   2012  
 
  (in millions of
U.S. dollars)

   
 

Sales

    6,272     6,471     (3.1 )

Cost of sales

    3,862     3,760     2.7  
               

Gross profit

    2,410     2,711     (11.1 )

Selling, transportation and marketing expenses

    850     797     6.6  

General and administrative expenses

    282     249     13.3  

Research and development expenses, net

    83     74     12.2  

Other expenses

    110     61     80.3  

Other income

    (16 )   (24 )   (33.3 )
               

Operating income

    1,101     1,554     (29.2 )
               

Finance expenses

    158     82     92.7  

Finance income

    (131 )   (21 )   523.8  
               

Finance expenses, net

    27     61     (55.7 )
               

Share in earnings of equity accounted investees

    26     27     (3.7 )
               

Income before taxes on income

    1,100     1,520     (27.6 )

Taxes on income

    280     218     28.4  
               

Income for the year

    820     1,302     (37.0 )
               
               

Attributable to:

                   

Shareholders of the Company

    818     1,300     (37.1 )

Non-controlling interests

    2     2      
               

Income for the year

    820     1,302     (37.0 )
               
               

56


Table of Contents

    Sales

        Our sales in 2013 amounted to approximately $6,272 million, compared with approximately $6,471 million in 2012, a decrease of approximately 3.1%. This decrease is due mainly to a decrease in the selling prices that led to a decrease in the total sales of approximately $495 million. On the other hand, this decrease was partly offset by an increase in the quantities sold, including the first time consolidation of the financial statements of certain companies acquired which led to an increase in sales of approximately $230 million and a change in the currency exchange rates, which contributed to an increase in sales of approximately $65 million.

        Below is a geographical breakdown of our sales according to customer location:

 
  Year Ended
December 31,
 
 
  2013   2012  
 
  (in millions of
U.S. dollars)

 

Israel

    319     325  

North America

    1,207     1,252  

South America

    748     815  

Europe

    2,378     2,332  

Asia

    1,464     1,615  

Rest of the world

    156     132  
           

Total

    6,272     6,471  
           
           

        The sales breakdown indicates an increase in sales in Europe, stemming mainly from an increase in the quantities of potash sold. On the other hand, there was a decrease in sales, mainly in Asia, as a result of a decline in the selling prices of potash and fertilizers in India, a decrease in sales in South America, deriving mostly from impact of the decline in the price of potash, and a decrease in sales in North America, mainly due to a decline in sales of bromine-based flame retardants, inorganic bromine products, and chlorine based biocides for water treatment.

    Cost of Sales

        Our cost of sales in 2013 amounted to approximately $3,862 million, compared with approximately $3,760 million in 2012, an increase of approximately $102 million. The increase stems from an expense, in the amount of approximately $133 million, resulting from an increase in quantities sold, which includes first-time consolidation of the financial statements of companies acquired in 2012 and 2013, the impact of a change in the exchange rates, in the amount of approximately $85 million, and a decline in value of inventory, in the amount of approximately $10 million. This increase was partly offset by a decline in energy costs and raw-material prices (mainly sulfur), in the amount of approximately $98 million, and by a decrease in royalties and selling commissions due to a decrease in total sales, in the amount of approximately $29 million.

    Gross profit

        Our gross profit amounted to $2,410 million in 2013, compared with gross profit of $2,711 million in 2012, a decrease of approximately $301 million. Our gross profit margin as a percentage of sales was approximately 38.4% in 2013, compared with approximately 41.9% in 2012.

    Selling and marketing expenses

        Our selling and marketing expenses amounted to approximately $850 million in 2013, compared with approximately $797 million in 2012. The selling and marketing expenses include, mainly, costs with respect to marine shipping, overland transport, selling commissions and employee salaries. The increase stems mainly from the increase in quantities sold and, accordingly, the quantities shipped, in the amount of

57


Table of Contents

approximately $43 million, a change in the exchange rates, in the amount of approximately $5 million, and an increase, in the amount of approximately $4 million, from the first-time consolidation of the results of companies and activities acquired in 2013 and 2012.

    General and administrative expenses

        Our general and administrative expenses amounted to approximately $281 million in 2013, compared with approximately $249 million in 2012. Our general and administrative expenses include mainly salaries. The salaries in Israel are paid in NIS. The increase stems primarily from the impact of currency exchange rates due to the strengthening of the average value of the NIS against the U.S. dollar during 2013, and an increase in expenses in connection with options granted to employees in 2012.

    Research and development expenses

        Our research and development expenses were approximately $83 million in 2013, compared with approximately $74 million in 2012.

    Operating income

        Our operating income amounted to approximately $1,101 million in 2013, compared with approximately $1,554 million in 2012, a decrease of approximately $453 million. The decrease in operating income stems mainly from the decrease in gross profit, the increase in selling and marketing expenses and general and administrative expenses, an expense, in the amount of approximately $60 million, in respect of a plan for early retirement in Rotem, an increase of the provision of approximately $25 million for removal of waste at Bromine Compounds and an impairment in the value of our assets, in the amount of approximately $10 million. Our operating income in 2012 was impacted by a provision for early retirement plans, in the amount of approximately $55 million, in Bromine Compounds and Rotem, and from income, in the amount of approximately $11 million, relating to a VAT refund outside Israel. Our operating margin (the ratio of operating income to sales) was about 17.6% in 2013, compared with about 24.0% in 2012.

    Finance expenses, net

        Our net finance expenses amounted to approximately $27 million in 2013, compared with net finance expenses of approximately $61 million in 2012. The decrease in net finance expenses in 2013 compared with 2012 stems mainly from an increase in finance income in 2013 as a result of change in the fair value of financial derivatives and from revaluation of net short-term financial liabilities, in the amount of $60 million. On the other hand, there was an increase in finance expenses due to the impact of exchange rate differences on provisions for employee benefits, in the amount of approximately $13 million, stemming from an upward revaluation of the NIS against the U.S. dollar, at the rate of about 7.0% in 2013, compared with an upward revaluation of the NIS against the U.S. dollar, at the rate of about 2.3%, in 2012. In addition, there was an increase in interest expense, which totaled approximately $42 million in 2013, compared with approximately $29 million in 2012.

        The increase in finance income from the change in fair value of derivative financial instruments from $8.5 million in 2012 to $122.9 million in 2013 was a result of the upward revaluation of the NIS against the U.S. dollar, as described above, and an increase in the fair value of hedges relating to marine shipping prices, which increased approximately 95% in 2013 as compared to prices at the end of 2012. For additional information about our hedging transactions, see "—Quantitative and Qualitative Disclosures About Market Risk."

    Tax expenses

        Our tax expenses amounted to approximately $280 million in 2013, compared to approximately $218 million in 2012. The tax rate on pre-tax income was about 25.5% in 2013 compared with about 14.3% in 2012. The increase in the tax rate in 2013 compared with 2012 is derived mainly from unusual tax

58


Table of Contents

expenses, in the amount of approximately $108 million, due to the Company's decision to release trapped earnings and the impact of updating our deferred taxes as a result of an increase in the corporate rate in Israel to 26.5% commencing from January 2014. This increase was partly offset by the impact of the change in the exchange rate of the U.S. dollar against the NIS in 2013, compared with 2012. We pay Israeli taxes in NIS but measure such taxes for our accounting purposes in U.S. dollars, so the appreciation of the NIS against the U.S. dollar in 2013 triggered an effective decline in the tax rate as measured in U.S. dollars. On December 29, 2013, an assessment was received from the tax authorities in Israel requiring us to make a further tax payment in addition to the amount we already paid in respect of 2009 to 2011, in the amount of approximately $230 million. We disagree with the position taken by the tax authorities, and we have contested the assessment issued by the tax authorities. No tax expenses were included in the financial statements in connection with this assessment.

        We currently benefit from certain tax laws that reduce our tax rate in Israel, which will gradually expire. See "Tax Considerations—Israeli Tax Considerations—Taxation of the Company—Reform of the Investments Law—2011."

    Net income

        The income attributable to the Company's shareholders amounted to approximately $819 million in 2013, compared with approximately $1,300 million in 2012, a decrease of approximately $481 million.


Year Ended December 31, 2012 Compared to Year Ended December 31, 2011

        Set forth below are our results of operations for the years ended December 31, 2012 and 2011.

 
  For the Years
Ended
December 31,
   
 
 
  % Increase
(Decrease)
 
 
  2012   2011  
 
  (in millions of
U.S. dollars)

   
 

Sales

    6,471     6,869     (5.8 )

Cost of sales

    3,760     3,768     (0.2 )
               

Gross profit

    2,711     3,101     (12.6 )

Selling, transportation and marketing expenses

    797     862     (7.5 )

General and administrative expenses

    249     265     (6.0 )

Research and development expenses, net

    74     70     5.7  

Other expenses

    61     30     103.3  

Other income

    (24 )   (4 )   500.0  
               

Operating income

    1,554     1,878     (17.3 )
               

Finance expenses

    82     104     (21.2 )

Finance income

    (21 )   (26 )   (19.2 )
               

Finance expenses, net

    61     78     (21.8 )
               

Share in earnings of equity accounted investees

    27     34     (20.6 )
               

Income before taxes on income

    1,520     1,834     (17.1 )

Taxes of income

    218     333     (34.5 )
               

Income for the year

    1,302     1,501     (13.3 )
               
               

Attributable to:

                   

Shareholders of the Company

    1,300     1,498     (13.2 )

Non-controlling interests

    2     3     (33.3 )
               

Income for the year

    1,302     1,501     (13.3 )
               
               

59


Table of Contents

    Sales

        Our sales in 2012 amounted to approximately $6,471 million, compared with approximately $6,869 million in 2011, a decrease of approximately 5.8%. This decrease was due to a decline in quantities sold, which gave rise to a decline in sales of approximately $398 million, and changes in currency exchange rates, which caused a decrease in sales of approximately $180 million. On the other hand, the decline was partly offset by an increase in selling prices, which led to an increase of approximately $50 million, and from the first-time consolidation of the financial statements of companies acquired during 2012 and 2011, which increased sales by $130 million.

        Below is a geographical breakdown of our sales according to customer location:

 
  Year Ended
December 31,
 
 
  2012   2011  
 
  (in millions of
U.S. dollars)

 

Israel

    325     256  

North America

    1,252     1,352  

South America

    815     665  

Europe

    2,332     2,390  

Asia

    1,615     2,059  

Rest of the world

    132     147  
           

Total

    6,471     6,869  
           
           

        This breakdown of sales indicates a decrease in sales, mainly in Asia, due to nonrenewal of potash supply contracts in the second half of 2012 in China and nonrenewal of potash supply contracts in India in 2012. Our imports of potash to India in 2012 were based on the contracts we signed in August 2011. On the other hand, there was an increase in sales in South America, stemming from an increase in sales of potash in this area.

    Cost of Sales

        Our cost of sales in 2012 amounted to approximately $3,760 million, compared with approximately $3,768 million in 2011, a decrease of approximately $8 million. The decrease stems from a decrease in the quantities sold, in the amount of approximately $120 million, and from the impact of the change in the exchange rates, in the amount of approximately $162 million. This decrease was mostly offset by the first time consolidation of the financial statements of companies acquired in 2012 and 2011, in the amount of approximately $100 million, an increase in energy costs and raw material prices, in the amount of approximately $104 million, and an increase in other operating expenses, in the amount of approximately $70 million.

    Gross profit

        Our gross profit amounted to approximately $2,711 million in 2012, compared with a gross profit of approximately $3,101 million in 2011, a decrease of approximately $390 million. Our gross profit margin as a percentage of sales amounted to approximately 41.9% in 2012, compared with approximately 45.1% in 2011.

    Selling and marketing expenses

        Our selling and marketing expenses amounted to approximately $797 million in 2012, compared with approximately $862 million in 2011, a decrease of approximately $65 million. The selling and marketing expenses include, mainly, costs with respect to marine shipping, overland transport, selling commissions and employee salaries. The decrease stems mainly from a decrease in quantities sold and shipping prices,

60


Table of Contents

which led to a decrease of approximately $92 million. On the other hand, this decrease was partly offset by an increase of approximately $15 million in expenses deriving from the first-time consolidation of the results of companies acquired during 2012 and 2011, and an increase of approximately $12 million in other operating expenses.

    General and administrative expenses

        Our general and administrative expenses amounted to approximately $249 million in 2012, compared with approximately $265 million in 2011. Our general and administrative expenses include mainly salaries. The salaries in Israel are paid in NIS. The decrease in general and administrative expenses derived mainly from the impact of currency exchange rates, stemming from the depreciation of the average value of the NIS against the U.S. dollar during 2012, and a decrease in salary expenses in connection with options granted to employees.

    Research and development expenses

        Our research and development expenses amounted to approximately $74 million in 2012, an increase of approximately $4 million compared with 2011.

    Operating income

        Our operating income amounted to approximately $1,554 million in 2012, a decrease of $324 million compared with 2011. The decrease in operating income stemmed mainly from the decrease in gross profit, and from an expense of approximately $55 million in respect of early retirement plans of certain subsidiaries. The decrease was partly offset by the decline in selling and marketing expenses and general and administrative expenses, by income stemming from VAT refunds received by a subsidiary outside Israel, in the amount of approximately $11 million, and by a past service cost adjustment due to implementation of IAS 19 (revised) in the amount of approximately $13 million.

        Our operating margin as a percentage of sales was approximately 24% in 2012, as compared with 27.3% in 2011.

    Finance expenses, net

        Our net finance expenses amounted to approximately $60.9 million in 2012, compared with net finance expenses of approximately $77.8 million in 2011. The main factors causing the decrease in net finance expenses in 2012 compared with 2011 were as follows:

    An upward revaluation of the NIS against the U.S. dollar at the period-end date (despite the depreciation of the average value of the NIS against the U.S. dollar during this period), at the rate of approximately 2.3% in 2012, compared with a devaluation of the NIS against the U.S. dollar at the rate of approximately 7.7% in 2011, caused income from transactions in financial derivatives and from revaluation of net short-term financial liabilities to amount to approximately $0.4 million in 2012 compared with expenses of approximately $44 million in 2011, mainly due to the positive fair value of U.S. dollar/NIS hedging transactions, partly offset by:

    Expenses in respect of the impact of exchange rate differences on provisions for employee benefits, in the amount of approximately $28 million.

        The increase in finance income from the change in fair value of derivative financial instruments from an expense of $44.7 million in 2011 to income of $8.5 million in 2012 was a result of the upward revaluation of the NIS against the U.S. dollar, as described above, partially offset by an increase in finance expenses from a decrease in the fair value of hedges relating to marine shipping prices, which decreased approximately 37% in 2012 as compared to prices at the end of 2011. For additional information about our hedging transactions, see "—Quantitative and Qualitative Disclosures About Market Risk."

61


Table of Contents

    Tax expenses

        Our tax expenses in 2012 amounted to approximately $217.6 million, compared to approximately $333.5 million in 2011. The tax rate on pre-tax income was 14.3% in 2012 compared to 18.2% in 2011. The lower tax percentage in 2012 compared with 2011 was affected by:

    deferred tax expenses recognized in 2011, of approximately $38 million, due to the passage by the Israeli Knesset of the Law for Revision of the Tax Burden (Legislative Amendments), 2011, which cancelled the reduction in the tax rate previously provided by the Economic Efficiency Law of 2009 and increased the corporate tax rate to 25% beginning in 2012;

    tax income in 2012 stemming from tax refunds in respect of distributions of dividends from subsidiaries operating outside Israel, in the amount of approximately $21 million;

    a tax credit received by a subsidiary outside Israel in 2012, in connection with investments in new production facilities, in the amount of approximately $11 million; and

    recognition of deferred tax assets in respect of carryforward tax losses of a subsidiary in Israel, in the amount of approximately $10 million;

      partly offset by:

    the increase in the tax rate on companies operating in Israel from 24% to 25% in 2012 due to the approval of the Law for Revision of the Tax Burden.

    Net income

        The income attributable to the Company's shareholders amounted to approximately $1,300 million in 2012, compared with approximately $1,498 million in 2011, a decrease of approximately $198 million.


Segment Information for Six Months Ended June 30, 2014 Compared to Six Months Ended June 30, 2013

 
  Six Months
Ended
June 30,
 
Sales by segment
  2014   2013  
 
  (in millions of
U.S. dollars)

 

Fertilizers

    1,754     2,081  

Industrial Products

    696     691  

Performance Products

    800     763  

Others and setoffs

    (102 )   (124 )
           

Total

    3,148     3,411  
           
           

Note: The sales data for the segments are before setoffs of inter-segment sales.

 
  Six Months
Ended
June 30,
 
Operating income by segment
  2014   2013  
 
  (in millions of
U.S. dollars)

 

Fertilizers

    331     599  

Industrial Products

    (79 )   98  

Performance Products

    90     87  

Others and setoffs

    (21 )   (28 )
           

Total

    321     756  
           
           

62


Table of Contents

    Fertilizers

        Below is a breakdown of the sales and operating income of our Fertilizers segment in the six months ended June 30, 2014 and 2013, by areas of operation (before setoffs of inter-segment sales):

 
  Six Months
Ended
June 30,
 
 
  2014   2013  

Sales

             

Potash

    52 %   54 %

Phosphate

    48 %   46 %

Operating income

             

Potash

    84 %   82 %

Phosphate

    16 %   18 %

    Sales

        Total sales in our Fertilizers segment in the six months ended June 30, 2014 amounted to approximately $1,754 million, a decrease of approximately $327 million compared with the six months ended June 30, 2013.

        The decrease in sales stems from a decrease in selling prices, which led to a decline in sales of approximately $368 million and from a drop in the quantities sold, in the amount of approximately $3 million. On the other hand, this decrease was partly offset by the impact of a change in exchange rates, in the amount of approximately $44 million.

    Operating Income

        Operating income in our Fertilizers segment in the six months ended June 30, 2014 amounted to approximately $331 million, a decrease of approximately $268 million compared with the six months ended June 30, 2013. Operating income, net of unusual items, as detailed below, amounted to approximately $355 million.

        The decrease in operating income in the six months ended June 30, 2014 stems mainly from a decrease in selling prices, which led to a decline in operating income of approximately $368 million, the impact of the strike at our Rotem subsidiary, in the amount of approximately $16 million, an unusual expense in connection with a provision for arbitration relating to royalties in respect of prior periods in the amount of approximately $8 million, and the impact of the change in the exchange rates in the amount of approximately $4 million. On the other hand, this decrease was partly offset as a result of a decline in raw-material prices and energy costs, in the amount of approximately $47 million, by a decrease, in the amount of approximately $29 million, in the royalties and selling commissions, mainly due to the decrease in sales, a decline in other operating expenses, in the amount of approximately $22 million, primarily due to a drop in salary expenses as a result of the retirement of employees at our Rotem subsidiary, a change in the product mix of the quantities sold having high marginal income, which led to an increase in income, in the amount of approximately $15 million, and from a decline in shipping expenses, in the amount of approximately $15 million.

    Potash

        Revenue from potash includes sales of potash from Israel, Spain (Iberpotash) and the United Kingdom (Cleveland Potash).

63


Table of Contents

        Below is a breakdown of revenue and operating income for potash sales in the six months ended June 30, 2014 and 2013.

 
  Six Months
Ended June 30,
 
 
  2014   2013  
 
  (in millions of
U.S. dollars)

 

Revenue*

    936     1,164  

Operating income

    277     489  

Adjusted operating income

    285     489  

*
Includes revenue from inter-segment sales.

        The decrease in revenue in the six months ended June 30, 2014 compared with the six months ended June 30, 2013 stems from a decrease in selling prices, which led to a decrease in sales, in the amount of approximately $280 million. In contrast, this decrease was partly offset by an increase in quantities sold, which led to an increase in revenue, in the amount of approximately $34 million, and the impact of the change in currency exchange rates, in the amount of approximately $18 million.

        The decrease in operating income in the six months ended June 30, 2014 stems mainly from a decrease in selling prices of potash, which led to a decline in operating income, in the amount of approximately $280 million, an increase in cost of sales due to an increase in quantities sold, in the amount of approximately $9 million, and from an unusual expense in connection with a provision for arbitration relating to royalties in respect of prior periods, in the amount of approximately $8 million. On the other hand, this decrease was partly offset by the impact of the increase in quantities of potash sold, in the amount of approximately $34 million, a decline, in the amount of approximately $17 million, stemming from a decrease in royalties and selling commissions, mainly as a result of the drop in sales, a decrease in energy costs, in the amount of approximately $18 million, a decrease in other operating expenses, in the amount of approximately $8 million, and a decline in shipping expenses, in the amount of approximately $8 million.

        Below is a breakdown of production, sales and closing inventories for potash in the six months ended June 30, 2014 and 2013.

 
  Six Months
Ended
June 30,
 
 
  2014   2013  
 
  (in thousands
of tons)

 

Production

    2,519     2,531  

Sales to external customers

    2,650     2,549  

Sales to internal customers

    168     139  

Total sales (including internal sales)

    2,818     2,688  

Closing inventory

    827     849  

        The quantity of potash sold to external customers in the six months ended June 30, 2014 was approximately 101 thousand tons higher than in the six months ended June 30, 2013, mainly due to an increase in quantities sold in China and Europe, which was partly offset by a decrease in quantities sold in India and South America. Production of potash in the six months ended June 30, 2014 was approximately 12 thousand tons lower than in the six months ended June 30, 2013, as a result of a decline in production in Spain and the United Kingdom.

64


Table of Contents

    Phosphates

        Revenue from fertilizers and phosphates derives from sales in and outside Israel of phosphate rock (as a raw material and for direct fertilization), fertilizers (including phosphate fertilizers and compound fertilizers, liquid fertilizers, slow-release fertilizers, controlled-release fertilizers and fully soluble fertilizers, which include different proportions of nitrogen, phosphorus and potassium), phosphoric acid used as a raw material for fertilizer production ("green acid"), and other products.

        Below is a breakdown of revenue and operating income for fertilizers and phosphates in the six months ended June 30, 2014 and 2013.

 
  Six Months
Ended
June 30,
 
 
  2014   2013  
 
  (in millions of
U.S. dollars)

 

Revenue*

    876     977  

Operating income

    51     108  

Operating income excluding unusual items(1)

    67     108  

*
Includes revenue from inter-segment sales.

(1)
Operating income excluding unusual items excludes certain items that we view as unusual and not typical of ongoing operations. Unusual items in the first half of 2014 included $16 million of production costs with respect to the strike at Rotem. There were no unusual items in the first half of 2013.

        The decrease in sales in the six months ended June 30, 2014 stems from a decrease in selling prices of phosphate fertilizers, which caused a decrease in sales of approximately $91 million, and a decline in quantities sold, which led to a decrease in sales of approximately $36 million. This decrease was partly offset as a result of the change in the currency exchange rates, in the amount of approximately $26 million.

        The decrease in operating income in the six months ended June 30, 2014 derives mainly from a decrease in selling prices, in the amount of approximately $91 million, a decline in quantities sold, in the amount of approximately $36 million, from the impact of the strike at our Rotem subsidiary, in the amount of approximately $16 million, and from the impact of the changes in currency exchange rates, in the amount of approximately $3 million. On the other hand, this decrease was partly offset as a result of a decrease in raw material prices, in the amount of approximately $35 million, a decrease in the cost of sales, in the amount of approximately $27 million, a decrease in the royalties and selling commissions in the amount of approximately $6 million, a drop in shipping expenses due to a fall in quantities sold, in the amount of approximately $5 million, and a decrease in other operating costs, mainly a decrease in salary expenses due to retirement of employees at our Rotem subsidiary, in the amount of approximately $15 million.

        Below is a breakdown of production and sales for fertilizers and phosphates in the six months ended June 30, 2014 and 2013.

 
  Six Months
Ended
June 30,
 
 
  2014   2013  
 
  (in thousands
of tons)

 

Phosphate rock

             

Production

    1,511     1,724  

Sales to external customers

    472     461  

Internal uses

    939     1,281  

Fertilizers

             

Production

    748     890  

Sales to external customers

    902     955  

        Phosphate rock is produced according to demand, both for internal uses and for sales to external customers, while maintaining appropriate inventory levels.

65


Table of Contents

        The quantity of the fertilizers sold in the six months ended June 30, 2014 was lower than in the six months ended June 30, 2013, mainly due to a decrease in quantities sold in Brazil. Production of fertilizers and phosphate rock was 142 thousand tons and 213 thousand tons lower, respectively, compared with the six months ended June 30, 2013, as a result of the strike at our Rotem subsidiary and the damage caused to the water heater at our Rotem subsidiary's sulfuric acid production facility, which has since been repaired.

    Industrial Products

    Sales

        The total sales of our Industrial Products segment in the six months ended June 30, 2014 was approximately $696 million, an increase of approximately $5 million compared with the six months ended June 30, 2013. This increase stems from an increase in the quantities sold, mainly of biocides used for water treatment, and of magnesium and magnesium-chloride products, in the amount of approximately $14 million, as well as the impact of the change in currency exchange rates, in the amount of approximately $5 million. This increase was mostly offset by a decline in selling prices, mainly of bromine-based flame retardants, inorganic bromine products and chlorine-based biocides for treatment of water, which all caused a reduction in sales, in the amount of approximately $14 million.

    Operating Income (Loss)

        Operating loss in the six months ended June 30, 2014 was approximately $79 million, compared with operating income of approximately $98 million in the six months ended June 30, 2013. Operating income after eliminating unusual items, as detailed below, in the six months ended June 30, 2014 amounted to approximately $62 million. Adjusted operating income as a percentage of sales amounted to approximately 8.9% in the six months ended June 30, 2014 compared with an operating income margin of approximately 14.2% in the six months ended June 30, 2013.

        Operating income decreased primarily as a result of an unusual expense in connection with a provision for royalties relating to prior periods due to an arbitration decision, in the amount of approximately $141 million, a decrease in selling prices, which led to a decline in operating income of approximately $14 million, a change in the mix of quantities sold and quantities produced of various products, which caused a decline in operating income of approximately $11 million, an increase in royalties in the six months ended June 30, 2014 as a result of the arbitration decision, in the amount of approximately $6 million, an increase in other operating expenses, in the amount of approximately $5 million, and from the impact of changes in currency exchange rates, in the amount of approximately $9 million. This decrease was partly offset by a decrease in raw material and energy prices, which increased operating income by approximately $9 million.

    Performance Products

    Sales

        Sales in our Performance Products segment in the six months ended June 30, 2014 amounted to approximately $800 million, an increase of approximately $37 million compared with the six months ended June 30, 2013. This increase stems from an increase in quantities sold, including the first-time consolidation of the financial statements of companies acquired during 2013 and in the six months ended June 30, 2014, in the amount of approximately $23 million, the impact of changes in currency exchange rates, in the amount of approximately $10 million, and an increase in selling prices, which led to an increase of approximately $4 million.

    Operating Income

        Our Performance Products segment's operating income in the six months ended June 30, 2014 amounted to approximately $90 million, an increase of approximately $3 million compared with the six months ended June 30, 2013. This increase was the result of an increase in quantities sold, including the first-time consolidation of the financial statements of companies acquired during 2013 and in the six

66


Table of Contents

months ended June 30, 2014, in the amount of approximately $5 million, an increase in selling prices, which led to an increase of approximately $4 million, and the impact of changes in currency exchange rates, in the amount of approximately $1 million. This increase was partly offset by additional costs and an increase in raw material costs, due to the strike at our Rotem subsidiary, in the amount of approximately $7 million.


Segment Information for Year Ended December 31, 2013 Compared to Year Ended December 31, 2012

 
  Year Ended
December 31,
 
Sales by segment
  2013   2012  
 
  (in millions of
U.S. dollars)

 

Fertilizers

    3,655.3     3,805.9  

Industrial Products

    1,296.7     1,417.4  

Performance Products

    1,574.7     1,472.1  

Others and setoffs

    (255.2 )   (224.0 )
           

Total

    6,271.5     6,471.4  
           
           

Note: The sales data for the segments are before setoffs of inter-segment sales.

 
  Year Ended
December 31,
 
Operating income by segment
  2013   2012  
 
  (in millions of
U.S. dollars)

 

Fertilizers

    821.1     1,158.8  

Industrial Products

    114.5     217.3  

Performance Products

    195.8     179.3  

Others and setoffs

    (30.0 )   (1.8 )
           

Total

    1,101.4     1,553.6  
           
           

    Fertilizers

        Below is a breakdown of the sales and operating income of our Fertilizers segment in 2013 and 2012, by areas of operation (before setoffs of inter-segment sales):

 
  Year Ended
December 31,
 
 
  2013   2012  

Sales

             

Potash

    54 %   56 %

Phosphate

    46 %   44 %

Operating income

             

Potash

    90 %   86 %

Phosphate

    10 %   14 %

    Sales

        Total sales of our Fertilizers segment in 2013 amounted to approximately $3,655 million, a decrease of approximately $151 million compared with 2012.

        The decrease in sales in 2013 stems mainly from a decrease in the selling price, in the amount of approximately $467 million. This decrease was partially offset by an increase in the quantities sold, including the first-time consolidation of acquired companies, which led to an increase in sales of

67


Table of Contents

approximately $269 million, and from the impact of changes in currency exchange rates, in the amount of approximately $49 million.

    Operating income

        Operating income in our Fertilizers segment in 2013 amounted to approximately $821 million, a decrease of approximately $338 million compared with 2012. Operating income as a percentage of sales was approximately 22.5% in 2013, compared with approximately 30.5% in 2012. Operating income, net of unusual items in 2013 ($60 million of early retirement expense) and 2012 ($33 million of early retirement expense), amounted to approximately $881 million and approximately $1,192 million, respectively, a decrease of approximately $311 million. Adjusted operating income as a percentage of sales was approximately 24.1% compared with approximately 31.1% in 2012.

        The decrease in operating income in 2013 is mainly due to a decrease in the selling prices of most of the segment's products, which led to a decrease in operating income of approximately $467 million, changes in currency exchange rates, in the amount of $18 million, a provision for early retirement in Rotem, in the amount of $60 million, and an impairment in the value of inventory, in the amount of $10 million. This decrease was partly offset by improved results of approximately $81 million due to higher quantities sold, mainly of potash (due to an increase in sales of $225 million that was partially offset by increases in the cost of sales of $104 million and transportation costs of $40 million due to the increase in quantities sold), and a decrease in total royalties and selling commissions of $30 million (stemming mainly from a decrease in sales). In addition, the decrease was partly offset by a decrease in raw material and energy prices, in the amount of approximately $72 million, and a reduction in other operating costs, in the amount of approximately $1 million. Operating income in 2012 was impacted by a provision for early retirement in Rotem in the amount of $33 million.

    Potash

        Revenue from potash includes sales of potash from Israel, Spain (Iberpotash S.A. ("Iberpotash")) and the United Kingdom (Cleveland Potash).

        Below is a breakdown of revenue and operating income for potash sales in 2013 and 2012.

 
  Year Ended
December 31,
 
 
  2013   2012  
 
  (in millions of
U.S. dollars)

 

Revenue*

    2,027     2,198  

Operating income

    740     996  

*
Includes revenue from inter-segment sales.

        The decrease in revenue in 2013 compared with 2012 stems mainly from a decrease in selling prices, which led to a decrease in revenue, in the amount of approximately $359 million. On the other hand, this decrease was partly offset by an increase in quantities sold, which caused an increase in sales of approximately $177 million, and the impact of the change in currency exchange rates, in the amount of approximately $10 million.

        The decrease in operating income in 2013 compared with 2012 is mainly due to the impact of the decrease in selling prices of potash, which reduced operating income by approximately $359 million, changes in currency exchange rates, in the amount of approximately $10 million, and an increase in other operating expenses, in the amount of approximately $9 million. This decrease was partly offset by improved results of approximately $81 million due to higher quantities sold (due to an increase in sales of $177 million that was partially offset by increases in the cost of sales of $70 million and transportation costs of $26 million due to the increase in quantities sold), a decrease in sales commissions of approximately

68


Table of Contents

$18 million (stemming mainly from a decrease in sales) and a decrease in energy prices, in the amount of approximately $24 million.

        Below is a breakdown of production, sales and closing inventories for potash in 2013 and 2012.

 
  Year Ended
December 31,
 
 
  2013   2012  
 
  (in thousands
of tons)

 

Production

    5,155     4,936  

Sales to external customers

    4,712     4,336  

Sales to internal customers

    323     293  

Total sales (including internal sales)

    5,035     4,629  

Closing inventory

    1,126     1,006  

        The quantity of potash sold to external customers in 2013 was about 376 thousand tons higher than in 2012, mainly as a result of an increase in quantities sold to China and Brazil. Production of potash in 2013 was about 219 thousand tons higher than in 2012, as a result of an improvement in production in our mines in Europe.

    Phosphates

        Revenue from fertilizers and phosphates derive from sales in and outside Israel of phosphate rock, fertilizers (including phosphate fertilizers, compound, liquid and fully soluble fertilizers and slow-release and controlled-release fertilizers), phosphoric acid used as a raw material for fertilizer production ("green acid") and other products.

        Below is a breakdown of revenue and operating income for fertilizers and phosphates in 2013 and 2012.

 
  Year Ended
December 31,
 
 
  2013   2012  
 
  (in millions of
U.S. dollars)

 

Revenues*

    1,754     1,727  

Operating income

    79     162  

Operating income excluding unusual items (1)

    139     195  

*
Includes revenue from inter-segment sales.
(1)
Operating income excluding unusual items excludes certain items that we view as unusual and not typical of ongoing operations. Unusual items in 2013 and 2012 included $60 million and $33 million, respectively, of early retirement expense at Rotem from a restructuring program.

        The increase in revenue in 2013 compared with 2012 is mainly due to an increase in quantities of phosphate fertilizers sold, including the first-time consolidation of the financial statements of certain companies acquired, which led to an increase in the total revenue in the amount of approximately $99 million, and the impact of changes in currency exchange rates, in the amount of approximately $39 million. This increase was mostly offset by a decrease in selling prices of fertilizers and phosphates products, which led to a decline in revenue of approximately $109 million.

        Operating income in 2013 was $79 million, a decrease of approximately $83 million as compared to operating income of $162 million in 2012. Operating income as a percentage of sales was 4.5% in 2013 as compared to 9.4% in 2012. Operating income in 2013 and 2012, after eliminating unusual items, amounted to approximately $139 million and approximately $195 million, respectively. Adjusted operating income, which reflects the elimination of the unusual items described above, as a percentage of sales, was approximately 7.9%, as opposed to an adjusted operating income rate of approximately 11.3% in 2012.

69


Table of Contents

        The decrease in operating income in 2013 compared with 2012 stems mainly from a decrease in selling prices, in the amount of approximately $109 million, partly offset by a decrease in sales commissions, in the amount of approximately $12 million (stemming mainly from a decrease in sales). The decrease in operating income was also due to a provision for early retirement in Rotem, in the amount of approximately $60 million (as compared to a similar provision in 2012 of $33 million), the impact of changes in currency exchange rates, in the amount of approximately $8 million, and impairment in the value of inventory, in the amount of approximately $10 million. This decrease was partly offset by a decrease in raw material prices, in the amount of approximately $52 million, and a decrease in other operating expenses, in the amount of approximately $7 million.

        In addition, operating income was affected by the sales increase, which was due to the increase in quantities sold of approximately $55 million, offset by the impact of higher cost of sales of approximately $40 million and transportation costs of approximately $16 million due to the increase in quantities sold.

        Below is a breakdown of production and sales for fertilizers and phosphates in 2013 and 2012.

 
  Year Ended
December 31,
 
 
  2013   2012  
 
  (in thousands
of tons)

 

Phosphate rock

             

Production

    3,578     3,513  

Sales to external customers

    879     739  

Internal uses

    2,577     2,491  

Fertilizers

             

Production

    1,747     1,598  

Sales to external customers

    1,695     1,575  

        Phosphate rock is produced according to demand, both for internal use and for sales to external customers, while maintaining appropriate inventory levels. Production of phosphate fertilizers in 2013 was higher than in 2012, mainly due to maintenance work in the production facilities performed in the first half of 2012.

    Industrial Products

    Sales

        The total sales of the Industrial Products segment in 2013 reached approximately $1,297 million, a decrease of approximately $120 million compared with 2012. The decrease in sales stems mainly from a decrease in the quantities sold, mainly of bromine-based flame retardants, inorganic bromine products and chlorine-based biocides for water treatment, which decreased the total sales by approximately $82 million, as well as from a decline in the selling prices in the amount of approximately $42 million. This decrease was offset in part by the impact of changes in currency exchange rates, in the amount of approximately $3 million.

    Operating income

        Operating income in 2013 totaled approximately $115 million, compared with operating income of approximately $217 million in 2012. Operating income in 2013 ($25 million update of a waste removal provision and $10 million asset write-down) and 2012 ($22 million of early retirement expense), after eliminating unusual items, amounted to approximately $150 million and approximately $239 million, respectively. Operating income as a percentage of sales was approximately 8.9% in 2013 compared to 15.3% in 2012. Adjusted operating income, which reflects the elimination of the unusual items described above, as a percentage of as a percentage of sales, was approximately 11.6%, compared with approximately 16.9% in 2012.

70


Table of Contents

        Operating income decreased primarily as a result of a decrease in the quantities sold and produced, which caused a decrease in operating income of approximately $49 million (due to a decrease in sales of $82 million that was partially offset by decreases in the cost of sales of $30 million and transportation costs of $3 million due to the decrease in quantities sold), and a decrease in the selling prices, which caused a decrease in operating income of approximately $42 million, expenses relating to update of the provision for waste removal, in the amount of approximately $25 million, an impairment of assets, in the amount of approximately $10 million, and the impact of changes in currency exchange rates, in the amount of approximately $9 million. This decrease was partly offset by a decrease in raw material and energy prices by approximately $14 million. Operating income in 2012 was impacted by a provision for early retirement, in the amount of approximately $22 million.

    Performance Products

    Sales

        Sales in our Performance Products segment in 2013 amounted to approximately $1,575 million, an increase of approximately $103 million compared with 2012.

        The increase in sales stems from an increase in quantities sold, including the first-time consolidation of the financial statements of companies acquired during 2013, which led to an increase of approximately $90 million, and from the impact of changes in exchange rates, which gave rise to an increase of approximately $12 million.

    Operating income

        The operating income in our Performance Products segment in 2013 amounted to approximately $196 million, an increase of approximately $17 million compared with 2012. The increase stems mainly from a decline in raw material prices, in the amount of approximately $24 million, and improved results of approximately $20 million due to higher quantities sold (due to an increase in sales of $70 million that was partially offset by increases in the cost of sales of $44 million and transportation costs of $6 million due to the increase in quantities sold). This increase was partly offset by an increase in other operating expenses, in the amount of approximately $16 million, and by the impact of unusual income in respect of a VAT refund, in the amount of approximately $11 million, recognized in 2012.


Segment Information for Year Ended December 31, 2012 Compared to Year Ended December 31, 2011

 
  Year Ended
December 31,
 
Sales by segment
  2012   2011  
 
  (in millions of
U.S. dollars)

 

Fertilizers

    3,805.9     4,089.4  

Industrial Products

    1,417.4     1,501.2  

Performance Products

    1,472.1     1,490.8  

Others and setoffs

    (224.0 )   (212.8 )
           

Total

    6,471.4     6,868.6  
           
           

Note: The sales data for the segments are before setoffs of inter-segment sales.

71


Table of Contents

 
  Year Ended
December 31,
 
Operating income by segment
  2012   2011  
 
  (in millions of
U.S. dollars)

 

Fertilizers (1)

    1,158.8     1,389.9  

Industrial Products (2)

    217.3     290.1  

Performance Products (3)

    179.3     191.0  

Others and setoffs

    (1.8 )   7.1  
           

Total

    1,553.6     1,878.1  
           
           

(1)
Includes an expense in respect of an early retirement plan for employees, in the amount of approximately $33 million, which was recognized during the fourth quarter of 2012.

(2)
Includes an expense in respect of an early retirement plan for employees, in the amount of approximately $22 million, which was recognized during the fourth quarter of 2012.

(3)
Includes income in respect of a VAT refund, in the amount of approximately $11 million, which was received by a foreign subsidiary during the fourth quarter of 2012.

    Fertilizers

        Below is a breakdown of the sales and operating income of our Fertilizers segment in 2012, by areas of operation (before setoffs of inter-segment sales):

 
  Year Ended
December 31,
 
 
  2012   2011  

Sales

             

Potash

    56 %   60 %

Phosphate

    44 %   40 %

Operating income

   
 
   
 
 

Potash

    86 %   85 %

Phosphate

    14 %   15 %

    Sales

        Total sales of our Fertilizers segment in 2012 amounted to approximately $3,806 million, a decrease of approximately $283 million compared with 2011, constituting a decrease of approximately 7%.

        The decrease in sales stems mainly from a decline in quantities sold, mainly of potash, which gave rise to a fall in sales of approximately $288 million, along with the impact of changes in currency exchange rates, primarily the euro against the U.S. dollar, which caused a drop in sales of approximately $108 million. On the other hand, there was a favorable impact due to inclusion of the results of companies acquired during 2011, which increased sales by approximately $108 million, and a price increase of approximately $5 million.

    Operating income

        Operating income in our Fertilizers segment in 2012 amounted to approximately $1,159 million, a decrease of approximately $231 million compared with 2011. Operating income as a percentage of sales was approximately 30.5% in 2012, compared with approximately 34.0% in 2011.

        The decrease in operating income stems mainly from a decline in quantities sold, which decreased operating income by approximately $165 million (due to a decrease in sales of $291 million that was partially offset by decreases in the cost of sales of $73 million and transportation costs of $53 million due to

72


Table of Contents

the decrease in quantities sold), an increase in the prices of raw materials and energy, which unfavorably impacted operating income by approximately $50 million, unusual expenses relating to an early retirement plan for employees, in the amount of approximately $33 million, and an increase in the prices of inputs and other operating expenses, in an amount of $11 million. The decrease was partly offset by first-time consolidation of the financial statements of companies acquired in 2011, which increased operating income by approximately $17 million, and as a result of a past service cost adjustment due to implementation of IAS 19 (revised) in the amount of approximately $13 million.

    Potash

        Revenue from potash includes sales of potash from Israel, Spain (Iberpotash) and the United Kingdom (Cleveland Potash).

        Below is a breakdown of revenue and operating income for potash sales in 2012 and 2011.

 
  Year Ended
December 31,
 
 
  2012   2011  
 
  (in millions of
U.S. dollars)

 

Revenue*

    2,198.3     2,506.2  

Operating income

    996.5     1,182.0  

*
Includes revenue from inter-segment sales.

        The decrease in revenue in 2012 compared with 2011 stems mainly from a decline in quantities of potash sold, in the amount of approximately $276 million, which was impacted by the nonrenewal of the supply agreement to China in the second half of 2012, and nonrenewal of the supply agreement to India in 2012. Imports of potash to India in 2012 were based on the contracts we signed in August 2011. In addition, the impact of changes in currency exchange rates, mainly the euro against the U.S. dollar, caused a decrease in sales of approximately $42 million. On the other hand, an increase in selling prices of potash, net of a decline in selling prices of certain byproducts, triggered an increase in sales of approximately $11 million.

        The decrease in operating income in 2012 is mainly due to a decrease in quantities of potash sold, in the amount of approximately $161 million (due to a decrease in sales of $276 million that was partially offset by decreases in the cost of sales of $69 million and transportation costs of $46 million due to the decrease in quantities sold), an increase in energy prices, in the amount of approximately $20 million, an increase in the prices of inputs and other operating expenses, in the amount of approximately $17 million, and the impact of changes in currency exchange rates, mainly the euro against the U.S. dollar, in the amount of approximately $11 million. The decrease was partly offset by changes in currency exchange rates, mainly the NIS against the U.S. dollar, in the amount of approximately $16 million, along with an increase in selling prices of approximately $10 million.

        Below is a breakdown of production, sales and closing inventories for potash in 2012 and 2011.

 
  Year Ended
December 31,
 
 
  2012   2011  
 
  (in thousands
of tons)

 

Production

    4,936     4,261  

Sales to external customers

    4,336     4,904  

Sales to internal customers

    293     268  

Total sales (including internal sales)

    4,629     5,172  

Closing inventory

    1,006     699  

73


Table of Contents

        Production of potash in 2012 was higher than in 2011, mainly due to an increase in production in Spain along with a strike in our plants in Sodom in the first quarter of 2011, which caused immediate production losses of approximately 450 thousand tons. In 2012, production of potash continued to be impacted by low production quantities in the United Kingdom. The increase in the closing inventory stems from relatively low sales to China and India.

    Phosphates

        Revenue from fertilizers and phosphates derive from sales in and outside Israel of phosphate rock (as a raw material and for direct fertilization), fertilizers (including phosphate fertilizers and compound fertilizers, liquid fertilizers, slow-release fertilizers, controlled-release fertilizers and fully soluble fertilizers, which include different proportions of nitrogen, phosphorus and potassium), phosphoric acid used as a raw material for fertilizer production ("green acid"), and other products.

        Below is a breakdown of revenue and operating income for fertilizers and phosphates in 2012 and 2011.

 
  Year Ended
December 31,
 
 
  2012   2011  
 
  (in millions of
U.S. dollars)

 

Revenue*

    1,727.1     1,697.7  

Operating income

    162.4     207.8  

*
Includes revenue from inter-segment sales.

        The increase in revenue in 2012 compared with 2011 is mainly due to inclusion of the results of companies consolidated for the first time in 2011, which increased revenue by approximately $108 million. On the other hand, the fall in quantities of fertilizers sold decreased revenue by approximately $5 million, the drop in selling prices of phosphate fertilizers decreased revenue by approximately $10 million and the impact of changes in currency exchange rates, mainly the euro/U.S. dollar rate, led to a decline in revenue of approximately $64 million.

        The decrease in operating income in 2012 compared with 2011 is mainly due to the decrease in the selling prices of phosphate fertilizers, in the amount of approximately $10 million, a decrease in quantities sold, in the amount of approximately $5 million, and an increase in production costs, in the amount of approximately $5 million. This decrease was partly offset by a decrease in transportation costs of approximately $7 million. The decrease in operating income was also due to an increase in raw material and energy prices, which unfavorably impacted operating income by approximately $30 million, and unusual expenses recognized in connection with an early retirement plan, in the amount of approximately $33 million. The decrease was partly offset by the first-time inclusion of results of companies acquired during 2011, in the amount of approximately $17 million, and by a past service cost adjustment due to the implementation of IAS 19 (revised), in the amount of approximately $13 million.

74


Table of Contents

        Below is a breakdown of production and sales for fertilizers and phosphates in 2012 and 2011.

 
  Year Ended
December 31,
 
 
  2012   2011  
 
  (in thousands
of tons)

 

Phosphate rock

             

Production

    3,513     3,105  

Sales to external customers

    739     720  

Internal uses

    2,491     2,454  

Fertilizers

             

Production

    1,598     1,570  

Sales to external customers

    1,575     1,638  

        Phosphate rock is produced according to demand, both for internal uses and for sales to external customers, while maintaining appropriate inventory levels.

        The phosphate markets in 2012 were relatively stable. Demand for phosphate fertilizers declined in the two largest markets, China and India, whereas the market in Brazil started to revive throughout 2012. In the remaining markets there was almost no change in demand.

    Industrial Products

    Sales

        The total sales of the Industrial Products segment in 2012 amounted to approximately $1,417 million, a decrease of approximately $84 million compared with 2011. The decrease in sales is due mainly to a decrease in the quantities sold, mostly of flame retardants, which decreased the sales by approximately $98 million, and from the impact of changes in currency exchange rates, in the amount of approximately $25 million. The decline in sales was partly offset by an increase in the selling prices, mainly of industrial bromine products, in the amount of approximately $39 million.

    Operating income

        The operating income in 2012 amounted to approximately $217 million, compared with operating income of approximately $290 million in 2011, a decline of approximately $73 million. Operating income as a percentage of sales was 15.3%, compared with 19.3% in 2011.

        The decrease in operating income derived from a decline in quantities sold, in the amount of approximately $41 million (due to a decrease in sales of $98 million that was partially offset by decreases in the cost of sales of $49 million and transportation costs of $8 million due to the decrease in quantities sold), an increase in the prices of raw materials and energy, in the amount of approximately $27 million, unusual expenses in connection with an early retirement plan for employees, in the amount of approximately $22 million, and an increase in other operating expenses, in the amount of approximately $29 million. The decrease in operating income resulting from the above items was partly offset by an increase in the selling prices, in the amount of approximately $39 million, and from the impact of changes in the currency exchange rate, in the amount of approximately $7 million.

    Performance Products

    Sales

        The total sales in our Performance Products segment amounted to approximately $1,472 million in 2012, a decrease of approximately $19 million compared with 2011.

75


Table of Contents

        The decrease in the total sales stems from a decline in the quantities sold, which gave rise to a decrease of approximately $13 million, and the impact of the change in the currency exchange rate, in the amount of approximately $47 million. The decrease was moderated somewhat by an increase in the selling prices in the amount of approximately $20 million, and from first-time consolidation of companies during 2011, in the amount of approximately $22 million.

    Operating income

        The operating income in our Performance Products segment in 2012 amounted to approximately $179 million, a decrease of approximately $12 million compared with 2011. The decrease stems mainly from an increase in raw material and energy prices, in the amount of approximately $27 million, the impact of changes in currency exchange rates, in the amount of approximately $6 million, and an increase in other operating expenses, in the amount of approximately $10 million. The decrease in operating income resulting from these items was partly offset by an increase in selling prices, in the amount of approximately $20 million, and by the impact of unusual income in respect of a VAT refund, in the amount of approximately $11 million. In addition, operating income was affected by improved results of $13 million due to the increase in quantities sold, offset by the impact of increases in the cost of sales of approximately $10 million and in transportation costs of approximately $3 million due to the increase in quantities sold.


Liquidity and Capital Resources

    Overview

        We have significant liquidity and capital resources as of June 30, 2014 with approximately $177.8 million in cash and cash equivalents. Our net financial liabilities were $2,652 million as of June 30, 2014, including $2,057.1 million of long-term debt (excluding current portion) and debentures and $858.7 million of short-term debt (including current portion of long-term debt).

        Our policy is to secure sources of financing for our operating activities and investments, while diversifying the sources of financing among various financial instruments, and between local and international financing entities. Our sources of financing are short- and long-term bank loans, mainly from international banks and institutional entities in Israel, debentures issued to the public and to institutional investors in Israel and the United States, and securitization of customer receivables whereby some of our subsidiaries sell their customer receivables in return for a cash payment. Our policy is to fully utilize the different financing facilities according to our cash flow requirements, alternative costs and market conditions.

        Distributions of dividends to us from our subsidiaries and transfers of funds through certain countries may under certain circumstances result in the creation of tax liabilities. However, taxes on dividend distributions and funds transfers have not had and are not expected to have a material impact on our ability to meet our cash obligations.

        Our management believes our sources of liquidity and capital resources, including working capital, are adequate for our current requirements and business operations and will be adequate to satisfy our anticipated requirements during at least the next twelve months for working capital, capital expenditures and other corporate needs.

        In addition to our normal operating expenses, including debt service, and our capital expenditures, we also will likely need to make a significant one-time payment to the State of Israel as a result of a recent partial arbitration award. See "Business—Mineral Extraction and Mining Operations—Concessions and Mining Rights—Israel." On May 19, 2014, we received the partial award of an arbitration panel that our subsidiary, Dead Sea Works, has to pay royalties to the State of Israel on the sale of downstream products manufactured by subsidiaries that are controlled by us that have production plants both in and outside the Dead Sea area, including outside Israel. The arbitrators' award was given with respect to fundamental determinations with respect to the liability to pay royalties on downstream products and does not include

76


Table of Contents

any reference to the financial calculations arising out of the award. The financial calculation will be resolved during the next phase of the arbitration. In the second quarter of 2014, in accordance with our estimate, based on the advice of our legal advisors, we recorded a provision in the amount of approximately $135 million due to the implementation of the partial arbitration award for the years 2000 through 2013. This provision amount includes, inter alia, interest and deduction of tax implications. In addition, as a result of the arbitrators' decision, the current expense in the first half of 2014 in respect of royalties increased by approximately $6 million. The arbitrators' award is partial and the financial calculations as to the method of implementation of the award have yet to be determined by the arbitrators. Therefore, our estimation is based on various assumptions regarding the manner of calculating the royalties pursuant to the partial arbitration award and reflects the best estimate of the expenditure that will be required to settle the liability as of June 30, 2014. The final amount that will be determined by the arbitrators at the end of the second stage of the arbitration after the arbitration panel determines the financial calculations as noted above, may differ, including materially, from this provision amount. We expect to fund all required payments out of cash generated from operating activities or available liquidity under our various debt facilities.

    Sources and Uses of Cash

        The following table sets forth our cash flows for the periods indicated:

 
  Six Months Ended
June 30,
  For the Years Ended
December 31,
 
 
  2014   2013   2013   2012   2011  
 
   
   
  (in millions of U.S. dollars)
 

Net cash provided by operating activities

    287     617     1,127     1,727     1,359  

Net cash used in investing activities

    (507 )   (391 )   (839 )   (741 )   (626 )

Net cash provided by (used in) financing activities

    210     (190 )   (310 )   (1,019 )   (834 )

    Operating Activities

        Net cash flow from operating activities has provided us with a significant source of liquidity. In the six months ended June 30, 2014, net cash provided by operations was approximately $287 million, compared with approximately $617 million in the six months ended June 30, 2013. Most of the decline in cash flows from operating activities derived from the decrease in operating income and changes in working capital in the "receivables" category, mainly as a result of longer credit periods granted to customers of our Fertilizers segment in China. This decline was moderated by an unusual non-cash expense with respect to a provision for royalties due to the arbitration decision in the amount of approximately $135 million. In the first quarter of 2014, we included a provision in the amount of approximately $51 million, which was based on principles agreed to in assessment hearings between subsidiaries in Europe and the relevant tax authorities. After the end of the first quarter of 2014, we settled such tax matters for an amount approximating the tax provision, so there are no longer significant uncertainties regarding the provision amount. In 2013, net cash provided by operations was $1,126.9 million, compared with $1,727.2 million in 2012 and $1,358.7 million in 2011. Most of the decline in cash flows from operating activities derives from the decline in income and change in working capital, mainly as a result of the increase in trade receivables due to the increase in sales in the fourth quarter of 2013 compared with the fourth quarter of 2012. The increase in cash flows in 2012 compared with 2011 was impacted mainly by an increase in working capital in 2011, which was offset by the decline in income in 2012 compared with 2011. In addition, cash flows from operating activities in 2011 were impacted by a payment in the amount of approximately $165 million to the tax authorities in Israel as part of an assessments agreement for the years 2004 to 2008, which was paid in 2011.

77


Table of Contents

    Investing Activities

        In the six months ended June 30, 2014, net cash used in investing activities was approximately $506.6 million, compared with approximately $390.9 million in the six months ended June 30, 2013. New cash investments in property, plant and equipment decreased mainly due to progress with respect to the construction of the new power plant at Sodom. However, cash used for prior investments in property, plant and equipment increased from approximately $382 million for the six months ended June 30, 2013 to approximately $412 million for the six months ended June 30, 2014, mainly as a result of payments made to suppliers of property, plant and equipment in the six months ended June 30, 2014. Net cash used in investing activities was $839.3 million in 2013, compared with $740.7 million in 2012 and $625.5 million in 2011. The increase in net cash used in investing activities between 2013 and 2012 was due primarily to the performance of work on the dike surrounding the evaporation ponds of our Fertilizers segment at the Dead Sea, construction work with respect to a new power station in Sodom and the increase of the production capacity in our mines in Europe. The increase in net cash used in investing activities between 2012 and 2011 was due primarily to an increase in the acquisition of property, plant and equipment relating to investments stemming from the dynamic compacting of the dike surrounding the evaporation ponds of our Fertilizers segment at the Dead Sea, an investment as part of plan to gradually increase the production capacity of the Sodom plants, the commencement of construction of a new power plant at Sodom and improvement of our logistics setup.

    Financing Activities

        Net cash provided by financing activities was $210.0 million in the six months ended June 30, 2014, compared with $190.5 million used in the six months ended June 30, 2013. The primary reason for the increase in net cash provided by financing activities was the cash flows from the receipt of long-term debt in the amount of $847.9 million in the six months ended June 30, 2014 compared with $199.4 million in the six months ended June 30, 2013, partly offset by dividends paid in the amount of $673.3 million in the six months ended June 30, 2014 compared with $359.4 million for the six months ended June 30, 2013. Net cash used in financing activities was $310.0 million in 2013, compared with $1,018.6 million in 2012 and $833.7 million in 2011. The primary reasons for the decrease in net cash used in financing activities between 2013 and 2012 were dividends paid in the amount of $634.4 million in 2013 compared with $1,019.2 million in 2012 and short-term credit in the amount of $263.1 million in 2013 compared to short-term credit paid in the amount of $50.9 million in 2012. The primary reason for the increase in net cash used in financing activities between 2012 and 2011 was short-term credit paid in the amount of $50.9 million in 2012 compared to short-term credit in the amount of $316.9 million in 2011, partly offset by dividends paid in the amount of $1,019.2 million in 2012 compared to $1,131 million in 2011.

        As of June 30, 2014, our non-current liabilities consisted of loans from financial institutions in the amount of $1,782.0 million, loans from others in the amount of $6.9 million and non-marketable debentures in the amount of $275.0 million. For information about the currencies in which our liabilities are denominated and their interest rates, see note 17(B) to our audited financial statements included elsewhere in this prospectus. As of June 30, 2014, we had $310.0 million of unutilized long-term credit lines. Descriptions of our principal financing arrangements are set forth below.

        A portion of our loans bear variable interest rates based on short-term LIBOR for period of one to six months, plus a margin as defined in each loan agreement. Therefore, we are exposed to changes in cash flows arising from changes in these interest rates. Some of the loans and debentures issued by us bear fixed interest for the entire loan period. We hedge part of this exposure using financial instruments to fix and to provide a range of interest rates in order to adjust our actual interest rate structure to match our projections regarding anticipated developments in the interest rate market.

        For a description of material covenants in our loan agreements and any potential concerns relating to compliance, see note 17(D) to our audited financial statements included elsewhere in this prospectus.

78


Table of Contents

    Credit Agreements

        In December 2010, we received a loan from a European bank in the amount of €100 million (approximately $138 million). The loan is repayable on December 15, 2015. The interest rate on the loan is Euribor plus 1.14%.

        In March 2011, we entered into an agreement with a consortium of 17 international banks for a credit facility of $675 million. The credit facility is for five years, and is repayable in full in March 2016. The credit agreement does not include a commitment to utilize a minimum amount of the credit line, but a non-utilization commission applies at the rate of 0.28% per year. As of December 31, 2013 we had utilized $505 million from this credit facility.

        On September 11, 2012, we received a loan in the amount of $50 million from a third party, bearing interest at the three-month LIBOR plus a margin of 0.7%. The loan is extended every three months on the same terms on which it was received. The last date on which the loan was extended was December 11, 2013.

        In December 2011, we entered into an agreement with a consortium of seven international banks for a credit facility of $650 million. The credit facility is for five years, and is repayable in full in December 2016. The credit agreement does not include a commitment to utilize a minimum amount of the credit line, but a non-utilization commission applies at the rate of 0.35% per year. As of December 31, 2013, we had utilized $314 million of this credit facility.

        In the second half of 2011, we entered into an agreement with a European bank for a credit facility of €100 million (approximately $138 million). The credit facility is for six years, and is repayable in full at the end of the period. The interest rate on the loan is LIBOR plus 0.9% to 1.4%, depending on the extent of the credit utilized. As of December 31, 2013, the credit facility had not been used. In the second quarter of 2014, we replaced this credit facility, as described below.

        In December 2012, we entered into a credit facility agreement with a European bank for a loan of approximately €100 million (approximately $138 million). As of December 31, 2013, we had utilized $100 million from this facility. The repayment date for this amount is in December 2019. The interest rate on this amount is LIBOR plus 1.4%. The amount that is utilized from this credit facility must be repaid six years from the date of utilization but no later than December 2021.

        During 2013, we received a number of short-term loans from Israeli banks. As of June 30, 2014, the total amount of the loans was approximately $294 million.

        In May 2014, we signed an agreement with a European bank whereby the bank provided a credit facility in the amount of €50 million. This credit facility is for a period of five years and is to be repaid in full at the end of the period. It bears variable interest based on Euribor plus a margin of 0.95% to 1.25%. A non-utilization commission may be charged at the rate of 0.35% per year. As of June 30, 2014, this credit facility had not been used.

        In June 2014, we signed loan agreements with a number of international institutional entities in the aggregate amount of approximately €57 million and approximately $45 million. The proceeds of these loans were received in July 2014. The loans are to be repaid in a period of between five to ten years, where some of the loans bear fixed interest in the range of 2.1% to 3.75%, some bear variable interest based on LIBOR plus 1.55% and some bear variable interest based on Euribor plus a margin of 1.4% to 1.7%.

        In the first half of 2014, we entered into an undertaking with a European bank whereby the bank provided a credit facility in the amount of €100 million and $100 million. This credit facility is for a period of six years and is to be repaid in full at the end of the period. The euro credit facility replaces the credit facility provided by the bank to us in November 2011, which had not been utilized. The dollar facility bears variable interest based on LIBOR plus 0.9% to 1.4% and the euro facility bears variable interest based on Euribor plus 0.9% to 1.4%. A non-utilization commission may be charged at the rate of 0.35% per year.

79


Table of Contents

Approximately $63 million has been utilized out of the dollar credit facility as of the date of this prospectus.

    2012 Controlling Shareholder Loan

        On June 26, 2012, we received a short-term loan in the amount of $50 million from our controlling shareholder, Israel Corporation, that bears interest at the three-month LIBOR plus a margin of 0.7% (1.22%). Commencing from December 24, 2012, the loan was extended every three months on the same terms on which it was originally received. On September 26, 2013, the loan period was extended by an additional six months, and the interest rate was updated to a rate of 0.86%. On March 26, 2014, the loan period was extended by an additional six months and the interest rate was updated to a rate of 0.77625%. The terms of this loan are similar to market terms.

    Securitization Transaction

        On July 2, 2010, we and certain subsidiaries entered into a number of securitization agreements with Rabobank International and Credit Agricole (the "Lending Banks") for the sale of our customer receivables to a foreign company established specifically for this purpose that is neither owned nor controlled by us (the "Acquiring Company").

        The Acquiring Company finances acquisition of the receivables by means of a loan received from a financial institution, which is not related to us, which finances the loan out of the proceeds from the issuance of commercial paper on the U.S. commercial paper market. The repayment of both the commercial paper and the loan are backed by credit lines from the Lending Banks. The amount of cash that will be received in respect of the initial sale of the customer debts in the securitization transaction will be up to $350 million.

        The acquisition is on an ongoing basis, such that the proceeds received by the Acquiring Company from customers whose receivables were sold are used to acquire new trade receivables.

        We and our subsidiaries are entitled to sell our trade receivables to the Acquiring Company for the five-year period ending in July 2015, although both parties have the option at the end of each year to give notice of cancellation of the securitization transaction.

        The selling price of the trade receivables is the amount of the debt sold, less the calculated interest cost based on the anticipated period between the sale date of the customer debt and its repayment date.

        Upon acquisition of a receivable, the Acquiring Company pays the majority of the sale price in cash and the remainder in a subordinated note, which is paid after collection of the receivable sold. The cash portion of the consideration varies according to the composition and behavior of the customer portfolio.

        Our subsidiaries handle collection of the trade receivables included in the securitization transaction on behalf of the Acquiring Company.

        In addition, as part of the agreements a number of conditions were set in connection with the quality of the customer portfolios, which give the Lending Banks the option to terminate the undertaking or determine that some of the subsidiaries, the customer portfolios of which do not meet the conditions provided, will no longer be included in the securitization agreement.

        The securitization of trade receivables does not meet the conditions for disposal of financial assets prescribed in International Standard IAS 39, regarding Financial Instruments—Recognition of Measurement, since we did not transfer all of the risks and rewards deriving from the trade receivables. Therefore, the amounts received from the Acquiring Company are presented as a financial liability as part of the short-term credit. As of June 30, 2014, utilization of the securitization facility and trade receivables within this framework amounted to $341 million compared to approximately $207 million as of June 30, 2013.

80


Table of Contents

    2005 Debentures

        In 2005, we issued debentures to institutional investors in a private placement in the United States in the amount of $125 million bearing fixed interest. The repayment date of the debentures is March 3, 2015. As of December 31, 2013, the outstanding balance of the debentures was approximately $67 million, bearing interest at a fixed rate of 5.72%.

    April 2009 Debentures

        On April 27, 2009, we issued three series of debentures in a private offering by way of tender to institutional investors, for an amount equal to NIS 695 million (approximately $167 million). The debentures were issued in the following three series:

    Series A—approximately NIS 452 million in aggregate principal amount of debentures linked to the Consumer Price Index published by the Israeli Central Bureau of Statistics ("CPI"), to be redeemed at the end of 5 years.

    Series B—approximately NIS 61 million in aggregate principal amount of debentures not linked to the CPI or the U.S. dollar, to be redeemed at the end of 4.5 years.

    Series C—approximately NIS 182 million in aggregate principal amount of debentures linked to the U.S. dollar, to be redeemed at the end of 4.5 years.

        In August 2009, the debentures were registered for trading on the TASE. The interest rate determined in the tender after registration of the debentures on the stock exchange is 3.4% per annum for the CPI-linked debentures, 5.25% per annum for the NIS debentures and 2.4% above the six-month U.S. dollar LIBOR, for the U.S. dollar-linked debentures.

    September 2009 Debentures

        On September 9, 2009, we issued three series of debentures (including one new series and expansion of two existing series) by means of a public tender for an amount equal to NIS 898 million (approximately $235 million). The debentures were issued in three series, as follows:

    Expanded Series B—approximately NIS 696 million in aggregate principal amount of debentures not linked to the CPI or the U.S. dollar, to be redeemed at the end of about 4 years, bearing interest at the rate of 5.25%. The debentures were issued at a price of NIS 1.031 per unit and at an effective interest rate of 5%.

    Expanded Series C—approximately NIS 102 million in aggregate principal amount of debentures linked to the U.S. dollar, to be redeemed in about 4 years, bearing interest at the rate of 2.4% above the six-month U.S. dollar LIBOR (which was 4.4% on the issuance date). The debentures were issued at a price of NIS 0.913 per unit and at an effective interest rate of 4.7%.

    Series D—approximately NIS 100 million in aggregate principal amount of NIS debentures not linked to the CPI or the U.S. dollar, to be redeemed at the end of about 5 years, bearing interest at the rate of 1.45% above the three-month NIS Telbor rate.

        In respect of our NIS and index-linked series, we have executed transactions in derivatives that swap the NIS cash flows with U.S. dollar cash flows.

        On October 31, 2013, the Series B debentures and the Series C debentures were repaid in full, in the amounts of approximately $209 million and approximately $70 million, respectively. On April 30, 2014, the Series A debentures were repaid in full, in the amount of approximately $147 million. As of June 30, 2014, the liability in respect of the Series D debentures was approximately $29 million. These debentures are to be repaid in full on October 31, 2014.

81


Table of Contents

    2013 Debentures

        In November 2013, a wholly owned and controlled subsidiary of ours entered into an agreement with institutional and international investors to make a private offering in the United States of unregistered debentures in an amount of up to $275 million. Our subsidiary issued three series of debentures in an aggregate principal amount of $275 million, the proceeds of which were received in January 2014.

        The debentures were issued in three series, as follows:

    $84 million of debentures with a repayment date of January 15, 2021 bearing interest at a fixed rate of 4.55%.

    $145 million of debentures with a repayment date of January 15, 2024 bearing interest at a fixed rate of 5.16%.

    $46 million of debentures with a repayment date of January 15, 2026 bearing interest at a fixed rate of 5.31%.


Related and Interested Parties

Controlling Shareholder

        Our parent company is Israel Corporation, a public company listed for trading on the TASE. Immediately prior to this offering, Israel Corporation holds approximately 52.38% of our outstanding ordinary shares. With respect to any ordinary shares Israel Corporation sells directly to the underwriters, it will cease to have voting rights. With respect to any ordinary shares subject to the forward sale agreements, and made available to the forward counterparties under these agreements, Israel Corporation will cease to have voting rights with respect to these ordinary shares and will, at the relevant settlement dates, regain voting rights with respect to all or a portion of the ordinary shares it makes available to the forward counterparties under these agreements if it elects cash settlement or net physical settlement.

        Israel Corporation exercises control over our operations and business strategy and has sufficient voting power to control many matters requiring approval by our shareholders, including:

    the composition of our Board of Directors (other than external directors, as described under "Management—External Directors");

    mergers or other business combinations;

    certain future issuances of ordinary shares or other securities; and

    amendments to our Articles of Association.

        However, Israel Corporation does not exercise control with respect to our compensation policy and related party transactions, since these must be approved by a majority of our non-related shareholders.

        Following this offering, Israel Corporation will still have a major impact on the general meeting of our shareholders and will de facto have the power to appoint directors and have a strong influence upon the composition of our Board of Directors.


Critical Accounting Policies and Estimates

        The following is a description of certain key accounting policies on which our financial condition and results of operations are dependent. The key accounting policies generally involve complex quantitative analyses or are based on subjective judgments or assumptions. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under current circumstances. Actual results may differ from these estimates if assumptions and conditions change. For a full description of our significant accounting policies, see note 3 to our audited financial statements included elsewhere in this prospectus.

82


Table of Contents

    Employee Benefits

        According to International Standard IAS 19, some of our employee benefit plans constitute a defined benefit plan as defined in IAS 19. Such plans principally include liabilities for pension and severance benefits.

        In computing pension liability, we use various assessments. These assessments include, among other things, the interest rate for discounting our pension liability and the pension fund assets, assessments regarding the long-term increase in wages and an assessment of the life expectancy of the group of employees entitled to a pension. Assessment of the interest rate for purposes of discounting our pension liability and the pension fund assets is based on the rate of return on bonds of corporations operating in countries where an active market exists for corporate bonds and on the rate of return on government bonds for companies operating in countries where there is no active market for corporate bonds. The rate of return on long-term bonds changes according to market conditions. As a result the discount rate will also change as will the pension liability and the pension fund assets. The assessment regarding the increase in wages is based on our forecasts in accordance with past experience and existing labor agreements. Such assessments may be different than the actual wage increases. The life expectancy assessment is based on actuarial research published in each country. This research is updated every several years, and accordingly the life expectancy assessment may be updated.

        Measurement of the liability for severance pay is based upon an actuarial assessment, which takes into account various assessments including, among others, the future increase in employee wages and the rate of employee turnover. The measurement is made on the basis of discounting the expected future cash flows according to the interest rate on high ranking highly rated government bonds. In addition, the severance pay deposits are measured according to their fair value. Changes in the assumptions used for the calculation of the liability for severance pay and the related plan assets for severance pay could increase or decrease the net liability for severance pay recognized.

    Environmental and Contingent Liabilities

        We produce fertilizers and chemical products and, therefore, are exposed in our ordinary course of business to obligations and commitments under environmental and related laws and regulations. We recognize a liability in our books when such liability is expected, is derived from a liability event that has already occurred and can be reliably measured. Assessment of the liability is based mostly on past experience, familiarity with the legal requirements concerning our areas of operation, as well as assessments regarding contingent claims existing against us based on opinions of legal advisors and other experts. As explained in note 23 to our audited financial statements, a number of lawsuits are pending against us, the results of which may have a material impact on our results of operations.

        When assessing the possible outcomes of legal claims that were filed against us and our investee companies, we base our assessments on the opinions of our legal advisors. These opinions of the legal advisors are based on their best professional judgment, and take into consideration the current stage of the proceedings and the legal experience accumulated with respect to the various matters. As the results of the claims will ultimately be determined by the courts or as part of a settlement, they may be different from these estimates by us and our legal advisors.

    Property, Plant and Equipment

        Property, plant and equipment items are depreciated using the straight-line method over their estimated useful lives.

        We evaluate the estimated useful lives of the property, plant and equipment by means of a comparison to the sector in which we operate, the level of upkeep of the facilities and the performance of the facilities over the years. Changes in these estimates in succeeding periods could increase or decrease the rate of depreciation of the facilities.

83


Table of Contents

    Impairment of Assets

        We examine at every reporting date whether there have been events or changes in circumstances indicating that there has been an impairment of one or more nonmonetary assets. When there are indications of impairment, an examination is made as to whether the carrying amount of the investment can be recovered from the discounted cash flows anticipated to be derived from the asset, and if necessary, we record an impairment provision up to the amount of the recoverable value. Assessment of the impairment of goodwill and of other intangible assets having an indeterminable lifespan is performed once a year or more frequently when indications of impairment exist.

        The recoverable value of the asset or the cash generating unit is determined based on the higher of the fair value of the asset less realization costs and the present value of the future cash flows expected from the continued use of the asset in its existing state, including the cash flows expected upon removal of the asset from service and its eventual sale (value in use).

        The future cash flows are discounted to their present value using a discount rate that reflects assessments of the market participants of the time value of money and the risks specific to the asset. The estimates regarding cash flows are based on past experience with respect to this asset or similar assets, and on our best assessments regarding the economic conditions that will exist during the asset's remaining useful life.

        The estimates of the future cash flows are based on our forecasts. Since the actual cash flows could be different than our forecasts, the amount of the realizable value determined in the examination of impairment in value may change in succeeding periods, such that in the future an additional reduction of the value of the assets or elimination of a reduction recorded in prior periods may be required.

        There were no indicators of impairment in 2011, 2012 or 2013, except for impairment in one of our cash-generating units of approximately $10 million, which was recognized as an impairment of property, plant and equipment in 2013. The cash-generating unit had no intangible or goodwill assets. As of the date of our most recent impairment analysis with respect to our goodwill and other indefinite lived intangible assets, none of our other cash-generating units was at risk for an impairment charge.

    Business Combinations

        We are required to allocate the cost of acquiring companies and operations in business combinations on the basis of the estimated fair value of the assets and liabilities acquired. We use the valuations of external independent appraisers and internal valuations for purposes of determining the fair value. The valuations include assessments and estimates of management concerning expected cash flow forecasts from the acquired business, and models for calculating the fair value of the acquired items and their depreciation period. Management's estimates have an impact on the balance of assets and liabilities acquired and the depreciation and amortization in the statement of income. Management's estimates of the forecasted cash flows and useful lives of the acquired assets may differ from the actual results.

    Taxes on Income

        We are subject to income taxes in numerous jurisdictions and, therefore, our management is required to exercise considerable judgment in order to determine the aggregate provision for taxes. A provision in respect of uncertain tax positions is recorded where it is more likely than not that a flow of economic resources will be required in order to discharge the obligation.

        The deferred taxes are computed according to the tax rates expected to apply when the timing differences are realized, as stated in note 3(O) to our audited financial statements. The tax rate expected to apply upon the realization of the timing differences applying to Benefited Enterprises in Israel entitled to tax benefits is based on forecasts of future revenues to be earned by such Benefited Enterprises in proportion to our total revenues. For additional information about Benefited Enterprises in Israel, see

84


Table of Contents

"Tax Considerations—Israeli Tax Considerations." Changes in these assessments could lead to changes in the book value of these tax assets, the tax liabilities and the results of operations.

    Inventories

        Inventories are measured in the financial statements at the lower of cost or net realizable value. The net realizable value is an estimate of the selling price in the ordinary course of business, less the estimate of the cost of completion and the estimate of the costs needed to effect the sale. The selling price is estimated on the basis of the selling price expected at the time of realization of the inventories. A decrease in the expected selling price could cause a decrease in the book value of the inventories and therefore our results of operations. Raw materials are written down to realizable value, which is based on the realization values of the inventories of the finished products in which they are included, only when the finished products in which they are included are expected to be sold at prices below cost. In cases where the replacement price of raw materials serves as the best available evidence for realizable value, measurement of realizable value is based on the replacement price. A decline in the expected replacement value could give rise to a decline in the value of the inventories of raw materials in the books and our results of operations.

        Part of the raw materials, work in process and finished goods are in bulk. The quantities are based on estimates made, for the most part, by third parties who measure the volume and density of the inventory. Variances in the estimates used in determining the assessments may cause a change in the value of the inventory in the books.


Principal Capital Expenditures and Divestitures

        We had capital expenditures of approximately $957.9 million, $779.6 million and $947.3 million in 2011, 2012 and 2013, respectively. Our principal capital expenditures since January 1, 2011 have consisted of work on the dike surrounding the evaporation ponds of our Fertilizers segment at the Dead Sea, construction work with respect to a new power station at Sodom, investments as part of a plan to gradually increase the production capacity of the Sodom plans, investments to increase the production capacity of our mines in Europe, improvements in our logistics setup and the purchase and refurbishing of isotanks for transporting bromine. We have financed our capital expenditures primarily from cash flows from operations and expect to finance our capital expenditures for the rest of 2014 using cash flows from operations and our debt facilities.

        Our capital expenditures currently in progress are primarily in Israel and Spain, including the completion of the construction of the dike at Pond 5 in the Dead Sea, expansion of our production capacity at the Suria site in Spain. We will fund these capital expenditures using cash flows from operations and our debt facilities. As of the date of this prospectus, there is an agreement between Dead Sea Works and the State of Israel regarding financing of the costs of the dike (the temporary defenses stage) pursuant to which Dead Sea Works will bear 39.5% of the financing and the State of Israel will bear the rest. On July 8, 2012, we entered into an agreement with the government of Israel, relating to a permanent solution for the increase in the level of Pond 5. The permanent solution for the rising of the level of the Dead Sea is by means of full harvesting of the salt from Pond 5. Upon completion of the salt harvesting, the process of production of the raw materials will no longer cause or require raising of the water level of Pond 5. Planning and execution of the salt harvesting will be performed by us. This project will constitute an Israeli national infrastructure project that will be promoted by the Israeli Committee for National Infrastructures and starting January 1, 2017, the water level in Pond 5 will not rise above 15.1 meters. The statutory infrastructure of the salt harvesting project is presently being discussed by the Board of National Infrastructures and its approval is expected in 2014. Concurrently, we are performing additional activities relating to the salt harvesting project. According to the Dead Sea Protection Company, the total cost of the salt harvesting is estimated, as of October 2010, to be in an undiscounted amount of NIS 7 billion (a discounted amount of NIS 3.8 billion). The Israeli government will bear up to 20% of the cost of the salt harvesting. The Israeli government's maximum commitment (20% of NIS 3.8 billion, the discounted

85


Table of Contents

amount) is linked to the CPI and bears interest at the rate of 7%. See note 23(C)(4) to our consolidated financial statements for further details regarding this agreement and the related costs.

        With respect to our activities that do not constitute our core businesses, we are examining various possibilities in connection with the continued integration of such activities in our Company and are preparing to divest activities that are not synergetic with our activities. As of the date of this prospectus, we are taking various measures to execute these activities in a monetary scope estimated by us in the range of $300 million to $500 million, including by means of contacting potential purchasers and/or requesting to receive offers. However, binding agreements have not yet been signed and, accordingly, there is no certainty that binding agreements will be signed or that one or more of these transactions will be completed.

    Sodom Power Plant Construction Contract

        On June 28, 2012, Dead Sea Works entered into agreements regarding a project to construct a new dual-fuel cogeneration plant in Sodom with a production capacity of 330 tons of steam per hour and 250 megawatts of electricity that will fulfill all the electricity and steam requirements of the production plants at the Sodom site in the upcoming years. The project is expected to be completed in the middle of 2015. The cost of the project is estimated at approximately $320 million.


Off-Balance Sheet Arrangements

        We do not have any off-balance sheet arrangements.


Contractual Obligations

        The following table presents information related to our contractual obligations, including estimated interest payments, as of December 31, 2013.

 
  As at December 31, 2013  
 
  Total
Amount
  12 months
or Less
  1 - 2 years   3 - 5 years   More than
5 years
 
 
  (in millions of U.S. dollars)
 

Credit from banks and others (not including current maturities)

    538.5     543.7              

Trade payables

    669.1     669.1              

Other payables

    387.0     387.0              

Operating lease obligations

    201.8     30.1     33.5     50.2     88.0  

Purchase obligations(1)

    1,465.3     537.4     549.8     325.5     52.6  

Non-convertible debentures (including current maturities and interest)

    242.8     185.3     70.8          

Long-term bank loans (including current maturities and interest)

    1,247.6     25.0     39.2     1,017.9     260.2  
                       

    4,752.1     2,377.6     693.3     1,393.6     400.8  

(1)
Information excludes ordinary course agreements for purchases within the next twelve months.

Financial liabilities—derivative instruments utilized for economic and accounting hedging

                               

Interest rate swaps and options

    8.3     1.8     4.0     2.6      

Foreign exchange derivatives

    10.0     10.0              
                       

    18.3     11.8     4.0     2.6      

86


Table of Contents


Quantitative and Qualitative Disclosures About Market Risk

    Risk Management

        In the ordinary course of our business activities, we are exposed to various market risks that are beyond our control, including fluctuations in the prices of certain of our products and inputs, currency exchange rates, interest rates, energy prices and marine transportation prices, that may have an adverse effect on the value of our financial assets and liabilities, future cash flows and profit. As a result of these market risks, we could suffer a loss due to adverse changes in the prices of our products or our inputs, foreign exchange rates, interest rates, energy prices or marine transportation prices.

        For financial assets and financial liabilities in currencies that are not the functional currency of our subsidiaries, our policy is to minimize this exposure as far as possible by the use of various hedging instruments. We do not use hedging instruments to hedge the prices of our products. We do not hedge against severance pay liabilities and our tax results since the exposure is long term. For hedging against the prices of crude oil, marine transportation prices, projected income and expenses in currencies that are not the functional currency of our subsidiaries, and interest rates, our policy is to hedge, as described below.

        Our subsidiaries regularly monitor the extent of our exposure and the hedging rates for the various risks described below. The hedging policy for all types of exposure is discussed by our Board of Directors as part of the annual budget discussions and our Board of Directors establishes our maximum exposure according to a value-at-risk model. Together with the presentation of quarterly financial results, our audit and finance committee receives quarterly reports on exposure and hedging rates and determines if our hedging policy should be revised. Management implements our hedging policy with reference to actual developments and expectations in the various markets.

        We use financial instruments and derivatives for hedging purposes only. These hedging instruments reduce our exposure as described above. Most of these transactions do not meet the hedging conditions provided in IFRS, and therefore they are measured at fair value, and changes in the fair value are charged immediately to profit and loss. The counterparties for our derivatives transactions are banks. We believe the credit risk in respect thereof is negligible.

        As part of our swap transactions, we replace the variable interest rate paid on loans received with fixed interest with rates between 1.4% and 3.4%. In our cap and floor transactions, we fix the fluctuation of the variable interest loans in the range of 1% to 3.2%.

        In 2009, we issued four series of listed debentures amounting to NIS 1.6 billion. On October 31, 2013, the Series B and C debentures, were repaid in full in exchange for prices of approximately $209 million and $70 million, respectively. On April 30, 2014, the Series A debentures were repaid in full, in the amount of approximately $147 million. As of June 30, 2014, the liability in respect of the Series D debentures was approximately $29 million. These debentures are to be repaid in full on October 31, 2014.

        With respect to our CPI-linked NIS liabilities, we executed transactions in derivatives to replace NIS cash flows with U.S. dollar cash flows. In the third quarter of 2009, we acquired derivatives to hedge the exposure to changes in the cash flows of the expanded debentures (Series B), in respect of changes in the exchange rates of the NIS against the U.S. dollar. This hedging transaction was treated in the financial statements as an accounting hedge. This hedging was terminated along with the repayment of Series B debentures on October 31, 2013.

        In the third quarter of 2012, we acquired a derivative to hedge against the exposure to changes in the cash flows of the project for construction of a new cogeneration plant in Sodom, stemming from changes in the exchange rate of the U.S. dollar against the euro. The transactions for hedging construction of the power station in Sodom comply with the conditions for treatment as an accounting hedge under IFRS. Changes in the fair value of the derivative used to hedge cash flows, in respect of the effective portion, are recorded in other comprehensive income. In 2013, other comprehensive income was recognized in the amount of about

87


Table of Contents

$1.7 million. Changes in the fair value of the derivative relating to the non-effective portion are recorded in the statement of income.

        None of our other hedging transactions are accounted for as accounting hedges in our financial statements.

        For additional information about our hedging activities, see note 27 to our audited financial statements included elsewhere in this prospectus.

    Exchange Rate Risk

        The U.S. dollar is the principal currency of the business environment in which most of our subsidiaries operate. The majority of our activities—sales, purchase of materials, selling, marketing expenses and financing expenses, as well as the purchase of property, plant and equipment—are executed mainly in U.S. dollars, and so the U.S. dollar is used as the functional currency for measurement and reporting of the Company and the majority of our subsidiaries.

        We have a number of consolidated subsidiaries overseas and one local subsidiary in Israel, whose functional currencies are their local currency—mainly the euro, the British pound, the Brazilian real, the NIS and the Chinese yuan.

        Set forth below is a description of our principal exposures in respect of changes in currency exchange rates.

        Transactions by our subsidiaries in currencies that are not their functional currency expose us to changes in the exchange rates of those currencies compared with their functional currencies. Measurement of this type of exposure is based on the ratio of net income to expenses in each currency that are not the functional currency of that company.

        Part of the costs of our inputs in Israel are denominated and paid in NIS. Thus, we are exposed to a strengthening of the NIS exchange rate against the U.S. dollar (NIS appreciation). This exposure is similar to the exposure described above for transactions in foreign currencies but is much larger than the other currency exposures.

        The results for tax purposes of us and some of our subsidiaries operating in Israel are measured in NIS. As a result, we and some of our subsidiaries are exposed to the difference between the rate of the change in the U.S. dollar exchange rate and the measurement base for tax purposes (the NIS) in respect of those subsidiaries.

        Our subsidiaries have severance pay liabilities that are payable in the local currency, and in Israel they are sometimes also affected by rises in the CPI. Our subsidiaries in Israel have reserves to cover part of these commitments, which are denominated in NIS and affected by the performance of the funds in which the sums are invested. As a result, we are exposed to changes in the exchange rates of the U.S. dollar against various local currencies in respect of net liabilities for severance pay.

        Our subsidiaries have financial assets and liabilities that are denominated in or linked to currencies other than their functional currencies. A surplus of assets over liabilities denominated in currencies that are not the functional currency creates exposure for us in respect of exchange rate volatility.

        With respect to investment in subsidiaries whose functional currency is not the U.S. dollar, the end-of-period balance-sheet balances of these companies are translated into U.S. dollars based on the exchange rate of the U.S. dollar in relation to the reporting currency of these companies at the end of the relevant period. The beginning-of-period balance-sheet balances, as well as capital changes during the period, are translated into U.S. dollars at the exchange rate at the beginning of the period or on the date of the change in capital, respectively. The differences arising from the effect of the change in the exchange

88


Table of Contents

rate between the U.S. dollar and the currency in which the companies report create exposure. The effects of this exposure are charged directly to equity.

        Our Finance Forum (whose members are the senior financial managers of our Company and each of our segments) periodically examines the extent of the hedging implemented for each of the exposures described above, and decides on the required scope of the hedging. We use various financial instruments for our hedging activity, including derivatives.

        The tables below set forth the sensitivity of our derivative instruments and certain balance sheet items to 5% and 10% increases and decreases in exchange rates as of December 31, 2013.

 
  Increase (decrease)
in fair value
   
  Increase (decrease)
in fair value
 
 
  Increase of
10%
  Increase of
5%
  Fair value   Decrease of
5%
  Decrease of
10%
 
 
  (in millions of U.S. dollars)
 

U.S. dollar/NIS

                               

Type of instrument

                               

Cash and cash equivalents

    (3.2 )   (1.6 )   32.1     1.6     3.2  

Short term deposits and loans

    (0.1 )   (0.1 )   1.4     0.1     0.1  

Trade receivables

    (6.2 )   (3.1 )   61.9     3.1     6.2  

Receivables and debit balances

    (2.2 )   (1.1 )   22.1     1.1     2.2  

Long-term deposits and loans

    (0.6 )   (0.3 )   6.0     0.3     0.6  

Credit from banks and others

    0.1     0.0     (0.6 )   0.0     (0.1 )

Trade payables

    25.2     12.6     (251.6 )   (12.6 )   (25.2 )

Other payables

    15.3     7.6     (152.9 )   (7.6 )   (15.3 )

Debentures

    17.8     8.9     (177.8 )   (8.9 )   (17.8 )

Long-term loans

    17.3     8.6     (172.9 )   (8.6 )   (17.3 )

Options

    (51.4 )   (28.6 )   28.2     36.4     78.2  

Forward

    (20.4 )   (10.7 )   1.3     11.8     25.0  

Swap

    (31.8 )   (16.8 )   21.9     17.4     38.4  

Total

    (40.2 )   (24.6 )   (580.9 )   34.1     78.2  

 

 
  Increase (decrease)
in fair value
   
  Increase (decrease)
in fair value
 
 
  Increase of
10%
  Increase of
5%
  Fair value   Decrease of
5%
  Decrease of
10%
 
 
  (in millions of U.S. dollars)
 

CPI

                               

Type of instrument

                               

Long-term deposits and loans

    0.2     0.1     1.9     (0.1 )   (0.2 )

Fixed-interest debentures

    (14.9 )   (7.4 )   (148.7 )   7.4     14.9  

CPI/U.S. dollar swap

    3.9     2.0     9.5     (2.0 )   (3.9 )

Forward CPI

    6.4     3.2     (1.1 )   (3.2 )   (6.4 )

Total

    (4.4 )   (2.1 )   (138.4 )   2.1     4.4  

89


Table of Contents


 
  Increase (decrease)
in fair value
   
  Increase (decrease)
in fair value
 
 
  Increase of
10%
  Increase of
5%
  Fair value   Decrease of
5%
  Decrease of
10%
 
 
  (in millions of U.S. dollars)
 

Euro/U.S. dollar

                               

Type of instrument

                               

Cash and cash equivalents

    (6.5 )   (3.2 )   64.9     3.2     6.5  

Short term deposits and loans

    (0.1 )   0.0     0.8     0.0     0.1  

Trade receivables

    (29.1 )   (14.6 )   291.3     14.6     29.1  

Receivables and debit balances

    (2.8 )   (1.4 )   28.0     1.4     2.8  

Long-term deposits and loans

    0.0     0.0     0.5     0.0     0.0  

Credit from banks and others

    10.8     5.4     (108.2 )   (5.4 )   (10.8 )

Trade payables

    24.5     12.3     (245.3 )   (12.3 )   (24.5 )

Other payables

    12.9     6.5     (129.4 )   (6.5 )   (12.9 )

Long-term loans from banks

    15.2     7.6     (152.4 )   (7.6 )   (15.2 )

Options

    10.2     4.9     (2.3 )   (5.1 )   (9.6 )

Forward

    (56.2 )   (26.6 )   0.5     24.1     46.0  

Total

    (21.1 )   (9.1 )   (251.6 )   6.4     11.5  

 

 
  Increase (decrease)
in fair value
   
  Increase (decrease)
in fair value
 
 
  Increase of
10%
  Increase of
5%
  Fair value   Decrease of
5%
  Decrease of
10%
 
 
  (in millions of U.S. dollars)
 

British pound/U.S. dollar

                               

Type of instrument

                               

Cash and cash equivalents

    (1.8 )   (0.9 )   17.9     0.9     1.8  

Trade receivables

    (3.3 )   (1.7 )   33.1     1.7     3.3  

Receivables and debit balances

    (0.5 )   (0.2 )   4.9     0.2     0.5  

Credit from banks and others

    1.6     0.8     (16.0 )   (0.8 )   (1.6 )

Trade payables

    1.4     0.7     (14.1 )   (0.7 )   (1.4 )

Other payables

    0.9     0.5     (9.4 )   (0.5 )   (0.9 )

Forward

    (5.2 )   (2.4 )   1.0     2.2     4.2  

Total

    (6.9 )   (3.2 )   17.4     3.0     5.9  

 

 
  Increase (decrease)
in fair value
   
  Increase (decrease)
in fair value
 
 
  Increase of
10%
  Increase of
5%
  Fair value   Decrease of
5%
  Decrease of
10%
 
 
  (in millions of U.S. dollars)
 

British pound/Euro

                               

Type of instrument

                               

Forward

    0.0     0.0     0.0     0.0     (0.1 )

Options

    (1.7 )   (0.7 )   0.3     1.0     2.2  

Total

    (1.7 )   (0.7 )   0.3     1.0     2.1  

90


Table of Contents


 
  Increase (decrease)
in fair value
   
  Increase (decrease)
in fair value
 
 
  Increase of
10%
  Increase of
5%
  Fair value   Decrease of
5%
  Decrease of
10%
 
 
  (in millions of U.S. dollars)
 

Japanese yen/U.S. dollar

                               

Type of instrument

                               

Cash and cash equivalents

    (0.4 )   (0.2 )   4.2     0.2     0.4  

Trade receivables

    (0.8 )   (0.4 )   7.8     0.4     0.8  

Long-term deposits and loans

    0.0     0.0     0.2     0.0     0.0  

Trade payables

    0.1     0.0     (1.0 )   0.0     (0.1 )

Other payables

    0.0     0.0     (0.3 )   0.0     0.0  

Options

    0.8     0.4     0.5     (0.5 )   (1.0 )

Forward

    0.5     0.2     0.4     (0.3 )   (0.6 )

Total

    0.2     0.0     11.8     (0.2 )   (0.5 )

 

 
  Increase (decrease)
in fair value
   
  Increase (decrease)
in fair value
 
 
  Increase of
10%
  Increase of
5%
  Fair value   Decrease of
5%
  Decrease of
10%
 
 
  (in millions of U.S. dollars)
 

Brazilian real/U.S. dollar

                               

Type of instrument

                               

Cash and cash equivalents

    (1.0 )   (0.5 )   10.1     0.5     1.0  

Trade receivables

    (1.1 )   (0.6 )   11.2     0.6     1.1  

Trade payables

    0.9     0.4     (8.8 )   (0.4 )   (0.9 )

Other payables

    0.1     0.0     (1.0 )   0.0     (0.1 )

Total

    (1.1 )   (0.7 )   11.5     0.7     1.1  

 

 
  Increase (decrease)
in fair value
   
  Increase (decrease)
in fair value
 
 
  Increase of
10%
  Increase of
5%
  Fair value   Decrease of
5%
  Decrease of
10%
 
 
  (in millions of U.S. dollars)
 

Chinese yuan/U.S. dollar

                               

Type of instrument

                               

Cash and cash equivalents

    (1.9 )   (1.0 )   19.4     1.0     1.9  

Trade receivables

    (1.2 )   (0.6 )   11.7     0.6     1.2  

Receivables and debit balances

    0.0     0.0     0.3     0.0     0.0  

Trade payables

    0.2     0.1     (1.8 )   (0.1 )   (0.2 )

Other payables

    0.6     0.3     (5.9 )   (0.3 )   (0.6 )

Total

    (2.3 )   (1.2 )   23.7     1.2     2.3  

    Interest Rate Risk

        We have loans bearing variable interest that expose our finance expenses and cash flows to changes in those interest rates. With respect to our fixed-interest loans, there is exposure to changes in the fair value of the loans due to changes in the market interest rate.

        Our Finance Forum examines the extent of the hedging in order to adjust the structure of the actual interest to our expectations with regard to the anticipated developments in the interest rate, taking into account the cost of the hedging. The hedging is implemented by using a fixed interest range and by hedging variable interest.

91


Table of Contents

        The table below sets forth the sensitivity of certain financial instruments to 0.5% and 1% increases and decreases in LIBOR as of December 31, 2013.

 
  Increase (decrease)
in fair value
   
  Increase (decrease)
in fair value
 
 
  Increase of
1%
  Increase of
0.5%
  Fair value   Decrease of
0.5%
  Decrease of
1%
 
 
  (in millions of U.S. dollars)
 

Type of instrument

                               

Fixed-U.S. dollar interest debentures

    0.8     0.4     (69.9 )   (0.4 )   (0.8 )

Collar transactions

    1.5     0.9     (1.9 )   (0.8 )   (0.9 )

Swap transactions

    4.8     2.4     (3.4 )   (2.5 )   (5.1 )

NIS/U.S. dollar swap

    13.3     6.8     12.3     (7.2 )   (14.6 )

Total

    20.4     10.5     (62.9 )   (10.9 )   (21.4 )

        The table below sets forth the sensitivity of certain financial instruments to 0.5% and 1% increases and decreases in the CPI as of December 31, 2013.

 
  Increase (decrease)
in fair value
   
  Increase (decrease)
in fair value
 
 
  Increase of
1%
  Increase of
0.5%
  Fair value   Decrease of
0.5%
  Decrease of
1%
 
 
  (in millions of U.S. dollars)
 

Sensitivity to changes in the index
interest rate

                               

Type of instrument

                               

Fixed-interest debentures

    0.5     0.2     (148.7 )   (0.2 )   (0.5 )

CPI/U.S. dollar swap

    (0.1 )   (0.1 )   9.5     0.1     0.1  

Total

    0.4     0.1     (139.2 )   (0.1 )   (0.4 )

        The table below sets forth the sensitivity of certain financial instruments to 0.5% and 1% increases and decreases in the NIS interest rate as of December 31, 2013.

 
  Increase (decrease)
in fair value
   
  Increase (decrease)
in fair value
 
 
  Increase of
1%
  Increase of
0.5%
  Fair value   Decrease of
0.5%
  Decrease of
1%
 
 
  (in millions of U.S. dollars)
 

Sensitivity to changes in the index
interest rate

                               

Type of instrument

                               

NIS/U.S. dollar swap

    (13.1 )   (6.7 )   13.2     7.0     14.4  

    Energy Price Risk

        Execution of hedging is determined by appropriate personnel after consultation with Israeli and foreign energy advisors.

92


Table of Contents

        The table below sets forth the sensitivity of instruments hedging energy price risk to 5% and 10% increases and decreases in energy prices as of December 31, 2013.

 
  Increase (decrease)
in fair value
   
  Increase (decrease)
in fair value
 
 
  Increase of
10%
  Increase of
0.5%
  Fair value   Decrease of
0.5%
  Decrease of
10%
 
 
  (in millions of U.S. dollars)
 

Type of instrument

                               

Energy hedges

    2.9     1.4     1.6     (1.3 )   (2.3 )

    Marine Transportation Price Risk

        We purchase hedges on part of our exposure to marine bulk transportation prices. Hedging is executed by the appropriate personnel, after consultation with overseas experts.

        The table below sets forth the sensitivity of instruments hedging marine transportation price risk to 5% and 10% increases and decreases in marine transportation prices as of December 31, 2013.

 
  Increase (decrease)
in fair value
   
  Increase (decrease)
in fair value
 
 
  Increase of
10%
  Increase of
0.5%
  Fair value   Decrease of
0.5%
  Decrease of
10%
 
 
  (in millions of U.S. dollars)
 

Type of instrument

                               

Marine shipping hedges

    3.8     1.9     5.6     (1.9 )   (3.8 )

93


Table of Contents


BUSINESS

Company Overview

        We are a leading specialty minerals company that operates a unique, integrated business model. We extract raw materials and utilize sophisticated processing and product formulation technologies to add value to customers in three attractive end-markets: agriculture, food and engineered materials. These three end-markets constitute over 90% of our revenue. Our operations are organized into three segments: (1) Fertilizers, which operates the raw material extraction for us and markets potash, phosphates and specialty fertilizers; (2) Industrial Products, which primarily extracts bromine from the Dead Sea and produces and markets bromine and phosphorus compounds for the electronics, construction, oil and gas drilling and automotive industries and (3) Performance Products, which mainly produces, markets and sells a broad range of downstream phosphate-based food additives and industrial intermediates.

        Our principal assets include:

        For the year ended December 31, 2013, we generated total sales of $6.3 billion, operating income of $1.1 billion, net income of $820.2 million and Adjusted EBITDA of $1.6 billion. Our Fertilizers segment sold 4.7 million tons of potash to external customers, 0.9 million tons of phosphate rock and 1.7 million tons of phosphate fertilizers, generating sales of $3.4 billion, operating income of $821.1 million and Adjusted EBITDA of $1.1 billion. Our Industrial Products segment generated sales of $1.3 billion, operating income of $114.5 million and Adjusted EBITDA of $224.7 million. Our Performance Products segment generated sales of $1.5 billion, operating income of $195.8 million and Adjusted EBITDA of $242.4 million. See "Prospectus Summary—Summary Historical Consolidated Financial Data" for a definition of Adjusted EBITDA and a reconciliation to the comparable IFRS measure.

94


Table of Contents

2013 Revenue Contribution by Segment

  2013 Adjusted EBITDA Contribution by Segment (1)


GRAPHIC

 


GRAPHIC

Total: $6.3 billion

  Total: $1.6 billion

(1)
Excludes Adjusted EBITDA attributable to Other and eliminations. Does not sum to 100% due to rounding.

2013 Revenue Contribution by End-Market

  2013 Adjusted EBITDA Contribution by End-Market


GRAPHIC

 


GRAPHIC


Our Industry

        The majority of our businesses compete in the global fertilizer and specialty chemicals industries.

    Fertilizers

        Fertilizers serve an important role in global agriculture by providing vital nutrients that help increase both the yield and the quality of crops. We supply two of the three essential nutrients—potassium, phosphorous and nitrogen—required for plant growth. There are no known substitutes for these nutrients. Although these nutrients are naturally found in soil, they are depleted over time by farming, which leads to declining crop yields and land productivity. To replenish these nutrients, farmers must apply fertilizers. The demand for fertilizers is volatile and seasonal, and pricing decreased in 2013; however, since the beginning of 2014, there have been price increases in some of the fertilizer products, particularly phosphate fertilizers. In our estimation, the policy of most countries is to ensure an orderly supply of high-quality food to their residents, including by encouraging agricultural production, which should preserve the long-term growth trend of fertilizer consumption.

        Potash, the salt form of potassium, helps regulate a plant's physiological functions and improves plant durability, providing crops with protection from drought, disease, parasites and cold weather. Unlike phosphate and nitrogen, potash does not require additional chemical conversion to be used as a fertilizer and is mined either from conventional underground mines or, less frequently, from surface or sub-surface brines, such as our operations in the Dead Sea. According to estimates from the United States Geological Survey, six countries accounted for approximately 87% of the world's aggregate potash production and the top seven producers operated approximately 78% of world production in 2013. Worldwide sales of potash

95


Table of Contents

recovered in 2013, as compared to 2012, although at a lower rate than expected at the beginning of 2013, due to a number of principal reasons: an erosion of 18% in the exchange rate of the Indian rupee against the U.S. dollar between January and November 2013, a fall in the prices of agricultural commodities in the fourth quarter of 2013 and the announcement of Uralkali, the Russian potash producer, in July 2013 of its exit from the joint potash marketing company with Belaruskali and a change in its selling strategy and transition to a policy favoring quantity over price while taking advantage of the company's full production capacity. This announcement triggered a fall in potash prices in the markets and also caused a postponement in potash purchases by customers due to their expectation of further price declines. In the fourth quarter of 2013, the demand for potash stabilized, and in the first half of 2014, there was further improvement, and prices, particularly of granulated potash, continued to rise, mainly in Europe and the United States. Global potash demand for agricultural uses is projected to grow at an average annual rate of 3% from 2013 through 2018 according to the IFA.

        Phosphate, a salt of phosphoric acid, is essential to plant root development and is required for photosynthesis, seed germination and efficient usage of water. Phosphate fertilizers are produced from phosphate rock, sulfuric acid and ammonia. The principal phosphate fertilizer producing regions are those with plentiful supplies of high quality, low-cost phosphate rock. The vast majority of the world's phosphate rock production in 2013 was in China, the United States, Morocco and Russia. Global phosphoric acid demand for all uses is forecast to grow at an annual rate of 2% through 2018 according to the IFA. Worldwide demand and prices for phosphate fertilizers were weak during all of 2013, mainly as a result of low demand in India and postponement of purchases throughout the world. Towards the end of 2013, phosphate prices started to rise moderately and continued to climb in the first quarter of 2014 due to strong demand in South America, commencement of preparation of the North American buyers for the upcoming season and return to the market of other buyers that had postponed purchases based on an expectation of continued price declines. At the beginning of the second quarter of 2014, there was a trend of declining prices, which reversed during the quarter.

        Barriers to adding new potash and phosphate production are significant. Adding new capacity requires long lead time and billions of dollars of capital per operation. In potash, economically recoverable deposits are scarce, typically deep in the earth and geographically concentrated. We believe that current potash market prices do not support the development of new (greenfield) mines. In phosphates, the need for economic access to multiple raw material feedstocks (phosphate rock, sulfuric acid and ammonia) combined with complex downstream production processes also act as significant barriers to entry.

        The specialty fertilizers market is growing faster than the conventional fertilizers market. Specialty fertilizers are often used for specialty crops (such as greenhouses and horticulture) but are rapidly expanding into usage for larger specialty field crops. Farmers are looking for fertilizers that are customized to meet the needs of specific crops and climates, to maximize yield and quality. Specialty fertilizers, such as controlled release fertilizers (which allow for the release of nutrients over time), slow release fertilizers (which allow for a very slow release of nutrients), liquid fertilizers (integrated in irrigation systems) and soluble fertilizers (integrated in drip irrigation systems and foliar spraying), ensure the timely and proportionate release of nutrients, thus not only significantly reducing their environmental impact but also providing highly efficient fertilization for a wide range of agricultural crops, including fruits, vegetables and high-value perennial crops. Increasing consumer demand for healthier food is expected to drive the growth of the specialty agriculture end-market, including specialty fertilizers.

    Specialty Phosphates

        Phosphate is also used in a broad range of downstream products in the food, electronics, energy and construction industries. These phosphate derivatives deliver additional and attractive margins. Main usage areas are: (1) food additives for improved texture and stability of processed foods such as meat, bakery, dairy and beverage products and (2) technical phosphates for usage in road surfaces, oil and paint additives, flame retardants and fire extinguishing. Demand for phosphate-based products is driven by global economic growth and improved living conditions. As global population grows, living standards

96


Table of Contents

improve and consumers demand more sophisticated food products, demand for phosphate-based products increases.

    Bromine

        The largest commercial use of bromine is brominated flame retardants, which accounts for approximately 40% of current demand for bromine. Flame retardants help materials such as plastic enclosures for consumer electronics, printed circuit boards, insulation materials for construction, furniture, automobiles, and textiles meet fire-safety requirements. The flame retardant market has contracted in the past few years. On the other hand, alternative uses of bromine have grown considerably, with bromine now used in a number of newer applications, including water purification, shale gas fracking, oil and gas drilling and other industrial uses. Many new applications are under development by us and our competitors.

        Bromine is found naturally in seawater, underground brine deposits and other water reservoirs, such as the Dead Sea, and is extracted by evaporation. The Dead Sea is the world's premier source of bromine, with concentration levels significantly higher than in regular seawater, and it accounts for about half of the global supply. Because it has the highest concentration of bromine, the Dead Sea is the most economical supply source as the least amount of water must be extracted and evaporated to generate bromine.

        The bromine industry is highly concentrated, with three companies accounting for approximately 80% of worldwide capacity in 2013 (us, Albemarle and Chemtura). Barriers to entry are significant, primarily due to the lack of economically feasible bromine supplies, and the requirement for a dedicated, complex and sophisticated global supply chain, such as the need for isotanks to transport bromine. We estimate that approximately 70% of global elemental bromine production is consumed internally, as there is a very small market for merchant bromine. As such, bromine production requires downstream compound production facilities.


Highly Integrated and Synergistic Value Chain

GRAPHIC

        Over 90% of our revenue is derived from three highly attractive end-markets: agriculture, food and engineered materials.

    Agriculture

        Global fertilizer demand is driven by grain demand and prices, which are primarily driven by population growth and dietary changes in the developing world:

    Population and Income Growth.   Historically, growth in world fertilizer consumption has been closely correlated with growth in world population, which is expected to increase by over 1.0 billion to reach 8.3 billion by 2030, according to the U.S. Census Bureau. Currently, developed countries use fertilizer more intensively than developing countries and therefore produce crops at much higher

97


Table of Contents

      yields. Economic growth in emerging markets is increasing food demand and thus fertilizer use. Populations in emerging markets are also shifting to more protein-rich diets as incomes increase, with such increased consumption requiring more grain for animal feed. According to the IMF, income per capita in developing countries is expected to grow by 6.0% annually up to 2018.

    Declining Arable Land per Capita.   As the world's population grows, mainly in cities, farmland per capita decreases and more food production is required from each acre of farmland. This, in turn, requires increased yield on existing farms. According to data from the FAO, the amount of arable land per capita is expected to decrease from 0.218 hectares per person to 0.197 hectares per person between 2012 and 2030. Significant amounts of new arable land are only available in limited quantities, mainly in Brazil. Therefore, the only viable path to increase crop production is through the yield increase in existing farms in developing countries, mainly in China, India, Russia, Africa and Central America. We believe fertilizers (especially more potash and phosphates) together with water availability and better seeds are the main route to higher yields.

    Low Grain Stock-to-Use.   The pressure on food demand is expected to continue to result in relatively low historical levels of the grain stock-to-use ratio (a metric indicating the level of carryover stock), as illustrated by the chart below. The grain stock-to-use ratio was approximately 20.8% for the 2013/2014 season, which represented an increase from a low of 16.6% for the 2006/2007 season but a decrease as compared to the high of 28.9% for the 2000/2001 season, according to data from the USDA. Based on a report published by the USDA in July 2014, an increase is expected in the grain stock-to-use ratio to approximately 21.3% at the end of the 2014/2015 season. A decline in the grain stock-to-use ratios generally indicates that grain prices will increase (due to limited stockpiles and tighter grain supply). This generally is a positive development for fertilizers, as higher grain prices support more fertilizer use. LOGO

98



Table of Contents

    Food

        Consumer demand for different food products in developed countries has changed dramatically over the last several decades, driven by increased per capita incomes, demographic shifts and lifestyle changes. Longer working hours, changing family structures, increased awareness of nutrition and health issues and access to a broader variety of food products result in growing demand for sophisticated, higher-quality products with longer shelf-lives such as convenience food and processed food products.

        This changing demand includes greater demand for processed food products with enhanced nutritional value and balance and with improved flavor, texture and appearance. An increasingly longer supply chain and consumer awareness of waste of foods also drives the demand for longer shelf-life and food stability. These secular trends act as long-term drivers of demand for food additives such as phosphate derivatives, phosphate-based formulations and hygiene products for the processed meat, bakery, dairy and beverages industries.

    Engineered Materials

        Demand for engineered materials, which include bromine-, phosphorus-and phosphate-based products, is driven by increased construction, and greater demand for energy, potable water and pharmaceutical products. Increased standards of living also increase regulation and growing environmental awareness. These trends result in greater demand for flame retardants, bromine- and chlorine-based biocides for water purification and waste water treatment and bromine-, magnesia- and potassium chloride-based intermediates for the pharmaceutical industry.

        Additionally, growth in oil and gas exploration is expected to continue to drive demand for bromine-based completion fluids and for bromine-based biocides used for fracking. Worldwide annual average oil rig count has been growing at a compounded annual growth rate of 4.0%, from 2,395 in 2004 to 3,412 in 2013.


Our Competitive Strengths

        We attribute our success to the following strengths:

    Unique portfolio of mineral assets.   We benefit from our access to resource-rich, long-life and low-cost raw materials, mainly potash and bromine. Our access to these resources is based upon exclusive concessions and licenses from the State of Israel, and leases and concessions from local governments in the United Kingdom and Spain. Access to these assets provides us with a consistent, reliable supply of raw materials, allowing us to produce our products on a large scale and in a cost-effective manner.

    Dead Sea in Israel:     Our potash and bromine production facilities at the Dead Sea enjoy low production costs due to the high concentration and virtually unlimited supply of minerals contained in the Dead Sea. Extraction of potash and bromine occurs via solar evaporation, a low-cost process, as compared to mining potash from underground deposits or extracting bromine from less concentrated sources, which are more energy intensive. The hot and dry climate of the Dead Sea allows us to store at a low cost, very large amounts of potash (exceeding one full year of production) outdoors. This storage capacity enables us to operate worldwide potash facilities at full production capacity despite periodic fluctuations in demand. In addition, we benefit from the geographic proximity of our facilities in Israel to seaports and from Israel's geographic positioning vis-à-vis our main geographical markets (especially the fast growing markets of India, China and Brazil), reducing transportation and logistics costs. While we benefit from these advantages, we expect to incur significant infrastructure-related costs to fully harvest salt from Pond 5 at our Dead Sea complex, which is our central evaporation pond, to avoid the need to continue to raise the water level in the pond. In addition, while the supply

99


Table of Contents

        in the Dead Sea is virtually unlimited, our access to this supply of potash and bromine is subject to permitting and concession rights in Israel, the need to construct a new pumping station and the potential obligation to pay higher taxes and royalties. See "Risk Factors—Risks Related to Our Business."

      United Kingdom and Spain assets:     In addition to our operations in Israel, we mine potash in the United Kingdom and Spain. Access to these assets provides us with production and logistics flexibility, geographical proximity to European clients, business diversification and additional reserves for future growth.

      Our integrated phosphate value chain:     Due to our access to the phosphate rock in the Negev Desert, we are the only sizeable backward integrated phosphate player. We mine and process phosphate rock from three open-pit mines under mining concessions with the State of Israel. Approximately three-quarters of the phosphate rock produced is used internally to manufacture phosphate fertilizers and phosphoric acid, with the balance sold to external producers. See "Risk Factors—Risks Related to Our Business—Our mining operations are dependent on concessions, licenses and permits granted to us by the respective governments in the countries where they are located."

    Diversification into higher value-added specialty products leveraging our integrated business model.   Our integrated production processes are based on a synergistic value chain that allows us to both efficiently convert raw materials into value-added downstream products and utilize by-products. For example, in phosphates we utilize our backward integration to produce higher-margin specialty phosphates used in food ingredients and engineered materials applications. Our food ingredients provide solutions for improved texture and shelf-life for meat, dairy and bakery products. In addition, as a by-product of our potash production at the Dead Sea, we generate brines with the highest bromine concentration globally. Our bromine-based products serve the electronics, construction, oil and gas and other industries. Our potash mine in the United Kingdom also contains another mineral (polysulphate) which can be mined using the same infrastructure and addresses unmet emerging mineral needs of farmers.

    Leading positions in markets with high barriers to entry.   We are a global leader in many of the key markets in which we operate, including PK fertilizers, specialty fertilizers and phosphates, elemental

100


Table of Contents

      bromine and phosphate-based food additives. We believe we are generally ranked among the top three leaders in our markets, as shown in the table below:

Product
  Rank   End-markets

Potash

  #2 in Western Europe and
#6 Worldwide
  Agriculture

PK fertilizers

 

#1 in Western Europe

 

Agriculture

Specialty fertilizers

 

#1 Worldwide in MAP/MKP
soluble fertilizers,
#2 (tied) in Europe in
controlled-release fertilizers and
#1 in the United States
in controlled-release
fertilizers

 

Agriculture

Phosphate-based food additives

 

Top 3 Worldwide

 

Food

Specialty phosphates

 

Top 2 Worldwide

 

Food / Engineered Materials

Elemental bromine

 

#1 Worldwide

 

Engineered Materials

Phosphorus-based flame retardants

 

#1 Worldwide

 

Engineered Materials

Forest fire retardants

 

#1 Worldwide

 

Engineered Materials

      Most of our businesses rely on natural resources that are scarce and concentrated in the hands of a few market participants, making it difficult for new competitors to enter our businesses. Our exclusive concessions, intellectual property and proprietary technologies, world-wide marketing and distribution network and high industry start-up costs for new market entrants further add significant barriers to entry.

    Strategically located production and logistics assets.   We benefit from the proximity of our facilities, both in Israel and Europe, to developed economies (Western Europe) and emerging markets (such as China, India and Brazil). For example, in Israel, we ship from two seaports: the Port of Ashdod (with access to Europe and South America) and the Port of Eilat (with access to Asia, Africa and Oceania). Access to these two ports provides us with two distinctive advantages versus our competitors: (1) we have lower plant gate-to-port costs and ocean freight costs, which lowers our overall cost structure and (2) we have faster time to markets due to our proximity to end-markets, allowing us to opportunistically fill short lead-time orders, strengthening our position with our customers. In addition, we are the sole producer with the ability to transport potash and phosphates from the same port (which we do in Israel). Our sales are balanced between emerging markets (approximately 40% of 2013 sales) and developed economies (approximately 60% of 2013 sales).

    Significant operating cash flow generation and return on capital.   Our businesses have historically generated significant amounts of cash flow, having generated $1.7 billion and $1.1 billion of operating cash flow in 2012 and 2013, respectively. We are able to generate significant levels of cash flow due to the size and scale of our business and our relatively high margins. These cash flows have enabled us to produce high returns on capital, appropriately maintain and expand our production facilities and take advantage of acquisition opportunities. In addition, since 2007, we have had a policy of paying a quarterly dividend of up to 70% of our net income. This policy has resulted in a strong dividend yield of 8% (equal to the total dividend per share in NIS distributed from net income in 2013, including a special one-time $500 million dividend, divided by the average price per share on the TASE during 2013).

    Highly knowledgeable people and culture of collaboration and determination.   Our operations are managed by an international management team with extensive industry experience. We develop

101


Table of Contents

      leaders with strong experience in their fields and the culture to drive change and innovation in our Company. We also bring in leaders from outside the Company to supplement our expertise. We focus on nurturing and empowering talent through a global platform of qualification, collaboration and communication that reinforces innovation.


Our Strategy

        Our "2020—Next Step Forward" corporate strategy is targeted to fulfill essential needs in our three core markets. We have developed a strategic plan based on three value-creation pillars: (1)  Efficiency: improve existing operations; (2)  Growth : organic and external expansion of our value chain from specialty minerals into the agriculture, food and engineered materials markets; and (3)  Enablers : create one global ICL, strengthen innovation, provide an empowering environment to our people and align management with our stakeholders to support our growth and efficiency goals. We intend to implement this strategy while maintaining our strong financial position and our current dividend policy of distributing up to 70% of our net income.

        Our key strategic initiatives include:

    Continuously improve the cost position of our distinctive mineral asset base.   We have identified, and have started implementing cost reduction initiatives in our potash and phosphate operations. At our facility in Spain, we are consolidating our activities from two facilities into one facility while maintaining our production capacity. This will help us lower our fixed costs of production. At Cleveland Potash in the United Kingdom, we are upgrading our production facilities to improve utilization rates, which will significantly reduce fixed costs per ton. Finally, at the Dead Sea in Israel, we are increasing the potential production capacity of our potash processing plants, and implementing process efficiencies to improve our utilization rates. In phosphates, we intend to transform our cost base by implementing an efficiency plan at our Rotem site, including headcount reductions that are currently being implemented and process improvements to increase utilization rates. Regarding the plan for efficiency and integration of the global processes into our Company, as well as the plan for reducing the production cost of our specialty minerals pursuant to the strategic plan described below, we estimate that these activities, the execution of which we have already started, will give rise to savings by the end of 2016 in the amount of approximately $350 million annually compared with 2013. Our estimate is based on projections made by our management and subjective assessments that are based on the experience we have accumulated and on actual process improvements. While the cost savings and efficiencies to be generated by our strategic plan described above is presented with numerical specificity, and we believe such targets to be reasonable as of the date of this prospectus, the manner of implementation of the strategic plan and the expected timing thereof and its impact may be different, possibly even significantly different, than that forecasted. This may result from various factors, including the situation prevailing in the market, competition, regulation and the risk factors characterizing our activities. Accordingly, our actual results may differ from these targets and the differences may be material and adverse, particularly if actual events adversely differ from one or more of our key assumptions. We caution investors not to place undue reliance on any of these assumptions and targets. See "Special Note Regarding Forward-Looking Statements" for additional information regarding these forward-looking statements and "Risk Factors."

    Streamline and integrate our global processes.   We have also identified several areas of efficiency improvements such as procurement, pricing, energy, R&D and other shared services. For example, in procurement we are optimizing expenditures by consolidating our purchasing activities on a global basis. In energy, we are improving technical systems to optimize usage and are building a cogeneration power plant based on natural gas (dual-fuel) in order to achieve energy self-sufficiency in Israel by 2016.

102


Table of Contents

    Expand our production capabilities and reserves base.   We plan to increase our potash production capability to approximately 6 million tons per year by 2018. This will be achieved through debottlenecking in Spain and improved utilization rates in Israel and the United Kingdom. At Cleveland Potash, we are extending the mining area to provide additional reserves and to increase our low-cost polysulphate production, a new fertilizer targeting low sulfur soils. In addition, we are evaluating further capacity increases in our current potash assets and at other potential potash locations. In phosphate, we are increasing our production in Rotem by approximately 15% by improving utilization rates. In addition, we are seeking governmental and municipal approvals for a new mining site—Barir field—in the Negev Desert in Israel, which, if granted, will provide further cost savings and increased scale through a focused investment program. See "Risk Factors—Risks Related to Our Business—Our mining operations are dependent on concessions, licenses and permits granted to us by the respective governments in the countries where they are located." Separately, we are assessing additional phosphate reserves in emerging markets with an intention to develop a full phosphate franchise in key regions in the world. Consistent with this strategy, we are in active discussions concerning phosphate franchises in key emerging markets. As of the date of this prospectus, we are negotiating with a third party for the engagement in joint ventures for current and future activities relating to the mining and sale of phosphate rock in emerging markets as well as for the production, marketing and distribution of downstream products of phosphate rock in the aforementioned markets. As of the date of this prospectus, the negotiations have not yet ripened into in-principle commercial agreements and the parties have not yet reached essential agreement regarding the structure of the transaction and the consideration to be paid by the Company, and therefore definitive agreements have yet to be signed and there is no certainty that these negotiations will ultimately result in definitive binding agreements or that such transactions will be consummated. If the negotiations ripen into definitive agreements, the Company estimates that the consideration it pays will be hundreds of millions of dollars.

    Expand market demand for our products.   In potash, we will increase our investment in educating emerging market farmers on the economic benefits of applying the optimal levels of potash. In particular, we are focusing on India and Africa due to our current position in these markets, our proximity to them and the currently low application of potash in these markets. This demand creation is intended to secure above-average sales growth in potash for us. We intend to continue driving demand growth for bromine through the development of new products and new applications by increasing our R&D spending, utilizing our industry knowledge, collaborating with others and by advocating for fire safety and mercury control regulations in emerging markets.

    Grow our value-added downstream products.   As part of our growth strategy we intend to use our strong cash flow to further grow our specialty and value-added products organically and through acquisitions. This will allow us to drive strong growth in our businesses and continue to evolve from a product-based to a market-focused organization. In the fast growing and high return-on-assets specialty fertilizers business, we are improving our core technologies and expanding our geographical footprint in liquid fertilizers, advanced coated fertilizers and soluble fertilizers. In food, we intend to expand our existing phosphate-based texture and stability solutions to emerging markets. In addition, we are constantly collaborating with our customers to develop new formulations. The next phase of this strategy is to leverage our expertise and technology platform to provide enhanced texture and stability solutions beyond additives based solely on phosphates, including through acquisitions, strategic partnerships and joint ventures. Finally, in engineered materials, we intend to utilize our expertise and technology in developing bromine and phosphate-based solutions for industrial applications. With respect to our activities that do not constitute our core businesses, we are examining various possibilities in connection with the continued integration of such activities in our Company and are preparing to divest activities that are not synergetic with our activities. As of the date of this prospectus, we are taking various measures to execute these activities in a monetary scope estimated by us in the range of $300 million to $500 million, including

103


Table of Contents

      by means of contacting potential purchasers and/or requesting to receive offers. However, binding agreements have not yet been signed and, accordingly, there is no certainty that binding agreements will be signed or that one or more of these transactions will be completed. Our goal is to generate over 10% of sales from new product introduction in our specialty businesses (outside potash and commodity phosphates) by 2018.

    Further develop and enhance our "One ICL" culture and empower our people.   In order to achieve our strategies and continue to carry out our evolution from a natural resources company to an essential needs company, we believe we must continue to enable our people to thrive within our organization and are implementing our "One ICL" strategy. Under our "One ICL" strategy, we are working to harmonize our systems (for example, by moving to a single global enterprise resource planning system) and processes and better share best practices across our Company to ensure that we provide the best services within our end-markets and avoid product or divisional silos. We will continue to identify and reward top performing employees and will move them to the right locations within the organization where they can be most effective, while incentivizing them through compensation and performance assessments to help us achieve our goals.

104


Table of Contents


Our Corporate Structure

        The following chart presents our corporate structure, indicating our significant subsidiaries and respective ownership interests as of December 31, 2013.

GRAPHIC

        All of the companies included in the chart above are wholly owned by us with the exception of I.D.E. Technologies Ltd. ("IDE"), which is a jointly controlled company held 50% by us and 50% by Delek Infrastructures Ltd., and Sinobrom, which is held 75% by ICL-IP Europe B.V. and 25% by ShangDong Haihua Company Limited. Unless otherwise indicated in the chart above, all of our significant subsidiaries are Israeli companies.


Our History

        We were established in 1968 as a government owned and operated company in Israel and operate today as a limited liability company under the laws of Israel. In 1975, the shares of various development

105


Table of Contents

companies (including, among others, Dead Sea Works, the companies today consolidated as Rotem, the bromine companies and Tami) were transferred to us. In 1992, following a decision by the Israeli government to privatize our Company, Israel published its tender prospectus, and the shares of ICL were listed on the TASE. Prior to our public share issuance, we issued to Israel a Special State Share in our Company and our main Israeli subsidiaries. See "Description of Share Capital—The Special State Share."

        In 1995, Israel sold its controlling interest in us (representing approximately 24.9% of our shares) to Israel Corporation, which was controlled at that time by the Eisenberg family. A majority of the ordinary shares held by Israel were sold during the following years. In 2000, Israel ceased to be an interest holder in terms of holding any ordinary shares in us, but it retained the Special State Share. In 1999, the Ofer Group acquired the Eisenberg family's shares in Israel Corporation. Immediately prior to this offering, Israel Corporation holds approximately 52.38% of our outstanding ordinary shares. With respect to any ordinary shares Israel Corporation sells directly to the underwriters, it will cease to have voting rights. With respect to any ordinary shares subject to the forward sale agreements, and made available to the forward counterparties under these agreements, Israel Corporation will cease to have voting rights with respect to these ordinary shares and will, at the relevant settlement dates, regain voting rights with respect to all or a portion of the ordinary shares it makes available to the forward counterparties under these agreements if it elects cash settlement or net physical settlement.

        The following is a list of significant acquisitions and joint ventures that have contributed to the growth of our business since 1968:

    our acquisition of Giulini Chemie, a specialty chemicals company based in Ludwigshafen, Germany, in 1977;

    our acquisition of a fertilizer plant in Amsterdam, Holland, in 1982;

    our acquisition of Clearon Corp., a manufacturer in the United States of biocides for water treatment, in 1995;

    our acquisition of BK Ladenburg, a chemical company based in Ladenburg, Germany, in 1996;

    the commencement in 1997 of our magnesium production operations in Israel in a joint venture with Volkswagen;

    our acquisition in 1998 of control of Iberpotash, our Spanish mining operation and our subsequent acquisition of the remainder of Iberpotash;

    our acquisition, primarily in 2000, of the publicly-held minority interests in several of our principal subsidiaries;

    our acquisition of Cleveland Potash, our mining operation in the United Kingdom, in 2002;

    our acquisition of a 51% interest in BKGLC in China in 2004;

    our acquisition of operations and assets for our Performance Products segment from Astaris LLC, a U.S. company, in 2005;

    our acquisition of Supresta, a manufacturer of phosphorus flame retardants and other phosphorus-based products with plants in the United States and Germany, in 2007;

    our acquisition of the water treatment unit of the Henkel Group, a Germany company, in 2008;

    our five acquisitions, mainly in the fields of food hygiene and potable water, in 2009: Medentech (Ireland), Primalab (France), Argochem and Merak (Eastern Europe), Metakorn (China) and Edda, Hyproclean and the cleaning products division of Ukline (Germany);

106


Table of Contents

    our acquisition of shares in Nutrisi Holdings in 2011, resulting in 100% ownership of Nutrisi Holdings, a Belgian holding company that owns 50% of Nu3, a manufacturer of soluble NPK fertilizer components;

    our acquisition in February 2011 of the companies, assets and activities of business unit in the specialty fertilizers area owned by the U.S. company, Scotts Miracle-Gro Company (subsequently renamed Everris);

    our acquisition in April 2011 of 100% ownership of A. Fuentes Mendea S.A., a Spanish company engaged in the production and marketing of specialty fertilizers in Spain;

    our acquisition in December 2011 of 50% of the shares of Tetrabrom Technologies Ltd., bringing our aggregate shareholdings to 100% of the share capital of Tetrabrom;

    our acquisition of all of the shares of the Belgian company Nu3 NV and sale of all of our shares in the Dutch company Nu3 BV, due to the liquidation of the Nu3 partnership, at the end of 2012;

    our acquisition from Thermphos International B.V. in February 2013 of the production assets and activities of a plant in Knapsack, Germany used for marketing and producing P2S5 phosphates; and

    our acquisition of Hagesud Group, a German producer of premium spice blends and food ingredients for meat processing, in January 2014.

        In addition, in December 2013 we announced that we have entered into a definitive agreement to acquire Vale Fertilizantes's share in Fosbrasil, S.A., a joint venture producing purified phosphoric acid and raw materials for fertilizers located in Brazil. The Fosbrasil transaction is subject to the approval of Brazilian anti-trust authorities and other customary approvals.

        In February 2014, we signed a strategic agreement with Allana Potash ("Allana"), the shares of which are traded on the Toronto Stock Exchange, in connection with the development of a potash mine in Ethiopia.


Public Takeover Offers

        In October 2012, Potash Corporation of Saskatchewan announced that it was considering an offer to purchase our company. However, in April 2013, Potash Corporation of Saskatchewan announced that it would no longer pursue such a bid.


Segment Information

        We are a multinational company that operates mainly in the areas of fertilizers and specialty chemicals, in three segments: Fertilizers, Industrial Products and Performance Products. In addition, we have other operations that include water desalination and magnesium manufacturing.

        A description of our three operating segments follows.

    Fertilizers

        Our Fertilizers segment develops, manufactures, markets and sells fertilizers that are based primarily on potash (potassium chloride) and phosphate. In 2013, the total sales of our Fertilizers segment were $3,655 million and accounted for approximately 58.3% of our total sales (including sales to other segments of the Company), while operating income for the segment totaled $821 million, representing approximately 73.6% of our total operating income. Our Fertilizers segment is also a key player in the specialty fertilizers market.

        Our Fertilizers segment did not have any single customer that accounted for more than 10% of its total sales in 2013.

107


Table of Contents

        Nitrogen, phosphorus and potassium (N, P and K) constitute the three major nutrients required for plant growth. There are currently no artificial substitutes for phosphorous or potassium. All three of these major plant nutrients are naturally present in soil in different concentrations, but the continued growing of crops depletes soil of nutrients and therefore each nutrient must be replenished from external sources through the use of fertilizers. We sell phosphorus- and potassium-based products.

        Each of these three nutrients plays a different role in plant development. Potassium and phosphorus are vital for many of a plant's physiological processes, including strengthening cereal stalks, stimulating root development, leaf and fruit health, and accelerating the growth rate of crops. Without these nutrients, crops cannot achieve their growth potential. Potassium also enhances a plant's ability to withstand drought and cold, the efficient use of nitrogen and other nutrients necessary for plant development and the durability of agricultural produce in storage and transportation, thereby prolonging the shelf life of produce.

        In the short term, demand for fertilizers is volatile and is affected by factors such as weather in the world's key agricultural growing regions, fluctuations in planting main crops, agricultural input costs, agricultural product prices and developments in biotechnology. Some of these factors are influenced by subsidies and lines of credit granted to farmers or to producers of inputs for agriculture in various countries, and by environmental regulations. In addition, currency exchange rates, legislation and international trade policies have an impact on the supply, demand and level of consumption of fertilizer worldwide. In spite of the volatility that can be caused in the short term as a result of these factors, we believe that the policy of most countries is to ensure orderly and high-quality supply of food to the population and thereby to encourage agricultural production, which we expect to preserve the long-term growth trend of the fertilizers market.

    Our Products

        The main products of our Fertilizers segment are potash and fertilizers and phosphates, including specialty fertilizers. In 2013, potash represented approximately 53.6% of our Fertilizers segment's sales (including sales from our other segments and prior to eliminations) and 90.4% of income from ordinary activities (including income from inter-segment sales and prior to eliminations) while fertilizers and phosphates represented approximately 46.4% of our Fertilizers segment's sales (including sales from our other segments and prior to eliminations) and 9.6% of income from ordinary activities (including income from inter-segment sales and prior to eliminations).

        Potash.     Potash is the common name for potassium chloride, which is the most common source of potassium for plants. Our Fertilizers segment sells potash for direct application as a fertilizer and to compound fertilizer manufacturers. Our Fertilizers segment also uses potash for its own production of compound fertilizers, based mainly on phosphate and potash.

        Our Fertilizers segment produces potash from the Dead Sea and from underground mines in Spain and the United Kingdom. The potash production process in Israel is based on extracting the carnallite in a chemical process. The carnallite, which is a compound of potassium chloride and magnesium chloride, precipitates in some of the largest solar evaporation ponds in the world, which contain brines drawn from the Dead Sea. The carnallite is transferred to the plants where a chemical process breaks down the carnallite crystal into potash using two parallel technologies ("hot" and "cold" crystallization).

        Extraction of potash from underground mines in Spain and the United Kingdom is carried out by mining sylvinite (a mixture of potash and salt found in varying potash concentrations). The potash is separated from the salt in production plants near the mines.

        We also produce polysulphate (also known as polyhalite), which is a mineral used in its natural form as fertilizer for agriculture, fertilizer for organic agriculture and a raw material for production of specialty fertilizers. Polysulphate is composed of potash, sulfur, calcium and magnesium, which are essential

108


Table of Contents

components for improvement of crops and agricultural products. Our commercial sales of polysulphate started in 2012.

        Fertilizers and Phosphates.     Phosphorus, which is derived from phosphate rock, directly contributes to a wide range of physiological processes in a plant, including production of sugars (including starch), photosynthesis and energy transfer. Phosphorus strengthens plants, stimulates root development, promotes flower formation and accelerates crop development.

        The principal raw material used in the production of phosphate products is phosphate rock. Our Fertilizers segment mines phosphate rock from open-pit mines located in the Negev Desert. In 2013, 75.0% of the phosphate rock produced was used to manufacture phosphate fertilizers and phosphoric acid. The balance of the phosphate rock was sold to external producers who manufacture phosphoric acid and fertilizers and as a direct application fertilizer. The policy of our Fertilizers segment is to use most of the phosphate rock we produce to create downstream products.

        Our Fertilizers segment produces fertilizer-grade phosphoric acid, phosphate fertilizers, compound fertilizers and specialty fertilizers at its facilities in Israel. Our Fertilizers segment also has facilities for the production of phosphate fertilizers and specialty compound fertilizers in the Netherlands, Germany, the United States, Spain, India and Belgium, as well as animal feed additives facilities in Turkey and in Israel. In addition to phosphate rock, phosphoric acid production also requires significant quantities of sulfur, which our Fertilizers segment purchases from third parties.

        Most of the compound fertilizers manufactured by our Fertilizers segment are based on the elements phosphorus and potassium. Some of the compound fertilizers also contain nitrogen, which our Fertilizers segment acquires from third parties and incorporates with the phosphorus and potassium. Our Fertilizers segment is active in developing downstream products based on phosphate rock, including phosphate fertilizers and compound and specialty fertilizers.

        Specialty fertilizers allow more accurate application of the essential nutrients for plant development (phosphorus, potassium and nitrogen). These fertilizers include:

    Controlled-release fertilizers, which allow accurate release of nutrients over time, and slow-release fertilizers, which allow very slow release of nutrients (nitrogen and potassium only). These fertilizers have a special coating that allows prolonged release of nutrients (over several weeks to several months, compared to regular fertilizer that dissolves in the soil and is available for up to four weeks);

    Soluble fertilizers, which are fully water-soluble, and fully-soluble NPK compound fertilizers, commonly used for fertilization through drip irrigation systems and foliar spraying to optimize fertilizer efficiency in the root zone and to optimize yields;

    Liquid fertilizers, used for intensive agriculture and integrated in irrigation systems (mainly drip systems); and

    Growing media used as a bed for various crops, usually containing controlled-release fertilizers and crop-protection products.

        Since 2011, we have significantly expanded our specialty fertilizer operations by completing the acquisition of the following companies:

    Everris (formerly Scotts Global Pro), a multinational company, whose core activity is the manufacture and sale of high-quality specialty fertilizers, including controlled-release, slow-release and soluble fertilizers;

    Fuentes Fertilizantes, a leading company in Spain that manufactures and distributes liquid and soluble fertilizers, NPK compounds and conventional fertilizers; and

109


Table of Contents

    Nu3, a manufacturer of soluble NPK fertilizer components.

        In February 2014, we signed a strategic agreement with Allana, the shares of which are traded on the Toronto Stock Exchange, in connection with the development of a potash mine in Ethiopia. Based on feasibility studies, we believe the mine will produce approximately one million tons of potash per year within a period of less than five years. Pursuant to the agreement, we acquired units of Allana (which includes shares and options), for a total amount of approximately $23 million. We hold approximately 16% of Allana's shares, with an option to increase our holdings to approximately 37%. Proceeds of the issuance will fund development and production of the mine project. This project, once completed, should give us access to low cost potash in a location that provides us access to the African market and is located only 400 miles from Djibouti, a port on the Red Sea that has access to the Indian and Southeast Asian markets. In addition, we signed an exclusive sale (offtake) agreement with Allana whereby we will be entitled to purchase the mine's output. Under the agreement, we will provide support to Allana and will also provide technical and engineering assistance with respect to development and operation of the mine, based on the knowledge that we have accumulated in these activity areas. The planned mine received an environmental permit in May 2013 and a mining license in October 2013, and it is receiving broad support from the Ethiopian authorities due to the opportunity for economic and social development in the Afar region in Ethiopia and in Djibouti.

    Production

        Our Fertilizers segment's principal production facilities include its plants in Israel (potash, phosphate rock, sulfuric acid, phosphoric acid, phosphate fertilizers, special compound fertilizers, liquid fertilizers and soluble NPK fertilizers), Spain (potash, raw salt, liquid fertilizers, soluble fertilizers and NPK-based compound fertilizers), the United Kingdom (potash, polysulphate, raw salt and peat as growing media), the Netherlands (mainly fertilizers based on phosphate and potash and slow-release and controlled-release fertilizers), Germany (mainly fertilizers based on phosphates and potash), Belgium (soluble NPK fertilizers), India (soluble NPK fertilizers), the United States (slow-release and controlled-release fertilizers and soluble NPK fertilizers) and Turkey (phosphate-based products used as animal feed additives).

        Our Fertilizers segment's manufacturing plants, distribution centers and sales offices are set forth in the map below.

GRAPHIC

110


Table of Contents

        Our current annual potential production capacity is approximately 6 million tons of potash, 4.5 million tons of phosphate rock, 1.9 million tons of phosphate fertilizers and compound fertilizers, 220,000 tons of soluble fertilizers, 450,000 tons of liquid fertilizers, 110,000 tons of controlled-release fertilizers and 300,000 tons of growing media. The potential production capacity of our various plants is based on the hourly output of the plants, multiplied by potential hours of operation per year. This calculation assumes continuous production over the year, 24 hours a day, with the exception of a few days for planned maintenance and repairs. Actual production is usually lower than potential production capacity, due to unexpected breakdowns, special maintenance operations and market conditions. We expect to increase our actual potash production to approximately 6 million tons per year by 2018.

        Our production of potash increased at an average annual growth rate of 5.4% between 1973 and 2013, and we are advancing a plan for a further, gradual increase of between 300,000 and 500,000 tons per year in potash production capacity at the Sodom facilities, to be implemented by the end of 2014. We expect that this investment will create surplus production capacity at our production plants in relation to the amount of raw materials at our evaporation ponds, thereby adding flexibility to our production process and optimizing the timing of production and sales over time.

        In 2011, our Board of Directors approved the consolidation of Iberpotash's operations from two sites to one site, as part of an efficiency plan with respect to Iberpotash. As part of this plan, the production on the Suria site in Spain, including a mine and a plant, is being expanded gradually, and mining and production at the other production site will be terminated. In the first stage of the plan, we have commenced digging an access tunnel to the mine and expanding potash production at the mine and granulation capacity. In addition, the first stage will entail establishing a production plant for vacuum salt (salt with high chemical purity) at Suria. The second stage would include further expansion of potential potash production capacity, to 1 million tons, commencing in 2017, of which approximately 50,000 tons would be technical potash, and will reach a potential production capacity of approximately 1.5 million tons of vacuum salt. At the same time, we expect our granulation capacity to grow to a level of approximately 1 million tons per year. We estimate that implementation of the first stage of the plan, at an estimated investment of €175 million (approximately $241 million), will be completed by the end of 2015. We believe that implementation of the first stage of the plan will reduce expenses and contribute to streamlining, which will reduce potash production costs and contribute to conformity of production with environmental standards. Implementation of the second stage will result in higher potash production at one site compared to production at two separate sites.

        To help achieve these expansion plans in Spain, on June 19, 2014, one of our subsidiaries, ICL Iberia ("ICL Iberia"), signed a memorandum of understanding with the Dutch company Akzo Nobel Chemicals International B.V. ("AkzoNobel"), a leading producer of vacuum salt in Europe for the chemicals industry, for establishment of joint ventures for the processing and packaging of an annual quantity of 1.5 million tons of vacuum salt for various industrial applications and an annual quantity of 50,000 tons of white potash. The entire amount of the vacuum salt will be sold to and marketed exclusively by AkzoNobel to the European market and other markets outside Europe. The entire amount of the white potash will be sold and marketed exclusively by us. It was agreed that ICL Iberia and AkzoNobel will act to formulate a set of agreements that will govern the relations between them and between the new companies that will be incorporated for purposes of the joint ventures, for a period of 30 years. The memorandum of understanding will remain in effect until December 31, 2014 or until any other date that the parties may mutually agree to. If a definitive set of agreements is not signed by such date, the memorandum of understanding will cease to be effective. However, there is no certainty that this transaction will ultimately be completed, including on the dates indicated.

        Based on these planned expansions, we expect that the annual potential potash production capacity of our production plants will reach 6.5 million tons by the end of 2015.

111


Table of Contents

        We also are undertaking other initiatives to expand and diversify our potash resources. In the United Kingdom, we are working to extend our mining area to increase reserves and increasingly utilizing the polysulphate resources to increase our production. We have commenced the implementation of an investment plan to increase the annual polysulphate production at our site in England from the current production level of approximately 130,000 metric tons to approximately 600,000 metric tons to capitalize on demand and reduce costs per ton. We estimate that this expansion of polysulphate production will require an investment of approximately £38 million. In Ethiopia, we have invested in the development of a potash mine by Allana that, once complete, should give us access to low cost potash in a location that provides us access to the African market and is located only 400 miles from Djibouti, a port on the Red Sea that has access to the Indian and Southeast Asian markets.

        We are also exploring ways to increase our phosphate production, including through the Barir field in Israel. Separately, we are assessing additional phosphate reserves in emerging markets with an intention to develop a full phosphate franchise in key regions of the world. Consistent with this strategy, we are in active discussions concerning phosphate franchises in key emerging markets.

    Competition

        Potash.     The potash market is characterized by a relatively small number of manufacturers, some of which export jointly. See "Risk Factors—Risks Related to Our Business—Our operations and sales are subject to the volatility of market supply and demand and we face significant competition from some of the world's largest chemical companies." The ability to compete in the market is dependent mainly on production costs and logistics. Moreover, there are high entry barriers for new players. The barriers to entry in the potash market are high due to the large investments required to establish production plants for the basic minerals and the relatively long time required to establish these plants. In addition, this industry requires appropriate concessions and proximity of production facilities to quarries.

        The significant competitors of our Fertilizers segment in international trade in the potash sector are Potash Corporation of Saskatchewan (Canada), Belaruskali (Belarus), Mosaic (Canada and the United States), Uralkali (Russia), K+S (Germany), Agrium (Canada), APC (Jordan) and SQM (Chile).

        Although there is currently over-capacity in the industry, various companies have announced plans to develop new mines and other companies have announced plans to expand their production capacity. There is uncertainty in respect of realization of the production capacities as well as the timing for their achievement. In addition, a number of companies have announced their examination of the possibility of entering into the potash industry.

        Fertilizers and Phosphates.     The phosphate fertilizer market is extremely competitive and is characterized by a relatively large number of competitors, including international companies and government-owned companies. The main competitive factor in the field of fertilizers is the price. The ability to compete in the market is dependent mainly on relative production costs and logistics. For this reason, companies located in proximity to sources of raw materials, ports and customers benefit from competitive advantages. Additional factors that affect competition to a certain extent include product quality, range of products, service and the capacity to develop new products that provide unique solutions.

        There are phosphate mines and production facilities in many countries, including Morocco, China, Russia, Jordan, the United States, Brazil, Saudi Arabia and Tunisia. The main phosphate producers who compete with us are Mosaic (United States), Potash Corporation of Saskatchewan (Canada), OCP (Morocco), Group Chimique Tunisienne (Tunisia), Vale (Brazil), Ma'aden (Saudi Arabia), the Roullier Group (Europe) and various Russian and Chinese producers. We believe a number of producers are approaching depletion of their higher-quality reserves.

112


Table of Contents

        We believe our Fertilizers segment benefits from the following competitive advantages:

    The low cost of potash production;

    An integrated value chain that allows our Fertilizers segment to use the phosphate rock it manufactures for use in the production of its phosphate fertilizers rather than purchasing phosphate rock from third party suppliers;

    Logistical advantages due to its geographical location, access to nearby ports in Israel and Europe and relative proximity to its customers;

    We are the only producer with the ability to ship potash and phosphate together, which reduces costs; and

    Logistical synergies due to potash operations in Israel, where the hot and dry climate of the Dead Sea enables us to store, at very low cost, a large quantity of potash in an open area thereby allowing us to consistently produce at Sodom at full capacity, independent of fluctuations in global potash demand.

    Raw Materials and Suppliers

        We produce a significant portion of our primary raw materials, including potash and phosphorus, through our mining operations in Israel, Spain and the United Kingdom, as discussed further below. See "—Mineral Extraction and Mining Operations" for further information on our mining operations.

        The primary raw materials acquired from external sources are sulfur and raw materials used to produce slow-release fertilizers, including ammonia, potassium hydroxide and coating materials. We seek to maintain inventories of sulfur, phosphate and other auxiliary materials in quantities that take into account the projected level of production based on consumption characteristics, supply dates, distance from the supplier and other logistical considerations. The other primary components we use for production of potash are natural gas, electricity, industrial water and maintenance supplies.

    Sales, Marketing and Distribution

        The primary markets of our Fertilizers segment are Brazil, Europe, China and India. Our Fertilizers segment sells its fertilizer products primarily via a network of its own sales offices as well as sales agents throughout the world.

        Most of our Fertilizers segment's sales are not transacted by means of long-term contracts or orders, but rather via current orders close to the date of supply. Consequently, the concept of a backlog is not meaningful.

        The prices of potash and fertilizers are determined in negotiations between the manufacturers and the customers and are affected mainly by the relationship between the market demand and the available supply at that date as well as the size of the customer and term of the agreement. Prices for relatively long-term contracts are not necessarily similar to spot prices.

        In Indian and Chinese markets, it is customary to negotiate centrally with respect to potash agreements, some of which are with commercial entities connected to the governments of those countries. Our Fertilizers segment has agreements in China with distributors and NPK producers. Under these agreements, the agreed price is usually for six months.

113


Table of Contents

        In the beginning of 2013, our Fertilizers segment signed three-year framework contracts with a number of customers in China for the sale of 3.3 million tons of potash. The sale prices in accordance with these agreements will be determined in negotiations between the parties from time to time. As part of these agreements, in January and February of 2014, our Fertilizers segment signed agreements for the supply of potash in the first half of 2014 in a scope substantially similar to the contracts signed with its customers for the first half of 2013. The contracts were signed at a price of $305 per ton CFR, constituting a price reduction of approximately $95 per ton CFR compared with the contracts signed in 2013. During the second half of 2013, a number of sale transactions to customers in China were executed based on the current spot rate. The imports into China in the first half of 2014 were 3.9 million tons, an increase of approximately 6% compared with the first half of 2013.

        In the Indian market, a change in the subsidy policies for fertilizers and the devaluation of the local currency against the U.S. dollar gave rise to a significant increase in the retail price of potash and phosphates to farmers and a drop in demand. Imports of potash into India fell from 4.5 million tons in 2011 to 3.4 million tons in 2012 and to 3.1 million tons in 2013. In the first quarter of 2014, the potash manufacturers signed contracts for the agricultural year beginning on April 1, 2014 and ending on March 31, 2015 at a price that embodies a decline of $105 per ton compared with the price closed in the prior supply contracts in India in the beginning of 2013. In the period between April 2014 and the date of this prospectus, our Fertilizers segment agreed with its customers in India to supply potash for the 2014/2015 agricultural year in an aggregate quantity of approximately 825 thousand tons (including optional quantities). The selling price agreed to is about the same as the price set in transactions with other producers supplying potash to the Indian market. The imports into India in the first half of 2014 increased by 29% compared to the first half of 2013 and stood at 1.5 million tons.

        In other markets, potash is usually imported by a larger number of customers, and the potash price is determined between the suppliers and the customers for shorter periods (quarterly, monthly or even for each individual shipment). In these markets, we have trade relations with most of the large customers.

        In Sodom, we benefit from being able to store very large amounts of potash (exceeding one full year of production) outside. Due to the hot and dry climate in Sodom, potash can be stored in piles in open areas. Therefore, the potash production in the production facilities in Sodom is not necessarily dependent on the rate of sales. Output that is not sold is stored in open areas within the plant in Sodom. This advantage generally affords our Fertilizers segment greater production flexibility in Spain and the United Kingdom as well because we can sell from Europe while holding our main potash inventory in Sodom. At the end of 2013, the inventory of potash stood at approximately 1.1 million tons as a result of the lower quantities sold starting in the third quarter of 2013 due to Uralkali's public announcement. At the end of the first quarter of 2014, the inventory of potash stood at approximately 0.9 million tons.

        Regarding phosphate fertilizers, our Fertilizers segment's strategy is to optimize profits by choosing whether to sell or store phosphate rock, fertilizer-grade phosphoric acid, phosphate fertilizers or compound fertilizers or to produce pure phosphoric acid. The inventory policy is set accordingly.

        Our Fertilizers segment transports its products from Israel to customers overseas by ships (mainly in bulk) that it leases in the marketplace and loads using designated facilities in the ports of Ashdod on the Mediterranean Sea and Eilat on the Red Sea. Our Fertilizers segment also has special port facilities for bulk loading in Barcelona (Spain), Amsterdam (the Netherlands), Ludwigshafen (Germany) and Teesside (UK).

        Our Fertilizers segment grants credit terms to its clients according to customary practices in their locations. The segment's credit sales are generally covered by trade credit risk insurance or by letters of credit from banks with high credit ratings.

    Seasonality

        The seasonal nature of demand for our Fertilizers segment's products gives rise generally to quarterly sales volatility, as sales levels in the second and third quarters are generally higher than sales in the first

114


Table of Contents

and fourth quarters. In recent years, due to various influences on the timing of sales, primarily price fluctuations and the effects of negotiations in China and India and changes in the timing of fertilizer imports to Brazil, the effects of seasonality explained above have been reduced as compared to earlier periods.

    Industrial Products

        Our Industrial Products segment develops, manufactures, markets and sells bromine and phosphorus-based flame retardants for the electronics, automotive and construction industries, bromine compounds for industrial use and agricultural use, clear bromine-based brine fluids for the oil and gas drilling completions industry and biocides for water treatment. These products are principally based upon bromine, magnesia, chlorine and salts from the Dead Sea and phosphorus and chlorine purchased from third parties. In 2013, the total sales of our Industrial Products segment were $1,297 million and accounted for approximately 20.7% of our total sales (including sales to other segments of the Company), while operating income for the segment totaled $115 million, representing approximately 10.3% of our total operating income. During 2013, our Industrial Products segment used approximately 70% of the bromine it produced for its own production.

        Our Industrial Products segment did not have any single customer that accounted for more than 10% of our total sales in 2013.

        Bromine is an element from the halogen family known for its variety of uses in many industries. It is used in the production of a range of bromine compounds. Bromine is found naturally in seawater, underground brine deposits and the Dead Sea. Its concentration varies depending upon its source. The method for extracting bromine depends on the nature of its source and its concentration. The lower the concentration of bromine in the brines, the harder and more expensive it is to extract.

        The Dead Sea is the world's major source of bromine and the concentration of salts in the Dead Sea is significantly higher than the concentration in regular seawater. Although there are other sources of bromine around the world, about half of the global supply comes from the Dead Sea.

        The operations of our Industrial Products segment are largely affected by the level of operations in the electronics, construction, automotive, oil drilling, furniture, pharmaceutical, agricultural, textile and water treatment markets. In 2013, 39% of worldwide use of bromine was for flame retardants, 8% was for water treatment, 16% was for clear brine fluids, 17% was for intermediates, 15% was for industrial uses and 5% was for other uses.

        Pressure is increasingly being exerted by "green" organizations in the area of environmental protection to reduce the use of bromine-based flame retardants. On the other hand, additional and new uses for bromine and its related compounds are being developed, along with regulation in various countries leading to increased use of bromine and bromine compounds. The economic slowdown in the world over the past several years, which continued in 2013, triggered a slowdown in the demand for electronic products and in the construction area. This trend, along with the decline in sales of personal computers due to increased use of tablets and smartphones, caused a decline in the demand for flame retardants, mainly bromine based, for the electronics and construction sectors. There was a certain improvement in demand for bromine-based flame retardants during the second quarter of 2014 for some of the uses in the electronics sector.

        In 2013 and the first half of 2014, elemental bromine prices were relatively stable in the United States and China, whereas there were price declines in Europe and India. In the first half of 2014, the demand continued to be strong in the market for clear brine fluids for oil and gas drilling completions due to the relatively high number of drillings in the Gulf of Mexico.

        In 2013, the market for biocides for treatment of swimming pools was impacted by falling prices as a result of a strategy by our competitors to increase their market share. In the beginning of 2013, the U.S. Department of Commerce decided to impose anti-dumping taxes on manufacturers of chlorine-based

115


Table of Contents

biocides from China, at the rate of about 30% to 38%. In the beginning of 2014, the anti-dumping taxes on the Chinese were increased by approximately 20%, and at the beginning of April 2014, the U.S. Department of Commerce gave notice of the imposition of anti-dumping taxes on Japanese manufacturers at a rate of 59% to 109%. The anti-dumping tax on biocides in the U.S. market will permit us to obtain a better position in the market even though this impact had not yet been expressed due to the fact that most of the transactions in this market are based on annual contracts. Demand for bromine-based biocides used for water treatment continued to be strong in the first half of 2014. The market for de-icing salts was characterized by high demand in 2013 and in the first half of 2014. The market for organic bromides for neutralizing mercury (Merquel products) remained unchanged in 2013 and was characterized by an increase in demand in the first half of 2014 due to cold weather conditions and high gas prices.

        The development of technology that allows the production of shale gas and its application in the United States presents business opportunities, including an increase in demand for bromine-based biocides.

    Our Products

        The following table sets forth the principal products of our Industrial Products segment, as well as their primary applications and primary end-markets.

Product
  Primary Application   Primary End-Markets

Bromine—and Phosphorus-based Flame Retardants

  Flame retardant additives   Electronics, Automotive, Construction, Furniture, Textiles

Elemental Bromine

  Chemicals reagent, rubber ingredient   Tire manufacturing, Pharmaceuticals, Agriculture

Organic Bromine Compounds

  Insecticides, solvents for chemical synthesis and chemical intermediates   Pharmaceuticals, Agriculture

Clear Brines

  Completion fluids   Oil and Gas

Merquel

  Mercury emission control   Emission control in coal-fired power plants

Bromine—and Chlorine-based Biocides

  Water treatment disinfection   Pools, Spas, Cooling Towers, Paper, Sanitation, Oil and Gas Drilling and Fracking

Calcined and Specialty Magnesia

  Magnesia derivatives, vulcanization control, antacid medication, food additives   Chemical, Rubber, Adhesives, Metallurgy, Food, Pharmaceuticals

Chlorine-based Salts (Magnesium, Sodium Chloride and Pure Potash)

  De-icing, dust control, salt, electrolysis   Municipal, Textiles, Cosmetics, Food, Water, Electrochemicals

        Our Industrial Products segment also develops innovative products and new applications for existing products. In 2013, our Industrial Products segment spent approximately $29 million on new product development and support and improvement of existing manufacturing processes. Our new products introduced in recent years include Merquel (inorganic bromides for neutralization of mercury), FR122P flame retardant (a bromine-based polymer flame retardant), TexFRon (a polymeric textile flame retardant product), FR-1410 (a high-bromine content flame retardant), new products for polyurethane and SaFRon 6605 (a phosphorus- and bromine-based product targeting flame retarding rigid polyurethane spray in-place insulation systems).

116


Table of Contents

        Merquel.     Mercury emissions in the atmosphere have been proven to be detrimental to health. In February 2009, the United States announced a change in policy and even initiated an international treaty, which had already been signed by approximately 147 countries by the end of 2013, with the goal of reducing mercury emissions. In December 2011, a law was passed by the U.S. Environmental Protection Agency ("EPA") that requires significant reduction of mercury emissions in the United States beginning in 2015. Concurrently, the United States continues to incentivize reductions in mercury emissions by providing tax rebates. At the end of 2008, our Industrial Products segment launched a new product line, Merquel, based on inorganic bromides, which together with certain technologies is targeted to enable efficient neutralization of mercury to the limits determined by the authorities (a 91% reduction in mercury emissions). Full application of the standards in all of the coal-fired power stations would require use of significant quantities of inorganic bromides. Our Industrial Products segment has invested in an extensive logistics system in the United States to allow ongoing supply to the United States market and is making preparations to build the production and logistics capacity required for reliable supply to this market and for other countries that adopt similar legislation.

        In 2013, sales of Merquel remained stable. In 2015, sales of this product are expected to grow with the commencement of application of the EPA regulation and entry into service of additional power plants in the United States that use Merquel.

        FR122P Flame Retardant.     In January 2012, we signed an agreement with the chemistry company Dow Global Technologies to use certain of its patents and know-how to produce an innovative bromine-based polymer flame retardant, which is considered especially effective. We expect that the FR122P flame retardant will be a substitute for the HBCD bromine-based flame retardant which is currently used in the construction insulation industry but is being phased out in Europe by August 2015. Our Industrial Products segment has initiated production of FR122P at its plant in the Netherlands and is in the advanced stages of construction of a production plant in Israel, which has the capacity to produce approximately 10,000 tons per year. The Netherlands facility currently has the capacity to produce approximately 2,400 tons per year.

        TexFRon.     In 2012, we began to sell TexFRon, a polymeric textile flame retardant product. We developed the TexFRon product line in-house within the R&D activities of our Industrial Products segment. TexFRon products are designed to provide high-level fire retardant solutions for fire retardant textile and adhesive applications. They are an effective replacement for DECA (likely to be prohibited for all uses in Europe in 2017 at the earliest) and offer enhanced sustainability compared to other existing products.

        FR-1410.     We recently began to sell FR-1410, which is a high-bromine content, effective flame retardant, following the expiration of our competitors' patents. This flame retardant is primarily used in the electronics, construction and home appliance markets.

        New Products for Polyurethane.     Our new products for polyurethane include the following:

    Fyrol HF-5, developed and commercialized specifically in response to IKEA's most recent update to their finished furniture specifications that imposed bans on specific flame retardants and substantially reduced VOC emissions from the flexible polyurethane components of their finished furniture goods. Ikea has specifically approved Fyrol HF-5 for use in its upholstered furniture products.

    Fyrol HF-9, developed and commercialized in response to California's addition of TDCP to the Proposition 65 list of substances designated by the State of California as a known carcinogen. Fyrol HF-9 represents an improvement in sustainability compared to the technology used by the upholstered furniture value chain to ensure resistance of flexible polyurethane foam when exposed to an open flame ignition source. Additionally, Fyrol HF-9 performs well in flexible polyurethane foam upholstered furniture applications from a cost performance and foam discoloration perspective.

117


Table of Contents

    Fyrol HF-10, recently developed and commercialized to represent an even greater product differentiation in terms of volatile organic compounds for flexible polyurethane foam automotive applications. It has been developed specifically to support our Industrial Products segment's announced exit from TDCP for automotive applications by the end of 2015 and to support the global automotive industry's move away from TDCP through an orderly and structured process.

        SaFRon 6605.     The SaFRon product line represents our Industrial Products segment's efforts to commercialize the robust synergies of phosphorus and bromine in rigid polyurethane thermal insulation applications. SaFRon 6605 is a phosphorus- and bromine-containing product specifically targeting flame retarding rigid polyurethane spray in-place insulation systems to meet flammability standards and building codes to promote the safety in use of spray systems. SaFRon 6605 is unique and differentiated because it offers high halogen content, which translates to efficiency in the use of any product commercially offered for this application.

    Production

        Our Industrial Products segment's major manufacturing facilities are in Israel (bromine, Dead Sea salts, bromine compounds and magnesia), the Netherlands (bromine compounds), Germany (phosphorus compounds), France (specialty magnesia products and calcium compounds used as raw materials in health foods and food additives), Ireland (chlorine-based biocides for water treatment), the United States (chlorine-based biocides for water treatment and production of phosphorus compounds) and China (bromine compounds).

        Our Industrial Products segment's principal manufacturing plants, distribution centers and sales offices are set forth in the map below.

GRAPHIC

        In 2013, we produced 172,000 tons of bromine and 196,000 tons of bromine compounds. In 2013, production of chlorine-based biocides reached 16,000 tons, production of phosphate compounds reached 90,000 tons and production of magnesia products reached 43,000 tons. Our maximum annual capacity is approximately 280,000 tons of elemental bromine, 400,000 tons of bromine compounds, 37,000 tons of chlorine-based biocides, 150,000 tons of phosphorus compounds, 53,000 tons of magnesia and 430,000 tons of Dead Sea salts.

    Competition

        Our Industrial Products segment is the world's leading producer of elemental bromine, accounting for approximately a third of total international production of bromine, according to internal assessments. Our Industrial Products segment estimates that it and its two main competitors, Albemarle and Chemtura,

118


Table of Contents

accounted in 2013 for approximately 80% of the worldwide consumption of bromine and approximately 64% of the bromine compounds. Chinese production accounts for much of the remainder, but the quantity of brine available for producing bromine in China continues to decline, leading to lower production capacity. Chemtura and Albemarle produce bromine primarily from underground brine sources in the United States. Albemarle also has a joint venture with a Jordanian company to produce bromine and bromine compounds which started operations in November 2002 and is located on the Jordanian side of the Dead Sea with access to the same source of raw materials that we have. In the beginning of 2013, Albemarle doubled the production capacity of bromine and expanded its production capacity of bromine compounds it produces at the site of its joint venture in Jordan. Chemtura purchases bromine and some other bromine compounds from our Industrial Products segment under long-term contracts. In January 2010, Chemtura and Albemarle signed a long-term strategic agreement. Under the agreement, Albemarle supplies Chemtura with a number of principal products, including flame retardants, and organic and inorganic bromine-based compounds. As of June 30, 2014, we did not expect this agreement to have a negative effect on our Industrial Products segment.

        The main barrier to entry in the bromine and bromine compound market is access to an economically viable source of bromine in high enough concentration. In addition, the bromine business requires a complex logistics system based on special containers (isotanks) for transporting the bromine. The need for the logistics system is a barrier to entry to competitors in the global trade in bromine.

        The main competitors of our Industrial Products segment in the bromine-based flame retardant market are Albemarle and Chemtura, as well as a number of producers in China. The relatively low production cost of bromine affords our Industrial Products segment a competitive advantage. Bromine production requires a complex logistical system based on a fleet of special containers (isotanks) specifically designed to transport bromine. One of the advantages of our Industrial Products segment is having the largest fleet of isotanks in the world, which enables it to transport relatively large quantities of bromine around the world. Our Industrial Products segment has contracted with a supplier of isotanks to expand its existing fleet. During 2013, all of the new isotanks were received from the manufacturer. In addition, our Industrial Products segment has a widespread worldwide marketing network and a range of high-quality products, combined with a technical support system that works closely with customers, providing a good competitive position in its target markets. In China, for example, our Industrial Products segment's network includes three production facilities in China, a sales site, a bromine containers farm, and sales and technical support networks. In the Netherlands, our Industrial Products segment has a bromine compound production facility, which gives it a competitive advantage in Europe. The phosphorus-based flame retardant and functional fluids production plants in the United States and Europe are situated in close proximity to our Industrial Products segment's principal customers.

        In the phosphorus-based flame retardants market, competition is mainly from Chinese manufacturers operating in the local market and in markets outside China, mainly Europe and the United States. Access to a source of high-quality, low-cost phosphorus improves the capacity to compete in this market.

        There are many competitors in the market for biocides for water treatment, and entry barriers are mainly related to the process for obtaining a license to sell.

        There are several competitors in the magnesium chloride industry. The entry barrier to this market is low, as any company with access to magnesium chloride can produce the solution.

        There are a number of small competitors in the pure potash market. Pure potash is a high-quality potash used mainly in the food and pharmaceutical industries. The main entry barrier is access to potash and the technological knowledge required for its crystallization.

        In part of the biocide industry, the magnesia industry and the industry for other salts, our Industrial Products segment has a leading position in certain niche products.

119


Table of Contents

    Raw Materials and Suppliers

        The principal raw materials used by our Industrial Products segment are bromine and bromine compounds, magnesia, chlorine-based biocides, Dead Sea salts and phosphorus-based products. We produce a significant portion of our raw materials through our extraction operations. See "—Mineral Extraction and Mining Operations" for further information on our extraction operations.

        Elemental bromine is produced from the end brines (salt solutions) that result from the processes carried out to produce potash from carnallite. The brine is pumped into our Industrial Products segment's plant in Sodom, where bromine is produced in an oxidation process using chlorine.

        Chlorine is produced by electrolysis of sodium chloride and as a by-product of the magnesium production process of Dead Sea Magnesium Ltd. ("Dead Sea Magnesium"). The electrolysis facility and the magnesium plant are located next to the bromine facility in Sodom. The sodium chloride used in the electrolysis process is a by-product of the potash production in Sodom.

        Our Industrial Products segment uses elemental bromine to manufacture bromine compounds at its facilities in Israel, the Netherlands and China. Our Industrial Products segment sells the balance of its elemental bromine to third parties. Most bromine compounds are manufactured by chemical processes involving bromine together with a range of other raw materials, of which the most important are Bisphenol A, which is used to manufacture the bromine-based flame retardant TBBA, and phosphorus, which is used to manufacture phosphorus-based flame retardants. Furthermore, our Industrial Products segment purchases many other raw materials required for production of the various products.

        The following is a graphic representation of the production process.

GRAPHIC

        Some of the brine that remains after the production of potash is rich in magnesium chloride. This brine is pumped to our Industrial Products segment's facilities at Mishor Rotem. At these facilities, in a process utilizing magnesium chloride and other materials, magnesia (magnesium oxide) is produced. The magnesia is further processed into several grades of magnesia.

        Our Industrial Products segment produces chlorine-based biocides at its facilities in the United States and Ireland. For production of chlorine-based disinfection products (biocides), our Industrial Products segment purchases chlorine, urea and caustic soda from local manufacturers and cyanuric acid from Chinese manufacturers.

        Dead Sea salts are manufactured at a facility in Sodom. The production starts from materials and brines produced as by-products of potash production. For example, magnesium chloride flakes are produced from brines rich in magnesium chloride that remain after potash is separated from carnallite. Various types of sodium chloride are also extracted from the salt that remains after potash is separated from carnallite.

120


Table of Contents

        Elemental phosphorus (P 4 ) is produced in a roasting process from ores originating in Central Asia (Kazakhstan), the United States or China. Products based on phosphorus are produced in our Industrial Products segment's factories in the United States and Germany. Our Industrial Products segment uses elemental phosphorus to produce phosphorus compounds at its factories. The basic phosphorus compound (POCl 3 ) is manufactured in a chemical process that combines phosphorus, chlorine and oxygen. The reaction of this compound with a variety of other raw materials (such as propylene oxide or epichlorohydrin) creates the commercial phosphorus compounds.

        The following is a graphic representation of the production process.

GRAPHIC

        Our Industrial Products segment seeks to maintain raw material inventories in quantities that take into account the projected level of production based on consumption characteristics, supply dates, distance from the supplier and other operational and logistical considerations.

121


Table of Contents

    Sales, Marketing and Distribution

        Our Industrial Products segment's principal markets are Western Europe, the United States, China, Japan and Taiwan. Our Industrial Products segment sells its products primarily through a network of marketing companies, which have agents and distributors throughout the world. Commissions are paid to agents as is customary in the sector. Most of our Industrial Products segment's sales are not transacted by means of long-term contracts or orders, but rather via current orders close to the date of supply. Consequently, the concept of a backlog is not meaningful for our Industrial Products segment.

        In addition, our Industrial Products segment has framework agreements with specific customers, under which the customer can purchase up to previously agreed maximum quantities of a product during the term, on the basis of which the customer issues purchase orders to our Industrial Products segment from time to time. In some of the agreements, sales prices have been fixed, at times with an update mechanism as well. These fixed prices have not had a substantial adverse effect on our results.

        Our Industrial Products segment's policy is to seek to maintain adequate inventory, which varies from product to product, to ensure orderly supply to customers in light of the customers' distance from production centers and their requirements for inventory availability, and in conjunction with optimization of the inventory storage costs. Therefore, portions of finished product inventories are held in storage facilities in the destination countries.

        Our Industrial Products segment extends credit terms to its customers according to customary practices in their locations. The segment's sales are generally covered by trade credit risk insurance or by letters of credit from banks with high credit ratings.

    Seasonality

        Our Industrial Products segment's operations are not characterized by regular seasonal fluctuations. However, amounts sold of some of its products fluctuate between the various seasons. Agricultural products are characterized by relatively high sales in the second and third quarters. Biocides for swimming pools are characterized by relatively lower sales in the fourth quarter. Salts for de-icing are characterized by relatively higher sales in the first and fourth quarters. The net impact of these diverse seasonal differences on our Industrial Products segment has not been meaningful.

    Performance Products

        Our Performance Products segment develops, produces, markets and sells a broad range of phosphate-based products as part of our strategy of increasing our production of downstream products with higher added value. Our Performance Products segment also develops, produces, markets and sells alumina-based products and other industrial performance products. In 2013, the total sales of our Performance Products segment were $1,575 million and accounted for approximately 25.1% of our total sales (including sales to other segments of the Company), while operating income for the segment totaled $196 million, representing approximately 17.6% of our total operating income.

        Approximately 76% of our Performance Products segment's external sales in 2013 were of phosphoric acid of various grades (technical, food, electronics and polyphosphoric acid) and its downstream products. These products are produced in part using phosphate rock that is mined by our Fertilizers segment and the phosphoric acid manufactured from that phosphate rock and in part using elemental phosphorus (P 4 ) and phosphoric acid that is purchased from third parties.

        Our Performance Products segment did not have any single customer that accounted for more than 10% of our total revenue in 2013.

122


Table of Contents

        Most of our Performance Products segment products are affected by the global economic situation, competition in our target markets, price fluctuations in the fertilizer market, which affect the price of the main raw materials of our Performance Products segment, and fluctuation in energy prices, which mainly affect production costs of thermal phosphoric acid.

        In spite of the uncertain economic atmosphere in the global markets in 2013, demand improved across business lines. Although demand increased in 2013, customers and competitors created pressure to lower prices of phosphorus-based products. Furthermore, new regulations surrounding the use of phosphate salts in dishwasher detergent (STPP) have also led to some downward pricing pressure on phosphorus-based products in Europe. The atmosphere of uncertainty in the United States resulted in lower growth rates in this market and caused a slow recovery of the market. Our Performance Products segment began preparations for the expected increase in demand for low-sodium foods in the United States and has launched a food strategy to meet the demand for healthy and nutritious ingredients.

        We have recently expanded our Performance Products Segment's operations by completing the acquisition of Hagesud Group, a German producer of premium spice blends and food ingredients for meat processing, in January 2014. This transaction includes the acquisition of all of the operating assets of the Hemmigen, Germany-based company, including Hagesud's existing business, state-of-the-art production technology and warehouse facilities located in Hemmigen, Dortmund and Ottensoos, Germany with approximately 200 employees.

        In addition, our Performance Products segment acquired the phosphorus pentasulfide (P 2 S 5 ) assets and business operations of Thermphos International B.V. located in Knapsack, Germany in March 2013, and supplemented its production of hygiene products by acquiring the Eclean Company, which is based in China, in April 2013.

        In December 2013, our Performance Products segment entered into a definitive agreement to acquire Vale Fertilizantes's share in Fosbrasil S.A., a joint venture producing purified phosphoric acid and raw materials for fertilizers located in Brazil. Our acquisition of Vale Fertilizantes's share in Fosbrasil, S.A. is subject to the approval of Brazilian anti-trust authorities and other customary approvals. As a result of this acquisition, we acquired control of Fosbrasil, S.A. and accordingly, Fosbrasil will be consolidated in our financial statements.

    Our Products

        Our Performance Products segment's products are designed for a wide range of uses and industries. The main markets of our Performance Products segment include food, detergent, metallurgy, paint and coating, electronics, footwear, paper, pharmaceuticals, water treatment, concrete, oil additives and firefighting.

123


Table of Contents

        The following chart illustrates how our Performance Products segment is part of our strategy to manufacture downstream products with higher added value based on phosphate rock. The countries and areas named in parentheses are the locations of our production sites.

GRAPHIC

        The main products of our Performance Products segment are as follows.

        Pure Phosphoric Acid—Technical Grade, Food-Grade Acid, Electronics-Grade Acid and Polyphosphoric Acid.     The acid is used as raw material in the food, metal treatment, electronics and construction industries. Our Performance Products segment is the world's leading manufacturer of pure phosphoric acid. Our Performance Products segment manufactures and markets phosphoric acid of varying grades, primarily for the food industry. The product mix of our Performance Products segment includes specialized acids with high added value that are used in the electronics and construction industries.

        Phosphate Salts and Food Additives.     These products are designed for diverse uses, including treatment of metals, paints and coating, detergents, toothpastes and food additives. Our Performance Products segment manufactures and markets products with high added value, including phosphate salts, produced in Germany, the United States, Brazil and China, which are primarily based on phosphoric acid. Our Performance Products segment uses much of the phosphate salts that it produces as raw material to manufacture food additives in many countries in the world. The food additives of our Performance Products segment target the processed meat, fish and seafood markets, the cheese and milk products markets and the baked goods industry.

        Other Phosphate—and Phosphorus-Based Products.     The primary markets for these products are:

    Hygiene products:   a range of disinfectant and cleaning materials for various uses in the foodservice industry, including products for cleaning dairies, farms, industrial kitchens and other types of food facilities. Our Performance Products segment produces the products in France, Germany and Austria.

    Fire prevention and retardant products (fire safety):   fire safety products prevent fires, mainly in forests and open areas, by spraying products from an aircraft. We are one of the world's leading manufacturers of phosphate-based fire retardant products, which are used primarily to fight forest fires. These materials are produced in North America and France.

124


Table of Contents

    P 2 S 5 :   used as a primary ingredient in lubricating oil additives and insecticides.

        Other Products.     Our Performance Products segment manufactures a wide range of specialized products that are not phosphate-based and which require specific competencies. Among these are the following products:

    Thermoplastic products (Rhenoflex):   thermoplastic materials are plastic materials that can be molded with heat. Our Performance Products segment develops, manufactures and markets unique, environmentally-friendly, patent-protected thermoplastic products for reinforcing the toes and heels of shoes and for the production of other leather goods such as handbags and suitcases. Among our Performance Products segment customers are some of the leading manufacturers of quality footwear in the world. Production facilities are based in Germany and China.

    Chemicals for water and paper (APW—alumina compounds, paper and water chemicals):   our Performance Products segment manufactures and markets a wide range of alumina compounds and other chemicals (polymers) for the paper industry and other industries, cement additives and chemicals for treatment of industrial and drinking water. In 2008, our Performance Products segment expanded its water-treatment operations by acquiring the water treatment business of the German company Henkel. This business includes the production of performance products for treating water used in cooling towers, by power stations, heating systems, drinking water, sewage treatment and purification. Most of the production facilities are in Germany.

    Pharma, cosmetics and gypsum (PCG):   our Performance Products segment manufactures and markets active materials and other products for the pharmaceutical and cosmetics industries and also manufactures synthetic gypsum, mainly for the medical, dental and hobby industries. Production facilities are based in Germany and China.

        A significant portion of our Performance Products segment products are proprietary and have well-recognized brand names in their relevant markets, including Fibrisol, Brifisol, Joha, Tari, Rhenoflex, Anti Germ, Py-Ran, Nutrifos, Levn-Lite and Phos-chek.

        Our Performance Product segment's highly sophisticated technology platform for the development of texture and stability solutions has allowed it to develop expertise in phosphate and phosphorous-based food additives, fire retardants and water treatment products and a leadership position in these market segments.

    Production

        Our Performance Products segment manufactures its products in its facilities in Germany, the United States, Israel, Brazil, France, China, the United Kingdom, Argentina, Austria, Australia and Mexico. In Mishor Rotem in Israel, our Performance Products segment manufactures pure phosphoric acid by means of purifying fertilizer-grade phosphoric acid produced by our Fertilizers segment. Our Performance Products segment also manufactures thermal phosphoric acid in the United States by utilizing elemental phosphorous and purchasing purified phosphoric acid from third parties.

125


Table of Contents

        Our Performance Products segment's principal manufacturing plants, distribution centers and sales offices are set forth in the map below.

GRAPHIC

        In 2013, we produced 211,000 tons of pure phosphoric acid (in terms of Phosphorus Pentoxide), 396,000 tons of phosphate salts and food additives, 68,000 tons of other phosphate-based products and 284,000 tons of other products. Our maximum annual capacity is approximately 291,000 tons of pure phosphoric acid (in terms of phosphoric oxide), 474,000 tons of phosphate salts and food additives, 134,000 tons of other phosphate-based products and 491,000 tons of other products at our Performance Products segment.

    Competition

        Our Performance Products segment has a leading position in the field of pure phosphoric acid and its downstream products. Our Performance Products segment's competitors are large and mid-size international chemical companies, which have manufacturing and marketing presences in various countries, as well as regional companies that reap the benefits of being local manufacturers in a regional marketplace. In every field, many companies compete with our Performance Products segment by offering similar or substitute products.

        Competition in our Performance Products segment centers on product characteristics, price, quality, service and the ability to address customers' needs.

        The primary competitors of our Performance Products segment in each field are set forth below.

        Phosphate-Based Products:

    Pure phosphoric acid, phosphate salts and food additives:   Our Performance Products segment's main competitors are: Chemische Fabrik Budenheim KG, Innophos Inc., Prayon, Potash Corporation of Saskatchewan, Adithya Birla, Haifa Chemicals Ltd. and various Chinese producers.

    Hygiene products:   The main competitors in Central Europe are: Ecolab Inc., Diversey Inc. and Hypred.

    P 2 S 5 :   Our Performance Products segment's main competitors are: ChemTrade Logistics Company in North America and Italmatch Chemicals in Brazil and Singapore.

126


Table of Contents

        Other Products:

    Chemicals for water and paper:   The primary competitors of our Performance Products segment are BASF AG, Hercules-Ashland's water technologies (which was sold to Clayton, Dubilier & Rice in 2014), Kemira Oy, Ecolab Inc., GE Water Technologies and AkzoNobel.

    Pharmaceuticals, cosmetics and gypsum:   The primary competitors of our Performance Products segment are Reheis Inc. and Summit in the area of antiperspirants, SPI Pharma in the area of pharmaceutical products, and GC Corporation in the field of gypsum.

    Thermoplastics:   The primary competitors of our Performance Products segment are Tecno-Gi (SPA) and local manufacturers in China and Taiwan.

    Raw Materials and Suppliers

        The primary raw material for manufacture of phosphate salts and food additives is pure phosphoric acid, which is produced by purifying fertilizer-grade phosphoric acid as well as via a thermal process from elemental phosphorus (P 4 ). Our Performance Products segment obtains fertilizer-grade phosphoric acid from our Fertilizers segment and also obtains P 4 and purified phosphoric acid from external manufacturers.

        Our Performance Products segment has a long-term supply contract with a supplier of phosphoric acid that guarantees regular supply of this raw material through 2018. In addition, we have a long-term supply agreement for P 4 with another supplier through 2022.

        In addition to pure phosphoric acid, our Performance Products segment uses hundreds of other raw materials, which it purchases from many suppliers. After phosphoric acid, the raw material with the greatest total cost is caustic soda.

        Our Performance Products segment seeks to maintain raw material inventories in quantities that take into account the projected level of production based on consumption characteristics, supply lead time, distance from the supplier and other logistical considerations.

    Sales, Marketing and Distribution

        Our Performance Products segment sells its products mainly to industrial and commercial customers in Europe, North America, South America and Asia. Our Performance Products segment's marketing network is based primarily on an extensive internal marketing organization and, to a lesser extent, on external distributors and selling agents.

        To market and sell many of its performance products effectively, our Performance Products segment's marketing personnel work closely with customers in order to tailor the products to the customers' needs. Our Performance Products segment is not dependent on external marketing forces.

        Most of our Performance Products segment sales are made under agreements with terms of less than one year or through spot orders placed close to the date of supply. In addition, our Performance Products segment has framework agreements with specific customers, through which the customer can purchase up to previously agreed maximum quantities of product during the term, on the basis of which the customer issues purchase orders to our Performance Products segment from time to time.

        Most sales of performance products do not take place according to long-term orders or contracts, but are regularly ordered close to the time of supply. Consequently, the concept of a backlog is not meaningful for our Performance Products segment.

127


Table of Contents

        Our Performance Products segment's strategy is to maintain adequate inventories to ensure orderly supply to customers in light of the customers' distance from the manufacturing locations and their requirements for inventory availability, and in conjunction with optimization of the inventory's storage costs. Therefore, portions of finished product inventories are held in storage facilities in the destination countries.

        Our Performance Products segment extends credit terms to its clients according to customary practices in their locations. The segment's sales are generally covered by trade credit risk insurance or by letters of credit from banks with high credit ratings.

    Seasonality

        The target markets of most our Performance Products segment's products are not characterized by seasonality, except for flame retardants, which have a higher sales volume in the spring and summer due to the many fires in North America during this period.

    Other Activities

        IDE, our 50%-owned non-consolidated affiliate, is in the following fields: constructing and selling water desalination plants, selling water, operating and maintaining water treatment and desalination plants and developing and producing industrial evaporators and heat pumps. IDE has deployed approximately 400 water desalination plants in more than 40 countries worldwide and seeks to address a wide range of the world's clean water challenges. IDE's core competencies are in membrane and thermal desalination, industrial evaporators and heat pumps.

        DSM produces, markets and sells pure magnesium and magnesium alloys. It also produces dry carnallite and related by-products, including chlorine and sylvinite. DSM is the second largest magnesium producer in the Western world after US Magnesium.


Principal Properties and Leases

        Under the Israeli Dead Sea Concession Law, 1961, as amended in 1986 (the "Concession Law"), we have lease rights until 2030 for the salt and carnallite ponds, pumping facilities and productions plants at Sodom. We have other production facilities in Israel, situated on land with a long-term lease, including the plants at Mishor Rotem (mainly leased until 2028 to 2041), the Oron and Zin sites of our Fertilizers segment (leased until 2017 to 2024), production and transportation facilities at Neot Hovav of our Industrial Products segment (leased until 2024 to 2048), as well as production, storage and transportation facilities and chemicals and research laboratories at Kiryat Ata (leased until 2046 to 2049) that belong to our Fertilizers segment and our Industrial Products segment. We also have warehouses and loading and unloading sites at the Ashdod (leased until 2016, although we are currently negotiating an extension) and Eilat ports that belong to our Fertilizers segment.

        We have additional production facilities outside Israel, the main ones being:

    Germany:    production plants of our Performance Products segment at Ludwigshafen and Ladenburg are owned by the ICL Group.

    The Netherlands:    production plants of our Industrial Products segment at Terneuzen that are owned, a facility of our Fertilizers segment in Amsterdam held under a lease until 2034 (or under certain conditions up to 2044) and a production facility in the southern Netherlands on land that is partly owned and partly held under a long-term lease.

    Spain:    the concessions at the potash and salt mines are held under the concession agreements described below. The potash and salt production plant, and the warehouses, as well as the loading and unloading facilities of our Fertilizers segment at Catalonia, are owned by the ICL Group. Our

128


Table of Contents

      Fertilizers segment also has a liquid fertilizer and soluble fertilizer production plant in Totana, another plant for mixing solid fertilizers in Cartagena and a concession on two ports in Cartagena and Almeria until 2024 and 2014, respectively. We are endeavoring to renew the concession in Almeria for an additional two years.

    The United Kingdom:    the rights to the potash and salt mines are held under the concession agreements described below. The potash and salt and production plants and the warehouses of our Fertilizers segment in Cleveland are owned by the ICL Group. The warehouses and bulk loading and unloading facilities at the port are leased until the middle of 2014. We are endeavoring to renew the lease agreement. The Company owns three mines and one plant for producing peat of our Fertilizers segment at Everris in the United Kingdom.

    The United States:    the production plant of our Industrial Products segment in West Virginia is owned by the ICL Group, the packaging facility of that location is leased through 2017, and the production plants of our Performance Products segment in Lawrence, Kansas and St. Louis, Missouri are owned by the ICL Group. The production plants of our Fertilizers segment in South Carolina are operated under leases ending in 2015 (which we are endeavoring to renew) and 2021, respectively.

        The following table sets forth certain information regarding our principal properties as of December 31, 2013.

Property Type
  Location   Size   Products   Owned/Leased

Headquarters

  Tel Aviv, Israel   17,222 square feet   Company headquarters   Leased

Plant

 

Sodom, Israel

 

13,099,679 square feet (not including ponds or magnesium factory)

 

Fertilizers segment products and power station

 

Leased

Plant

 

Sodom, Israel

 

2,326,060 square feet

 

Industrial Products segment products

 

Sub-concession

Pumping station

 

Sodom, Israel

 

920,314 square feet

 

Pumping station for Fertilizers segment

 

Concession

Transportation Facility

 

Sodom, Israel

 

1,970,333 square feet

 

Transportation facility

 

Owned on leased land

Plant

 

Mishor Rotem, Israel

 

27,524,194 square feet

 

Fertilizers segment products

 

Owned on leased land

Plant

 

Mishor Rotem, Israel

 

10,763,910 square feet

 

Industrial Products segment products

 

Owned on leased land

Plant

 

Neot Hovav, Israel

 

3,761,987 square feet

 

Industrial Products segment products

 

Owned on leased land

Plant

 

Oron, Israel

 

4,413,240 square feet (not including phosphate reserve)

 

Fertilizers segment products

 

Owned on leased land

Plant

 

Zin, Israel

 

8,483,916 square feet

 

Fertilizers segment products

 

Owned on leased land

Plant

 

Kiryat Ata, Israel

 

6,888,903 square feet

 

Fertilizers segment products

 

Leased

Warehouse and loading site

 

Ashdod, Israel

 

664,133 square feet

 

Warehouse for Fertilizers segment products with capacity of 412,769 metric tons

 

Leased

129


Table of Contents

Property Type
  Location   Size   Products   Owned/Leased

Warehouse and loading site

 

Eilat, Israel

 

152,557 square feet

 

Warehouse for Fertilizers segment products with capacity of 96,162 metric tons

 

Leased

Plant

 

Catalonia, Spain

 

48,491,416 square feet

 

Mines, manufacturing facilities and warehouses for Fertilizers segment products

 

Owned

Plant

 

Totana, Spain

 

2,210,261 square feet

 

Fertilizers segment products

 

Owned

Plant

 

Cartagena, Spain

 

209,853 square feet

 

Warehouse for Fertilizers segment products

 

Owned

Port

 

Cartagena, Spain

 

184,342 square feet

 

Storage for Fertilizers segment products

 

Concession

Port

 

Almeria, Spain

 

28,761 square feet

 

Storage for Fertilizers segment products

 

Concession

Plant

 

Cleveland, United Kingdom

 

13,239,609 square feet

 

Fertilizers segment products

 

Owned

Office

 

Ipswich, United Kingdom

 

3,274 square feet

 

Fertilizers segment office

 

Leased

Plant

 

Nutberry, United Kingdom

 

322,917 square feet

 

Fertilizers segment products

 

Owned

Peat Moor

 

Nutberry, United Kingdom

 

12,916,692 square feet

 

Peat mine

 

Owned

Peat Moor

 

Douglas Water, United Kingdom

 

4,843,759 square feet

 

Peat mine

 

Owned

Peat Moor

 

Cerca, United Kingdom

 

4,305,564 square feet

 

Peat mine

 

Leased

Plant

 

Bitterfeld, Germany

 

514,031 square feet

 

Industrial Products segment products with annual productive capacity of 190,000 metric tons

 

Owned

Plant

 

Ladenburg, Germany

 

8,072,933 square feet

 

Performance Products segment products with annual productive capacity of 148,780 metric tons

 

Owned

Plant

 

Hemmingen, Germany

 

175,042 square feet

 

Performance Products segment products with annual productive capacity of 2,500 metric tons

 

Owned

Plant

 

Duesseldorf, Germany

 

1,614,587 square feet

 

Performance Products segment products with annual productive capacity of 224,000 tons

 

Leased

Plant

 

Ludwigshafen, Germany

 

231,263 square feet

 

Performance Products and Fertilizers segments products

 

Owned and leased

Plant

 

Terneuzen, the Netherlands

 

930,271 square feet

 

Industrial Products segment products

 

Owned

130


Table of Contents

Property Type
  Location   Size   Products   Owned/Leased

Plant

 

Amsterdam, the Netherlands

 

349,827 square feet

 

Fertilizers segment products and logistics center

 

Owned plant on leased land

Plant

 

Heerlen, the Netherlands

 

481,802 square feet

 

Fertilizers segment products

 

Owned and Leased

Plant

 

Calais, France

 

538,196 square feet

 

Industrial Products segment products with annual productive capacity of 22,000 metric tons

 

Owned

Plant

 

Wexford, Ireland

 

88,000 square feet site (30,139 square feet buildings)

 

Industrial Products segment products with annual productive capacity of 1.8 billion tablets.

 

Owned

Plant

 

Belgium

 

128,693 square feet

 

Fertilizers segment products

 

Owned

Plant

 

Kamloops, British Columbia, Canada

 

392,040 square feet

 

Performance Products segment products

 

Leased

Plant

 

Stugeon County, Alberta, Canada

 

56,425 square feet

 

Performance Products segment products with annual productive capacity of 305,253 gallons

 

Leased

Plant

 

South Charleston, West Virginia, United States

 

475,000 square feet

 

Industrial Products segment products with annual productive capacity of 54,431 metric tons

 

Leased

Plant

 

South Charleston, West Virginia, United States

 

1,829,520 square feet (plant footprint of 871,200 square feet)

 

Industrial Products segment products with annual productive capacity of 36,287 metric tons

 

Owned

Plant

 

North Charleston, South Carolina, United States

 

60,000 square feet

 

Fertilizers segment products with annual productive capacity of 13,608 metric tons

 

Leased

Plant

 

Summerville, South Carolina, United States

 

41,000 square feet

 

Fertilizers and Performance Products segments products

 

Leased

Plant

 

Lawrence, Kansas, United States

 

179,689 square feet

 

Performance Products segment products with annual productive capacity of 97,069 metric tons

 

Owned

Plant

 

Carondelet, Missouri, United States

 

172,361 square feet

 

Performance Products segment products with annual productive capacity of 50,953 metric tons

 

Owned

Office

 

St. Louis, Missouri, United States

 

35,000 square feet

 

Administrative office

 

Leased

Plant

 

Rancho Cucamonga, California, United States

 

103,600 square feet

 

Performance Products segment products with annual productive capacity of 11,322 metric tons

 

Leased

131


Table of Contents

Property Type
  Location   Size   Products   Owned/Leased

Plant

 

Gallipolis Ferry, West Virginia, United States

 

17,424,000 square feet (plant footprint of 1,742,400 square feet)

 

Industrial Products segment products with annual productive capacity of 68,039 metric tons

 

Owned

Plant

 

Sao Jose dos Campos, Brazil

 

1,088,242 square feet (plant footprint of 79,298 square feet)

 

Performance Products segment products with annual productive capacity of 27,000 metric tons

 

Leased

Plant

 

Nuevo Leon, Mexico

 

152,406 square feet (plant footprint of 103,420 square feet)

 

Performance Products segment products with annual productive capacity of 41,800 metric tons

 

Owned

Plant

 

Bandirma, Turkey

 

375,187 square feet

 

Fertilizers segment products with annual productive capacity of 45,359 metric tons

 

Owned

Plant

 

Lian Yungang, China

 

358,665 square feet

 

Industrial Products segment products with annual productive capacity of 4,300 metric tons

 

Owned

Plant

 

Shan Dong, China

 

691,771 square feet

 

Industrial Products segment products

 

Owned

Plant

 

Jiangyin, Jaingsu, China

 

717,770 square feet

 

Performance Products segment products with annual productive capacity of 20,866 metric tons

 

Land Use Right (expires on January 31, 2054)

Plant

 

Jiaxing, China

 

828,017

 

Industrial Products segment products

 

Owned


Other Leases, Licenses and Permits

    Well Production Permits

        The supply of water to our Fertilizers segment plants at the Dead Sea is via a series of wells that we operate, both within and outside the concession area. Our Fertilizers segment has lease agreements and production permits for these wells.

        Dead Sea Works has permits to draw water from the wells at Ein Ofarim received from the Water Authority. The lease period from Israel Lands Administration (ILA) for these wells expired in February and March 2009. An application to extend the lease period was submitted to ILA, but after a lengthy procedure, it was rejected. Our Fertilizers segment is taking action to change ILA's decision. The application was discussed recently in ILA's Exemptions Committee, which approved the application. This application is subject to the approval of the Israeli Minister of Finance.

    Business Licenses and Other Permits

        In November 2013, a reform in the Business Licensing Law, 1968, came into effect which determines, among other things, that business licenses will no longer be perpetual, but rather each business license will be valid for a term of between one to fifteen years, depending on the type of activity the license covers. In addition, some of the activities requiring a license in accordance with the Business License Ordinance, 2013, shall be subject to unified specifications which will be published by the authorities as specified in the Ordinance, including the Ministry of Environmental Protection.

132


Table of Contents

        To date, we have been issued valid business licenses for our sites in Israel in perpetuity, in accordance with the law. Under the abovementioned reform, all of our businesses licenses will expire and require renewal three years after the applicable "Unified Specifications" are published, except power stations and storage of fertilizers, which will remain in perpetuity.

        In addition, our Fertilizers segment and our Industrial Products segment have valid toxic substance permits under the Israeli Hazardous Materials Law (1993), issued by the Ministry of Environmental Protection. The term of the toxic substance permits is one year. Renewal of permits is performed on an ongoing basis. Additional conditions were set out in the toxic substances permit received by Bromine Compounds, including requirements for risk management and seismic surveys Bromine Compounds is required to perform in accordance with the Ministry's guidelines.

        The plants in our Fertilizers segment have valid permits for discharging industrial wastewater into the Dead Sea and into the Mediterranean Sea (Deshanim plant), under the Israeli Prevention of Sea Pollution from Land-Based Sources Law (1988), which requires renewal from time to time. The costs of renewal of these licenses are not material.

        Our Industrial Products plants at Sodom and Mishor Rotem have valid permits for discharging industrial wastewater into the Dead Sea which requires renewal from time to time. The Industrial Products plant in Neot Hovav discharges industrial wastewater into the evaporation ponds in accordance with the plant's business license requirements. The costs of renewal of these licenses are not material.

        The segment companies operate in accordance with conditions set out in the licenses and permits. If there is any discrepancy in respect of the requirements of these conditions, the companies take immediate action to remedy the discrepancy in coordination with the Ministry of Environmental Protection.

        The Ministry of Environmental Protection has commenced implementation of the integrated licensing methodology, which is based on the Integrated Pollution Prevention and Control ("IPPC") directive that was adopted by the European Union in 1996. Pursuant to this directive, large factories are required to make use of the best available techniques ("BAT") in every environment on which they have an impact, while making integrative reference to all of such aspects. The BAT is provided in allocation documents, which are published by the European Union and detail every type of industry to which BAT is relevant for elimination or reduction of environmental harm. However, the Israeli Clean Air Law, 2008 (the "Clean Air Law") adopted this methodology only partially since it addresses only emissions into the atmosphere. In order to permit the integration required in the directive, the Ministry of Environmental Protection has added requirements for implementation of the IPPC methodology in the business licenses of factories considered to be "emission sources requiring a permit" under the Clean Air Law. The conditions are stipulated by the Ministry prior to submission of the request for an emission permit so that the permit request (concerning emissions into the atmosphere) will be filed together with the information required for determination of the conditions in other areas under the integrated licensing methodology, including, among other things, runoff, waste, treatment of hazardous substances and energy savings. In the first stage, a factory is required to perform a survey of these differences and to submit such survey to the Ministry. It is anticipated that concurrent with the issuance of an air emission permit, or shortly thereafter, the factory will receive additional conditions, including requirements for implementation of the BAT in these areas. The Ministry of Environmental Protection issued a requirement for additional information under the integrated methodology for most our plants that are required to obtain an air emission permit under the Clean Air Law. In July 2013, the Ministry issued to our Dead Sea Bromine plant additional conditions to its business licenses, requiring the submission of additional information, including a historical land survey. The submission deadline for the historical land survey has been postponed to September 2014. We are preparing for the implementation of the additional conditions.

        As of the date of this prospectus, it is not possible to know what will be required of us or what will be the cost involved with implementation of these requirements, if any.

133


Table of Contents


Mineral Extraction and Mining Operations

        The following is a description of the material properties where we extract minerals and conduct mining.

    The Dead Sea

        Over 40% of our net sales in 2013 related to products that were based on minerals that we extracted from the Dead Sea, including potash, bromine, sodium chloride, magnesia, magnesium chloride and magnesium. The concentration of these minerals in the Dead Sea has generally remained steady in recent years, although it is subject to increase as a result of the diversion, for consumer purposes, of the waters that flow into the Dead Sea. The level of concentration also increases in periods of relative drought when the flow of water into the Dead Sea diminishes. The Dead Sea contains a supply of these raw materials that is, for all practical purposes, unlimited.

        Our extraction of minerals from the Dead Sea begins with an evaporation process facilitated by the hot and dry climate of the Dead Sea region. This area is located approximately 1,361 feet below sea level, which is considered to be the lowest place on earth. The Dead Sea is divided into two parts: a northern lake and an area in the south that consists of our evaporation ponds.

        The production process begins with the pumping of water from the northern lake to our adjacent evaporation ponds. Our pumping station P-88 has a capacity of 100,000 cubic meters per hour. Each year we pump approximately 400 million cubic meters of water from the northern lake into the evaporation ponds and return it to the northern part of the Dead Sea at the end of the process. In 2013, we produced from this water approximately 3.6 million metric tons of potash, 172 thousand metric tons of bromine, 26 thousand metric tons of magnesium, 256 thousand metric tons of salt and 91 thousand metric tons of magnesium chloride solids. We plan to build a new pumping station from the northern basin to the evaporation ponds, as part of the preparations for the receding level of the Dead Sea and the removal of pumping station P-88 from service. However, we have experienced a delay in receiving approvals from the various government agencies that must approve our statutory plans for our new pumping station. In light of the delay in approval of the statutory plans, we are required to make an additional investment to extend the life of pumping station P-88 for an additional three years.

        The evaporation ponds extend over an area of approximately 146 square kilometers. They include a subsystem of 35 ponds for salt precipitation and ponds for the precipitation of carnallite.

        The salt pond known as Pond 5 is the largest pond in the complex. It has an area of approximately 80 square kilometers. It was built during the 1960s by the construction of a large dam, sealed by a clay core, in the area that was then the southern part of the Dead Sea. Evaporation from this pond increases the concentration of the brines contained therein to a stage of sodium chloride saturation. This causes the sodium chloride to precipitate to the bottom of the pond. The remaining brines are rich in potash, magnesium and bromine. They are pumped to other ponds, where evaporation results in further increases of mineral concentration, causing carnallite to precipitate. Carnallite is the raw material used for the production of potash, magnesium, chlorine and magnesium chloride. The carnallite is collected by our floating harvester barges and pumped as a slurry to our production plants. We use the remaining end-brine as a raw material in the production of bromine.

        The precipitated sodium chloride, or salt, creates a layer on the pond bed of approximately 20 million tons annually. The process of production of the raw material requires that a fixed brine volume is preserved in the pond. To this end, the water level of the pond is raised by approximately 20 centimeters annually. The Ein Boqeq and Hamei Zohar hotels, the town of Neve Zohar and other facilities and infrastructures are located on the western beach of this pond. Raising the water level of the pond above a certain level is likely to cause structural damage to the foundations and the hotel buildings situated close to the water's edge and to other infrastructure on the western shoreline of the pond, depending on the height

134


Table of Contents

to which the water level is raised and the location of the relevant object. Already in 1971 it was widely known, including by the various authorities, that the level of Pond 5 was rising by 20 centimeters each year. Most of the hotels signed a document confirming their knowledge regarding the rising level and that it would be taken into account in planning and constructing the hotels, and that they would bear the costs of constructing protection and that they would have no claim against Dead Sea Works in relation to the rising level.

        The annual increase in water level and resulting potential damage requires the establishment of defenses. Such protections are divided into two stages. The first is the stage of temporary defenses, which are supposed to provide protection pending the implementation of a permanent solution. The second stage is that of the permanent solution which is supposed to provide permanent protection.

        The temporary defenses have been underway for a number of years and are characterized by constructing a dike along the west coast of the pond, opposite the relevant hotels in some of the places with a system to lower the ground water. These dikes will be raised from time to time, in consideration of the height of the pond. As of the date of this prospectus, there is an agreement between Dead Sea Works and the government of Israel regarding financing of the costs of the temporary defenses—Dead Sea Works will bear 39.5% of the financing and the government of Israel will bear the remaining cost. For information about the appendix to this agreement signed in July 2012, see Note 23(C)(4) to our audited financial statements. There is no certainty that construction of these defenses will be finished on the dates required by the height of the level of Pond 5, since there could be delays deriving from, among other things, the need to receive the permits required by law (which are subject to complex and lengthy proceedings), and for other reasons. Delays in constructing the interim defenses could cause significant damage to the hotels and/or to Dead Sea Works.

        On July 8, 2012, we entered into an agreement with the government of Israel relating to a permanent solution for the rise of the water in level of Pond 5. The permanent solution is to be carried out by means of full harvesting of the salt from the floor of the pond. Upon completion of the salt harvesting, the process of production of the raw material will no longer require us to constantly raise the water level in the pond. Planning and execution of the salt harvesting will be performed by us. This project will constitute an Israeli national infrastructure project that will be promoted by the Israeli Committee for National Infrastructures. Our agreement with the government requires that, starting January 1, 2017, the water level in Pond 5 will not rise above 15.1 meters, dictating a stringent timetable for the project. Our failure to consistently maintain the water level below the 15.1 meter threshold from January 1, 2017 onward could impact our production. The statutory infrastructure of the salt harvesting project is presently being discussed by the Board of National Infrastructures and its approval is expected in 2014. Concurrently, we are performing additional activities relating to the salt harvesting project.

        According to the Dead Sea Protection Company, the total cost of the salt harvesting is estimated, as of October 2010, to be in an undiscounted amount of NIS 7 billion (a discounted amount of NIS 3.8 billion). The Israeli government will bear up to 20% of the cost of the salt harvesting. The Israeli government's maximum commitment (20% of NIS 3.8 billion, the discounted amount) is linked to the CPI and bears interest at the rate of 7%.

        An additional plan relating to our ability to make land examinations in the area was also recently approved by the Israeli government. Approval of each of the stages of the plan by the relevant dates set out in the project schedule is essential for continuation of Dead Sea Works' production process, and delays could have an unfavorable impact on the process and, accordingly, could give rise to damage or losses. In order to advance execution of the new pumping station discussed above and the salt harvesting set up, the Committee for National Infrastructures held a hearing in which it approved the location of the pumping station, allowing us to proceed with its construction.

135


Table of Contents

        Construction of a new partition in the middle of the dike surrounding Pond 5 was almost fully completed in 2013. The objective of this project is to minimize seepage from the dike. This project includes raising the dike by another meter, which is expected to be completed by the end of 2014.

        The phenomenon of sinkholes, which is attributed mainly to the lowering of the water level of the Dead Sea, is increasing in the Dead Sea area. The receding level of the Dead Sea is not to be confused with the rise of the water level in Pond 5 discussed above, and the two seemingly contradictory phenomena are occurring simultaneously, as Pond 5 is located on a different plane than the main body of the sea lying to its north, necessitating a special pumping station to constantly feed the pond with water. See "Risk Factors—A new pumping station will be required due to the receding water level of the Dead Sea." While the water level of Pond 5 is rising due to the accumulation of salt on its floor and the continuous pumping of water from the northern basin of the Dead Sea, the water level of such northern basin is receding. Most of the sinkholes caused by the receding level of the Dead Sea develop near the northern basin of the sea, where there is little operation by our Fertilizers segment. Sinkholes have also appeared near the evaporation ponds and in other places in the Dead Sea Works area. Development of a sinkhole under a dike could cause the dike to burst, causing loss of the solutions in the pond. Our Fertilizers segment is working to locate the development of these sinkholes in the area of the plant and along the dikes, and to fill them when they appear.

        We own and operate a 110 megawatt power station that provides the majority of the power used in our production plants at the Dead Sea. The balance is purchased from Israel Electric, a state-owned utility. In 2012, construction of a new power station in Sodom fueled by natural gas was approved. The power station will have a production capacity of 290 MW, which will supply the electricity requirements of the production facilities at Sodom. Operation of the station is planned to start in the middle of 2015. We intend to obtain the natural gas to supply the power plant pursuant to certain contracts. See note 23(A)(6) for a discussion of these contracts.

        Our Dead Sea property is accessible by conveyor belt from the plant to the railway and from Highway 90 in Israel.

    The Negev Desert

        We currently operate large surface phosphate mining sites at Oron, Rotem and Zin in the Negev Desert. In addition, the Israeli Minister of National Infrastructures under the Israeli Mines Ordinance, through the Supervisor of Mines in his Office (the "Supervisor"), has decided to extend the area of the Rotem field concession (valid until the end of the 2021) so that it covers the Hatrurim field. The area of the Rotem concession has been so extended, and the matter has been transferred to the Israel Lands Administration ("ILA") to deal with the extension of the area of the mining permit for the Rotem field, in line with the extension of the concession area.

        Each of these fields has a similar stratigraphy and geological setting with the phosphate preserved as relatively narrow elongated bodies along the margins and within the axes of two northeast to southwest trending asymmetrical synclines (basin or trough-shaped folds in the rock layer whose upper components are younger than those below) or monoclines (step-like folds in the rock layer). Oron and Rotem lie within a single syncline to the northwest of the Zin syncline. The three deposits have been proved over extensive distances in terms of length (Rotem 10 kilometers, Oron 16 kilometers and Zin 22 kilometers) and width (4 kilometers each). They are all known to extend further in terms of length but are limited in operational size by their proximity to national nature reserves where mining is prohibited by law. The Campanian (Upper Cretaceous period) phosphate rock deposits of Israel are part of the Mediterranean phosphate belt extending from Turkey, through Jordan and Israel, and westward through Egypt, Tunisia and Morocco. We began operations at Oron in the 1950s, and at Rotem and Zin in the 1970s. These sites are accessible by road and rail. We have long-term leases to all the land on which our Israeli facilities are located but we

136


Table of Contents

operate under mining concessions and licenses granted to us by the Israeli Minister of National Infrastructures and by the ILA. See "—Concessions and Mining Rights" below.

        We also are seeking authorization to mine phosphates at the Barir, or South Zohar, field. The plan for mining phosphates in Barir is in planning approval stages, and it has not yet been decided whether to file the plan with the proper authorities. Residents of the surrounding towns and villages in the area have objected to the filing of the plan and continuation of advancement of the planning stages in respect thereof, due to the fear of environmental and health dangers they contend will be caused as a result of operation of the mine. We believe that the mining activities in Barir field do not involve any dangers to the environment or to people and, accordingly, we proposed to appoint an independent expert that will examine the opposing opinions existing with respect to the matter. After an expert appointed by the Ministry of the Prime Minister expressed his opinion that there is no health hazard in the Barir mine, the Ministry of Health appointed an expert on its behalf to examine the matter before the Ministry formulates an opinion. On April 3, 2014, we learned that the Israeli Ministry of Health had received the opinion of its expert and, after reading the opinion, the Israeli Ministry of Health decided to oppose mining, including exploratory mining, in the Barir field. We disagree with the Israeli Ministry of Health's interpretation of this opinion. Based on our understanding of this opinion, we believe this opinion does not contradict our position that the mining activities in Barir field do not involve any risks to the environment or to people. The residents of nearby towns are continuing to object to advancement of the mining plan and even to mining tests. Non-receipt of approval to mine in the Barir field will significantly harm our future mining reserves in the medium and long term.

        In addition, the future of our Rotem operation potentially rests on our ability to mine resources of brown and bituminous phosphate, as these are the only resources that are likely to be converted to reserves in the future. Currently, the reserve of bituminous phosphate (approximately 2.4 million metric tons at Zin) is being mined and used in a blending process with other lower organic material to produce fertilizer products. However, due to the higher organic content of bituminous phosphate, with respect to the production of phosphoric acid, bituminous phosphate on its own would currently require the use of pyrolysis (decomposing organic material by heat) for processing, which is a costly and high energy operation, or another process. However, our Rotem subsidiary is developing and has pilot-plant-tested a process using only beneficiation (the separation of phosphorus from the surrounding organic material). The results indicate improvements in the phosphorus grade from 25-26% to 31-32%, and reduction in the organic content by half. Further pilot plant testing of the bituminous phosphate has been carried out and has produced an acid that has a light green color ("green acid").

137


Table of Contents

        The following map indicates the location of our mining operations in the Negev Desert:

GRAPHIC

        The method of mining is by conventional open pit or quarrying methods, using drilling and blasting where necessary, hydraulic excavators and rigid dump trucks or dozers with rippers for overburden removal and front end loaders and trucks for phosphate removal. Each mine site has varying numbers and thicknesses of overburden, inter-burden and phosphate rock layers, so the mining techniques at each site vary. At Rotem, the mining of phosphate and stripping of waste is entirely conventional and consists of 190-metric ton trucks and 18 cubic meter bucket shovel operations. Oron and Zin sites use contractors exclusively for all operations, and equipment at these sites is smaller. Typically, the excavator bucket capacities are in the range of 3 to 7 cubic meters and the trucks have capacity of 45 to 65 metric tons.

        Phosphate rock from the Rotem mine is transported by truck to a nearby beneficiation plant at Mishor Rotem. At that plant, we also operate two sulfuric acid plants, three phosphoric acid plants, one phosphoric acid refining plant, three superphosphate plants, two granular fertilizer plants, one MKP (mono-potassium phosphate) plant and one oil shale burning plant. We also have beneficiation plants at both Oron and Zin. As part of the beneficiation process, the mined material is crushed and coarse flint and limestone components are removed. Most of this material is then washed to reduce the chlorine content and clay is removed to produce a multi-purpose phosphate product. This beneficiation stage is sufficient to produce a high-grade material, most of which is used to produce phosphoric acid and fertilizers. In

138


Table of Contents

addition, some of this material is sold to other phosphoric acid and fertilizer producers and some is sold for direct application as fertilizer.

        The plant at Mishor Rotem is powered by electricity that we generate at our sulfuric acid plants and by oil shale that we mine at Rotem for fuel. Any surplus power is sold to Israel Electric. All of the power utilized by the Oron and Zin beneficiation plants is purchased from Israel Electric.

        The following stratigraphic columns show the sequence of the geological formation at our Israeli operations:

GRAPHIC

139


Table of Contents

GRAPHIC

140


Table of Contents

GRAPHIC

141


Table of Contents

        The following table sets forth for the periods indicated the amount of our total mine production of raw ore (and associated grade) supplied to our beneficiation plants from our mines in the Negev Desert:

 
  Year ended December 31,  
 
  2013   2012   2011  

Millions of metric tons produced

    6.3     6.2     7.5  

Grade (% P 2 O 5 before/after beneficiation)

    26/31.5     26/31.5     26/31.5  

        The following table sets forth, for the periods indicated, the approximate amount of product produced after processing by our operations in the Negev Desert:

 
  Year ended December 31,  
 
  2013   2012   2011  
 
  (thousands of
metric tons)

 

Phosphate Rock

    3,700     3,600     3,600  

Green Phosphoric Acid

    535     467     482  

Fertilizers

    897     733     745  

White Phosphoric Acid

    139     117     129  

MKP

    47     39     41  

    Spain

        We conduct our potash mining operations in Spain through our indirect wholly-owned subsidiary, Iberpotash, and its wholly-owned subsidiary, Trafico de Mercancias. There are three underground mines that make up Iberpotash's complex: Suria, Cabanasas and Vilafruns. We currently operate two mines, the Cabanasas mine, which is located in the town of Suria, approximately 12 kilometers north of the district capital of Manresa in the Cardoner river valley, and the Vilafruns mine, which is located in the town of Sallent, approximately 13 kilometers east of Suria in the Llobregat river valley. The Suria mine is closed and it is planned that the Vilafruns mine will close by the end of 2015. We may be forced to cease production at Vilafruns earlier than that if our appeal of the Spanish court's suspension of our environmental license for that site is denied. See "—Legal Proceedings—Spain Mining License Matters." Production at the Cabanasas mine is expected to increase up to approximately 800,000 tons per annum when production at the Vilafruns mine ceases and is expected to reach 1,000,000 tons per annum (double current levels) two years after production at Vilafruns ceases. We own all of the land on which our Spanish surface facilities are located. The Spanish government owns all of the underground mining rights and has granted to us concessions to conduct mining operations under our land. See "—Concessions and Mining Rights—Spain" below.

        The Cabanasas and Vilafruns mines are both in the province of Barcelona and are located approximately 530 to 900 meters below ground. Each mine has two access points and mining is by a modified room and pillar method. All of the mine sites are served by roads and are near major highways.

        Extraction of potash from underground mines in Spain is carried out by mining sylvinite (a mixture of potash and salt found in varying potash concentrations). The potash is separated from the salt in production plants near the mines. For a description of our efficiency plan at Iberpotash, see "—Segment Information—Fertilizers—Production."

142


Table of Contents

        The following map indicates the location of our Spanish mining operations:

GRAPHIC

        Potash was first discovered in 1912 at Suria and commercial development was started in 1920. We purchased our three Spanish mines in 1998. Potash of late Eocene age occurs in the northeast corner of the Ebro Evaporite Basin which lies along the southern flank of the Pyrenees. Sylvinite and carnallite occur towards the top of the Cardona Halite at depths which vary considerably as a result of deformations associated with the Pyrenean fold and thrust belt. The potash seams (when seen underground) can, in places, be contorted on a local scale due to this deformation of the area. Two main potash seams are mined in the deposit, Capa A and Capa B at both the Vilafruns and Cabanasas mines. Within these seams, sylvinite occurs as thin beds interleaved with halite and with occasional thin clay partings in each of the

143


Table of Contents

seams. The sylvinite is high grade and with very low levels of insolubles. The following stratigraphic column shows the sequence of the geological formation at our Spanish operations:

GRAPHIC

        We own and operate two processing plants, one in Suria and one in Vilafruns. The operations at these plants include crushing, grinding, desliming, froth flotation and drying. The output of our Spanish mines is transported by truck and railroad to the Port of Barcelona, which is located approximately 80 kilometers from the mines. We operate extensive port facilities, including warehouses and loading docks, in Barcelona. All of the power utilized by our Spanish mining operations is purchased from third-party electric companies.

144


Table of Contents

        The following table sets forth, for the period indicated, the amount of potash ore processed at our Spanish mining operations and the grade of this potash ore at our Spanish processing plant

 
  Year ended
December 31,
 
 
  2013   2012   2011  

Vilafruns

                   

Ore processed (in millions of metric tons)

    2.3     2.3     1.9  

Grade (% KCl)

    23.44 %   22.30 %   22.41 %

Cabanasas

                   

Ore processed (in millions of metric tons)

    1.9     1.9     1.7  

Grade (% KCl)

    27.07 %   27.35 %   26.42 %

Total

                   

Ore processed (in millions of metric tons)

    4.2     4.2     3.6  

    United Kingdom

        Our mining operations in the United Kingdom are conducted by our indirect, wholly owned subsidiary, Cleveland Potash. Our mine and processing plant is located approximately 340 kilometers north of London and approximately 40 kilometers east of Middlesbrough, England in the North York Moors National Park. The mine was originally designed, developed and operated by Imperial Chemical Industries and Charter Consolidated and the first potash was extracted in 1973. We purchased the mine, including mining leases and mineral extraction licenses, in 2002 from the then-owner, Anglo American Corporation.

        Our mining operations in the United Kingdom are conducted both under land and under the North Sea. Mining operations are conducted at depths of as much as 1,300 meters below ground onshore and 850 meters below the surface of the North Sea. The operations under the North Sea are currently conducted as far as eleven kilometers offshore. Although we own the land on which our minehead and related surface operations are conducted, substantially all of our United Kingdom subsurface operations are conducted either under land that we do not own or under the North Sea. We have the right to conduct our mining operations pursuant to the mining leases and mineral extraction licenses described below. See "—Concessions and Mining Rights" below. Extraction of potash from underground mines in the United Kingdom is carried out by mining sylvinite (a mixture of potash and salt found in varying potash concentrations). The potash is separated from the salt in production plants near the mines.

145


Table of Contents

        The following map indicates the location of our United Kingdom mining operations:

GRAPHIC

        Our United Kingdom mining operations are situated close to the western limits of potash and salt deposition in the Zechstein Basin extending inland in the United Kingdom and below the North Sea to Germany. The potash seam is of the Permian Evaporite Series and is overlain by some 800 meters to 1,300 meters of younger sedimentary rocks. The potash seam averages 7 meters in thickness but varies from zero to more than 20 meters in thickness. As part of the same Permian evaporite sequence, an approximately 11 meters thick polysulphate layer exists approximately 150 meters below the potash deposits. Cleveland Potash has evaluated the potential of this polysulphate as a separate resource, and completed an access

146


Table of Contents

decline into the polysulphate bed in 2010 from one of their main salt roadways. The following stratigraphic column shows the sequence of the geological formation at our United Kingdom mining operations:

GRAPHIC

        Our United Kingdom mine has been extensively explored using a combination of surface (sparse) and underground drilling. The underground long hole (horizontal) drilling and 3-D seismic (offshore) surveys are used to delinate areas of minerals well in advance of mining. The mine is accessed by two vertical shafts. One shaft hoists potash and salt and the other provides service access. Mining currently takes place in two discrete areas. Mining is by continuous miners with shuttle cars and by a modified room and pillar method. The mine has been designated as a "gassy" mine, containing methane gas. Our mining operations in the United Kingdom are powered primarily by electricity supplemented from our onsite power plant. We purchase the balance of our power requirements for these mining operations from the national grid and the electricity regional supply company.

147


Table of Contents

        Our processing operations include crushing, grinding, froth flotation and drying. The plant was built in 1971 and has been upgraded periodically. Products are transported on a rail line that we own that extends approximately eight kilometers from our minehead to a junction with the national rail network. We lease and operate two principal storage and loading facilities, one at the Teesdock facility, which is located on the River Tees, and one at the Ayrton Works road depot in Middlesbrough.

        The following table sets forth, for the indicated periods, the amount of potash ore mined at our United Kingdom mining operations and the grade of this potash in terms of potassium chloride ("KCl") and insoluble clay minerals ("insols"):

 
  Year ended
December 31,
 
 
  2013   2012   2011  

Potash Ore (millions of metric tons)

    2.30     1.83     1.75  

Grade (% KCl)

    31.3 %   30.4 %   32.3 %

Grade (% insols)

    13.4 %   13.8 %   14.6 %

    Concessions and Mining Rights

    Israel

        Dead Sea Works Ltd. Concession.     Pursuant to the Concession Law and the concession indenture attached as an addendum to the Concession Law, Dead Sea Works was granted a concession to utilize the resources of the Dead Sea and to lease the land required for its plants in Sodom for a period ending on March 31, 2030, accompanied by a priority right to receive the concession after its expiration. In exchange for the concession, Dead Sea Works pays royalties to the Israeli government, calculated at the rate of about 5% of the value of the products at the factory gate, less certain expenses, and our Fertilizers segment also pays lease fees.

        As for the royalties payment by Dead Sea Works, the State of Israel was permitted to demand reconsideration with respect to the rate of the royalties relating to the quantity in excess of three million tons of potash manufactured in any year from 2010 and thereafter, provided the rate of the royalties with respect to such excess does not exceed 10% of the value of the product at the factory gate, less certain expenses.

        In December 2010, a letter was received from the Israeli Accountant General containing a demand for a hearing regarding increasing the amount of the royalties, as part of an arbitration proceeding between the parties.

        As part of the agreement with the State of Israel signed in July 2012, regarding performance of a harvest of the salt, it was also agreed with the Government regarding an increase in rate of the royalties to 10% (in place of 5%) in respect of sales of potash in a quantity in excess of 1.5 million tons per year.

        Dead Sea Works grants a sub-concession to Dead Sea Bromine Company Ltd. ("Dead Sea Bromine Company") to produce bromine and its compounds from the Dead Sea, the expiration date of which is concurrent with Dead Sea Works' concession. We pay royalties to the Israeli government on products manufactured by the Dead Sea Bromine Company. In addition, there is an arrangement relating to payment of royalties by Dead Sea Magnesium for production of magnesium metals by virtue of a specific arrangement with the State of Israel provided in the Israeli government's decision dated September 5, 1993. Pursuant to the arrangement, royalties are paid by Dead Sea Magnesium on the basis of carnallite used for production of magnesium.

        The arrangement with Dead Sea Magnesium provides that during 2006 the State of Israel may demand a reconsideration in connection with the amount of the royalties and the method or their calculation for 2007 and thereafter. The State of Israel's demand for reconsideration, as stated, was first received at the end of 2010.

        In 2006, a letter was received from the Accountant General of the Israeli Ministry of Finance claiming an underpayment of royalties amounting to hundreds of millions of NIS.

148


Table of Contents

        Pursuant to the concession, disputes between the parties relating to the concession, including royalties, are to be decided by an arbitration panel of three arbitrators (each side appoints an arbitrator and these two appoint the third). On January 9, 2011, the State of Israel and Dead Sea Works turned to arbitration for purposes of deliberating and deciding the issue of the manner of calculation of the royalties by the concessionaire and royalties to be paid for magnesium metals and payment or refunds (if any) due deriving from these matters. Each of the parties appointed an arbitrator on its behalf and these arbitrators appointed the third arbitrator. As part of the arbitration proceedings, the State of Israel is claiming the amount of $265 million in respect of underpayment of royalties for the years 2000 through 2009, with the addition of interest and linkage differences, and a change in the method of calculating royalty payments from the sale of metal magnesium.

        After studying the State of Israel's allegations in respect of prior years, we concluded, on the basis of a legal opinion we received, that the royalties we paid and their manner of calculation were consistent with the provisions of the concession. The same method of calculation was applied consistently since the time we were a government company, and was known to the State of Israel and accepted by it. Accordingly, and on the basis of the legal opinion we received, no provision was recorded in our financial statements with respect to royalties that the State of Israel contends were underpaid as of December 31, 2013 or June 30, 2014.

        On May 19, 2014, we received the partial arbitration award. The main points of the arbitrators' award are as follows:

    Dead Sea Works has to pay royalties to the State of Israel on the sale of downstream products manufactured by subsidiaries that are controlled by us that have production plants both in and outside the Dead Sea area, including outside Israel.

    The royalties shall be paid according to the value of the downstream products, which will be set according to the formula prescribed in Section 15(a)(2) of the Concession Deed (the sale price of the downstream product to unrelated third parties minus the deductions set forth in sub-sections (I), (II) and (III) of that section).

    With respect to metal magnesium, it was decided that the State of Israel and Dead Sea Works should exhaust their discussions on the subject of the royalties to be paid by Dead Sea Works on this material and, if no agreement is reached, the subject will be returned to arbitration.

        The arbitrators' award was given with respect to fundamental determinations with respect to the liability to pay royalties on downstream products and does not include any reference to the financial calculations arising out of the award. The financial calculation will be resolved during the next phase of the arbitration.

        In the second quarter of 2014, in accordance with our estimate, based on the advice of our legal advisors, we recorded a provision in the amount of approximately $135 million due to the implementation of the partial arbitration award for the years 2000 through 2013. This provision amount includes, inter alia, interest and deduction of tax implications. In addition, as a result of the arbitrators' decision, the current expense in the first half of 2014 in respect of royalties increased by approximately $6 million. The arbitrators' award is partial and the financial calculations as to the method of implementation of the award have yet to be determined by the arbitrators. Therefore, our estimation is based on various assumptions regarding the manner of calculating the royalties pursuant to the partial arbitration award and reflects our best estimate of the expenditure that will be required to settle the liability as of June 30, 2014. The final amount that will be determined by the arbitrators at the end of the second stage of the arbitration after the arbitration panel determines the financial calculations as noted above may differ, including materially, from this provision amount. In the second stage of the arbitration, which will deal with determination of the amounts of the royalties, we intend to claim that the correct amount of the royalties is significantly lower than the amount stated.

        In 2013, our subsidiary, Dead Sea Works, paid royalties to the State of Israel on sales of bromine in the amount of approximately $10.3 million. According to the assumptions on the basis of which the provision was made, as mentioned above, Dead Sea Works would have been required to pay additional

149


Table of Contents

royalties in 2013 in the amount of approximately $11.4 million (before tax) on downstream products. The amount of royalties to be paid in the future for the aforementioned downstream products will be derived from, among other things, the quantities sold, market prices and the mix of products and therefore may differ from the amounts which would have been paid for the year 2013, as mentioned above. Together with our financial and legal advisors, we are reviewing the arbitration panel's award and its implications.

        The higher royalty rate will reduce our margin on downstream products, and certain of our products may no longer be attractive. As discussed under "Prospectus Summary—Recent Developments," we are undergoing a review of our plans in Israel and continue to evaluate the impact of the arbitration proceedings.

        In 2011, 2012 and 2013, Dead Sea Works paid royalties to the Israeli government in the amount of approximately $76 million, $125 million and $110 million, respectively.

        Rotem Concession.     Rotem has been mining phosphates in the Negev in Israel for the last fifty years. The mining is conducted in accordance with phosphate mining concessions, which are granted from time to time by the Supervisor, accompanied by mining authorizations issued by the ILA. The Oron concession was first granted in 1952. The Zin concession was first granted in the 1970s as part of the Oron concession and the joint concession was subsequently renamed Zafir. The Zafir concession (consisting of both the Oron and Zin concessions) was renewed every 3 years and in 1995, it was renewed for 10 years and in 2002, it was renewed until 2021. The Rotem concession was first granted in 1970 and it was also renewed in 1995 for 10 years and in 2002, it was renewed until 2021. The Zin concession was first granted in 1970 and it has been renewed as necessary. There is no tender process under the Mines Ordinance procedure. Given the high cost of constructing downstream processing facilities (which any other bidder would need to construct near the fields), we have not faced competition for these concessions in the past. The concessions relate to the quarry (phosphate rock) whereas the authorizations relate to use of land as active mine sites.

        Under the terms of these concessions, Rotem is required to pay the State of Israel royalties based on a formula stipulated in the Israeli Mines Ordinance. The formula for the royalties was updated in February 2010 as part of a compromise agreement that settled all the disputes regarding past royalties and formulas for future royalties. However, in June 2013, the Minister of Finance, Mr. Yair Lapid, gave notice regarding an establishment of a public committee, headed by Professor Eytan Sheshinski, for examination of the policy with respect to the royalties received by the State of Israel from private entities, including us, for use of national natural resources such as potash and phosphate. The committee is required, among other things, to examine the royalties policy from a broad perspective, while making reference to the impacts on the present agreements between the various parties engaged in these matters and the State of Israel. A similar committee established in 2011 for the oil and gas industries concluded that the tax and royalty rates should be increased significantly. If the committee determines that the taxes and royalties we pay should be increased and the Israeli government agrees, it could have a material adverse effect on us. On November 4, 2013, we submitted our position in writing to the committee. Our request, dated December 3, 2013, to exclude this matter from the committee's jurisdiction was denied by the Minister of Treasury. On May 18, 2014, the committee released its draft recommendations for public comment. The principal draft recommendations are as follows:

    The government take on natural resources should include royalties, a tax on natural resources and regular corporate tax;

    The unified royalty rate for natural resources in Israel should be 5% from the sales ex plant (compared to the current phosphate royalty rate of 2% ex mine and the potash royalty rate of 5% on the first 1.5 million tons sold and 10% on any additional quantities sold; the bromine royalty rate would remain unchanged at the current 5%); the basis for the calculation of the royalties (which is not identical for each product) will be determined by the State of Israel;

    The new "natural resources tax" would apply to the operating profit of each company that exploits natural resources in Israel (according to the adjusted accounting profit and loss statement) at the

150


Table of Contents

      suggested rate of 42%, which would be fixed after the deduction of an 11% return on the book value (after depreciation) of the company's fixed assets; and

    The changes with respect to Dead Sea Works would require legislation, which would come into effect no earlier than January 1, 2017, although the taxes applicable to phosphate and bromine operations could be implemented sooner.

        On August 4, 2014, we orally presented our position to the Sheshinski Committee. The key arguments we presented are as follows:

    The Sheshinski Committee erred in its calculation of our asset base for purposes of determining the rate of return from which the "surplus profits" are derived, and in its establishment of a common rate of return on the basis of this asset base. As a result of these two pivotal errors, the proposed new natural resources tax would not be imposed solely on "surplus profits";

    The proposed taxation model was established on the basis of our data relating only to activities with respect to potash production from the Dead Sea. However, ICL is not only "Potash", and the Sheshinski Committee has to separately examine each of the other natural resources we produce (bromine, magnesium and phosphates), and make a fundamental examination of the individual characteristics of each activity sector;

    The Committee's Interim Recommendations are not consistent with the principles and targets that were established by the Sheshinski Committee to guide it in its work. For example: (1) the marginal tax rate on the "surplus profits" will be in fact higher than the rate the Sheshinski Committee intended to impose and the Government's take will be in fact higher than the Sheshinski Committee intended; (2) the tax burden will increase when mineral prices decline, and accordingly the proposed fiscal arrangement is regressive, even though the Sheshinski Committee planned that it will be progressive; (3) the average tax burden on us will be significantly higher than that which is customary elsewhere in the world; and (4) the Committee's Interim Recommendations are not neutral in their impact on our potential investment decisions compared to the current regime, and would force us to reexamine all our investments in Israel and, unfortunately, to reallocate planned investments from Israel to other countries;

    Alongside the apparent benefits that derive from the Committee's Interim Recommendations, the Committee's Interim Recommendations will have a number of deleterious impacts, including: damage to the Israeli GDP and exports; significant damage to the economy in the Negev; significant negative impact on employment of Negev residents; a decrease in collection of other taxes and an increase in the Government's expenses;

    The Sheshinski Committee did not take into account the fact that the Government has already taken a number of steps that have increased its take of our revenues, which is already at a rate customary elsewhere in the world, including the amendment of the Law for the Encouragement of Capital Investments; imposition on us of most of the costs relating to steps to protect Dead Sea hotels; and an increase in the rate of the royalties paid in respect of sale of potash, as well as the extension of royalties to include downstream products pursuant to the recently concluded arbitration;

    Adoption of the Committee's Interim Recommendations would constitute a violation of agreements signed by the Government, including the Concession Agreement, which determines the consideration that we are to pay the Government up to 2030 and the Salt Harvesting Agreement; accordingly, a law enacting the Committee's Interim Recommendations would be unconstitutional.

        On August 6, 2014, our Board of Directors discussed the impact of the Committee's Interim Recommendations and the Royalties Arbitration, as well as the need to implement cost-cutting and efficiency plans, and resolved to take certain actions described in "Prospectus Summary—Recent Developments."

        For information regarding Dead Sea Works's commencement of an arbitration proceeding in connection with what we view as the Israeli government's breach of our concession agreement with respect

151


Table of Contents

to the Dead Sea due to its convening of this committee, see note 23 to our audited financial statements and "—Legal Proceedings—Dead Sea Works Proceedings."

        In 2011, 2012 and 2013, Rotem paid approximately $4 million, $6 million and $4 million, respectively, in royalties to the Israeli government. In terms of particular conditions that our Rotem subsidiary must meet in order to retain the concessions, we must comply with various reporting requirements in addition to the payment of royalties.

        Rotem has the following three mining concessions, which cover a total area of approximately 55,327 acres:

        1.     Rotem Field—valid up to the end of 2021;

        2.     Zafir Field—(Oron-Zin)—valid up to the end of 2021;

        3.     Hatrurim Field—The Supervisor has decided to extend the area of the Rotem field concession (valid until the end of the 2021) so that it covers the Hatrurim Field. The area of the Rotem concession has been so extended, and the matter has been transferred to the ILA to deal with the extension of the area of the mining permit for the Rotem Field, in line with the extension of the concession area.

        Rotem has applied well in advance for land leases of the mining areas and has had little difficulty in renewing those leases in the recent past. The earliest renewal required for any of the existing relevant leases will be in 2021. In terms of the process for renewal, we only need to submit a simple application for renewal with standard geological information. Recently, there has also been a need for planning permission and ILA authorization but it is not required by law.

        In September 2012, a committee was set up by the Chief Executive Officer of the Israeli Ministry of Energy and Water, including representatives of the Israeli Ministry of Energy and Water, the Israeli Geological Institute and the Israeli Ministry of Economy, Trade and Industry, in order to look into use of the phosphate resource in Israel, and to submit recommendations regarding the annual quantity of mining of phosphates, the manner of use of the phosphates layers and the stages for restoring the mine areas. The committee has not yet completed its work.

        The mining and quarrying activities require zoning approval of the site based on a plan in accordance with the Israeli Planning and Building Law, 1965. These plans are updated, as needed, from time to time. As of the date of this prospectus, there are various requests at different stages of deliberations before the planning authorities.

        At the end of 2009, at the recommendation of a team accompanying preparation of a new site plan for the Oron-Zin area, the Local District Board approved an extension of the execution stages of the site plan from 1991, which zones the Zàfir site (Oron-Zin) for mining up to the end of 2013, and in September 2013, the Local District Board approved the extension of additional stages through the end of 2015. The process of getting these extensions approved consists of an ongoing process with mining execution stages in permitted mining zones.

        Our plan for mining phosphates in Barir field (South Zohar) in the Negev is in planning approval stages, and it has not yet been decided whether to file the plan with the proper authorities. On April 3, 2014, we learned that the Israeli Ministry of Health had received the opinion of its expert (who was appointed to examine the environmental and health consequences resulting from operation of the mine) and, after reading the opinion, the expert decided to oppose mining, including exploratory mining, in the Barir field. We disagree with the Israeli Ministry of Health's interpretation of this opinion. In our estimation, and based on our understanding of this opinion, this opinion does not contradict our position that the mining activities in Barir field do not involve any risks to the environment or to people. See "—The Negev Desert" above.

    Spain

        The Spanish government owns all of the underground mining rights and has granted to us concessions to conduct mining operations under our land pursuant to mining legislation enacted in 1973 and related regulations. Further to this legislation, the government of the Catalonia region issued special mining

152


Table of Contents

regulations relating to individual mining areas. The mining permits (or concessions) in Spain are administrated by the regional governments (in Catalonia, the Generalitat), except those special reserved areas that are still being administrated by the Spanish central government. There are several such areas in Spain, including Reserva Catalana. Iberpotash owns the rights to mine the 126 concessions that are not part of the Reserva Catalana given by the Generalitat and the rights to mine the Reserva Catalana concessions given by the Spanish central government. Two separate and independent processes of paying fees and renewals are thus involved.

        Originally, the concessions were divided among several mining companies in the area. However, as companies were acquired or relinquished their concessions, Iberpotash obtained these concessions. As a result, Iberpotash now holds mining concessions for each of 126 different relevant sites for our current and potential future mining activities. As part of the renewal process, we must prepare and present a basic technical report describing the intended use of the mines. The concessions cover a total area of 42,489 hectares in the province of Barcelona and 26,809 hectares in the province of Lerida. The mining royalties in 2013 amounted to approximately €0.2 million.

        Regarding the Reserva Catalana, an additional area beyond the 126 sites referred to above, a request was submitted to extend the concession period for a period of 30 years, commencing in October 2012. At the present time, no mining activities are being carried out in this area. The administrative activities to extend the concession period have not yet been completed by the National Mining Authority. However, the mining rights are still valid, and Iberpotash is currently in the process of renewing these rights before their expiration.

        Iberpotash has applied well in advance for concessions for the mining areas and has not had any difficulty in renewing those leases in the recent past. The earliest renewal required for any of the 126 existing relevant concessions will be in 2037, and most of the concessions are effective up to 2067. The currently planned life of the Cabanasas mine is 28 years, so renewal of some concessions may be required in order to permit mining for the entire life of the mine. As is required by law, the concessions must be renewed prior to the expiration date. If a concession were to expire for some reason, a bidding process would start.

    United Kingdom

        United Kingdom Mining Concession.     Cleveland Potash's mining concession in the United Kingdom is based on approximately 114 mining leases and licenses for extracting various minerals, in addition to numerous easements and rights of way from private owners of land under which Cleveland Potash operates or, in the case of mining underneath the North Sea, granted by the United Kingdom (Crown Estates). These mining rights total approximately 92,340 acres. The terms of all of these leases, licenses, easements and rights of way extend until 2015 to 2038. In 2013, mining royalties amounted to about £2.7 million.

        All of our older leases were taken for a period of 50 years in the 1970s, so most of these run until the early to mid-2020s, except for the lease with the Crown Commissioners (Crown Estates) for the offshore rights, which was recently renewed and expires in 2034. The lease with the Crown Commissioners includes provisions to explore and exploit the polysulphate. Our recently acquired leases were obtained in the late 1990s and early 2000s, and they all have a 35 year lease period with a 35 year option to extend the lease. To acquire the leases, Cleveland Potash used local solicitors and contacted the individual landowners. The onshore lease currently covering 18% of the proved and provable reserves area at our mine in the United Kingdom is due for renewal in 2015. Negotiations have begun to extend this lease both geographically and temporally, as this area is important for our underground mining activities at the Boulby mine. Historically, the renewal of leases has not been problematic and we believe that we have or will receive all government approvals and permits necessary for our reserves in the United Kingdom. There is no competition for mineral leases because Cleveland Potash has already secured the planning permission ("Planning Permission") for potash and rock-salt extraction in the area and has all the necessary government approvals and permits for mineral extraction. A planning permission, which is granted by local authorities in the United Kingdom, is the permission required in order to be allowed to build on land or change the use of land or buildings. When leases expire, there has been no interest from other companies and there is

153


Table of Contents

no competitive bidding. Cleveland Potash has a preferential right to renew the leases as it has the Planning Permission to extract potash-bearing minerals. The entities involved in renewing or obtaining new leases are Cleveland Potash, local solicitors and individual landowners who own the mineral rights, as described above. The particular conditions that must be met in order to retain the leases are the annual guaranteed payment of rent and a royalty payment for minerals extracted from the property to the landowner.

        Several small areas remain with no mining lease as these are areas where either the mineral owners have refused to grant a lease or mineral ownership is in many small patches under various domestic properties. However, none of these has a significant impact on exploration or development and there are no plans to pursue them further.

        Cleveland Potash practices a rolling lease acquisition program and currently holds mineral leases for approximately 70% of the area over which it has been granted Planning Permission for mineral extraction. Historically, Cleveland Potash has been very successful in obtaining leases. We are confident that we will be able to obtain the remainder of the resource and reserve leases, as historically there has been no competition in the area for potash mineral leases and our few failures to option leases in the past have been limited to very small leases that can easily be circumvented during mining. The small area of leases that Cleveland Potash does not have are situations where the individual landowners have refused to grant a mineral leases and no other party has been granted a lease.

        United Kingdom Concession.     A subsidiary in the United Kingdom, in our Fertilizers segment, mines peat, which constitutes a raw material for production of detached platforms for improvement of land and for use as soil substitutes on growing platforms, in our mines in the United Kingdom (Creca, Nutberry and Douglas Water). The Nutberry and Douglas Water sites are owned by the subsidiary, whereas Creca is held under a long-term lease. The mining permits were granted through the year 2024. The mining permits are granted by the local authorities for time periods fixed in advance of 14 years and are renewed after being examined.

    Reserves

        We believe we have a broad and high-quality mineral reserves base due to our strategically located mines and facilities. "Reserves" are defined by SEC Industry Guide 7 as that part of a mineral deposit which could be economically and legally extracted or produced at the time of the reserve determination. Industry Guide 7 divides reserves between "proven (measured) reserves" and "probable (indicated) reserves" which are defined as follows:

    Proven (measured) reserves.    Reserves for which (1) quantity is computed from dimensions revealed in outcrops, trenches, workings or drill holes; grade and/or quality are computed from the results of detailed sampling and (2) the sites for inspection, sampling and measurement are spaced so closely and the geologic character is so well defined that size, shape, depth and mineral content of reserves are well-established.

    Probable (indicated) reserves.    Reserves for which quantity and grade and/or quality are computed from information similar to that used for proven (measured) reserves, but the sites for inspection, sampling, and measurement are farther apart or are otherwise less adequately spaced. The degree of assurance, although lower than that for proven (measured) reserves, is high enough to assume continuity between points of observation.

        We categorize our reserves in accordance with these SEC definitions. The quantity and nature of the mineral reserves at each of our properties are estimated by our internal geologists and mining engineers. Our internal geologists and engineers prepare our reserve estimates, and these estimates have been reviewed by DMT Consulting Limited (formerly known as IMC Group Consulting Ltd.), an independent third party, to assure their reasonableness.

154


Table of Contents

    Israel

        The following table sets forth information regarding our estimates of our phosphate reserves in Israel (all of which are wholly-owned by us) as of December 31, 2013:

 
  Category   White
Phosphate
(millions of
metric tons)
  Low
Organic
Phosphate
(millions of
metric tons)
  High
Organic
Phosphate
(millions of
metric tons)
  Bituminous
Phosphate
(millions of
metric tons)
  Recoverable
Reserves
(millions of
metric tons)
  Average
Grade
(% P 2 O 5 )
 

Rotem

  Proven         14.8             14.8     26.3 %

Zin

  Proven         13.6 *   8.8     2.4     24.8     25 %

Oron

  Proven     24.0                 24.0     23.5 %

Total (Proven)

                                63.6        
                                         
                                         

*
Based on current and projected production rates over an 8 year Life of Mine Plan. Reserves are available totaling 19.9 million metric tons, if sales and production rates were to increase during that 8-year period.

        In determining these reserves, a cut-off grade of 20 to 25% P 2 O 5 was applied, depending on the processing characteristics of the phosphate rock and the proposed process route. The cut-off grade differs for each mine in accordance with the beneficiation process: a cut-off grade of 20% P 2 O 5 was applied at Oron; a cut-off grade of 23% P 2 O 5 was applied at Zin; and a cut-off grade of 25% P 2 O 5 was applied at Rotem. The cut-off grade for Oron is lower because our Rotem subsidiary has the appropriate beneficiation process for a well-crystalized carbonate matrix in the white phosphate and therefore an effective flotation process. The cut-off grade for the Rotem mine is higher because the beneficiation process there has a limited grinding and flotation system, and only medium to high grade phosphate can be fed. The cut-off grade for Zin is slightly higher than that of Oron because of the presence of marl and clay that harms the efficiency of the flotation system at that mine. The parameters used in determining the cut-off grade took into account the geology (continuity, structure), mining method, mining recovery, dilution, metallurgical/processing factors, technical feasibility, operating costs and historical and current product prices. The parameters employed in the calculation are as follows: on-site tons (obtained in terms of the density of the mineral); recovery factor (takes into account the values obtained historically during the mining of the phosphate); recoverable tons (tons of mineral which can be mined, in terms of the recovery factor); mineable tons (recoverable tons from which the tons produced are discounted); stripping ratio (the quantity of waste removed per ton of phosphate rock mined); planned dilution; cost per ton for mining (typically related to transport distance to beneficiation/process plant); cost per ton including reclamation; and unplanned dilution (a value of 5% unplanned dilution is considered taking into account the data from the mining in and the data from the base area of the anticline). Our Rotem subsidiary's yearly mining plan is not determined by the cut-off grade and the fluctuation of commodity prices rarely affects its cut-off grade because our Rotem subsidiary will handle volatility in commodities prices by lowering its operating costs in one of several ways (for example, by negotiating with contractors or using a cheaper mining method).

        The cut-off grade calculations come from historical yield data and our Rotem subsidiary's historical experience with mining, adequately calculated and modelled by its geologists, operation engineers and economists. The calculation takes the ore grade in-situ, converts it into extracted ore with our Rotem subsidiary's mining method and estimates the plant yield depending on the grade. Economic modelling further gives the cut-off figures currently used by our Rotem subsidiary.

        The proven reserves above the cut-off grade were obtained from the calculated on-site resources taking into account the mining method, mining recovery, dilution, and in-plant recovery, based on our Rotem subsidiary's historical data. Mining recovery and dilution factors, which are required in the conversion of resources to reserves and take into account the particular mining method and the geological conditions at the respective mine, consist of historical yield data and are based on the previous five years' experience. For our deposits, the mining recovery ranges from 81% to 92%: 81% at Zin, 87% at Oron and 92% at Rotem. Our Rotem subsidiary uses a mining dilution of approximately 2.5% depending on the

155


Table of Contents

width, smoothness and inclination of the layers. Reserve tonnages and grades are quoted as those that are expected to be delivered to the treatment plant and are subject to metallurgical recovery factors. The current metallurgical recovery varies for each mine as it consists of historical yield data, and it is currently between 46% (at Oron and Rotem) and 48% (at Zin). These differences in metallurgical recovery rates are due to differences in the beneficiation process at the different mines. Proven reserves have been explored by borehole intersections typically at 50 to 70 meters spacing. Each of the three plants at the mines has been developed over the past few decades for the optimum upgrading of the phosphate rock to concentrate ore containing typically 31 to 32% P 2 O 5 . Tonnage conversion factors are 1.8 for most phosphate horizons, with 2.0 being used in hard, calcareous beds. These factors are used on the basis of long experience and are considered to be reasonable.

        In calculating the cut-off grade and reserves, an average of the previous three years' market prices and operating costs was used as part of the calculations to ensure economic viability. The following table sets forth information regarding the average market price per ton of product for the years 2011 to 2013:

 
  For the year ended December 31,  
 
  2013   2012   2011  
 
  Average
Market Price ($/ton)

  Average
Market Price ($/ton)

  Average
Market Price ($/ton)

 

MGA (green phosphoric acid)

    705     851     895  

WPA (white phosphoric acid)

    1,392     1,473     1,473  

MKP (monopotassium phosphate)

    1,480     1,521     1,654  

MAP (monoammonium phosphate)

    1,128     1,133     1,228  

GTSP (granulated triple super phosphate)

    374     448     510  

GSSP (granulated single super phosphate)

    214     231     247  

Rock phosphate

    110     148     139  

        The three-year average market prices used to calculate our reserves for the years 2011 to 2013 are as follows: $815 per ton for MGA, $1446 per ton for WPA, $1546 per ton for MKP, $1156 per ton for MAP, $439 per ton for GTSP, $231 per ton for GSSP, and $132 per ton for rock phosphate.

        In calculating the reserves, an average of the previous three years' currency conversion rates were used as part of the calculations to ensure economic viability. The following table sets forth information regarding the currency conversion rates for the years 2010 to 2013:

 
  Average Currency
Exchange Rate
 
 
  For the year ended December 31,  
 
  2013   2012   2011  

Dollar ($) / NIS

    3.611     3.856     3.578  

Euro (€) / Dollar ($)

    1.328     1.286     1.392  

Pound (£) / Dollar ($)

    1.565     1.585     1.604  

        The life of the mine at Rotem is approximately 8 years based on reserves of 14.8 million metric tons of low organic/low magnesium phosphate. The low organic, low magnesium phosphates are suitable for phosphoric acid production. The annual production (mining) rate for the low organic/low magnesium phosphate at Rotem is 1.9 million metric tons per year.

        The life of the mine at Oron is approximately 8 years based on a reserve of 24.0 million metric tons and an average production of 3.0 million metric tons per year of white phosphate.

        The life of the mine at Zin is 8 years based on a reserve of 24.8 million metric tons and a production of 3.1 million metric tons per year as follows:

    Low organic phosphate—1.7 million metric tons per year

    High organic phosphate—1.1 million metric tons per year

    Bituminous phosphate—0.3 million metric tons per year

156


Table of Contents

        As described under "—Mineral Extraction and Mining Operations—The Negev Desert," we primarily use white/low organic phosphate rock, and blend in bituminous phosphate, in our operations. To utilize additional resources after our reserves are utilized, we would be required to modify our processes and add costly technologies.

        Our concessions for these mining operations expire at the end of 2021. For details regarding these concessions and the related permits please see "—Mineral Extraction and Mining Operations—Concessions and Mining Rights—Israel" above. Except as noted in "—Mineral Extraction and Mining Operations—Concessions and Mining Rights—Israel" above, we believe that we have all government approvals and permits necessary for our reserves in Israel.

    Spain

        The following table sets forth our estimated potash reserves for our Spanish mining operations (all of which are wholly-owned by us) as of December 31, 2012 (latest date for which information is available):

Mine
  Reserve Category   Millions of
metric tons
  Average
Grade
(% KCl)
 

Cabanasas

  Proven     12.8     26.9  

  Probable     92.0     25.5  
               

  Total Proven and Probable     104.8     25.7  
               

Vilafruns

  Proven     9.l     22.7  

  Probable     8.3     22.0  
               

  Total Proven and Probable     17.4     22.4  
               

Total (1)

  Proven and Probable     122.3     25.2  
               
               

(1)
Amounts may not sum due to rounding.

        In determining these reserves, a cut-off grade of 19% KCl was applied at Cabanasas and a cut-off grade of 18% KCl was applied at Vilafruns. The parameters used in determining the cut-off grade took into account the geology (continuity, structure), mining method, mining recovery, dilution, metallurgical/processing factors, operating costs and historical and current product prices. The parameters employed in the calculation are as follows: on-site tons (obtained in terms of the density of the mineral); recovery factor (takes into account the values obtained historically during the mining of the Cabanasas and Vilafruns mines); recoverable tons (tons of mineral which can be mined, in terms of the recovery factor); mineable tons (recoverable tons from which the tons produced are discounted); planned dilution (in terms of the thickness of the folded layer and the mined height); unplanned dilution (a value of 5% unplanned dilution is considered taking into account the data from the mining in Vilafruns and the data from the base area of the anticline); and striation (% salt dilution that's defined in terms of the folded depth of the layer considered). Iberpotash's yearly mining plan is not determined by the cut-off grade and the fluctuation of commodity prices rarely affects its cut-off grade because Iberpotash will handle volatility in commodities prices by lowering its operating costs in one of several ways (for example, by negotiating with contractors).

        The cut-off grade calculations come from historical yield data and Iberpotash's historical experience with mining, adequately calculated and modelled by its geologists, operation engineers and economists. The calculation takes the ore grade in-situ, converts it into extracted ore with Iberpotash's mining method and estimates the plant yield depending on the grade. Economic modelling further gives the cut-off figures currently used by Iberpotash.

        The proven and probable reserves above the cut-off grade were obtained taking into account the mining method, mining recovery, dilution, striation, geological conditions and in-plant recovery, based on Iberpotash's historical data. The mining recovery and dilution factors, which are required in the conversion of resources to reserves and take into account the particular mining method and the geological conditions at the respective mine, consist of historical yield data and are based on sixteen years of historical data at our Cabanasas and Vilafruns mines and the mining recovery ranges from approximately 65 to 75% by

157


Table of Contents

Iberpotash's "room and pillar" modified layout. Reserve tonnages and grades are quoted as those that are expected to be delivered to the treatment plant and are subject to metallurgical recovery factors. Metallurgical recovery factors consist of historical yield data and are based on the previous five years' experience and current recoveries are 89.0% KCl for the Suria plant (Cabanasas) and 85.0% KCl for the Sallent plant (Vilafruns). Proven reserves have been explored by borehole intersections typically at 100 to 200 meters spacing while probable reserves have been explored by boreholes up to 1,600 meters spacing. The final product is well over 95% KCl to avoid quality loses.

        In calculating the cut-off grade and reserves, an average of the previous three years' market prices and operating costs was used as part of the calculations to ensure economic viability. The following table sets forth information regarding the average market prices for potash per ton of product for the years 2010 to 2013:

 
  For the year ended December 31,  
 
  2013   2012   2011   2010  
 
  Average Market Price (€/ton)
  Average Market Price (€/ton)
  Average Market Price (€/ton)
  Average Market Price (€/ton)
 

    262.9     311.3     301.2     242.3  

        The three-year average market price used to calculate our reserves for potash per ton of product for the years 2010 to 2012 is 285.3 euros per ton.

        In calculating the reserves, an average of the previous three years' currency conversion rates were used as part of the calculations to ensure economic viability. The following table sets forth information regarding the currency conversion rates for the years 2010 to 2013:

 
  Average Currency Exchange Rate
For the year ended December 31,
 
 
  2013   2012   2011   2010  

Euro (€) / Dollar ($)

    1.328     1.286     1.392     1.327  

        The Suria plant utilizes ore mined from Cabanasas and has a current capacity to produce approximately 530,000 tons per annum of potash. The Sallent plant utilizes ore mined from Vilafruns and has a current capacity to produce approximately 500,000 tons per annum of product; this plant will be gradually phased out as Suria is upgraded.

        The earliest renewal required for any of the 126 existing relevant concessions will be no earlier than 2037, and most of the concessions are effective up to 2067. For details regarding these concessions, please see "—Mineral Extraction and Mining Operations—Concessions and Mining Rights—Spain" above. Except as noted in "—Mineral Extraction and Mining Operations—Concessions and Mining Rights—Spain" above, we have all government approvals and permits necessary for our reserves in Spain.

    United Kingdom

        The following table sets forth our estimated potash reserves for our United Kingdom mining operations (all of which are wholly-owned by us) as of December 31, 2012 (latest date for which information is available):

Reserve Category
  Millions of
metric tons
  Average
Grade
(% KCl)
 

Proven

    15.8     31.6  

Probable

    4.7     33.2  
           

Total Proven and Probable

    20.5     32.0  
           
           

158


Table of Contents

        In determining these reserves, a cut-off grade of 30% KCl was applied in both the south (onshore) and the north (offshore), at a mining extraction height of 3.8 meters (though thinner sections of potash can be taken, with the inclusion of salt dilution in the floor of the seam) and a maximum distance of 15 kilometers from the shafts. The parameters used in determining the cut-off grade took into account the geology (continuity, structure), mining method, mining recovery, dilution, and metallurgical/processing factors. The parameters employed in the calculation are as follows: in-situ tons (obtained in terms of volume and density of the mineral); mining recovery factor (based on values obtained historically during mining potash ore); mineable tons (recoverable tons of mineral which can be mined in terms of the mining layout and recovery factors); and dilution (based on values obtained historically during mining potash). Operating costs and historical and current product prices are taken into account, but the cut-off grade determination is largely influenced by optimization of the beneficiation process, in particular the flotation system, as our calculation is largely based on getting the right grade of ore into the treatment plant. Cleveland Potash's yearly mining plan is not determined by the cut-off grade and the fluctuation of commodity prices rarely affects its cut-off grade because Cleveland Potash will handle volatility in commodities prices by lowering its operating costs in one of several ways (for example, by negotiating with contractors). Over the last three years, the cut-off grade has remained at 30% and has not changed as a result of market price or operating cost fluctuations or as a result of currency conversion factor changes.

        The cut-off grade calculations come from historical yield data and Cleveland Potash's historical experience with mining, adequately calculated and modelled by its geologists, operation engineers and economists. The calculation takes the ore grade in-situ, converts it into extracted ore with Cleveland Potash's mining method and estimates the plant yield depending on the grade. Economic modelling further gives the cut-off figures currently used by Cleveland Potash.

        The proven and probable reserves above the cut-off grade were obtained taking into account losses for mining recovery, dilution factors, mining method and geological conditions based on Cleveland Potash's historical data. The mining recovery and dilution factors, which are required in the conversion of resources to reserves and take into account the particular mining method and the geological conditions, consist of historical yield data and are based on the previous five years' experience and generally, the dilution factor is a 10 to 17% reduction on KCl and a small increase in the percentage of insoluble material. Reserves tonnages and grades are quoted as those that are expected to be delivered to the treatment plant and are subject to metallurgical recovery factors. Metallurgical recovery factors consist of historical yield data and are based on the previous five years' experience and current recovery is 81%. Proven reserves have been explored by borehole intersections typically at 150 meters spacing or less while probable reserves have been explored by boreholes at 150 to 500 meters spacing.

        In calculating the cut-off grade and reserves, an average of the previous three years' market prices and operating costs was used as part of the calculations to ensure economic viability. The following table sets forth information regarding the average market prices for potash per ton of product for the years 2010 to 2013:

 
  For the year ended December 31,  
 
  2013   2012   2011   2010  
 
  Average Market Price (£/ton)
  Average Market Price (£/ton)
  Average Market Price (£/ton)
  Average Market Price (£/ton)
 

    238.0     265.1     270.4     234.0  

        The three-year average market price used to calculate our preserves for potash per ton of product for the years 2010 to 2012 is £256.1 per ton.

        In calculating the reserves, no currency conversion factors were used as Cleveland Potash works only with the British pound.

        The potash mined at Boulby has, over the past 15 years, declined in potash grade from about 40% to just over 30% KCl. The NaCl content has risen from 47% to about 55%, while the content of insoluble impurities has also risen from about 12% to about 15% over this time. The plant capacity at Boulby is approximately 3 million tons per annum. The final product is potash at an average grade of 95.5% KCl. Annual potash production is approximately 600,000 tons per annum.

159


Table of Contents

        The earliest renewal required for any of the 114 existing relevant leases will be no earlier than 2015. For details regarding these concessions, please see "—Mineral Extraction and Mining Operations—Concessions and Mining Rights—United Kingdom" above. Except as noted in "—Mineral Extraction and Mining Operations—Concessions and Mining Rights—United Kingdom" above, we believe that we have or will receive all government leases and licences necessary for our reserves in the United Kingdom.

    Logistics

    Israel

        Much of the output of our Dead Sea facilities is transported by a conveyor belt that extends for 18.1 kilometers to the railhead at Mishor Rotem. We built, own and operate the conveyor belt. The output is then transported to the port of Ashdod by train and by truck. We also transport some of the output from our Dead Sea facilities by truck to the ports of Eilat and Haifa.

        Most of our products, whether in solid or liquid state, are transported in bulk from Rotem, Oron and Zin by road or rail to either the port of Ashdod or Eilat. From Eilat, our products are transported by ship to markets in the Far East, and from Ashdod, they are transported by ship to Europe and South America.

        Within the Rotem site, there is a rail loading facility that typically loads up to 30 wagons for each delivery. Each rail train can comprise a combination of 60 ton and 65 ton wagons carrying fertilizer and 52 ton wagons specifically for transporting acid. Every day, six rail trains leave the Rotem site, which equates to over 10,000 tons of products being transported by rail from the Rotem site to Ashdod per day, or approximately four million tons per year. Three to four million tons of products are transported by road from Rotem to the port of Eilat, since there are no rail links between the Rotem site and Eilat.

        Our wholly owned subsidiary Tovala is responsible for transporting phosphate rock from the Oron and Zin processing facilities in road-going rigid trucks and trailers. Each trailer has a payload of 40 tons. Approximately 0.4 million tons of rock leave Zin by truck for delivery to the port of Eilat each year. In addition, 0.30 million tons are transported from Zin to Rotem for further processing. From the Oron mine, another 1.0 million tons are transported to Rotem via the road network. All road transportation of products leaving Zin goes directly to Rotem for further processing or to the port of Eilat.

        From Ashdod, approximately 65,000 tons to 200,000 tons of sulfur are transported to Rotem each year by these 40 ton road trucks and trailers. This represents around 10% of all sulfur leaving Ashdod, and the remaining 90% is transported via rail. In general, 10% of all products leaving Rotem are transported via the road and all material goes to the port at Ashdod.

        In addition, sulfur arrives at the port of Ashdod from overseas, where it is loaded into road-going trucks and transported to our sulfur dispatch 5 kilometers away. At the depot, it is loaded into rail cars and then transported to Rotem.

        The port of Ashdod is located on the Mediterranean coast, approximately 40 kilometers south of Tel Aviv and approximately 120 kilometers northwest of the Rotem site. Ashdod port has two ship loading facilities, a linear berth with ship loading and a second berth with a radial ship loading facility. It is a deep water berth of 15.5 meters deep that can accommodate panamax-sized vessels capable of 65,000 ton payloads. The two largest warehouses at Ashdod contain phosphate rock, which is stored under cover. Freight cars enter the facility and off-load the product through floor grids directly onto a conveyor which takes the product to the storage warehouse. A stacker-reclaimer operates within the warehouse to stock pile the material and collects it for transportation onto a delivery conveyor, which takes it to the ship loader. Ships are loaded via a Cleveland Cascade by a series of conveyors that can deliver product from any one of our five storage warehouses.

        The port of Eilat is located in the far south of Israel on the Red Sea coast. It is 180 kilometers due south of Rotem and is accessible by road. Shipping from the port of Eilat is relatively low compared to Israel's other ports at Ashdod and Haifa due to the fact that there is no deep water berth. At present, we operate from one berth via a single ship loader. Typically, ships arriving at Eilat are capable of holding approximately 35,000 ton payloads.

        There are currently no areas which present themselves as limiting factors for transporting our products to the worldwide markets. The only exception to this is the lack of a rail link to the port of Eilat. The Israeli government, however, has plans to resolve this issue, which could potentially increase trade with Far East countries.

160


Table of Contents

        We also have storage and logistics facilities in Ludwigshafen, Germany; Amsterdam, the Netherlands; and Rouen, France.

    Spain

        Ore is taken by 25 ton road haulage trucks from the Cabanasas and Vilafruns mines to the Suria and Sallent plants, respectively. The salt product is transported by articulated truck to an Iberpotash-owned terminus in the port of Barcelona. A truck fleet comprises 25-27 ton capacity articulated road trucks used to transport the salt from the mine. Up to 40 trucks per day are dispatched from the mine road load out to the port. The mine also uses the port of Tarragona to export specific products.

        Iberpotash owns and maintains 1.5 kilometers and 3 kilometers of standard gauge railway at Cabanasas and Vilafruns, respectively, that links to the national rail network. Each train set comprises of 850 ton payload comprising approximately 20 freight cars with two trains per working day. The rail route for potash transport to the terminus in the port of Barcelona comprises an 82 kilometer rail route from Suria to Manresa to the port of Barcelona and 88 kilometers from Vilafruns to the same destination. Iberpotash owns and operates its own port facilities which comprise bulk salt and potash storage facilities comprised of freight car and rail truck conveyor unloading facilities and the product storage warehouses. The stockpiled product warehouses are equipped with rail mounted traverse mechanical conveyor re-claimer which dispatch the products onto a conveyor out load system.

        The Cabanasas/Suria and Vilafruns/Sallent complexes have one rail load out system each for the rail to port transport systems comprising of plant connected storage conveyor to a rapid loading bunker loading facility which fills each 45.7 ton freight car. The bulk cargo vessels are loaded by a gantry mounted conveyor with granulated product unloaded into the bulk carriers hold via flexible delivery chute. The train electric traction engine and bulk freight car rolling stock is operated by the owner and operator FFCC ( Ferrocarrils de la Generalitat de Cataluña ).

        The port of Barcelona is of commercial importance to the Catalan region. The port is managed by the Port Authority of Barcelona and comprises an area of 7.86 square kilometers divided into three zones. The port is undergoing an enlargement program to double its size. The Barcelona industrial port is to the south, and comprises the Free Port of Barcelona, which has a tariff-free industrial park.

    United Kingdom

        The Boulby mine comprises a network of underground roads extending 14.5 kilometers under the North Sea and inland, totaling over 1,000 kilometers of roadway. The mine is served with good road, rail, and water links to the national networks and is provided with good potable water and strong, stable electric power supplies.

        Road transport movements from site are limited to a maximum of 150,000 tons per annum and a maximum of 66 road wagons per day (no road movements are allowed on Sundays or bank holidays) in accordance with the North Yorkshire National Parks agreements. This limitation is not expected to interfere with future production due to Cleveland Potash's commitment to maintaining the rail link to Teesdock. Cleveland Potash is in full compliance with all road and rail requirements.

        The Boulby mine benefits from a Cleveland Potash-owned rail line (which extends eight kilometers from the mine head to a junction with the national rail network). From this junction the products continue to Teesport, Middlesbrough. Teesport handles most of the bulk export cargo from the mine, via a ship/road/rail terminal located at Teesport's potash and rock salt terminal which is designed specifically for this function.

        The mine has three separate integrated conveyor load out systems, one for each product:

    (1)
    Granulated and standard potash product;

161


Table of Contents

    (2)
    White soluble powder potash product; and

    (3)
    De-icing salt, polysulphate and sylvinite potash product.

        The rail load out products are transported on a Cleveland Potash-owned rail line which extends approximately eight kilometers from the mine head to a junction with the national rail network, from where the products continue to Teesport, Middlesbrough, via Network Rail, owner and operator of the main-line.

        The rolling stock is provided by NACCO and the engines are owned and operated by Freightliner. Each 900 ton train set comprises of 15 trucks, each with a 60 ton payload.

        Cleveland Potash leases and operates two principal storage and loading facilities:

    (1)
    Teesdock facility, which is located on the River Tees; and

    (2)
    The Ayton Works road depot in Middlesbrough.

        Eight trains per day take rock-salt, potash and polysulphate to the Teesdock. Most of the output goes into agricultural fertilizers: large quantities (around 50% of production) are exported by sea from Tees Dock to European Union countries and other overseas customers.

        Rock-salt is taken by train to Teesdock, and mostly sent by ship to English and Scottish east coast ports for sale to local authorities for de-icing roads.


Research and Development Policies

        Our R&D expenses, net were $70.1 million, $74.1 million and $82.9 million in 2011, 2012 and 2013, respectively.

        Our Fertilizers segment's R&D activities in 2013 focused on the following items:

    Improvement of the quality of the products being sold;

    Research regarding environmental protection, including development of methods for reducing and treating effluents;

    Development of alternative methods for increasing production of carnallite, including examination of the feasibility of mining in underground locations in Sodom, as well as increasing utilization of carnallite;

    Adaptation of types of phosphate rock to production of phosphoric acid and its downstream products as part of an effort to exploit existing phosphate reserves;

    Development of technology for use of bituminous phosphate as a source for production of phosphoric acid and downstream products;

    Development of high-acid products allowing diverse applications of soluble fertilizers;

    Development of controlled-release products with coating materials of compositions and thicknesses unlike those currently available in the market and development of micro-nutrients;

    Development of controlled-release products combined with pesticides;

    Development of biodegradable coatings for controlled-release fertilizers;

    Development of polysulphate-based fertilizers as raw materials for the specialty fertilizer industry;

    Development of applications preserving water and fertilizers around the root; and

    Geological examination of our concessions in Spain in order to ascertain whether a significant expansion is possible.

162


Table of Contents

        Our Fertilizers segment's total R&D expenses in 2013 were approximately $23 million.

        The R&D activities of our Industrial Products segment are part of the segment's strategic plan. Therefore, the expenses in the segment's five-year plan are expected to increase in the upcoming years—both due to an internal increase and as a result of cooperative efforts with universities, research institutes and other research bodies. The activities will focus primarily on identifying additional uses for bromine and its derivatives, as well as developments in the area of phosphates.

        The R&D activities of our Industrial Products segment are as follows:

        Environmental:

    Brominated polymers: continued development of brominated flame retardants, which are flame retardants in general, and DECA and FR 1410 substitutes in particular. Due to the size (molecular weight) of polymer molecules, it is unlikely that they will penetrate oily body tissue and remain there.

    Textiles: continues development of TexFRon, a series of textile flame-retardant products. TexFRon is an effective and environmentally-friendly solution for diverse textile products, replacing DECA and offering a transparent and laundry-durable solution that is not currently available on the market. We commenced selling the product in 2012.

    Energy storage: continued development of bromine-based solutions for storing energy.

    Merquel: continued research as support for use of bromine products to reduce mercury emissions in coal-fueled power stations.

    Ecological research to improve sewage treatment, reduction of air emissions and solid waste.

        New Products:

    Biocides: continued development of new materials for water treatment and prevention of biofilm (algae) in irrigation systems and industrial cooling water. In addition, there is research activity for polymer synthesis with biocidal activity.

    Phosphorus-based products: development of new phosphorus-based products and/or integration of phosphorus/bromine chemistry mainly in the polyurethane field—(i.e., flexible and rigid foam). A common application is fire retardants for polyurethanes used as insulation in the construction, furniture and automobile industries. In addition, new lubricating oils have been developed.

        Others:

    Support of production: improving product quality and lowering production costs by changing and improving processes, while using the principles of green chemistry (for example, reduction of use of organic solvents in production processes). There is extensive use of a "sustainability index" model for new products, which includes various parameters relating to product properties.

    Engineering: research in the area of construction materials in order to overcome problems of accelerated wear and tear of building materials, corrosion prevention, equipment adaptation, and tests in accelerated aging.

        Our Industrial Products segment's total R&D expenses in 2013 were approximately $29 million.

163


Table of Contents

        The principal R&D activities of our Performance Products segment in 2013 are as follows:

      Pure phosphoric acid, phosphate salts and food additives:

      Development of innovative products (mainly specialty products) in order to strengthen our Performance Product segment's position in the markets in which it is active, including mainly: components based on natural materials that improve the characteristics of food products and contribute to prolonging the shelf life of these products; low-sodium products based on raw materials from the Dead Sea; new phosphate based fire retardant for automotive uses; advanced additives for paints and coatings (i.e. preventing tannin stains on coated wood surfaces); phosphate-based blood coagulation system for medical uses; and environmentally-friendly formulations for control of forest fires.

      Process development for improving competitiveness as global supplier for phosphoric acid specialties, including in particular: process for making poly-phosphoric acid; process for making electronic grade pure phosphoric acid based on the wet process route; and development of designated equipment for safe use of phosphoric acid to improve asphalt surfaces.

      In other fields: environmentally-friendly corrosion inhibitors for industrial water systems, which allow for the replacement of the toxic substance Hydrazin; development of zirconium-based ceramic materials for dental uses; development of unique gypsum based material for 3D printing; development of a process for recycling various waste materials from footwear plants as well as development of Renoprint technology for use in this industry; development of chemicals for improvement of applications in the paper recycling industry; and adjusting existing products to new laws (particularly biocide-related laws and the REACH Directive).

        Our Performance Products segment's total R&D expenses in 2013 were approximately $19 million.

        In the past, some of our Israeli subsidiaries received grants from the Office of the Chief Scientist in the Israeli Ministry of the Economy ("OCS") under the Law for the Encouragement of Industrial Research and Development, 1984, and the regulations promulgated thereunder (the "R&D Law"). In general, the grants are required to be repaid in the form of royalties on the revenues, if any, generated by the funded projects, plus interest. Our remaining financial obligations under the grants are minimal. According to the R&D Law, the transfer of OCS-funded know-how is subject to OCS approval and to possible payments to the OCS in the event of transfer of the know-how outside of Israel.


Intellectual Property

        We believe that protecting our intellectual property is one of the methods of protecting and developing our business activities.

        Our Fertilizers segment has 13 groups of patents, mostly related to derivatives of the Osmocote brand, for specific soluble fertilizers, production technology of coatings (P 1 , P 2 ), and for applications of controlled fertilizer compounds and plant protection products.

        We have 324 Industrial Products patents that have been registered over the years and an additional 230 patent applications that are in various stages of evaluation around the world. As at the date of this prospectus, these patents protect a relatively small portion of our Industrial Products segment products. During 2013, 60 new patent applications by our Industrial Products segment were approved.

        Our Performance Products segment has, in various countries, approximately 1,515 registered trademarks and approximately 543 registered patents.

        We do not believe that the expiration or violation by any of our entities of any particular patent would have a material effect on our operations or our financial results.

164


Table of Contents


Insurance

        We have insurance for property, physical damage and consequential loss, on standard policy terms for our industry. Our total insurance takes into account the maximum expected loss to us as a result of earthquake damage to property in the Dead Sea region, based on an assessment solicited from expert consultants. Our property in Israel is protected, in accordance with the Israeli Property Tax and Compensation Fund Law, against physical damage as a result of a terror event or act of war.

        Cleveland Potash does not purchase insurance for underground property damage because its management has determined that the cost of the premium required for the proposed coverage does not justify purchasing the insurance.

        We have product liability, third party and employers' liability insurance, on policy terms customary for our industry. We also purchase other insurance, such as credit insurance, cargo insurance, insurance against ongoing ecological damage, third party insurance, insurance to cover officially ordered cleaning of contaminated ground, officers insurance, construction and erection insurance and fidelity insurance.

        We have a captive insurance company that purchases from insurance companies that insure part of the risk of our subsidiaries, in consideration for a premium at the standard rate in the insurance market for the risk acquired. In this way, we increase the deductible at the group level beyond the deductible at the individual company level, so as to reduce the cost of the premium paid to the external insurance market and the cost of the risk to the Group. As of December 31, 2013, the captive company participates in the deductible in property, product liability and third party, credit, employers' liability and ecological insurance.


Sustainable Development Policy

        We apply an overall policy of sustainable development that integrates social, economic and environmental considerations into all of our business activities. The policy stresses social responsibility, which includes contributions to the community, taking responsibility for the safety, hygiene and well-being of our employees, reducing environmental impacts and creating a dialogue and transparent communication channel with the authorities, as well as other matters.


Regulatory and Environmental, Health and Safety Matters

        Some of our products are potentially harmful to the environment and the health and safety of the public as a result of the effluents, air emissions and waste that are generated during the production of our products. These substances can cause pollution that necessitates remediation, clean up or other response action. In addition, some of our products may be hazardous to those who are exposed to them during their production, transportation, storage or use. Consequently, some of our operations and products are subject to environmental, health and safety regulation. There is also a risk of claims in respect of bodily injury or property damage.

        We routinely undertake environmental, health and safety capital projects and incur related expenditures. In 2013, we spent approximately $132 million on matters related to the environment and environmental conservation, of which approximately $44 million were related to investments in plant and equipment and approximately $88 million were a current expense. In 2014, we expect to spend approximately $156 million on environmental matters, of which approximately $63 million will relate to investments in plant and equipment and approximately $93 million will be a current expense. We have continually increased our investments in the environment while making improvements and reducing our impact on the environment. We expect that in upcoming years, there will not be a decline in the scope of the costs relating to environmental matters.

        Descriptions of certain government regulations relating to environmental and other matters that have a material effect on our business are set forth below.

165


Table of Contents

    Limits on Cadmium in Phosphate Fertilizers

        Phosphate rock, which our Fertilizers segment mines, contains cadmium in various concentrations. Cadmium is considered to have a harmful effect on the environment. Most countries to which our Fertilizers segment sells phosphate fertilizers do not presently limit quantities of cadmium in fertilizer. The European Union has been conducting a series of public hearings prior to enacting regulations limiting the maximum concentration of cadmium permitted in phosphate fertilizers anywhere within the European Union. The regulations are expected to be published in 2016 with a transition period of several years, and at the end of the transition period the producers will be required to abide by the limitations. The cadmium content in the phosphate fertilizer products of our Fertilizers segment does not exceed the permissible quantity compared with the anticipated future limitations in the European Union. A number of European countries in Scandinavia (Finland, Denmark and Sweden) have already instituted local limitations with respect to the cadmium content in fertilizers; however, these limitations are not binding on the entire European Union.

    Salt Accumulation at Mines in Spain

        Our Fertilizers segment has two potash production sites in Spain. Salt, which accumulates in heaps, is a byproduct of potash production. Most of the accumulated salt is of no use. Periodically, our Fertilizers segment needs to obtain permits to make these salt heaps on its sites and it must also renew its "environmental license" once every eight years.

        Regarding the license for salt heaps on the sites: for the first site, there is a permit to heap salt on the site sufficient until 2026 at current production levels. For the second site, where our Fertilizers segment intends to shut down mining, there is a heaping license for the site sufficient, at current production rates, for another one and a half years (until about the middle of 2015). Our Fertilizers segment is acting to extend the license until the end of mining in 2015.

    Product Regulation and Registration

        Insecticides (Including Soil Fumigation).     In most countries, this material and any product containing this material must be registered prior to import or sale in that country. Sale is restricted according to the level of the hazard (disease/organism) and the crop or yield for which the permit was granted in that country. The permit is generally for a limited time and needs to be renewed in order to continue selling.

        Water Treatment (Biocides).     In a number of countries, this material and any product containing this material, must be registered prior to import or sale in that country. Sale is limited to those commercial uses for which the permit is received in a given country. The licensing is generally for a limited time and needs to be renewed in order to continue selling. Beginning in 2013, the Biocide Law in the European Union, which replaced the Biocide Directive, entered into effect. The Biocide Directive also implemented a process of re-licensing every existing biocide on the market. Our Industrial Products segment submitted files for renewing licenses for existing biocides for various uses, according to the timetable set in the Law. Under the Directive, during the course of the licensing process, it is permitted to continue selling the products for the uses sold to date, on the condition that a licensing file is submitted for the use and the active substance in the product. The new Biocide Law continues the Biocide Directive with respect to the completion of the licensing process of the substances; however, the responsibility was transferred to ECHA. In addition, the Biocide Law introduced changes regarding the continued approval of products containing active biocides in the various countries, along with additional changes.

        Chemicals.     In some areas of the world (such as the European Union, the United States, Canada, Japan, Korea and China), chemicals may be sold only after registration and authorization by the authorities. Trade restrictions for use apply to some of the products of our subsidiary Bromine Compounds stemming from the requirements of international treaties. Our Industrial Products segment registers the products that it develops and sells as required under local laws.

166


Table of Contents

    Chemical Registration in Europe (REACH)

        A statute covering the framework for licensing and evaluation of chemicals in the European Union (known as "REACH") became effective as of June 1, 2007. The statute applies to chemicals already on the market, as well as to new chemicals. Pursuant to this legislation, manufacturers in the common market and importers of chemicals or importers of certain products containing chemicals are required to submit dossiers containing detailed information of every substance or chemical compound manufactured or imported into Europe, in quantities of more than one ton per year (the amount and content of the information depends on the volume of production and/or sales in Europe, and the nature of the product in terms of its effect on health and the environment). Some of the products will undergo risk evaluation based on the information that is submitted, and others will only be able to be sold in the future under an appropriate permit. Such a permit will only be granted on the basis of quantified evidence relating to management of the product with regard to health and environmental aspects, the lack of appropriate alternatives, and a socio-economic evaluation. Certain persistent, environmentally toxic substances will require permits based only on a socio-economic evaluation and on the condition that an alternative development plan be submitted, in order to encourage a transition to use of less hazardous substances.

        The statute is being implemented gradually, between 2008 and 2018, under the supervision of ECHA.

        Apart from higher production and raw material costs following implementation of REACH, under the law our subsidiaries incur costs in the field of licensing, control and implementation of product stewardship programs with customers. Another possible risk caused by REACH legislation is reduction in usage of a product or material, or removal of certain products from the European market. Likewise, there will be products and compounds that require investment in alternative research and development due to the need to remove certain components from use in the European market.

        All of our segments are implementing REACH and are registering their chemicals as required by law.

        Likewise, all the chemicals have been reclassified in line with the CLP regulations (classification, labeling and packaging of substances and mixtures), that took effect in Europe in December 2010.

        All of our segments submitted applications for permits for all the chemicals relevant for their businesses in Europe (production and sale) within the timetables set in the law (2010 and 2013). We have also volunteered to lead and prepare a number of leading files for the entire industry (lead registrant).

        Under the law, ECHA publishes, and regularly adds to, a list of substances defined as "substances of very high concern." As of the date of this prospectus, this list includes several products of our Industrial Products segment, as discussed below.

    Limitations on the Use of Certain of Our Chemical Products

        Various countries are assessing possible limitations on the use of chemicals, and this assessment includes flame retardants. Below are details regarding the main proceedings known to us as of the date of this prospectus.

    The flame retardant HBCD is on the list of materials requiring authorization under the REACH regulation, after being defined as a "substance of very high concern" by the European Union. The implication is that manufacture and use of HBCD will be prohibited in the European Union unless, on the basis of a socio-economic evaluation, it is proven that the need for the product for a particular use is greater than the risk, and that there are no alternatives to using the product. The results of the preliminary authorization process are expected in the first half of 2015. As of the date of this prospectus, there is no ban on the use of the substance. In addition, HBCD was classified at two United Nations conventions (Stockholm Convention UNEP and UNECE) as a persistent organic pollutant. The implication of the classification is that the process for taking the substance off the market in Europe could occur by the end of 2014, earlier than expected. Nonetheless, in light of the fact that there is still no HBCD substitute available in commercial quantities, in May

167


Table of Contents

      2013 a decision was made by the Stockholm Convention to permit an exemption from the prohibition and to permit use only in polystyrene insulation plates in buildings for an additional period of up to five years. This approval will be realized only by countries that are members of the Convention that show a need in the additional period and that are recorded in the request for exemption from the prohibition. Our Industrial Products segment has a substitute for HBCD called FR122P in the commercial stage.

    The bromine-based flame retardant DECA is banned for use in electrical and electronic applications in the European Union. In addition, due to the definition of DECA as a "substance of very high concern," it will most likely be prohibited for all uses in the European Union in 2017 at the earliest. As part of the restriction campaign led by the European Chemicals Agency ("ECHA"), during 2013, DECA was proposed as a candidate for deliberations at the Stockholm Convention in the United Nations as a substance having POP characteristics. The deliberations commenced in October 2013 and the decision-making process is expected to be completed in May 2017 at the earliest. Imposition of the prohibition against use is expected to enter into effect at the end of 2018. In North America, the three largest manufacturers of bromine-based flame retardants (Albemarle, Chemtura and our Industrial Products segment) phased out their production of DECA in 2013. We commenced selling TexFRon, a substitute for DECA, in 2012.

    Propyl bromide, produced by our Industrial Products segment, was defined as a substance of very high concern in the European Union in December 2012. Propyl bromide's use as degradable raw material will not be affected (since it is not included in this process). With respect to other uses, there is still no decision regarding prohibition. The definition of propyl bromide as a substance of very high concern is not expected to significantly impact us.

    TXP (Tri Xylyl Phosphate), which is used as a softening substance in the plastics industry, has also been defined as an SVHC in Europe. This limitation does not significantly affect us.

    In October 2011, the phosphorus-based flame retardant TDCPP was classified as a carcinogen in California. In November 2012, our Industrial Products segment announced that it will no longer sell the substance to the furniture industry beginning in 2013, and by the end of 2015 it will no longer produce the substance. Concurrently, we have developed two alternative products that have reached the stage of commercialization.

    Air Quality—Israel

        During production, our facilities emit pollutants that could be harmful to people or to the environment, if they were to be emitted into the environment in concentrations or amounts exceeding the permitted levels. The materials emitted are volatile organic compounds, inorganic compounds and particles. We are taking the necessary measures to prevent the uncontrolled emissions of these substances, in accordance with the provisions of the law and the conditions set forth in our business licenses, through the use of accepted technologies.

        A master plan is in place at our Fertilizers segment's facilities in Israel to reduce point source and fugitive emissions into the atmosphere. In this context, a second system to control stack emissions at a rotary dryer at Dead Sea Works started routine operation due to the good performance of the first system that was installed in 2013. During 2013, the upgrading of the absorption systems in the phosphoric acid plant was completed, and an upgrade was also made to the absorption system in the fertilizer plant. In addition, a project is underway for the installation of two large extraction and filtering systems to reduce emission of particle materials in Zin's factories. At our Fertilizers segment's plants in Israel, a master plan is being implemented to install continuous control and detection measures in the stacks. At the Mishor Rotem site, placement of a detection system on the fences and the stacks was completed. Mishor Rotem's plants are preparing for the establishment of a system of air quality monitoring stations, in coordination with the local council and the environmental authorities. At the Fertilizers and Chemicals facility, an ammonia emissions reduction project is underway, by installation of a demister in the stack of the nitrate

168


Table of Contents

ammonia manufacturing facility. Our Fertilizers segment's plants in Israel are in the process of converting to natural gas. Conversion to gas significantly reduces emissions into the atmosphere.

        Our Industrial Products segment operates advanced monitoring methods to identify deviations in the plants' operation and emission systems and prevent their occurrence and takes steps to prevent uncontrolled emissions according to the laws and the conditions set out in its business license, using accepted technology. Leak detection and repair (LDAR) methodologies are also applied. LDAR provides guidance for monitoring components to detect non-specific emissions and integrated pollution prevention and control (IPPC) to prevent emission of hazardous substances into the air. Below is a list of principal actions taken by our Industrial Products segment in regard to air quality:

    Investments were made in the production facilities in order to improve recycling of solvents and other organic materials, and absorption via active charcoal systems, in order to achieve reduction of the amount of these materials emitted into the air.

    Investments were made in monitoring and detection systems, in order to ascertain that there are no deviations in the plants' operation and emission systems. Furthermore, these systems were connected to the facilities' production control systems, so that before any deviation occurs, the facility's production process is terminated.

    Systems were implemented for the collection and treatment of volatile organic compound emissions from the plants' stacks. This system performs additional treatment regarding the volatile organic emissions using a catalytic oxidizing technology.

    Ongoing work is executed for the control and treatment of diffused emissions with the assistance of a European company.

    Continuing joint work by the Mishor Rotem factories, including Periclase, together with the Ministry for the Environment and the Environmental Unit of the Eastern Negev Council to set up a regional air monitoring system.

    In 2009, continuous monitoring systems for the stacks of the Periclase plant were purchased, in coordination with the Ministry of Environmental Protection. These systems were installed in 2010. However they have not yet succeeded in operating continuously. Notwithstanding the difficulties, we are making efforts in order to bring the system into good working order. The Ministry has been updated accordingly.

    During 2012 to 2013, emergency systems were acquired and upgraded in Bromine's factory in Sodom in order to ensure compliance with the standards covering emissions into the atmosphere in a case of a shutdown of the power station, in accordance with the requirements of the Ministry of Environmental Protection.

    The Israeli Clean Air Law—Air Emission Permit

        On July 31, 2008, the Clean Air Law was enacted to regulate the treatment and control of air pollution in Israel. The law is effective as of 2011.

        The Clean Air Law addresses, inter alia, fixed sources (including our plants) and is intended to serve as a platform for implementing the IPPC directive that was adopted by the European Union in 1996.

        The Clean Air Law differentiates between plants defined in the IPPC directive as having significant environmental impact (IPPC plants), which include our plants in Israel, and the other plants. In accordance with the Clean Air Law, operations of IPPC plants are subject to a valid emission permit. The emission permit should include specific instructions based on BAT.

        On June 22, 2010, the Ministry of Environmental Protection enacted the Clean Air Regulations (Emission Permits), 2010, which set requirements for applying for and obtaining an emission permit. To determine the BAT, these regulations refer to the European BAT Reference Documents ("BREF") and

169


Table of Contents

require selection of the BAT from known technologies (except in special circumstances that require specific explanations).

        As of the date of this prospectus, our magnesium company and our Industrial Products plant in Neot Hovav (Bromine Compounds Ltd.) have received air emission permits, including provisions regarding application of the BAT, as well as provisions with respect to monitoring, control and reporting to the Ministry of Environmental Protection. We are taking steps to implement an improvement plan to address the requirements of the air emission permits in coordination with the Ministry of Environmental Protection. The cost of these measures is included in our capital budget for environmental protection matters.

        The estimated capital investment required in order to comply with the Neot Hovav facility's new air emission permit's requirements, which was received in August 2013, is approximately $15 million, until the end of 2017. Our facility in Neot Hovav (Bromine Compounds Ltd.) meets the material conditions in the air emission permit.

        Our other Industrial Products segment plants in Israel have submitted applications for air emission permits in March 2014.

        The Rotem site at Mishor Rotem is a source of emissions as defined in the Clean Air Law, and is classified as a chemical plant, and therefore it has submitted an application for an emission permit. The power station at the Dead Sea Works site in Sodom is a source of emissions which requires a permit according to the Clean Air Law, and is classified as being in the energy industry and therefore will need to apply for an emission permit by March 1, 2015. Under the terms of the Clean Air Law, we expect that the air emission permit will apply to the entire Dead Sea Works site rather than to the power station alone.

    Report of Pollutant Release to the Environment

        In accordance with new legislation regarding the duty to report polluting releases into the atmosphere (Pollutant Release and Transfer Register—PRTR), during 2013, our factories in Israel recently began to report with respect to the quantities of pollutants released into the environment according to the provisions of the law. This law is based on the conventional legislation in Europe. Under the law, the data reported is published to the public on the Ministry's website. In January 2014, the Ministry of Environmental Protection published a list of emissions and transfers to the environment in accordance with the reports received from all of the reporting factories, including us. Beginning in 2014, the PRTR report is required to be submitted by March 31 of each year.

    Greenhouse Gas Issues

        Climate change is of increasing concern to governments, non-governmental organizations, and the general public. Increasing regulation of greenhouse gases ("GHGs") could impact our operations by requiring changes to our production processes or increasing raw material, energy, production or transportation costs. We are striving to become a leader in reduction of emissions in general and GHG emissions in particular. Our efforts include reduction of GHG emissions in production processes (including conversion to natural gas, replacement of shielding gas in magnesium production, and energy efficiency improvements) and development of new products that contribute to GHG emissions reductions. We annually measure the balance of GHG emission in most of our locations and measure the carbon footprint of over 50 of our products. We report our GHG emissions to the Carbon Disclosure Project.

        In 2013, we submitted a comprehensive report to the Carbon Disclosure Project on our greenhouse gas emissions and our strategy for addressing climatic changes with respect to our activities in 2012. Our high level of transparency achieved a score of 98 (out of 100). This score places us among the 50 highest scores for all reporting companies in the world and is the highest score for an Israeli company.

170


Table of Contents

    European Plan for Trade in GHG Emissions

        The European Union as a party that signed the Kyoto Protocol, the framework treaty of the United Nations for coping with climate changes, agreed on a mandatory target for reducing the greenhouse emission gases. The main tool for achieving the reduction targets is the EU Emissions Trading Scheme ("ETS"), which was started on January 1, 2005. In the first and second stages of the ETS, the European countries agreed that every industrial company that emits GHGs above the agreed minimum threshold is required to report its emissions and to limit the emissions to the gradually decreasing periodic quota. In addition, companies were allowed to realize a monetary gain or benefit by trading and selling unused emission permits. The third phase of the ETS commenced on January 1, 2013 and will run up to December 31, 2020. The third phase includes additional emission sources on our sites in Europe that are subject to the ETS and accordingly, the quantity of our GHG emissions subject to the ETS will increase.

    The European Energy Efficiency Law

        The new Energy Efficiency Directive of the European Union entered into effect on December 4, 2012. Most of the requirements in the Energy Efficiency Directive must be implemented by companies in the European Union no later than June 5, 2014. The Energy Efficiency Directive provides a joint framework to advance energy efficiency in the European Union, in order to achieve the European Union's energy goals by 2020. These goals include the reduction of GHG emissions by 20% compared with the levels in 1990, an increase in the rate of consumption of renewable energy sources to 20% of total energy consumption and an improvement in energy efficiency by 20%. Accordingly, all countries that are members of the European Union are required to increase the efficiency of their energy consumption in all stages of the energy chain—conversion, transportation and final use.

    Bill for Prevention of Land Contamination and Restoration of Contaminated Lands

        In August 2011, the Proposed Law for Prevention of Land Contamination and Restoration of Contaminated Lands, 2012 passed in the first of three readings by the Israeli parliament. In May 2013, a hearing with respect to the proposed law commenced. The highlights of the proposed law in its present version are set forth below.

        The proposed law defines land contamination and contamination land, among other things, as all that exceeds a concentration of contaminating materials in the land above certain preliminary or specific thresholds. This means that there is no quantitative criterion for defining contamination and there is no exception for negligible contamination. Moreover, the proposed law imposes a comprehensive prohibition against land contamination, both in public and private areas. Accordingly, the proposed law is expected to apply to industrial plants and to infrastructure facilities.

        The law will require conducting an historical survey of plants and sites regarding which there is a fear of land contamination. The Ministry of Environmental Protection will be permitted to order submission of risk surveys and land surveys and may demand filing of a plan for treating the land, provide instructions with reference to the manner of treating contamination events and the way for restoring suspect lands or lands found to be contaminated, cancel or intensify the specific threshold values provided in the risk survey, approve or reject treatment plans, add or change provisions, etc. The proposed law will require the owners or holders of contaminated land to carry out activities involving performance of surveys even if they did not cause the contamination. However, the owners or holders will be entitled to receive indemnification, as part of a civil proceeding, from contaminators if their identity is known. It was also proposed to set up an assistance fund for a party that is required to treat land contaminated by another party in circumstances where it is not possible to receive indemnification from the contaminating party. It was proposed that the financing for the fund shall come from, among other things, a fee made on industrial plants and holders of hazardous materials. At this stage, it is not possible to know what will be the rate of the fee if ultimately made.

171


Table of Contents

        It is unclear what will be the final version of the law and when it will be approved. If the law is passed in its present version, it will apply to our manufacturing sites. At every such site, an historical land survey will be made and according to the decision of the Ministry of Environmental Protection, there may be further requirements and surveys as a result thereof and instructions to clean up the land, to the extent contamination is found in the land, as defined in the law. At this juncture, prior to a land survey having been conducted, as required, it is not possible to know the extent of the exposure to obligations under the law and the cost thereof.

        On April 2014, the Ministry of Environmental Protection published for public comments a draft of policy principles regarding land contamination, which reflects the policy practiced by the Ministry, as expressed both in the business licenses and poisons permits issued by the Ministry. In that regard, the policy will make no material change in the current legal situation. The pertinent change that results from the implication of the proposed policy in regard to the Company is that all major industrial facilities (including all of our manufacturing sites) will be required by their business licenses to conduct historical surveys.

        Currently, almost no historical land surveys have been carried out on our sites in Israel, since the Ministry of Environmental Protection postponed the deadline required to submit these surveys to September 2014.

        At the Sodom site, an area with crude oil contamination has been found near the operational salt reservoir. Our Dead Sea Works subsidiary submitted a plan to the Ministry of Environmental Protection for treatment at the site and is waiting for its instructions. Costs for the coming years will be affected by the Bill for Prevention of Land Contamination and Restoration of Contaminated Lands, which is under legislative processes, as mentioned above.

        In addition, groundwater study in Dead Sea Works' power stations' contaminated oil tank farm showed no contamination in groundwater; however, soil rehabilitation is expected in the future. At the old gas station, boreholes were drilled and oil is being pumped from the contaminated soil and groundwater.

        There is an ongoing implementation of a multi-year master plan to prevent ground pollution by fuels or oils at our Rotem sites. This year the upgrade of the refueling station for heavy equipment on the Rotem site was completed.

    Liquid and Solid Waste

        During the production processes at ICL's facilities, industrial solid waste and wastewater are produced. According to the discharge permit, wastewater is channeled into water sources or evaporation ponds.

        In Spain, a multi-year program is underway to restore salt piles while paying close attention to the issue of wastewater drainage and handling of sludge.

        At Dead Sea Works, a project was completed for restoring 100% of the runoff of the facility for the treatment of sanitary waste for the production facility. In addition, a detailed plan was approved for restoration of the bulky waste at the plant site

        At the Rotem site, a master plan for treating waste is being applied with the principal aims of reducing effluent quantities, recycling wastewater, reducing water consumption, treatment of wastewater at the start of the flow and neutralization and restoration of wastewater reservoirs.

        At the Fertilizers and Chemical Substances facility, a comprehensive examination is presently underway aimed at finding a solution to the plant's compliance with standards covering treatment of the plant's wastewater flowing into the Kishon River, as directed by the "Inbar Committee".

172


Table of Contents

        Our Industrial Products segment operates a special authorized laboratory for monitoring and analyzing wastewater quality. In addition, our Industrial Products segment operates a facility in Neot Hovav for biological treatment of the plant's wastewater.

        A sanitary facility at the Bromine Compounds plant for the independent treatment of the sanitary effluents is being operated at the facility.

        Our Industrial Products segment has completed construction of an independent wastewater removal system at the Bromine Compounds plant. The system includes a piping system and the plant's own evaporation ponds. The system was built according to US standards, including leakage monitoring and air monitoring. In 2013, the construction was completed and all the plant's wastewater is presently being pumped into the new evaporation ponds.

        Our Industrial Products segment established a thickening and filtration facility to treat solid waste at the Periclase plant. The facility is in the test run stages.

        In 2013, the project for installation of technology helping to reduce free bromine in wastewater was completed, in accordance with the requirements of the Ministry's Division of Seas and Beaches.

        Our manufacturing facility at Neot Hovav contains solid waste. Pursuant to the requirements of the Ministry of Environmental Protection, that manufacturing facility is required to treat the existing waste and waste produced in ongoing operations. The treatment will take place, in part, at a restoration facility of hydro-bromine acid. After a re-examination, in 2013 we decided to increase the provision for treatment of waste in our financial statements by about $25 million, as a result of a change in estimate and the assignment of the waste treatment to third parties. Management estimates, as of the approval date of our audited financial statements, that the provision included in the financial statements is sufficient to cover the estimated cost of treating the historical waste. At this stage, prior to the planned commencement of the operation of the waste treatment facility, which is currently in the test-run stages, the waste is stored in a special site in coordination with the Israeli Ministry of Environmental Protection and will be treated in part by outside parties and in part by us. For more detailed information, see note 22 to our audited financial statements.

    Hazardous Substances

        As part of its activities, our various segments produce, store and use materials that are defined as hazardous materials according to the Israeli Hazardous Substances Law, 1993, under the requirements of a toxic substances permit issued by the Ministry of Environmental Protection. These materials include fuels, acids, sulfur, bromine, chlorine, ammonia and various organic compounds. Leakage or loss of control of these materials could cause an environmental incident and cause damage to people and to the environment. We take measures to prevent such occurrences, and, at the same time, prepare for such occurrences by means of emergency teams and appropriate equipment to deal with these types of events.

    Regulation of Concessions and Mining Activities

        For information about laws and legal arrangements related to our concessions and mining rights and other related licenses and permits, see "—Mineral Extraction and Mining Operations" and "—Other Leases, Licenses and Permits," respectively.

    Price Monitoring

        The prices of fertilizer-grade phosphoric acid for local Israeli customers are regulated under the Supervision of Prices for Commodities and Services Law 1996. The quantity of these products sold in Israel by our Fertilizers segment is not material to us.

        We and some of our subsidiaries have been declared a monopoly in Israel in the following areas: potash, phosphoric acid, sulfuric acid, ammonia, chemical fertilizers, phosphates, bromine and bromine

173


Table of Contents

compounds. Due to their having been declared monopolies, we are subject to limitations set forth in Chapter 4 of the Restrictive Business Practices Law, 1988, most significantly its prohibition on monopolies against abusing their positions as monopolies. In the first half of 2014 and in 2013, approximately 5% of our revenue derived from Israeli sales and, therefore, in our estimation, the abovementioned declaration has not had a material impact on us. We also have an internal antitrust compliance program.


Employees

        As of June 30, 2014, we had a workforce of 12,275 employees. Of these, 50 were employed at our headquarters and the balance were employed by our various subsidiaries.

    Breakdown of Employees by Area of Activity

 
  2013   2012   2011  

Production

    9,070     8,981     8,756  

Marketing and sales

    1,416     1,351     1,337  

Management & administration

    1,250     1,134     1,114  

Research and development

    416     410     407  

Total employees

    12,152     11,876     11,614  

    Breakdown of Employees by Segment

 
  2013   2012   2011  

Fertilizers

    6,073     5,920     5,777  

Industrial Products

    2,637     2,621     2,647  

Performance Products

    2,992     2,887     2,755  

Other (includes employees of DSM and ICL management)

    450     448     435  

Total employees

    12,152     11,876     11,614  

    Geographic Breakdown of Employees

 
  2013   2012   2011  

Israel

    5,238     5,198     5,089  

Germany

    1,317     1,267     1,270  

Spain

    1,205     1,215     1,160  

UK

    1,156     1,062     1,037  

Netherlands

    462     450     435  

USA

    1,121     1,080     1,040  

China

    621     606     567  

France

    351     350     358  

Brazil

    132     96     102  

Other

    549     552     556  

Total employees

    12,152     11,876     11,614  

        We began to implement an efficiency plan at Rotem near the end of 2012. The purpose of the efficiency plan is to reduce our production costs in order to improve our competitive position. The efficiency plan in 2013 included, among other things, the early retirement of approximately 115 of our employees. As of the date of this prospectus, all of our employees have agreed to the plan. We expect to take steps to complete the implementation of the efficiency plan in the near future. In 2012 and 2013, we recorded an expense in the amount of approximately $60 million and $33 million, respectively, relating to early retirement at Rotem.

174


Table of Contents

        In the first half of 2014, we continued the planning for the establishment of joint service centers in Israel and Europe. The service centers in Europe and in Israel will provide services to all our companies in Europe and Israel, respectively. The activities to be included in these service centers include accounting and finance, human resources, information technology, procurement and legal. Establishment of these service centers is expected to contribute to the implementation of process consolidation in the Company and improvement of internal governance, and is also expected to give rise to cost savings, mainly as a result of savings related to procurement costs and the reduction in the number of personnel presently existing in such departments.

        In most of our subsidiaries in Israel, labor disputes have been announced or have been recently completed, mainly due to the efficiency plan and other strategic plans that we are implementing, as well as our planned Israeli service center. In some of our production facilities in Israel, our employees have taken retaliatory measures. For example, a strike at our Rotem subsidiary in Israel recently ended. These labor disputes could result in continuation of these retaliatory measures and even to a complete shutdown of production. It takes time to return to full capacity production in all facilities.

    Employment Agreements, Collective Bargaining Agreements and Temporary Employees

        ICL employees in Israel are employed under collective or personal employment agreements. The collective bargaining agreements are signed for specified terms and are renewed from time to time. By law, in the event a new collective bargaining agreement is not signed, the terms of the original agreement are extended for a period of an additional year or for an unlimited term, as the case may be, unless one party gives the other notice of cancellation. As of the date of this prospectus, no notice of cancellation had been given for any of the collective bargaining agreements referred to above.

        Dead Sea Works, Rotem, Fertilizers and Chemical Materials Ltd. ("FCM"), Dead Sea Magnesium and Bromine Compounds have collective bargaining agreements with termination dates ranging from July 2016 to the end of 2018.

        Senior employees in special positions and members of management are employed under personal agreements. These agreements are not limited by time and can be terminated with prior notice of a few months.

        Local employees of our subsidiaries overseas are employed according to the employment terms prevalent in the countries in which they are employed. Most of our overseas employees, primarily in Germany, the Netherlands, the United Kingdom, Spain and the United States, are employed under collective bargaining agreements.

        A relatively limited number of the employees at our sites in Israel are employed by personnel agencies for short terms. In addition, we have contracted in Israel with subcontractors for various outsourcing services such as security, packaging, maintenance, catering, cleaning and other services. In accordance with the decision of the boards of directors of ICL and its Israeli subsidiaries in October 2004, contractors who employ workers at our plants in Israel are required to give employees working on a regular basis for ICL salary terms beyond those required by law. Pursuant to this decision, the employers are obligated to grant these employees, in addition to current salary that must be at least 5% higher than the minimum wage stipulated by law, pension contributions, severance pay contributions, vacation pay, uniforms and meals.

        On July 11, 2013, a collective bargaining agreement was signed between the Organization of Cleaning Companies in Israel setting the salary and employment conditions of the employees of these companies. The agreement applies to employers in the cleaning and maintenance sector in Israel that are members of the Organization of Cleaning Companies.


Legal Proceedings

        In addition to the specific legal proceedings referred to below, a number of other claims are pending against the Company and various subsidiaries (including lawsuits), amounting to about $65 million in the

175


Table of Contents

aggregate as of December 31, 2013. We have recorded provisions in a total amount of about $6 million on account of such claims. In addition, part of these claims are covered by insurance policies. In the opinion of our management, the provisions recorded adequately reflect the exposure presented by these claims to the Company and its relevant subsidiaries.

    Tax Proceedings

        On December 29, 2013, an assessment was received from the Israeli tax authorities whereby we are required to pay additional tax beyond the amount we already paid for 2009 to 2011 in the amount of approximately $230 million. The assessment did not apply to prior years because we have a formal agreement with the tax authorities with respect to our taxes through 2008. The primary contention of the tax authorities is that our subsidiaries, Dead Sea Works and Rotem, are not entitled to benefits under the Law for Encouragement of Capital Investments commencing from the date on which Amendment No. 60 to this law entered into effect in 2005. We disagree with the position of the tax authorities and we have appealed the assessment of the tax authorities. No tax expenses were included in our financial statements as a result of the assessment.

    Dead Sea Works Proceedings

    Dead Sea Works Sheshinski Committee Arbitration

        The Israeli Minister of Finance, Mr. Yair Lapid, has established a public committee, headed by Professor Eytan Sheshinski, for examination of the policy with respect to the royalties received by the State of Israel from private entities, including us, for use of national natural resources such as potash and phosphate. The committee is required, among other things, to examine the royalties policy from a broad perspective, while making reference to the impacts on the present agreements between the various parties engaged in these matters and the State of Israel.

        Our position is that there is no room for imposing any type of additional royalties on us. On November 4, 2013, we submitted our position in writing to the committee. On December 3, 2013, we contacted the Israeli Minister of Finance in order to request that the matter be excepted from the committee's letter of appointment; however, our request was denied. On December 16, 2013, our representatives appeared before the committee members. On March 18, 2014, Dead Sea Works notified the Israeli government of its intention to file a claim in the framework of an arbitration proceeding in connection with breach of its concession agreement, which provides Dead Sea Works, among other things, the exclusive right to produce from the Dead Sea quarries. Dead Sea Works also gave notice of appointment of an arbitrator on its behalf and requested appointment of an arbitrator on behalf of the State of Israel. On March 27, 2014, the Israeli Ministry of Finance notified us that it has rejected Dead Sea Works's request to appoint an arbitrator on behalf of the State of Israel. The Israeli Ministry of Finance contends that the establishment of the committee falls with the State of Israel's administrative authorities and does not constitute a disagreement or dispute between the parties according to the concession agreement. The State of Israel further argues that an arbitration panel is not the appropriate forum for challenging the establishment of the committee and its work and that the establishment of the committee does not fall under the relevant clause in respect of which the parties may turn to arbitration. We believe that the arbitration claim concerns a monetary claim under the concession agreement that was anchored by law and, in accordance with such law, Dead Sea Works demands compensation for all damages that have been and will be caused as a result of the breach of the agreement by the State of Israel. Since the Israeli Ministry of Finance has rejected Dead Sea Works's request to appoint an arbitrator, on April 30, 2014, Dead Sea Works filed a request in the Jerusalem District Court that such court exercise its power under section 8 of the Israeli Arbitration Law, 5728-1968 and order the appointment of an arbitrator on behalf of the State of Israel for the purpose of managing the arbitration process between Dead Sea Works and the State of Israel in accordance with the binding arbitration arrangements between the parties. A court hearing was held on July 10, 2014 but the Court's decision has not yet been received.

176


Table of Contents

        On May 18, 2014, the committee released its draft recommendations for public comments. For a description of the draft recommendations, see "Business—Mineral Extraction and Mining Operations—Concessions and Mining Rights—Israel."

        We believe the State of Israel's conduct in taking unilateral steps to re-examine the consideration Dead Sea Works is to pay in respect of the rights granted to it in its concession agreement constitutes a violation of the concession agreement that is embedded in the Concession Law. The Concession Law provides, among other things, that every doubt, disagreement or dispute that arises between the parties to the concession agreement is to be resolved by means of an arbitration proceeding. In addition, we believe the State of Israel's conduct constitutes a violation of its duty to act in a customary manner and in good faith when fulfilling the obligations and utilizing the rights deriving from the concession agreement, and ignores the significant provisions of the concession agreement that anchor the consents of the State of Israel and Dead Sea Works with reference to the full consideration Dead Sea Works will pay to the State of Israel in respect of the right granted to it relating to the quarries at the Dead Sea. In light of these violations, Dead Sea Works believes that it has a right to compensation regarding all the damages that have been and will be caused as a result of the State of Israel's conduct.

    Dead Sea Works Royalties Arbitration

        For a description of the arbitration proceeding between Dead Sea Works and the State of Israel relating to the calculation of royalties and a summary of the arbitration panel's decision with respect to the first phase of that proceeding, see "Business—Mineral Extraction and Mining Operations—Concessions and Mining Rights—Israel."

        On June 10, 2014, the Israel Securities Authority (the "ISA") rejected a petition from C.F.A. Drilling Ltd. to compel us to publish the full partial award of the arbitration panel on our website. Following this rejection, C.F.A. Drilling Ltd., which claims to be one of our shareholders and is also the plaintiff seeking certification of a class action against us (see "—Securities Law Proceedings" below), filed an economic administrative petition on June 24, 2014 with the Economic Department of the District Court of Tel Aviv to overrule the ISA's decision and to compel us to publish the full decision. Together with our legal advisors, we are reviewing this petition.

    Dead Sea Works Litigation

        In a petition filed by the Hotels Union in Israel in November 2013, the court rejected the request to issue an interim order preventing raising of the dike by the Government Company for Protection of the Dead Sea Ltd. that was intended to protect the western coast of Pond 5 (where a number of hotels are located) against a rise in the water level of Pond 5. A hearing was scheduled for September 15, 2014 with respect to the petition of the Hotels Union for an order requiring the defendants to explain why the building permit relating to the raising of the dike should not be revoked. However, the petition was dismissed on September 10, 2014.

        On May 1, 2014, some of the hotels in the Dead Sea area filed a separate administrative petition and a request for issuance of an interim order (in the District Court for Jerusalem) against the Regional Planning Board and the Company for the Protection of the Dead Sea (the respondents), or injunctive orders prohibiting the Regional Planning Board from hearing the request for a building permit for raising the dikes in the area of Nevei Zohar and a prohibition against performance of the work on the Nevei Zohar beaches by the Company for Protection of the Dead Sea. In this petition, we are not named as a respondent. On June 1, 2014, a hearing was held wherein the Court gave the force of a court decision to the compromise proposed as part of the separate petition, whereby the Company for Protection of the Dead Sea will be required to provide the petitioners documents and plans in connection with the request for a building permit, and the petitioners are to submit their responses to the plans, as stated, which will be restricted solely to the matter of the timetables and the manner of execution of the plan and where no

177


Table of Contents

objections will be heard regarding the height of the dike and the height of the water level. No interim order was issued.

        Delays in raising the dikes may prevent the raising of water level in Pond 5 and consequently may cause a reduction in our production capacity.

    Personal Injury Claims

        During the 1990s, several claims were made against some of our subsidiaries by plaintiffs from various countries who worked mostly as banana plantation workers, who allegedly have been injured by exposure to Di-Bromo-Chloropropane ("DBCP") produced many years ago by a number of manufacturers, including large chemical companies and, according to the plaintiffs, some of our subsidiaries. As of December 31, 2013, our subsidiaries are parties to one legal proceeding by nine plaintiffs who are requesting certification of their claim as a class action. The claim is for bodily injury and therefore the amount of claimed damages has not been stated. We believe the quantities of materials supplied by us to the relevant countries in the relevant periods was, if at all, small compared to the quantities of material sold by other chemical manufacturers.

        In the opinion of management and our legal advisors, it is not possible to estimate the results of the above claims. Nonetheless, it is estimated that our overall exposure would not exceed $20 million.

    Environmental Claims

    Kishon River Wastewater Matters

        The production site of FCM, a company in our Fertilizers segment, borders the Kishon River. For decades FCM, along with many other entities, municipalities and plants, has diverted wastewater to the Kishon River.

        Between 2001 and 2005, a number of claims for monetary damages were filed in the Haifa District Court against FCM and a series of other defendants (including the State of Israel) by 50 individuals (or their heirs or dependents), most of them fishermen who had worked, according to the claims, in the Kishon's fishing harbor. According to the plaintiffs, the flow of sewage to the Kishon River by each of the chemical plants operating on the river banks has caused the plaintiffs' cancer and other illnesses. Dozens of factories, local governments and insurance companies were added as third-party defendants. In the course of examining the claims, ten plaintiffs withdrew their claims, which were dismissed.

        On November 3, 2013, a court judgment was rendered rejecting the plaintiffs' claim for damages. On February 9, 2014, the court issued a decision regarding the legal fees. In its decision, the court charged all the plaintiffs for the defendants' costs, in the amount of about NIS 4.6 million. Of the total expenses charged to the plaintiffs, it was determined that an amount of more than NIS 1.1 million is to be paid to FCM. The plaintiffs requested from the court to extend the date in order to file an appeal on their behalf.

        Based on the evaluation of its legal advisors, and in light of the court's detailed and reasoned decision, the Company estimates that the chances of the appeal succeeding (if ultimately filed) are unlikely.

        Between 2000 and 2007, a number of claims were filed in the District Court at Haifa against a list of defendants by former soldiers (and their heirs and dependents). The plaintiffs claim that contact with toxic substances in and around the Kishon River caused them cancer and other diseases. Several dozen factories (including FCM), local governments, including the State of Israel, and insurance companies were joined as third-party defendants.

        On June 17, 2013, a court decision was rendered rejecting the claim for damages of 72 former soldiers (and their heirs and dependents) in the consolidated cases (one claim was rejected at the hearing and another 16 non-consolidated cases remain). On November 24, 2013, the plaintiffs filed an amended notice of appeal with the Israeli Supreme Court. Based on the evaluation of our legal advisors, and in light of the court's detailed and reasoned decision, we estimate that the chances of an appeal succeeding are unlikely.

178


Table of Contents

        On February 23, 2014, a court hearing was held in connection with the claims in the unconsolidated cases and it was decided to stay the hearing until the Supreme Court renders its decision with reference to the appeal filed with respect to the consolidated cases. Based on the evaluation of our legal advisors, and based on the court's holdings with respect to the consolidated cases, we estimate that the chances that the claim will be accepted in the unconsolidated cases are unlikely.

    Neot Hovav Pollutant Matters

        Three claims were filed with the District Court at Beer Sheva in March and June 2007 against the State of Israel and the Industrial Local Council at Neot Hovav, in whose jurisdiction the Neot Hovav plants operate, including the plants of our Industrial Products segment. The plaintiffs argue that various pollutants in the vicinity of Neot Hovav have caused their illnesses, including, among other things, respiratory diseases, spontaneous abortion, birth defects, diseases of the nervous system, cancer, and other illnesses. The claims rely, among other things, on results of an epidemiological study. The claims sue for sums for treatment expenses incurred by the plaintiffs, as well as compensation for pain and suffering, distress, and punitive damages. The plaintiffs are suing for a total sum of approximately $69 million.

        In May 2008, the Local Council filed a third party notice against a number of plants at Neot Hovav, including factories of our Industrial Products segment. In December 2008, the State of Israel also filed a third party notice against the same factories. The notices alleged that if the Council or the State of Israel is held to be liable to compensate the defendants, then the liability for compensation must be imposed on the plants, or they must be required to indemnify the Council or the State of Israel for any compensation that they are required to pay to the plaintiffs.

        On January 9, 2013, a judgment was rendered rejecting the claim against the defendants, including ICL's plants.

        On February 20, 2013, the plaintiffs filed an appeal with the Supreme Court. In the Company's estimation, based on the assessment of its legal advisors, the chances that the appeal will be accepted are unlikely and, accordingly, no provision was included in the financial statements.

    Spain Mining License Matters

        Our subsidiary in Spain, Iberpotash, has two potash production sites in the towns of Suria and Sallent. As a by-product of the potash production process, salt is produced and heaps up in piles. Most of the piled up salt is not usable. Every eight years (as is true for every other company in Spain), Iberpotash is required to obtain the renewal of the previously approved environmental license. The two sites received environmental licenses that are valid up to 2015 and 2016 (subject to the proceeding described in the paragraph below). Regarding the license to pile up salt on the site, with respect to the first site in the town of Suria, there is room to pile up salt that is sufficient for approximately 13 years (up to 2026) at the current production level; with respect to the second site in the town of Sallent, where we intend to discontinue mining activities by the end of 2015, there is room to pile up salt that is sufficient, at the current level of production, for an additional year and a half. In February 2014, the regional court determined that the permit given by the Generalitat (the regional government) to Iberpotash was not in compliance with the requirements to perform salt piling in the site. The court's determination is not final, and the Generalitat and Iberpotash have appealed to the Spanish Supreme Court. We estimate that the legal process will last much more than one year. As result, we do not expect there to be a significant impact on our Spanish mining operations since we expect to close the Vilafruns mine at Sallent by the end of 2015.

        In October 2013, a regional court decision was rendered cancelling the environmental mining license of a subsidiary in Spain at Vilafruns, based on the contention that the license granted by the government had deficiencies. The company and the regional government filed an appeal to the Spanish Supreme Court. The company is endeavoring to obtain a permit that will rectify the deficiencies described in the court decision. We expect that this site will be closed before the legal process finishes.

179


Table of Contents

        In a subsidiary in Spain located in the town of Suria, there are two legal proceedings being carried on against the government of Catalonia, each relating to the grant of urban and environmental approvals for our efficiency plan with respect to Iberpotash. As part of these proceedings, it was alleged that the project work requires a significant change in the environmental license and that the government must require the company to make an environmental impact survey. Accordingly, the plaintiffs are requesting termination of the project work. In February 2014, the company received from the Spanish Environmental Protection Authorities a favorable survey for the first stage of the efficiency plan with respect to the impact on the environment and approval of the Environmental Impact Declaration. This survey was a critical stage in the process for obtaining the renewal of the environmental license from the authorities, which was subsequently obtained in April 2014. We believe continuation of the legal proceeding has become superfluous now that the environmental license has been received.

    Securities Law Proceedings

        On August 29, 2013, a petition for certification of a claim as a class action against us, Israel Corporation, Potashcorp Cooperative Agricultural Society Ltd., the members of our Board of Directors and our CEO, was filed in the District Court in Tel Aviv, on the grounds of misleading information, deception and non-disclosure of material information in our reports, allegedly in violation of the provisions of the Israeli Securities Law and the general laws. The aggregate amount of the damage claimed is $0.79 billion (NIS 2.75 billion) or $0.95 billion (NIS 3.28 billion). In February 2014, a response to the petition was submitted and a hearing was set for July 2014 to determine whether to dismiss the case at the initial stages. This hearing was subsequently rescheduled for November 2014. In our opinion, based on the position of our legal advisors, even if the motion to dismiss is denied, the chances of our winning the case exceed the chances that we will lose. Accordingly, no provision was included in the financial statements.

    Commercial Proceedings

        In 2008, an agreement between Haifa Chemicals and Dead Sea Works was cancelled and the parties did not succeed in reaching a new agreement. Haifa Chemicals believed that the price Dead Sea Works demanded in exchange for potash was unfair, based on the contention that it was unable to operate at that price. In 2009, Haifa Chemicals notified its employees of a shutdown of the production lines at its factory until purchase of potash could be resumed at prices it deemed acceptable. At the same time, Haifa Chemicals contacted the Israeli Minister of Finance and the Israeli Minister of Industry, Commerce and Labor and requested that they use their authority to subject potash prices to supervision. The parties agreed in principle to appoint an arbitrator to set the price of potash. Arbitration began in May 2009 and in March 2014, the arbitration decision was issued.

        The decision includes a formula on the basis of which the selling price of potash between Dead Sea Works and Haifa Chemicals will be determined for a period of ten years from the date of the decision and with respect to the period from the commencement of arbitration. The price formula provides that the selling price during a quarter will be based on a price equal to the lower of the weighted average of the lowest three FOB selling prices of potash sold by Dead Sea Works in the prior quarter and the average of the two lowest FOB selling prices of potash sold by Dead Sea Works to large buyers (foreign buyers who purchase 150,000 or more tons per year) in the prior quarter, less certain expenses and a discount of 2%. In certain circumstances, this base price may be adjusted to equal the production cost plus approximately 15%. This adjusted price would apply to a certain quantity of the potash, while the base price would continue to apply to the remainder of the potash.

        In our estimation, based on the price formula set forth in the arbitration decision, we are entitled to receive payments in respect of prior periods. Haifa Chemicals continues to resist making such payments and has made other claims against us seeking offsetting monetary amounts as part of this effort.

180


Table of Contents


MANAGEMENT

Directors and Senior Management

        The following table lists the names and ages of our directors. The address for our directors is c/o Israel Chemicals Ltd., 23 Aranha Street, Millennium Tower, Tel Aviv, 61070, Israel.

Name
  Age   Position

Nir Gilad

    57   Chairman of the Board of Directors

Yaacov Dior

    69   Director

Ovadia Eli

    69   Director

Chaim Erez

    78   Director

Dr. Miriam Haran

    64   Director

Victor Medina

    75   Director

Prof. Yair Orgler

    74   Director

Avisar Paz

    57   Director

Eran Sarig

    40   Director

Avraham (Baiga) Shochat

    78   Director

Aviad Kaufman

    43   Director

        All of our directors are independent under the rules applicable to U.S. companies listed on the NYSE, except for Messrs. Nir Gilad, Avisar Paz, Eran Sarig and Aviad Kaufman by virtue of the positions they hold with our controlling shareholder. Six of our directors are not considered independent directors under Israeli law due to either a relationship with our controlling shareholder or the length of their tenure on our Board of Directors. Three of our directors are "external directors" and an additional two directors were designated as "independent directors" under the Israeli Companies Law, 1999 (the "Companies Law") as described below under "—External Directors."

        The following table lists the names, ages and positions of our senior management. The address for our senior management is c/o Israel Chemicals Ltd., 23 Aranha Street, Millenium Tower, Tel Aviv, 61070, Israel.

Name
  Age   Position

Stefan Borgas

    49   Chief Executive Officer

Avi Doitchman

    52   Executive Vice President, Chief Financial Officer & Strategy, Manager of Market Risk Management

Nissim Adar

    62   Chief Executive Officer of our Fertilizers segment

Eli Amit

    59   Senior Vice President of Economics

Herzel Bar-Niv

    64   Vice President of International Taxation

Amir Benita

    40   Vice President of Accounting

Shmuel Daniel*

    63   Internal Auditor

Dan (Dani) Chen

    62   Executive Vice President of Corporate Relations

Israel Dreyfuss

    33   Controller

Eyal Ginzberg

    51   Chief Technology Officer

Asher Grinbaum

    64   Executive Vice President & Chief Operating Officer

Michael Hazzan

    48   Vice President of Finance

Lisa Haimovitz

    48   Vice President, General Counsel and Corporate Secretary

Hezi Israel

    46   Vice President of Business Development and Strategy

Ofer Lifshitz

    55   Senior Vice President for Global Processes

Yakir Menashe

    42   Senior Vice President of Human Resources

Osnat Sessler**

    46   Vice President of Investor Relations and Communications

Ronnie Shushan

    46   Senior Vice President for Investments and Project Management

Mark Volmer

    50   Chief Executive Officer of our Performance Products segment

Charles M. Weidhas

    55   Chief Executive Officer of our Industrial Products segment

*
On July 31, 2014, Shlomo Ben-Shimol ceased serving as the Internal Auditor, and on August 1, 2014, Shmuel Daniel commenced serving as the Internal Auditor.

**
Osnat Sessler ceased to serve in this position as of March 18, 2014.

181


Table of Contents

        Nir Gilad.     Mr. Gilad has served as Chairman of our Board of Directors since January 2008. Mr. Gilad also serves as President and Chief Executive Officer of Israel Corporation. He is also Chairman of the Boards of Directors of H.L. Management and Consulting (1986) Ltd., IC Green Energy Ltd. and OPC Rotem Ltd. Previously, he served as Deputy Chief Executive Officer of Israel Corporation, Deputy Chief Executive Officer of Migdal Insurance and Financial Holdings Ltd., Chief Executive Officer of Migdal Investments Management (2001), Chairman of Migdal Capital Markets, Accountant-General of the Israeli Ministry of Finance and Chief Financial Officer of Israel Aircraft Industries Ltd. Mr. Gilad serves as a director in companies fully owned by Israel Corporation, observing director in IC Power Israel Ltd. and director in Tower Semiconductor Ltd. and Qoros Automotive Co. Ltd. (formerly known as Chery Quantum Auto Co. Ltd. 2007). Mr. Gilad holds a B.A. in Economics and Agricultural Administration from the Hebrew University, Jerusalem and an MBA, majoring in Finance, in Business Management from Bar Ilan University.

        Yaacov Dior.     Mr. Dior has served as a director since October 2011. Mr. Dior was Chief Executive Officer of IDT Carmel LTD and Chairman of the Board of Kneh Hakol Ltd. He is an External Director of Clal Insurance Holdings Ltd. and has served as Chairman of the Boards of Directors of Cellarix Mobile Payments Ltd. (up to January 21, 2013). Mr. Dior was the Chief Executive Officer of Visa from 1988 to 1995 and was a member of the Board of Directors of Israel Credit Card Ltd. (Visa CAL). He was Chief Executive Officer of Visa Alpha from 1995 to 2000. Mr. Dior is a Member of Friends of Bar-Ilan University and Chairman of the Audit Committee of Bar-Ilan University. In addition, Mr. Dior is a Member of the Public Committee of Alut—the National Association for Autistic Children and a Member of the Association of Friends of Meir Hospital. Mr. Dior holds a B.A. in Economics and Political Science from the Hebrew University of Jerusalem and an MBA from Tel Aviv University.

        Ovadia Eli.     Mr. Eli has served as a director since August 2011. Mr. Eli has served as Chairman of the Board of the Israel Airports Authority, Shmanim Basisiim Haifa Ltd. (until May 31, 2011) and I.C.P.I. He is a Director of Salt Industries Israel Ltd. and Shaarei Ribit, Ltd. Mr. Eli serves as a director of Zim Integrated Shipping Services Ltd., OPC Rotem Ltd., IC Power Israel Ltd., IC Power Ltd. and Adriel Israel Properties Ltd. Mr. Eli holds a BA from the University of Haifa and is a graduate of the Lifshitz Teachers Academy, Jerusalem.

        Chaim Erez.     Mr. Erez has served as a director since February 1996 and has served as a director of several public companies. Between 1988 and 1996, he served as Chief Executive Officer of our Company and as Chairman of the Board of several of our subsidiaries. He was also a research fellow in the area of company privatization and local government at the London School of Economics. Mr. Erez has served as Chairman of the Armored Corps Memorial Site and Museum in Latrun and as a director at Africa-Israel Investments Ltd., Eldan-Tech Ltd. and Anglo Israel Control Systems (1998) Ltd. Mr. Erez holds a BA in History from Tel Aviv University and an MA in Political Science from Haifa University.

        Dr. Miriam Haran.     Dr. Haran has served as a director since September 2009. Dr. Haran has served as Director General of Israel's Ministry of the Environment. Dr. Haran serves as the head of Ono Academic College's MBA Program in Environmental Management, consultant for Ashkelon-Eilat Pipeline Ltd. and board member of the Company for Environmental Services (2008-2012). Dr. Haran also serves as Chairman, Consumer Council, and Board member in M.A.I (recycling electrical and electronic waste). Dr. Haran holds a Ph.D in Organic Chemistry from Brandeis University and a B.Sc. in Natural Sciences from the Hebrew University of Jerusalem.

        Victor Medina.     Mr. Medina has served as a director since September 2006. Mr. Medina has served as Chief Executive Officer of United Mizrahi Bank Ltd. Between 1990 and 1995, he served as Chairman of our Board of Directors. He previously served as Director-General of the Israeli Ministry of Finance. He has held senior positions in the Bank of Israel, inter alia as a member of the bank's senior management with responsibility for the Monetary Department, the Foreign Currency Supervision Department and the Credit Department. Mr. Medina serves as the Chairman of the Boards of Directors of Migdal Capital

182


Table of Contents

Markets and Aptateck Ltd. Mr. Medina holds a BA in Economics and Political Sciences and an MA in Economics, majoring in Finance and Banking, from the Hebrew University of Jerusalem.

        Prof. Yair Orgler.     Prof. Orgler has served as a director since September 2006. Prof. Orgler has served as Professor of Finance and Banking, Dean of the Faculty of Management and Vice Rector of Tel Aviv University. He has published and edited ten books in his areas of specialization as well as dozens of scientific and professional articles. He served for ten years as the Chairman of the Board of the TASE. Prof. Orgler founded and served as an active Chairman of Maalot Israel first Securities Rating Company Ltd. He has served and serves as director of various additional public companies. Prof. Orgler is Chairman of the Finance and Audit Committee of the Israel Cancer Association and Professor Emeritus at Tel Aviv University. Prof. Orgler served as an outside director in Bank Hapoalim Ltd. (2007-2010) and Itamar Medical Ltd. (2007-2013). He is an outside director in Gazit-Globe Ltd. and a director in Ceragon Networks Ltd. and Atidim-High-Tech Industrial Park Ltd. Prof. Orgler also is a member of the management committee of Academic College of Tel Aviv-Yaffo, Secure Future, Association of Public Companies and Friends of the Reut Medical Center. Prof. Orgler holds a B.Sc. in Industrial Engineering and Management from the Technion-Israel Institute of Technology in Haifa, an M.Sc. in Industrial Engineering from the University of Southern California (USC) and a Ph.D. in Industrial Administration from Carnegie Mellon University, Pittsburgh.

        Avisar Paz.     Mr. Paz has served as a director since April 2001. Mr. Paz serves as the Chief Financial Officer of Israel Corporation and as a director of various subsidiaries. Mr. Paz previously served as Chief Financial Officer and Controller of another company. He serves as a director of Oil Refineries Ltd. Mr. Paz holds a BA in Economics and Accounting from Tel Aviv University and is a certified public accountant in Israel.

        Eran Sarig.     Mr. Sarig has served as a director since October 2010. Mr. Sarig serves as Executive Vice President of Business Development and Strategy of Israel Corporation and from 2007 to 2010 served as Director of Corporate Business Development, Teva Pharmaceutical Industries Ltd. He serves as a director of Oil Refineries Ltd. and IC Power Ltd. He holds an LLB from Tel Aviv University School of Law, LLM from Duke University School of Law and MBA from the Herzliya Interdisciplinary Center.

        Avraham (Baiga) Shochat.     Mr. Shochat has served as a director since January 2006. Mr. Shochat has served as Minister of Finance in Israel, as Chairman of the Knesset Finance Committee and in additional positions in the Israeli government and the Knesset. He has served and serves as director in a number of public and private corporations and has also served as Mayor of the Arad Local Council. Mr. Shochat has served as advisor to the CEO of Baran Group Ltd. (up to January 2008), Chairman of the Investments Committee of the Israel Infrastructure Fund and director of Mizrahi Tefahot Bank Ltd. (until September 2012). Mr. Shochat serves as Chairman of the Board, Citipass Ltd. and as a director of Alon USA, Direct Insurance-Financial Investments Ltd., Israel Infrastructure Fund, Sian Holdings Enterprises Ltd., Bituach Yashir Financial Holdings and Carasso Motors Ltd. and is a Trustee on the Board of trustees of Tel Hai Academic College and a member of the Israel Science Foundation. Mr. Shochat holds a B.Sc. in Civil Engineering from the Technion-Israel Institute of Technology in Haifa.

        Aviad Kaufman.     Mr. Kaufman has served in his current position since March 2014. He is the Chief Financial Officer of Quantum Pacific (UK) LLP and a director of Israel Corporation, Lynav Holdings Ltd., Lynav Maritime Ltd. and Marabel II Ltd. Mr. Kafuman is an accountant and has a BA in Economics and Accounting from the Hebrew University and an MBA majoring in Finance from Tel Aviv University.

        Stefan Borgas.     Mr. Borgas has served in his current position since September 2012. Mr. Borgas previously served as Chief Executive Officer of Lonza-Group (2004 to 2012) and is a director at Syngenta Group. He holds a BA in Business Administration from the University of Saarbrucken (Germany) and an MBA from the University of St. Gallen (Switzerland).

        Avi Doitchman.     Mr. Doitchman has served in his current position since February 2000. He is a director of Rotem, Dead Sea Works, Dead Sea Bromine Company, Bromine Compounds, IDE, ICL Fine

183


Table of Contents

Chemicals Ltd., Ferson Chemicals Ltd. and PAMA (Energy Resources Development) Ltd. and is a member of the Executive Committee of the Public Companies Association. Mr. Doitchman holds a BA in Accounting from Bar Ilan University. He is a certified public accountant in Israel.

        Nissim Adar.     Mr. Adar has served in his current position since October 2013. Mr. Adar previously served as Chief Executive Officer of our Industrial Products segment (2008 to October 2013) and is currently Chairman of Tami. Mr. Adar holds a BA in Chemical Engineering and MBA in Industrial Management from Ben Gurion University of the Negev.

        Eli Amit.     Mr. Amit has served in his current position since January 2002. He is the Chairman of the board of directors of Dead Sea Magnesium and is a director at Dead Sea Works, Rotem, Dead Sea Bromine Company and Bromine Compounds. Mr. Amit holds a BA in Economics and Philosophy and an MBA from Tel Aviv University, as well as an MA in Economics from Northwestern University.

        Herzel Bar-Niv.     Mr. Bar-Niv has served in his current position since January 2008. Mr. Bar-Niv has served as the Controller of the Company, and as the chairman of the audit committee at Makefet Fund. Mr. Bar-Niv holds a BA in Economics and Accounting from Bar llan University. He is a certified public accountant in Israel.

        Amir Benita.     Mr. Benita has served in his current position since July 2007. Mr. Benita has served as controller of the Company and as senior lecturer in accounting studies at the College of Management. He serves as a director of Dead Sea Magnesium. Mr. Benita holds a BA in Business Management and Accounting from the College of Management and is a certified public accountant in Israel.

        Shmuel Daniel.     Mr. Daniel has served in his current position since August 2014. Mr. Daniel previously served as Chief Financial Officer of our Industrial Products segment (2011 to 2014). He holds a BA in Economy and Statistics, and Accounting from the Ben-Gurion University. He is a certified public accountant in Israel.

        Dan (Dani) Chen.     Mr. Chen has served in his current position since October 2013. Mr. Chen was Chief Executive Officer of our Fertilizers segment until October 2013. He holds a BA in Electrical Engineering from the Technion-Israel Institute of Technology in Haifa and an MA in Industrial Management from Ben Gurion University of the Negev.

        Israel Dreyfuss.     Mr. Dreyfuss has served in his current position since June 2012. Mr. Dreyfuss has served as an accountant with Phoenix Insurance Agency, and worked in the Corporate Department of the Israel Securities Authority. He has also been a lecturer at the Hebrew University. Mr. Dreyfuss holds a BA in accounting and law and an MBA from the Hebrew University of Jerusalem. He is a certified public accountant and attorney in Israel.

        Eyal Ginzberg.     Mr. Ginzberg has served in his current role since June 2013. Mr. Ginzberg has served as Chief Executive Officer of F&C and IMI Research, as well as the Chief Executive Officer of Fertilizers & Chemicals Ltd. Mr. Ginzberg holds a BA in Chemical Engineering from Ben Gurion University of the Negev.

        Asher Grinbaum.     Mr. Grinbaum has served in his current position since January 2008. He has served as a director at Dead Sea Works, Rotem, Dead Sea Bromine Company and Bromine Compounds and has served as chairman of the management committee of Beersheba Theatre. He has also served as a member of the management committee of Israel Chemical Society and of the management committee of the "To See" Association. He holds a BA in Mechanical Engineering and an MA in Business Management, both from Ben Gurion University of the Negev.

        Michael Hazzan.     Mr. Hazzan has served in his current position since March 2012. Mr. Hazzan served as the Finance Manager of the Company. He is a director of Ferson Chemical Materials Ltd., ICL Fine Chemicals Ltd., IDE and Dead Sea Magnesium. Mr. Hazzan holds a BA in Economics from Tel Aviv University and an M.A. in Economics from Bar llan University.

184


Table of Contents

        Lisa Haimovitz.     Ms. Haimovitz has served in her current position since May 2009. Ms. Haimovitz has also served as the Vice President for Strategy in the Delek Group. She holds an LLB and an MBA from Tel Aviv University and is a member of the Israel Bar.

        Hezi Israel.     Mr. Israel has served in his current position since March 2012. Mr. Israel has served as the Vice President of Strategy and Business Development for the Company's Industrial Products segment. He holds an MBA and a BA in Economics and Political Science from Tel Aviv University.

        Ofer Lifshitz.     Mr. Lifshitz has served in his current role since June 2013. Mr. Lifshitz previously served as our Industrial Products segment's Deputy Chief Executive Officer (2008 to 2013). Mr. Lifshitz holds a BA in Economics and MBA in Industrial Management from Ben Gurion University of the Negev.

        Yakir Menashe.     Mr. Menashe has served in his current position since March 2012. Mr. Menashe has served as a Vice President of Regulatory Affairs and Assistant to the Chief Executive Officer of the Company. His a director of Dead Sea Magnesium. Mr. Menashe holds a BA in Law from the College of Management. He is a licensed attorney in Israel.

        Osnat Sessler.     Ms. Sessler served as the Vice President of Investor Relations and Communications from January 2003 until March 18, 2014. Ms. Sessler holds a BA in Economics from UCLA and an MBA from Yale University. In August 2013, Ms. Sessler was appointed to set up the European Service Center under the authority of Mr. Eli Glazer, in his position as Chief Executive Officer of ICL Europe.

        Ronnie Shushan.     Mr. Shushan has served in his current position since May 2014. Mr. Shushan previously served as CEO, ICL Fertilizers Europe (2012 to 2014) and Senior Vice President of Finance, ICL Fertilizers (2008 to 2012). Mr. Shushan holds a BA in Economics and Accounting from Ben Gurion University of the Negev.

        Mark Volmer.     Mr. Volmer has served in his current position since November 2013. Mr. Volmer has served as a business executive with BASF, heading its Construction Chemicals business in Asia Pacific. Mr. Volmer holds an M.Sc. in Chemistry from Vrije University and an MBA from the Rotterdam School of Management, Erasmus University.

        Charles M. Weidhas.     Mr. Weidhas has served in his current position since October 2013. He previously served as the Chief Executive Officer of our Performance Products segment (November 2007 to October 2013). Mr. Weidhas holds a B.Sc. in Chemical Engineering and an MBA from Northeastern University.

    Family Relationships

        There are no family relationships between any members of our executive management and our directors.

    Arrangements for Election of Directors and Members of Management

        There are no arrangements or understandings with major shareholders, customers, suppliers or others pursuant to which any of our executive management or our directors were selected.


Corporate Governance Practices

        We are incorporated in Israel and therefore subject to various corporate governance requirements under the Companies Law relating to such matters as external directors, the audit committee, the compensation committee and the internal auditor. These matters are in addition to the requirements of the NYSE and relevant provisions of U.S. securities laws that will apply to us following this offering. As a foreign private issuer whose shares will be listed on the NYSE in connection with this offering, we have the option to follow certain Israeli corporate governance practices rather than those of the NYSE, except to the extent that such laws would be contrary to U.S. securities laws and provided that we disclose the

185


Table of Contents

practices that we are not following and describe the home country practices we follow instead. We intend to rely on this "foreign private issuer exemption" with respect to the following NYSE requirements:

    Nominating/Corporate Governance Committee.   Under Section 303A.04 of the NYSE Listed Company Manual (the "LCM"), a U.S. domestic listed company, other than a controlled company, must have a nominating/corporate governance committee composed entirely of independent directors. We are a controlled company, so we would be exempt from this requirement under U.S. law. Our controlling shareholder, Israel Corporation, has significant control over director nominations.

    Equity Compensation Plans.   Under Section 303A.08 of the LCM, shareholders must be given the opportunity to vote on all equity-compensation plans and material revisions thereto, with certain limited exemptions as described therein. We follow the requirements of the Companies Law, under which approval of equity-compensation plans and material revisions thereto is within the authority of the board of directors. However, under the Companies Law, any compensation to directors, the chief executive officer or a controlling shareholder or another person in which a controlling shareholder has a personal interest, including equity-based compensation, generally requires the approval of the compensation committee, the board of directors and the shareholders, in that order. The compensation of directors and officers is generally required to comply with a shareholder-approved compensation policy, which is required to include a monetary cap on the value of equity compensation that may be granted to any director or officer.

    Shareholder Approval of Securities Issuances.   Under Section 312.03 of the LCM, shareholder approval is a prerequisite to (a) issuing common stock, or securities convertible into or exercisable for common stock, to a related party, a subsidiary, affiliate or other closely related person of a related party or any company or entity in which a related party has a substantial interest, if the number of shares of common stock to be issued exceeds either 1% of the number of shares of common shares or 1% of the voting power outstanding before the issuance, and (b) issuing common stock, or securities convertible into or exercisable for common stock, if the common stock has, or will have upon issuance, voting power equal to or in excess of 20% of the voting power outstanding before the issuance or the number of shares of common stock to be issued is equal to or in excess of 20% of the number of shares of common stock before the issuance, in each case subject to certain exceptions. We seek shareholder approval for all corporate actions requiring such approval under the requirements of the Companies Law, which are different from the requirements for seeking shareholder approval under Section 312.03 of the LCM. Under the Companies Law, shareholder approval is a prerequisite to any extraordinary transaction with a controlling shareholder or in which a controlling shareholder has a personal interest, as described below under "—Fiduciary Duties and Approval of Related Party Transactions—Approval of Related Party Transactions." Under the Companies Law, shareholder approval is also a prerequisite to a private placement of securities if it will cause a person to become a controlling shareholder or if:

    the securities issued amount to 20% or more of the company's outstanding voting rights before the issuance;

    some or all of the consideration is other than cash or listed securities or the transaction is not on market terms; and

    the transaction will increase the relative holdings of a 5% shareholder or will cause any person to become, as a result of the issuance, a 5% shareholder.

        Except as stated above, we intend to substantially comply with the rules applicable to U.S. companies listed on the NYSE. We may in the future decide to use other foreign private issuer exemptions with respect to some or all of the other NYSE listing requirements. Following our home country governance practices, as opposed to the requirements that would otherwise apply to a company listed on the NYSE, may provide less protection than is accorded to investors under NYSE listing requirements applicable to domestic issuers. For more information, see "Risk Factors—Risks Related to Our Ordinary Shares and This Offering—As a foreign private issuer, we are permitted to follow certain home country corporate

186


Table of Contents

governance practices instead of applicable SEC and NYSE requirements, which may result in less protection than is accorded to investors under rules applicable to domestic issuers."


Board of Directors

        According to our Articles of Association, we must have at least seven and no more than twenty directors. Our directors are normally elected by our shareholders at our annual meeting. Our Board of Directors is also authorized to appoint directors in order to fill vacancies or for any other reason. Each of our directors, other than our external directors, serves from the date of election or appointment until our next annual meeting of shareholders. A majority of the members of our Board of Directors must be both citizens and residents of Israel. The approval of at least a majority of the voting rights represented at a shareholders' meeting and voting on the matter is generally required to remove any of our directors from office (other than external directors).

        Our Board of Directors currently consists of eleven directors. In the event of a stalemate in a vote of our Board of Directors, our Chairman of the Board has the right to cast the deciding vote. All of our directors are independent under the rules applicable to U.S. companies listed on the NYSE, except for Messrs. Nir Gilad, Avisar Paz, Eran Sarig and Aviad Kaufman by virtue of the positions they hold with our controlling shareholder. Three of our directors are external directors and an additional two directors were designated "independent directors" under the Companies Law. We do not have service contracts with our current directors.


External Directors

        As a public Israeli company, we are required by the Companies Law to have at least two external directors who meet certain independence criteria to ensure that they are unaffiliated with us and our controlling shareholder. The definition of "external director" under the Companies Law and the definition of "independent director" under the NYSE rules overlap to a significant degree such that we would generally expect a director who qualifies as one to also qualify as the other. Since the definitions are not identical, however, it is possible for a director to qualify as one and not as the other. For example, one of our directors would not qualify as an "external director" under the Companies Law because he is also a director of another subsidiary of Israel Corporation, while he continues to qualify as an "independent director" under NYSE rules.

        An external director must also have either financial and accounting expertise or professional qualifications, as defined in regulations promulgated under the Companies Law, and at least one of the external directors is required to have financial and accounting expertise. An external director is entitled to reimbursement of expenses and compensation as provided in regulations promulgated under the Companies Law but is otherwise prohibited from receiving any other compensation from us, directly or indirectly, during his term and for two years thereafter.

        Under the Companies Law, external directors must be elected at a shareholders' meeting by a simple majority of the votes cast on the matter, provided that such majority includes a majority of the votes cast by non-controlling shareholders and shareholders who do not have a personal interest in the election (excluding a personal interest that did not result from the shareholder's relationship with the controlling shareholder), unless the votes cast by such shareholders against the election did not exceed 2% of our aggregate voting rights. External directors serve for up to three terms of three years each, and our audit and finance committee and Board of Directors may nominate them for additional terms under certain circumstances. Even if an external director is not nominated by our Board of Directors for reelection for a second or third term, shareholders holding at least 1% of our voting rights have the right to nominate the external director for reelection. In such a case, the reelection can be approved without the approval of our controlling shareholder if it is approved by a majority of the votes cast by non-controlling shareholders and shareholders who do not have a personal interest in the election (excluding a personal interest that did not result from the shareholder's relationship with the controlling shareholder) and the votes cast by such shareholders approving the election exceed 2% of our aggregate voting rights. A term of an external director may be terminated prior to expiration only by a shareholder vote, by the same threshold required

187


Table of Contents

for election, or by a court, but in each case only if the external director ceases to meet the statutory qualifications for election or if the external director violates his duty of loyalty to us.

        Under the Companies Law, each committee of a company's board of directors that is authorized to exercise powers of the board of directors is required to include at least one external director, and all external directors must be members of the company's audit committee and compensation committee.

        We currently have three external directors: Prof. Yair Orgler, whose third term commenced on September 5, 2012, Dr. Miriam Haran, whose second term commenced on August 29, 2012, and Mr. Yaacov Dior, whose first term commenced on October 5, 2011.


Financial Experts

        Our Board of Directors has resolved that at least three of its members must have financial and accounting expertise, as defined in regulations promulgated under the Companies Law. Our Board of Directors has determined that nine of our current directors meet such qualifications.

        In addition, our Board of Directors has determined that all members of our audit and finance committee are financially literate as determined in accordance with NYSE rules and that Mr. Dior and Prof. Orgler are qualified to serve as "audit committee financial experts" as defined by SEC rules.


Alternate Directors

        Our Articles of Association provide, consistent with Israeli law, that any director may appoint another person who is not a director or an alternate director to serve as his alternate director, subject to the approval of the Board of Directors. The term of an alternate director can be terminated at any time by the appointing director or the Board of Directors and automatically terminates upon the termination of the term of the appointing director. The Companies Law stipulates that an external director may not appoint an alternate director except under very limited circumstances. An alternate director has the same rights and responsibilities as a director, except for the right to appoint an alternate director. As of the date of this prospectus, no director has appointed any other person as an alternate director.


Our Committees

        Our Board of Directors has established the following committees. Each committee operates in accordance with a written charter that sets forth the committee's structure, operations, membership requirements, responsibilities and authority to engage advisors.

        Under the Companies Law, the board of directors of a public company must establish an audit committee. The audit committee must consist of at least three directors who meet certain independence criteria and must include all of the company's external directors. The chairman of the audit committee is required to be an external director. The responsibilities of an audit committee under the Companies Law include identifying and addressing flaws in the business management of the company, reviewing and approving related party transactions, establishing whistleblower procedures, overseeing the company's internal audit system and the performance of its internal auditor, and assessing the scope of the work and recommending the fees of the company's independent accounting firm. In addition, the audit committee is required to determine whether certain related party actions and transactions are "material" or "extraordinary" for the purpose of the requisite approval procedures under the Companies Law and to establish procedures for considering proposed transactions with a controlling shareholder.

        In accordance with U.S. law and NYSE requirements, our audit and finance committee is also responsible for the appointment, compensation and oversight of the work of our independent auditors and for assisting our Board of Directors in monitoring our financial statements, the effectiveness of our internal controls and our compliance with legal and regulatory requirements.

        Our audit and finance committee consists of five directors: Prof. Yair Orgler (Chairman), Mr. Yaacov Dior, Dr. Miriam Haran, Mr. Victor Medina and Mr. Avraham (Baiga) Shochat. Our audit and finance

188


Table of Contents

committee complies with the requirements applicable to U.S. companies that are listed on the NYSE. All of the members are external directors or independent directors as defined in the Companies Law. All of the members are also independent as defined in SEC rules and NYSE listing requirements. Our Board of Directors has determined that all members of our audit and finance committee are financially literate as determined in accordance with NYSE rules and that Prof. Orgler and Mr. Dior are qualified to serve as "audit committee financial experts" as defined by SEC rules.

        Under the Companies Law, the board of directors of a public company must establish a compensation committee. The compensation committee must consist of at least three directors who meet certain independence criteria and include all of the company's external directors, who are required to constitute a majority of its members. The chairman of the compensation committee must be an external director. The remaining members are required to meet certain independence criteria and be paid in accordance with the regulations governing the compensation of external directors. The responsibilities of a compensation committee under the Companies Law include recommending to the board of directors, for ultimate shareholder approval by a special majority, a policy governing the compensation of directors and officers based on specified criteria, reviewing modifications to and implementing such compensation policy from time to time and approving the actual compensation terms of directors and officers prior to approval by the board of directors.

        Our human resources and compensation committee is also charged with oversight of our human resources strategy and key programs, including our "One ICL" program, senior leadership development, bonus and equity plans and top management evaluation and succession planning.

        Our human resources and compensation committee consists of three directors, Mr. Yaacov Dior (Chairman), Prof. Yair Orgler and Dr. Miriam Haran. All of the members are external directors as defined in the Companies Law and independent as defined in the NYSE listing requirements applicable to U.S. companies.

        Our environment, safety and public affairs committee is charged with oversight of our environment and safety policies and programs and our community outreach, public relations and advocacy programs. It consists of four directors, Mr. Eran Sarig (Chairman), Mr. Chaim Erez, Dr. Miriam Haran and Mr. Avraham (Baiga) Shochat.

        The purpose of our operations committee is to assist our Board of Directors in fulfilling its responsibilities with respect to our capital management, business operations and strategy implementation, including M&A transactions and research and development strategy. Our operations committee is not authorized to exercise any power of our Board of Directors and therefore is entitled to include members who are not directors. The committee consists of six members, Mr. Nir Gilad (Chairman), Mr. Ovadia Eli, Mr. Chaim Erez, Mr. Victor Medina, Mr. Avisar Paz and Mr. Eran Sarig.


Internal Auditor

        Under the Companies Law, the board of directors is required to appoint an internal auditor recommended by the audit committee. The role of the internal auditor is to examine, among other things, whether the company's actions comply with applicable law and proper business procedures. The internal auditor may not be an interested party, a director or an officer of the company, or a relative of any of the foregoing, nor may the internal auditor be our independent accountant or a representative thereof. Our chief internal auditor oversees the work of various internal auditors throughout our organization. Our chief internal auditor is Mr. Shmuel Daniel, who is a certified internal auditor and certified public accountant in Israel. The chief internal auditor serves for a period of three years. Mr. Shmuel Daniel was appointed as of August 1, 2014.

189


Table of Contents


Fiduciary Duties and Approval of Related Party Transactions

        Israeli law imposes a duty of care and a duty of loyalty on all directors and officers of a company. The duty of care requires a director or officer to act with the level of care with which a reasonable director or officer in the same position would have acted under the same circumstances. The duty of care includes, among other things, a duty to use reasonable means, under the circumstances, to obtain information on the advisability of a given action brought for his approval or performed by virtue of his position and other important information pertaining to such action. The duty of loyalty requires the director or officer to act in good faith and for the benefit of the company.

        Under the Companies Law, a related party transaction may be approved only if it is for the benefit of the company. A transaction that is not an extraordinary transaction in which a director or officer has a personal interest requires the approval of the board of directors, unless the articles of association of the company provide otherwise. Our Articles of Association provide that such a transaction, if it does not relate to a director's or officer's compensation terms, may be approved by any of our Board of Directors, our audit and finance committee, a disinterested director or officer or a person authorized for this purpose by our Board of Directors. If the transaction is an extraordinary transaction, it must be approved by the audit committee and the board of directors, and, under certain circumstances, by the shareholders of the company. An "extraordinary transaction" is a transaction other than in the ordinary course of business, other than on market terms or that is likely to have a material impact on the company's profitability, assets or liabilities.

        Pursuant to the Companies Law, extraordinary transactions in which a controlling shareholder has a personal interest require the approval of the audit committee, or the compensation committee if the transaction is in connection with employment or service with the company, the board of directors and the shareholders of the company. The shareholder approval must be by a simple majority of all votes cast, provided that (i) such majority includes a simple majority of the votes cast by non-controlling shareholders having no personal interest in the matter or (ii) the total number of votes of shareholders mentioned in clause (i) above who voted against such transaction does not exceed 2% of the total voting rights in the company.

        The Companies Law prohibits any director who has a personal interest in an extraordinary transaction from being present for the discussion and voting pertaining to such transaction in the audit committee or board of directors. Notwithstanding, a director who has a personal interest may be present at the meeting and vote on the matter if a majority of the directors or members of the audit committee have a personal interest in the approval of such transaction. If a majority of the members of the board of directors have a personal interest in the transaction, such transaction also requires shareholder approval.

        Under the Companies Law, we are required to approve, at least once every three years, a compensation policy with respect to our directors and officers. Following the recommendation of our human resources and compensation committee, the compensation policy must be approved by our Board of Directors and our shareholders. The shareholder approval must be by a simple majority of all votes cast, provided that (i) such majority includes a simple majority of the votes cast by non-controlling shareholders having no personal interest in the matter or (ii) the total number of votes of shareholders mentioned in clause (i) above who voted against such transaction does not exceed 2% of the total voting rights in the company. In general, the compensation terms of directors, the chief executive officer and any employee or service provider who is considered a controlling shareholder must be approved separately by the compensation committee, the board of directors and the shareholders. Generally, shareholder approval is

190


Table of Contents

not required for director compensation payable in cash up to the maximum amount set forth in the regulations governing the compensation of external directors. The compensation terms of other officers who report directly to the chief executive officer require the approval of the compensation committee and the board of directors.

        On July 17, 2013, our Board of Directors approved the compensation policy for our directors and officers in accordance with the recommendation of our human resources and compensation committee, which approved the compensation policy on July 16, 2013. Our compensation policy was approved by our shareholders on August 26, 2013. In March 2014, our human resources and compensation committee and our Board of Directors approved certain amendments to our compensation policy including, among other things, with regard to the method of calculating the target bonus for officers who have not served or who have served in another position in the Company in the three years prior to the bonus, the possibility of awarding a special bonus and certain amendments to the equity bonus mechanism (including with regard to possible minimum vesting period). In August 2014, our human resources and compensation committee and our Board of Directors approved additional specific amendments to our compensation policy which, among other things:

        We have convened a general meeting of our shareholders scheduled for October 20, 2014 for the approval of these amendments.


Compensation of Directors and Officers

        External directors may be compensated only in accordance with regulations promulgated under the Companies Law. These regulations permit the payment of cash compensation within a specified range, depending on the size of the company, or cash or equity compensation that is consistent with the compensation paid to the other independent directors. All of our directors are entitled to receive cash compensation in the maximum amount set for our external directors in the regulations. In 2013, this amount for each director was approximately $42,000 per year and $1,700 per meeting attended, which amounted to aggregate compensation of approximately $1.0 million that was paid to our Board of Directors in that year. Directors who are employees of Israel Corporation do not receive additional fees for their services as directors. Instead, those fees are included in the annual management fees we pay to

191


Table of Contents

Israel Corporation. We do not have any agreement with directors providing for benefits upon termination of employment.

        The aggregate compensation paid to all of the members of our senior management (including the officers listed in the table below) was approximately $8 million in 2013. The following table and accompanying footnotes describe certain payments made to senior officers of the Company through the end of fiscal year 2013:

 
  Details of the Recipient   Payments for services  
Name
  Position   Scope of
position
  Holding in
equity
  Salary   Compensation (1)   Bonus (2)   Share-based
payment
  Total  
 
   
   
   
  (in thousands of U.S. dollars)
 

Stefan Borgas (3)

  Chief Executive Officer     100 %   0.00 %   1,003     1,495     1,735     2,319 (8)   5,549  

Charles Weidhas (4)

  Chief Executive Officer, Industrial Products     100 %   0.00 %   371     1,120     310     745 (9)   2,175  

Asher Grinbaum (5)

  Executive Vice President     100 %   0.00 %   452     745     476     745 (10)   1,966  

Dani Chen (6)

  Executive Vice President     100 %   0.00 %   384     643     434     745 (11)   1,822  

Nissim Adar (7)

  Chief Executive Officer, ICL Fertilizers     100 %   0.00 %   384     634     428     745 (12)   1,807  

(1)
The salary set out in the above table includes all of the following components: monthly salary, social benefits, customary social and related provisions, company car and reimbursement of telephone expenses.

(2)
The bonus that appears in the above table represents the bonus with respect 2013, which was set in accordance with the provisions in our compensation policy and the bonus plan that was approved for Mr. Borgas by the general meeting of our shareholders in August 2013, and for the other officers, by our human resources and compensation committee and Board of Directors in August 2013. The table also includes the bonus paid to Mr. Borgas with respect to 2012, for a total of NIS 1,236 thousand, as approved by the general meeting of our shareholders in August 2013.

(3)
Mr. Stefan Borgas has served as our Chief Executive Officer since September 20, 2012. Mr. Borgas's employment agreement is for an unlimited period and may be terminated by either party at any time. His monthly salary, as of December 31, 2013, is $83,333. Stefan Borgas' salary is paid in NIS at the representative exchange rate on the date of payment. In addition to his monthly salary, Stefan Borgas is entitled to a monthly participation for the cost of a residence, in an amount of up to $8,250, for the shorter of the duration of the period of his employment with us or three years. Mr. Borgas is also entitled to a participation in education expenses of his children in Israel in a total annual net amount of up to $10,000 per child. In addition, Mr. Borgas is entitled to coverage for the cost of airplane tickets for two annual vacations in Europe for himself and for his family, as well as participation in his medical insurance. With respect to severance, other than in cases where the right to compensation is revoked under Israeli law, Mr. Borgas is entitled to a prior notice payment equivalent to 6 months' salary if his resignation is at his request, and equivalent to 12 months' salary if his resignation is initiated by us. In addition to the amounts provided regularly for pension and compensation, the severance compensation for Mr. Borgas will be calculated and paid based on the seniority he accumulates in our Company and on the basis of his last monthly salary multiplied by the number of years he is employed by us.

(4)
Mr. Charles Weidhas served until September 30, 2013 as Chief Executive Officer of our Performance Products segment. Beginning on October 1, 2013, he serves as Chief Executive Officer of our Industrial Products segment. Mr. Weidhas's employment agreement is for an unlimited period and may be terminated by either party at any time by written notification. Mr. Weidhas has a notice period and an adjustment period of 6 months each and is entitled to one-time relocation expenses for a total of $60,000 net and to life insurance and health insurance for himself and his family. For a period of 5 years, Mr. Weidhas is entitled to coverage for the cost of airplane tickets for two annual visits to the United States for himself and his wife. Mr. Weidhas's monthly salary as of December 31, 2013 is approximately NIS 117,000. His employment agreement states that his salary will be updated twice a year according to the rise in the CPI in the months that passed since the last update. He is also entitled to maintain the net amount in respect of all payments made to him as would be obtained in the United States (tax equalization). In addition to the amount provided regularly to the pension fund and/or to the managers insurance, Mr. Weidhas is entitled to severance payment equal to his last salary multiplied by the number of years he serves as Chief Executive Officer of our Industrial Products segment.

(5)
Mr. Asher Grinbaum serves as executive vice-president and Chief Operating Officer. The 1994 employment contract with Mr. Grinbaum, as amended to date, states that Mr. Grinbaum's salary will be updated twice a year according to the rise in the CPI in the months that passed since the last update. The employment contract is not limited in time and will remain in force until it is ended by one of the parties by means of providing prior written notification. Mr. Grinbaum is entitled to an adaptation period of 6 months. According to the employment contract and the salary updates, as decided by our Board of Directors from time to time, Mr. Grinbaum's salary as of December 31, 2013 was approximately NIS 137,000. In addition Mr. Grinbaum is

192


Table of Contents

    entitled, beyond the current provisions for pension benefits and/or managers' insurance, to additional severance pay equal to his last salary times the years of his service with us.

(6)
Mr. Dan (Dani) Chen served until September 30, 2013 as Chief Executive Officer of our Fertilizers segment, and beginning on October 1, 2013, serves as Executive Vice President for our Corporate Relations department. The 1978 employment contract with Mr. Chen, as amended to date, states that Mr. Chen's salary will be updated twice a year according to the rise in the CPI in the months that passed since the last update. The employment contract is not limited in time and will be in force until it is ended by one of the parties giving prior written notification. Mr. Chen is entitled to a notice period of 6 months. According to the employment contract and the salary updates, as decided by our Board of Directors from time to time, Mr. Chen's salary as of December 31, 2013 is approximately NIS 117,000. In addition, Mr. Chen is entitled, beyond the current provisions for pension funds and/or managers' insurance, to severance pay in the amount of his last salary multiplied by the number of years of his service with us.

(7)
Mr. Nissim Adar served until September 30, 2013 as Chief Executive Officer of our Industrial Products segment and beginning on October 1, 2013, serves as Chief Executive Officer of our Fertilizers segment. The 2002 employment contract with Mr. Adar as amended to date, states that Mr. Adar's salary will be updated twice a year according to the rise in the CPI in the months that passed since the last update. The employment contract is not limited in time and will be in force until it is ended by one of the parties giving prior written notification. Mr. Adar is entitled to a notice period of 6 months. According to the employment contract and the salary updates, as decided by decisions of our Board of Directors from time to time, Mr. Adar's salary as of December 31, 2013 is about NIS 117,000. In addition, Mr. Adar is entitled, beyond the current provisions for pension benefits and/or managers' insurance, to severance pay equal to the amount of his last salary multiplied by the number of years of his service with us.

(8)
On November 26, 2012, an allotment of 1,190,000 non-negotiable options, for no consideration, was approved for Mr. Stefan Borgas under our 2012 Plan. On December 30, 2012, the options were assigned to a trustee in Mr. Borgas's favor. The options are exercisable into our ordinary shares at an exercise price of NIS 46.6 (subject to adjustments) and in three portions beginning in January 2015. The weighted financial value of these options, on the date of approval, was NIS 11.9 for the first and second portions, and NIS 12.7 for the third portion. The amount appearing in the table reflects the aggregate expenditure recorded by us in 2013 with regard to the allocation of options to Mr. Borgas, based on generally accepted accounting principles. The exercise price for converting the options into shares as of March 18, 2014 is NIS 42.92. This price is 41% higher than the last share price prior to March 18, 2014 (meaning, these options are "out of the money"). Yet the table above includes an amount which is 66% of the value of all the options allocated to Mr. Borgas (due to generally accepted accounting principles).

(9)
On January 7, 2010, an allotment of 350,000 non-negotiable options, for no consideration, was approved for Mr. Charles Weidhas under our 2010 Plan. The options are exercisable into our ordinary shares at an exercise price of NIS 53.1 in three portions, commencing in January 2011. The weighted financial value of each option on the eve of approval was NIS 18.1 for the first and second portions and NIS 19.3 for the third portion. The financial value was based on the price of our ordinary shares on the TASE on the eve of the allotment, which was NIS 53.1, the same as the exercise price. Mr. Weidhas did not exercise these options and they expired.

On November 26, 2012, an allotment of 380,000 non-negotiable options was approved, for no consideration for Mr. Weidhas under our 2012 Plan. On December 30, 2012, the options were allocated to a trust on behalf of Mr. Weidhas. The options are exercisable into our ordinary shares at an exercise price of NIS 46.6 (subject to adjustments) and in three portions beginning in January 2015. The weighted financial value of these options, on the date of approval, was NIS 11.9 for the first and second portions, and NIS 12.7 for the third portion. The exercise price for converting the options into shares as of March 18,2014 was NIS 42.92. This price is 41% higher than the last share price prior to March 18, 2014 (meaning these options are "out of the money"). Yet the table above includes an amount which is 66% of the value of all the options allocated to Mr. Weidhas (due to generally accepted accounting principles).

(10)
On January 7, 2010, an allotment of 350,000 non-negotiable options, for no consideration, was approved for Mr. Asher Grinbaum under our 2010 Plan. The options are exercisable into our ordinary shares at an exercise price of NIS 53.1 in three portions, beginning in January 2011. The weighted financial value of each option on the eve of approval is NIS 18.1 for the first and second portions and NIS 19.3 for the third portion, based upon the price of the share of NIS 1 par value in the TASE on the eve of the grant, which was NIS 53.1, the same as the exercise price. The amount appearing in the table reflects the aggregate expenditure recorded by us with respect to granting of options, based on generally accepted accounting principles. In 2013, Mr. Grinbaum exercised 233,333 options from the first and second portions. The third portion options were not exercised and expired in January 2014.

On November 26, 2012, an allotment of 380,000 non-negotiable options was approved, for no consideration, for Mr. Asher Grinbaum under our 2012 Plan. On December 30, 2012 the options were allocated to a trustee on behalf of Mr. Grinbaum. The options are exercisable into our shares at an exercise price of NIS 46.6 (subject to adjustments) in three portions beginning in January 2015. The weighted financial value of these options, on the date of approval, was NIS 11.9 for the first and second portions, and NIS 12.7 for the third portion. The amount appearing in the table reflects the aggregate expenditure recorded by us with regard to granting of options, based on generally accepted accounting principles. The exercise price for converting the

193


Table of Contents

    options into shares as of March 18,2014 was NIS 42.92. This price is 41% higher than the last share price prior to March 18, 2014 (meaning these options are "out of the money"). Yet the table above includes an amount which is 66% of the value of all the options allocated to Mr. Grinbaum (due to generally accepted accounting principles).

(11)
On January 7, 2010, an allotment of 350,000 non-negotiable options, for no consideration, was approved for Mr. Dani Chen under our 2010 Plan. The options are exercisable into our shares at an exercise price of NIS 53.1 in three portions, beginning in January 2011. The weighted financial value of each option, immediately prior to the approval, is NIS 18.1 for the first and second portions and NIS 19.3 for the third portion, based upon the price of the share of NIS 1 par value on the TASE on the eve of the grant, which was NIS 53.1, the same as the exercise price. The amount appearing in the table reflects the aggregate expenditure recorded by us with respect to granting of options, based on generally accepted accounting principles. In 2013, Mr. Chen exercised 233,333 options from the first and second portions. The third portion options were not exercised and expired in January 2014.

On November 26, 2012, an allotment of 380,000 non-negotiable options was approved, for no consideration, for Mr. Dani Chen under our 2012 Plan. On December 30, 2012, the options were assigned to a trustee in Mr. Chen's favor. The options are exercisable into our ordinary shares at an exercise price of NIS 46.6 (subject to adjustments) and in three portions beginning in January 2015. The weighted financial value of these options, on date of approval, was NIS 11.9 for the first and second portions, and NIS 12.7 for the third portion. The amount appearing in the table reflects the aggregate expenditure recorded by us with respect to granting of options, based on generally accepted accounting principles. The exercise price for converting the options into shares as of March 18, 2014 is NIS 42.92. This price is 41% higher than the last share price prior to March 18, 2014 (meaning, these options are "out of the money"). Yet the table includes an amount which is 66% of the value of all the options allocated to Mr. Chen (due to generally accepted accounting principles).

(12)
On January 7, 2010, an allotment of 350,000 non-negotiable options, for no consideration, was approved for Mr. Nissim Adar, under our 2010 Plan. The options are exercisable into our ordinary shares at an exercise price of NIS 53.1 in three portions, beginning in January 2011. The weighted financial value of each option, immediately prior to the approval, is NIS 18.1 for the first and second portions and NIS 19.3 for the third portion, based upon the price of the share of NIS 1 par value in the TASE on the eve of the allotment, which was NIS 53.1, the same as the exercise price. The amount that appears in the table reflects our indirect expenses for the allotment of the options based on generally accepted accounting principles. In 2013, Mr. Adar exercised 233,333 options of the first and second portions. The third portion options were not exercised and expired in January 2014.

On November 26, 2012, an allotment of 380,000 non-negotiable options was approved, for no consideration, for Mr. Nissim Adar under our 2012 Plan. On December 30, 2012, the options were assigned to a trustee in Mr. Adar's favor. The options are exercisable into our ordinary shares at an exercise price of NIS 46.6 (subject to adjustments) in three portions beginning in January 2015. The weighted financial value of these options, on the date of approval, was NIS 11.9 for the first and second portions, and NIS 12.7 for the third portion. The amount that appears in the table reflects our indirect expenses for the grant of the options and is based on generally accepted accounting principles. The exercise price for converting the options into shares as of the date of publication of our audited financial statements in Israel is NIS 42.92. This price is 41% higher than the last share price prior to the date of publication of our audited financial statements in Israel (meaning, these options are "out of the money"). Yet the table above includes an amount which is 66% of the value of all the options allocated to Mr. Adar (due to generally accepted accounting principles).

        In December 2012, Amendment 20 to the Companies Law entered into effect, whereby public companies such as us were required to set a compensation policy for their directors and officers. At the same time, we decided to formulate a comprehensive compensation plan (the "Global Compensation Plan") for our and our subsidiaries' directors and officers, in and outside Israel, to create an orderly system of principles and rules for provision of compensation and incentives to directors and officers. In the view of our management, the Global Compensation Plan is a central tool for administering our senior management personnel resources, which drive our growth. The goal of the plan is to recruit, preserve and advance experienced and leading managers, in and outside Israel, and to provide them incentives by means of an incentive package that creates a proper balance between fixed and variable compensation components, while applying our long-standing profit-sharing policy.


Pensions, Retirement and Similar Benefits

        We set aside or accrued approximately $0.85 million in the aggregate for pension or other retirement benefits for our directors and senior management in 2013.

194


Table of Contents


Incentive Compensation Plans

    The 2007 Options Plan

        On January 28, 2007, the Company's Board of Directors approved a plan (the "2007 Plan") for a grant of 12.9 million non-transferable options to purchase our ordinary shares, to a group of officers and other senior employees holding management positions with the Company and companies it controls, in and outside Israel.

        Between January and March 2007, 11.8 million options were granted under the 2007 Plan, of which 2.2 million were granted to our former Chief Executive Officer.

        The options from the 2007 Plan vested in three equal annual installments from the date of approval of the Board of Directors. The expiration date of the options was 60 months after the date of approval of the Board of Directors.

    The 2010 Options Plan

        On January 7, 2010, our Board of Directors approved a plan (the "2010 Plan") for the grant of 10,930,500 non-transferable options to 318 of our executives and senior employees in Israel and overseas, including 1,100,000 options to our former Chief Executive Officer and 800,000 options to our Chairman of the Board. On February 15, 2010, at an extraordinary general meeting of our shareholders, the grant to the Chairman of the Board was approved. The options vested in three equal annual installments from the date of approval of the Board of Directors. The expiration date of the options for the first and second installments was at the end of 36 months from the date of grant and the expiration date of the options for the third portion was at the end of 48 months from the date of grant.

    The 2012 Options Plan

        On November 26, 2012, our Board of Directors approved a plan (the "2012 Plan") for the grant of up to 12,000,000 non-marketable options for no consideration to 416 of our officers and senior employees in Israel and overseas. On December 27, 2012, 11,999,400 options were issued. The issuance included a material private placement of 1,190,000 options to our Chief Executive Officer. This grant format of the options plan includes a "cap" for the value of a share where if, as at the exercise date, the closing price of an ordinary share is higher than twice the exercise price (the "Share Value Cap"), the number of the exercised shares will be reduced so that the product of the exercised shares actually issued to the offeree multiplied by the share closing price will equal the product of the number of exercised options multiplied by the Share Value Cap. The options may be exercised in three equal tranches on December 26, 2013, 2014 and 2015. The expiration date of the options for the first and second tranches is at the end of 48 months from the approval of the Board of Directors and the expiration date of the options for the third tranche is at the end of 60 months from the issuance date.

        Upon exercise, every option may be converted into one ordinary share of NIS 1 par value of the Company. The ordinary shares issued as a result of exercise of the options have the same rights as the Company's ordinary shares, immediately upon their issuance. The options issued to the employees in Israel are covered by the provisions of Section 102 of the Israeli Income Tax Ordinance (New Version) and the regulations promulgated thereunder. The Company elected that the issuance will be made through a trustee, under the Capital Gains Track.

        The exercise price is linked to the CPI that is known as of the date of payment, which is the exercise date. In a case of distribution of a dividend by the Company, the exercise price is reduced, on the "ex-dividend" date, by the amount of the dividend per share (gross), based on the amount thereof in NIS on the effective date. The options are not marketable and may not be transferred.

195


Table of Contents

    Fair Value of Options

        The fair value of the options granted under the 2007 Plan and 2010 Plan were estimated on the basis of the Black-Scholes model for the pricing of options. The fair value of the options issued in the 2012 Plan was valued on the basis of a binomial model for valuing options. The parameters used in applying the models are as follows:

 
  2007 Plan   2010 Plan   2012 Plan  

Share price (in NIS)

    25.59     53.1     46.6  

CPI-linked exercise price (in NIS)

    25.59     53.1     46.6  

First and second tranches

    24.60 %   54.98 %   36.7 %

Third tranche

    24.60 %   48.45 %   44.2 %

First and second tranches

    4     2.5     4  

Third tranche

    4     3.5     5  

Risk-free interest rate:

                   

First and second tranches

    3.34 %   0.59 %   0.22 %

Third tranche

    3.34 %   1.29 %   0.54 %

Fair value (in $ millions)

    17.9     54.3     37.7  

    The 2013 Cash Incentive Plan

        On May 12, 2013, our Board of Directors decided to approve a long-term compensation plan (the "2013 Plan") for approximately 11,300 of our employees, in and outside Israel, who are not participants in our 2012 Plan. The maximum cost of the new plan is approximately $45 million. Based on the criteria set forth in the 2013 Plan, every participant will be paid an amount of up to $4,050, subject to our net income in each of the three years 2013, 2014 and 2015 meeting the requirements set forth in the plan. As of December 31, 2013, the requirements of the 2013 Plan had not been met and therefore no liability was included in our financial statements in respect of the 2013 Plan.

    The 2014 Equity Compensation Plan

        On August 6, 2014, our Board of Directors approved an issuance of up to approximately 4,384,540 non-marketable options, for no consideration, exercisable for approximately 4,384,540 of our ordinary shares, and up to approximately 1,025,449 restricted shares, to approximately 450 of our officers and senior employees. The issuance includes a private placement of 367,294 options and 85,907 restricted shares to our Chief Executive Officer, which is subject to approval by the general meeting of our shareholders scheduled for October 20, 2014. This grant format of the options plan includes a "cap" for the value of a share where if, as at the exercise date, the closing price of an ordinary share is higher than twice the exercise price (the "Share Value Cap"), the number of the exercised shares will be reduced so that the product of the exercised shares actually issued to the offeree multiplied by the share closing price will equal the product of the number of exercised options multiplied by the Share Value Cap.

        The options and restricted shares will vest in three equal tranches: one-third at the end of 24 months from December 1, 2014, one-third at the end of 36 months from December 1, 2014 and one-third at the end of 48 months from December 1, 2014. The expiration date of the options in the first tranche is at the end of 48 months from December 1, 2014, the expiration date of the options in the second tranche is at the end of 60 months from December 1, 2014 and the expiration date of the options in the third tranche is at the end of 72 months from December 1, 2014.

        Upon exercise, every option may be converted into one ordinary share of NIS 1 par value of the Company, subject to adjustment as set forth above. The ordinary shares issued as a result of exercise of the options will have the same rights as our ordinary shares, immediately upon their issuance. The options issued to the employees in Israel are covered by the provisions of Section 102 of the Israeli Income Tax

196


Table of Contents

Ordinance (New Version) and the regulations promulgated thereunder. We elected that the issuance will be made through a trustee, under the Capital Gains Track.

        The exercise price is approximately $8.4 for each option, linked to the CPI that is known as of the date of payment, which is the exercise date. In case of distribution of a dividend by the Company, the exercise price is reduced on the ex-dividend date, by the amount of the dividend per share (gross), based on the amount thereof in NIS on the effective date. The options are not marketable and may not be transferred.

    Fair Value of Options and Restricted Stock

        The fair value of the options was estimated by means of application of a binomial options pricing model and is approximately $8.4 million as of August 6, 2014. The expected volatility for the first, second and third tranches is approximately 29.37%, 31.24% and 40.77%, respectively, which was determined on the basis of the historical volatility in the Company's share prices. The expected life of the options was determined on the basis of management's estimate of the period the employees will hold the options, taking into consideration their position with the Company and our past experience regarding the turnover of employees. The risk-free interest rate was determined on the basis of the yield to maturity of NIS-denominated Israeli government debentures, with a remaining life equal to the anticipated life of the options.

        The fair value of the restricted shares is $8.4 million. The value of the restricted shares was determined based on the closing price on the stock market on the last trading day prior to the approval date of the Board of Directors.

        The cost of the benefit embedded in the above-mentioned plan will be recognized in the statement of income over the vesting period.

        In addition, a long-term remuneration plan was approved for approximately 11,800 non-management Company employees that are not included in the plan for issuance of options and restricted shares, as described above, in the aggregate scope of up to approximately $17 million.


Loans Extended and Guarantees Provided

        We have not extended any loans to members of our Board of Directors or to our executive officers, nor have we guaranteed any loans on their behalf.

197


Table of Contents


CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

Transactions with Related Parties

        We intend to enter into a registration rights agreement with Israel Corporation in connection with this offering. We obtained shareholder approval of our entry into this agreement on May 8, 2014. We expect such agreement will provide for customary demand, piggyback and shelf registration rights and will provide that we will perform various actions and comply with various requirements to facilitate and promote such registrations, as well as cover certain expenses of Israel Corporation in connection with any such registration.

        On August 30, 2007, following approval by our audit and finance committee and our Board of Directors, our shareholders approved a framework resolution, which was amended on November 10, 2008, to purchase an insurance policy for two-tier coverage of director and officer liability in conjunction with Israel Corporation. The first tier, which was shared with Israel Corporation, had a joint liability limit of up to $20 million, and the premiums were paid 55% by us and 45% by Israel Corporation. The second tier covered us alone for up to $185 million. On August 16, 2011, our Board of Directors, in accordance with the authority vested in them by our shareholders, approved raising the second tier insurance to $200 million.

        On August 29, 2012, following approval by our audit and finance committee and our Board of Directors, our shareholders approved a new framework resolution to purchase an insurance policy for two-tier coverage of director and officer liability in conjunction with Israel Corporation. The first tier, which is shared with Israel Corporation, has a joint liability limit of up to $20 million, and the premiums are paid 42.5% by us and 57.5% by Israel Corporation. The second tier covers us alone for up to $200 million. This framework resolution is valid for up to three years.

        In August 2013, following approval by our audit and finance committee and our Board of Directors, our shareholders approved an increase of the total insurance cap to $350 million.

        On August 31, 2014, we announced that our audit and finance committee and our Board of Directors had approved the renewal of our insurance policy in accordance with the three-year framework resolution approved by our shareholders in 2012 and our compensation policy. The new insurance policy, which entered into effect as of September 1, 2014, includes a joint tier with Israel Corporation with a joint liability limit up to $20 million and a separate tier that covers us alone with a liability limit up to $200 million.

        In connection with this offering, we expect to update the terms of our insurance policy for directors and officers in accordance with the practice of companies listed in the United States, including with respect to the limit of liability, the premium and the apportioning of the insurance premium to be paid between us and Israel Corporation. The insurance policy would include a joint tier with Israel Corporation with a liability limit of up to $20 million and a separate tier that covers us alone for up to $350 million, with our directors and officers as beneficiaries of both tiers. In contrast to our existing policy, premiums on the joint tier will be paid 60% by us and 40% by Israel Corporation. The new insurance policy was approved by our shareholders, as a three year framework resolution, on May 8, 2014.

        We have paid our parent company, Israel Corporation, annual management fees since 1996. In June and July of 2009, following approval by our audit and finance committee, our Board of Directors and shareholders, respectively, approved an increase in the management fees to $3.5 million per year for each of the years from 2009 to 2011. On July 20, 2009, the revision was approved at the general meeting of our

198


Table of Contents

shareholders. On October 5, 2011, after approval by our audit and finance committee and our Board of Directors, the extension of the previous management fees paid to Israel Corporation and/or H.L. Management and Consulting (1986) Ltd., a wholly owned subsidiary of Israel Corporation, was approved for three years from January 1, 2012 through December 31, 2014 at the general meeting of our shareholders. Management services include routine general consultation, such as professional, financial, strategic and managerial consultation, and consultation and representation in communication and regulation issues. The parties may agree to expand the management services to additional areas. We currently pay Israel Corporation annual management fees of $3.5 million, plus VAT.

        A subsidiary in our Performance Products segment entered into a long-term agreement with an interested party of the Company for the acquisition of food-quality phosphoric acid. The agreement was signed before the subsidiary was acquired by us and is in effect until 2018.

        On February 28, 2013, our audit and finance committee and our Board of Directors authorized certain of our Israeli subsidiaries in our Industrial Products segment to purchase electricity from OPC Rotem Ltd. During 2013, additional subsidiaries from our Fertilizers segment entered into an agreement with OPC Rotem Ltd. to purchase electricity in accordance with the amended agreement authorized on February 28, 2013.

        On June 26, 2012, we received a short-term loan in the amount of $50 million from our controlling shareholder, Israel Corporation, that bears interest at the three-month LIBOR plus a margin of 0.7% (1.22%). Commencing from December 24, 2012, the loan was extended every three months on the same terms on which it was originally received. On September 26, 2013, the loan was extended for a period of six months based on the six-month LIBOR plus a margin of 0.49% (0.86%). On March 26, 2014, the loan period was extended by an additional six months and the interest rate was updated to a rate of 0.77625%. The terms of this loan are similar to market terms.

        The table below sets forth certain income statement information with respect to our related party transactions for the period indicated.

 
  For the year ended
December 31
 
 
  2013   2012   2011  
 
  (in thousands of U.S. dollars)
 

Sales

    9,958     14,693     11,674  

Cost of sales

    131,845     94,512     72,528  

Selling, transport and marketing expenses

    18,424     36,019     41,159  

Management fees to the parent company

    4,002     3,792     3,500  

199


Table of Contents

        The table below sets forth certain balance sheet information with respect to our related party transactions for the periods indicated.

 
  As at December 31  
 
  2013   2012   2011  
 
  (in thousands of U.S. dollars)
 

Long-term deposits, net of current maturities

    780     958     1,152  

Current maturities of long-term deposits

    260     239     230  

Other current assets

    6,342     6,824     6,337  

Other current liabilities (1)

    73,558     73,087     17,883  

(1)
The Company declares a dollar dividend that is paid in NIS, pursuant to the exchange rate on the effective date. The Company executes a hedging transaction in order to hedge the exposure to changes in the U.S. dollar/NIS exchange rate. The dividend paid to the Company's controlling shareholder, Israel Corporation, is made partly based on the exchange rate on the effective date and partly based on the exchange rate on the date of distribution. In addition, the dividend paid to an interested party is made pursuant to the exchange rate on the date of distribution.

        For additional information regarding our related party transactions, see note 29 to our audited financial statements.

200


Table of Contents


PRINCIPAL AND SELLING SHAREHOLDERS

        The following table presents as of September 12, 2014 (unless otherwise noted below) the beneficial ownership of our ordinary shares by each person who is known by us to be the beneficial owner of 5% or more of our outstanding ordinary shares and each of our directors and executive officers. The data presented is based on information provided to us by the holders or disclosed in public regulatory filings. Israel Corporation is expected to sell shares directly to the underwriters and to enter into forward sale agreements with the forward counterparties. The ordinary shares offered under this prospectus are being sold, as applicable, by Israel Corporation and by the forward counterparties in connection with the forward sale agreements. See "Underwriting" for more details.

        We are not controlled by another corporation, by any foreign government or by any natural or legal person except as set forth herein, and we know of no arrangements that would, at a subsequent date, result in a change of control of our Company other than as described in "Risk Factors—Risks Related to Our Ordinary Shares and the Offering—If our existing shareholders sell additional ordinary shares, or if these shares are sold by others, either on the TASE or the NYSE, after this offering, or if the forward counterparties or their affiliates sell additional ordinary shares to adjust their respective hedge positions during the terms of the forward sale agreements, the market price of our ordinary shares could decline."

 
  Ordinary Shares
Beneficially Owned
Prior to the Offering and Forward Sale Agreements (1) (2)
  Ordinary Shares
Being Sold Directly or Subject to the Forward Sale Agreements (3)
  Ordinary Shares
Beneficially Owned
After the Offering and Forward Sale Agreements (1) (3)
  Special State
Share
 
Shareholder
  Number   %   Number   %   Number   %   Number   %  

Israel Corporation Ltd. (4)

    665,485,881 (5)   52.38 %   72,414,256     5.70 %   593,071,625     46.68 %        

PotashCorp Agricultural Cooperative Society Ltd. (6)

    176,088,630     13.86 %           176,088,630     13.86 %        

State of Israel (7)

                            1     100 %

Yair Orgler

    1,600     *             1,600     *          

Avraham Shochat

    2,000     *             2,000     *          

Michael Hazzan

    23,633     *             23,633     *          

Avi Doitchman

    158,666     *             158,666     *          

Eli Amit

    63,326     *             63,326     *          

Dani Chen

    148,466     *             148,466     *          

Herzel Bar Niv

    40,333     *             40,333     *          

Ofer Lifshitz

    57,000     *             57,000     *          

Asher Grinbaum

    126,666     *               126,666     *          

Nissim Adar

    126,666     *               126,666     *          

Lisa Haimovitz

    27,333     *               27,333     *          

Amir Benita

    18,333     *               18,333     *          

Yakir Menashe

    18,333     *               18,333     *          

Hezi Israel

    27,333     *               27,333     *          

Eyal Ginzberg

    30,000     *               30,000     *          

Charlie Weidhas

    126,666     *               126,666     *          

Israel Dreyfuss

    2,000     *               2,000     *          

Shmuel Daniel

    46,666     *               46,666     *          

Ronnie Shushan

    55,000     *               55,000     *          

*
Less than 1%

(1)
The ordinary shares beneficially owned includes options that are exercisable within 60 days of September 12, 2014 in the following amounts: Michael Hazzan (18,333); Avi Doitchman (126,666); Eli Amit (54,333); Dani Chen (126,666); Herzel Bar Niv (18,333); Ofer Lifshitz (55,000); Asher Grinbaum (126,666); Nissim Adar (126,666); Lisa Haimovitz (27,333); Amir Benita (18,333); Yakir Menashe (18,333); Hezi Israel (27,333); Eyal Ginzberg (30,000); Charlie Weidhas (126,666); Israel Dreyfuss (2,000); Shmuel Daniel (46,666); and Ronnie Shushan (55,000).

201


Table of Contents

(2)
The percentages shown are based on 1,270,425,548 ordinary shares issued and outstanding as of September 12, 2014 (after excluding shares held by us or our subsidiaries). In accordance with the rules of the SEC, beneficial ownership includes voting or investment power with respect to securities and includes the shares issuable pursuant to options that are exercisable within 60 days of September 12, 2014. Shares issuable pursuant to options are deemed outstanding for computing the percentage of the person holding such options but are not outstanding for computing the percentage of any other person.

(3)
Assumes the sale by Israel Corporation of the maximum number of shares expected to be sold directly to the underwriters (36,207,128 ordinary shares) and expected to be subject to the forward sale agreements with the forward counterparties (36,207,128 ordinary shares), or a total of 72,414,256 ordinary shares. Of these shares, 62,000,000 shares are being offered under this prospectus. With respect to any ordinary shares Israel Corporation sells directly to the underwriters, it will cease to have voting rights. With respect to any ordinary shares subject to the forward sale agreements, and made available to the forward counterparties under these agreements, Israel Corporation will cease to have voting rights with respect to these ordinary shares and will, at the relevant settlement dates, regain voting rights with respect to all or a portion of the ordinary shares it makes available to the forward counterparties under these agreements if it elects cash settlement or net physical settlement.

(4)
Israel Corporation Ltd., or Israel Corp., is a public company listed for trading on the TASE. Based on the information we have received from Israel Corp., Millennium Investments Elad Ltd. ("Millennium") and Mr. Idan Ofer are considered joint controlling shareholders of Israel Corp. for purposes of the Israeli Securities Law. Both Millennium and Mr. Ofer hold shares in Israel Corp. directly, and Mr. Ofer serves as a director of Millennium and has an indirect interest in Israel Corp. as a beneficiary of a trust that has indirect control of Millennium. Millennium holds approximately 46.94% of the share capital of Israel Corp. To the best of our knowledge, Millennium is held by Mashat Investments Ltd. ("Mashat") and by XT Investments Ltd. ("XT Investments"), with 80% and 20% holdings, respectively. Mashat is a private company, which is wholly owned by a Dutch company, Ansonia Holdings B.V. ("Ansonia"). Ansonia is a wholly owned subsidiary of Jeremy Corporation N.V. (registered in Curaçao), which is a wholly owned subsidiary of the Liberian company, Court Investments Ltd. ("Court"). Court is wholly owned by a foreign discretionary trust of which Mr. Idan Ofer is a beneficiary. XT Investments, which directly holds approximately 1.24% of the share capital of Israel Corp., is a shareholder in Millennium. XT Investments is a private company, wholly owned by XT Holdings Ltd. ("XT Holdings"), a private company whose ordinary shares are held in equal shares by Orona Investments Ltd. (which is indirectly controlled by Mr. Ehud Angel) and by Lynav Holdings Ltd., a company that is controlled by a foreign discretionary trust of which Mr. Idan Ofer is the principal beneficiary. Mr. Ehud Angel holds a special share that gives him, inter alia, under certain limitations for certain issues, an additional vote on the board of directors of XT Holdings. In addition, Kirby Enterprises Inc., which is indirectly held by a foreign trust that holds Mashat in which Mr. Idan Ofer is a beneficiary, holds approximately 0.74% of the share capital of Israel Corp. Furthermore, Mr. Idan Ofer holds directly approximately 3.85% of the share capital of Israel Corp.

(5)
As of September 10, 2014, 372 million ordinary shares had been pledged by Israel Corporation to secure certain liabilities, almost entirely comprised of margin loans with an aggregate outstanding principal amount of $1.034 billion. See "Risk Factors—Risks Related to Our Ordinary Shares and the Offering—If our existing shareholders sell additional ordinary shares, or if these shares are sold by others, either on the TASE or the NYSE, after this offering, or if the forward counterparties or their affiliates sell additional ordinary shares to adjust their respective hedge positions during the terms of the forward sale agreements, the market price of our ordinary shares could decline."

(6)
PotashCorp Agricultural Cooperative Society Ltd. is an Israeli subsidiary of Potash Corporation of Saskatchewan Inc., a Canadian corporation whose shares are listed for trading on the Toronto Stock Exchange and the NYSE.

(7)
For a description of the different voting rights held by the holder of the Special State Share, see "Description of Share Capital—The Special State Share."

        Based upon a review of the information provided to us by the TASE, as of February 13, 2014, there were 49,786 holders of record of our ordinary shares, of which 621 record holders holding 119,903,799 ordinary shares, or approximately 9.3% of our outstanding ordinary shares, had registered addresses in the United States. These numbers are not representative of the number of beneficial holders of our ordinary

202


Table of Contents

shares nor is it representative of where such beneficial owners reside, since many of these shares were held of record by brokers or other nominees.


Significant Changes in Ownership by Major Shareholders

        There have not been any significant changes in ownership by our principal shareholders of our ordinary shares since January 1, 2011.

203


Table of Contents


DESCRIPTION OF SHARE CAPITAL

         The following description of our share capital and provisions of our Articles of Association are summaries and are qualified by reference to the Articles of Association, which have been filed with the SEC as an exhibit to our registration statement, of which this prospectus forms a part.

        As of June 30, 2014, our authorized share capital consisted of 1,484,999,999 ordinary shares, par value NIS 1 per share, of which 1,295,015,589 ordinary shares were issued and outstanding (including shares held by us or our subsidiaries), and 1 Special State Share, par value NIS 1 per share, which was issued and outstanding. All of our outstanding shares have been validly issued, fully paid and are non-assessable. As of June 30, 2014, 24,590,041 ordinary shares were held by us or our subsidiaries. Shares acquired by our subsidiaries prior to February 2000 have both economic rights and voting rights. However, in accordance with Israeli law, ordinary shares issued to our subsidiaries or purchased by our subsidiaries after February 2000 have economic rights but not voting rights. Shares held by us have no economic rights or voting rights. Therefore, out of the ordinary shares held by us or our subsidiaries, 24,590,041 have no voting rights.

        As of June 30, 2014, an additional 11,993,400 ordinary shares were issuable upon the exercise of outstanding options granted to our officers and employees at a weighted average exercise price of NIS 42.6585 per share. On August 6, 2014, our Board of Directors approved an issuance of up to approximately 4,384,540 non-marketable options, for no consideration, exercisable for approximately 4,384,540 of our ordinary shares, and up to approximately 1,025,449 restricted shares, to approximately 450 of our officers and senior employees. See "Management—Incentive Compensation Plans" for more information about our outstanding option plans.

        Since January 1, 2011, the only changes to our issued capital have been due to issuances of ordinary shares upon the exercise of options granted to our officers and employees. In 2011, 2012 and 2013, 2,991,740, 2,159,929 and 6,633,574 options under our equity compensation plans were exercised, resulting in the sale to certain of our officers and senior employees at a weighted average exercise price of NIS 18.61, NIS 16.84 and NIS 47.01, respectively, of 2,991,740, 2,159,929 and 6,633,574 ordinary shares, respectively. In the first half of 2014, no options under our equity compensation plans were exercised.

        We are an Israeli company incorporated with limited liability and our affairs are governed by the provisions of our Memorandum of Association and Articles of Association, each as amended and restated from time to time, and by the provisions of applicable Israeli law, including the Companies Law.

        Our number with the Israeli Registrar of Companies is 520027830. The purposes of our Company appear in Section 2 of our Memorandum of Association and Section 3 of our Articles of Association. They authorize us to engage in any lawful activity whatsoever, including any activities in the fields of extraction, manufacturing, trade, transport, marketing and distribution of various ores, minerals and substances or compounds, including downstream products or related products. In addition, our Articles of Association authorize us to donate reasonable amounts to any worthy causes. Our registered office is at Millennium Tower, 23 Aranha Street, Tel Aviv, 61070, Israel.


The Board of Directors

        Under the Companies Law and our Articles of Association, our Board of Directors may exercise all powers and take all actions that are not required under the Companies Law or under our Articles of Association to be exercised or taken by another corporate body, including the power to borrow money for the purposes of our Company. Our directors are not subject to any age limit requirement, nor are they disqualified from serving on our Board of Directors because of a failure to own a certain amount of our shares. For more information about our Board of Directors, see "Management."

204


Table of Contents


Our Ordinary Shares

        Subject to the rights of holders of shares with preferential or special rights which may be authorized in the future, holders of our ordinary shares are entitled to participate in the payment of dividends pro rata in accordance with the amounts paid-up or credited as paid-up on the par value of such ordinary shares at the time of payment without taking into account any premium paid thereon. In the event of our liquidation, holders of our ordinary shares are entitled to a pro rata share of surplus assets remaining over liabilities, subject to rights conferred on any class of shares which may be issued in the future, again in accordance with the amounts paid-up or credited as paid-up on the par value of such ordinary shares, without taking into account any premium paid thereon.

        According to the Companies Law, a company may make a distribution of dividends out of its profits on the condition that there is no reasonable concern that the distribution may prevent the company from meeting its existing and expected obligations when they fall due. The Companies Law defines such profit as retained earnings or profits accrued in the last two years, whichever is greater, according to the last reviewed or audited financial statements of the company, provided that the date of the financial statements is not more than six months before the distribution. Declaration of dividends ordinarily requires a resolution of our Board of Directors but does not require shareholder approval.

        Under Israeli law, holders of ordinary shares are permitted to freely convert dividends and liquidation distributions into non-Israeli currencies, provided that we have withheld Israeli income tax with respect to such amounts. Certain reporting obligations may apply. Pursuant to the Bank of Israel Law, 5570-2010, currency control measures may be imposed by governmental action, under special circumstances, at any time.

        Holders of our ordinary shares are entitled to one vote for each share on all matters submitted to a vote of shareholders, subject to any special rights of the Special State Share or to any class of shares that may be authorized in the future. Cumulative voting is not permitted for the election of directors.

        The quorum required for a meeting of shareholders consists of at least two shareholders, present in person or by proxy, jointly holding more than 50% of the issued shares conferring voting rights. A shareholders' meeting will be adjourned for lack of a quorum, after half an hour from the time set for such meeting, to the same day in the following week at the same time and place, or any time and place as our Board of Directors designates in a notice to the shareholders. If at such adjourned meeting a quorum as specified above is not present within half an hour from the time designated for holding the meeting, two shareholders jointly holding at least one-third of the issued shares, present in person or by proxy shall constitute a quorum.

        The Chairman of our Board of Directors is entitled to preside as Chairman of each shareholders' meeting. If he is absent, his deputy or another shareholder elected by the present shareholders will preside. The Chairman has a casting vote in the event of a tie at shareholders' meetings.

        A simple majority is sufficient to approve shareholders' resolutions, including any amendment to our Articles of Association, unless otherwise required by our Articles of Association or by law. Certain actions require the consent of the holder of the Special State Share. See "—The Special State Share" below.

205


Table of Contents

        We are required to hold an annual meeting of our shareholders once every calendar year, but no later than 15 months after the date of the previous annual meeting. All meetings other than the annual meeting of shareholders are referred to as special meetings. Our Board of Directors may call special meetings whenever it sees fit, at such time and place as it may determine. In addition, the Companies Law provides that the board of directors of a public company is required to convene a special meeting upon the request of:

        The Companies Law enables our Board of Directors to fix a record date to allow us to determine the shareholders entitled to notice of, or to vote at, any meeting of our shareholders. Under current regulations, the record date may be not more than forty days and not less than four days prior to the date of the meeting and notice is required to be published at least 21 or 35 days prior to the meeting, depending on the type of items on the agenda.

        The rights attached to a class of shares may be altered by the approval of the shareholders of such class holding a majority of the voting rights of such class. The provisions in our Articles of Association pertaining to general meetings also apply to any special meeting of a class of shareholders. The quorum required for such special meeting is at least two persons who are the holders of more than 50% of the issued shares of that class represented in person or by proxy at such meeting. If such special meeting is adjourned due to a lack of quorum, the quorum required at the subsequent meeting will be at least two persons who are holders of at least one-third of the issued shares of that class or their proxies.

        No preemptive rights are attached to our ordinary shares.

        The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our Memorandum of Association, our Articles of Association or the laws of the State of Israel, except for ownership by nationals of some countries that are, or have been, in a state of war with Israel and except for transfers regulated by the terms of the Special State Share.


The Special State Share

        The State of Israel holds a nontransferable Special State Share in ICL in order to preserve the State's vital interests. Any change in provisions of our Articles of Association relating to the rights attached to the Special State Share requires approval from the State of Israel. The Special State Share grants its holder the rights described below.

        Without the approval of the holder of the Special State Share, the sale or transfer of material assets of the Company or granting any other rights in the abovementioned assets, not in the ordinary course of our business, whether in one transaction or in a series of transactions, is invalid. The holder of the Special State Share has the right to oppose the transfer of a material asset as stated above only if, in its opinion, such transfer is likely to harm one of the "State's vital interests" enumerated below. Restrictions are similarly imposed on voluntary liquidation, mergers and reorganizations, excluding certain exceptional cases enumerated in our Articles of Association.

206


Table of Contents

        In addition, without the approval of the holder of the Special State Share, any acquisition or holding of 14% or more of our outstanding share capital is not valid. In addition, any acquisition or holding of 25% or more of our outstanding share capital (including an increase of holdings to 25%) is not valid without the approval of the holder of the Special State Share, even if in the past the approval of the holder of the Special State Share had been received for ownership of less than 25%. Our Articles of Association set forth procedures required to be followed by a person who intends to acquire shares in an amount that would require the approval of the holder of the Special State Shares. A pledge over shares is treated like an acquisition of shares. As a condition to voting at any shareholders' meeting, each interested party in the Company, including a holder of 5% or more of our outstanding shares, will be required to certify in writing that the voting power derived from the holding of shares does not require the approval of the holder of the Special State Share or that such approval has been obtained.

        In addition to the above, the approval of the holder of the Special State Share is required for the ownership of any shares that grant their holder the right, ability or practical potential to appoint directly or indirectly 50% or more of our directors, and such appointments will not be valid as long as that approval has not been obtained.

        The holder of the Special State Share has the right to receive information from us, as provided in our Articles of Association. Our Articles of Association also provide that the holder of the Special State Share will use this information only to exercise its rights under the Articles of Association for purposes of protecting the State's vital interests.

        Our Articles of Association also impose a periodic reporting obligation on us for the benefit of the holder of the Special State Share, regarding all asset-related transactions approved by our Board of Directors during the three months prior to the date of the report, any changes in share capital ownership and any voting agreements among the Company's shareholders signed during that period.

        The following are the "State's vital interests" as defined in our Articles of Association for purposes of the Special State Share:

        Furthermore, our headquarters and the ongoing management and control over our business activities must be in Israel. The majority of the members of our Board of Directors must be Israeli citizens and residents. In general, meetings of our Board of Directors must take place in Israel.

        Other than the rights enumerated above, the Special State Share does not grant the holder any voting or equity rights.

        The State of Israel also holds a Special State Share in the following ICL subsidiaries: Dead Sea Works, Dead Sea Bromine Company, Rotem, Bromine Compounds, Tami and Dead Sea Magnesium. The rights

207


Table of Contents

granted by these shares according to the Articles of Association of these subsidiaries are substantially similar to the rights enumerated above. The full provisions governing the rights of the Special State Share appear in our Articles of Association and in the Articles of Association of Dead Sea Works, Rotem, Dead Sea Bromine Company, Bromine Compounds, Tami and Dead Sea Magnesium and are available for the public's review. We report to the State of Israel on an ongoing basis in accordance with the provisions of our Articles of Association. Certain asset transfer or sale transactions that in our opinion require approval, have received the approval of the holder of the Special State Share.


Anti-Takeover Provisions; Mergers and Acquisitions

        The Companies Law permits mergers with the approval of each party's board of directors and shareholders. In accordance with the Companies Law, our Articles of Association provide that a statutory merger may be approved at a shareholders meeting by a majority of the voting rights represented at the meeting, in person or by proxy, and voting on the merger. Shares held by the other party to the merger and the shares of any person holding at least 25% of the outstanding voting shares or the means of appointing the board of directors of the other party to the merger, or the relatives or companies controlled by these persons, are excluded from the vote. In addition, our Articles of Association provide that a merger must be approved by the holder of our Special State Share.

        Under the Companies Law, a merging company must inform its creditors of the proposed merger. Any creditor of a party to the merger may seek a court order blocking the merger if there is a reasonable concern that the surviving company will not be able to satisfy all of the obligations of the parties to the merger. In addition, a merger may not be completed until at least 50 days have passed from the date that a merger proposal was filed with the Israeli Registrar of Companies by each party and 30 days have passed since the merger was approved by the shareholders of each party.

        Mergers may also be conducted by court order under a plan of arrangement.

        The Companies Law provides that an acquisition of shares in a public company must be made by means of a tender offer if, as a result of the acquisition, the purchaser would become a holder of 25% of the voting rights in the company, unless there is already a person holding 25% of the voting rights in the company. Similarly, the Companies Law provides that an acquisition of shares in a public company must be made by means of a tender offer if as a result of the acquisition the purchaser would become a holder of more than 45% of the voting rights in the company, unless there is already a person holding more than 45% of the voting rights in the company. These requirements do not apply if the acquisition (i) occurs in the context of a private placement by the company that received shareholder approval or (ii) was from a 25% or 45% shareholder, as the case may be. The tender offer must be extended to all shareholders, but the offeror is not required to purchase more than 5% of the company's outstanding shares, regardless of how many shares are tendered by shareholders. The tender offer generally may be consummated only if (i) at least 5% of the voting rights in the company will be acquired by the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer.

        If as a result of an acquisition of shares the acquirer will hold more than 90% of a company's outstanding shares, the acquisition must be made by means of a tender offer for all of the outstanding shares. If as a result of a full tender offer the acquirer would own more than 95% of the outstanding shares (including a majority of the shares held by disinterested shareholders), then all the shares that the acquirer offered to purchase will be transferred to it. The Companies Law provides for appraisal rights if any shareholder files a request in court within six months following the consummation of such a tender offer and the payment of the fair value of the shares by the acquirer, but the acquirer is entitled to stipulate that tendering shareholders forfeit their appraisal rights. If as a result of a full tender offer the acquirer would

208


Table of Contents

own 95% or less of the outstanding shares, then the acquirer may not acquire shares that will cause his shareholding to exceed 90% of the outstanding shares.

        Israeli tax considerations may make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty with Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent on the fulfillment of numerous conditions, including a holding period of two years from the date of the transaction during which sales and dispositions of shares of the merging companies are restricted. Moreover, with respect to certain share swap transactions, the tax deferral is for a limited period and can become payable even if no actual disposition of the shares has occurred.


Shareholder Duties

        Under the Companies Law, a shareholder has a duty to act in good faith and customary manner toward the company and other shareholders and to refrain from abusing its power in the company. This duty applies, inter alia, when voting at a meeting of shareholders on the following matters:

        In addition, certain shareholders have a duty of fairness toward the company. These shareholders include any controlling shareholder, any shareholder who knows that it possesses the power to determine the outcome of a shareholder vote and any shareholder who, under the company's articles of association, has the power to appoint or to prevent the appointment of a director or officer of the company or another power with respect to the company. The Companies Law does not define the substance of this duty of fairness. However, a shareholder's breach of the duty of fairness is subject to laws regarding breaches of contracts and takes into account the status of such shareholder with respect to the company.


Listing

        We have been approved to list our ordinary shares on the NYSE under the symbol "ICL."


Transfer Agent and Registrar

        We have appointed American Stock Transfer & Trust Company, LLC, New York, New York, as the transfer agent and registrar for our ordinary shares. The nominee company to the TASE in whose name most of our ordinary shares are held of record is Registration Company of Bank Hapoalim Ltd.

209


Table of Contents


SHARES ELIGIBLE FOR FUTURE SALE

        Prior to this offering, our ordinary shares have been traded only on the TASE. The prevailing market price of our ordinary shares could be adversely affected by future sales of our ordinary shares in the public market, the availability of such shares for sale in the public market or the perception that future sales could occur.

        We have a total of 1,295,015,589 ordinary shares outstanding (including 24,590,041 ordinary shares held by us or our subsidiaries), assuming no exercise of any options outstanding as of December 31, 2013. All of our outstanding ordinary shares will be freely transferable and may be resold in the United States without restriction or further registration under the Securities Act, except for shares held by us, our "affiliates," as that term is defined in Rule 144 under the Securities Act, or as provided below under "—Lock-Up Agreements" and "—Stock Options and Restricted Shares." Under Rule 144 under the Securities Act, an "affiliate" of a company is a person that directly or indirectly controls, is controlled by or is under common control with that company. Affiliates may sell only the volume of shares described below and their sales are subject to the additional restrictions described below.


Rule 144

        In general, under Rule 144 under the Securities Act, a person (or persons whose shares are aggregated) who is not deemed to have been an affiliate of ours at any time during the three months preceding a sale, and who has beneficially owned restricted securities within the meaning of Rule 144, for at least six months (including any period of consecutive ownership of preceding non-affiliated holders) would be entitled to sell those shares, subject only to the availability of current public information about us. A non-affiliated person who has beneficially owned restricted securities within the meaning of Rule 144 for at least one year would be entitled to sell those shares without regard to the provisions of Rule 144.

        A person (or persons whose shares are aggregated) who is deemed to be an affiliate of ours and who has beneficially owned restricted securities within the meaning of Rule 144 for at least six months would be entitled to sell within any three-month period a number of shares that does not exceed the greater of one percent of our then-outstanding ordinary shares or the average weekly trading volume of our ordinary shares on the NYSE during the four calendar weeks preceding such sale. Such sales are also subject to certain manner of sale provisions, notice requirements and the availability of current public information about us.


Stock Options and Restricted Shares

        As of December 31, 2013, 15,742,655 ordinary shares were issuable upon the exercise of options outstanding under our incentive compensation plans at weighted average exercise prices of NIS 45.98 per share and NIS 44.59 per share with respect to the 2010 Plan and 2012 Plan, respectively, of which 3,747,255 options under the 2010 Plan expired in January 2014 without exercise. As of June 30, 2014, 11,993,400 ordinary shares were reserved for issuance under our option plans. See "Management—Incentive Compensation Plans" for more information about our stock options.

        In addition, on August 6, 2014, our Board of Directors approved an issuance of up to approximately 4,384,540 non-marketable options, for no consideration, exercisable for approximately 4,384,540 of our ordinary shares, and up to approximately 1,025,449 restricted shares, to approximately 450 of our officers and senior employees. See "Management—Incentive Compensation Plans—The 2014 Equity Compensation Plan."

        Upon completion of this offering, we intend to file a registration statement under the Securities Act covering all ordinary shares subject to outstanding options. This registration statement will become effective immediately upon filing, and shares registered thereunder will be available for sale in the open market, subject to Rule 144 volume limitations applicable to affiliates, vesting restrictions with us or the contractual restrictions described below.

210


Table of Contents


Lock-up Agreements

        We, our directors and officers and Israel Corporation will sign lock-up agreements with the underwriters that will, subject to certain exceptions, restrict the sale of ordinary shares held by them for 180 days following the date of this prospectus, subject to extension in the case of an earnings release or material news or a material event relating to us. Morgan Stanley & Co. LLC may, in its sole discretion, release all or any portion of the shares subject to lock-up agreements. See "Underwriting" for a description of these lock-up agreements.

211


Table of Contents


TAX CONSIDERATIONS

         The following are material Israeli and U.S. federal income tax consequences of the ownership and disposition of ordinary shares, but it does not purport to be a comprehensive description of all the tax considerations that may be relevant to a decision to own ordinary shares. This discussion does not address all the aspects of Israeli or U.S. tax law that may be relevant to an investor in light of its particular circumstances or to certain types of investors subject to special treatment under applicable law. The following discussion also contains an overview of the current tax regime applicable to companies in Israel, with specific reference to its effect on us. This discussion is based upon the tax laws of Israel and regulations thereunder and on the tax laws of the United States and regulations thereunder as of the date hereof, which are subject to change.


Israeli Tax Considerations

Taxation of the Company

General Corporate Tax Structure

        Israeli companies are generally subject to corporate tax on their taxable income at the rate of 25% for the 2013 tax year and 26.5% for the 2014 tax year. Pursuant to an amendment to the Israeli Income Tax Ordinance [New Version], 1961 (the "Tax Ordinance"), which came into effect on January 1, 2014, the corporate tax rate is scheduled to remain at 26.5% for future tax years. Israeli companies are generally subject to capital gains tax at the corporate tax rate. For information about the new "natural resources tax" proposed by the Sheshinski Committee, see "Prospectus Summary—Recent Developments."


Tax Benefits under the Law for the Encouragement of Capital Investments

        The Law for the Encouragement of Capital Investments, 1959 (the "Investments Law"), as in effect until April 2005, provides that a capital investment in eligible facilities may, upon application to the Investment Center of the Ministry of Industry and Trade (currently called the Ministry of the Economy) of the State of Israel, be designated as an Approved Enterprise. See below regarding an amendment to the Investments Law that came into effect in 2005 and a reform of the Investments Law that came into effect in 2011.

        Each certificate of approval for an Approved Enterprise relates to a specific investment program delineated both by its financial scope, including its capital sources, and by its physical characteristics, e.g., the equipment to be purchased and utilized pursuant to the program. Taxable income of a company derived from an Approved Enterprise is subject to company tax at the maximum rate of 25% (rather than the regular corporate tax rate) for the applicable benefit period. The benefit period is typically seven years commencing from the year in which the Approved Enterprise first generated taxable income (limited to 12 years from commencement of production or 14 years from the start of the year of receipt of approval, whichever is earlier) and, under certain circumstances (as further detailed below), could extend to a period of ten years. Tax benefits under the Investments Law also apply to income generated by a company from the grant of a usage right with respect to know-how developed by the Approved Enterprise, income generated from royalties, and income derived from a service which is auxiliary to such usage right or royalties, provided that such income is generated within the Approved Enterprise's ordinary course of business.

        A company that has an Approved Enterprise program is eligible for further tax benefits if it qualifies as a "foreign investors' company." A "foreign investors' company" is a company more than 25% of whose share capital (calculated as combined share and loan capital) is owned by non-Israeli residents. A company that qualifies as a foreign investors' company and has an Approved Enterprise program is eligible for tax benefits for a ten-year benefit period. As specified below, depending on the geographic location of the Approved Enterprise within Israel, income derived from the Approved Enterprise program may be exempt from tax on its undistributed income for a period of between two and ten years and will be subject to a

212


Table of Contents

reduced tax rate for the remainder of the benefits period. The tax rate for the remainder of the benefits period is between 10% and 25%, depending on the level of foreign investment in each year.

        A company with an Approved Enterprise designation may elect to forego certain government grants extended to Approved Enterprises in return for an "alternative package of benefits." Under such alternative package of benefits, a company's undistributed income derived from an Approved Enterprise will be exempt from corporate tax for a period of between two and ten years from the first year of taxable income, depending on the geographic location of the Approved Enterprise within Israel, and such company will be eligible for the tax benefits under the Investments Law for the remainder of such benefits period.

        A company that has elected such alternative package of benefits and that subsequently pays a dividend out of income derived from an Approved Enterprise during the tax exemption period will be subject to corporate tax in respect of the amount distributed (including the tax thereon) at the rate which would have been applicable had the company not elected the alternative package of benefits (10%-25%, depending on the extent of foreign ownership of the company's share capital). The dividend recipient is taxed at the reduced rate applicable to dividends from Approved Enterprises (15%) if the dividend is distributed out of income derived during the tax exemption period. This tax must be withheld by the company at source, regardless of whether the dividend is converted into foreign currency.

        The benefits available to an Approved Enterprise are contingent upon the satisfaction of certain conditions stipulated in the law and applicable regulations and the criteria set forth in the specific certificates of approval. In the event that these conditions are not satisfied, in whole or in part, we would be required to refund the amount of tax benefits received, as adjusted for increases in the consumer price index, plus interest.

        The production facilities of several group companies in Israel have received Approved Enterprise status under the Investments Law. We believe our Approved Enterprises operate in substantial compliance with all applicable conditions and criteria. We cannot assure you that we will continue to receive benefits for such programs at the current levels, if at all. For further information, see note 20 to our audited financial statements included elsewhere in this prospectus.

        On April 1, 2005, an amendment to the Investment Law came into effect, which is referred to as Amendment No. 60. Amendment No. 60 revised the criteria for investments qualified to receive tax benefits. An eligible investment program under the amendment will qualify for benefits as a Benefited Enterprise (rather than the previous terminology of Approved Enterprise). Among other things, the amendment provides tax benefits to both local and foreign investors and simplifies the approval process. The period of tax benefits for a new Benefited Enterprise commences in the year in which taxable income is first generated by the company, or a later year selected by the company, on the condition that the company meets certain provisions set forth in the Investment Law. Amendment No. 60 applies to Benefited Enterprise programs in which the year of commencement of benefits under the Investments Law is 2004 or later, unless such programs received "Approved Enterprise" approval from the Investment Center on or prior to March 31, 2005, in which case the provisions of the amendment do not apply. Generally, under the amendment a company that is Abundant in Foreign Investment (as defined in the Investments Law) is entitled to an extension of the benefits period by an additional five years, depending on the rate of its income that is derived in foreign currency.

        Amendment No. 60 changes the definition of "foreign investment" in the Investments Law to require a minimal investment of NIS five million by foreign investors. Furthermore, such definition was also amended to include the purchase of outstanding shares of the company from an existing shareholder, provided that the company's outstanding and paid-up share capital exceeds NIS five million. Such changes to the aforementioned definition are retroactive from 2003.

213


Table of Contents

        Amendment No. 60 also added a specific taxation package, referred to as the "Ireland Track". Upon election, the Ireland Track provides for a 10-year term with a corporate tax rate of 11.5% and a tax rate of 4% on the distribution of dividends to foreign investors (15% to Israeli resident investors), with no further corporate tax implications on the distributing company.

        The production facilities of several group companies in Israel claimed Benefited Enterprise status under the Investments Law, and specifically under the Ireland Track. We believe our Benefited Enterprises operate in substantial compliance with all applicable conditions and criteria. We cannot assure you that our programs will continue to receive benefits at the current levels, if at all. For further information, see note 20 to our audited financial statements included elsewhere in this prospectus.


Reform of the Investments Law—2011

        On December 29, 2010, the Israeli Parliament approved an amendment to the Investments Law, effective as of January 1, 2011, which constitutes a reform of the incentives regime under such law, or the Investments Law Reform. Its provisions apply with respect to "preferred income" (as defined in the Investments Law Reform) produced from or generated by a new type of program called a Preferred Enterprise or Special Preferred Enterprise. The Investments Law Reform replaces the previous regime of Approved Enterprises and Benefitted Enterprises, although pre-existing programs are permitted to continue until the expiration thereof.

        The Investments Law Reform modifies the objectives of the Investments Law to focus on achieving enhanced growth in the business sector, improving the Israeli industry's competitiveness in international markets and creating employment and development opportunities in remote areas of Israel. It allows enterprises meeting certain criteria to enjoy grants as well as tax benefits. It also introduces changes to the map of geographic development areas for purposes of entitlement to preferential terms under the Investments Law.

        The main points of the Investments Law Reform are a standard reduced tax rate on all revenues that are entitled to benefits, which include the following:

214


Table of Contents

        The Investments Law Reform provides various transition provisions which allow, under certain circumstances, the application of the new regime to investment programs previously approved or elected under the Investments Law.

        Under the Investments Law Reform, incentives are not available to an industrial enterprise that is a mine, another plant for the extraction of minerals, or an oil exploration enterprise. Consequently, our plants that are defined as mining or mineral extraction operations will be unable to benefit from the incentives under the Investments Law Reform. The Investments Law Reform did not affect the incentives under pre-existing Approved Enterprises and Benefitted Enterprises, which are permitted to continue until the expiration thereof. Following the expiration of such existing programs, our effective tax rate in Israel (where we generate most of our profits) is expected to increase up to 26.5% beginning in 2018.


Tax Benefits Under the Law for the Encouragement of Industry (Taxes)

        According to the Law for the Encouragement of Industry (Taxes), 1969, or the Industry Encouragement Law, an "industrial company" is a company resident in Israel, at least 90% of the income of which, in a given tax year, determined in Israeli currency (exclusive of income from certain government loans, capital gains, interest and dividends), is derived from an enterprise whose major activity in a given tax year is industrial production activity.

        Under the Industry Encouragement Law, industrial companies are entitled to the following preferred corporate tax benefits:

        Eligibility for benefits under the Industry Encouragement Law is not subject to receipt of prior approval from any governmental authority.

        We believe that we currently qualify as an industrial company within the definition of the Industry Encouragement Law. We cannot assure you that we will continue to qualify as an industrial company or that the benefits described above will be available to us in the future.


Israeli Transfer Pricing Regulations

        On November 29, 2006, Income Tax Regulations (Determination of Market Terms), 2006, promulgated under Section 85A of the Tax Ordinance, came into effect. Section 85A of the Tax Ordinance and such regulations generally require that all cross-border transactions carried out between associated parties will be conducted on an arm's length basis and will be taxed accordingly. The Company and its Israeli subsidiaries conduct transactions with non-Israeli group companies and believe they are in compliance with Section 85A of the Tax Ordinance and such regulations. However, no assurance can be given that the Israeli tax authorities will not challenge the pricing for any of our related party transactions.

Taxation of Investors

        In the opinion of Goldfarb Seligman & Co., the following are material Israeli income tax consequences to the investors described below of owning and disposing of our ordinary shares, but it does

215


Table of Contents

not purport to be a comprehensive description of all the tax considerations that may be relevant to a particular person's decision to acquire the ordinary shares.


Capital Gains Tax

        Israeli law generally imposes a capital gains tax on the sale of any capital assets by residents of Israel, as defined for Israeli tax purposes, and on the sale of capital assets located in Israel, including shares of Israeli companies, by non-residents of Israel, unless a specific exemption is available or unless a tax treaty between Israel and the shareholder's country of residence provides otherwise. The law distinguishes between real gain and inflationary surplus. The inflationary surplus is a portion of the total capital gain that is equivalent to the increase of the relevant asset's purchase price which is attributable to the increase in the Israeli consumer price index or a foreign currency exchange rate between the date of purchase and the date of sale. The real gain is the excess of the total capital gain over the inflationary surplus.

        Generally, as of January 1, 2012, the tax rate applicable to capital gains derived from the sale of shares, whether listed on a stock market or not, is the corporate tax rate in Israel (26.5% commencing from January 2014) for Israeli companies and 25% for Israeli individuals, unless such shareholder claims a deduction for finance expenses in connection with such shares, in which case the gain will generally be taxed at a rate of 30%. Additionally, if such shareholder is considered a "significant shareholder" at any time during the 12-month period preceding such sale, the tax rate will be 30%. A "significant shareholder" is defined as one who holds, directly or indirectly, including together with others, at least 10% of any means of control in the company. However, different tax rates will apply to dealers in securities. Israeli companies are subject to the corporate tax rate on capital gains derived from the sale of listed shares.

        As of January 1, 2013, shareholders who are individuals with taxable income that exceeds NIS 800,000 in a tax year (linked to the Israeli consumer price index each year—NIS 811,560 for 2014) will be subject to an additional tax at the rate of 2% on the portion of their taxable income for such tax year that is in excess such threshold. For this purpose, taxable income includes taxable capital gains from the sale of our shares and taxable income from dividend distributions.

        Non-Israeli residents are generally exempt from Israeli capital gains tax on any gains derived from the sale of shares of Israeli companies publicly traded on a recognized stock exchange outside Israel, so long as such shareholders did not acquire their shares prior to the company's initial public offering and the gains did not derive from a permanent establishment of such shareholders in Israel. However, shareholders that are non-Israeli corporations will not be entitled to such exemption if Israeli residents hold an interest of more than 25% in such non-Israeli corporation or are the beneficiaries or are entitled to 25% or more of the revenues or profits of such non-Israeli corporation, whether directly or indirectly.

        In certain instances where our shareholders may be liable to Israeli tax on the sale of their ordinary shares, the payment of the consideration may be subject to the withholding of Israeli tax at the source.

        In addition, pursuant to the Convention between the Government of the United States of America and the Israeli government with respect to Taxes on Income, as amended, or the U.S.-Israel Tax Treaty, the sale, exchange or disposition of ordinary shares by a person who qualifies as a resident of the United States within the meaning of the U.S.-Israel Tax Treaty and who is entitled to claim the benefits afforded to such person by the U.S.-Israel Tax Treaty generally will not be subject to the Israeli capital gains tax unless such person holds, directly or indirectly, shares representing 10% or more of our voting power during any part of the 12-month period preceding such sale, exchange or disposition, subject to particular conditions, or the capital gains from such sale, exchange or disposition can be allocated to a permanent establishment in Israel or is considered to be derived from or sale of Israeli real property interests for purposes of the U.S.-

216


Table of Contents

Israel Tax Treaty. If a U.S. investor is not exempt from Israeli taxes under the U.S.-Israel Tax Treaty, such U.S. investor may be subject to Israeli tax, to the extent applicable as described above; however, under the U.S.-Israel Tax Treaty, such person may be permitted to claim a credit for such taxes against the U.S. federal income tax imposed with respect to such sale, exchange or disposition, subject to the limitations in U.S. laws applicable to foreign tax credits. The U.S.-Israel Tax Treaty does not relate to U.S. state or local taxes.


Taxation of Dividend Distributions

        Israeli resident individuals are generally subject to Israeli income tax on the receipt of dividends paid on our ordinary shares, other than bonus shares (share dividends). As of January 1, 2012, the tax rate applicable to such dividends is 25% or 30% for a shareholder that is considered a significant shareholder at any time during the 12-month period preceding such distribution. Dividends paid from income derived from Approved, Benefited or Preferred Enterprises (accrued up to December 31, 2013) are subject to withholding at the rate of 15%. Dividends paid from income derived from Approved or Preferred Enterprises accrued from January 1, 2014 will be subject to withholding at the rate of 20%.

        Israeli resident companies are generally exempt from tax on the receipt of dividends paid on our ordinary shares (excluding dividends paid from income derived from Approved or Benefited Enterprises).

        We cannot assure you that we will designate the profits that are being distributed in a way that will reduce shareholders' tax liability.

        Non-residents of Israel are subject to income tax on income accrued or derived from sources in Israel, including dividends paid by Israeli companies. On distributions of dividends other than stock dividends, income tax (generally collected by means of withholding) will generally apply at the rate of 25%, or 30% for a shareholder that is considered a significant shareholder (as defined above) at any time during the 12-month period preceding such distribution, unless a different rate is provided in a treaty between Israel and the shareholder's country of residence. Dividends paid from income derived from Approved, Benefited or Preferred Enterprises (accrued up to December 31, 2013) are subject to withholding at the rate of 15%, or 4% for Benefited Enterprises in the Ireland Track. Dividends paid from income derived from Approved or Preferred Enterprises accrued from January 1, 2014 will be subject to withholding at the rate of 20%.

        If the dividend is attributable partly to income derived from an Approved, Benefited or Preferred Enterprise, and partly to other sources of income, the withholding rate will be a weighted-average rate reflecting the relative portions of the various types of income.

        Under the U.S.-Israel Tax Treaty, the maximum tax on dividends paid to a holder of ordinary shares who qualifies as a resident of the United States within the meaning of the U.S.-Israel Tax Treaty is 25%. The treaty provides for reduced tax rates on dividends if (a) the shareholder is a U.S. corporation holding at least 10% of our issued voting power during the part of the tax year that precedes the date of payment of the dividend and held such minimal percentage during the whole of its prior tax year, and (b) not more than 25% of the Israeli company's gross income consists of interest or dividends, other than dividends or interest received from subsidiary corporations or corporations 50% or more of the outstanding voting shares of which is owned by the Israeli company. The reduced treaty rate, if applicable, is 15% in the case of dividends paid from income derived from Approved, Benefited or Preferred Enterprise or 12.5% otherwise.

217


Table of Contents


Material U.S. Federal Income Tax Considerations for U.S. Holders

        In the opinion of Davis Polk & Wardwell LLP, the following are material U.S. federal income tax consequences to the U.S. Holders described below of owning and disposing of our ordinary shares, but it does not purport to be a comprehensive description of all the tax considerations that may be relevant to a particular person's decision to acquire the ordinary shares. This discussion applies only to a U.S. Holder that acquires the ordinary shares in this offering and holds the ordinary shares as capital assets for U.S. federal income tax purposes. In addition, it does not describe all of the tax consequences that may be relevant in light of a U.S. Holder's particular circumstances, including alternative minimum tax consequences, any aspect of the provisions of the Internal Revenue Code of 1986, as amended (the "Code") commonly known as the Medicare tax and tax consequences applicable to U.S. Holders subject to special rules, such as:

        If an entity that is classified as a partnership for U.S. federal income tax purposes owns ordinary shares, the U.S. federal income tax treatment of a partner will generally depend on the status of the partner and the activities of the partnership. Partnerships owning ordinary shares and partners in such partnerships should consult their tax advisers as to the particular U.S. federal tax consequences of owning and disposing of the ordinary shares.

        This discussion is based on the Code, administrative pronouncements, judicial decisions, and final and proposed Treasury regulations, changes to any of which subsequent to the date of this offering may affect the tax consequences described herein.

        For purposes of this discussion, a "U.S. Holder" is a person who, for U.S. federal income tax purposes, is a beneficial owner of ordinary shares and is:

        U.S. Holders should consult their tax advisers concerning the U.S. federal, state, local and foreign tax consequences of owning and disposing of our ordinary shares in their particular circumstances.

        This discussion assumes that we are not, and will not become, a passive foreign investment company, as described below.

218


Table of Contents

        Distributions paid on our ordinary shares, other than certain pro rata distributions of ordinary shares, will be treated as dividends to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Because we do not calculate our earnings and profits under U.S. federal income tax principles, it is expected that distributions generally will be reported to U.S. Holders as dividends. Subject to applicable limitations, dividends paid to certain non-corporate U.S. Holders may be taxable at the favorable tax rates applicable to "qualified dividend income". Non-corporate U.S. Holders should consult their tax advisers regarding the availability of these favorable rates on dividends in their particular circumstances. Dividends will not be eligible for the dividends-received deduction generally available to U.S. corporations under the Code. Dividends will generally be included in a U.S. Holder's income on the date of receipt.

        Dividend income will include any amounts withheld by us in respect of Israeli taxes, and will be treated as foreign-source income for foreign tax credit purposes. Subject to applicable limitations, some of which vary depending upon the U.S. Holder's circumstances, Israeli taxes withheld from dividends on our ordinary shares will be creditable against the U.S. Holder's U.S. federal income tax liability. The rules governing foreign tax credits are complex, and U.S. Holders should consult their tax advisers regarding the creditability of foreign taxes in their particular circumstances. In lieu of claiming a foreign tax credit, U.S. Holders may, at their election, deduct foreign taxes, including Israeli taxes, in computing their taxable income, subject to applicable limitations. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year.

        For U.S. federal income tax purposes, gain or loss realized on the sale or other taxable disposition of our ordinary shares will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder held the ordinary shares for more than one year. The amount of the gain or loss will equal the difference between the U.S. Holder's tax basis in the ordinary shares disposed of and the amount realized on the disposition, in each case as determined in U.S. dollars. This gain or loss will generally be U.S.-source gain or loss for foreign tax credit purposes. The deductibility of capital losses is subject to limitations.

        In general, a non-U.S. corporation will be a "passive foreign investment company" (a "PFIC") for any taxable year if (i) 75% or more of its gross income consists of passive income or (ii) 50% or more of the average quarterly value of its assets consists of assets that produce, or are held for the production of, passive income. For purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as if it held its proportionate share of the assets of the other corporation and received directly its proportionate share of the income of the other corporation. Passive income generally includes dividends, interest, rents, royalties and gains from transactions in commodities (other than certain active business gains from the sales of commodities).

        Based on the manner in which we operate our business, we believe that we were not a PFIC for our most recent taxable year and do not expect to become a PFIC for our current taxable year or in the foreseeable future. However, because PFIC status depends on the composition and character of a company's income and assets and the value of its assets from time to time, there can be no assurance that we will not be a PFIC for any taxable year.

        If we were a PFIC for any taxable year during which a U.S. Holder held ordinary shares, gain recognized by a U.S. Holder on a sale or other disposition (including certain pledges) of the ordinary shares would be allocated ratably over the U.S. Holder's holding period for the ordinary shares. The amounts allocated to the taxable year of the sale or other disposition and to any year before we became a PFIC would be taxed as ordinary income. The amount allocated to each other taxable year would be

219


Table of Contents

subject to tax at the highest rate in effect for individuals or corporations, as appropriate, for that taxable year, and an interest charge would be imposed on the resulting tax liability for each such taxable year. Further, any distribution in respect of ordinary shares in excess of 125% of the average of the annual distributions received by a U.S. Holder during the preceding three years or the U.S. Holder's holding period, whichever is shorter, would be subject to taxation in the same manner.

        Alternatively, if we were a PFIC and the ordinary shares were "regularly traded" on a "qualified exchange" (such as the NYSE, where our ordinary shares are expected to be listed), a U.S. Holder could make a mark-to-market election with respect to our ordinary shares that would result in tax treatment different from the general tax treatment for PFICs described above. U.S. Holders should consult their tax advisers regarding the consequences of making a mark-to-market election in the case that we were a PFIC.

        A timely election to treat a company that is a PFIC as a qualified electing fund ("QEF election") would result in further alternative treatment (which alternative treatment could, in certain circumstances, mitigate the adverse tax consequences of owning shares in a PFIC). U.S. Holders should be aware, however, that we do not intend to provide the information that would be necessary for U.S. Holders to make a QEF election if we were a PFIC.

        If we were a PFIC for any taxable year during which a U.S. Holder owned ordinary shares, the U.S. Holder generally will be required to file annual reports on Internal Revenue Service Form 8621. In addition, the favorable tax rates described above with respect to dividends paid to certain non-corporate U.S. Holders would not apply if we were a PFIC for the taxable year of distribution or the preceding taxable year.

        U.S. Holders should consult their tax advisers regarding the potential application of the PFIC rules.

        Payments of dividends and sales proceeds that are made within the United States or through certain U.S.-related financial intermediaries generally are subject to information reporting, and may be subject to backup withholding, unless (i) the U.S. Holder is a corporation or other exempt recipient or (ii) in the case of backup withholding, the U.S. Holder provides a correct taxpayer identification number and certifies that it is not subject to backup withholding. Backup withholding is not an additional tax. The amount of any backup withholding from a payment to a U.S. Holder will be allowed as a credit against the holder's U.S. federal income tax liability and may entitle it to a refund, provided that the required information is timely furnished to the Internal Revenue Service.

        Certain U.S. Holders who are individuals (and under proposed regulations, certain entities controlled by individuals) may be required to report information relating to their ownership of securities of non-U.S. issuers, such as our ordinary shares, unless the securities are held in accounts at financial institutions (in which case the accounts may be reportable if maintained by non-U.S. financial institutions). U.S. Holders should consult their tax advisers regarding their reporting obligations with respect to the ordinary shares.

220


Table of Contents

UNDERWRITING

        Our ordinary shares are being sold by Morgan Stanley & Co. LLC, Barclays Capital Inc. and the other underwriters named in this prospectus.

        This is a combined offering of an aggregate amount of 62,000,000 of our ordinary shares, comprised of the sale by Israel Corporation of 36,207,128 of our ordinary shares and the expected sale by the forward counterparties of 25,792,872 of our ordinary shares to hedge their positions under the forward sale agreements described below. Our controlling shareholder, Israel Corporation, is selling 36,207,128 of our ordinary shares. In addition, Israel Corporation expects to enter into forward sale agreements with the forward counterparties. The forward counterparties will sell our ordinary shares under this prospectus through the underwriters to hedge their respective positions under the forward sale agreements. Israel Corporation will make available the ordinary shares to be sold under this prospectus to the forward counterparties.

        In connection with the foregoing, and under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the underwriters named below, for whom Morgan Stanley & Co. LLC and Barclays Capital Inc. are acting as representatives, have severally agreed to purchase, and Israel Corporation and the forward counterparties, as applicable, have agreed to sell to them, severally, the number of shares indicated below:

Name
  Number of
Shares
 

Morgan Stanley & Co. LLC

       

Barclays Capital Inc. 

       

Deutsche Bank Securities Inc. 

       

Goldman, Sachs & Co. 

       

BMO Capital Markets Corp. 

       
       

Total:

    62,000,000  
       

        The underwriters and the representative are collectively referred to as the "underwriters" and the "representative," respectively. The underwriters are offering the ordinary shares subject to their acceptance of the ordinary shares from the forward counterparties or Israel Corporation (as the case may be) and subject to prior sale. The underwriting agreement provides that the obligations of the several underwriters to pay for and accept delivery of the ordinary shares offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and pay for all of the ordinary shares offered by this prospectus if any such shares are taken. However, the underwriters are not required to take or pay for the ordinary shares covered by the underwriters' option described below.

        Our controlling shareholder, Israel Corporation, expects to enter into forward sale agreements with the forward counterparties, pursuant to which Israel Corporation will sell, and the forward counterparties will purchase, up to 36,207,128 ordinary shares, subject to the terms and conditions of the forward sale agreements. To support its obligations under the forward sale agreements, the selling shareholder will make available 36,207,128 ordinary shares to the forward counterparties, a portion of which will be sold under this prospectus. Settlement under the forward sale agreements is scheduled to occur on various dates between 2016 and 2019, with Israel Corporation having the option to elect cash settlement or net physical settlement in lieu of delivering all the shares. To the extent Israel Corporation elects cash settlement or net physical settlement under the forward sale agreements, the forward counterparties will return to Israel Corporation all or a portion of the ordinary shares it previously made available to the forward counterparties.

        We will not receive any proceeds from the sale of the ordinary shares by the underwriters, whether in connection with the forward sale agreements or the sale of ordinary shares by Israel Corporation directly

221


Table of Contents

to the underwriters. Israel Corporation will receive proceeds from its sale of the ordinary shares directly to the underwriters and will receive proceeds from the forward counterparties if it enters into the forward sale agreements.

        The underwriters initially propose to offer part of the ordinary shares directly to the public at the offering price listed on the cover page of this prospectus and part to certain dealers. After the initial offering of the ordinary shares, the offering price and other selling terms may from time to time be varied by the representative. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters' right to reject any order in whole or in part.

        Israel Corporation has granted the underwriters the right to purchase up to 6,200,000 additional ordinary shares. To the extent the option is exercised, each underwriter will become obligated, subject to certain conditions, to purchase about the same percentage of the additional ordinary shares as the number listed next to the underwriter's name in the preceding table bears to the total number of ordinary shares listed next to the names of all underwriters in the preceding table.

        The following table shows the per share and total public offering price, underwriting discounts and commissions, and proceeds before expenses to Israel Corporation or to the forward counterparties, as applicable. These amounts are shown assuming both no exercise and full exercise of the underwriters' option to purchase up to an additional 6,200,000 ordinary shares from Israel Corporation.

 
   
  Total  
 
  Per
Share
  No
Exercise
  Full
Exercise
 

Public offering price

  $     $     $    

Underwriting discounts and commissions

  $     $     $    

Proceeds, before expenses, to the forward counterparties

  $     $     $    

Proceeds, before expenses, to Israel Corporation

  $     $     $    

        Israel Corporation has agreed to reimburse the underwriters for certain out-of-pocket expenses incurred by them, including fees and disbursements of their counsel, up to an aggregate of $500,000, in connection with this offering.

        We and Israel Corporation have agreed to indemnify the several underwriters against certain liabilities, including liabilities under the Securities Act of 1933.

        The underwriters have informed us that they do not intend sales to discretionary accounts to exceed 5% of the total number of ordinary shares offered by them.

        We have been approved to list the ordinary shares on the NYSE under the symbol "ICL."

        We, our directors and officers, and Israel Corporation have agreed that, without the prior written consent of Morgan Stanley & Co. LLC on behalf of the underwriters, we and they will not, during the period ending 180 days after the date of this prospectus (the "restricted period"):

222


Table of Contents

whether any such transaction described above is to be settled by delivery of ordinary shares or such other securities, in cash or otherwise. In addition, we and each such person agrees that without the prior written consent of Morgan Stanley & Co. LLC on behalf of the underwriters, we or such other person will not, during the restricted period, make any demand for, or exercise any right with respect to, the registration of any ordinary shares or any security convertible into or exercisable or exchangeable for ordinary shares.

        The restrictions described in the immediately preceding paragraph do not apply, among other exceptions, to:

        The restricted period described in the preceding paragraph will be extended if:

223


Table of Contents

in which case the restrictions described in the preceding paragraph will continue to apply until the expiration of the 18-day period beginning on the issuance of the earnings release or the occurrence of the material news or material event.

        Morgan Stanley & Co. LLC, in its sole discretion, may release the ordinary shares and other securities subject to the lock-up agreements described above in whole or in part at any time with or without notice.

        In order to facilitate the offering of the ordinary shares, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of the ordinary shares. Specifically, the underwriters may sell more shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is covered if the short position is no greater than the number of shares available for purchase by exercising the option or purchasing shares in the open market. In determining the source of shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of shares compared to the price available under the option. The underwriters may also sell shares in excess of the option, creating a naked short position. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the ordinary shares in the open market after pricing that could adversely affect investors who purchase in this offering. As an additional means of facilitating this offering, the underwriters may bid for, and purchase, ordinary shares in the open market to stabilize the price of the ordinary shares. These activities may raise or maintain the market price of the ordinary shares above independent market levels or prevent or retard a decline in the market price of the ordinary shares. The underwriters are not required to engage in these activities and may end any of these activities at any time.

        A prospectus in electronic format may be made available on websites maintained by one or more underwriters, or selling group members, if any, participating in this offering. The representative may agree to allocate a number of ordinary shares to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated by the representative to underwriters that may make Internet distributions on the same basis as other allocations.

        The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective affiliates have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and expenses.

        In addition, in the ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers and may at any time hold long and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective affiliates may also make investment recommendations or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities and instruments.

        An affiliate of Goldman, Sachs & Co., one of the underwriters in this offering, is a lender under a margin loan with Israel Corporation, pursuant to which Israel Corporation has pledged 36 million of our ordinary shares. See "Risk Factors—Risks Related to Our Ordinary Shares and the Offering—If our existing shareholders sell additional ordinary shares, or if these shares are sold by others, either on the TASE or the NYSE, after this offering, or if the forward counterparties or their affiliates sell additional ordinary shares to adjust their respective hedge positions during the terms of the forward sale agreements, the market price of our ordinary shares could decline."

224


Table of Contents


Conflicts of Interest

        Some of our ordinary shares will be sold by the underwriters in connection with the forward sale agreements. Because each of Morgan Stanley & Co. LLC and Goldman, Sachs & Co. is acting as an underwriter for the offering and will receive, in its (or its respective affiliate's) capacity as a forward counterparty, at least 5% of the proceeds of this offering, a conflict of interest under FINRA Rule 5121 is deemed to exist. Accordingly, this offering will be conducted in accordance with FINRA Rule 5121, which requires, among other things, that a "qualified independent underwriter" has participated in the preparation of, and has exercised the usual standards of due diligence with respect to, this prospectus and the registration statement of which this prospectus is a part. Barclays Capital Inc. has agreed to act as a qualified independent underwriter for this offering and Barclays Capital Inc. has participated in due diligence and the preparation of this prospectus and the registration statement of which this prospectus is a part. Barclays Capital Inc. will not receive any additional fees for serving as a qualified independent underwriter in connection with this offering. We have agreed to indemnify Barclays Capital Inc. against liabilities incurred in connection with acting as a qualified independent underwriter, including liabilities under the Securities Act. Additionally, pursuant to FINRA Rule 5121, Morgan Stanley & Co. LLC will not confirm sales to any account over which is exercise discretionary authority without the specific prior written approval of the account holder.


Selling Restrictions

        In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a "Relevant Member State") an offer to the public of any of our ordinary shares may not be made in that Relevant Member State, except that an offer to the public in that Relevant Member State of any of our ordinary shares may be made at any time under the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member State:

        For the purposes of this provision, the expression of an "offer to the public" in relation to any of our ordinary shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any of our ordinary shares to be offered so as to enable an investor to decide to purchase any of our ordinary shares, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State, and the expression "2010 PD Amending Directive" means Directive 2010/73/EU.

225


Table of Contents

        Each underwriter has represented and agreed that:

        This prospectus does not constitute a prospectus under the Israeli Securities Law, 5728-1968, and has not been filed with or approved by the Israel Securities Authority. In Israel, this prospectus is being distributed only to, and is directed only at, investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50 million and "qualified individuals," each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors, in each case, purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are qualified investors. Qualified investors will be required to submit written confirmation that they fall within the scope of the Addendum.

226


Table of Contents


EXPENSES RELATED TO THE OFFERING

        Set forth below is an itemization of the total expenses, excluding underwriting discounts and commissions, that we expect to incur in connection with this offering. With the exception of the SEC registration fee and the FINRA filing fee, all amounts are estimates.

 
  Amount
To Be Paid
 

SEC registration fee

  $ 67,287  

FINRA filing fee

    78,862  

NYSE listing fee

    250,000  

Transfer agent's fees

    8,000  

Printing and engraving expenses

    500,000  

Legal fees and expenses

    1,165,000  

Accounting fees and expenses

    2,000,000  

Miscellaneous

    391,000  
       

Total

  $ 4,460,149  
       
       

        The selling shareholder will pay the underwriting discounts and commissions in connection with this offering and has also agreed to reimburse the underwriters for certain out-of-pocket expenses incurred by them (including the fees and disbursements of counsel for the underwriters) up to an aggregate of $500,000.

227


Table of Contents


LEGAL MATTERS

        The validity of the ordinary shares and certain other matters of Israeli law will be passed upon for us by Goldfarb Seligman & Co., Tel Aviv, Israel. Certain matters of U.S. law will be passed upon for us by Davis Polk & Wardwell LLP, New York, New York. Certain matters of Israeli law will be passed upon for the underwriters by Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co. and certain matters of U.S. law will be passed upon for the underwriters by Cleary Gottlieb Steen & Hamilton LLP, New York, New York. Skadden, Arps, Slate, Meagher & Flom LLP will provide advice to the selling shareholder as to various matters in connection with this offering.


EXPERTS

        The consolidated financial statements of Israel Chemicals Ltd. as of December 31, 2013 and 2012 and for each of the years in the three-year period ended December 31, 2013, have been included herein and in the registration statement in reliance upon the report of Somekh Chaikin, Member Firm of KPMG International, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing.

        The information appearing in this prospectus concerning estimates of our proven and probable mineral reserves was derived from the report of DMT Consulting Limited (formerly known as IMC Group Consulting Limited), independent mining engineers and geologists, and has been included herein under the authority of DMT Consulting Limited (formerly known as IMC Group Consulting Limited), as experts with respect to the matters covered by such report and in giving such report.

228


Table of Contents


ENFORCEMENT OF JUDGMENTS

        We are incorporated under the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli experts named in this prospectus, many of whom reside outside the United States, may be difficult to obtain within the United States. Furthermore, because a substantial portion of our assets and many of our directors and officers are located outside the United States, any judgment obtained in the United States against us or many of our directors and officers may not be collectible within the United States.

        We have been informed by our legal counsel in Israel, Goldfarb Seligman & Co., that it may be difficult to assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws if they determine that Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. There is little binding case law in Israel addressing these matters. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process. Certain matters of procedure will be governed by Israeli law.

        Subject to specified time limitations and legal procedures, under the rules of private international law currently prevailing in Israel, Israeli courts may enforce a final U.S. judgment in a civil matter, including judgments based upon the civil liability provisions of the U.S. securities laws and including a monetary or compensatory judgment in a non-civil matter, provided that:

        If a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and transferred out of Israel. The usual practice in an action before an Israeli court to recover an amount in a non-Israeli currency is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date of the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli CPI plus interest at the annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rate fluctuations.

229


Table of Contents


WHERE YOU CAN FIND MORE INFORMATION

        We have filed with the SEC a registration statement on Form F-1 under the Securities Act of 1933, as amended, with respect to the ordinary shares that are being offered by this prospectus. This prospectus, which is part of the registration statement, does not contain all of the information set forth in the registration statement and the exhibits and schedules thereto. Please refer to the registration statement, exhibits and schedules for further information with respect to us and our ordinary shares.

        When this registration statement becomes effective, we will be subject to the information reporting requirements of the Exchange Act, applicable to foreign private issuers and under those requirements will file reports with the SEC. Accordingly, we will be required to file reports and other information with the SEC, including annual reports on Form 20-F and reports on Form 6-K, which will include English translations or, in certain instances, English summaries of our material home country documents, including our filings in Israel referred to below. You may read and copy the registration statement, including the related exhibits and schedules, and any document we file with the SEC without charge at the SEC's public reference room at 100 F Street, N.E., Room 1580, Washington, DC 20549. You may also obtain copies of the documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Room 1580, Washington, DC 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. The SEC also maintains an Internet website that contains reports and other information regarding issuers that file electronically with the SEC. Our filings with the SEC will also available to the public through the SEC's website at http://www.sec.gov.

        As a foreign private issuer, we will be exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our directors, officers and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act and we are also exempt from Regulation FD. However, we will file with the SEC, within 120 days after the end of each fiscal year, or such applicable time as required by the SEC, an annual report on Form 20-F containing financial statements audited by an independent registered public accounting firm, and will submit to the SEC, on a Form 6-K, unaudited quarterly financial information. Our financial statements will be prepared in accordance with IFRS, as issued by the IASB.

        In addition, since our ordinary shares are traded on the TASE, we have filed Hebrew language periodic and immediate reports with, and furnish information to, the TASE and the Israel Securities Authority (the "ISA"), as required under Chapter F of the Israel Securities Law, 1968. Copies of our filings with the ISA can be retrieved electronically through the MAGNA distribution site of the ISA (www.magna.isa.gov.il) and the TASE website (www.maya.tase.co.il). Based on the approval of our shareholders on May 8, 2014, commencing from the later of the date of our listing on the NYSE and October 31, 2014, our Israeli reporting requirements will be governed by Chapter E'3 of the Israeli Securities Law, 1968, which generally requires filing with the ISA only copies of the English-language reports filed with the SEC. Nevertheless, we have undertaken toward Israel Corporation, for so long as Israel Corporation is a reporting company under Israeli law, to file reports in the United States and Israel about events outside the ordinary course of our business that we would be required to file under Chapter F of the Israeli Securities Law, 1968, and to provide to Israel Corporation any other information about our business that it requires to meet its disclosure obligations under applicable law.

        We maintain a corporate website at www.icl-group.com. Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.

230


Table of Contents

Index to Consolidated Financial Statements

Report of Independent Registered Public Accounting Firm

  F-2

Consolidated Statements of Financial Position

  F-3

Consolidated Statements of Income

  F-5

Consolidated Statements of Comprehensive Income

  F-6

Consolidated Statements of Changes in Equity

  F-7

Consolidated Statements of Cash Flows

  F-8

Notes to the Consolidated Financial Statements

  F-9

Condensed Consolidated Unaudited Interim Statements of Financial Position

 
F-117

Condensed Consolidated Unaudited Interim Statements of Income

  F-119

Condensed Consolidated Unaudited Interim Statements of Comprehensive Income

  F-120

Condensed Consolidated Unaudited Interim Statements of Changes in Equity

  F-121

Condensed Consolidated Unaudited Interim Statements of Cash Flows

  F-126

Notes to the Condensed Consolidated Interim Financial Statements (Unaudited)

  F-127

F-1


Table of Contents


Report of Independent Registered Public Accounting Firm

The Board of Directors and Shareholders
Israel Chemicals Ltd.

        We have audited the accompanying consolidated statements of financial position of Israel Chemicals Ltd. and subsidiaries (the Company) as of December 31, 2013 and 2012, and the consolidated statements of income, comprehensive income, changes in equity and cash flows, for each of the years in the three-year period ended December 31, 2013. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

        We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

        In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company and its subsidiaries as of December 31, 2013 and 2012, and the results of its operations, and its cash flows for each of the years in the three-year period ended December 31, 2013, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.

/s/ Somekh Chaikin
Somekh Chaikin
Certified Public Accountants (Isr.)
Member Firm of KPMG International
Tel Aviv, Israel
March 18, 2014

F-2


Table of Contents


Consolidated Statements of Financial Position as at December 31,

 
  Note   2013   *2012  
 
   
  US$ thousands
  US$ thousands
 

Current assets

                   

Cash and cash equivalents

          188,340     206,067  

Short-term investments and deposits

    6     96,388     142,689  

Trade receivables

    7     1,057,028     1,034,668  

Derivatives and other receivables

    27,16,8     186,317     217,021  

Current tax assets

          105,270     56,469  

Inventories

    9     1,408,297     1,406,151  
                 

Total current assets

          3,041,640     3,063,065  
                 

Non-current assets

                   

Investments in equity-accounted investees

    10     174,511     173,952  

Long-term deposits and receivables

    12     15,768     22,080  

Surplus in defined benefit plan

    21     83,124     69,193  

Long-term derivative instruments

    27,16     7,619     17,515  

Non-current inventories

    9     62,252     54,723  

Deferred tax assets

    20     111,157     112,189  

Property, plant and equipment

    13     3,686,240     3,097,385  

Intangible assets

    14     791,174     734,809  
                 

Total non-current assets

          4,931,845     4,281,846  
                 

Total assets

          7,973,485     7,344,911  
                 
                 

*
Restated—retrospective application—see Note 3R

   

The accompanying notes are an integral part of these financial statements.

F-3


Table of Contents


Consolidated Statements of Financial Position as at December 31, (Continued)

 
  Note   2013   *2012  
 
   
  US$ thousands
  US$ thousands
 

Current liabilities

                   

Short-term credit and current portion of long-term debt

    17     718,284     552,062  

Trade payables

    18     669,102     640,396  

Provisions

    22     38,485     40,217  

Derivatives and other payables

    27,19,16     500,453     545,872  

Current tax liabilities

          33,717     30,651  
                 

Total current liabilities

          1,960,041     1,809,198  
                 

Non-current liabilities

                   

Long-term debt

    17     1,243,638     916,594  

Debentures

    17     67,000     228,708  

Long-term derivative instruments

    27,16     6,582     23,812  

Deferred taxes, net

    20     220,877     215,149  

Employee benefits

    21     702,103     685,716  

Provisions

    22     94,570     77,470  
                 

Total non-current liabilities

          2,334,770     2,147,449  
                 

Total liabilities

          4,294,811     3,956,647  
                 

Equity

    24              

Share capital

          542,853     542,769  

Share premium

          133,633     101,501  

Capital reserves

          84,715     45,312  

Retained earnings

          3,152,832     2,935,537  

Treasury shares

          (260,113 )   (260,113 )
                 

Total Shareholder's equity

          3,653,920     3,365,006  
                 

Non-controlling interests

          24,754     23,258  
                 

Total equity

          3,678,674     3,388,264  
                 

Total liabilities and equity

          7,973,485     7,344,911  
                 
                 

*
Restated—retrospective application—see Note 3R

/s/ Nir Gilad

Nir Gilad
Chairman of the Board of Directors
  /s/ Stefan Borgas

Stefan Borgas
Chief Executive Officer
  /s/ Avi Doitchman

Avi Doitchman
Executive VP, CFO and Strategy

Approval date of the financial statements: March 18, 2014.

   

The accompanying notes are an integral part of these financial statements.

F-4


Table of Contents


Consolidated Income Statements for the Year Ended December 31,

 
  Note   2013   *2012   *2011  
 
   
  US$ thousands
  US$ thousands
  US$ thousands
 

Sales

  26A     6,271,542     6,471,433     6,868,550  

Cost of sales

  26B     3,861,572     3,760,235     3,767,962  
                   

Gross profit

        2,409,970     2,711,198     3,100,588  

Selling, transportation and marketing expenses

  26D     850,325     797,291     861,976  

General and administrative expenses

  26E     281,491     248,782     265,142  

Research and development expenses, net

  26C     82,870     74,099     70,126  

Other expenses

  26G     110,194     61,085     29,929  

Other income

  26G     (16,276 )   (23,691 )   (4,660 )
                   

Operating income

        1,101,366     1,553,632     1,878,075  
                   

Finance expenses

        158,403     81,595     103,637  

Finance income

        (131,548 )   (20,701 )   (25,825 )
                   

Finance expenses, net

  26F     26,855     60,894     77,812  
                   

Share in earnings of equity accounted investees

  10     25,685     26,555     34,265  
                   

Income before income taxes

        1,100,196     1,519,293     1,834,528  

Income taxes

  20     280,023     217,561     333,470  
                   

Net income

        820,173     1,301,732     1,501,058  
                   
                   

Attributable to:

                       

The shareholders of the Company

        818,573     1,300,076     1,498,151  

Non-controlling interests

        1,600     1,656     2,907  
                   

Net income

        820,173     1,301,732     1,501,058  
                   
                   

 
   
  US $   US $   US $  

Earnings per share attributable to the shareholders of the company:

  28                    

Basic earnings per share

        0.644     1.024     1.182  

Diluted earnings per share

        0.644     1.024     1.177  

*
Restated—retrospective application—see Note 3R

   

The accompanying notes are an integral part of these financial statements.

F-5


Table of Contents


Consolidated Statements of Comprehensive Income for the Year Ended December 31,

 
  2013   *2012   *2011  
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Net Income

    820,173     1,301,732     1,501,058  
               

Components of other comprehensive income that may be reclassified subsequently to net income

                   

Currency translation effects

    49,142     24,674     (45,216 )

Gain (losses) on derivatives designated as cash flows hedge

    1,718     15,634     (15 )

Unrealized gain (losses) on available for sale financial assets

            (3,756 )

Income tax relating to items that may be reclassified subsequently to net income

    (898 )   313     1,186  
               

Total

    49,962     40,621     (47,801 )
               

Items that will not be reclassified to net income

                   

Actuarial gains (losses) from defined benefit plans

    47,282     (43,904 )   (38,219 )

Income tax relating to items that will not be reclassified to net income

    (14,172 )   9,018     8,040  
               

Total

    33,110     (34,886 )   (30,179 )
               

Total comprehensive income

    903,245     1,307,467     1,423,078  
               
               

Attributable to:

                   

The shareholders of the Company

    901,749     1,305,242     1,420,267  

Non-controlling interests

    1,496     2,225     2,811  
               

Total comprehensive income

    903,245     1,307,467     1,423,078  
               
               

*
Restated—retrospective application—see Note 3R

   

The accompanying notes are an integral part of these financial statements.

F-6


Table of Contents


Consolidated Statements of Changes in Equity

 
  Attributable to the shareholders of the Company    
   
 
 
  Share
capital
  Share
premium
  Cumulative
translation
adjustment
  Capital
reserves
  Treasury
Shares,
at cost
  Retained
earnings
  Total
shareholder's
equity
  Non-
controlling
interests
  Total
equity
 
 
  US$ thousands
 

For the year ended December 31, 2013

                                                       

Balance as at January 1, 2013*

   
542,769
   
101,501
   
(30,063

)
 
75,375
   
(260,113

)
 
2,935,537
   
3,365,006
   
23,258
   
3,388,264
 

Exercise of options

    84     32,132         (32,216 )                    

Share-based compensation

                21,776             21,776         21,776  

Dividends paid

                        (634,388 )   (634,388 )       (634,388 )

Taxes on shares-based compensation

                (223 )           (223 )       (223 )

Comprehensive income

            49,246     820         851,683     901,749     1,496     903,245  
                                       

Balance as at December 31, 2013

    542,853     133,633     19,183     65,532     (260,113 )   3,152,832     3,653,920     24,754     3,678,674  
                                       
                                       

For the year ended December 31, 2012*

                                                       

Balance as at January 1, 2012

   
542,377
   
94,798
   
(54,168

)
 
53,866
   
(260,113

)
 
2,689,569
   
3,066,329
   
23,922
   
3,090,251
 

Exercise of options

    392     6,703         (3,295 )           3,800         3,800  

Share-based compensation

                8,668             8,668         8,668  

Dividends paid

                        (1,019,222 )   (1,019,222 )   (2,889 )   (1,022,111 )

Taxes on shares-based compensation

                189             189         189  

Comprehensive income

            24,105     15,947         1,265,190     1,305,242     2,225     1,307,467  
                                       

Balance as at December 31, 2012

    542,769     101,501     (30,063 )   75,375     (260,113 )   2,935,537     3,365,006     23,258     3,388,264  
                                       
                                       

*
Restated—retrospective application—see Note 3R

 
  Attributable to the shareholders of the Company    
   
 
 
  Share
capital
  Share
premium
  Cumulative
translation
adjustment
  Reserve
available
for sale
financial
assets
  Capital
reserves
  Treasury
Shares,
at cost
  Retained
earnings
  Total
shareholder's
equity
  Non-
controlling
interests
  Total
equity
 
 
  US$ thousands
 

For the year ended December 31, 2011*

                                                             

Balance as at January 1, 2011

   
541,858
   
90,675
   
(9,048

)
 
2,427
   
44,166
   
(260,113

)
 
2,212,145
   
2,622,110
   
22,280
   
2,644,390
 

Exercise of options

    519     4,123             (4,548 )           94         94  

Share-based compensation

                    15,476             15,476         15,476  

Dividends paid

                            (961,330 )   (961,330 )   (1,169 )   (962,499 )

Acquisition of non-controlling interests

                            (29,218 )   (29,218 )       (29,218 )

Taxes on shares-based compensation

                    (1,070 )           (1,070 )       (1,070 )

Comprehensive income

            (45,120 )   (2,427 )   (158 )       1,467,972     1,420,267     2,811     1,423,078  
                                           

Balance as at December 31, 2011

    542,377     94,798     (54,168 )       53,866     (260,113 )   2,689,569     3,066,329     23,922     3,090,251  
                                           
                                           

*
Restated—retrospective application—see Note 3R

   

The accompanying notes are an integral part of these financial statements.

F-7


Table of Contents


Consolidated Statements of Cash Flows for the Year Ended December 31,

 
  2013   *2012   *2011  
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Cash flows from operating activities

                   

Net Income

    820,173     1,301,732     1,501,058  

Adjustments for:

                   

Depreciation and amortization

    347,741     322,511     315,625  

Interest expenses, net

    41,951     28,529     28,160  

Share in earning of equity-accounted investees

    (25,685 )   (26,555 )   (34,265 )

Loss (Gain) on sale of property, plant and equipment, net

    (1,958 )   602     (2,017 )

Share-based compensation

    21,776     8,668     15,476  

Gain on sale of available for sale securities

            (4,535 )

Revaluation of assets and liabilities denominated in foreign currencies

    29,541     7,511     (22,351 )

Gain on achievement of control of an associated company

    (1,827 )   (1,945 )    

Income tax expenses

    280,023     217,561     333,470  
               

    1,511,735     1,858,614     2,130,621  

Change in inventories

    4,061     (54,852 )   (218,887 )

Change in trade and other receivables

    19,614     217,118     (260,508 )

Change in trade and other payables

    (84,903 )   (71,612 )   157,258  

Change in provisions and employee benefits

    53,782     30,973     (9,173 )
               

    1,504,289     1,980,241     1,799,311  

Income taxes paid

    (333,794 )   (220,179 )   (415,192 )

Interest received

    2,380     12,207     11,722  

Interest paid

    (45,966 )   (45,051 )   (37,097 )
               

Net cash provided by operating activities

    1,126,909     1,727,218     1,358,744  
               

Cash flows from investing activities

                   

Increase in long-term deposits

        (2,397 )   (2,147 )

Proceeds from sale of property, plant and equipment

    3,304     924     4,616  

Short-term loans and deposits, net

    38,770     (16,099 )   342,699  

Business acquisitions, net of cash acquired

    (63,057 )   (11,875 )   (437,475 )

Dividend from equity-accounted investees

    23,168     17,089     15,821  

Purchases of property, plant and equipment, net

    (826,588 )   (711,721 )   (546,664 )

Investment grants received

                1,194  

Purchases of intangible assets

    (22,093 )   (11,350 )   (16,901 )

Sale of securities classified as available-for-sale

                14,421  

Investments and loans to equity-accounted investees

        (8,521 )   (4,545 )

Proceeds from sale of long-term deposits

    7,164     3,241     3,452  
               

Net cash used in investing activities

    (839,332 )   (740,709 )   (625,529 )
               

Cash flows from financing activities

                   

Proceeds from exercise of share options

        3,800     94  

Dividend paid to the shareholders

    (634,388 )   (1,019,222 )   (1,131,033 )

Dividend paid to non-controlling interests

        (2,889 )   (1,169 )

Receipt of long-term debt

    674,736     362,001     864,486  

Repayment of long-term debt

    (613,457 )   (311,415 )   (882,986 )

Short-term credit from banks and others, net

    263,119     (50,899 )   316,942  
               

Net cash used in financing activities

    (309,990 )   (1,018,624 )   (833,666 )
               

Net change in cash and cash equivalents

    (22,413 )   (32,115 )   (100,451 )

Cash and cash equivalents as at January 1

    206,067     238,141     344,287  

Net effect of currency translation on cash and cash equivalents

    4,686     41     (5,695 )
               

Cash and cash equivalents as at December 31

    188,340     206,067     238,141  
               
               

*
Restated—retrospective application—see Note 3R

   

The accompanying notes are an integral part of these financial statements.

F-8


Table of Contents


Notes to the Consolidated Financial Statements

Note 1—General

A.    The reporting entity

        Israel Chemicals Ltd. (hereinafter—"the Company" or "ICL"), is a Company domiciled and incorporated in Israel and the shares of which are traded on the Tel-Aviv Stock Exchange. The address of the Company's registered office is 23 Aranha St., Tel-Aviv, Israel. The Company and its subsidiaries and associated companies (hereinafter—"the Group") is a leading specialty minerals group that operates a unique, integrated business model. We competitively extract raw materials, utilize sophisticated processing and product formulation technologies to add value to customers in three attractive end-markets: agriculture, food and engineered materials. These three end markets constitute over 90% of our revenues today. Our operations are organized into three segments: (1) Fertilizers, which operates the raw material extraction for ICL and markets potash, phosphates and specialty fertilizers; (2) Industrial Products, which primarily extracts bromine from the Dead Sea and produces and markets bromine and phosphorus compounds for the electronics, construction, oil & gas and automotive industries and (3) Performance Products, which mainly produces, markets and sells a broad range of downstream phosphate-based food additives and industrial intermediates. The Company is a subsidiary of Israel Corporation Ltd.

        Our principal assets include: One of the world's richest, longest-life and lowest-cost sources of potash and bromine (the Dead Sea). Additionally, Potash mines in the United Kingdom and Spain. Bromine compounds processing facilities located in Israel, in the Netherlands and in China. A unique integrated phosphate value chain, from phosphate rock mines in the Negev Desert in Israel into production facilities of value-added products in Israel, Europe, US, Brazil and China. An extensive global logistics and distribution network with operations in over 30 countries and a focused and highly experience group of over 500 technical experts developing production processes, new applications, formulations and products for our 3 key end markets agriculture, food and engineered materials. The Company and some of the Group companies were declared a monopoly with respect to some of the products they manufacture and/or sell in Israel.

        ICL operates in the markets for potash, bromine, pure phosphoric acid, special phosphates, bromine-based and phosphorus-based flame retardants and chemicals for the prevention of the spreading of fires.

        ICL's products are used mainly in the areas of agriculture, electronics, food, fuel and gas exploration, water purification and desalination, detergents, paper, cosmetics, medicines, vehicles, aluminum and others.

        The Company's overseas operations consist mainly of the production of products that are integrated with or based on the activities of the companies in Israel or in closely related fields. About 95% of the Group's products are sold to customers outside of Israel.

B.    State share

        The State of Israel holds a Special State Share in ICL and in some of its subsidiaries, entitling the State the right to safeguard the State of Israel interests (see Note 24).

C.    Definitions

        1.     Subsidiary—a company over which the Company has control and the financial statements of which are fully consolidated with the Company's statements as part of the consolidated financial statements.

F-9


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 1—General (Continued)

        2.     Associated company—a company, which is not a subsidiary, over the financial and operational policies of which the Company has significant influence, and the investment in which is presented on the basis of the equity method of accounting. Significant influence is deemed to exist when the holding percentage in the said company is 20% or more, unless there are circumstances that contradict this assumption.

        3      Investee company—(a) a subsidiary or (b) a joint venture of which the Company's direct or indirect investment is included in the financial statement based on the equity method.

Note 2—Basis of Preparation of the Financial Statements

A.    Statement of compliance with International Financial Reporting Standards

        The consolidated financial statements have been prepared by the Group in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Boards (IASB).

        The consolidated financial statements were authorized for issuance by the Company's Board of Directors on March 18, 2014.

B.    Functional and presentation currency

        Items included in the consolidated financial statements of the Company and each of its subsidiaries are measured using the currency of the primary economic environment in which the individual entity operates ("the functional currency"). The consolidated financial statements are presented in United States Dollars ("US Dollars"; $), which is the functional currency of the Company and the majority of its subsidiaries.

C.    Basis of measurement

        The consolidated financial statements have been prepared on the historical cost basis except for derivative financial instruments, securities held for trade and financial instruments classified as available for-sale that are stated at fair value.

        Deferred tax assets and liabilities are recognized for temporary differences between the carrying amounts of assets and liabilities and their value for taxation purposes. The deferred taxes are measured at the tax rates expected to apply to the temporary differences when they reverse, based on the laws that have been enacted or effectively enacted as at the reporting date.

        Inventories are measured at the lower of cost and net realizable value.

        Provisions are recognized according to the best estimate at the end of the reporting period of the outflow required to settle the obligation presently. When the value of time is significant, the future cash flows are discounted at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability.

        For information regarding the measurement basis of assets and liabilities in respect of employee benefits—see Note 3J.

D.    Operating cycle

        The Company's regular operating cycle is one year. As a result, the current assets and the current liabilities include items the realization of which is intended and anticipated to take place within one year.

F-10


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 2—Basis of Preparation of the Financial Statements (Continued)

E.    Use of estimates and judgment

        In preparation of the financial statements in accordance with IFRS as issued by the IASB, Company Management is required to use judgment when making estimates and assumptions that affect implementation of the accounting policies and the amounts of assets, liabilities, income and expenses. It is clarified that the actual results may be different from these estimates.

        At the time of formulating the accounting estimates used in preparation of the Company's financial statements, Company Management is required to make assumptions regarding circumstances and events involving significant uncertainty. When using its judgment in determining the estimates, Company Management uses past experience, various facts, outside experts and reasonable assumptions in accordance with the circumstances appropriate to each estimate.

        The estimates and the assumptions used in preparation of the financial statements are reviewed on an ongoing basis. Revisions to estimates are recognized prospectively.

        Presented hereunder is information with respect to estimates for which significant value adjustment risk exist, and were made while implementing the accounting policies that have a material impact on the financial statements:


1. Employee benefits

        According to International Standard IAS 19, some of the Group's employee benefit plans constitute a defined benefit plan as defined in IAS 19. Such plans include principally, liabilities for pension and severance benefits.

        In computing the pension liability, the Company uses various assessments. These assessments include, among other things, the interest rate for discounting the Company's pension liability and the pension fund assets, assessments regarding the long-term increase in wages and an assessment of the life expectancy of the group of employees entitled to a pension. Assessment of the interest rate for purposes of discounting the Company's pension liability and the pension fund assets is based on the rate of return on bonds of corporations operating in countries where an active market exists for corporate bonds and on the rate of return on government bonds for companies operating in countries where there is no active market for corporate bonds. The rate of return on long-term bonds changes according to market conditions. As a result the discount rate will also change as will the pension liability and the pension fund assets. The assessment regarding the increase in wages is based on the Company's forecasts in accordance with past experience and existing labor agreements. Such assessments may be different than the actual wage increases.

        The life expectancy assessment is based on actuarial research published in each country. This research is updated every several years, and accordingly the life expectancy assessment may be updated.

        Measurement of the liability for severance pay is based upon an actuarial assessment, which takes into account various assessments, among others, the future increase in employee wages and the rate of employee turnover. The measurement is made on the basis of discounting the expected future cash flows according to the interest rate on highly rated government bonds. In addition, the severance pay deposits are measured according to their fair value. Changes in the assumptions used for the calculation of the liability for severance pay and the related plan assets for severance pay could increase or decrease the net liability for severance pay recognized.

F-11


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 2—Basis of Preparation of the Financial Statements (Continued)


2. Environmental and contingent liabilities

        The Company produces fertilizers and chemical products and, therefore, is exposed in its ordinary course of business to obligations and commitments under environmental and related laws and regulations. The Company recognizes a liability in its books when such liability is expected, is derived from a liability event that has already occurred and can be reliably measured. Assessment of the liability is based mostly on past experience, familiarity with the legal requirements concerning the Company's areas of operation, as well as assessments regarding contingent claims existing against the Company based on opinions of legal advisors and other experts. As explained in Note 23 to the financial statements, a number of lawsuits are pending against the Company, the results of which may have a material impact on its results.

        When assessing the possible outcomes of legal claims that were filed against the Company and its investee companies, the Company bases itself on the opinions of its legal advisors. These opinions of the legal advisors are based on the best of their professional judgment, and take into consideration the current stage of the proceedings and the legal experience accumulated with respect to the various matters. As the results of the claims will ultimately be determined by the courts or as part of a compromise, they may be different from the aforesaid estimates of the Company and its advisors.


3. Property, plant and equipment

        Property, plant and equipment items are depreciated using the straight-line method over their estimated useful lives.

        The Company evaluates the estimated useful lives of the property, plant and equipment by means of a comparison to the sector in which the Group operates, the level of upkeep of the facilities and the performance of the facilities over the years. Changes in these estimates in succeeding periods could increase or decrease the rate of depreciation of the facilities.


4. Impairment of assets

        The Company examines at every reporting date whether there have been events or changes in circumstances indicating that there has been an impairment of one or more non-monetary assets. When there are indications of impairment, an examination is made as to whether the carrying amount of the investment can be recovered from the discounted cash flows anticipated to be derived from the asset, and if necessary it records an impairment provision up to the amount of the recoverable value. Assessment of the impairment of goodwill and of other intangible assets having an indeterminable lifespan is performed once a year or more frequently when indications of impairment exist.

        The recoverable value of the asset or the cash generating unit is determined based on the higher of the fair value of the asset less realization costs and the present value of the future cash flows expected from the continued use of the asset in its existing state, including the cash flows expected upon removal of the asset from service and its eventual sale (value in use).

F-12


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 2—Basis of Preparation of the Financial Statements (Continued)

        The future cash flows are discounted to their present value using a discount rate that reflects assessments of the market participants of the time value of money and the risks specific to the asset. The estimates regarding cash flows are based on past experience with respect to this asset or similar assets, and on the Company's best assessments regarding the economic conditions that will exist during the asset's remaining useful life.

        The estimates of the future cash flows are based on the Company's forecasts. Since the actual cash flows could be different than the Company's forecasts, the amount of the realizable value determined in the examination of impairment in value may change in succeeding periods, such that in the future an additional reduction of the value of the assets may be required or elimination of the reduction recorded in prior periods.


5. Business combinations

        The Company is required to allocate the cost of acquiring companies and operations in business combinations on the basis of the estimated fair value of the assets and liabilities acquired. The Company uses the valuations of external independent appraisers and internal valuations for purposes of determining the fair value. The valuations include assessments and estimates of Management concerning expected cash-flow forecasts from the acquired business, and models for calculating the fair value of the acquired items and their depreciation period. Management's estimate has an impact on the balance of assets and liabilities acquired and the depreciation and amortization in the statement of income. Management's estimates of the forecasted cash flows and useful lives of the acquired assets may differ from the actual results.


6. Taxes on Income

        The Company and the Group companies are assessed for income tax purposes in numerous jurisdictions and, therefore, Company Management is required to exercise considerable judgment in order to determine the aggregate provision for taxes. A provision in respect of uncertain tax positions is recorded where it is more likely than not that a flow of economic resources will be required in order to discharge the obligation. The deferred taxes are computed according to tax rates expected to apply when the timing differences are realized, as stated in Note 3O. The tax rate expected to apply upon the realization of the timing differences applying to Beneficiary Enterprises in Israel entitled to tax benefits is based on forecasts of future revenues to be earned by such Beneficiary Enterprises in proportion to the Company's total revenues. Changes in these assessments could lead to changes in the book value of these tax assets, the tax liabilities and the results of operations.


7. Inventories

        Inventories are measured in the financial statements at the lower of cost or net realizable value. The net realizable value is an estimate of the selling price during the ordinary course of business, less the estimate of the cost of completion and the estimate of the costs needed to effect the sale. The selling price is estimated on the basis of the selling price expected at the time of realization of the inventories; a decrease in the expected selling price could cause a decrease in the book value of the inventories and the results of operations accordingly. Raw materials are written down to realizable value, which are based on the realization values of the inventories of the finished products in which they are included, only when the finished products in which they are included are expected to be sold at prices below cost. In cases where the replacement price of raw materials serves as the best available

F-13


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 2—Basis of Preparation of the Financial Statements (Continued)

evidence for realizable value, measurement of realizable value is based on the replacement price. A decline in the expected replacement value could give rise to a decline in the value of the inventories of raw materials in the books and the results of operations, respectively.

        Part of the raw materials, work in process and finished goods are in bulk. The quantities are based on estimates made, for the most part, by third-parties who measure the volume and density of the inventory. Variances in the estimates used in determining the assessments may cause a change in the value of the inventory in the books.

Note 3—Significant Accounting Policies

        The accounting policies in accordance with IFRS are consistently applied by the Group companies for all the periods presented in these consolidated financial statements.

A.    Basis for Consolidation

1. Subsidiaries

        Subsidiaries are entities that are controlled by the Group. Control exists when the Group, or the holder of the rights, is exposed to variable yields from its involvement in the investee company and the Group has the ability to impact these yields by means of its influence over the investee company. When examining control, actual rights held by the Group and by others are taken into account. The financial statements of the subsidiaries are included in the consolidated financial statements from the date control was acquired until the date control ceases to exist


2. Associated companies

        Associated companies are entities regarding which the Group has significant influence over their financial and operational policy, however control thereof has not been obtained. Associated companies are accounted for using the equity. The consolidated financial statements include the Group's share in the net revenues and expenses of associated companies.


3. Intercompany balances and transactions eliminated in the consolidation

        Intercompany balances within the Group and unrealized income and expenses deriving from intercompany transactions are eliminated in preparation of the consolidated financial statements. Unrealized income deriving from transactions with associated companies was eliminated against the investment based on the Group's rights in these investments.


4. Non-controlling interests

        The non-controlling interests represent the interest in the net assets of subsidiaries that are allocated to rights not owned by the Company, whether directly or indirectly through subsidiaries. The non-controlling interests are presented in the consolidated statement of financial position in the equity section, separate from the equity attributable to the Company's shareholders. The share of the non-controlling interests in the Group's results is presented in the consolidated statement of income as an allocation of the total income or loss for the period between the non-controlling interests and the Company's shareholders.

F-14


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 3—Significant Accounting Policies (Continued)

        Transactions with non-controlling interests where control is retained, are accounted for as an equity transaction. Differences between the consideration paid and the change in the non-controlling interests is recorded to the share of the Company's shareholders directly to the retained earnings.


5. Business combinations

        The Group implements the "acquisition method" for all business combinations. The acquisition date is the date on which the acquiring entity obtains control over the acquired entity.

        The Group recognizes goodwill as at the acquisition date based on the fair value of the consideration paid less the net amount attributed in the acquisition to the identifiable assets acquired and the liabilities undertaken. The consideration paid includes the fair value of contingent consideration. Subsequent to the acquisition date, the Group recognizes changes in the fair value of contingent consideration classified as a liability in the statement of income.

        Costs related to the acquisition incurred by the purchaser in respect of the acquisition such as: brokers' commissions, consultants' commissions, legal fees and valuations, are recorded as an expense in the period the services are received.

B.    Foreign Currency

1. Transactions in foreign currency

        Transactions in foreign currency are translated into the functional currency of the Company and each of its subsidiaries based on the exchange rate in effect on the dates of the transactions. Monetary assets and liabilities denominated in foreign currency on the report date are translated into the functional currency of the Company and each of its subsidiaries based on the exchange rate in effect on that date. Exchange rate differences in respect of monetary items are the difference between the net book value in the functional currency at the beginning of the period plus the payments during the period and the net book value in foreign currency translated based on the rate of exchange at the end of the period. Exchange rate differences deriving from translation into the functional currency are recognized in the statement of income Non-monetary items denominated in foreign currency and measured in terms of historical cost are translated using the exchange rate in effect on the date of the transaction.


2. Foreign activities

        The assets and liabilities of foreign activities, including goodwill and adjustments to fair value created upon acquisition, were translated into dollars according to the rates of exchange in effect on the date of the report. Income and expenses of the foreign activities were translated into dollars according to the rates of exchange that were in effect on the transaction dates.

        Exchange rate differences in respect of the translation are recorded in other comprehensive income, as part of the reserve for translation of foreign activities. When a foreign activity is realized that causes a loss of control, the accumulated amount in the translation reserve of foreign activities is transferred to the income statement as part of the gain or loss on realization of the investment.

        Gains and losses from exchange rate differences deriving from loans received from or granted to foreign activities, the settlement of which is not planned and is not expected to take place in the

F-15


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 3—Significant Accounting Policies (Continued)

foreseeable future, are included as part of the net investment in the foreign activities and are recognized in other comprehensive income in a reserve for translation of foreign activities.

C.    Financial Instruments

1. Non-derivative financial instruments

        Non-derivative financial instruments include investments in shares and debt instruments, including trade and other receivables, cash and cash equivalents, loans and credit received, and trade and other payables.

        With respect to instruments not presented at fair value through the statement of income, the initial recognition is at fair value with the addition of all allocable directly related transaction costs.

        The Group initially recognizes receivables and deposits on the date they are created. The rest of the financial assets purchased in the regular way, including assets designated at fair value through the statement of income, are initially recognized on the trade date when the Group becomes a party to the instrument's contractual conditions, that is, on the date the Group committed to buy or sell the asset. Financial assets are eliminated when the contractual rights of the Group to the cash flows deriving from the financial assets expire, or when the Group transfers the financial assets to others without retaining control or effectively transfers all of the risks and rewards deriving from the asset. Acquisitions and sales of financial assets made in the usual manner are recognized on the trade date, that is, on the date the Group committed to buy or sell the asset. Financial liabilities are eliminated when the Group's obligation as described in the contract expires or when it is paid or cancelled.

        A financial asset and a financial liability are offset and the amounts are presented on a net basis in the statement of financial position where the Group has a currently enforceable legal right to offset the amounts recognized and the intention is to settle the asset and liability on a net basis or to realize the asset and settle the liability concurrently


Cash and cash equivalents

        Cash includes cash balances that are available for immediate use and deposits at call. Cash equivalents include short-term investments, where the period of time from the original deposit and up to the redemption date is up to three months, having high liquidity that can be easily converted into known amounts of cash and that are subject to an insignificant risk in connection with changes in value.


Financial assets available for sale

        After the initial recognition, these investments are measured based on fair value, where the changes therein, except for losses from impairment and gains or losses from changes in the exchange rate, are recorded directly in other comprehensive income and presented in the capital reserve for financial assets available for sale. A dividend received in respect of financial assets available for sale is recorded in the statement of income at the time of entitlement to the payment. When the investment is eliminated, the gains or losses accumulated in equity are transferred to the statement of income.


Loans and receivables

        Loans and receivables are non-derivative financial instruments having fixed payments or payments that can be fixed that are not traded on an active market. After the initial recognition, the loans and

F-16


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 3—Significant Accounting Policies (Continued)

debit balances are measured based on amortized cost using the effective interest rate method while taking into account transaction costs and net of provisions for impairment.


2. Derivative financial instruments

        The Group holds derivative financial instruments for the purpose of economic (non-accounting) hedging against foreign currency risks, risks with respect to commodity prices, marine shipping prices, and interest risks. In addition, for purposes of an accounting hedge, the Company holds derivative financial instruments for hedging the exposure to changes in the cash flows of an undertaking for construction of a new cogeneration power plant in Sodom. On the commencement date of the accounting hedge, the Group formally documents the hedge ratio between the hedging instrument and the hedged item, including the risk management target and the Group's strategy with respect to execution of the hedge, as well as the manner in which the Group estimates the effectiveness of the hedge ratio.

        Derivatives are recognized according to fair value and the attributable transaction costs are recorded in the statement of income as incurred. Changes in the fair value of the derivatives are recorded in the statement of income, except for derivatives used to hedge cash flows, as detailed below.


Cash flow hedges

        Changes in the fair value of derivatives used to hedge cash flows, in respect of the effective portion of the hedge, are recorded through other comprehensive income directly in a capital reserve. With respect to the non-effective part, changes in the fair value are recognized in the statement of income. The amount accumulated in the capital reserve is removed and included in the statement of income in the same period as the hedged cash flows affect profit or loss under the same line item in the statement of income as the hedged item.

        Where the hedged item is a non-financial asset, the amount recorded in the capital reserve is transferred to the book value of the asset, upon recognition thereof.

        If the hedging instrument no longer meets the criteria for hedge accounting, expires or is sold, terminated or exercised, hedge accounting is discontinued. The cumulative gain or loss previously recognized through other comprehensive income and presented in the hedging reserve in equity remains there until the forecasted transaction occurs or is no longer expected to occur. If the forecasted transaction is no longer expected to occur, the cumulative gain or loss previously recognized in the hedging reserve is recognized immediately in profit or loss.


Economic hedge that does not meet the conditions of an accounting hedge

        Changes in the fair value of derivatives that do not meet the conditions of an accounting hedge in accordance with IFRS, after the date of the initial recognition thereof, are recorded in the statement of income as financing income or expenses.


3. CPI-linked assets and liabilities not measured at fair value

        The value of index-linked financial assets and liabilities, which are not measured based on fair value, are revalued every period in accordance with the actual rate of increase in the CPI.

F-17


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 3—Significant Accounting Policies (Continued)

D.    Property, plant and equipment

1. Recognition and measurement

        Property, plant and equipment are presented at cost after deducting the related amounts of government grants and less accumulated depreciation and provision for impairment.

        The cost includes expenses that can be directly attributed to purchase of the asset. The cost of assets that were constructed independently includes the cost of the materials and direct salary costs, as well as any additional costs that are directly attributable to bringing the asset to the required position and condition so that it will be able to function as management intended, as well as an estimate of the costs to dismantle and remove the items and to restore its location, where there is an obligation to dismantle and remove or to restore the site. The cost of purchased software, which constitutes an inseparable part of operating the related equipment, is recognized as part of the cost of said equipment.

        Spare parts for facilities are valued at cost determined based on the moving average method, after recording a write-down in respect of obsolescence. The portion designated for current consumption is presented in the inventories "category" in the current assets' section.

        Where significant parts of an item of property, plant and equipment (including costs of major periodic inspections) have different life expectancies, they are treated as separate items (significant components) of the property, plant and equipment.

        Changes in a commitment to dismantle and remove items and to restore their location, except for changes stemming from the passage of time, are added to or deducted from the cost of the asset in the period in which they occur.

        Gains and losses on disposal of a property, plant or equipment item are determined by comparing the proceeds from disposal with the carrying amount of the asset, and are recognized net in the income statement in the "other income" or "other expenses" category, as applicable.


2. Subsequent costs (costs incurred after the initial recognition date)

        The cost of replacing part of an item of property, plant and equipment and other subsequent costs are recognized as part of the book value of the item if it is expected that the future economic benefit inherent therein will flow to the Group and that its cost can be reliably measured. The book value of the part that was replaced is eliminated. Routine maintenance costs are charged to the statement of income as incurred.


3. Depreciation

        Depreciation of an item of property, plant and equipment begins when it is available for use, that is, when it has reached the place and condition required in order that it can be used in the manner contemplated for it by Management.

        Depreciation is recorded in the statement of income according to the straight-line method over the estimated useful life of each significant component of the property, plant and equipment items. Owned land is not depreciated.

F-18


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 3—Significant Accounting Policies (Continued)

        The estimated useful life for the current period and comparative periods is as follows:

 
  In Years  

Land development, roads and structures

    10 - 30  

Facilities, machinery and equipment

    8 - 25  

Dams and ponds

    6 - 40 (1)

Heavy mechanical equipment, train cars and tanks

    5 - 10  

Office furniture and equipment, motor vehicles, computer equipment and other

    3 - 20  

(1)
Mainly 40 years

E.    Intangible Assets

1. Goodwill

        Goodwill is created as a result of acquisition of subsidiaries. Acquisition of non-controlling interests are transactions with shareholders and goodwill is not recognized on such acquisitions.


Subsequent measurement

        Goodwill is measured at cost less accumulated losses from impairment.


2. Costs of exploration and evaluation of resources

        Costs incurred in respect of exploration of resources and the evaluation thereof are recognized as intangible assets. The expenditures are recognized on the cost basis less a provision for impairment.

        The cost includes, among other things, costs of performing research studies, drilling costs and activities in connection with assessing the technical feasibility with respect to the commercial viability of extracting the resources.


3. Research and development

        Expenditure on research activities is recognized in profit or loss as incurred.

        Development expenditure is capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group has the intention and sufficient resources to complete development and to use or sell the asset. Otherwise, development expenditure is recognized in profit or loss as incurred. Subsequent to initial recognition, development expenditure is measured at cost less accumulated amortization and any accumulated impairment loss.


4. Other intangible assets

        Other intangible assets purchased by the Group, with a defined useful life, are measured according to cost less amortization and accumulated losses from impairment.

        Intangible assets with indefinite useful lives are measured according to cost less accumulated losses from impairment.

F-19


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 3—Significant Accounting Policies (Continued)


5. Subsequent costs

        Subsequent costs are recognized as an intangible asset only when they increase the future economic benefit inherent in the asset for which they were incurred. All other costs, including costs relating to goodwill or trademarks developed independently, are charged to the statement of income as incurred.


6. Amortization

        Amortization is recorded in the statement of income according to the straight-line method from the date the assets are available for sale, over the estimated useful economic life of the intangible assets, except for customer relationships and geological surveys, which are amortized according to the rate of consumption of the economic benefits expected from the asset on the basis of cash flow forecasts. Goodwill and intangible assets having an indefinite lifespan are not amortized on a systematic basis but, rather, are examined at least once a year for purposes of impairment in value.

        The estimated useful life for the current period and comparative periods is as follows:

 
  In Years  

Concessions—over the balance of the concession granted to the companies

       

Software costs

    3 - 10  

Trademarks

    5 - 30  

Customer relationships

    15 - 25  

Agreements with suppliers

    5  

Patents

    7 - 20  

Non-competition agreement

    5  

        Deferred expenses in respect of geological surveys are amortized over their useful life based on a geological estimate of the amount of the material that will be produced from the mining site.

        The estimates regarding the amortization method and useful life are reviewed, at a minimum, at the end of every reporting year and are adjusted where necessary. The Group assesses the useful life of the customer relationships on an ongoing basis, based on an analysis of all of the relevant factors and evidence, considering the experience the Company has with respect to recurring orders and churn rates and considering the future economic benefits expected to flow to the Company from these customer relationships.

        The Group periodically examines the estimated useful life of an intangible asset that is not amortized in order to determine if events and circumstances continue to support the determination that the intangible asset has an indefinite life.

F.     Leased Assets

        Leases, where the Group assumes substantially all the risks and rewards of ownership of the asset, are classified as financing leases. Upon initial recognition, the leased assets are measured and a liability is recognized at an amount equal to the lower of its fair value or the present value of the future minimum lease payments. Subsequent to initial recognition, the asset is accounted for in accordance with the accounting policy applicable to that asset.

F-20


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 3—Significant Accounting Policies (Continued)

        Other leases are classified as operating leases where the leased assets are not recognized in the Group's statement of financial position. Payments under an operating lease are recorded in the statement of income on the straight-line method, over the period of the lease.

G.    Inventories

        Inventories are measured at the lower of cost or net realizable value. The cost of the inventories includes the costs of purchasing the inventories and bringing it to its present location and condition. In the case of work in process and finished goods, the cost includes the proportionate part of the manufacturing overhead based on normal capacity. Net realization value is the estimated selling price in the ordinary course of business, after deduction of the estimated cost of completion and the estimated costs required to execute the sale.

        The cost of the inventories of raw and auxiliary materials, maintenance materials, finished goods and goods in process, is determined mainly according to the "moving average" method.

        If the benefit from stripping costs (costs of removing waste produced as part of a mine's mining activities during its production stage) is realized in the form of inventories, the Company accounts for these stripping costs as inventories. In a case where the benefit is improved access to the quarry, the Company recognizes the costs as a non-current addition to the asset, provided the criteria presented in IFRIC 20 are met.

        Inventories which are expected to be sold in a period of more than 12 months from the reporting date are presented as non-current inventories, as part of non-current assets.

H.    Capitalization of Borrowing Costs

        Borrowing costs are capitalized to qualifying assets (assets that require a significant period of time to prepare them for their intended use or sale) during the period required for their completion and establishment until the time when they are ready for their intended use. Non-specific borrowing costs are capitalized to the investment in qualifying assets using an interest rate that is the weighted-average of the interest rates in respect of those credit sources that were not capitalized specifically. Other borrowing costs are charged to the statement of income as incurred.

I.     Impairment

1. Financial assets

        An impairment of a financial asset is examined when there is objective evidence that one or more events have occurred that may have had a negative impact on the estimate of the future cash flows from the asset.

        Objective evidence that financial assets have been impaired can include a contractual default by a debtor, restructuring of an amount due to the Group on terms that the Group would not otherwise consider, indications that a debtor or issuer will enter into bankruptcy, or the disappearance of an active market for a security.

        The loss from impairment in the value of a financial asset measured according to amortized cost is calculated as the difference between the book value of the asset and the present value of the estimated future cash flows, discounted using the original effective interest rate. A loss from impairment in value of a financial asset classified as "available for sale" is calculated on the basis of its present fair value.

F-21


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 3—Significant Accounting Policies (Continued)

Regarding significant financial assets, the need for an impairment in value is examined for each asset separately.

        Losses from impairment in value, except for losses relating to a financial asset classified as "available for sale", are recorded in the statement of income. An accumulated loss, which relates to a financial asset classified as "available for sale" that was previously recorded to equity, is transferred to the statement of income where it sustains a significant or continuing decline in its fair value below the original cost.

        The Group examines evidence of impairment for receivables and loans on a specific basis.

        An impairment loss is cancelled if the cancellation can be related objectively to an event occurring after the impairment loss was recognized. Cancellation of an impairment loss for financial assets is recorded in the statement of income, except for cancellation of an impairment loss for financial assets classified as "available-for-sale" that are equity instruments, which are recognized directly in other comprehensive income.


2. Non-financial assets

        In every reporting period, an examination is made with respect to whether there are signs indicating impairment in value of the Group's non-financial assets, other than inventories and deferred tax assets. If such signs exist, the estimated recoverable amount of the asset is calculated. The Group conducts an annual examination of the recoverable amount of goodwill and intangible assets with indefinite useful lives or that are not available for use, or more frequently if there are indications of impairment.

        The recoverable amount of an asset or a cash-producing unit is the higher of its value in use or the net selling price (fair value less realization costs). When determining the value in use the Group discounts the anticipated future cash flows according to a pre-tax discount rate that reflects the market evaluations regarding the time value of money and the specific risks relating to the asset. For purposes of testing impairment in value, the assets are grouped together into the smallest group of assets that yields cash flows from continuing use, which is essentially independent of the other assets and other groups ("cash generating unit"). Goodwill purchased in the context of business combinations is allocated for the purpose of examining impairment in value to cash-producing units that are expected to yield benefits from the synergy of the combination.

        Losses from impairment of value are recognized when the book value of the asset or of the cash-producing unit exceeds the recoverable value and are recorded in the statement of income. Losses from impairment of value that were recognized for cash-producing units are first allocated to reducing the book value of the goodwill attributed to these units and afterwards to reducing the book value of the other assets in the cash-producing unit, proportionately.

        A loss from impairment in value of goodwill is not cancelled. Regarding other assets with respect to which losses from impairments of value were recognized in previous periods, in each reporting period an examination is made as to whether there are signs indicating that these losses have decreased or no longer exist. A loss from impairment of value is cancelled if there has been a change in the estimates used to determine the recoverable value, only if the book value of the asset, after cancellation of the loss from impairment of value, does not exceed the book value, after deduction of depreciation or amortization, that would have been determined if the loss from impairment of value had not been recognized.

F-22


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 3—Significant Accounting Policies (Continued)

J.     Employee Benefits

        The Group has several post-employment benefit plans. The plans are funded partly by deposits with insurance companies or funds managed by a trustee, and they are classified as defined contribution plans and as defined benefit plans.


1. Defined contribution plans

        A defined contribution plan is a post-employment benefit plan under which the Group pays fixed contributions into a separate entity and has no legal or constructive obligation to pay further amounts if the fund does not have sufficient assets to pay all the employee benefits relating to the employee's service in the current and prior periods.

        The Group's obligation to make deposits in a defined contribution plan is recorded as an expense in the statement of income in the periods during which the employees provided the services.


2. Defined benefit plans

        Defined benefit plans are retirement benefit plans that are not defined contribution plans.

        The Group's net obligation, regarding defined benefit plans for post-employment benefits, is calculated for each plan separately by estimating the future amount of the benefit to which an employee will be entitled as compensation for his services in the current and past periods. The benefit is presented at present value after deducting the fair value of the plan assets. The discount rate for the Group companies operating in countries having a "deep" market wherein there is a high level of trading in corporate bonds is in accordance with the yield on the corporate bonds. The discount rate for the Group companies operating in countries not having a market wherein there is a high level of trading in corporate bonds, including Israel, as stated above, is in accordance with the yield on government bonds—the currency and redemption date of which are similar to the terms binding the Group. The calculations are performed by a qualified actuary using the projected unit credit method.

        When on the basis of the calculations a net asset is created for the Group, the asset is recognized up to the net present value of the available economic benefits in the form of a refund from the plan or by a reduction in future deposits to the plan. An economic benefit in the form of a refund from the plan or a reduction in future deposits will be considered available when it can be realized in the lifetime of the plan or after settlement of the obligation.

        Costs in respect of past services are recognized immediately and without reference to whether or not the benefits have vested.

        The movement in the net liability in respect of a defined benefit plan that is recognized in every accounting period in the statement of income is comprised of the following:

              (i)  Current service costs—the increase in the present value of the liability deriving from employees' service in the current period.

             (ii)  The net financing income (expenses) are calculated by multiplying the net defined benefit liability (asset) by the discount rate used for measuring the defined benefit liability, as determined at the beginning of the annual reporting period.

            (iii)  Exchange rate differences;

F-23


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 3—Significant Accounting Policies (Continued)

            (iv)  Past service costs and plan reduction—the change in the present value of the liability in the current period as a result of a change in post-employment benefits attributed to prior periods.

        The difference, as at the date of the report, between the net liability as at the beginning of the period plus the movement in profit and loss as detailed above, and the actuarial liability less the fair value of the fund assets at the end of the period, reflects the balance of the actuarial income or expenses recognized in other comprehensive income and is recorded in retained earnings.

        The net financing income (expenses) are recognized in the statement of income as part of the cost of the employees' wages.

        The current interest costs and return on plan assets are recognized as expenses and interest income in the respective financing category.


3. Other long-term employee benefits

        Some of the Company's employees are entitled to other long-term benefits that do not relate to a post-retirement benefit plan. Actuarial gains and losses are recorded directly to the statement of income in the period in which they arise.

        In cases where the amount of the benefit is the same for every employee, without taking into account the years of service, the cost of the benefit is recognized when entitlement to the benefit is determined. The amount of these benefits is discounted to its present value in accordance with an actuarial evaluation.


4. Early retirement pay

        Early retirement pay is recognized as an expense and as a liability when the Group has clearly undertaken to pay it, without any reasonable chance of cancellation, in respect of termination of employees before they reach the customary age of retirement according to a formal, detailed plan. The benefits provided to employees upon voluntary retirement are charged when the Group proposes a plan to the employees encouraging voluntary retirement, it is expected that the proposal will be accepted and it is possible to reliably estimate the number of employees that will accept the proposal.


5. Short-term benefits

        Obligations for short-term employee benefits are measured on a non-discounted basis, and the expense is recorded at the time the said service is provided.

        A provision for short-term employee benefits in respect of cash bonuses is recognized when the Group has a current legal or implied obligation to pay the said amount for services provided by the employee in the past and it is possible to reliably estimate the amount.

        Classification of employee benefits as a short-term employee benefit or a long-term employee benefit (for measurement purposes) is determined based on the Group's expectation with respect to full utilization of the benefits and not based on the date on which the employee is entitled to utilize the benefit.

F-24


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 3—Significant Accounting Policies (Continued)


6. Share-based compensation

        The fair value on the grant date of Share-based compensation awards granted to employees is recognized as a salary expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards. The amount recognized as an expense in respect of Share-based compensation awards that are conditional upon meeting vesting conditions that are service conditions, is adjusted to reflect the number of awards that are expected to vest.

K.    Provisions

        A provision is recognized when the Group has a present legal or implied obligation as the result of an event that occurred in the past, that can be reliably estimated and when it is expected that a flow of economic benefits will be required in order to settle the obligation. The provisions are made by means of discounting of the future cash flows at a pre-tax interest rate reflecting the current market estimates of the time value of money and the risks specific to the liability, and without taking into account the Company's credit risk. The book value of the provision is adjusted in every period in order to reflect the amount of time that has elapsed and is recognized as financing expenses. In rare cases where it is not possible to estimate the outcome of a potential liability, no provision is recorded in the financial statements.


1. Warranty

        A provision for warranty is recognized when the products or services, in respect of which the warranty is provided, are sold or performed. The provision is based on historical data and on a weighting of all possible expenses according to their probability of occurrence.


2. Provision for environmental costs

        The Group recognizes a provision for an existing obligation for prevention of environmental pollution and anticipated provisions for costs relating to environmental restoration stemming from current or past activities.

        Costs for preventing environmental pollution that increase the life expectancy or efficiency of a facility or decrease or prevent the environmental pollution are recorded as a provision, are capitalized to the cost of the property, plant and equipment and are depreciated according to the usual depreciation rates used by the Group.


3. Legal claims

        A provision for legal claims is recognized when the Group has an express or implied legal obligation as a result of an event that occurred in the past, if it is more likely than not that an outflow of economic resources will be required to settle the obligation and it can be reliably estimated. Where the time value is significant, the provision is measured based on its present value.

L.    Revenue Recognition

Sale of goods

        Revenue from the sale of goods in the ordinary course of business is measured at the fair value of the consideration received or receivable, net of returns, trade discounts and volume rebates. When the

F-25


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 3—Significant Accounting Policies (Continued)

credit period is short and constitutes the accepted credit in the industry, the future consideration is not discounted.

        Revenue is recognized when persuasive evidence exists (usually in the form of an executed sales agreement) that the significant risks and rewards of ownership have been transferred to the buyer, recovery of the consideration is probable, the associated costs and possible return of goods can be estimated reliably, there is no continuing management involvement with the goods, and the amount of revenue can be measured reliably. If it is probable that discounts will be granted and the amount can be measured reliably, then the discount is recognized as a reduction of revenue as the sales are recognized.

M.   Treasury stock

        Where share capital recognized as equity has been reacquired by the Group, the amount of the consideration paid including direct expenses, is deducted from equity. The reacquired shares are classified as treasury shares and are presented as a deduction from equity.

N.    Financing Income and Expenses

        Financing income includes income from interest on amounts invested (including available for sale financial assets), gains from exchange rate differences, gains from derivative financial instruments recognized in the statement of income, and gains from available-for-sale financial assets. Interest income is recognized as accrued, using the effective interest method.

        Financing expenses include interest on loans received, changes in the time value of provisions, securitization transaction costs, losses from impairment of available for sale financial assets, losses from derivative financial instruments, changes due to the passage of time in liabilities in respect of defined benefit plans for employees less interest income deriving from plan assets of a defined benefit plan for employees and losses from exchange rate differences. Borrowing costs, which are not capitalized, are recorded in the income statement using the effective interest method.

        Gains and losses from exchange rate differences and from derivative financial instruments are reported on a net basis, as financing income or financing expenses, based on the fluctuation in the exchange rates and based on their position (net gain or loss).

        In the statements of cash flows, interest received and interest paid are presented as part of cash flows from operating activities.

O.    Taxes on Income

        Taxes on income include current and deferred taxes.

        The current tax is the amount of tax that is expected to be paid on the taxable income for the year, which is calculated according to the tax rates in effect based on the law that was finally legislated or effectively legislated as at the date of the report, and includes changes in tax payments attributed to prior years, and payment of tax in respect of distribution of a dividend.

        Recognition of deferred taxes is according to the balance sheet approach, relating to temporary differences between the book values of the assets and liabilities for purposes of financial reporting and their value for tax purposes. The Company does not recognize deferred taxes for the following temporary differences: initial recognition of goodwill, initial recognition of assets and liabilities for

F-26


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 3—Significant Accounting Policies (Continued)

transactions that do not constitute a business combination and do not impact the accounting income and the income for tax purposes, as well as differences deriving from investments in subsidiaries, investee companies and associated companies that are presented according to equity method, if it is not expected that they will reverse in the foreseeable future and if the Group controls the date the provision will reverse, whether via sale or distribution of a dividend. The deferred taxes are measured according to the tax rates expected to apply to the temporary differences at the time they are realized, on the basis of the law that was finally legislated or effectively legislated as at the date of the report. The Company offsets deferred tax assets and liabilities if there is an enforceable legal right to offset current tax assets and liabilities and they are attributable to the same taxable income and are taxed by the same tax authority for the same assessed company or for different companies that intend to settle current tax assets and liabilities on a net basis or if the tax assets and liabilities are settled concurrently.

        A deferred tax asset is recognized in the books when it is expected that in the future there will be taxable income against which the temporary differences can be utilized. Deferred tax assets are examined at each reporting date, and if it is not expected that the related tax benefits will be realized, they are written down.

        The Group could become liable for additional taxes in the case of distribution of intercompany dividends between the Group companies. These additional taxes are not included in the financial statements in light of the policy of the Group companies not to cause distribution of a dividend that involves additional taxes to the paying company in the foreseeable future. In cases where an investee company is expected to distribute a dividend involving additional tax, the Company records a reserve for taxes in respect of the said additional tax it is expected to incur due to distribution of the dividend.

        Deferred taxes in respect of intra-company transactions in the consolidated financial statements are recorded according to the tax rate applicable to the buying company.

        Deferred and current taxes relating to items recognized in shareholders' equity and/or other comprehensive income are recorded directly in shareholders' equity or other comprehensive income, respectively.

P.     Earnings per share

        The Group presents basic and diluted earnings per share data for its ordinary share capital. The basic earnings per share are calculated by dividing the income or loss attributable to the holders of the Company's ordinary shares by the weighted-average number of ordinary shares outstanding during the year, after adjustment in respect of treasury shares. The diluted earnings per share are determined by adjusting the income or loss attributable to the holders of the Company's ordinary shares and the weighted-average number of ordinary shares outstanding for the effect of options for shares granted to employees.

Q.    Segment Information

        An operating segment is a component of the Group that meets the following three conditions:

            1.     It engages in business activities from which it is expected to earn revenues and incur expenses, including revenues and expenses relating to transactions between the Group companies;

F-27


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 3—Significant Accounting Policies (Continued)

            2.     Its operating results are reviewed regularly by the Group's chief operating decision maker in order to make decisions about resources to be allocated to the segment and to assess its performance, and

            3.     Separate financial information is available in respect thereof.

        Inter-segment pricing is determined based on transaction prices in the ordinary course of business.

        Segment results, assets and liabilities include items that are directly attributable to the segment and items that can reasonably be attributed to it. Asset and liability items that were not allocated consist primarily of investments, loans and credit, assets of the Company's headquarters, as well as tax assets and liabilities.

        Unallocated items of revenue and expense include financing income and expenses on investments, loans and credit, administrative and general costs attributed to the Company's headquarters and taxes.

        Capital expenses of the segment are the total costs that were incurred during the period for purchasing property, plant and equipment and intangible assets.

R.    Initial Application of New Standards

        IFRS 11 "Joint Arrangements" (hereinafter—"the Standard").     The Standard replaced the requirements of IAS 31 "Interests in Joint Ventures" (hereinafter—"IAS 31") and amended part of the requirements in IAS 28 "Investments in equity-accounted investees".

        The Standard defines joint arrangements as arrangements over which two or more parties have joint control.

        A distinction exists in the standard between joint operations and joint ventures:

        Joint operations—are arrangements wherein the parties having joint control have rights in the assets relating to the arrangement and obligations to discharge the liabilities relating to the arrangement, regardless of whether or not the joint arrangement is structured in a separate vehicle. The accounting treatment of joint operations is similar to the accounting treatment in IAS 31 for jointly controlled assets and operations, that is, the assets, liabilities and transactions are recognized and accounted for according to the relevant standards.

        Joint ventures—all joint arrangements which are structured in a separate vehicle in which the parties having joint control have rights to the net assets of the joint arrangement. Joint ventures are accounted for using the equity method only (the option to apply the proportionate consolidation method has been eliminated).

        As a result of adoption of the standards, jointly-controlled companies that were previously included using the proportionate consolidation method, are presented based on the equity method of accounting. The Standard applies to annual reporting periods commencing on January 1, 2013, and is applied retrospectively. Accordingly, the statements of financial position, income, comprehensive income, changes in equity and cash flows and the notes to the financial statements have been restated. The impact of the above-mentioned Standard on the financial statements was not material.

        Amendment to IAS 19 "Employee Benefits" (hereinafter—"the Amendment").     Pursuant to the Amendment costs in respect of past service are recognized immediately without reference to whether or not these benefits have vested. Calculation of the net financing income or expenses is made by

F-28


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 3—Significant Accounting Policies (Continued)

multiplying the defined benefit liability (asset) by the discount rate used to measure the defined benefit obligation. Accordingly, calculation of the actuarial gains or losses will also change. In addition, the Amendment changed the definitions of short-term employee benefits and of other long-term employee benefits, so that instead of determining the classification as short-term or long-term based on the date of eligibility, the classification depends on the dates when the entity expects the benefits to be fully utilized.

        The Amendment applies to annual periods beginning on January 1, 2013 on a retrospective basis (except for certain relief enumerated in the Amendment). Accordingly, the statements of financial position, income, changes in equity and cash flows and the notes to the financial statements have been restated.

        The impact of the above-mentioned Amendment on the financial statements is not material.

        IFRIC Interpretation 20 "Stripping Costs in the Production Stage in the Site Mining Process" (hereinafter—"the Interpretation").     The Interpretation applies to costs of removing waste created in the course of mining operations of an open mine during the mine's production stage ("stripping costs"). Pursuant to the Interpretation, if the benefit of the stripping costs is realized on the form of inventories produced, the entity is to account for these stripping costs in accordance with IAS 2 as inventories. If the benefit is improved access to the quarry, the entity is to recognize these costs as an addition to a non-current asset, provided the criteria appearing in the Interpretation are fulfilled.

        The Interpretation is being applied for reporting periods commencing on January 1, 2013, by means of retrospective application.

        The impact of the above-mentioned Interpretation on the financial statements is not significant.

        Amendment to IFRS 13 "Measurement of Fair Value" (hereinafter—"the Amendment").     Pursuant to the Amendment, when measuring the fair value of a liability account is to be taken of the impact of the entity's own credit risk. If an asset or liability measured at fair value has a bid price and an ask price, the price in the range between them that best reflects fair value under the circumstances will be used for measuring fair value.

        The Amendment was applied prospectively where the Standard's disclosure requirements do not apply to comparative data for periods prior to the first time application.

        Amendment to IAS 36 "Impairment in Value of Assets, Disclosure regarding the Recoverable Amount of Non-Financial Assets" (hereinafter—"the Amendment").     The Amendment includes new disclosure requirements for cases wherein an impairment in value is recognized and the recoverable amount is determined as fair value less selling costs. In addition, the Amendment cancels the requirement to provide disclosure of the recoverable amount of significant cash-generating units, even if no impairment was recognized in respect thereof.

        The Amendment is applicable on a retroactive basis. The mandatory effective date of the Amendment is for annual periods beginning on or after January 1, 2014.

        Amendment to IFRS 12 "Disclosure of Rights in Other Entities" (hereinafter—"the Amendment").     The Amendment includes comprehensive disclosure requirements with respect to rights in subsidiaries, joint arrangements, investments in equity-accounted investees and in non-consolidated structured entities.

        The Amendment applies to reporting periods commencing on January 1, 2013, and is to be applied retrospectively (except for certain relief provisions included in the Amendment).

F-29


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 3—Significant Accounting Policies (Continued)

        The impact of the above-mentioned Amendment on the financial statements is not significant. The disclosures are included in note 10.

S.     New Standards and Interpretations not yet Adopted

        IFRIC Interpretation 21 "Impositions" (hereinafter—"the Interpretation").     The Interpretation provides guidelines in connection with the accounting treatment of a liability to pay government impositions that are covered by IAS 37 "Provisions", contingent liabilities and contingent assets, and government impositions that are not covered by IAS 37 since the timing and amount of their repayment are certain. An "imposition" is defined as an outflow of resources imposed on an entity by the government by means of legislation and/or regulation. The Interpretation provides that a liability for payment of an imposition will be recognized only upon occurrence of the event that creates the liability for payment, even in cases where the entity has no practical possibility of avoiding the event.

        The Interpretation is to be applied for annual periods commencing on January 1, 2014. The impact of the above-mentioned Standard on the financial statements is not expected to be material.

T.     Indices and exchange rates

        Balances in or linked to foreign currency are included in the financial statements at the representative exchange rate on the date of the report. Balances linked to the Consumer Price Index (hereinafter—"the CPI") are included on the basis of the index relating to each linked asset or liability.

        Data regarding the representative exchange rates and the CPI are as follows:

 
  CPI (points)   Exchange rate
of the US dollar
relative to the shekel
  Exchange rate
of the US dollar
relative to the euro
 

December 31, 2013

    120.0     3.471     0.726  

December 31, 2012

    117.9     3.733     0.759  

December 31, 2011

    116.0     3.821     0.774  

Changes during the year ended:

   
 
   
 
   
 
 

December 31, 2013

    1.8 %   (7.0 )%   (4.3 )%

December 31, 2012

    1.6 %   (2.3 )%   (1.9 )%

December 31, 2011

    2.2 %   7.7 %   3.3 %

Note 4—Determination of Fair Values

        As part of the accounting policies and disclosures, the Group is required to determine the fair value of both financial and non-financial assets and liabilities. The fair values have been determined for measurement and/or disclosure purposes based on the methods described below. Further information about the assumptions made in determining the fair values is disclosed in the notes specific to that asset or liability.

A.    Property, plant and equipment

        The fair value of property, plant and equipment recognized in a business combination is based on the cost model or on the market value model. According to the cost model, the fair value of the property, plant and equipment is based on the depreciated replacement price of the item measured.

F-30


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 4—Determination of Fair Values (Continued)

The depreciated replacement price takes into account adjustments in respect of physical wear and tear and obsolescence of the property, plant and equipment item. According to the market value model, the fair value is based on the selling price determined in sale transactions of similar assets, while making adjustments to the asset items sold and the asset item acquired in the business combination

B.    Intangible assets

        The fair value of patents and trademarks acquired in a business combination is based on the discounted estimated royalty payments that would be required to be paid if the patent or trademark was not owned. The fair value of customer relationships acquired in a business combination is determined using the multi-period excess earnings method, whereby the fair value of the asset is estimated after deducting a fair return on all other assets that are part of creating the related cash flows.

        The fair value of other intangible assets is based on the discounted cash flows expected to be derived from the use and eventual sale of the assets

C.    Inventories

        The fair value of inventories acquired in a business combination is determined as follows:

            (1)   Finished goods inventories—on the basis of the estimated selling price of the products in the ordinary course of business, less the estimated selling costs as well as a reasonable margin in respect of the efforts required for completion and sale of the inventories.

            (2)   Inventory of work-in-progress—determined on the basis of estimates described in Section 1 above, less costs required for its completion.

            (3)   Inventory of raw materials—based on replacement value.

D.    Investments in securities

        The fair value of financial assets classified as available-for-sale and as held-for-trading is determined based on their market price at date of the report. If the an asset or liability measured at fair value has a bid price and an ask price, the price in the range between them that best reflects fair value under the circumstances will be used for measuring fair value.

E.    Derivatives

        The fair value of forward contracts on foreign currency is determined by averaging the exchange rate and the appropriate interest coefficient for the period of the transaction and the relevant currency index.

        The fair value of currency options is determined based on the Black and Scholes model, taking into account the intrinsic value, standard deviation and the interest rates.

        The fair value of interest rate swap contracts is determined by discounting the estimated amount of the future cash flows on the basis of the terms and length of period to maturity of each contract, while using market interest rates of similar instruments at the date of measurement.

        Future contracts on energy prices are presented on the basis of quotes of the prices of products on an ongoing basis.

F-31


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 4—Determination of Fair Values (Continued)

        The reasonableness of the market price is examined by comparing it to quotations by banks.

        For further information regarding the fair value hierarchy—see Note 27 regarding financial instruments.

F.     Liabilities in respect of debentures

        The fair value of the liabilities and the debentures is determined for disclosure purposes only.

        The fair value of marketable debentures is determined based on the stock market prices as at the date of the report. The fair value of the non-marketable debentures is calculated based on the present value of future cash flows in respect of the principal and interest components, discounted at the market rate of interest as at the reporting date.

G.    Share-based compensation

        The fair value of employee share options and of share appreciation rights is measured using the Black and Scholes model or a binomial model, in accordance with the plan (see Note 24). The model's assumptions include the share price on the measurement date, exercise price of the instrument, expected volatility (based on the weighted-average historic volatility), the weighted-average expected life of the instruments (based on historical experience and general option-holder behavior), expected dividends, and the risk-free interest rate (based on government debentures).

H.    Contingent consideration in respect of business combinations

        The fair value of contingent consideration is calculated at the time of the business combination using the income approach based on the expected payment amounts and their associated probabilities. When the contingent consideration is long term in nature, the liability is discounted to present value using the market interest rate as at the reporting date

Note 5—Operating Segments

A.    General

1. Information on business segments:

        ICL is a multi-national enterprise, which operates mainly in the fields of fertilizers and specialty chemicals, in three reporting segments—fertilizers (that includes potash and phosphate), industrial products and performance products. The segments are described below:

        ICL Fertilizers —ICL Fertilizers extracts potash from the Dead Sea and mines and produces potash and salt from subterranean mines in Spain and the UK. ICL Fertilizers processes the potash into its types and markets it throughout the world. This segment also uses part of the potash to produce compound fertilizers.

        In addition, ICL Fertilizers mines and processes phosphate rock in open mines in the south of Israel, and produces sulfuric acid in Israel, agricultural phosphoric acid, phosphate fertilizers, compound fertilizers, based mainly on potash and phosphate, liquid fertilizers and soluble fertilizers. ICL Fertilizers also manufactures compound fertilizers in the Netherlands, Germany and Belgium, liquid fertilizers and soluble fertilizers in Spain, slow-release fertilizers and controlled-release fertilizers

F-32


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 5—Operating Segments (Continued)

in the Netherlands and in the United States, and phosphate-based food additives for livestock, in Turkey and in Israel.

        ICL Fertilizers markets its products worldwide, mainly in Europe, Brazil, India, China and Israel. The activities of ICL Fertilizers also include the activities of Mifalei Tovala Ltd., which is engaged in the transportation of cargo, mainly of ICL companies in Israel, since a large part of the Company's activities consists of bulk transport of cargo of the ICL Fertilizers segment.

        ICL Industrial Products —ICL Industrial Products produces bromine out of a solution that is created as a by-product of the potash production process in Sodom, Israel, as well as bromine-based compounds. ICL Industrial Products uses most of the bromine it produces for self-production of bromine compounds at production sites in Israel, the Netherlands and China. In addition, ICL Industrial Products extracts salt, magnesia and chlorine from Dead Sea brine, and produces chlorine-based products in Israel and the United States. In addition, ICL Industrial Products engages in the production and marketing of flame retardants and additional phosphorus-based products.

        ICL Performance Products —ICL Performance Products cleans some of the agricultural phosphoric acid manufactured by ICL Fertilizers, purchases clean phosphoric acid from other sources and also manufactures thermal phosphoric acid. The clean phosphoric acid and the thermal phosphoric acid are used to manufacture downstream products with high added value, phosphate salts, which are also used as a raw material for manufacturing, food additives, hygiene products and flame-retardants and fire extinguishment products. ICL Performance Products also manufactures phosphorous derivatives based on phosphorous acquired from outside sources and manufactures specialty products, based on aluminum acids (hereinafter—"Aluminia") and other raw materials. The manufacturing of ICL's performance products is mostly carried out at production sites in Europe, (particularly in Germany), the United States, Brazil, Israel, China, Mexico and other countries.

        In addition to the segments described above, ICL has other operations, including production and marketing of pure magnesium as well as magnesium alloys.


2. Segment assets and liabilities

        Segment assets include all the operating assets used by the segment and consist principally of cash and cash equivalents, trade and other receivables, inventories, property, plant and equipment and intangible assets, net of allowances and provisions. Most of these assets can be directly attributed to the individual segments. Segment liabilities include all the operating liabilities and consist principally of trade payables and wages, which are scheduled for current payment, and liabilities for employee benefits. Segment capital expenditures for each of the reporting periods also include property, plant and equipment and intangible assets acquired as part of business combinations.


3. Inter—segment transfers

        Segment revenues, segment expenses and segment results include transfers between business segments and between geographical segments. Such transfers are accounted for at arm's length, representing prices charged to external customers for similar goods. These transfers are eliminated as part of consolidation of the statements.

F-33


Table of Contents

Notes to the Consolidated Financial Statements (Continued)

Note 5—Operating Segments

B.    Operating segment data:

 
  Fertilizers    
   
   
   
   
 
 
  Industrial
products
  Performance
products
  Other
activities
   
   
 
 
  Potash   Phosphate   Eliminations   Total   Eliminations   Consolidated  
 
  US$ thousands
 

Year 2013:

                                                       

Sales to external parties

    1,797,360     1,584,420         3,381,780     1,277,432     1,496,601     115,729         6,271,542  

Inter-segment sales

    229,237     169,815     (125,567 )   273,485     19,253     78,095     38,980     (409,813 )    
                                       

Total sales

    2,026,597     1,754,235     (125,567 )   3,655,265     1,296,685     1,574,696     154,709     (409,813 )   6,271,542  
                                       
                                       

Income from ordinary activities

    740,342     79,494     1,235     821,071     114,525     195,797     (16,574 )         1,114,819  
                                           

Unallocated expenses and intercompany eliminations

                                                    (13,453 )
                                                       

Operating income

                                                    1,101,366  

Financing expenses

                                                    (158,403 )

Financing income

                                                    131,548  

Share in profit of investee companies accounted for using the equity method of accounting

                                                    25,685  
                                                       

Income before taxes on income

                                                    1,100,196  
                                                       
                                                       

Other Data:

                                                       

Segment assets

    2,712,374     1,660,265     (77,795 )   4,294,844     1,775,407     1,202,911     94,665     (150,455 )   7,217,372  

Unallocated assets

                                                    756,113  
                                                       

Consolidated total assets

                                                    7,973,485  
                                                       
                                                       

Segment liabilities

    649,312     563,078     (53,035 )   1,159,355     424,498     352,643     69,179     (48,092 )   1,957,583  

Unallocated liabilities

                                                    2,337,228  
                                                       

Consolidated total liabilities

                                                    4,294,811  
                                                       
                                                       

Capital expenditures

    551,508     141,983         693,491     141,338     93,394     8,860         937,083  

Unallocated capital expenditures

                                                    10,180  
                                                       

Total capital expenditures

                                                    947,263  
                                                       
                                                       

Depreciation and amortization

    100,533     117,895         218,428     75,071     46,580     6,323         346,402  

Unallocated depreciation and amortization

                                                    1,339  
                                                       

Total depreciation and amortization

                                                    347,741  
                                                       
                                                       

F-34


Table of Contents

Notes to the Consolidated Financial Statements (Continued)

Note 5—Operating Segments (Continued)

 
  Fertilizers    
   
   
   
   
 
 
  Industrial
products
  Performance
products
  Other
activities
   
   
 
 
  Potash   Phosphate   Eliminations   Total   Eliminations   Consolidated  
 
  US$ thousands
 

Year 2012:

                                                       

Sales to external parties

    1,964,741     1,568,944         3,533,685     1,401,645     1,406,626     129,477         6,471,433  

Inter-segment sales

    233,587     158,151     (119,544 )   272,194     15,778     65,491     49,907     (403,370 )    
                                       

Total sales

    2,198,328     1,727,095     (119,544 )   3,805,879     1,417,423     1,472,117     179,384     (403,370 )   6,471,433  
                                       
                                       

Income from ordinary activities

    996,491     162,419     (88 )   1,158,822     217,336     179,256     630           1,556,044  
                                           

Unallocated expenses and intercompany eliminations

                                                    (2,412 )
                                                       

Operating income

                                                    1,553,632  

Financing expenses

                                                    (81,595 )

Financing income

                                                    20,701  

Share in income of investee companies accounted for using the equity method of accounting

                                                    26,555  
                                                       

Income before taxes on income

                                                    1,519,293  
                                                       
                                                       

Other Data:

                                                       

Segment assets

    2,230,177     1,690,603     (86,841 )   3,833,939     1,705,510     1,153,942     90,142     (64,908 )   6,718,625  

Unallocated assets

                                                    626,286  
                                                       

Consolidated total assets

                                                    7,344,911  
                                                       
                                                       

Segment liabilities

    640,407     522,327     (60,846 )   1,101,888     473,342     338,564     82,383     (68,467 )   1,927,710  

Unallocated liabilities

                                                    2,028,937  
                                                       

Consolidated total liabilities

                                                    3,956,647  
                                                       
                                                       

Capital expenditures

    428,474     151,235         579,709     138,488     47,727     7,798         773,722  

Unallocated capital expenditures

                                                    5,894  
                                                       

Total capital expenditures

                                                    779,616  
                                                       
                                                       

Depreciation and amortization

    110,217     101,393         211,610     61,998     42,451     5,614         321,673  

Unallocated depreciation and amortization

                                                    838  
                                                       

Total depreciation and amortization

                                                    322,511  
                                                       
                                                       

F-35


Table of Contents

Notes to the Consolidated Financial Statements (Continued)

Note 5—Operating Segments (Continued)

 
  Fertilizers    
   
   
   
   
 
 
  Industrial
products
  Performance
products
  Other
activities
   
   
 
 
  Potash   Phosphate   Eliminations   Total   Eliminations   Consolidated  
 
  US$ thousands
 

Year 2011 :

                                                       

Sales to external parties

    2,284,707     1,544,296         3,829,003     1,486,796     1,426,366     126,385         6,868,550  

Inter-segment sales

    221,451     153,356     (114,416 )   260,391     14,362     64,475     40,992     (380,220 )    
                                       

Total sales

    2,506,158     1,697,652     (114,416 )   4,089,394     1,501,158     1,490,841     167,377     (380,220 )   6,868,550  
                                       
                                       

Income from ordinary activities

    1,181,985     207,801     128     1,389,914     290,111     191,012     13,573           1,884,610  
                                           

Unallocated expenses and intercompany eliminations

                                                    (6,535 )
                                                       

Operating income

                                                    1,878,075  

Financing expenses

                                                    (103,637 )

Financing income

                                                    25,825  

Share in income of investee companies accounted for using the equity method of accounting

                                                    34,265  
                                                       

Income before taxes on income

                                                    1,834,528  
                                                       
                                                       

Other Data:

                                                       

Segment assets

    2,082,060     1,628,302     (74,014 )   3,636,348     1,620,111     1,101,498     82,844     (49,753 )   6,391,048  

Unallocated assets

                                                    572,626  
                                                       

Consolidated total assets

                                                    6,963,674  
                                                       
                                                       

Segment liabilities

    619,857     495,106     (48,107 )   1,066,856     459,644     318,429     75,448     (50,406 )   1,869,971  

Unallocated liabilities

                                                    2,003,454  
                                                       

Consolidated total liabilities

                                                    3,873,425  
                                                       
                                                       

Capital expenditures

    241,707     455,339         697,046     116,956     133,757     9,444         957,203  

Unallocated capital expenditures

                                                    701  
                                                       

Total capital expenditures

                                                    957,904  
                                                       
                                                       

Depreciation and amortization

    105,935     105,376         211,311     57,660     40,231     5,722         314,924  

Unallocated depreciation and amortization

                                                    701  
                                                       

Total depreciation and amortization

                                                    315,625  
                                                       
                                                       

F-36


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 5—Operating Segments (Continued)

C.    Information on geographical segments:

        Following is data regarding the distribution of the Group's sales by geographical location of the customers:

 
  For the year ended December 31  
 
  2013   2012   2011  
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Europe

    2,378,397     2,331,808     2,390,324  

Asia

    1,463,622     1,615,202     2,058,596  

North America

    1,207,221     1,252,269     1,351,978  

South America

    747,589     815,181     665,462  

Others

    155,753     132,203     146,468  
               

    5,952,582     6,146,663     6,612,828  

In Israel

    318,960     324,770     255,722  
               

    6,271,542     6,471,433     6,868,550  
               
               

        Following is data regarding the distribution of the Group's sales by geographical location of the assets:

 
  For the year ended December 31  
 
  2013   2012   2011  
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Israel

    3,095,136     3,438,575     3,802,981  

Europe

    2,715,573     2,601,443     2,625,047  

United States

    1,099,152     1,115,106     1,042,121  

Others

    382,159     402,792     448,329  
               

    7,292,020     7,557,916     7,918,478  

Intercompany transactions—mainly from Israel

    (1,020,478 )   (1,086,483 )   (1,049,928 )
               

    6,271,542     6,471,433     6,868,550  
               
               

        Following is data regarding the operating income by geographical location of the assets from which the income was produced:

 
  For the year ended December 31  
 
  2013   2012   2011  
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Israel

    711,222     1,092,348     1,393,161  

Europe

    299,127     282,486     330,707  

United States

    115,764     134,825     143,511  

Others

    35,167     37,871     53,169  

Eliminations

    (59,914 )   6,102     (42,473 )
               

Total

    1,101,366     1,553,632     1,878,075  
               
               

F-37


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 5—Operating Segments (Continued)

        Following is data reflecting the carrying value of allocated segmental assets and allocated segmental additions to property, plant and equipment and intangible assets by the geographical location of the assets:

 
  Carrying value of assets as at December 31   Additions to property, plant and equipment, and intangible assets for the year ended December 31  
 
  2013   2012   2011   2013   2012   2011  
 
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
 

Israel

    4,159,207     3,738,589     3,642,746     671,087     553,979     421,637  

Europe

    2,240,248     2,064,569     1,852,702     236,086     176,176     356,108  

United States

    921,961     971,141     969,403     20,160     31,813     162,732  

Others

    309,134     315,332     328,278     9,750     11,754     16,726  

Eliminations

    (413,178 )   (371,006 )   (402,081 )            
                           

Total

    7,217,372     6,718,625     6,391,048     937,083     773,722     957,203  
                           
                           

        Following is data depreciation and amortization by geographical areas:

 
  Year ended December 31  
 
  2013   2012   2011  
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Israel

    172,112     158,394     163,550  

Europe

    117,225     116,778     108,252  

United States

    45,217     34,545     32,200  

Others

    13,187     12,794     11,623  
               

Total

    347,741     322,511     315,625  

Note 6—Short-Term Investments, Deposits and Loans

 
  As at December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

Trading securities

    36,140     44,114  

Deposits in banks and financial institutions and short-term loans

    58,954     97,222  

Current maturities of long-term deposits

    1,294     1,353  
           

    96,388     142,689  
           
           

Note 7—Trade Receivables

 
  As at December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

Trade—open accounts:

             

Non-Israeli

    997,490     981,492  

Israeli

    70,318     64,539  
           

    1,067,808     1,046,031  

Less—allowance for doubtful debts

    10,780     11,363  
           

    1,057,028     1,034,668  
           
           

F-38


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 8—Other Receivables, including Derivative Instruments

 
  As at December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

Israeli government institutions

    17,028     20,151  

Non-Israeli government institutions

    31,145     43,456  

Prepaid expenses

    26,193     37,961  

Advances to suppliers

    7,828     6,802  

Derivatives

    62,235     40,068  

Other

    41,888     68,583  
           

    186,317     217,021  
           
           

Note 9—Inventories

 
  As at December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

Finished products

    887,377     846,733  

Work in progress

    248,303     256,643  

Raw materials and supplies

    214,225     245,040  

Spare parts and maintenance supplies

    120,644     112,458  
           

    1,470,549     1,460,874  

Less—non-current inventories (presented in non-current assets)

    62,252     54,723  
           

    1,408,297     1,406,151  
           
           

Note 10—Investment in Investee Companies

A.    Movement during the year in investments in equity-accounted investees

 
  US$ thousands  

Balance as at January 1, 2013

    173,952  

Changes during the year:

       

Share in earnings

    25,685  

Dividends received

    (23,168 )

Increase in rate of holdings in associated company—initial consolidation

    (1,769 )

Cumulative translation adjustments

    (189 )
       

Balance as at December 31, 2013

    174,511  
       
       

F-39


Table of Contents

Notes to the Consolidated Financial Statements (Continued)

Note 10—Investment in Investee Companies (Continued)

B.    Condensed data with respect to equity-accounted investees

        Set forth below is condensed financial data with respect to equity-accounted investees which are individually insignificant without adjustments for the ownership rates held by the Group.

 
  Current
assets
  Non-current
assets
  Total
assets
  Current
liabilities
  Non-current
liabilities
  Total
liabilities
  Revenues   Expenses   Profit  
 
  US$ thousands
 

Joint arrangements as at December 31, 2013

    400,734     662,469     1,063,203     318,837     394,546     713,383     474,311     419,161     55,150  

Joint arrangements as at December 31, 2012

    379,423     543,547     922,970     249,970     362,466     612,436     550,267     497,103     53,164  

F-40


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 10—Investment in Investee Companies (Continued)

C.    Investee companies

        Additional details regarding investee companies held directly by the Company:

 
   
   
  Amounts provided by
the Company to the
Investee companies
   
 
 
  Country of
incorporation
  Company
Equity
Holding
  Investment in
the Investee
companies
 
 
  Loans   Guarantees  
 
   
   
  US$ thousands
 

2013

                             

Dead Sea Works Ltd. 

  Israel     100 %               1,972,305  

Dead Sea Bromine Company Ltd. 

  Israel     100 %               307,685  

Rotem Amfert Negev Ltd. 

  Israel     100 %   440,000           1,122,854  

Dead Sea Periclase Ltd. 

  Israel     100 %               60,682  

Mifalei Tovala Ltd. 

  Israel     100 %               41,145  

"Ferson" Chemicals Ltd. 

  Israel     100 %               1,597  

ICL Fine Chemicals Ltd. 

  Israel     100 %               (106 )

Dead Sea Magnesium Ltd. 

  Israel     100 %               52,922  

IDE Technologies Ltd

  Israel     50 %         64,855     111,584  

ICL Finance B.V. 

  The Netherlands     100 %               86,123  

ICL Finance Inc., USA

  U.S.A.     100 %               29,585  

Twincap Forsakrings AB

  Sweden     100 %               6,385  

Hoyermann Chemie GmbH

  Germany     100 %               11,144  

2012

 
 
   
 
   
 
   
 
   
 
 

Dead Sea Works Ltd. 

  Israel     100 %               1,972,305  

Dead Sea Bromine Company Ltd. 

  Israel     100 %               307,685  

Rotem Amfert Negev Ltd. 

  Israel     100 %   440,000           1,122,854  

Dead Sea Periclase Ltd. 

  Israel     100 %               60,682  

Mifalei Tovala Ltd. 

  Israel     100 %               41,145  

Rotem Amfert Negev B.V. 

  The Netherlands     *32.60 %               27,647  

ICL Financing and Issuing Ltd. 

  Israel     100 %               3  

"Ferson" Chemicals Ltd. 

  Israel     100 %               1,597  

ICL Fine Chemicals Ltd. 

  Israel     100 %               (106 )

Dead Sea Magnesium Ltd. 

  Israel     100 %               52,922  

IDE Technologies Ltd

  Israel     50 %         64,027     111,584  

ICL Finance B.V. 

  The Netherlands     100 %               86,123  

ICL Finance Inc., USA

  U.S.A.     100 %               29,585  

Twincap Forsakrings AB

  Sweden     100 %               6,385  

Hoyermann Chemie GmbH

  Germany     100 %               166  

*
The balance of the holding is by a subsidiary.

Note 11—Business Acquisitions

         A.     In February 2013, the Group acquired the production assets and activities of a plant in Knapsack Germany used for marketing and production P2S5 phosphates. The plant was acquired from the international company, Thermphos International B.V.

         B.     In December 2013, the Group signed an agreement for acquisition of the production assets and activities of the Hagesud Company in Germany, a producer of high-quality spice mixtures and food additives for meat processing. The deal was closed subsequent to the balance sheet date, in January 2014.

         C.     In December 2013, the Group undertook to acquire the interest of Vale Fertilizantes in Fosbrasil S.A., which is a joint venture for production of phosphoric acid and choice fertilizers, located

F-41


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 11—Business Acquisitions (Continued)

in Brazil. Acquisition of Vale's share will increase ICL's share to a majority holding in Fosbrasil, which is a leading producer of phosphoric acid in South America. Approval of the acquisition is subject to approval of the Anti-Trust Authority in Brazil as well as other relevant approvals.

         D.     The above acquisitions are immaterial.

         E.     Subsequent to the date of the financial statements, in February 2014, the Group signed a strategic agreement with Allana Potash, a company traded on the Toronto stock exchange in connection with development of a potash mine in Ethiopia. Pursuant to the agreement, ICL will acquire units of Allana (which includes shares and options), for a total amount of about $23 million. Pursuant to the agreement, if all approval will be received ICL will hold about 16% of the shares of Allana Potash, with an option to increase its holdings to about 37%.

Note 12—Long-Term Deposits and Receivables

A.    Composition

 
  As at December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

Bank deposits and other

    4,634     10,432  

Less—current maturities

    1,294     1,353  
           

    3,340     9,079  

Other receivables

    12,428     13,001  
           

    15,768     22,080  
           
           

B.    Long-term deposits and receivables classified by currency and interest rates

 
  Weighted average interest rate    
   
 
 
  As at December 31  
 
  As at
December 31
2013
 
 
  2013   2012  
 
  %
  US$ thousands
  US$ thousands
 

In Israeli currency

    2.8     4,247     4,423  

In non-Israeli currency:

                   

US dollar

            5,536  

Other

    0.2     387     473  
                 

          4,634     10,432  
                 
                 

C.    The deposits and receivables (net of current maturities) mature in the following years after each reporting date as follows:

 
  As at December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

Second year

    1,162     7,030  

Third year

    935     812  

Fourth year

    735     664  

Fifth year

    188     498  

Sixth year and thereafter

    320     75  
           

    3,340     9,079  
           
           

F-42


Table of Contents

Notes to the Consolidated Financial Statements (Continued)

Note 13—Property, Plant and Equipment

 
  Land, land
development,
roads and
buildings
  Installations,
machinery
and
equipment
  Dikes and
evaporating
ponds
  Heavy
mechanical
equipment,
railroad
cars and
tanks
  Furniture,
office
equipment,
vehicles,
computer
equipment
and other
  Plants under
construction(2)
  Spare parts
for
installations
  Total  
 
  US$
thousands

  US$
thousands

  US$
thousands

  US$
thousands

  US$
thousands

  US$
thousands

  US$
thousands

  US$
thousands

 

Cost(1)

                                                 

Balance as at January 1, 2013

    669,934     4,534,314     1,176,122     161,571     232,740     452,572     7,778     7,235,031  

Additions

    59,646     335,576     242,767     10,765     15,912     200,235         864,901  

Additions in respect of business combinations

    351     3,038         3,284     2,254     4         8,931  

Disposals

    (7,237 )   (67,552 )       (11,871 )   (3,047 )       (175 )   (89,882 )

Translation differences

    18,408     36,944     10,207     234     3,887     7,303         76,983  
                                   

Balance as at December 31, 2013

    741,102     4,842,320     1,429,096     163,983     251,746     660,114     7,603     8,095,964  
                                   

Accumulated depreciation(1)

                                                 

Balance as at January 1, 2013

    342,158     2,866,356     663,898     90,849     174,385             4,137,646  

Additions

    18,629     190,039     66,881     7,949     15,494             298,992  

Disposals

    (5,636 )   (66,117 )       (10,169 )   (2,194 )           (84,116 )

Impairment

        10,000                         10,000  

Translation differences

    11,881     24,789     7,591     333     2,608             47,202  
                                   

Balance as at December 31, 2013

    367,032     3,025,067     738,370     88,962     190,293             4,409,724  
                                   

Depreciated balance as at December 31, 2013

    374,070     1,817,253     690,726     75,021     61,453     660,114     7,603     3,686,240  
                                   
                                   

F-43


Table of Contents

Notes to the Consolidated Financial Statements (Continued)

Note 13—Property, Plant and Equipment (Continued)

 
  Land, land
development,
roads and
buildings
  Installations,
machinery
and
equipment
  Dikes and
evaporating
ponds
  Heavy
mechanical
equipment,
railroad
cars and
tanks
  Furniture,
office
equipment,
vehicles,
computer
equipment
and other
  Plants under
construction(2)
  Spare parts
for
installations
  Total  
 
  US$
thousands

  US$
thousands

  US$
thousands

  US$
thousands

  US$
thousands

  US$
thousands

  US$
thousands

  US$
thousands

 

Cost(1)

                                                 

Balance as at January 1, 2012

    627,155     4,270,257     987,564     146,987     218,762     249,130     7,303     6,507,158  

Additions

    36,252     280,680     191,096     19,843     20,582     199,568     475     748,496  

Additions in respect of business combinations

    4,970     1,257             594             6,821  

Disposals

    (3,447 )   (41,027 )   (6,855 )   (6,120 )   (8,691 )           (66,140 )

Translation differences

    5,004     23,147     4,317     861     1,493     3,874         38,696  
                                   

Balance as at December 31, 2012

    669,934     4,534,314     1,176,122     161,571     232,740     452,572     7,778     7,235,031  
                                   

Accumulated depreciation(1)

                                                 

Balance as at January 1, 2012

    324,373     2,715,874     594,142     90,047     167,320             3,891,756  

Additions

    17,038     173,975     73,512     5,991     14,723             285,239  

Disposals

    (2,533 )   (37,858 )   (6,855 )   (5,656 )   (8,462 )           (61,364 )

Translation differences

    3,280     14,365     3,099     467     804             22,015  
                                   

Balance as at December 31, 2012

    342,158     2,866,356     663,898     90,849     174,385             4,137,646  
                                   

Depreciated balance as at December 31, 2012

    327,776     1,667,958     512,224     70,722     58,355     452,572     7,778     3,097,385  
                                   
                                   

1.
Property, plant and equipment includes assets that have been fully depreciated and which are still in use. The original cost of those assets as of December 31, 2013 is about $2,569 million (as at December 31, 2012 $2,344 million).

2.
Plants under construction—the changes represent additions during the year, net of transfers to property, plant and equipment.

F-44


Table of Contents

Notes to the Consolidated Financial Statements (Continued)

Note 14—Intangible Assets

A.    Composition

 
  Intangible assets acquired   Intangible assets internally developed   Others   Total  
 
  Goodwill   Concessions
and
mining
rights(1)
  Trademarks   Technology/
patents
  Customer
relationships
  Exploration
and
evaluation
assets
  Technology/
patents
  Development
costs
   
   
 
 
  US$
thousands

  US$
thousands

  US$
thousands

  US$
thousands

  US$
thousands

  US$
thousands

  US$
thousands

  US$
thousands

  US$
thousands

  US$
thousands

 

Cost

                                                             

Balance as at January 1, 2013

    281,005     158,398     110,590     68,190     205,008     21,121     368     7,016     124,177     975,873  

Additions

        469     91     353         2,105     62         19,013     22,093  

Additions in respect of business combinations

    2,907         182         48,481                 253     51,823  

Disposals

                                         

Translation differences

    6,928     2,729     1,183     3,443     7,395     552     7     265     414     22,916  
                                           

Balance as at December 31, 2013

    290,840     161,596     112,046     71,986     260,884     23,778     437     7,281     143,857     1,072,705  
                                           

Amortization and impairment losses

                                                             

Balance as at January 1, 2013

    22,853     41,780     14,474     20,181     53,690     4,132     258     5,698     77,998     241,064  

Amortization for the year

        3,250     4,837     4,390     14,826     1,091     16     175     8,959     37,544  

Translation differences

    737     64     (646 )   838     1,055     66     7     229     573     2,923  
                                           

Balance as at December 31, 2013

    23,590     45,094     18,665     25,409     69,571     5,289     281     6,102     87,530     281,531  
                                           

Amortized Balance as at December 31 ,2013

    267,250     116,502     93,381     46,577     191,313     18,489     156     1,179     56,327     791,174  
                                           
                                           

F-45


Table of Contents

Notes to the Consolidated Financial Statements (Continued)

Note 14—Intangible Assets (Continued)

 
  Intangible assets acquired   Intangible assets internally developed   Others   Total  
 
  Goodwill   Concessions
and
mining
rights(1)
  Trademarks   Technology/
patents
  Customer
relationships
  Exploration
and
evaluation
assets
  Technology/
patents
  Development
costs
   
   
 
 
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
 

Cost

                                                             

Balance as at January 1, 2012

    273,022     156,761     109,820     66,266     197,256     19,635     341     6,901     119,637     949,639  

Additions

        456         1,047         2,855             6,810     11,168  

Additions in respect of business combinations

    4,983         307         4,237                     9,527  

Disposals

                        (1,600 )               (1,600 )

Translation differences

    3,000     1,181     463     877     3,515     231     27     115     (2,270 )   7,139  
                                           

Balance as at December 31, 2012

    281,005     158,398     110,590     68,190     205,008     21,121     368     7,016     124,177     975,873  
                                           

Amortization and impairment losses

                                                             

Balance as at January 1, 2012

    22,533     38,504     9,522     15,944     41,167     4,525     174     5,410     71,660     209,439  

Amortization for the year

        3,249     5,009     4,027     13,371     1,184     56     191     8,224     35,311  

Translation differences

    320     27     (57 )   210     (848 )   23     28     97     (1,886 )   (2,086 )

Disposals

                        (1,600 )               (1,600 )
                                           

Balance as at December 31, 2012

    22,853     41,780     14,474     20,181     53,690     4,132     258     5,698     77,998     241,064  
                                           

Amortized Balance as at December 31, 2012

    258,152     116,618     96,116     48,009     151,318     16,989     110     1,318     46,179     734,809  
                                           
                                           

(1)
A subsidiary in Spain has mining rights intended for future development of new mines for quarrying potash, in the amount of about $59 million. Part of these rights are effective up to 2037 while the balance is effective up to 2067. Development of the new mines has not yet commenced and, accordingly, amortization of the rights in the real estate has not yet commenced.

F-46


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 14—Intangible Assets (Continued)

B.    Total book value of intangible assets having defined useful lives and those having indefinite useful lives are as follows:

 
  As at December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

Intangible assets having a defined useful life

    488,140     441,185  

Intangible assets having an indefinite useful life

    303,034     293,624  
           

    791,174     734,809  
           
           

Note 15—Impairment Testing for Property, Plant and Equipment and Cash Generating Units Containing Goodwill

A.    Impairment testing for cash generating units containing goodwill and intangible assets with an indefinite useful life

        For the purpose of impairment testing, goodwill and intangible assets with an indefinite useful life are allocated to the cash-generating units which represent the lowest level within the Group at which the goodwill is monitored for internal management purposes.

        The aggregate carrying amounts of goodwill and intangible assets with an indefinite useful life allocated to each unit are as follows:

 
  As at December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

Goodwill

             

Potash, Spain

    4,425     4,235  

Specialty Fertilizers

    64,383     65,019  

Industrial Products, Europe

    40,159     38,336  

Industrial Products, United States

    56,826     56,826  

Performance Products, United States

    11,489     11,638  

Fertilizers, Israel

    23,707     20,120  

Industrial Products, Israel

    3,708     3,708  

Performance Products, Europe

    51,017     46,185  

Performance Products, South America

    11,536     12,085  
           

    267,250     258,152  
           

Trademarks

             

Industrial Products, United States

    13,000     13,000  

Industrial Products, Europe

    8,913     8,601  

Performance Products, United States

    13,871     13,871  
           

    35,784     35,472  
           

    303,034     293,624  
           
           

F-47


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 15—Impairment Testing for Property, Plant and Equipment and Cash Generating Units Containing Goodwill (Continued)

        Value in use was determined by discounting the future cash flows generated from the continuing operation of the cash-generating unit and was based on the following key assumptions:

 
  Discount
rate
  Average
annual
growth rate
(1 - 5 years)
  Long-term
growth rate
  Period of
projected
cash flows
 

Industrial Products, United States

    9.5 %   6.5 %   2.0 %   5 years  

Industrial Products, Europe

    9.0 %   6.2 %   2.0 %   5 years  

Performance Products, United States

    8.8 %   3.2 %   2.0 %   5 years  

Performance Products, Europe

    9.2 %   8.0 %   1.5 %   5 years  

Performance Products, South America

    9.0 %   8.0 %   1.5 %   5 years  

Potash, Spain

    9.5 %   0.0 %   0.0 %   5 years  

Specialty Fertilizers

    9.5 %   2.5 %   2.0 %   5 years  

        The recoverable value of the above mentioned units is based on their value in use. The value in use of the units examined has been determined by an internal valuation made by the Company. It has been determined in all cases, except for impairment of property, plant and equipment, in the amount of about $10 million, which was recognized during 2013 in a company from the Industrial Products' segment in the United States, that the stated value of the units in the financial statements is lower than their recoverable value, and accordingly no impairment loss has been recognized in respect of such units.

        The Company does not believe that any of its significant cash-generating units were at risk for an impairment charge based on the most recent testing with respect to goodwill and other indefinite lived intangible assets.

        The estimates and assumptions represent Management's assessment of future trends in the industry and are based on both external sources and internal sources.

Note 16—Derivative Instruments

 
  As at December 31,
2013
  As at December 31,
2012
 
 
  Assets   Liabilities   Assets   Liabilities  
 
  US$ thousands
  US$ thousands
 

Included in current assets and liabilities:

                         

Foreign currency and CPI derivative instruments

    55,293     (10,016 )   39,088     (5,733 )

Interest derivative instruments

    858     (1,765 )   257     (1,846 )

Derivative instruments on energy and marine transport

    6,084         723     (13,434 )
                   

    62,235     (11,781 )   40,068     (21,013 )
                   
                   

Included in non-current assets and liabilities:

                         

Foreign currency and CPI derivative instruments

    3,419         10,951     (2,676 )

Interest derivative instruments

    3,072     (6,582 )   6,564     (17,528 )

Derivative instruments on energy and marine transport

    1,128             (3,608 )
                   

    7,619     (6,582 )   17,515     (23,812 )
                   
                   

F-48


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 17—Credit from Banks and Others

A.    Composition

 
  As at December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

Current liabilities

             

Short-term credit:

             

From financial institutions

    438,538     179,822  

From the parent company(1)

    50,000     50,000  

Other liabilities

    50,000     50,000  
           

    538,538     279,822  
           

Current maturities of long-term loans:

             

From financial institutions

    1,792     2,428  

Other long-term loans

    2,169     2,873  

From marketable debentures

    175,785     266,939  
           

    179,746     272,240  
           

    718,284     552,062  
           
           

(1)
For details—see Note 29.

Non-current liabilities

             

Loans from financial institutions*

    1,239,705     895,967  

Other loans

    7,894     25,928  
           

    1,247,599     921,895  

Less—current maturities in respect of loans from financial institutions and others

    3,961     5,301  
           

    1,243,638     916,594  
           
           

Marketable debentures

    175,785     428,647  

Non-marketable debentures

    67,000     67,000  
           

    242,785     495,647  

Less—current maturities

    175,785     266,939  
           

    67,000     228,708  
           
           

Total non-current liabilities

    1,310,638     1,145,302  
           
           

*
The Group has the right to make early repayment of the loans from financial institutions.

F-49


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 17—Credit from Banks and Others (Continued)

B.    Classified by currency and interest rates

 
  Weighted average
interest rate as at
December 31
2013
  As at December 31  
 
  2013   2011  
 
  %
  US$ thousands
  US$ thousands
 

Current liabilities (without current maturities)

                   

Short-term credit from financial institutions:

                   

In Dollar

    1.1     313,671     155,873  

In Euro

    1.1     105,840     13,076  

In other currencies

    2.0     19,027     10,873  

Short-term credit from the parent company and others:

                   

In Dollar

    0.9     100,000     100,000  
                 

          538,538     279,822  
                 
                 

Non-current liabilities (including current maturities)

                   

Loans from financial institution:

                   

In Dollar(1)

    1.4     914,686     748,588  

In Israeli currency—unlinked

    4.7     172,860      

In Euro(2)

    1.5     152,159     147,379  
                 

          1,239,705     895,967  
                 

Loans from others:

                   

In Dollar

    3.5     3,590     17,164  

In Euro

    4.2     2,697     5,465  

In other currencies

    2.0     1,607     3,299  
                 

          7,894     25,928  
                 

          1,247,599     921,895  
                 
                 

Non-marketable debentures—in dollar

   
5.7
   
67,000
   
67,000
 
                 
                 

Marketable debentures(3):

                   

In Dollar

    3.3         70,170  

In Israeli currency—unlinked

    2.4     28,773     224,314  

In Israeli currency—linked to CPI

    3.4     147,012     134,163  
                 

          175,785     428,647  
                 
                 

Unutilized long-term credit lines(4):

          682,000     702,000  
                 
                 

(1)
The interest in respect of most of the dollar debt is determined based on LIBOR + a margin at a rate of about 1.1%.

(2)
The interest in respect of the Euro debt is determined partly based on the Euribor + a margin at a rate of about 1.2%.

(3)
See Section F.

(4)
See Sections H, I, J and M.

F-50


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 17—Credit from Banks and Others (Continued)

C.    Maturity periods

        The credit and the loans from banks and others including debentures (net of current maturities) mature in the years after the date of the report, as follows:

 
  As at December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

Second year

    226,049     192,978  

Third year

    821,543     199,545  

Fourth year

    7,451     748,627  

Fifth year

    7,341     388  

Sixth year and thereafter

    248,254     3,764  
           

    1,310,638     1,145,302  
           
           

D.    Restrictions on the Group relating to the receipt of credit

        As part of the loan agreements the Group has signed, various restrictions were provided including financial covenants, a cross-default mechanism and a negative pledge.

        Set forth below is information regarding the financial covenants applicable to the Company as part of the loan agreements and the compliance therewith:

Financial Covenants(1)
  Financial Ratio Required under
the Agreement
  Financial Ratio
December 31,
2013
  Financial Ratio
December 31,
2012
 

Equity

  Equity greater than 2,000 million dollar     3,654
million dollars
     

The Company's equity will not be less than $700 million plus 25% of the annual net income commencing from 2005 and thereafter(2)

  Equity greater than 2,895 million dollar     3,654
million dollars
    3,365
million dollars
 

The ratio of the EBITDA to the net interest expenses

  Equal to or greater than 3.5     37.38     68.18  

Ratio of the net financial debt EBITDA

  Less than 3.5     0.93     0.61  

Ratio of the financial liabilities of the subsidiaries to the total assets of the consolidated company

  Less than 10%     0.39 %   0.71 %

Ratio of the net financial debt to the equity

  Less than 2.1     0.40     0.35  

(1)
All of the above financial covenants are based on the data from the Company's consolidated financial statements.

F-51


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 17—Credit from Banks and Others (Continued)

(2)
This covenant is in respect of non-traded debentures issued in 2005, outstanding balance as of December 31, 2013 is $67 million. The required financial ratio for this covenant as of December 31, 2013 is $2,690 million.

E.    Sale of receivables under securitization transaction

        On July 2, 2010, the Company and certain Group subsidiaries (hereinafter—"the Subsidiaries") entered into a number of securitization agreements with Rabobank International and Credit Agricol (hereinafter—"the Lending Banks") for the sale of their customer debts to a foreign company which was established specifically for this purpose and which is neither owned nor controlled by the ICL Group (hereinafter—"the Acquiring Company").

        The Acquiring Company finances acquisition of the debts by means of a loan received from a financial institution, which is not related to ICL, which finances the loan out of the proceeds from the issuance of commercial paper on the U.S. commercial paper market. The repayment of both the commercial paper and the loan are backed by credit lines from the Lending Banks. The amount of cash that will be received in respect of the initial sale of the customer debts in the securitization transaction will be up to $350 million.

        The acquisition is on an ongoing basis, such that the proceeds received from customers whose debts were sold are used to acquire new trade receivables.

        The period in which the Subsidiaries are entitled to sell their trade receivables to the Acquiring Company is five years from the closing date of the transaction, where both parties have the option at the end of each year to give notice of cancellation of the transaction. The securitization agreement will expire in July 2015.

        The selling price of the trade receivables is the amount of the debt sold, less the calculated interest cost based on the anticipated period between the sale date of the customer debt and its repayment date.

        Upon acquisition of the debt, the Acquiring Company pays the majority of the debt price in cash and the remainder in a subordinated note, which is paid after collection of the debt sold. The rate of the cash consideration varies according to the composition and behavior of the customer portfolio.

        The Subsidiaries handle collection of the trade receivables included in the securitization transaction, on behalf of the Acquiring Company.

        In addition, as part of the agreements a number of conditions were set in connection with the quality of the customer portfolios, which gives the Lending Banks the option to end the undertaking or determining that some of the Subsidiaries, the customer portfolios of which do not meet the conditions provided, will no longer be included in the securitization agreement.

        The securitization of trade receivables does not meet the conditions for disposal of financial assets prescribed in International Standard IAS 39, regarding Financial Instruments—Recognition and Measurement, since the Group did not transfer all of the risks and rewards deriving from the trade receivables. Therefore, the receipts received from the Acquiring Company are presented as a financial liability as part of the short-term credit. As of December 31, 2013, utilization of the securitization facility and trade receivables within this framework amounted to $285 million (As at December 31, 2012, approximately $163 million).

F-52


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 17—Credit from Banks and Others (Continued)

        Once the Company transferred its trade receivables, it no longer has the right to sell them to another party. In the case of a credit fault, the Company bears 30% of the overall secured trade receivable balance.

        The value of the transferred assets (which is approximately their fair value), fair value of the associated liabilities and net position are as follows:

 
  Year Ended December 31,  
 
  2013   2012   2011  
 
  (in thousands of U.S. dollars)
 

Value of the transferred assets

    285,246     162,681     310,465  

Fair value of the associated liabilities

    284,978     162,506     310,088  

Net position

    268     176     377  

F.     Issuance of Debentures

        On April 27, 2009 and on September 9, 2009, the Company issued four series of debentures, for a consideration of NIS 1,593 million (approximately $402 million). The debentures were issued in the following four series:

            1.     Series A—approximately NIS 452 million debentures linked to the CPI, to be redeemed at the end of 5 years, bearing interest at the annual rate of 3.4%.

            2.     Series B—approximately NIS 757 million debentures not linked to the CPI, to be redeemed at the end of 4.5 years, bearing interest at the annual rate of 5.25%.

            3.     Series C—approximately NIS 284 million debentures linked to the dollar, to be redeemed at the end of 4.5 years, bearing interest at the rate of 2.4% above the six-month dollar Libor rate.

            4.     Series D—approximately NIS 100 million debentures, unlinked, to be redeemed at the end of 5 years, bearing interest at the rate of 1.45% above the three-month shekel Telbor rate.

        On October 31, 2013, the debentures (Series B and Series C) were repaid in full for a consideration of $209 million and $70 million, respectively.

        As of December 31, 2013, the liability in respect of the Series D debentures was about $29 million. These debentures are to be repaid in full on October 31, 2014.

G.     In December 2010, the Company received a loan from a European Bank in the amount of €100 million. Repayment of the loan is on December 15, 2015. The interest rate on the loan is Eurobor + 1.14%.

H.     On March 14, 2011, the Company signed an agreement with a group of 17 banks from Europe, the United States and Israel whereby these banks made available to the Company credit in the amount of $675 million. The credit line is for a period of 5 years and will be paid in one lump-sum at the end of the period. On the amount of the credit actually utilized, graduated annual interest will be paid, as follows:

—Up to 33% of the credit utilized:   Libor + 0.8%.
—From 33% to 66% of the credit utilized:   Libor + 0.95% (on the full amount utilized).
—More than 66% of the credit utilized:   Libor + 1.1% (on the full amount utilized).

F-53


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 17—Credit from Banks and Others (Continued)

        The credit agreement does not include a commitment to utilize a minimum amount of the credit line. A non-utilization commission will apply at the rate of 0.28% per year. As of the date of the financial statements, $505 million of the credit facility had been utilized.

I.     In December 2011, the Company entered into an undertaking with 7 international banks whereby the banks will provide the Company a credit line, in the aggregate amount of $650 million. The credit line is for a period of five years and is to be repaid in full at the end of the period. The progressive interest rate to be paid over actual credit utilized will be based as follows:

—Up to 33% of the credit is utilized:   Libor + 1%.
—From 33% up to 66% of the credit is utilized:   Libor + 1.2% (on the entire amount utilized).
—From 66% and above of the credit is utilized:   Libor + 1.4% (on the entire amount utilized).

        The credit agreement does not include a commitment to utilize a minimum amount of the credit line. A non-utilization commission will apply at a rate of 0.35% per year.

        As of the date of the report, the amount of $314 million had been utilized out of the credit line.

J.     In the second half of 2011, the Company signed an agreement with a European bank whereby the bank provided a credit line, in the amount of €100 million. The credit line is for a period of six years and is to be repaid in full at end of the period. The interest rate on the loan is Libor + 0.9%-1.4%. As of the date of the report, the credit line had not been utilized.

K.     On June 26, 2012, the Company received a short-term loan in the amount of $50 million from the Company's controlling shareholder (Israel Corporation Ltd.). The terms of the loan are similar to market conditions. For additional details—see Note 29 "Related Parties".

L.     On September 11, 2012, the Company received a loan in the amount of $50 million from a third party, bearing interest at the three-month Libor rate plus a margin of 0.7%. The loan is extended every three months on the same terms on which it was received. The last date on which the loan was extended was December 11, 2013.

M.     In December 2012, the Company signed a credit line agreement with a European bank, in the amount of €100 million. In December 2013, the Company utilized $100 million from this loan. This amount is to be repaid in December 2019. The interest rate on the credit is Libor + 1.4%. The amount that will be utilized from this framework is to be repaid 6 years from the date of withdrawal of the fiscal year funds, however not later than December 2021.

N.     During 2013, the Company received a number of short-term loans from Israeli banks. As of date of the report, the total amount of the loans was about $140 million.

        In November 2013, the Company signed a loan agreement with several institutional entities, in the amount of NIS 170 million, bearing a fixed interest at a rate of 4.74%, The loan is to be repaid in increments until November 2024 (average life of seven years).

O.     In November 2013, the Company entered into an undertaking with international institutional investors for execution of a private placement of unregistered debentures in the United States. The amount issued is $275 million, for a period of 7-12 years, as follows: the amount of $84 million bearing

F-54


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 17—Credit from Banks and Others (Continued)

fixed interest at an annual rate of 4.55% for a period of 7 years, the amount of $145 million bearing fixed interest at an annual rate of 5.16% for a period of 10 years and the amount of $46 million bearing fixed interest at an annual rate of 5.31% for a period of 12 years. Subsequent to the balance sheet date, in January 2014, the proceeds from the private issuance of the debentures were received.

Note 18—Trade Payables

 
  As at December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

Open accounts

    657,897     624,381  

Checks payable

    11,205     16,015  
           

    669,102     640,396  
           
           

Note 19—Derivatives and Other Payables

 
  As at December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

Government of Israel—mainly in respect of royalties

    53,941     75,190  

Employees

    275,692     275,672  

Accrued expenses

    73,354     78,714  

Derivative instruments

    11,781     21,013  

Benefits for early retirement

    19,330     25,607  

Others

    66,355     69,676  
           

    500,453     545,872  
           
           

Note 20—Taxes on Income

A.    Taxation of companies in Israel

1. Measurement of results for tax purposes under the Income Tax (Inflationary Adjustments) Law, 1985 (hereafter—"the Inflationary Adjustments Law")

        The Income Tax Law (Adjustments for Inflation)—1985 (hereinafter—the Law), which is effective as from the 1985 tax year, introduced the concept of measurement of results for tax purposes on a real (net of inflation) basis. On February 26, 2008, the Knesset enacted the Income Tax Law (Adjustments for Inflation) (Amendment No. 20) (Restriction of Commencement Period), 2008, whereby the effective period of the Adjustments Law ceased at the end of the 2007 tax year and the depreciation of property, plant and equipment, are adjusted up to the end of the 2007 tax year, and from this time forward their linkage will be discontinued.

        The Income Tax Regulations (Adjustments for Inflation) (Rates of Depreciation), 1986, which allow depreciation at rates different than those in Section 21 of the Ordinance, apply even after the Adjustments Law is no longer in effect, and therefore the Company continues to claim accelerated depreciation, in certain situations, on the basis of these Regulations (the regulations ended December 31, 2013 and were not extended).

F-55


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 20—Taxes on Income (Continued)

2. Income tax rates

        Presented hereunder are the tax rates relevant to the Company in the years 2011-2013:

2011—24%    
2012—25%    
2013—25%    

        On August 5, 2013 the Israeli Knesset passed the Law for Changes in National Priorities (Legislative Amendments for Achieving Budget Objectives in the Years 2013 and 2014)—2013, by which, inter alia, the corporate tax rate would be raised by 1.5% to a rate of 26.5% as from 2014.

        In addition, the Israeli Law for the Encouragement of Capital Investments was amended such that the tax rate applicable to a Preferred Company in Development Area A will be 9% whereas the tax applicable to companies in the rest of Israel will be 16%. The impact of the legislation on the financial statements for 2013 is recognition of tax expenses, in the amount of about $11 million, against adjustment of the balance of the deferred taxes.


3. Tax benefits under the Israeli Law for the Encouragement of Capital Investments, 1959 (hereinafter—"The Encouragement Law")

a)
Beneficiary Enterprises

        The production facilities of some of the subsidiaries in Israel (hereinafter—"the Subsidiaries") received "Beneficiary Enterprise" status under the Encouragement Law, including Amendment No. 60 to the Law published in April 2005.

        The benefits granted to the Company are mainly:

1)
Reduced tax rates

        During the benefits period—10 years commencing in the first year in which the companies earn taxable income from the Benefited Enterprises (provided the maximum period to which it is restricted by law has not elapsed)—tax applies to the income of the companies from the Benefited Enterprises they own at the rates of 0% for the Regular Track and 11.5% for the Ireland Track instead of the regular tax rate (see A(2) above).

        The Company has Benefited Enterprises under the Regular Track (tax rate 0%) and Benefited Enterprises under the Ireland Track (tax rate 11.5%).

        In the event of distribution of a cash dividend out of income that was exempt from tax, as stated above, the Company will have to pay tax at the grossed-up rate of 25% in respect of the amount distributed (see also Sections b and c below). The temporary difference related to distribution of a dividend from exempt income as of December 31, 2013, in respect of which deferred taxes were not recognized, is in the amount of about $734 million.

        The part of the taxable income entitled to benefits at reduced tax rates is calculated on the basis of the ratio of the turnover of the "Benefited Enterprise" to the Company's total turnover. The turnover attributed to the "Benefited Enterprise" is generally calculated according to the increase in the turnover compared to a "base" turnover, which is the average turnover in the three years prior to the year of election of the "Benefited Enterprise".

F-56


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 20—Taxes on Income (Continued)

2)
Accelerated depreciation

        In respect of buildings, machinery and equipment used by the Approved Enterprise, the Company is entitled to claim accelerated depreciation as provided by law, commencing from the year each asset is placed in service.

b)
Preferred Enterprises

        On December 29, 2010, the Israeli Knesset approved the Economic Policy Law for 2011-2012, whereby the Law for the Encouragement of Capital Investments, 1959, was amended (hereinafter—"the Amendment to the Law"). The Amendment to the Law is effective from January 1, 2011 and its provisions will apply to preferred income derived or accrued by a Preferred Enterprise (industrial plant that fulfills the law's provisions regarding qualifying as a competitive plant contributing to the Gross Domestic Product (GDP) or a competitive plant in the area of renewable energy) in 2011 and thereafter. A company may choose to not be included in the scope of the Amendment of the Law and to remain in the scope of the law before its amendment until the end of the benefits period. The 2012 tax year is the last year the Company may choose a Preferred Enterprise as the election year, provided that the minimum qualifying investment began in 2010.

        As part of the Amendment, the existing tax benefit tracks were eliminated (the tax exempt track, the "Ireland track" and the "Strategic" track) and two new tax tracks were introduced in their place—a Preferred Enterprise and a Special Preferred Enterprise, which mainly provide a uniform and reduced tax rate for all the Company's income entitled to benefits, as follows:

        (1)   For a Preferred Enterprise—in 2011-2012 tax years—a tax rate of 10% for Development Area A and of 15% for the rest of the country. In 2013 tax year—a tax rate of 7% for Development Area A and of 12.5% for the rest of the country, and as from the 2014 tax year—9% for Development Area A and 16% for the rest of the country.

        (2)   A Special Preferred Enterprise—for a period of 10 consecutive years a reduced tax rate of 5% if it is located in Development Area A or of 8% if it is located in the rest of the country.

        The Amendment to the Law also provides that no tax will apply to a dividend distributed out of preferred income to a shareholder that is a company—both at the level of the distributing company and at the shareholder level. A tax rate of 15% will apply to a dividend distributed out of preferred income to an individual shareholder or foreign resident, subject to treaties for prevention of double taxation. Furthermore, the Amendment to the Law provides relief with respect to tax paid on a dividend received by an Israeli company from profits of an approved/alternative/beneficiary enterprise that accrued in the benefits period according to the provisions of the law before its amendment, if the company distributing the dividend notifies the Tax Authorities by June 30, 2015 that it is applying the provisions of the Amendment to the Law and the dividend is distributed after the date of the notice.

        The Amendment to the law does not apply to an Industrial Enterprise that is a mine, other facility for production of minerals or a facility for exploration of fuel. Therefore, ICL plants that are defined as mining plants and mineral producers will not be able to take advantage of the tax rates proposed as part of the new law. The Company has Preferred Enterprises at the tax rate of 7%.

        Nonetheless, tax benefits to which a Benefited Plant is entitled will not be cancelled in respect of investments up to December 31, 2012. Therefore, those plants will be able to utilize the tax benefits in respect of qualifying investments made up to December 31, 2012, in accordance with the provisions of the old law.

F-57


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 20—Taxes on Income (Continued)

        As at the approval date of the financial statements, the Company is examining the impact of the law and its application with respect to the companies operating in Israel.

        On July 29, 2013, the Israeli Knesset approved the Budget Law and the Law for Change of National Priorities (Legislative Amendments for Achieving the Budget Targets for 2013 and 2014), 2013. As part of this legislation, it was determined that the tax rate for an individual and a foreign resident on a dividend that is distributed commencing from January 1, 2014 and the source of which is preferred income, will increase to 20% in place of the present rate of 15%.

c)
Trapped Earnings Law—Temporary Order

        On November 5, 2012, the Israeli Knesset passed Amendment No. 69 and Temporary Order to the Law for the Encouragement of Capital Investments, 1959 (hereinafter—"the Temporary Order"), which offers a reduced tax rate arrangement to companies that received an exemption from Companies Tax under the aforesaid law. The Temporary Order provides that companies that choose to apply the Temporary Order (effective for one year), will be entitled to a reduced tax rate on the "release" of exempt profits (hereinafter—"the Beneficiary Companies Tax Rate"). The release of exempt profits will make it possible to distribute them without additional tax at the company level and will also make it possible to use the profits without the restrictions that applied to the use of the exempt profits.

        The Beneficiary Companies Tax Rate will be determined according to the rate of exempt profits the company chooses to release from its entire exempt profits, and will be between 30% and 60% of the Companies Tax rate that would have applied to the revenue in the year it was produced if it had not been exempt, but in any event no less than 6%. Furthermore, a company that chooses to pay the Beneficiary Companies Tax Rate will have to invest in an industrial enterprise up to 50% of the tax saving it obtained, within a period of 5 years beginning from the year of notice. Failure to comply with this condition will require the company to pay additional Companies Tax.

        On November 4, 2013, the Company's Board of Directors decided to apply the Temporary Order and to release part of the exempt earnings. As a result, the amount of about NIS 3.8 billion (about $1.1 billion) of the exempt earnings was released. Accordingly, the Company recognized current tax expenses in respect of payment of the preferred Companies Tax, in the amount of about NIS 377 million (about $108 million).


4. The Law for the Encouragement of Industry (Taxation), 1969

        (A)  Some of the Company's Israeli subsidiaries are "Industrial Companies", as defined in the above-mentioned law. As such, these companies are entitled to claim depreciation at increased rates for equipment used in industrial activities, as stipulated in the regulations published under the Inflationary Adjustments Law.

        (B)  The industrial enterprises held by the Company and some of its Israeli subsidiaries have a common line of production and are therefore entitled to file consolidated tax returns in accordance with Section 23 of the Law for the Encouragement of Industry. Accordingly, each of the said companies is entitle to offset its tax losses against the taxable income of the other company.

F-58


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 20—Taxes on Income (Continued)

B.    Taxation of non-Israeli subsidiaries

        Subsidiaries incorporated outside of Israel are assessed for tax under the tax laws in their countries of residence. The principal tax rates applicable to the major subsidiaries outside Israel are as follows:

  Subsidiary incorporated in the Netherlands—tax rate of 25%.        
  Subsidiary incorporated in Germany—tax rate of 29%.        
  Subsidiary incorporated in the United States—tax rate of 40%.        
  Subsidiary incorporated in Spain—tax rate of 30%.        
  Subsidiary incorporated in United Kingdom—tax rate of 23%*.        
*
Commencing from April 1, 2013, the tax rate in the United Kingdom was reduced24% to 23%, and is expected to be reduced to 21% starting April 1, 2014, and to 20% starting April 1, 2015.

C.    Carried forward tax losses

        As at December 31, 2013, the balances of the carryforward tax losses of subsidiaries, for which deferred taxes were created, amount to about $94 million (December 31, 2012—about $105 million).

        The balances of the carryforward tax losses of subsidiaries, for which deferred taxes were not created is about $27 million.

        The capital losses for tax purposes available for carryforward to future years amount to about $23 million. In accordance with an assessment agreement with the Israeli Tax Authorities, it will be possible to utilize most of these losses only against capital gains the Group companies have from a sale of shares of companies in which they hold directly at least 30%, to a company they control, directly or indirectly, at the rate of at least 50%. Deferred taxes were not recorded in respect of these capital losses. These losses are linked to the CPI as stated in Paragraph A(1) above.

D.    Tax assessments

        The Company and its Israeli subsidiaries that are being consolidated for tax purposes have received final tax assessments up to and including the 2008 tax year.

        The rest of the Israeli subsidiaries have final tax assessments up to and including the 2009 tax year.

        Significant subsidiaries outside of Israel have final tax assessments up to and including the 2007 tax year (for the majority of them).

        On December 29, 2013, an assessment was received from the Israeli Tax Authority ("ITA") whereby the Company is required to pay tax in addition to the amount it already paid in respect of the years 2009-2011, in the amount of about $230 million. The main contentions of the ITA is that ICL's subsidiaries: Dead Sea Works and Rotem Amfert Negev, are not entitled to benefits under the Law for Encouragement of Capital Investments—this being from the date of entry into effect of Amendment No. 60 to this Law, in 2005. The Company disagrees with the ITA's position and it has a legal opinion supporting its position. The Company has filed an appeal of the ITA's assessment. No tax expenses have been included in the financial statements as a result of the said assessment.

F-59


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 20—Taxes on Income (Continued)

E.    Deferred income taxes

1. The composition of the deferred taxes and the changes therein, are as follows:

 
  In respect of financial position   In respect
of carry
forward
tax losses
(see E
above)
   
 
 
  Depreciable
property,
plant and
equipment
  Inventories   Provisions
for
employee
benefits
  Other   Total  
 
  US$ thousands
 

Balance as at January 1, 2012

    (299,570 )   42,193     117,473     5,399     46,662     (87,843 )

Changes in 2012:

                                     

Changes in respect of business combinations

    72             (1,211 )       (1,139 )

Amounts recorded to a capital reserve

            8,976     189     (1,889 )   7,276  

Translation differences

    (1,065 )   159     1,073     (508 )   390     49  

Amounts recorded in the statement of income

    (32,839 )   3,693     14,455     (23,028 )   16,416     (21,303 )
                           

Balance as at December 31, 2012

    (333,402 )   46,045     141,977     (19,159 )   61,579     (102,960 )
                           
                           

Changes in 2013:

                                     

Amounts recorded to a capital reserve

            (14,172 )   (223 )   (4,376 )   (18,771 )

Translation differences

    1,303     1     (651 )   (473 )   (1,255 )   (1,075 )

Amounts recorded in the statement of income

    337     3,506     22,088     (8,491 )   (4,354 )   13,086  
                           

Balance as at December 31, 2013

    (331,762 )   49,552     149,242     (28,346 )   51,594     (109,720 )


2. Deferred taxes are presented in the statement of financial position as follows:

 
  As at December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

As part of non-current assets

    111,157     112,189  

As part of non-current liabilities

    (220,877 )   (215,149 )
           

    (109,720 )   (102,960 )
           
           


3. The currencies in which the deferred taxes are denominated:

 
  As at December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

Dollar

    (17,541 )   (7,557 )

Euro

    (16,535 )   (6,085 )

Shekels

    (84,510 )   (97,487 )

Other

    8,866     8,169  
           

    (109,720 )   (102,960 )
           
           

4. For companies in Israel—the deferred taxes as at December 31, 2013 are computed mainly at the weighted-average tax rate of 23% (December 31, 2012—23%). Regarding companies outside of Israel—see B above.

F-60


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 20—Taxes on Income (Continued)

F.     Taxes on income included in the income statements:

1.
Composition

 
  For the year ended December 31  
 
  2013   *2012   *2011  
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Current taxes

    185,230     201,061     244,063  

Deferred taxes

    (12,631 )   22,543     63,550  

Taxes in respect of release of trapped earnings

    108,623          

Taxes in respect of prior years*

    (1,199 )   (6,043 )   25,857  
               

    280,023     217,561     333,470  
               
               

*
Including deferred taxes in respect of prior years.

        2.     Following is a reconciliation of the theoretical tax expense, assuming all income is taxed at the regular tax rates (see A(2) above) and the tax expense presented in the statements of income:

 
  For the year ended December 31  
 
  2013   2012   2011  
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Income before taxes on income, as reported in the statements of income

    1,100,196     1,519,293     1,834,528  

Statutory tax rate

    25 %   25 %   24 %
               

Theoretical tax expense on this income

    275,049     379,823     440,287  

Less—tax benefits arising from reduced tax rate applicable to an "Approved Enterprise" and "Benefited Enterprise"

    7,072     (121,266 )   (127,917 )
               



 

 

282,121

 

 

258,557

 

 

312,370

 

Add (less)—the tax effect of:

                   

Differences between the basis of measurement for tax purposes and for financial reporting purposes (the dollar)

    (16,557 )   (6,965 )   7,648  

Differences in respect of foreign subsidiaries

    22,516     24,347     26,443  

Non-deductible expenses

    7,902     9,130     8,316  

Additional deduction for tax purposes for foreign subsidiaries and withholding of tax at the source in respect of a dividend from outside of Israel

    (5,903 )   (56,647 )   (43,958 )

Taxes in respect of prior years

    (1,199 )   (6,043 )   25,857  

Elimination of tax calculated in respect of the Company's share in losses (profits) of associated companies

    (6,421 )   (6,639 )   (8,224 )

Other differences

    (2,436 )   1,821     5,018  
               

Taxes on income included in the income statements

    280,023     217,561     333,470  
               
               

F-61


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 20—Taxes on Income (Continued)

G.    Taxes on income relating to equity items

 
  For the year ended December 31  
 
  2013   2012   2011  
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Tax recorded in other comprehensive income

                   

Actuarial gains from defined benefit plan

    (14,172 )   9,018     8,040  

Change in fair value of financial assets available-for-sale

            1,329  

Change in fair value of derivatives used for hedging cash flows

    (898 )   313     (143 )

Taxes in respect of exchange rate differences on equity loan to a subsidiary included in translation adjustment

    (4,376 )   (1,889 )   4,027  
               

    (19,446 )   7,442     13,253  
               
               

 

 
  For the year ended December 31  
 
  2013   2012   2011  
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Tax recorded directly in equity

                   

Tax benefits (taxes on income) in respect of issuance of shares to employees

    (223 )   189     (1,070 )
               
               

Note 21—Employee Benefits

A.    Composition

 
  As at December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

Present value of funded obligations

    784,256     783,813  

Less—fair value of plan assets

    761,257     704,858  
           

    22,999     78,955  

Present value of unfunded obligations

   
452,909
   
424,434
 

Post-retirement medical benefits

    3,812     7,666  
           

Recognized liability for defined benefit obligations plans

    479,720     511,055  

Liability for severance benefits

    158,589     131,075  
           

Total liability for employee benefits recognized in the statement of financial position

    638,309     642,130  
           
           

F-62


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 21—Employee Benefits (Continued)

        The liability in respect of employee benefits is presented in the statement of financial position as follows:

 
  As at December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

As part of non-current assets

    83,124     69,193  

As part of non-current liabilities

    702,103     685,716  

As part of current liabilities

    19,330     25,607  
           

    638,309     642,130  
           
           

        Composition of the plans' assets:

 
  As at December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

Equity instruments

             

With quoted market price

    242,516     201,924  

Without quoted market price

    307     247  
           

    242,823     202,171  

Debt instruments

             

With quoted market price

    192,603     336,336  

Without quoted market price

    172,490     14,450  
           

    365,093     350,786  

Deposits with insurance companies

    153,341     151,901  
           

    761,257     704,858  
           
           

B.    Linkage terms

 
  As at December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

Dollar

    9,671     15,871  

Euro

    168,216     169,640  

Israeli Shekel

    418,057     402,878  

British pound

    39,780     51,524  

Other

    2,585     2,217  
           

    638,309     642,130  
           
           

C.    Severance pay

1. Israeli companies

        Pursuant to Israeli labor laws and the labor contracts in force, the Company and its Israeli subsidiaries are required to pay severance pay to dismissed employees and employees leaving their

F-63


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 21—Employee Benefits (Continued)

employment in certain other circumstances. Severance pay is computed based on length of service and generally according to the latest monthly salary and one month's salary for each year worked.

        The liabilities relating to employee severance pay rights are covered as follows:

            a)    Under collective labor agreements, the Group companies in Israel make current deposits in outside pension plans for some of the employees. These plans generally provide full severance pay coverage and, in some cases, 72% of the severance pay liability.

            The severance pay liabilities covered by these plans are not reflected in the financial statements, since all the risks relating to the payment of the severance pay, as described above, have been transferred to the pension funds.

            b)    The Group companies in Israel make current deposits in Managers' Insurance policies in respect of employees holding management positions. These policies provide coverage for the severance pay liability in respect of the said personnel. Under employment agreements, these insurance policies are, subject to certain limitations, the property of the employees. The amounts funded in respect of these policies are not reflected in the balance statements of financial position since they are not under the control and management of the companies.

            c)     As to the balance of the liabilities that are not funded, as above, a provision is made in the financial statements based on an actuarial calculation.


2. Certain subsidiaries outside Israel

        Since the countries wherein these subsidiaries operate have no law requiring payment of severance pay, the Group does not include a provision in the financial statements for possible eventual future severance payments to employees, except in cases where part of the activities of the enterprise is discontinued and, as a result, the employees are dismissed.

D.    Pension and early retirement

        1.     Some of the Group's employees in and outside of Israel (some of whom have already left the Group) have defined benefit pension plans (within the companies) for their retirement. Generally, the terms of the plans provide that the employees are entitled to receive pension payments based on, among other things, their number of years of service (in certain cases up to 70% of their last base salary) or computed, in certain cases, based on a fixed salary.

        2.     In addition to the above, some Group companies have entered into an agreement with funds—and with a pension fund for some of the employees—under which such companies make current deposits with that fund which releases them from their liability for making a pension payment under the labor agreements to all of their employees upon reaching a retirement age. The amounts funded are not reflected in the statements of financial position since they are not under the control and management of the Group companies.

        3.     Employees of a subsidiary in Sodom, Israel are entitled to early retirement if they fulfill certain conditions, including age and seniority at the time of retirement.

        4.     In December 2013, Company Management approved a plan whereby a number of employees of the Rotem subsidiary may leave on early retirement prior to the retirement age provided by law. As

F-64


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 21—Employee Benefits (Continued)

a result, in 2013 the Group recorded an expense in the amount of about $60 million included in "other expenses" in the statement of income.

        In the months of November and December 2012, the Board of Directors of certain subsidiaries approved plans whereby a number of the subsidiaries' employees were permitted to take early retirement prior to the retirement age provided by law. In the statement of income for 2012, an expense was included in the amount of about $55 million in respect of the said early retirement plans.

E.    Post-employment retirement benefits

        Some of the retirees of the Group companies receive, aside from the pension payments from a pension fund, benefits that are primarily holiday gifts and weekend trips. The companies' liability for these costs accrues during the employment period. The Group companies include in their financial statements the projected costs in the post-employment period according to an actuarial calculation.

F      (1) Movement in present value of defined benefit plans

 
  For the year ended December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

Obligation in respect of defined benefit plan at beginning of the year

    1,215,913     1,059,925  

Current service costs

    43,166     34,460  

Interest costs

    48,434     49,627  

Employee contributions

    691     700  

Benefits paid

    (82,883 )   (46,225 )

Actuarial loses (gains) deriving from changes in financial assumptions

    (32,385 )   112,797  

Actuarial gains deriving from changes in demographic assumptions

    (1,498 )   (26,173 )

Increase in liabilities as part of business combinations

    1,682     533  

Past service cost

    (8,611 )   2,009  

Changes in respect of exchange rate differences

    40,364     12,225  

Changes in respect of translation differences

    16,104     16,035  
           

Obligation in respect of defined benefit plan at end of the year

    1,240,977     1,215,913  
           
           

F-65


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 21—Employee Benefits (Continued)


(2) Movement in plan assets for defined benefit plans

 
  For the year ended December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

Fair value of plan assets at beginning of the year

    704,858     609,177  

Interest income

    26,248     27,159  

Actuarial gains recognized in equity

    13,399     42,720  

Employer contributions

    23,868     35,587  

Employee contributions

    758     871  

Increase in assets as part of business combinations

    570      

Benefits paid

    (42,150 )   (30,708 )

Changes in respect of exchange rate differences

    20,989     6,023  

Changes in respect of translation differences

    12,717     14,029  
           

Fair value of plan assets at end of the year

    761,257     704,858  
           
           


(3) Expenses recognized in the income statement

 
  For the year ended December 31  
 
  2013   2012   2011  
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Current service costs

    43,166     34,460     34,546  

Interest costs

    48,434     49,627     53,259  

Interest income

    (26,248 )   (27,159 )   (31,218 )

Past service cost

    (8,611 )   2,009     14,860  

Exchange rate differences, net

    19,375     6,202     (14,604 )
               

    76,116     65,139     56,843  
               
               


(4) Actual and expected return

 
  For the year ended December 31  
 
  2013   2012   2011  
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Actual return on plan assets

    39,647     69,879     8,625  
               
               

Expected yield on plan assets

    26,248     27,159     31,218  
               
               

F-66


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 21—Employee Benefits (Continued)


(5) Actuarial gains and losses recognized directly in equity

 
  For the year ended December 31  
 
  2013   2012   2011  
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Cumulative amount (before tax) as at January 1

    170,321     126,417     88,198  

Actuarial losses (gains) deriving from changes in demographic assumptions

    (1,498 )   (26,173 )   4,847  

Actuarial losses (gains) deriving from changes in financial assumptions

    (45,784 )   70,077     33,372  
               

Cumulative amounts (before tax) as at December 31

    123,039     170,321     126,417  

Deferred taxes in respect of actuarial gains and losses recognized directly in equity

    (28,021 )   (42,193 )   (33,175 )
               

    95,018     128,128     93,242  
               
               


(6) a. Actuarial assumptions

        Principal actuarial assumptions at the reporting date (expressed as weighted averages):

 
  For the year ended
December 31
 
 
  2013   2012   2011  
 
  %
  %
  %
 

Discount rate as at December 31

    4.0     4.2     4.9  

Future salary increases

    4.4     3.8     4.2  

Future pension increase

    2.4     2.5     2.6  

        The assumptions regarding the future mortality rate are based on published statistics and accepted mortality tables.

        A one percentage point change in assumed healthcare cost trend rates does not have a material effect on the Company.


(6) b. Sensitivity analysis

        Assuming all other assumptions remain constant, the following reasonable possible changes effect the defined benefit obligation as of the date of the financial statements in the following manner:

 
  December 2013  
 
  Decrease 10%   Decrease 5%   Increase 5%   Increase 10%  
 
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
 

Significant actuarial assumptions

                         

Discount rate

    (61,154 )   (26,799 )   28,572     53,501  

Salary increase

    22,148     13,674     (11,818 )   (20,656 )

Mortality table

    (17,761 )   (8,663 )   9,284     15,491  

F-67


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 21—Employee Benefits (Continued)

         G.     The expenses recorded in respect of defined contribution plans in 2013 is about $26.4 million (in 2012, $24.1 million).

        The Group's estimate of the deposits expected to be made in 2014 in funded defined benefit plans is about $31.5 million.

        The Group's estimate life the defined benefit plans (based on a weighted-average), as at the end of the period, is about 14.4 years.

H.    Long-term remuneration plan

        On May 12, 2013, ICL's Board of Directors decided to approve a long-term remuneration plan for about 11,300 employees of the Company in and outside of Israel who are not managers that participated in the Company's options' plan (which was approved in November 2012) based on terms defined in the plan. The maximum cost of the plan is about $45 million. As at the date of the report, the terms defined in the plan were not met, thus no liability was included in the books in respect of this plan.

Note 22—Provisions

A.    Composition and changes in the provision

 
  Warranties   Site
restoration,
removal and
dismantling
of property,
plant and
equipment
items
  Legal claims   Other   Total  
 
  US$
thousands

  US$
thousands

  US$
thousands

  US$
thousands

  US$
thousands

 

Balance as at January 1, 2013

    1,028     77,947     3,392     35,320     117,687  

Provisions made during the period

    426     30,763     2,314     338     33,841  

Provisions reversed during the period

    (212 )   (84 )   (305 )   (2,764 )   (3,365 )

Effect of the passage of time (due to discounting)

        (2,597 )           (2,597 )

Payments during the period

    (697 )   (10,338 )   (1,947 )   (1,041 )   (14,023 )

Translation differences

    43     1,282     204     (17 )   1,512  
                       

Balance as at December 31, 2013

    588     96,973     3,658     31,836     133,055  
                       
                       

        Presentation in the statement of financial position:

 
  As at December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

In current liabilities

    38,485     40,217  

In non-current liabilities

    94,570     77,470  
           

    133,055     117,687  
           
           

F-68


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 22—Provisions (Continued)

B.    Restoration of mines and mining sites

        1.     The Group included a provision in the books for restoration of mines and mining sites. The provision is based on the discounted cash flows based on an estimate of the future expenses that will be required to close down the mines and to restore the mining sites. The estimated closing date of the mines is based on a geological evaluation of the quantity of potash remaining in the mines and the resources available to the subsidiaries.

        2.     Pursuant to the provisions of Spanish law covering environmental protection in connection with areas affected by mining activities, a subsidiary in Spain has submitted a plan for site clearance of mining waste adjacent to the subsidiary's two production sites. The plan to clear the waste from the two sites is intended to last for a period of about 24 years and 36 years. According to the subsidiary's estimate, the overall scope of the plan for site clearance of the mining waste will amount to $29 million (€21 million). As at December 31, 2013, a provision in the amount of $16 million (€11 million) is recorded in the financial statements. The provision was calculated on the basis of discounted projected costs of clearing the waste.

        3.     Manufacturing facility of the Group in Neot Hovav, Israel contains solid waste. Pursuant to the requirements of the Israeli Ministry of Environmental Protection, it is required to treat the existing (past) and ongoing waste. The treatment will be, among other things, through a restoration facility of hydro-bromine acid. After a re-examination, in 2013 Company management decided to increase the provision for treatment of waste in the financial statements by about $25 million, as a result of a change in estimate and the assignment of the waste treatment to third parties. Management's estimates, as of the approval date of the financial statements, that the provision included in the financial statements is sufficient to cover the estimated cost of treating the historical waste. At this stage, prior to the planned commencement of the operation of the waste treatment facility, which is presently in the test-run stages, the waste is stored in a special site in coordination with the Israeli Ministry of Environmental Protection—part of which is treated by outside parties and part of which will be treated by the Group.

        4.     From time to time, one of the Group's subsidiaries in Israel is required to examine various contentions regarding residual waste found in areas surrounding its manufacturing facilities in the Neot Hovav area in Israel or that there is subterranean penetration of waste created during the manufacturing process. The subsidiary may be required to clean up the relevant sites or the subterranean areas if and when it is found that it is responsible for the said contamination as stated. In the past several years, various examinations were being performed by various institutions in order to investigate land contamination in this area and in the area surrounding the subsidiary's site in Be'er Sheva, Israel.

Note 23—Commitments, Concessions and Contingent Liabilities

A.    Commitments

        1.     Several of the Group's subsidiaries have entered into agreements with suppliers in Israel and outside of Israel for the purchase of raw materials in the ordinary course of business, for various periods ending on December 31, 2018. The total commitments under the said purchase periods of the agreements is approximately $739 million as of December 31, 2013.

F-69


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 23—Commitments, Concessions and Contingent Liabilities (Continued)

        2.     Several of the Group's subsidiaries have entered into agreements with suppliers for acquisition of property, plant and equipment. As at December 31, 2013, the subsidiaries had capital purchase commitments of about $506 million.

        3.     A subsidiary in England has entered into several contracts for the lease of land used to mine potash. The lease fees are generally determined based on the quantity of potash mined in each leased area. The term of the two main lease contracts run up to 2015 and 2035. The contracts are usually signed for a term of 35 to 50 years. As at December 31, 2013, the remaining term covered by the lease contracts range from 2 to 25 years.

        4.     In September 2003, a long-term (20 year) supply agreement was signed between an Israeli subsidiary and a non-Israeli corporation commencing from January 2004, for the supply of bromine and bromine compounds by the subsidiary.

        5.     The Articles of Association of the Company and its Israeli subsidiaries include provisions that permit exemption, indemnification and insurance of the liability of officers, all in accordance with the provisions of the Israeli Companies Law and the Israeli Securities Law. The Company, with the approval of the Audit Committee, the Board of Directors and the General Meeting of the shareholders, granted its officers an exemption and letters of indemnification, and has also taken out an insurance policy covering directors and officers. The insurance and the compensation do not apply to those cases specified in Section 263 of the Israeli Companies Law. The exemption is for damage caused and/or to be caused by such officers, due to a breach of the duty of care to the Company. The amount of the indemnification payable by the Company under the letter of indemnification, in addition to amounts received from an insurance company, if any, for all of the officers on a cumulative basis, for one or more of the events detailed therein, was limited to $300 million. The insurance is renewed annually. The coverage in effect (including a joint layer with the parent company in the amount of $20 million) is in the aggregate amount of $220 million. On March 18, 2014 the Company's Board of Directors decided to summon a general meeting of the Company's shareholders' to approve an increase from $300 million to $350 million of the insurance coverage that was determined in the framework approved by the general assembly in August 2012, contingent upon the Company registering its shares for a public trade in the US market.

        6.     Several of the Group's subsidiaries in Israel have entered into agreements with various natural gas vendors for the supply of natural gas to the Group's manufacturing facilities in Israel. The Group committed to "take or pay" with respect to a minimum annual quantity of gas in a scope and in accordance with the mechanism provided in the agreements. The total quantities under the current existing agreements should provide the Group all its gas needs until September 30, 2017, including quantities required to operate the power station the Group intends to construct in Sodom, Israel, which is expected to start in the second half of 2015. The supply of the gas under the current existing agreements is for a term ending September 30, 2017. Additionally, upon a shortage of capacity in the production of gas, based on a decision of the Israeli Gas Authority, the allocation of the supply of gas might be limited to the Group's facilities together with other consumers connected to the national gas transport system, the allocation will be based on the formula provided in the decision of the Gas Authority.

        The Company anticipates that the amount of the annual consumption of the gas, after operation of the power station, as is expected to be received based on the Yam Thetys agreement and the Tamar Agreement, will be about BCM 0.76.

F-70


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 23—Commitments, Concessions and Contingent Liabilities (Continued)

        7.     On June 28, 2012, the Group entered into agreements regarding a project to construct a new cogeneration plant in Sodom, Israel (hereinafter—"the Cogeneration Project") with a production capacity of 330 tons of steam per hour and 250 megawatts of electricity that will provide all the electricity and steam requirements of the production plants at the Sodom site in the upcoming years. The Cogeneration Project is expected to be completed in the first half of 2015. The cost of the Cogeneration Project is estimated at about $320 million. The construction agreements are linked to the exchange rate of the euro.

        The Company entered into foreign-currency hedging transactions to hedge the exposure to changes in the Project's cash flows deriving from changes in the dollar/euro exchange rate. As at December 31, 2013, this hedging transaction meets the criteria of an accounting hedge. Accordingly, changes in the fair value of the derivative used to hedge cash flows, in respect of the effective hedging component, are recorded and recognized in other comprehensive income. Changes in the fair value of the derivative relating to the ineffective portion are recorded in the statement of income.

B.    Concessions

Dead Sea Works Ltd. (DSW)

        Pursuant to the Israeli Dead Sea Concession Law, 1961 (hereinafter—"the Concession Law"), as amended in 1986, and the concession indenture attached as an addendum to the Concession Law, the Company was granted a concession to utilize the resources of the Dead Sea and to lease the land required for its plants in Sodom for a period ending on March 31, 2030, accompanied by a priority right to receive the concession after its expiration, should the Government wish to offer a new concession. In consideration of the concession, the Company pays royalties to the Government of Israel, calculated at the rate of about 5% of the value of the products at the factory gate, less certain expenses, on annual quantity of potash sold in excess of 1.5 million there is a higher royalty rate of 10%.

        DSW granted a sub-concession to Dead Sea Bromine Ltd. to produce bromine and its compounds from the Dead Sea, the expiration date of which is concurrent with DSW's concession. The Group pays royalties to the Government of Israel on the products manufactured by the Bromine Company. In addition, there is an arrangement relating to payment of royalties by Dead Sea Magnesium for production of magnesium metals by virtue of a specific arrangement with the State provided in the Government's decision dated September 5, 1993. Pursuant to the arrangement, royalties are paid by Dead Sea Magnesium on the basis of carnallite used for production of magnesium.

        The arrangement with Dead Sea Magnesium provides that during 2006 the State may demand a reconsideration in connection with the amount of the royalties and the method or their calculation for 2007 and thereafter. The State's demand for reconsideration, as stated, was first received at the end of 2010, and the matter is presently in an arbitration proceeding, as described below.

        In 2006, a letter was received from the then Accountant General of the Israeli Ministry of Finance, claiming an underpayment of royalties amounting to hundreds of millions of shekels. Pursuant to the concession, disputes between the parties relating to the concession, including royalties, are to be decided by an arbitration panel of three arbitrators (each side appoints an arbitrator and these two appoint the third). On January 9, 2011, the State of Israel and the Company decided to turn to arbitration for purposes of deliberating and deciding the issue of the manner of calculation of the

F-71


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 23—Commitments, Concessions and Contingent Liabilities (Continued)

royalties under the concession and royalties to be paid for magnesium metals and payment or refunds (if any) due deriving from these matters. Each of the parties appointed an arbitrator on its behalf and these arbitrators appointed the third arbitrator. The arbitration proceedings have been concluded and the arbitration decision is expected to be rendered on the date to be determined by the arbitrators.

        In the statement of claim filed by the State of Israel in the arbitration proceedings, the State of Israel is claiming the amount of $265 million in respect of underpayment of royalties for the years 2000 through 2009, with the addition of interest and linkage differences, and change in the method of calculating royalty payments from the sale of metal magnesium.

        After studying the State of Israel's allegations in respect of prior years, the Company believes, on the basis of a legal opinion it received, that the royalties it had paid and their manner of calculation are consistent with the provisions of the concession. The same method of calculation was applied consistently since the time the Company was a government company, and was known to the State of Israel and accepted by it. Accordingly, and on the basis of the legal opinion the Company received, no provision has been recorded in the financial statements with respect to royalties that the State of Israel contends were underpaid.

        In 2013 and 2012, the Company paid royalties to the Government of Israel in the amounts of approximately $110 million and approximately $125 million, respectively.


Rotem

        Rotem has been mining phosphates in the Negev for the last fifty years. The mining is conducted in accordance with phosphate mining concessions, which are granted from time to time by the Minister of National Infrastructures under the Mines Ordinance, through the Supervisor of Mines in his Office (hereinafter—"the Supervisor"), accompanied by mining authorizations issued by the Israel Lands Administration (hereinafter—"the ILA"). The concessions relate to the quarry (phosphate rock) whereas the authorizations relate to use of land as active mine sites.


Mining concessions:

        Rotem has the following mining concessions:

                i.  Rotem Field—valid up to the end of 2021;

               ii.  Zafir Field—(Oron-Zin)—valid up to the end of 2021;

              iii.  Effa Field—the concession ended in 2013, the work in the field was completed and the site was restored to a status of a military training zone;

              iv.  Hatrurim Field—the Supervisor has decided to extend the area of the Rotem field concession (valid until the end of the 2021) so that it includes the Hatrurim Field. The area of the Rotem concession has been so extended, and the matter has been transferred to the ILA to deal with the extension of the area of the mining permit for the Rotem Field, in line with the extension of the concession area.

        In September 2012, a committee was set up by the CEO of the Israeli Ministry of Energy and Water, to examine the phosphates sector, including representatives of the Israeli Ministry of Energy and Water, from the Israeli Geological Institute and the Israeli Ministry of Economy, Trade and Industry, in

F-72


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 23—Commitments, Concessions and Contingent Liabilities (Continued)

order to look into use of the phosphate resource in Israel, and to submit recommendations regarding the annual quantity of mining of phosphates, the manner of use of the phosphates layers and the stages for restoring the mine areas. The committee published its recommendations and, among other things, it recommended to examine the possibility of imposing certain restrictions on the manner of the mining and utilization of the phosphates, and also recommended to approve mining in additional fields, such as, the Barir field. As at the date of the report, no operative decisions had been made based on the committee's recommendations. With respect to the Barir field, see "Planning and building" below.


Mining royalties:

        In respect of mining of the phosphate, Rotem is required to pay the State of Israel royalties based on a calculation format stipulated in the Israeli Mines Ordinance. The calculation format for the royalties was updated in February 2010 as part of a compromise agreement that settled all the disputes regarding past royalties and formulas for future royalties.

        In 2013 and 2012, Rotem paid royalties to Israeli government in the amounts of approximately $4 million and $6 million, respectively.


Planning and building:

        The mining and quarrying activities require zoning approval of the site based on a plan in accordance with the Israeli Planning and Building Law, 1965. These plans are updated, as needed, from time to time. As at the date of the report, there are various requests at different stages of deliberations before the planning authorities.

        At the end of 2009, at the recommendation of a team accompanying preparation of a new site plan for the Zin-Oron area in Israel, the Local District Board approved extension of the execution stages of the site plan from 1991, which zones the Zafir site (Zin-Oron) for mining up to the end of 2013, and in September 2013, the Local District Board approved extension of additional stages up to the end of 2015.

        The plan for mining phosphates in Barir field (South Zohar) is in planning approval stages, and it has not yet been decided whether to deposit it with the competent authorities. Israeli residents of Arad, the communities and the surrounding Bedouin villages in the area object to deposit of the plan and continuation of advancement of the planning stages in respect thereof, due to the fear of environmental and health dangers they contend will be caused as a result of operation of the mine. The Company believes that the mining activities in Barir field does not involve any risks to the environment or to people and, accordingly. After an expert appointed by the Israeli Ministry of the Prime Minister expressed his opinion that there is no health hazard in the Barir mine, the Israeli Ministry of Health appointed a committee on its behalf to examine the matter before the Israeli Ministry formulates an opinion. The residents of Arad are continuing to object to advancement of the mining plan and even to experimental mining. If mining approval is not received in Barir field, this will significantly impact the Group's future mining reserves in the medium and long term.

        3.     A subsidiary in Spain from the ICL Fertilizers segment was granted mining rights based on legislation of Spain's Government from 1973. Further to the legislation, the Government of the Catalonia region issued special mining regulations whereby the subsidiary, a company from the ICL Fertilizers segment, received single license for each of 126 different relevant sites for the current

F-73


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 23—Commitments, Concessions and Contingent Liabilities (Continued)

mining activities and possibilities for the future. Some of the licenses are valid up to 2037 and the rest are effective up to 2067. The mining royalties in 2013 amounted to about €0.2 million. Regarding an additional area beyond the areas referred to above, "Reserva Catalana," a request was submitted to extend, commencing from October 2012, the concession period for a period of 30 years. At the present time, no mining activities are being carried out in this area. The administrative activities to extend the concession period have not yet been completed by the National Mining Authority, however the mining rights are still valid.

        4.     The mining rights of a subsidiary in the United Kingdom, from the ICL Fertilizers segment (hereinafter—"CPL") are based on approximately 114 mining leases and licenses for extracting various minerals, in addition to numerous easements and rights of way from private owners of land under which CPL operates or, in the case of mining underneath the North Sea, granted by the British Crown. The terms of all of these leases, licenses, easements and rights of way extend until 2015-2038. In 2013, mining royalties amounted to about £2.7 million.

        5.     A subsidiary in the United Kingdom, from the ICL Fertilizers segment, mines peat, which constitutes a raw material for production of detached platforms for improvement of land and for use as soil substitutes on growing platforms, in the Company's mines in the United Kingdom (Creca, Nutberry and Douglas Water). The Nutberry and Douglas Water sites are owned by the subsidiary, whereas Creca is held under a long-term lease. The mining permits were granted through the year 2024. The mining permits are granted by the local authorities for time periods fixed in advance of 14 years and are renewed after being examined.

C.    Contingent liabilities

        1.     As at December 31, 2013, the total guarantees provided by the Group to third parties amount to $95 million. The guaranties provided by the Group in respect of loans taken out by the Group's subsidiaries amount to about $1,284 million.

        2.     During the 1990s several claims were made against few of the Group's subsidiaries in respect of plaintiffs from various countries, who worked mostly as banana plantation workers, who allegedly have been injured by exposure to Di Bromo Chloropropane ("DBCP") produced, many years ago, by a number of manufacturers, including large chemical companies. As at the date of approval of the financial statements, the Group's subsidiaries are parties to one legal proceeding by 9 plaintiffs who are requesting certification of their claim as a class action. The claim is for bodily injury and therefore the amount for the claims have not been stated. The Group believes the quantities of material supplied by the Group to the relevant countries in the relevant periods was, if at all, small compared with the quantities of material sold by other chemical manufacturers.

        In the opinion of Company Management, based on the estimation of its legal advisors, it is not possible to estimate the results of the above claims. Nonetheless, it is estimated that the overall exposure to the Group would not exceed $20 million.

F-74


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 23—Commitments, Concessions and Contingent Liabilities (Continued)

    3. Environmental

        The Group companies manufacture, store and sell hazardous chemical products and, therefore, they are exposed to risks deriving from damage to the environment. The companies invest significant amounts in order to comply with the environmental rules and regulations. In the estimation of Company Management and on the basis of information in its possession as at the signing date of the financial statements, the provision existing in the financial statements covers the quantifiable liabilities in respect of costs relating to environmental protection.

        a)    In December 2006, an agreement was signed between the Israeli Ministry of the Environment, the Manufacturers' Association, factories in Neot Hovav, Israel (including ICL Industrial Products) and the Sustainable Negev Association, which was approved by the District Court, whereby the Israeli Ministry and the factories agreed to commence accelerated negotiations for a period of six months (which ended in June 2007) regarding emissions into the air both from new and existing facilities, as well as diffused emissions, and prevention of pollution and odor hazards, on the basis of international standards. In April 2007, the government of Israel resolved, as part of a decision to move Israel Defense Forces' training bases to the Negev Junction near Neot Hovav, that government ministries would act to improve the air quality around the Neot Hovav Industrial Zone, in accordance with an outline agreed upon by the Israeli Ministry of Health, the Israeli Ministry of the Environment and the Israel Defense Forces.

        In December 2007, updated business license conditions were issued to Bromine Compounds Ltd. in Israel under which the treatment of effluents will be under the exclusive responsibility of each plant (including the removal stage). Under the conditions of the license, the wastewater from the facilities will be removed to the evaporation ponds and reservoirs that are operated and managed by the Council, until the end of 2009. After this date, independent removal systems will be operated under the management of each facility, and wastewater pumping into the current system will be prohibited. New dates were set, as a result of a postponement stemming from continuation of the statutory processes, which are also acceptable to the Israeli Ministry of Environmental Protection and the Local Industrial Council of Neot Hovav. In 2013, construction of the plant's independent evaporation ponds was completed and all the wastewater is being flowed into them.

        In September 2012, the plant submitted a request for an emissions permit pursuant to the Clean Air Law, 2008. The emissions permit was received in August 2013. The terms of the permit implement the principles of the European Directive in the atmosphere area, which are the strictest standards in Europe.

        b)    Pending proceedings relating to the Kishon River, Israel

        The production site of Fertilizers and Chemical Materials Ltd., a company in the ICL Fertilizers segment (hereinafter—"FCM") borders the Kishon River. For decades FCM, along with many other entities, municipalities and plants, has diverted wastewater to the Kishon River.

        Between 2001 and 2005, a number of claims for monetary damages were filed in the Haifa District Court against FCM and a series of other defendants (including the State of Israel) by 50 individuals (or their heirs or dependents), most of them fishermen who worked, according to the claims, in the Kishon's fishing harbor. According to the plaintiffs, the flow of sewage to the Kishon River by each of the chemical plants operating on the river banks has caused the plaintiffs' cancer and other illnesses. Dozens of factories, local governments and insurance companies were added as third-party defendants. In the course of examining the claims, ten plaintiffs withdrew their claims, which were dismissed.

F-75


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 23—Commitments, Concessions and Contingent Liabilities (Continued)

        On November 3, 2013, a court judgment was rendered rejecting the plaintiffs' claim for damages. On February 9, 2014, the court issued a decision regarding the legal fees. In its decision, the court charged all the plaintiffs for the defendants' costs, in the amount of about NIS 4.6 million. Of the total expenses charged to the plaintiffs, it was determined that an amount of more than NIS 1.1 million is to be paid to Fertilizers and Chemical Materials Ltd. The plaintiffs requested from the court to extend the date in order to file an appeal on their behalf.

        Based on the evaluation of its legal advisors, and in light of the court's detailed and reasoned decision, the Company estimates that the chances that of appeal succeeding (if ultimately filed) are unlikely.

        Between 2000 and 2007, a number of claims were filed in the District Court at Haifa against a list of defendants by former soldiers (and their heirs and dependents). The plaintiffs claim that contact with toxic substances in and around the Kishon River caused them cancer and other diseases. Several dozen factories (including FCM), governments, including the State of Israel, and insurance companies were added as third-party defendants.

        On June 17, 2013, a court decision was rendered rejecting the claim for damages of 72 former soldiers (and their heirs and dependents) in the consolidated cases (one claim was rejected at the hearing and another 16 non-consolidated cases remain). On November 24, 2013, the plaintiffs filed an amended notice of appeal with the Supreme Court. Based on the evaluation of its legal advisors, and in light of the court's detailed and reasoned decision, the Company estimates that the chances that of appeal succeeding are unlikely.

        On February 23, 2014, a court hearing was held in connection with the claims in the unconsolidated cases and it was decided to "freeze" the hearing until the Supreme Court renders its decision with reference to the appeal filed with respect to the consolidated cases. Based on the evaluation of its legal advisors, and based on the court's holdings with respect to the consolidated cases, the Company estimates that the chances that the claim will be accepted in the unconsolidated cases are unlikely.

        c.     Three claims were filed with the District Court at Beer Sheva, Israel in March and June 2007 against the State of Israel and the Industrial Local Council at Neot Hovav, Israel, in whose jurisdiction the Neot Hovav plants operate, including the plants of ICL Industrial Products. The plaintiffs argue that various pollutants in the vicinity of Neot Hovav have caused their illnesses, including, among other things, respiratory diseases, spontaneous abortion, birth defects, diseases of the nervous system, cancer, and other illnesses. The claims rely, among other things, on results of an epidemiological study. The claims sue for sums for treatment expenses incurred by the plaintiffs, as well as compensation for pain and suffering, distress, and punitive damages. The plaintiffs are suing for a total sum of approximately $69 million.

        In May 2008, the Local Council filed a third party notice against a number of plants at Neot Hovav, including factories of ICL Industrial Products. In December 2008, the State of Israel also filed a third party notice against the same factories. The notices alleged that if the Council or the State of Israel is held to be liable to compensate the defendants, then the liability for compensation must be imposed on the plants, or they must be required to indemnify the Council or the State of Israel for any compensation that they are required to pay to the plaintiffs. On January 9, 2013, a judgment was rendered rejecting the claim against the defendants, including ICL's plants. On February 20, 2013, the plaintiffs filed an appeal with the Supreme Court. In the Company's estimation, based on the

F-76


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 23—Commitments, Concessions and Contingent Liabilities (Continued)

assessment of its legal advisors, the chances that the appeal will be accepted are unlikely and, accordingly, no provision was included in the financial statements

    4. Increase in level of Pond 5, Israel

        The minerals from the Dead Sea are extracted by way of solar evaporation, whereby salt precipitates onto the bed of one of the evaporation ponds at Sodom, in one of the DSW's sites. The precipitated salt creates a layer on the pond bed of approximately 20 million tons annually. The process of production of the raw material requires that a fixed brine volume is preserved in the pond. To this end, the water level of the pond is raised by approximately 20 centimeters annually.

        The Ein Boqeq and Hamei Zohar hotels, the town of Neve Zohar and other facilities and infrastructures are located on the western beach of this pond. Raising the water level of the pond above a certain level is likely to cause structural damage to the foundations and the hotel buildings situated close to the water's edge and to other infrastructure on the western shoreline of the pond, depending on the height to which the water level is raised and the location of the relevant object.

        In July 2012, an appendix to the agreement from 2007 was signed relating to additional protections of beachfronts that are to be executed in order to permit strengthening of the water level. Based on the appendix to that agreement, the level of the DSW's participation in the beachfront protection will be 39.5%.

        On July 8, 2012, the Group entered into an agreement with the government of Israel, relating to a permanent solution for the increase in level of Pond 5. The permanent solution for the rising of the level of the Dead Sea is by means of full harvesting of the salt from Pond 5 (hereinafter—"the Salt Harvesting").Upon completion of the Salt Harvesting, the process of production of the raw material, will no longer cause or require raising of the water level in the Pond.The highlights of the agreement are set forth below:

        A.    Planning and execution of the Salt Harvesting will be performed by the Group.

        B.    The Salt Harvesting project, including a new pumping station to be constructed, constitute an Israeli national infrastructure project that will be promoted by the Israeli Committee for National Infrastructures.

        C.    Starting January 1, 2017, the water level in Pond 5 will not rise above 15.1 meters in the DSW's network. If there would be a material deviation from the timetables for construction of the Salt Harvesting project as a result of a requirement for changes by the planning institutions, as a result of which the Plan is not approved on time, without the Company having violated its obligations, the Company will be permitted to request raising of the water level above that level. The Company will be required to pay compensation for any damages caused, as a result of the rise in the water level. The statutory infrastructure of the Salt Harvesting project is presently being discussed by the Board of National Infrastructures and its approval is expected in 2014. Concurrently, the Group is performing additional activities relating to the harvesting project.

        D.    Pursuant to the Dead Sea Protection Company, the total cost of the Salt Harvesting is estimated, as at October 2010, in an undiscounted amount of NIS 7 billion. The Government will bear up to 20% of the cost of the Salt Harvesting. The Government's maximum commitment (20% of the discounted amount, 3.8 billion Shekel) is linked to the CPI and bears interest at the rate of 7%.

F-77


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 23—Commitments, Concessions and Contingent Liabilities (Continued)

        E.    Increase in the rate of the royalties from 5% to 10% of sales, for quantities of chloride potash DSW sells in excess of 1.5 million tons annually, this increase will apply to sales starting January 1, 2012. The Group also agreed that for the period starting January 1, 2010 and until January 1, 2012, for annual sales exceeding 3.0 million tons additional royalties at a rate of 5% will be paid.

        F.     As part of the agreement, the State of Israel declared that as of that date, it sees no need to make additional changes in its then specific fiscal policy regarding mining from the quarries at the Dead Sea, including the commercial utilization thereof and, accordingly, at that present time, it will not initiate and will not object, as applicable, to proposed laws regarding this matter. The Company's consent to the increase of the rate of the royalties, as stated in E above, is contingent on implementation of the Government of Israel's decision, as stated in this Section. The agreement further provides that if legislation is enacted that changes the specific fiscal policy in connection with profits or royalties deriving from mining of quarries from the Dead Sea, the Company's consent will not apply regarding an increase in the rate of royalties above on the surplus quantities referred to above, commencing from the date the additional tax is to be collected as stated in the legislation and the matter will be returned to arbitration. If such a situation does occur, the matter of the royalties' rate on the surplus quantity stated in E above, will be transferred to arbitration and each side will be permitted to raise any contention it could have raised immediately preceding signing of the above-mentioned agreement.

        On June 17, 2013, the Minister of Finance, Mr. Yair Lapid, gave notice regarding an establishment of a public committee, headed by Prof. Eytan Sheshinski, for examination of the policy with respect to the royalties received by the State of Israel from private entities, including the Company, for use of national natural resources. Pursuant to the appointment certificate the committee was granted, the committee is required, inter alia, to examine the royalties policy at a broad perspective, while making reference to the impacts on the present agreements between the various parties engaged in these matters and the State of Israel. In addition, the committee is required to examine the application of the principles formulated in connection with the Dead Sea quarries, taking into account, among other things, Government Decision No. 4060 and the detailed agreement signed with DSW in July 2012 as a result of this decision, and while addressing the public debate held regarding the possibility of merging the Company with a foreign company. Pursuant to the appointment certificate, the committee is expected to submit its recommendations to the Minister of Finance by June 2014.

        Pursuant to the Group's position, as it was presented to the committee, there is no room for imposing any type of additional royalties on the Group. On November 4, 2013, the Group submitted its position to the committee in writing. On December 3, 2013, the Group contacted the Minister of Finance, among other things, in the name of DSW, in order that the matter will be excepted from the committee's letter of appointment, however, its request was denied. On December 16, 2013, the Group's representatives appeared before the committee members. On March 18, 2014, DSW notified the Government of Israel of its intention to file a statement of claim in the framework of an arbitration proceeding in connection with breach of the concession agreement, which is in the addendum to the Dead Sea Concession Law, 1961 ("the Concession Agreement" and "the Dead Sea Concession Law"), which provides DSW, among other things, the exclusive right to produce from the Dead Sea quarries, and also gave notice of appointment of an arbitrator on its behalf and requested appointment of an arbitrator on behalf of the State of Israel.

        Based on the main reasons in the statement of claim, which was attached to DSW's notification to the State, the State's conduct in taking unilateral steps for examination of the consideration DSW is to

F-78


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 23—Commitments, Concessions and Contingent Liabilities (Continued)

pay to the State in respect of the rights granted to it in the Concession Agreement, in the manner described above, constitutes a violation of the Concession Agreement that is embedded in the Dead Sea Concession Law, which provides, among other things, that every doubt, disagreement or dispute that arises between the parties to the Concession Agreement is to be resolved by means of an arbitration proceeding. In addition to that stated, the State's conduct constitutes a violation of its duty to act in an accepted manner and in good faith when fulfilling the obligations and utilizing the rights deriving from the Concession Agreement, and ignoring the significant provisions of the Concession Agreement that anchor the consents of the State and DSW with reference to the full consideration DSW will pay to the State in respect of the right granted to it relating to the quarries at the Dead Sea. In light of these violations, DSW believes that it has a right to compensation regarding all the damages it was caused and will be caused as a result of the State's conduct.

        G.    Up to the time the required harvesting set-up is completed, additional interim construction of defenses and barriers are required. There is no certainty that construction of these defenses will be finished on the dates required by the height of the level of the Pond, since there could be delays deriving from, inter alia, the need to receive the permits required by law (which are subject to complex and lengthy proceedings), and for other reasons. Delays in constructing the interim defenses could cause significant damage to the hotels and/or to the Group.

        In a petition filed by the Hotels Union in November 2013, the court rejected the request to issue an interim order preventing raising of the dike by the Government Company for Protection of the Dead Sea Ltd. that was intended to protect the western coast of pond No. 5 (where a number of hotels are located) against a rise in the water level of pond No. 5. A hearing has been scheduled for September 15, 2014 with respect to the petition of the Hotels Union for an order requiring the defendants to explain why the building permit relating to the raising of the dike should not be revoked.

        Delays in raising of dikes may prevent the raising of water level in pond No. 5 and consequently may cause a reduction in our production capacity.

        5.     The subsidiary in Spain (IBP) has two potash production sites in the towns of Suria and Sallent. As a by-product of the potash production process, salt is produced and heaps up in piles. Most of the piled up salt is not usable (under the current conditions). Every 8 years (as is true for every other company in Spain) the Company is required to obtain the renewal of the approved environmental license. Regarding the environmental license, the two sites received licenses that are valid up to 2015 and 2016 (see Section 6 below). Regarding the license to pile up salt on the sites—with respect to the first site in the town of Suria, there is room to pile up salt on the site that is sufficient for about 13 years (up to 2026) at the current production level; with respect to the second site in the town of Sallent, on which the Company intends to discontinue the mining activities by the end of 2015, there is room to pile up salt on the site that is sufficient, at the current level of production, for an additional year and a half. In February 2014, the court determined that the permit given by the City Council of Sallent to the Company is not in compliance with the needed requirements to perform salt piling in the site. The court's determination is not final and the Generalitat and the Company appealed. The Company estimates that the legal process will last much more than one year so there would not be any significant impact because the Vilafruns mine at Sallent will be closed before. This judicial proceeding only concerns the town of Sallent.

        6.     In October 2013, a court decision was rendered cancelling the environmental mining license of a subsidiary in Spain at Vilafruns, based on the contention that the license granted by the government had deficiencies. The company and the government filed an appeal to the Supreme Court. The

F-79


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 23—Commitments, Concessions and Contingent Liabilities (Continued)

company is endeavoring to obtain a permit that will rectify the deficiencies described in the court decision. The current situation is the same as above; the site will be closed before the legal process finishes.

        7.     In a subsidiary in Spain located in the town of Suria there are two legal proceedings being carried on against the government of Catalonia, relating to the grant of urban and environmental approvals for the Phoenix project. As part of these proceedings, it was alleged that the project work requires a significant change in the environmental license, and the government must require the company to make an environmental impact survey. Accordingly, the plaintiffs are requesting to terminate the project work. In February 2014, the company received from the Environmental Protection Authorities a favorable survey for the first stage of the Phoenix project with respect to the impact on the environment and approved the Environmental Impact Declaration. This survey is a critical stage in the process for obtaining the renewal of the environmental license from the Authorities, which the Company expects to receive in the next few weeks following the date of the report. In the Company's estimate, upon receipt of the new license, continuation of the legal proceeding will become superfluous.

        8.     On August 29, 2013, a request for certification of a claim as a class action against the Company, Israel Corporation Ltd., Potashcorp Cooperative Agricultural Society Ltd., the members of the Company's Board of Directors and its CEO, was filed in the District Court in Tel-Aviv, on the grounds of a misleading detail, deception and non-disclosure of a material detail in the Company's reports, this being in violation of the provisions of the Securities Law and the general laws. The aggregate amount of the damage claimed is $0.79 billion (NIS 2.75 billion) or $0.95 billion (NIS 3.28 billion). Subsequent to the date of the statement of financial position, in February 2014, a response to the request was submitted and a hearing of the case set for July 2014. In the Company's opinion, based on the position of its legal advisors, the chances of that the request will be rejected are greater than the chances that it will be accepted. Accordingly, no provision was included in the financial statements.

        9.     In addition to the contingencies referred to in sections above, a number of claims are pending against the Group (including lawsuits). In respect of claims for an amount up to about $65 million as of December 31, 2013, the Group has recorded provisions as at that date of about $6 million. In addition, part of the above claims are covered by insurance policies. The Group's management believes, based on opinions of its legal counsel, that the provision recorded is sufficient to cover any liabilities that might arise.

Note 24—Equity

A.    Composition:

 
  As at December 31,   As at December 31, 2012  
 
  Authorized   Issued and paid   Authorized   Issued and paid  

Number of Ordinary shares of NIS 1 par value

    1,484,999,999     1,295,015,589     1,484,999,999     1,294,703,031  
                   
                   

Number of Special State share of NIS 1 par value

    1     1     1     1  
                   
                   

F-80


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 24—Equity (Continued)

        The reconciliation of the number of shares outstanding at the beginning and at the end of the period are as follows:

 
  Number of Outstanding Shares  

As at January 1, 2012

    1,293,098,052  

Options exercised during the year

    1,604,979  

As at December 31, 2012

    1,294,703,031  

Options exercised during the year

    312,558  

As at December 31, 2013

    1,295,015,589  

        Shares reserved for issue under options and contracts for the sale of shares including terms and amounts:

        As of December 31, 2013 the number of shares reserved for issuance under the Company's option plans was 15,742,655. In January 2014, 3,747,255 shares expired.

        The shares of ICL are listed for trade on the Tel-Aviv Stock Exchange. The closing price per share on the Tel-Aviv Stock Exchange on December 31, 2013 was NIS 28.93.

B.    Rights conferred by the shares

        The ordinary shares confer upon their holders voting rights (including appointment of directors by a simple majority at shareholders' meetings), the right to participate in shareholders' meetings, the right to receive profits and the right to a share in excess assets upon liquidation of ICL.

        The Special State of Israel Share, held by the State of Israel in order to safeguard matters of vital interest of the State of Israel, confers upon it special rights to make decisions among other things on the following matters:

    Sale or transfer of Company assets, which are "vital" to the State of Israel not in the ordinary course of business.

    Voluntary liquidation, change or reorganization of the organizational structure of ICL or merger (excluding mergers of entities controlled by ICL that would not impair the rights or power of the Government, as holder of the Special State Share).

    Any acquisition or holding of 14% or more of the issued share capital of ICL.

    The acquisition or holding of 25% or more of the issued share capital of ICL (including augmentation of an existing holding up to 25%), even if there was previously an understanding regarding a holding of less than 25%.

      Any percentage of holding of the Company's shares, which confers upon its holder the right, ability or actual possibility to appoint, directly or indirectly, such number of the Company's directors equal to half or more of the Company's directors actually appointed.

C.    Share-based payments to employees

        On January 28, 2007, the Company's Board of Directors approved a plan for a private issuance, for no consideration, of 12.9 million options exercisable for Company shares, to a group of officers and other senior employees holding management positions with the Company and companies it controls, in and outside of Israel.

F-81


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 24—Equity (Continued)

        During the months January-March 2007, 11.8 million options were issued from the plan, of which 2.2 million were issued to the former CEO of the Company.

        The options from the 2007 plan vested in three equal portions as follows: one-third at the end of 12 months from the approval date of the Board of Directors, one-third at the end of 24 months from the approval date of the Board of Directors, and one-third at the end of 36 months from the approval date of the Board of Directors. Each portion was locked up for exercise for one additional year after it vested. The expiration date of the options was 60 months after the approval of the Board of Directors.

        On January 7, 2010, ICL's Board of Directors approved an issuance of 10,930,500 nonmarketable options for no consideration to 318 ICL executives and senior employees in Israel and overseas. The issuance included a material private placement of 1,100,000 options to former CEO of the Company and 800,000 options to the Company's Chairman of the Board. On February 15, 2010, an Extraordinary General Meeting of ICL's shareholders approved the issuance to the Chairman of the Board. The options from the 2010 plan vested in three equal portions, as follows: one-third at the end of 12 months from the date of the Board's approval; one-third at the end of 24 months from the date of the Board's approval; and one-third at the end of 36 months from the date of the Board's approval. The expiration date of the options for the first and second portions is at the end of 36 months from the approval of the Board and the expiration date of the options for the third portion is at the end of 48 months from the Board's approval.

        On November 26, 2012, the Company's Board of Directors approved an issuance of up to 12,000,000 non-marketable options for no consideration to 416 ICL officers and senior employees in Israel and overseas. On December 27, 2012, 11,999,400 options were issued. The issuance included a material private placement of 1,190,000 options to the Company's CEO. This plan includes a "cap" for the value of the shares where if as at the exercise date the closing price of a Company share is higher than twice the exercise price ("the Share Value Cap"), the number of exercised shares will be reduced so that the product of the exercised shares actually issued to the offeree multiplied by the share closing price will equal the product of the number of exercised options multiplied by the Share Value Cap. The options may be exercised in three equal portions on December 26, 2013, 2014, and 2015. The expiration date of the options for the first and second portions is at the end of 48 months from the approval of the Board and the expiration date of the options for the third portion is at the end of 60 months from the issuance date.

        Upon exercise, every option may be converted into one ordinary share of NIS 1 par value of the Company. The ordinary shares issued as a result of exercise of the options have the same rights as the Company's ordinary shares, immediately upon their issuance. The options issued to the employees in Israel are covered by the provisions of Section 102 of the Israeli Income Tax Ordinance (New Version) and the regulations promulgated thereunder. The Company elected that the issuance will be made through a trustee, under the Capital Gains Track.

        The exercise price is linked to the CPI that is known as of the date of payment, which is the exercise date. In a case of distribution of a dividend by the Company, the exercise price is reduced, on the "ex-dividend" date, by the amount of the dividend per share (gross), based on the amount thereof in shekels on the effective date. The options are not marketable and may not be transferred.

        The fair value of the options granted under the 2007 and 2010 plans as stated above was estimated on the basis of the Black & Scholes model for the pricing of options. The fair value of the option

F-82


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 24—Equity (Continued)

issued in the said 2012 plan was valued on the basis of a binomial model for valuing options. The parameters used in applying the models are as follows:

 
  2007 Plan   2010 Plan   2012 Plan  

Share price (in $)

    6.03     14.3     12.1  

CPI-linked exercise price (in $)

    6.03     14.3     12.1  

Expected volatility:

   
 
   
 
   
 
 

First and second tranches

    24.60 %   54.98 %   36.70 %

Third tranche

    24.60 %   48.45 %   44.20 %

Expected life of options (in years):

   
 
   
 
   
 
 

First and second tranches

    4.0     2.5     4.0  

Third tranche

    4.0     3.5     5.0  

Risk-free interest rate:

   
 
   
 
   
 
 

First and second tranches

    3.34 %   0.59 %   0.22 %

Third tranche

    3.34 %   1.29 %   0.54 %

Fair value (in $ millions)

    17.9     54.3     37.7  

Weighted average grant date fair value per option (in $)

    1.5     5.0     3.1  

        The expected volatility was determined on the basis of the historical volatility in the Company's share prices.

        The tranches described above represent the vesting period of the options granted. Since the expected life for each tranche is different, the Company used different expected volatility and risk-free interest rates for each tranche.

        The expected life of the options was determined on the basis of Management's estimate of the period the employees will hold the options, taking into consideration their position with the Company and the Company's past experience regarding the turnover of employees.

        The risk-free interest rate was determined on the basis of the yield to maturity of shekel-denominated Israeli Government debentures, with a remaining life equal to the anticipated life of the option.

        The cost of the benefit embedded in the options from the 2010 and 2012 plans is recognized in the statement of income over the vesting period of each portion. Accordingly, in 2012 and 2013, the Company recorded expenses of about $21.8 million and about $8.7 million, respectively.

F-83


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 24—Equity (Continued)

        The movement in the options during 2013 and 2012 are as follows:

 
  Number of
options
2007 Plan
  Number of
options
2010 Plan
  Number of
options
2012 Plan
 

Balance as at January 1, 2012

    2,156,596     10,858,500      

Movement in 2012:

   
 
   
 
   
 
 

Allocated during the year

            11,999,400  

Exercised during the year

    (2,156,596 )   (3,333 )    

Forfeited during the year

        (11,000 )    
               

Total options outstanding as at December 31, 2012

        10,844,167     11,999,400  

Movement in 2013:

   
 
   
 
   
 
 

Exercised during the year

        (6,633,574 )    

Forfeited during the year

        (463,338 )   (4,000 )
               

Total options outstanding as at December 31, 2013

        3,747,255 (1)   11,995,400  
               
               

(1)
As at the date of the approval of the financial statements, the remaining balance of the options from the 2010 plan expired.

        The exercise price for options outstanding at the beginning and end of each period are as follows:

 
  As at  
 
  December 31,
2013
  December 31,
2012
  December 31,
2011
  January 1,
2011
 

2007 Plan US$

    N/A     N/A     4.36     5.33  

2010 Plan US$

    13.16     12.57     12.91     14.31  

2012 Plan US$

    12.85     12.26     N/A     N/A  

        The number of options vested at the end of each period and the weighted average exercise price for these options are as follows:

 
  For the year ended December 31  
 
  2013   2012   2011  

Number of options exercisable

    7,742,655     7,200,667     5,728,096  

Weighted average exercise price NIS

    45.11     46.92     37.02  

Weighted average exercise price US$

    13.00     12.57     9.69  

        The range of exercise prices and the weighted average remaining contractual life for the options outstanding at the end of each period are as follows:

 
  For the year ended December 31  
 
  2013   2012   2011  

Range of exercise price in NIS

    44.59-45.66     45.77-46.92     16.65-49.31  

Range of exercise price in US$

    12.85-13.16     12.26-12.57     4.36-12.91  

F-84


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 24—Equity (Continued)

        The average remaining contractual life for the outstanding vested options at the end of each period are as follows:

 
  For the year ended
December 31
 
 
  2013   2012   2011  

Average remaining contractual life for the outstanding vested options at the end of each period

    1.57         1.03  

D.    Dividends

Date of decision of the Board of Directors
to distribute the dividend
  Actual date of
distribution of
the dividend
  Gross amount of
the dividend
distributed
(in millions of $)
  Net amount of
the distribution
(net of the
subsidiary's share)
(in millions of $)
  Amount of
the dividend
per share
 

March 27, 2011

  May 15, 2011     170     169.7   $ 0.13  

May 15, 2011

  June 28, 2011     195     194.7   $ 0.15  

August 16, 2011

  September 26, 2011     298     297.5   $ 0.23  

November 20, 2011

  December 22, 2011     300     299.5   $ 0.24  

March 26, 2012

  April 30, 2012     260     259.5   $ 0.20  

May 22, 2012

  June 26, 2012     200     199.7   $ 0.16  

August 14, 2012

  September 12, 2012     285     284.5   $ 0.22  

November 20, 2012

  December 19, 2012     276     275.5   $ 0.22  

March 12, 2013

  April 25, 2013     147     146.7   $ 0.12  

May 12, 2013

  June 20, 2013     213     212.6   $ 0.17  

August 6, 2013

  September 16, 2013     221     220.6   $ 0.17  

November 12, 2013

  December 18, 2013     54.5     54.4   $ 0.04  

        Subsequent to the balance sheet date, on February 11, 2014, the Company's Board of Directors decided to distribute a dividend in the amount of $500 million (the net dividend, less the share of a subsidiary, amounts to $499.1 million), about $0.39 per share. The dividend was distributed on March 26, 2014.

        Subsequent to the balance sheet date, on March 18, 2014, the Company's Board of Directors decided to distribute a dividend in the amount of $83 million (the net dividend, less the share of a subsidiary, amounts to $82.9 million), about $0.07 per share. The dividend was distributed on May 27, 2014.

E.    Cumulative translation adjustment

        The translation reserve includes all translation differences arising from translation of financial statements of foreign operations.

F.     Reserve for available-for-sale financial assets

        The capital reserve comprises the cumulative net change in the fair value of available-for-sale financial assets until the investments are being disposed of or impaired.

F-85


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 24—Equity (Continued)

G.    Capital reserves

        The capital reserves include the compensation expenses for payroll against a corresponding increase in equity in respect of share-based compensation to employees (see C. above).

H.    Reserve for cash flows hedge

        The capital reserve for hedging cash flows includes the effective part of the change in the fair value of derivatives utilized for hedging shekel currency debentures, for hedging the exposure to changes in the cash flows of construction of the new cogeneration power plant Project in Sodom Israel, in connection with changes in the rates of exchange of the dollar against the euro (see Note 27).

I.     Treasury shares

        1)    As at December 31, 2013 and 2012, our subsidiaries held 2,216,541 ordinary shares of NIS 1 par value of the Company.

        2)    On September 3, 2008, the Company's Board of Directors decided to authorize the Company, to acquire from time to time until to June 30, 2009, ordinary shares of the Company up to 5% of the Company's issued and paid-up share capital—out of the Company's distributable earnings in accordance with the Israeli Companies Law. In total 22,373,500 shares were acquired by the Company, constituting about 1.74% of the Company's issued and paid-up share capital, for a total consideration of about $258 million.

        3)    In determining the amount of retained earnings available for distribution as a dividend, the Israeli Companies Law stipulates that the cost of the Company's shares acquired by a subsidiary (that is presented as a separate item within the Company's shareholders' equity as treasury shares) must be deducted from the overall amount of retained earnings.

Note 25—Pledges and Restrictions Placed in Respect of Liabilities

         A.     The Group has undertaken various obligations in respect of loans and credit received from non-Israeli banks, including a negative pledge whereby the Group, committed, among other things, in favor of the lenders, to limit guarantees and indemnities to third parties (other than the guarantees in respect to subsidiaries) up to an agreed amount for $550 million. The Group has also undertaken to grant loans only to subsidiaries and to associated companies in which it holds at least 25% of the voting rights—not more than stipulated by the agreement with the banks. ICL has also undertaken not to grant any credit, other than in the ordinary course of business, and not to register any charges, including rights of lien, except those defined in the agreement as "liens permitted to be registered" on its existing and future assets and income. For details with regards to the covenants in respect of these loans, see Note 17(D).

         B.     Certain of the Group's subsidiaries in Israel have received government grants from the State of Israel. The above companies have registered floating charges on all their assets in favor of the State of Israel as security for compliance with the grants' terms.

F-86


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 26—Details of Income Statement Items

 
  For the year ended December 31  
 
  2013   *2012   *2011  
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Sales

                   

Sales

    6,271,542     6,471,433     6,868,550  

Cost of sales(1)

   
 
   
 
   
 
 

Materials and spare parts

    1,485,149     1,520,414     1,710,058  

Power and energy

    380,807     404,373     363,530  

Labor and related expenses

    833,256     766,501     805,075  

Subcontracted work

    325,421     313,593     302,606  

Depreciation and amortization

    267,785     264,702     260,300  

Other production expenses

    359,728     347,826     343,192  

Logistics and port expenses

    68,224     65,833     66,147  
               

    3,720,370     3,683,242     3,850,908  

Decrease (increase) in inventories of finished products and work in progress

    141,202     76,993     (82,946 )
               

    3,861,572     3,760,235     3,767,962  
               
               

(1)   Net of amounts capitalized to property, plant and equipment under construction     16,535     20,970     21,052  
                   
                   

*

 

Restated—see Note 3R

 

 

 

 

 

 

 

 

 

 


 
  For the year ended December 31  
 
  2013   *2012   *2011  
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Research and development expenses, net

                   

Amount of expenses

    82,910     74,303     70,285  

Less—grants and participations, see Note 23

    40     204     159  
               

    82,870     74,099     70,126  
               
               

Selling, transport and marketing expenses

                   

Transport and insurance

    546,517     510,964     602,392  

Salaries and related expenses

    151,278     143,944     136,439  

Agents' commissions

    27,193     26,174     28,677  

Other

    125,337     116,209     94,468  
               

    850,325     797,291     861,976  
               
               

General and administrative expenses

                   

Salaries and related expenses

    162,894     141,105     145,285  

Buildings maintenance

    16,787     14,579     13,699  

Legal advice

    12,748     10,280     11,591  

Other**

    89,062     82,818     94,567  
               

    281,491     248,782     265,142  
               
               

**    Including movement in allowance for doubtful debts

    112     1,410     2,182  
               
               

F-87


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 26—Details of Income Statement Items (Continued)

Finance income recorded in the income statements:

                   

Interest income from bank deposits

    8,607     12,197     10,636  

Net change in fair value of derivative financial instruments

    122,941     8,504      

Gain on sale of financial assets available-for-sale

            4,535  

Net gain from changes in exchange rates

            10,654  
               

    131,548     20,701     25,825  
               
               

Finance expenses recorded in the income statements:

                   

Interest expenses to banks and others

    52,116     42,642     40,663  

Finance expenses in relation to employee benefits

    43,816     31,604     11,953  

Bank commissions

    2,654     2,755     8,859  

Net change in fair value of derivative financial instruments

            44,734  

Net loss from changes in exchange rates

    63,439     8,089      
               

Finance expenses

    162,025     85,090     106,209  

Net of interest expenses

    3,622     3,495     2,572  
               

    158,403     81,595     103,637  
               
               

Net finance expenses recorded in the income statements

    26,855     60,894     77,812  
               
               
*
Restated—see Note 3R


 
  For the year ended December 31  
 
  2013   2012   2011  
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Other income and expenses

                   

Gain on increase in rate of holdings in associated company

    1,827     1,945      

Capital gains from sale of fixed assets, net

    2,687         2,017  

VAT refund and deductions

        15,267      

Past service cost

    8,611          

Other

    3,151     6,479     2,643  
               

Other income recorded in the income statements

    16,276     23,691     4,660  
               
               

Expenses relating to an acquisition of subsidiary

            10,914  

Expenses in respect of early retirement(1)

    60,199     55,332     2,360  

Disposal of facilities that were taken out of use

        1,533      

Provision for treatment of waste

    25,000          

Past service cost

        2,009     14,860  

Impairment of assets

    10,658              

Other

    14,337     2,211     1,795  
               

Other expenses recorded in the income statements

    110,194     61,085     29,929  
               
               

(1)
See Note 21.

*
Restated—see Note 3R

F-88


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 27—Financial Instruments and Risk Management

A.    General

        The Group has extensive international operations wherein it is exposed to credit, liquidity and market risks (including currency, interest and other price risks). In order to reduce the exposure to these risks, the Group holds financial derivative instruments, (including forward transactions, SWAP transactions, and options) for purposes of economic (not accounting) hedging of foreign currency risks, commodity price risks, and interest risks. Furthermore, the Group holds derivative financial instruments to hedge its exposure to changes in the cash flows, some of which constitute an accounting hedge.

        The transactions in derivatives are executed with large Israeli and non-Israeli financial institutions, and therefore Group management believes the credit risk in respect thereof is low.

        This Note presents information about the Group's exposure to each of the above risks, and the Group's objectives, policies and processes for measuring and managing risk.

        The Group companies monitor on a regular basis the extent of the exposures and the hedges in respect thereof. The hedging policies of all the types of exposures are discussed by the Company's Board of Directors in the framework of the annual budget. The Company's Board of Directors Finance Committee receives a report every quarter in the framework of the discussion of the quarterly results, as a means of controlling implementation of the policies and for purposes of updating the policies, where necessary. The Group management implement the policies that are determined, while taking into consideration the actual and anticipated developments in the various markets.

B.    Groups and measurement bases of financial assets and financial liabilities

 
  As at December 31, 2013  
 
  Financial assets   Financial liabilities  
 
  Measured at
fair
value through
the statement
of income
  Loans and
receivables
  Measured at
fair
value through
the statement
of income
  Measured at
amortized
cost
 
 
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
 

Cash and cash equivalents

        188,340          

Short-term investments and deposits

    36,140     60,248          

Trade receivables

        1,057,028          

Derivatives and other receivables

    62,235     90,055          

Long-term deposits and other receivables

        7,325          

Long-term derivative instruments

    7,619              
                   

Total financial assets

    105,994     1,402,996          
                   

Short-term credit and current portion of long-term debt

                (718,284 )

Trade payables

                (669,102 )

Derivatives and other payables

            (11,781 )   (387,046 )

Long-term loans from banks and others

                (1,310,638 )

Long-term debt

            (6,582 )    
                   

Total financial liabilities

            (18,363 )   (3,085,070 )
                   

Total financial instruments, net

    105,994     1,402,996     (18,363 )   (3,085,070 )
                   
                   

F-89


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 27—Financial Instruments and Risk Management (Continued)

C.    Credit risk

(1) General

(a)
Customer credit risks

        Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises mainly from the Group's receivables from customers and from other receivables as well as from investments in securities.

        The Company sells to a wide range and large number of customers, including customers with material credit balances. On the other hand, the Company does not have a concentration of sales to individual customers.

        The Company has a regular policy of insuring the credit risk of all its customers by means of purchasing credit insurance with insurance companies, other than sales to government agencies and sales in small amounts. All other sales are executed only after receiving approval of coverage in the necessary amount from the insurance company, or other collaterals of a similar level.

        The use of an insurance company as aforementioned ensures that the credit risk is managed professionally and objectively by an expert external party and transfers most of the credit risk to third parties. Nevertheless, the common deductible in credit insurances is 10% (even higher in a small number of cases) thus the Group is still exposed to part of the risk, out of the total insured amount.

        In addition, the Group has an additional deductible of a cumulative annual amount of $3 million to $5 million through a reinsurance wholly owned captive Company. In addition the Group has a credit insurance provided by the government of Israel's foreign trade risks insurance company.

        Most of the Group's customers have been trading with the Group for many years and only rarely credit losses have been incurred by the Group. The financial statements include specific allowance for doubtful debts that appropriately reflect, in Management's opinion, the credit loss in respect of accounts receivables is doubtful.

(b)
Credit risks in respect of deposits

        The Group deposits its balance of liquid financial assets in bank deposits and in securities. All the deposits are with a diversified group of leading banks preferably with banks that provide loans to the Group.

F-90


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 27—Financial Instruments and Risk Management (Continued)


(2) Maximum Exposure to credit risk

        The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at the reporting date was:

 
  As at December 31  
 
  Carrying amount
(US$ thousands)
 
 
  2013   2012  

Cash and cash equivalents

    188,340     206,067  

Short-term investments and deposits

    96,388     142,689  

Trade receivables

    1,057,028     1,034,668  

Derivatives and other receivables

    152,290     172,252  

Long-term receivables and deposits

    7,325     13,708  

Long-term derivative instruments

    7,619     17,515  
           

    1,508,990     1,586,899  
           
           

        The maximum exposure to credit risk for trade receivables, at the reporting date by geographic region was:

 
  As at December 31  
 
  Carrying amount
(US$ thousands)
 
 
  2013   2012  

Eastern Europe

    29,679     29,950  

Western Europe

    343,793     342,635  

North America

    149,419     150,815  

South America

    121,573     136,423  

India

    85,155     124,998  

China

    162,785     80,136  

Israel

    71,247     63,723  

Other

    93,377     105,988  
           

    1,057,028     1,034,668  
           

F-91


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 27—Financial Instruments and Risk Management (Continued)


(3) Aging of debts and impairment losses

        The aging of trade receivables at the reporting date was:

 
  As at December 31  
 
  2013   2012  
 
  Gross   Impairment   Gross   Impairment  
 
  US$
thousands

  US$
thousands

  US$
thousands

  US$
thousands

 

Not past due

    928,217     (1,534 )   911,519     (1,036 )

Past due up to 3 months

    107,117     (609 )   99,597     (723 )

Past due 3 to 6 months

    20,584     (899 )   13,110     (233 )

Past due 6 to 9 months

    4,337     (1,193 )   12,139     (747 )

Past due 9 to 12 months

    561     (160 )   947     (1,170 )

Past due over 12 months

    6,992     (6,385 )   8,719     (7,454 )
                   

    1,067,808     (10,780 )   1,046,031     (11,363 )
                   
                   

        The movement in the allowance of doubtful accounts during the year was as follows:

 
  For the year ended December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

Balance as at January 1

    11,363     11,463  

Additional allowance

    830     1,484  

Write-offs

    (324 )   (791 )

Reversals

    (1,401 )   (1,048 )

First time consolidation

        76  

Changes due to translation differences

    312     179  
           

Balance as at December 31

    10,780     11,363  
           
           

D.    Liquidity risk

        Liquidity risk is the risk that the Group will not be able to meet its financial obligations as they fall due. The Group's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to timely meet its liabilities, under both normal and stressed conditions, without incurring unwanted losses.

        The Company manages the liquidity risk by holding cash balances, short-term deposits and secured bank credit facilities.

F-92


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 27—Financial Instruments and Risk Management (Continued)

        The following are the contractual maturities of financial liabilities, including estimated interest payments:

 
  As at December 31, 2013  
 
  Carrying
amount
  12 months
or less
  1 - 2 years   3 - 5 years   More than
5 years
 
 
  US$ thousands
 

Non-derivative financial liabilities

                               

Short-term credit (not including current maturities)

    538,538     543,724              

Trade payables

    669,102     669,102              

Other payables

    387,046     387,046              

Non-convertible debentures (including current maturities)

    242,785     185,306     70,832          

Long-term bank loans (including current maturities)

    1,247,599     25,003     39,243     1,017,938     260,202  
                       

    3,085,070     1,810,181     110,075     1,017,938     260,202  
                       

Financial liabilities—derivative instruments utilized for economic and accounting hedging

                               

Interest rate swaps and options

    8,347     1,765     4,000     2,582      

Foreign exchange derivatives

    10,016     10,016              
                       

    18,363     11,781     4,000     2,582      
                       

 
  As at December 31, 2012  
 
  Carrying
amount
  12 months
or less
  1 - 2 years   3 - 5 years   More than
5 years
 
 
  US$ thousands
 

Non-derivative financial liabilities

                               

Short-term credit (not including current maturities)

    279,822     282,809              

Trade payables

    640,396     640,396              

Other payables

    421,200     421,200              

Non-convertible debentures (including current maturities)

    495,647     290,055     169,664     78,497      

Long-term bank loans (including current maturities)

    921,895     8,919     34,213     886,252     4,115  
                       

    2,758,960     1,643,379     203,877     964,749     4,115  
                       
                       

Financial liabilities—derivative instruments utilized for economic and accounting hedging

                               

Interest rate swaps and options

    19,374     1,846     5,501     9,451     2,576  

Foreign exchange derivatives

    8,409     5,733     2,676          

Commodity and sea freight derivative instruments

    17,042     13,434     3,608          
                       

    44,825     21,013     11,785     9,451     2,576  
                       
                       

F-93


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 27—Financial Instruments and Risk Management (Continued)

E.    Market risk

        Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will affect the fair value or future cash flows of a financial instrument.


1. Interest risk

        The Group has loans bearing variable interests and therefore its financial results and cash flows are exposed to fluctuations in the market interest rates.

        ICL uses financial instruments, including derivatives, in order to hedge this exposure. The Group uses interest rate swap contracts and interest options mainly in order to reduce the exposure to cash flow risk in respect of changes in interest rates.

        In addition, in 2005 the Company issued debentures in the amount of $125 million, bearing fixed interest, the balance of which as at the date of the report is $67 million. The liability in respect of the debentures, which bears fixed interest, exposes the Company to fair value risk in respect of changes in the market interest rate. The Company executed swap transactions, in order to change the interest rate whereby it pays variable interest and receives fixed interest.


(a) Interest Rate Profile

        Following is the interest rate profile of the non-derivative interest-bearing financial instruments

 
  As at December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

Fixed rate instruments:

             

Financial assets

    11,504     12,958  

Financial liabilities

    (390,908 )   (413,284 )
           

    (379,404 )   (400,326 )
           
           

Variable rate instruments

             

Financial assets

    244,409     305,392  

Financial liabilities

    (1,638,014 )   (1,284,152 )
           

    (1,393,605 )   (978,760 )
           
           


(b) Sensitivity analysis for fixed rate instruments

        The Group's fixed rate financial assets and liabilities are not measured at fair value through the statement of income. Therefore, a change in interest rates at the reporting date would not affect profit and loss for changes in assets and liabilities at fixed interest.

F-94


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 27—Financial Instruments and Risk Management (Continued)


(c) Sensitivity analysis for variable rate instruments

        The below analysis assumes that all other variables (except for the interest rate), in particular foreign currency rates, remain constant.

 
  As at December 31, 2013
Impact on profit (loss)
 
 
  Decrease of
1% in interest
  Decrease of
0.5% in interest
  Increase of
0.5% in interest
  Increase of
1% in interest
 
 
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
 

Changes in Dollar interest

                         

Non-derivative instruments

    10,901     5,450     (5,450 )   (10,901 )

Cylinder instruments

    (890 )   (793 )   871     1,529  

Exchange instruments

    (5,052 )   (2,497 )   2,441     4,828  
                   

    4,959     2,160     (2,138 )   (4,544 )
                   
                   

Changes in Shekel interest

                         

Non-derivative instruments

    1,619     809     (809 )   (1,619 )

Exchange instruments

    3     1     (1 )   (3 )
                   

    1,622     810     (810 )   (1,622 )
                   
                   

Changes in Euro interest

                         

Non-derivative instruments

    1,945     972     (972 )   (1,945 )
                   
                   

Changes in other currencies interest

                         

Non-derivative instruments

    (528 )   (264 )   264     528  
                   
                   


(d) Terms of derivative financial instruments used to hedge interest risk

 
  As at December 31, 2013
 
  Carrying
amount
(fair value)
  Stated amount   Maturity
date
  Interest rate
range
 
  US$ thousands
  US$ thousands
  Years
  %

Dollar

                   

SWAP contracts from fixed interest to variable interest

    3,072     48,000   1 - 2   4.63%

SWAP contracts from variable interest to fixed interest

    (6,422 )   322,000   1 - 5   1.4% - 3.4%

Cylinder instruments

    (1,925 )   145,000   1 - 3   1.0% - 3.2%

Shekel

   
 
   
 
 

 

 

 

SWAP contracts from fixed interest to variable interest

    858     57,620   1   3.40%

F-95


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 27—Financial Instruments and Risk Management (Continued)

 

 
  As at December 31, 2012
 
  Carrying
amount
(fair value)
  Stated amount   Maturity
date
  Interest rate
range
 
  US$ thousands
  US$ thousands
  Years
  %

Dollar

                   

SWAP contracts from fixed interest to variable interest

    4,923     48,000   1 - 3   4.63%

SWAP contracts from variable interest to fixed interest

    (15,750 )   436,262   1 - 6   1.0% - 4.3%

Cylinder instruments

    (3,623 )   170,000   1 - 4   1.0% - 3.75%

Shekel

   
 
   
 
 

 

 

 

SWAP contracts from fixed interest to variable interest

    1,897     69,837   1 - 2   3.4% - 5.25%


2. Currency risk

        The Group is exposed to currency risk in relation with sales, purchases, assets and liabilities that are denominated in a currency other than the functional currency of the Group. The main exposure is the NIS, Euro, British Sterling, Chinese Yuan, Japanese Yen and Brazilian Real.

        The Group enters into foreign currency derivatives—forward exchange transactions and currency options—all in order to protect the Group from the risk that the eventual cash flows, resulting from existing assets and liabilities, and sales and purchases of goods within the framework of firm or anticipated commitments (based on a budget of up to one year), denominated in foreign currency, will be affected by changes in the exchange rates.

        In addition, on April 27, 2009, the Company issued three series of bonds in a private placement to institutional investors through an auction, for a consideration of NIS 695 million ($167 million). On September 9, 2009, the Company issued three series of bonds in a public offer through an auction, for a consideration of NIS 898 million (approximately $235 million). Some of the series were issued in shekel and some are CPI-linked bearing CPI-linked interest. In respect of the shekel and CPI-linked liabilities, the Company performed dollar-shekel swap transactions to transform its cash flow from shekels into dollars. The Company also performed transactions in derivatives to hedge the major portion of its risk in respect of changes in the CPI. The swap transactions are for a period of five years. This hedging transaction was not treated as an accounting hedge.

        Furthermore, in the third quarter of 2009, the Company invested in derivatives to hedge its risk in respect of changes in the cash flows of extended Series B debentures, in respect of changes in the shekel-dollar exchange rate. The swap transactions are for a period of four years. This hedging transaction was treated as an accounting hedge. As a result of the implementation of hedge accounting, the Company charged part of the changes in the fair value of the derivatives (a loss of $3.6 million) to capital reserves in the other comprehensive income.

        The Company made an investment in a derivative, to hedge the exposure to changes in the cash flows of a project for construction of a power plant in Sodom, deriving from changes in the dollar-euro exchange rate. The expected cost of the project sums to approximately $320 million. This hedging transaction meets the criteria of an accounting hedge. Accordingly, changes in the fair value of the derivative used to hedge cash flows, in respect of the effective hedging component, are recorded and recognized in other comprehensive income. Changes in the fair value of the derivative relating to the

F-96


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 27—Financial Instruments and Risk Management (Continued)

non-effective portion are recorded in the statement of income. In the period of the report, an amount of approximately $1.9 million was recognized in other comprehensive income.


(a) Sensitivity analysis

        A 10% strengthening at the rate of the US$ against the following currencies would have increased (decreased) profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant.

 
  As at December 31  
 
  Impact on profit (loss)  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

Non-derivative financial instruments

             

Dollar/Euro

    (31,093 )   (13,683 )

Dollar/NIS

    65,887     56,974  

Dollar/British Pound

    3,092     4,470  

Dollar/Japanese Yen

    (545 )   (824 )

Dollar/Chinese Yuan

    (141 )   (1,925 )

        A 10% weakening of the US$ against the above currencies at December 31 would have the same effect but in the opposite direction.

        Presented hereunder is a sensitivity analysis of the Group's foreign currency derivative instruments as at December 31, 2013. Any change in the exchange rates of the below principal currencies as at December 31 would have increased (decreased) profit and loss and equity by the amounts shown below (in US $ thousands). This analysis assumes that all other variables remain constant.

 
  As at December 31, 2013  
 
  Increase 10%   Increase 5%   Decrease 5%   Decrease 10%  
 
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
 

Euro/Dollar

                         

Forward transactions

    (56,203 )   (26,622 )   24,085     45,982  

Options

    10,241     4,853     (5,142 )   (9,581 )

Dollar/NIS

   
 
   
 
   
 
   
 
 

Forward transactions

    (20,423 )   (10,700 )   11,820     24,961  

Options

    (51,393 )   (28,601 )   36,421     78,212  

SWAP

    (28,294 )   (14,937 )   15,307     34,052  

JPY/Dollar

   
 
   
 
   
 
   
 
 

Forward transactions

    465     243     (269 )   (568 )

Options

    834     431     (457 )   (956 )

GBP/Dollar

   
 
   
 
   
 
   
 
 

Forward transactions

    (5,171 )   (2,449 )   2,216     4,231  

CPI

   
 
   
 
   
 
   
 
 

Forward transactions

    6,391     3,195     (3,195 )   (6,391 )

SWAP

    3,906     1,953     (1,953 )   (3,906 )

GBP/Euro

   
 
   
 
   
 
   
 
 

Forward transactions

    46     24     (27 )   (57 )

Options

    (1,746 )   (709 )   982     2,184  

F-97


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 27—Financial Instruments and Risk Management (Continued)


(b) Terms of derivative financial instruments used to economically hedge foreign currency risk

 
  As at December 31, 2013  
 
  Carrying amount   Stated amount   Average
exchange rate
 
 
  US$ thousands
  US$ thousands
   
 

Forward contracts

                   

NIS/Dollar

    1,311     223,605     3.50  

Dollar/Euro

    452     506,101     1.38  

Dollar/JPY

    400     5,511     97.40  

Euro/GBP

    (20 )   492     0.87  

Dollar/GBP

    987     46,555     1.62  

Other

    (1,953 )   21,325      

CPI

    (1,062 )   57,620      

Currency and interest SWAPs

   
 
   
 
   
 
 

Shekel and CPI to Dollars

    21,870     290,908      

Put options

   
 
   
 
   
 
 

NIS/Dollar

    31,667     697,000     3.60  

Dollar/Euro

    1,183     98,230     1.34  

Dollar/JPY

    (100 )   10,000     100.00  

Euro/GBP

    423     20,665     0.84  

Call options

   
 
   
 
   
 
 

NIS/Dollar

    (3,494 )   697,000     3.60  

Dollar/Euro

    (3,464 )   98,230     1.34  

Dollar/JPY

    595     10,000     100.00  

Euro/GBP

    (99 )   20,665     0.84  

F-98


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 27—Financial Instruments and Risk Management (Continued)

 

 
  As at December 31, 2012  
 
  Carrying amount   Stated amount   Average exchange
rate
 
 
  US$ thousands
  US$ thousands
   
 

Forward contracts

                   

NIS/Dollar

    4,588     260,950     3.80  

Dollar/Euro

    27     50,203     1.32  

Dollar/JPY

    907     15,191     81.00  

Euro/GBP

    (34 )   22,440     81.40  

Dollar/GBP

    (66 )   42,044     1.62  

Other

    (8 )   7,778      

CPI

    (826 )   53,576      

Currency and interest SWAPs

   
 
   
 
   
 
 

Shekel and CPI to Dollars

    10,764     304,344      

Put options

   
 
   
 
   
 
 

NIS/Dollar

    29,439     701,500     3.86  

Dollar/Euro

    233     29,376     1.28  

Dollar/JPY

    (35 )   14,500     79.13  

Euro/GBP

    5     3,954     0.79  

Call options

   
 
   
 
   
 
 

NIS/Dollar

    (4,149 )   701,500     3.87  

Dollar/Euro

    (436 )   29,398     1.28  

Dollar/JPY

    811     14,500     81.76  

Euro/GBP

    (22 )   3,954     0.79  

        The maturity date of all of the derivatives used to economically hedge foreign currency risk is up to a year.

F-99


Table of Contents

Notes to the Consolidated Financial Statements (Continued)

Note 27—Financial Instruments and Risk Management (Continued)

(c) Linkage terms of monetary balances—in thousands of Dollars

 
  As at December 31, 2013  
 
  US$   Euro   GBP   NIS   CPI   JPY   Others  

Non-derivative instruments:

                                           

Cash and cash equivalents

    29,384     64,862     17,941     32,096         4,201     39,856  

Short term investments and deposits

    84,212     815         1,431             9,930  

Trade receivables

    591,710     291,257     33,072     61,878         7,820     71,291  

Other receivables

    34,241     28,010     4,873     22,139         47     745  

Long-term receivables and deposits

    603     474         4,094     1,912     230     12  
                               

Total financial assets

    740,150     385,418     55,886     121,638     1,912     12,298     121,834  
                               

Short-term credit

    415,240     108,232     15,964     28,549     147,012     703     2,584  

Trade payables

    134,873     245,307     14,136     251,626         961     22,199  

Other payables

    84,327     129,360     9,441     152,949         301     10,668  

Long-term debt

    985,276     152,416         172,860         38     48  
                               

Total financial liabilities

    1,619,716     635,315     39,541     605,984     147,012     2,003     35,499  
                               

Total non-derivative financial instruments, net

    (879,566 )   (249,897 )   16,345     (484,346 )   (145,100 )   10,295     86,335  
                               

Derivative instruments:

                                           

Forward transactions

        506,101     46,555     223,605     57,620     (5,511 )   21,817  

Cylinder

        (98,230 )       697,000         (10,000 )   20,665  

SWAPS—dollar into shekel and CPI

                261,782     29,126          
                               

Total derivative instruments

        407,871     46,555     1,182,387     86,746     (15,511 )   42,482  
                               

Net exposure

    (879,566 )   157,974     62,900     698,041     (58,354 )   (5,216 )   128,817  
                               
                               

F-100


Table of Contents

Notes to the Consolidated Financial Statements (Continued)

Note 27—Financial Instruments and Risk Management (Continued)

 
  As at December 31, 2012  
 
  US$   Euro   GBP   NIS   CPI   JPY   Others  

Non-derivative instruments:

                                           

Cash and cash equivalents

    62,238     67,718     2,826     36,895         4,213     32,177  

Short-term investments and deposits

    127,011     1,688         9,593             4,397  

Trade receivables

    557,818     292,572     41,995     70,183         16,664     55,436  

Other receivables

    69,831     36,290     5,375     17,876         16     2,796  

Long-term receivables and deposits

    8,485     494         2,260     2,176     280     13  
                               

Total financial assets

    825,383     398,762     50,196     136,807     2,176     21,173     94,819  
                               

Short-term credit

    326,687     17,780         204,218             3,377  

Trade payables

    113,168     165,475     23,626     309,420         3,662     25,045  

Other payables

    79,290     134,264     10,486     181,582         339     15,239  

Long-term debt

    832,296     148,132         28,004     134,163     46     2,661  
                               

Total financial liabilities

    1,351,441     465,651     34,112     723,224     134,163     4,047     46,322  
                               

Total non-derivative financial instruments, net

    (526,058 )   (66,889 )   16,084     (586,417 )   (131,987 )   17,126     48,497  
                               

Derivative instruments:

                                           

Forward transactions

        50,204     42,044     260,950     53,576     (15,191 )   (30,218 )

Put options

        22                      

Cylinder

        29,376         701,500         14,500     3,954  

SWAPS—dollar into shekel and CPI

                270,335     24,242          
                               

Total derivative instruments

        79,602     42,044     1,232,785     77,818     (691 )   (26,264 )
                               

Net exposure

    (526,058 )   12,713     58,128     646,368     (54,169 )   16,435     22,233  
                               
                               

F-101


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 27—Financial Instruments and Risk Management (Continued)

3. Other price risk

A. Investment in securities

        The Group companies have an investment in marketable securities, in the amount of approximately $36 million. The impact of the change in the fair value of this investment will be recorded in the statement of income within financing expenses.


B. Hedging of marine shipping and energy transactions

        The Company is exposed to risk in respect of marine shipping and energy costs. The Company uses marine shipping and energy derivatives to hedge the risk that its cash flows will be affected by changes in marine shipping and energy prices. As at December 31, 2013, the fair value of the marine shipping and energy derivatives was approximately $7.2 million (asset).

F.     Fair value of financial instruments

        The Group's financial instruments mostly include non-derivative assets: cash and cash equivalents, investments, short-term deposits and loans, receivables and other current-receivable, long-term investments and receivables; non-derivative financial liabilities: short-term credit, payables and other current liabilities, long-term loans and other long-term liabilities; as well as derivative financial instruments.

        Due to their nature, the fair value of the financial instruments included in the working capital of the Group is generally identical or approximates their carrying value. The fair value of the long-term deposits and receivables and the long-term liabilities also approximates their carrying value, as these financial instruments bear interest at a rate which approximates the accepted interest market rate.

        The following table details the book value and the fair value of financial instrument groups presented in the financial statements not in accordance with their fair value:

 
  As at December 31, 2013   As at December 31, 2012  
 
  Carrying
amount
  Fair value   Carrying
amount
  Fair value  
 
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
 

Debentures bearing fixed interest

                         

Marketable(1)

    147,848     148,711     334,215     344,824  

Non-marketable(2)

    68,342     69,889     68,344     74,419  
                   

    216,190     218,600     402,559     419,243  
                   
                   

(1)
The fair value of the marketable debentures is based on the quoted stock exchange price and is classified as level 1 under the fair value hierarchy.

(2)
The fair value of the non-marketable debentures is based on a calculation of the present value of the cash flows based on the customary Libor rate for similar loans having similar characteristics and is classified as level 2 under the fair value hierarchy. The average discount rate as at December 31, 2013 is 3.6% (December 31, 2012—1.3%).

F-102


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 27—Financial Instruments and Risk Management (Continued)

G.    Hierarchy of fair value

        The following table presents an analysis of the financial instruments measured by fair value, using the valuation method (See Note 4 for more details regarding the valuation method).

        The following levels were defined:

            Level 1: Quoted (unadjusted) prices in an active market for identical instruments

            Level 2: Observed data (directly or indirectly) not included in Level 1 above.

 
  As at December 31, 2013  
 
  Level 1   Level 2   Total  
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Securities held for trading purposes

    36,140         36,140  

Derivatives used for hedging, net

        51,491     51,491  
               

    36,140     51,491     87,631  
               
               

Note 28—Earnings per Share

Basic earnings per share

        Calculation of the basic earnings per share for the year ended December 31, 2013, is based on the earnings allocated to the holders of the ordinary shares divided by the weighted-average number of ordinary shares outstanding, calculated as follows:

 
  For the year ended December 31  
 
  2013   2012   2011  
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Earnings attributed to holders of the ordinary shares

    818,573     1,300,076     1,498,151  
               
               

        Weighted average number of ordinary shares, in thousands:

 
  2013   2012   2011  

Balance as at January 1

    1,270,119     1,268,508     1,266,583  

Plus—options exercised for shares

    295     1,501     1,116  
               

Weighted-average number of ordinary shares used in computation of the basic earnings per share as at December 31

    1,270,414     1,270,009     1,267,699  
               
               

F-103


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 28—Earnings per Share (Continued)


Diluted earnings per share

        Calculation of the diluted earnings per share for the year ended December 31, 2013, is based on the earnings allocated to the holders of the ordinary shares divided by the weighted-average number of potential diluted ordinary shares, calculated as follows:

 
  For the year ended December 31  
 
  2013   2012   2011  
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Earnings attributed to the ordinary shareholders (diluted)

    818,573     1,300,076     1,498,151  
               
               

        Weighted average number of ordinary shares (diluted), in thousands:

 
  As at December 31  
 
  2013   2012   2011  

Weighted average number of ordinary shares used in the computation of the basic earnings per share

    1,270,414     1,270,009     1,267,699  

Effect of stock options

        108     5,246  
               

Weighted average number of ordinary shares used in the computation of the diluted earnings per share

    1,270,414     1,270,117     1,272,945  
               
               

        At December 31, 2013, 7,643.5 thousand options (at December 31, 2012 and 2011, 7,287 thousand and 3,643.5 thousand options, respectively) were excluded from the diluted weighted average number of ordinary shares calculation as their effect would have been anti-dilutive.

        The average market value of the Company's shares, for purposes of calculating the dilutive effect of the stock options, is based on the quoted market prices for the period in which the options were outstanding.

Note 29—Related and Interested Parties

        Related parties within the meaning thereof in IAS 24, "Related Parties"; Interested parties within the meaning thereof in Paragraph 1 of the definition of an "interested party" in a company, as defined in Section 1 of the Israeli Securities Law, 1968.


A. Parent company and subsidiaries

        The Group's parent company is Israel Corporation Ltd. Israel Corporation Limited is a public company listed for trading on the Tel Aviv Stock exchange (TASE). Based on the information the Company received from Israel Corp., Millennium Investments Elad Ltd (hereinafter, "Millennium") and Mr. Idan Ofer are considered joint controlling shareholders of Israel Corporation, for purposes of the Securities Law as both Millennium and Mr. Ofer hold shares in Israel Corporation directly, and Idan Ofer serves as a director of Millennium and has an indirect interest in Israel Corporation as a beneficiary of a trust that has indirect control of Millennium. Millennium holds approximately 46.94% of the share capital in Israel Corporation. To the best of the Company's knowledge, Millennium is held by Mashat Investments Ltd (hereinafter, "Mashat"), and by XT Investments Ltd (hereinafter, "XT Investments"), with 80% and 20% holdings, respectively. Mashat is a private company, wholly owned by a Dutch company Ansonia Holdings B. V. (hereinafter, "Ansonia"). Ansonia is a wholly-owned

F-104


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 29—Related and Interested Parties (Continued)

subsidiary of Jeremy Corporation N. V. (registered in Curaçao), which is a wholly owned subsidiary of the Liberian company Court Investments Ltd (hereinafter, "Court"). Court is wholly owned by a foreign discretionary trust of which Mr. Idan Ofer is a beneficiary. XT Investments, which directly holds approximately 1.24% of the share capital in Israel Corporation, is a shareholder in Millennium, as stated. XT Investments is a private company, wholly owned by XT Holdings Ltd (hereinafter, "XT Holdings), a private company whose ordinary shares are held in equal shares by Orona Investments Ltd (which is indirectly controlled by Mr. Ehud Angel) and by Lynav Holdings Ltd, a company that is controlled by a foreign discretionary trust of which Mr. Idan Ofer is the principal beneficiary. Mr. Ehud Angel holds a special share that gives him, inter alia, under certain limitations for certain issues, an additional vote on the board of directors of XT Holdings. In addition, Kirby Enterprises Inc., which is indirectly held by a foreign trust that holds Mashat in which, as stated, Mr. Idan Ofer is a beneficiary, holds approximately 0.74% of the share capital of Israel Corporation. Furthermore, Mr. Idan Ofer holds directly approximately 3.85% of the share capital of Israel Corporation.

        In addition, the right to appoint directors is decided upon in the general meeting the Company holds. Prior to the planned initial public offering of the Company's ordinary shares in the United States, Israel Corporation has rights in the general meeting above 50%. After the offering Israel Corporation may have less than 50%; however, it will still have a major impact on the general meeting and will de facto have the power to appoint directors and have a strong influence upon the composition of the Company's board of directors.

        Regarding the subsidiaries—see Note 30, regarding the Group entities.


B. Benefits to key management personnel (including directors)

        Senior management, in addition to their salaries, are entitled to non-cash benefits (vehicle and telephone). The Group contributes to a post-employment defined benefit plan on their behalf. In accordance with the terms of the plan, senior management retirement age is 67. Senior managers also participate in the options' plan for Company shares. (See Note 24C—Share-Based Payments).

        Benefits for key management personnel (in total 16 key management personnel including directors, in 2012—17 key management personnel) comprised:

 
  For the year ended December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

Short-term benefits

    8,743     8,087  

Post-employment benefits

    1,545     733  

Share-based payments

    6,040     2,023  
           

Total*

    16,328     10,843  
           
           



*

  To related parties employed by the Company     5,193     3,746  
               
               

*

  To related parties not employed by the Company     1,021     1,359  
               
               

F-105


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 29—Related and Interested Parties (Continued)


C. Ordinary transactions that are not exceptional

        The Company's Board of Directors, with the agreement of the Audit Committee, decided that a transaction with related parties will be considered an "insignificant" transaction for public reporting purposes if all the following conditions have been met:

            (1)   It is not an "extraordinary transaction" within its meaning in the Companies Law.

            (2)   The effect of each one of the parameters listed hereunder, is less than one percent (hereinafter—negligible status):

            For every transaction or arrangement that is tested for negligible status, the parameters will be examined, as long as they are relevant, and on the basis of ICL's consolidated financial statements, reviewed or audited, according to the issue, prior to the transaction as detailed below:

      Assets ratio—the amount of the assets in the transaction (acquired or sold assets) divided by total assets.

      Equity ratio—the increase or decrease in equity divided by total equity.

      Revenue ratio—estimated revenue from the transaction divided by annual revenue.

      Manufacturing expenses ratio—the amount of the expenses in the transaction divided by the annual cost of sales.

      Profit ratio—the profit or loss attributed to the transaction divided by total annual comprehensive income or loss during the period.

            (3)   The transaction is negligible also from a qualitative point of view. For the purpose of this criterion, it shall be examined whether there are special considerations justifying a special report on the transaction, even if it does not meet the quantitative criteria described above.

            (4)   In examining negligibility of the transaction occurring in the future, among other things, the probability of the transaction occurring should be examined.


D. Transactions with related and interested parties

 
  For the year ended December 31  
 
  2013   2012   2011  
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Sales

    9,958     14,693     11,674  
               
               

Cost of sales(1)

    131,845     94,512     72,528  
               
               

Selling, transport and marketing expenses

    18,424     36,019     41,159  
               
               

Management fees to the parent company(2)

    4,002     3,792     3,500  
               
               

(1)
A subsidiary in the Performance Products segment entered into a long-term agreement with an interested party of the Company for the acquisition of food quality phosphoric acid. The agreement was signed before the subsidiary was acquired by ICL and is in effect until 2018. Additionally, on February 28, 2013, ICL's audit committee and Board of Directors authorized to the certain of Group subsidiaries in Israel from the Industrial

F-106


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 29—Related and Interested Parties (Continued)

    Products segment to purchase electricity from the OPC Rotem company. During 2013, additional companies from the Fertilizers segment entered into an agreement with OPC Rotem company to purchase electricity in accordance to the amended agreement authorized on February 28, 2013.

(2)
In June 2009, following approval by the Audit Committee, the Company's Board of Directors approved a revision of the management fees payable to Israel Corp. to $ 3.5 million per year for each of the years from 2009 to 2011. On July 20, 2009, the revision was approved by the General Meeting of the Company's shareholders. On October 5, 2011 the General Meeting of the Company's shareholders approved an extension of the management agreement on the same terms for the years 2012 until 2014.

(3)
On June 26, 2012, the Company received a short-term loan in the amount of $50 million from the Company's controlling shareholder (Israel Corporation Ltd.) that bears interest at the 3-month Libor rate plus a margin of 0.7% (1.22%). Commencing from December 24, 2012, the loan was extended every three months on the same terms on which it was originally received. On September 26, 2013, the loan was extended for a period of six months based on the six-month Libor rate plus a margin of 0.49% (0.86%).


E. Balances with interested parties

        1)    Composition:

 
  As at December 31  
 
  2013   2012  
 
  US$ thousands
  US$ thousands
 

Long-term deposits, net of current maturities

    780     958  
           
           

Current maturities of long-term deposits

    260     239  
           
           

Other current assets

    6,342     6,824  
           
           

Other current liabilities (D2)

    73,558     73,087  
           
           

        2)    The Company declares a dollar dividend that is paid in NIS, according to the exchange rate on the effective date. The Company enters hedging transaction in order to hedge the exposure to changes in the dollar/shekel exchange rate. The dividend paid to the Company's controlling shareholder, Israel Corporation, is made partly based on the exchange rate on the effective date and partly based on the exchange rate on the date of distribution. In addition, the dividend paid to an interested party is made according to the exchange rate on the date of distribution.

F-107


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 30—Group Entities

 
   
  Percentage of Shareholding  
The Holding Company
  The Affiliate   Shares conferring
rights to
profits
  Voting shares  

Israel Chemicals Ltd., Israel

  Dead Sea Works Ltd., Israel     100.00     100.00  

  Dead Sea Bromine Company Ltd., Israel     100.00     100.00  

  Rotem Amfert Negev Ltd., Israel     100.00     100.00  

  Dead Sea Periclase Ltd., Israel***     100.00     100.00  

  Mifalei Tovala Ltd., Israel     100.00     100.00  

  I.D.E. Technologies Ltd., Israel     50.00     50.00  

  Ferson Chemicals Ltd., Israel     100.00     100.00  

  ICL Fine Chemicals Ltd., Israel     100.00     100.00  

  P.A.M.A (Energy Resources Development) Ltd., Israel***     25.00     25.00  

  Dead Sea Magnesium Ltd., Israel     100.00     100.00  

  ICL Finance B.V, The Netherlands     100.00     100.00  

  ICL Finance Inc., USA     100.00     100.00  

  Twincap Försäkrings AB, Sweden     100.00     100.00  

  Hoyermann Chemie GmbH, Germany     100.00     100.00  

Hoyermann Chemie GmbH, Germany

 

ICL-IP Bitterfeld Grundbesitz GmbH & Co KG, Germany*

   
5.10
   
5.10
 

  BK Giulini GmbH, Germany*     5.10     5.10  

Dead Sea Works Ltd., Israel

 

Ashli Chemicals (Holland) B.V., Israel

   
100.00
   
100.00
 

  Cleveland Potash ltd (CPL), U.K*     70.94     70.94  

Ashli Chemicals (Holland) B.V., Israel

 

Cleveland Potash ltd (CPL), U.K*

   
29.06
   
29.06
 

  ICL Finance Belgium NV, Belgium     100.00     100.00  

Cleveland Potash ltd (CPL), U.K

 

Constantine & Company (Export) Ltd., UK

   
50.00
   
50.00
 

  ICL Iberia Ltd, UK     100.00     100.00  

  ICL Iberia SCS, Spain*     100.00     100.00  

  Everris Ltd., UK     100.00     100.00  

ICL Iberia SCS, Spain

 

Iberpotash S.A., Spain

   
100.00
   
100.00
 

  Trafico de Mercancias S.A., Spain     100.00     100.00  

  Medentech Limited, Ireland     100.00     100.00  

  Absia SL, Spain     100.00     100.00  

  ICL Fosfatos Y Adtivos Servicios De Mexico, S.A. DE C.V., Mexico*     100.00     100.00  

F-108


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 30—Group Entities (Continued)

 
   
  Percentage of Shareholding  
The Holding Company
  The Affiliate   Shares conferring
rights to
profits
  Voting shares  

  ICL Fostfatos Y Aditivos Mexico, S.A. DE C.V, Mexico*     100.00     100.00  

  Everris Iberica Fertilizers SL, Spain     100.00     100.00  

  BK Giulini Iberica S.L, Spain     100.00     100.00  

  Fomento y Desarrollo Agrícola, S.L, Spain     100.00     100.00  

  Logística de Fertilizantes Fuentes, S.A. Spain     100.00     100.00  

  Agrocallejas mediterranea, S.L Unipersonal, Spain     100.00     100.00  

  Fuentes Fertilizantes S.L., Spain     100.00     100.00  

Medentech Limited, Ireland

 

Patentwise Ltd., Ireland***

   
100.00
   
100.00
 

Dead Sea Bromine Company Ltd., Israel

 

Bromine Compounds Ltd., Israel

   
100.00
   
100.00
 

  Tami (IMI) Institute for R&D Ltd., Israel     100.00     100.00  

  ICL JAPAN Ltd, Japan     100.00     100.00  

  Landchem Ltd., South Africa     100.00     100.00  

  Bromine and Chemicals Ltd., UK     100.00     100.00  

  Dead Sea Periclase Fused products Co., Israel*     99.00     99.00  

  ICL Management & Trading India Private Limited., India     100.00     100.00  

  ICL (Shanghai) Investment Co. Ltd., China     100.00     100.00  

Bromine Compounds Ltd., Israel

 

Tetrabrom Technologies Ltd., Israel

   
100.00
   
100.00
 

  Chemada Fine Chemicals Ltd., Israel     26.00     26.00  

  Bromine Compounds Marketing (2002) Ltd., Israel     100.00     100.00  

  Dead Sea Periclase Fused products Co., Israel*     1.00     1.00  

IMI Tami Institute for R&D Ltd., Israel

 

Potassium Nitrate Ltd., Israel***

   
50.00
   
50.00
 

  Novetide Ltd., Israel     50.00     50.00  

  Magsens Ltd., Israel***     22.20     22.20  

  ICL Innovation Ltd., Israel     100.00     100.00  

Rotem Amfert Negev Ltd., Israel

 

Agro-Vant, Israel

   
100.00
   
100.00
 

F-109


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 30—Group Entities (Continued)

 
   
  Percentage of Shareholding  
The Holding Company
  The Affiliate   Shares conferring
rights to
profits
  Voting shares  

  Fertilizers and Chemicals Ltd., Israel     100.00     100.00  

  Zuari Rotem specialty fertilizers Ltd., India     50.00     50.00  

  ICL Holding The Netherlands Cooperatief U.A., The Netherlands     100.00     100.00  

Fertilizers and Chemicals Ltd., Israel

 

Industrial Chemical Equipment Ltd., Israel

   
100.00
   
100.00
 

  Revivim In The Bay Water and Environment Ltd., Israel     100.00     100.00  

Industrial Chemical Equipment Ltd., Israel

 

Agripo Management services Ltd., Israel***

   
50.00
   
50.00
 

ICL Holding The Netherlands Cooperatief U.A., The Netherlands

 

Everris International B.V, The Netherlands

   
100.00
   
100.00
 

  Amsterdam Fertilizers B.V., The Netherlands     100.00     58.10  

  ICL IP Europe B.V., The Netherlands     100.00     100.00  

ICL-IP Europe B.V., The Netherlands

 

ICL-IP Terneuzen BV, The Netherlands

   
100.00
   
100.00
 

  Bromisa Industrial e Commercial Ltda, Brazil*     90.95     90.95  

  Lianyungang Dead Sea Bromine Compounds Co. Ltd, China     60.00     60.00  

  Sinobrom compounds Co. Ltd, China     75.00     75.00  

  Amsterdam Fertilizers B.V., The Netherlands         41.90  

ICL-IP Terneuzen BV, The Netherlands

 

Bromisa Industrial e Commercial Ltda, Brazil*

   
9.05
   
9.05
 

Everris International B.V, The Netherlands

 

Everris Kenya Ltd., Kenya*

   
50.00
   
50.00
 

F-110


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 30—Group Entities (Continued)

 
   
  Percentage of Shareholding  
The Holding Company
  The Affiliate   Shares conferring
rights to
profits
  Voting shares  

  Everris Malaysia Sdn. Bhd, Malaysia     100.00     100.00  

Amsterdam Fertilizers B.V., The Netherlands

 

Rotem Holding G.M.B.H., Germany

   
10.00
   
10.00
 

  ICL Holding beschränkt haftende OHG, Germany*     95.00     95.00  

  Finacil EEIG (European Economic Interest Grouping)****     12.50     12.50  

  BKG Puriphos B.V, The Netherlands     100.00     100.00  

  ICL Fertilizers Europe CV, The Netherlands*     100.00     100.00  

  NU3 NV, Belgium     100.00     100.00  

  Incap B.V, The Netherlands     100.00     100.00  

  Pekafert B.V., The Netherlands     100.00     100.00  

  ICL brasil Ltda., Brazil     100.00     100.00  

  P.M. Chemicals Srl, Italy     100.00     100.00  

  BKG Puriphos CV, The Netherlands*     0.35     0.35  

  BK Giulini Kimya ve Sanayi Ticaret A.S, Turkey*     100.00     100.00  

  Everris Kenya Ltd., Kenya*     50.00     50.00  

  Eurocil Luxembourg SA, Luxembourg*     1.00     1.00  

  BKG Finance NE BV, The Netherlands     100.00     100.00  

P.M. Chemicals Srl, Italy

 

Everris Italia S.r.l, Italy

   
100.00
   
100.00
 

BK Giulini Kimya ve Sanayi Ticaret A.S, Turkey

 

Rotem Kimyevi Maddeler Sanayi ve Ticaret A.S, Turkey

   
73.30
   
73.30
 

ICL Fertilizers Europe CV

 

BKG Puriphos CV, The Netherlands*

   
99.65
   
99.65
 

ICL Holding beschränkt haftende OHG, Germany

 

Stodiek Dunger GmbH, Germany

   
100.00
   
100.00
 

  ICL Holding Germany GmbH, Germany     100.00     100.00  

  Rotem Holding G.M.B.H, Germany*     90.00     90.00  

F-111


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 30—Group Entities (Continued)

 
   
  Percentage of Shareholding  
The Holding Company
  The Affiliate   Shares conferring
rights to
profits
  Voting shares  

  ICL Fertilizers Deutschland GmbH, Germany     100.00     100.00  

  Eisenbacher Dentalwaren ED GmbH, Germany     100.00     100.00  

  Adentatec GmbH Competence in Dental, Germany     100.00     100.00  

  Everris GmbH, Germany     100.00     100.00  

  Tiami Vattenkemi AB, Sweden     100.00     100.00  

ICL Holding Germany GmbH, Germany

 

ICL Holding beschränkt haftende OHG, Germany*

   
5.00
   
5.00
 

Incap B.V, The Netherlands

 

Intracap Insurance Ltd., Switzerland

   
100.00
   
100.00
 

ICL Brasil Ltda., Brazil

 

Fosbrasil S.A, Brazil

   
44.25
   
44.25
 

Pekafert B.V., The Netherlands

 

Eurocil Luxembourg SA, Luxembourg*

   
99.00
   
99.00
 

  Clearon Corp., USA*     2.00     2.00  

Eurocil Luxembourg S.A, Luxembourg

 

Anti-Germ Austria GmbH, Austria

   
100.00
   
100.00
 

  Anti-Germ Deutschland GmbH, Germany     100.00     100.00  

  ICL France S.A.S, France     100.00     100.00  

  Euro Clearon B.V, The Netherlands     100.00     100.00  

  Specialty Technologies Europe B.V, The Netherlands     100.00     100.00  

ICL France S.A.S, France

 

Scora S.A.S, France

   
100.00
   
100.00
 

Anti-Germ Austria GmbH, Austria

 

Anti-Germ CZ s.r.o, Czech Republic*

   
98.00
   
98.00
 

  Anti-Germ Hungary, Hungary     100.00     100.00  

  Anti-Germ Slovakia s.r.o., Slovakia     100.00     100.00  

Anti-Germ Slovakia s.r.o., Slovakia

 

Anti-Germ CZ s.r.o, Czech Republic*

   
2.00
   
2.00
 

BKG Puriphos B.V, The Netherlands

 

ICL ASIA Ltd., Hong Kong

   
100.00
   
100.00
 

Rotem Holding G.M.B.H. , Germany

 

BK Giulini, GmbH, Germany*

   
94.90
   
94.90
 

F-112


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 30—Group Entities (Continued)

 
   
  Percentage of Shareholding  
The Holding Company
  The Affiliate   Shares conferring
rights to
profits
  Voting shares  

  Fibrisol Service Ltd., UK     100.00     100.00  

  Fibrisol Service Australia Pty. Ltd., Australia     100.00     100.00  

  B.K Giulini Argentina S.A, Argentina*     95.00     95.00  

  Shanghai Tari International Ltd., China     51.00     51.00  

  Yunnan B.K Giulini Tianchuang Phosphate Co. Ltd., China     60.00     60.00  

  Fibrisol Muscalla GmbH, Germany*     34.65     34.65  

  ICL Polska Sp.z.o.o, Poland*     95.00     95.00  

  BK Giulini Leather Chemistry Co. Ltd., Hong Kong     100.00     100.00  

  BKG Personal Care Co. Ltd., Hong Kong     100.00     100.00  

  Flexotex GmbH, Germany     100.00     100.00  

  BKG Performance Products Jiangyin Co. Ltd., China*     53.05     53.05  

  ICL North America Inc., USA     100.00     100.00  

  BK Giulini Specialities Private Ltd., India     51.00     51.00  

  Turris Versicherungvermittlung GmbH, Germany     100.00     100.00  

  ICL IP Bitterfeld GmbH, Germany     100.00     100.00  

Fibrisol Service Australia Pty. Ltd., Australia

 

Everris Australia Pty. Ltd., Australia

   
100.00
   
100.00
 

BK Giulini Leather Chemistry Co. Ltd., Hong Kong

 

BKG Performance Products Jiangyin Co. Ltd., China*

   
11.00
   
11.00
 

ICL IP Bitterfeld GmbH, Germany

 

ICL-IP Bitterfeld Grundbesitz GmbH & Co KG, Germany*

   
94.90
   
94.90
 

Flexotex GmbH, Germany

 

BKG Finance Gmbh, Germany

   
100.00
   
100.00
 

  BKG Finance Sup GmbH, Germany     100.00     100.00  

ICL North America Inc, USA

 

Phosphorus Derivatives Inc., USA

   
100.00
   
100.00
 

F-113


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 30—Group Entities (Continued)

 
   
  Percentage of Shareholding  
The Holding Company
  The Affiliate   Shares conferring
rights to
profits
  Voting shares  

  ICL Performance Products Inc., USA     100.00     100.00  

  ICL IP America Inc., USA**     100.00     100.00  

  Everris NA Inc., USA     100.00     100.00  

  Clearon Corp., USA*     98.00     98.00  

ICL Performance Products Inc, USA

 

ICL Performance Products LP, USA*,**

   
99.00
   
99.00
 

  ICL Performance Products LLC., USA     100.00     100.00  

  ICL Performance Products Canada Ltd., Canada     100.00     100.00  

ICL Performance Products LLC

 

ICL Performance Products LP, USA*,**

   
1.00
   
1.00
 

BKG Personal Care Co., Ltd., Hong Kong

 

BKG Performance Products Jiangyin Co., Ltd., China*

   
35.95
   
35.95
 

BKG Performance Products Jiangyin Co., Ltd. Jiangyin, China*

 

Guangzhou Eclean Technology Co. Ltd., China

   
100.00
   
100.00
 

ICL ASIA Ltd, Hong Kong

 

ARM Ltd., Hong Kong

   
100.00
   
100.00
 

  ICL Fertilizers (India) Private Ltd., India     100.00     100.00  

  Jiaxing ICL Chemical Co., Ltd., China     100.00     100.00  

  Zhangjiagang FTZ ICL Trading Co. Ltd., China     100.00     100.00  

ARM Ltd., Hong Kong

 

ICL Trading (HK) Ltd., Hong Kong

   
100.00
   
100.00
 

  DDFR Corporation Ltd., Hong Kong     50.00     50.00  

  BK Giulini Hong Kong Ltd., Hong Kong     100.00     100.00  

  AUB Storing and Services (Hong Kong) Ltd., Hong Kong     55.00     55.00  

F-114


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 30—Group Entities (Continued)

 
   
  Percentage of Shareholding  
The Holding Company
  The Affiliate   Shares conferring
rights to
profits
  Voting shares  

BK Giulini Hong Kong Limited, Hong Kong

 

BK Giulini Hygiene Hong Kong Ltd., Hong Kong

    100.00     100.00  

  Angang BK Giulini Water Treatment Co Ltd., China     50.00     50.00  

B.K. Giulini GmbH, Germany

 

Fibrisol Muscalla GmbH, Germany*

   
65.35
   
65.35
 

  B.K. Mercosur S.A., Uruguay     100.00     100.00  

  Rhenoflex GmbH, Germany     100.00     100.00  

  Rotem do Brasil Ltd., Brazil     100.00     100.00  

  Tari International N.Z Ltd., New Zealand     100.00     100.00  

  ICL Polska Sp.z.o.o, Poland*     5.00     5.00  

  B.K Giulini Argentina S.A, Argentina*     5.00     5.00  

Rhenoflex GmbH, Germany

 

Gurit Worbla GmbH, Germany

   
100.00
   
100.00
 

Mifalei Tovala Ltd., Israel

 

Sherut Rail & Road Transportaion Services Registered Partnership, Israel

   
97.50
   
97.50
 

  M.M.M. Company United Landfill Industries (1998) Ltd., Israel     33.33     33.33  

I.D.E. Technologies Ltd., Israel

 

Ambient Technologies Inc., USA

   
100.00
   
100.00
 

  IDE Canaries S.A., Spain     100.00     100.00  

  Larnaca Water Partners, Cyprus*     95.00     95.00  

  Pelagos Desalination Services, Cyprus     100.00     100.00  

  Detelca UTE, Spain     20.00     20.00  

  Indian Desalination Engineering PVT Ltd., India     50.00     50.00  

  V.I.D Desalination Company Ltd., Israel     50.00     50.00  

  OTID desalination partnership, Israel     50.00     50.00  

  West Galile Desalination Company Ltd., Israel***     50.00     50.00  

  ADOM Ashkelon desalination Ltd., Israel     40.50     40.50  

  I.D.E.S.B DESALINATION PARTNERSHIP, Israel     50.00     50.00  

  H2ID Ltd., Israel     50.00     50.00  

F-115


Table of Contents


Notes to the Consolidated Financial Statements (Continued)

Note 30—Group Entities (Continued)

 
   
  Percentage of Shareholding  
The Holding Company
  The Affiliate   Shares conferring
rights to
profits
  Voting shares  

  OMIS Water Ltd., Israel     60.00     60.00  

  IDE Technologies India Private Ltd., India*     99.00     99.00  

  Sorek Desalination Ltd., Israel     51.00     51.00  

  Sorek Desalination Partnership, Israel     51.00     51.00  

  Sorek Operation and maintenance company Ltd., Israel     51.00     51.00  

  IDE Americas Inc., USA     100.00     100.00  

  Desalination Plants (Development of Zarchin Process) Ltd., Israel***     86.50     100.00  

  PCT Protective Coating Technologies Ltd., Israel     51.00     51.00  

  Idea Desalination Construction Partnership, Israel*     99.00     99.00  

Ambient Technologies Inc., USA

 

Larnaca Water Partners, Israel*

   
5.00
   
5.00
 

  IDE Technologies India Private Ltd., India*     1.00     1.00  

IDE Canaries S.A., Spain

 

Idea Desalination Construction Partnership, Israel*

   
1.00
   
1.00
 

Dead Sea Magnesium Ltd., Israel

 

M.R.I. Research & Development Ltd., Israel***

   
99.00
   
99.00
 

  Dead Sea Magnesium Inc., USA     100.00     100.00  

  Israeli Light Metal Initiative Ltd., Israel***     9.00     9.00  

*
The investee is also held by other Group companies.

**
There are preferred shares.

***
In liquidation/inactive.

****
The company is held by other group companies, where the holding percentage changes from time to time according to the provisions of the Articles of Association.

F-116


Table of Contents


Condensed Consolidated Unaudited Interim Statements of Financial Position

 
  June 30
2014
  June 30
2013
  December 31
2013
 
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Current assets

                   

Cash and cash equivalents

    177,777     238,998     188,340  

Short-term investments and deposits

    82,357     101,137     96,388  

Trade receivables

    1,274,061     1,237,634     1,057,028  

Derivatives and other receivables

    209,148     214,272     186,317  

Current tax assets

    93,106     69,511     105,270  

Inventories

    1,350,528     *1,353,674     1,408,297  
               

Total current assets

    3,186,977     3,215,226     3,041,640  
               

Non-current assets

                   

Investments in equity-accounted investees

    199,246     165,668     174,511  

Long-term deposits and receivables

    14,540     15,962     15,768  

Surplus in defined benefit plan

    83,588     74,260     83,124  

Long-term derivative instruments

    16,136     5,764     7,619  

Non-current inventories

    62,972     *45,829     62,252  

Deferred tax assets

    130,461     110,230     111,157  

Property, plant and equipment

    3,917,512     3,353,936     3,686,240  

Intangible assets

    824,717     768,690     791,174  
               

Total non-current assets

    5,249,172     4,540,339     4,931,845  
               

Total assets

    8,436,149     7,755,565     7,973,485  
               
               

*
Reclassified

   

The notes to the condensed consolidated interim financial statements are an integral part thereof.

F-117


Table of Contents


Condensed Consolidated Unaudited Interim Statements of Financial Position (Continued)

 
  June 30
2014
  June 30
2013
  December 31
2013
 
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Current liabilities

                   

Short-term credit and current portion of long- term debt

    858,671     814,254     718,284  

Trade payables

    639,149     707,133     669,102  

Provisions

    37,549     43,102     38,485  

Derivatives and other payables

    623,141     485,941     500,453  

Current tax liabilities

    41,700     44,134     33,717  
               

Total current liabilities

    2,200,210     2,094,564     1,960,041  
               

Non-current liabilities

                   

Long-term debt

    1,782,082     950,297     1,243,638  

Debentures

    275,000     94,604     67,000  

Long-term derivative instruments

    6,799     9,294     6,582  

Deferred taxes

    189,622     219,034     220,877  

Employee benefits

    726,080     658,724     702,103  

Provisions

    100,524     69,112     94,570  
               

Total non-current liabilities

    3,080,107     2,001,065     2,334,770  
               

Total liabilities

    5,280,317     4,095,629     4,294,811  
               

Equity

                   

Share capital

    542,853     542,853     542,853  

Share premium

    133,633     133,633     133,633  

Capital reserves

    80,301     (2,484 )   84,715  

Retained earnings

    2,632,915     3,221,738     3,152,832  

Treasury shares

    (260,113 )   (260,113 )   (260,113 )
               

Total shareholder's equity

    3,129,589     3,635,627     3,653,920  
               

Non-controlling interests

    26,243     24,309     24,754  
               

Total equity

    3,155,832     3,659,936     3,678,674  
               

Total liabilities and equity

    8,436,149     7,755,565     7,973,485  
               
               

/s/ Nir Gilad

Nir Gilad
Chairman of the Board of Directors
  /s/ Stefan Borgas

Stefan Borgas
Chief Executive Officer
  /s/ Avi Doitchman

Avi Doitchman
Executive VP, CFO and Strategy

Approval date of the financial statements: August 6, 2014.

   

The accompanying notes are an integral part of these condensed consolidated interim
financial statements.

F-118


Table of Contents


Condensed Consolidated Unaudited Interim Statements of Income

 
  For the six-month
period ended
  For the three-month
period ended
  For the year
ended
 
 
  June 30
2014
  June 30
2013
  June 30
2014
  June 30
2013
  December 31
2013
 
 
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
 

Sales

    3,148,217     3,410,507     1,535,544     1,770,066     6,271,542  

Cost of sales

    2,042,867     2,033,647     993,447     1,052,176     3,861,572  
                       

Gross profit

    1,105,350     1,376,860     542,097     717,890     2,409,970  

Selling, transport and marketing expenses

    429,077     433,759     208,865     225,054     850,325  

General and administrative expenses

    148,847     138,786     74,554     71,144     281,491  

Research and development expenses, net

    44,207     41,369     21,546     20,867     82,870  

Other expenses

    170,586     8,901     166,990     8,297     110,194  

Other income

    (8,366 )   (1,858 )   (7,605 )   (367 )   (16,276 )
                       

Operating income

    320,999     755,903     77,747     392,895     1,101,366  
                       

Finance expenses

    91,585     65,214     65,783     24,923     158,403  

Finance income

    (22,208 )   (47,337 )   (14,991 )   (8,837 )   (131,548 )
                       

Financing expenses, net

    69,377     17,877     50,792     16,086     26,855  
                       

Share in earnings of equity-accounted investees

    11,743     7,412     9,079     8,168     25,685  
                       

Income before income taxes

    263,365     745,438     36,034     384,977     1,100,196  

Income taxes

    63,305     123,128     (32,079 )   68,349     280,023  
                       

Net income

    200,060     622,310     68,113     316,628     820,173  
                       
                       

Attributable to:

                               

The shareholders of the Company

    198,502     621,521     67,242     316,173     818,573  

Non-controlling interests

    1,558     789     871     455     1,600  
                       

Net income

    200,060     622,310     68,113     316,628     820,173  
                       
                       

 

 
  US $   US $   US $   US $   US $  

Earnings per share attributable to the shareholders of the Company:

                               

Basic earnings per share

    0.156     0.489     0.053     0.249     0.644  
                       
                       

Diluted earnings per share

    0.156     0.489     0.053     0.249     0.644  
                       
                       

   

The accompanying notes are an integral part of these condensed consolidated interim
financial statements.

F-119


Table of Contents


Condensed Consolidated Unaudited Interim Statements of Comprehensive Income

 
  For the six-month
period ended
  For the three-month
period ended
  For the year
ended
 
 
  June 30
2014
  June 30
2013
  June 30
2014
  June 30
2013
  December 31
2013
 
 
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
 

Net income

    200,060     622,310     68,113     316,628     820,173  
                       

Components of other comprehensive income that may be reclassified subsequently to net income

                               

Currency translation effects

    (8 )   (24,650 )   (3,957 )   9,713     49,142  

Gain (losses) on derivatives designated as a cash flow hedge

    (9,685 )   (1,404 )   (2,823 )   4,967     1,718  

Income tax relating to items that may be reclassified subsequently to income

        (539 )       (270 )   (898 )
                       

Total

    (9,693 )   (26,593 )   (6,780 )   14,410     49,962  
                       

Items that will not be reclassified to net income

                               

Actuarial gains (losses) from defined benefit plan

    (59,197 )   30,601     (32,298 )   15,997     47,282  

Income tax relating to items that will not be reclassified to net income

    14,103     (6,548 )   8,366     (2,855 )   (14,172 )
                       

Total

    (45,094 )   24,053     (23,932 )   13,142     33,110  
                       

Total comprehensive income

    145,273     619,770     37,401     344,180     903,245  
                       
                       

Attributable to:

                               

The shareholders of the Company

    143,784     618,719     36,576     343,702     901,749  

Non-controlling interests

    1,489     1,051     825     478     1,496  
                       

Total comprehensive income

    145,273     619,770     37,401     344,180     903,245  
                       
                       

   

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

F-120


Table of Contents

Condensed Consolidated Unaudited Interim Statements of Changes in Equity

 
  Attributable to the shareholders of the Company    
   
 
 
  Share
capital
  Share
premium
  Cumulative
translation
adjustment
  Capital
reserves
  Treasury
shares,
at cost
  Retained
earnings
  Total
shareholders'
equity
  Non-
controlling
interests
  Total
equity
 
 
  US$ thousands
 

For the six-month period ended June 30, 2014

                                                       

Balance as at January 1, 2014

   
542,853
   
133,633
   
19,183
   
65,532
   
(260,113

)
 
3,152,832
   
3,653,920
   
24,754
   
3,678,674
 

Share-based compensation

                5,226             5,226         5,226  

Dividends paid

                        (673,325 )   (673,325 )       (673,325 )

Taxes on share-based compensation

                (16 )           (16 )       (16 )

Comprehensive income

            61     (9,685 )       153,408     143,784     1,489     145,273  
                                       

Balance as at June 30, 2014

    542,853     133,633     19,244     61,057     (260,113 )   2,632,915     3,129,589     26,243     3,155,832  
                                       
                                       

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

F-121


Table of Contents

Condensed Consolidated Unaudited Interim Statements of Changes in Equity (Continued)

 
  Attributable to the shareholders of the Company    
   
 
 
  Share
capital
  Share
premium
  Cumulative
translation
adjustment
  Capital
reserves
  Treasury
shares,
at cost
  Retained
earnings
  Total
shareholders'
equity
  Non-
controlling
interests
  Total
equity
 
 
  US$ thousands
 

For the six-month period ended June 30, 2013

                                                       

Balance as at January 1, 2013

   
542,769
   
101,501
   
(30,063

)
 
75,375
   
(260,113

)
 
2,935,537
   
3,365,006
   
23,258
   
3,388,264
 

Exercise of options

    84     32,132         (32,216 )                    

Share-based compensation

                11,436             11,436         11,436  

Dividends paid

                        (359,373 )   (359,373 )       (359,373 )

Taxes on share-based compensation

                (161 )           (161 )       (161 )

Comprehensive income

            (24,912 )   (1,943 )       645,574     618,719     1,051     619,770  
                                       

Balance as at June 30, 2013

    542,853     133,633     (54,975 )   52,491     (260,113 )   3,221,738     3,635,627     24,309     3,659,936  
                                       
                                       

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

F-122


Table of Contents

Condensed Consolidated Unaudited Interim Statements of Changes in Equity (Continued)

 
  Attributable to the shareholders of the Company    
   
 
 
  Share
capital
  Share
premium
  Cumulative
translation
adjustment
  Capital
reserves
  Treasury
shares,
at cost
  Retained
earnings
  Total
shareholders'
equity
  Non-
controlling
interests
  Total
equity
 
 
  US$ thousands
 

For the three-month period ended June 30, 2014

                                                       

Balance as at April 1, 2014

   
542,853
   
133,633
   
23,155
   
61,257
   
(260,113

)
 
2,680,945
   
3,181,730
   
25,418
   
3,207,148
 

Share-based payments

                2,627             2,627         2,627  

Dividends to equity holders

                        (91,340 )   (91,340 )       (91,340 )

Taxes on share-based compensation

                (4 )           (4 )       (4 )

Comprehensive income

            (3,911 )   (2,823 )       43,310     36,576     825     37,401  
                                       

Balance as at June 30, 2014

    542,853     133,633     19,244     61,057     (260,113 )   2,632,915     3,129,589     26,243     3,155,832  
                                       
                                       

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

F-123


Table of Contents

Condensed Consolidated Unaudited Interim Statements of Changes in Equity (Continued)

 
  Attributable to the shareholders of the Company    
   
 
 
  Share
capital
  Share
premium
  Cumulative
translation
adjustment
  Capital
reserves
  Treasury
shares,
at cost
  Retained
earnings
  Total
shareholders'
equity
  Non-
controlling
interests
  Total
equity
 
 
  US$ thousands
 

For the three month period ended June 30, 2013

                                                       

Balance as at April 1, 2013

   
542,853
   
133,633
   
(64,665

)
 
42,262
   
(260,113

)
 
3,105,052
   
3,499,022
   
23,831
   
3,522,853
 

Share-based payments

                5,697             5,697         5,697  

Dividends to equity holders

                        (212,629 )   (212,629 )       (212,629 )

Taxes on share-based compensation

                (165 )           (165 )       (165 )

Comprehensive income

            9,690     4,697         329,315     343,702     478     344,180  
                                       

Balance as at June 30, 2013

    542,853     133,633     (54,975 )   52,491     (260,113 )   3,221,738     3,635,627     24,309     3,659,936  
                                       
                                       

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

F-124


Table of Contents

Condensed Consolidated Unaudited Interim Statements of Changes in Equity (Continued)

 
  Attributable to the shareholders of the Company    
   
 
 
  Share
capital
  Share
premium
  Cumulative
translation
adjustment
  Capital
reserves
  Treasury
shares,
at cost
  Retained
earnings
  Total
shareholders'
equity
  Non-
controlling
interests
  Total
equity
 
 
  US$ thousands
 

For the year ended December 31, 2013

                                                       

Balance as at January 1, 2013

   
542,769
   
101,501
   
(30,063

)
 
75,375
   
(260,113

)
 
2,935,537
   
3,365,006
   
23,258
   
3,388,264
 

Exercise of options

    84     32,132         (32,216 )                    

Share-based compensation

                21,776             21,776         21,776  

Dividends paid

                        (634,388 )   (634,388 )       (634,388 )

Taxes on shares-based compensation

                (223 )           (223 )       (223 )

Comprehensive income

            49,246     820         851,683     901,749     1,496     903,245  
                                       

Balance as at December 31, 2013

    542,853     133,633     19,183     65,532     (260,113 )   3,152,832     3,653,920     24,754     3,678,674  
                                       
                                       

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

F-125


Table of Contents


Condensed Consolidated Unaudited Interim Statements of Cash Flows

 
  For the six-month
period ended
  For the three-month
period ended
  For the
year ended
 
 
  June 30
2014
  June 30
2013
  June 30
2014
  June 30
2013
  December 31
2013
 
 
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
 

Cash flows from operating activities

                               

Net income

    200,060     622,310     68,113     316,628     820,173  

Adjustments for:

                               

Depreciation and amortization

    177,346     163,928     91,243     81,428     347,741  

Interest expenses, net

    53,925     19,762     41,478     8,139     41,951  

Share in earnings of equity-accounted investees

    (11,743 )   (7,412 )   (9,079 )   (8,168 )   (25,685 )

Loss (gain) on sale of property, plant and equipment, net

    (6,380 )   258     (6,179 )   439     (1,958 )

Share-based compensation

    5,226     11,436     2,627     5,697     21,776  

Revaluation of assets and liabilities denominated in foreign currencies

    1,921     13,842     4,633     4,564     29,541  

Gain on achievement of control of an associated company

                    (1,827 )

Income tax expenses

    63,305     123,128     (32,079 )   68,349     280,023  
                       

    483,660     947,252     160,757     477,076     1,511,735  

Change in inventories

   
64,531
   
53,188
   
(18,282

)
 
42,693
   
4,061
 

Change in trade and other receivables

    (244,052 )   (194,803 )   (24,875 )   38,229     19,614  

Change in trade and other payables

    (39,447 )   (35,189 )   (87,006 )   (45,593 )   (84,903 )

Change in provisions and employee benefits

    118,000     (13,170 )   153,804     (9,832 )   53,782  
                       

    382,692     757,278     184,398     502,573     1,504,289  

Income taxes paid

   
(77,471

)
 
(120,635

)
 
(53,082

)
 
(64,591

)
 
(333,794

)

Interest received

    952     1,414     495     714     2,380  

Interest paid

    (19,367 )   (21,231 )   (12,343 )   (13,962 )   (45,966 )
                       

Net cash provided by operating activities

    286,806     616,826     119,468     424,734     1,126,909  
                       

Cash flows from investing activities

                               

Proceeds from sale of property, plant and equipment

    8,160     161     6,198     161     3,304  

Short-term loans and deposits, net

    14,791     39,650     (2,304 )   41,753     38,770  

Business acquisitions, net of cash acquired

    (71,994 )   (59,479 )   (17,855 )   (14,019 )   (63,057 )

Dividends from equity-accounted investees

    11,567     14,942     2,800     3,407     23,168  

Purchases of property, plant and equipment

    (411,838 )   (382,324 )   (192,696 )   (199,297 )   (826,588 )

Purchases of intangible assets

    (35,789 )   (4,809 )   (15,534 )   (3,615 )   (22,093 )

Investments in and loans to equity-accounted investees

    (22,614 )                

Proceeds from sale of long-term deposits

    1,158     928     653     466     7,164  
                       

Net cash used in investing activities

    (506,559 )   (390,931 )   (218,738 )   (171,144 )   (839,332 )
                       

Cash flows from financing activities

                               

Dividend paid to the shareholders

    (673,325 )   (359,373 )   (174,195 )   (359,373 )   (634,388 )

Receipt of long-term debt

    847,854     199,438     232,718     134,438     674,736  

Repayment of long-term debt

    (183,712 )   (155,361 )   (147,452 )   (122,656 )   (613,457 )

Short-term credit from banks and others, net

    219,172     124,799     119,211     101,101     263,119  
                       

Net cash provided by (used in) financing activities

    209,989     (190,497 )   30,282     (246,490 )   (309,990 )
                       

Net change in cash and cash equivalents

    (9,764 )   35,398     (68,988 )   7,100     (22,413 )

Cash and cash equivalents as at beginning of the period

    188,340     206,067     247,819     230,519     206,067  

Net effect of currency translation on cash and cash equivalents

    (799 )   (2,467 )   (1,054 )   1,379     4,686  
                       

Cash and cash equivalents as at end of the period

    177,777     238,998     177,777     238,998     188,340  
                       
                       

   

The accompanying notes are an integral part of these condensed consolidated interim
financial statements.

F-126


Table of Contents


Notes to the condensed consolidated interim financial statements

as at June 30, 2014 (Unaudited)

Note 1—The Reporting Entity

        Israel Chemicals Ltd. (hereinafter—"the Company" or "ICL"), is a Company domiciled and incorporated in Israel, the shares of which are traded on the Tel-Aviv Stock Exchange. The address of the Company's registered office is 23 Aranha St., Tel-Aviv, Israel. The Company and its subsidiaries, associated companies and joint ventures (hereinafter—"the Group") are a leading specialty minerals company that operates a unique, integrated business model. The Company extracts raw materials and utilizes sophisticated processing and product formulation technologies to add value to customers in three attractive end-markets: agriculture, food and engineered materials. These three end-markets constitute over 90% of the Company's present revenues. The Company's operations are organized into three segments: (1) Fertilizers, which operates the raw material extraction for the Company and markets potash, phosphates and specialty fertilizers; (2) Industrial Products, which primarily extracts bromine from the Dead Sea and produces and markets bromine and phosphorus compounds for the electronics, construction, oil & gas and automotive industries and (3) Performance Products, which mainly produces, markets and sells a broad range of downstream phosphate-based food additives and industrial intermediates. The Company is a subsidiary of Israel Corporation Ltd.

        The Company's principal assets include: Access to one of the world's richest, longest-life and lowest-cost sources of potash and bromine (the Dead Sea). Access to potash mines in the United Kingdom and Spain. Bromine compounds processing facilities located in Israel, the Netherlands and China. A unique integrated phosphate value chain, from phosphate rock mines in the Negev Desert in Israel to our of value-added products in Israel, Europe, U.S., Brazil and China. An extensive global logistics and distribution network with operations in over 30 countries and a focused and highly experienced group of technical experts developing production processes, new applications, formulations and products for our three key end-markets—agriculture, food and engineered materials. The Company and some of the Group companies were declared a monopoly with respect to some of the products they manufacture and/or sell in Israel.

        ICL operates in the markets for potash, bromine, pure phosphoric acid, special phosphates, bromine-based and phosphorus-based flame retardants and chemicals for the prevention of the spreading of fires. Potash and phosphates are main food prototypes in the areas of fertilizers. Bromine is used in a wide range of applications, primarily as a basic component of flame retardants.

        ICL's products are used mainly in the areas of agriculture, electronics, food, fuel and gas exploration, water purification and desalination, detergents, paper, cosmetics, medicines, vehicles, aluminum and others.

        The Group's overseas operations consist mainly of the production of products that are integrated with or based on the activities of the companies in Israel or in closely related fields. About 95% of the Group's products are sold to customers outside of Israel.

Note 2—Basis of Preparation of the Financial Statements

A.    Statement of compliance with International Financial Reporting Standards (IFRS)

        The condensed consolidated interim financial statements were prepared in accordance with IAS 34, "Interim Financial Reporting" and do not include all of the information required in complete, annual financial statements. These statements should be read together with the financial statements as at and for the year ended December 31, 2013 (hereinafter—"the Annual Financial Statements").

F-127


Table of Contents


Notes to the condensed consolidated interim financial statements (Continued)

as at June 30, 2014 (Unaudited)

Note 2—Basis of Preparation of the Financial Statements (Continued)

        The condensed consolidated interim financial statements were approved for publication by the Company's Board of Directors on August 6, 2014.

B.    Functional currency and presentation currency

        Items included in the condensed consolidated interim financial statements of the Company and each of its subsidiaries are measured using the currency of the primary economic environment in which each company operates. The consolidated financial statements are presented in United States Dollars ("US Dollars"; $), which is the functional currency of the Company and the majority of its subsidiaries.

C.    Use of estimates

        In preparation of the condensed consolidated interim financial statements in accordance with IFRS, as issued by the International Accounting Standards Board (IASB), Company management is required to use judgment when making estimates and assumptions that affect implementation of the policies and the amounts of assets, liabilities, income and expenses. It is clarified that the actual results are likely to be different from these estimates.

        Management's judgment, at the time of implementing the Group's accounting policies and the main assumptions used in the estimates involving uncertainty, are consistent with those used in the Annual Financial Statements.

Note 3—Significant Accounting Policies

A.
The Company's accounting policies in these condensed consolidated interim financial statements are the policies that were applied in the Annual Financial Statements as at December 31, 2013, except for that stated in Section B, below.

B.    Initial application of new accounting standards

        IFRIC Interpretation 21 "Levies" (hereinafter—"the Interpretation").     The Interpretation provides guidelines in connection with the accounting treatment of a liability to pay government levies that are within the scope of IAS 37 "Provisions, Contingent Liabilities and Contingent Assets", as well as with respect to government levies that are not within the scope of IAS 37 since the timing of their repayment and the amounts thereof are certain. A "levy" is defined as an outflow of resources imposed on an entity by the government through legislation and/or regulation. The Interpretation provides that a liability for payment of a levy is to be recognized upon occurrence of the event that creates the payment obligation, even in cases where the entity has no practical possibility of avoiding the event.

        The Interpretation applies to reporting periods commencing on January 1, 2014.

        The impact of the above-mentioned Interpretation on the condensed consolidated interim financial statements is not material.

F-128


Table of Contents


Notes to the condensed consolidated interim financial statements (Continued)

as at June 30, 2014 (Unaudited)

Note 3—Significant Accounting Policies (Continued)

C.    Indices and exchange rates

        Data regarding the representative exchange rates and the Consumer Price Index (CPI) are as follows:

 
  Consumer
Price
Index
  Dollar-NIS
exchange
rate
  Dollar-EUR
exchange
rate
 

Rates of change for the six months ended:

                   

June 30, 2014

    (0.3 )%   (1.0 )%   0.9 %

June 30, 2013

    1.3 %   (3.1 )%   1.0 %

Rates of change for the three months ended:

                   

June 30, 2014

    0.2 %   (1.4 )%   1.1 %

June 30, 2013

    1.3 %   (0.8 )%   (2.1 )%

Rates of change for the year ended December 31, 2013

    1.8 %   (7.0 )%   (4.3 )%

Note 4—Operating Segments

A.    General

        The basis for the breakdown into segments and the measurement basis for the income (loss) of the segments is the same as that presented in Note 5 "Operating Segments" in the annual financial statements.

F-129


Table of Contents

Notes to the condensed consolidated interim financial statements (Continued)

as at June 30, 2014 (Unaudited)

Note 4—Operating Segments (Continued)

B.    Operating segment data

 
  Fertilizers    
   
   
   
   
 
 
  Industrial
products
  Performance
products
  Other
activities
   
   
 
 
  Potash   Phosphate   Eliminations   Total   Eliminations   Consolidated  
 
  US$ thousands
 

For the six-month period ended June 30, 2014

                                                       

Sales to external parties

    832,642     803,543         1,636,185     687,584     761,082     63,366         3,148,217  

Inter-segment sales

    103,006     72,681     (57,832 )   117,855     8,590     38,500     14,679     (179,624 )    
                                       

Total sales

    935,648     876,224     (57,832 )   1,754,040     696,174     799,582     78,045     (179,624 )   3,148,217  
                                       
                                       

Income from ordinary activities

    277,233     51,125     2,681     331,039     (79,305 )   89,851     (4,887 )         336,698  
                                           

Unallocated expenses and intercompany eliminations

                                                    (15,699 )
                                                       

Operating income

                                                    320,999  

Financing expenses

                                                   
(91,585

)

Financing income

                                                    22,208  

Share in profits of investee companies accounted for using the equity method of accounting

                                                    11,743  
                                                       

Income before taxes on income

                                                    263,365  
                                                       
                                                       

Capital expenditures

    222,377     64,222         286,599     46,238     74,762     4,435         412,034  

Unallocated capital expenditures

                                                    34,989  
                                                       

Total capital expenditures

                                                    447,023  
                                                       
                                                       

Depreciation and amortization

    53,935     60,213         114,148     32,622     25,711     3,186         175,667  

Unallocated depreciation and amortization

                                                    1,679  
                                                       

Total depreciation and amortization

                                                    177,346  
                                                       
                                                       

F-130


Table of Contents

Notes to the condensed consolidated interim financial statements (Continued)

as at June 30, 2014 (Unaudited)

Note 4—Operating Segments (Continued)

B.    Operating segment data (Continued)

 
  Fertilizers    
   
   
   
   
 
 
  Industrial
products
  Performance
products
  Other
activities
   
   
 
 
  Potash   Phosphate   Eliminations   Total   Eliminations   Consolidated  
 
  US$ thousands
 

For the six-month period ended June 30, 2013

                                                       

Sales to external parties

    1,043,225     896,627         1,939,852     681,701     725,013     63,941         3,410,507  

Inter-segment sales

    120,900     80,545     (60,535 )   140,910     9,486     37,985     21,574     (209,955 )    
                                       

Total sales

    1,164,125     977,172     (60,535 )   2,080,762     691,187     762,998     85,515     (209,955 )   3,410,507  
                                       
                                       

Income from ordinary activities

    489,002     108,348     1,479     598,849     97,824     87,376     (11,453 )         772,596  
                                           

Unallocated expenses and intercompany eliminations

                                                    (16,693 )
                                                       

Operating income

                                                    755,903  

Financing expenses

                                                   
(65,214

)

Financing income

                                                    47,337  

Share in profits of investee companies accounted for using the equity method of accounting

                                                    7,412  
                                                       

Income before taxes on income

                                                    745,438  
                                                       
                                                       

Capital expenditures

    252,142     64,266         316,408     78,239     70,127     4,594         469,368  

Unallocated capital expenditures

                                                    3,619  
                                                       

Total capital expenditures

                                                    472,987  
                                                       
                                                       

Depreciation and amortization

    52,838     52,538         105,376     32,195     22,648     3,157         163,376  

Unallocated depreciation and amortization

                                                    552  
                                                       

Total depreciation and amortization

                                                    163,928  
                                                       
                                                       

F-131


Table of Contents

Notes to the condensed consolidated interim financial statements (Continued)

as at June 30, 2014 (Unaudited)

Note 4—Operating Segments (Continued)

B.    Operating segment data (Continued)

 
  Fertilizers    
   
   
   
   
 
 
  Industrial
products
  Performance
products
  Other
activities
   
   
 
 
  Potash   Phosphate   Eliminations   Total   Eliminations   Consolidated  
 
  US$ thousands
 

For the three-month period ended June 30, 2014

                                                       

Sales to external parties

    387,035     374,350         761,385     354,889     389,330     29,940         1,535,544  

Inter-segment sales

    57,359     37,092     (34,453 )   59,998     4,436     19,194     8,283     (91,911 )    
                                       

Total sales

    444,394     411,442     (34,453 )   821,383     359,325     408,524     38,223     (91,911 )   1,535,544  
                                       
                                       

Income from ordinary activities

    131,147     20,934     (874 )   151,207     (113,605 )   49,389     (1,782 )         85,209  
                                           

Unallocated expenses and intercompany eliminations

                                                    (7,462 )
                                                       

Operating income

                                                    77,747  

Financing expenses

                                                   
(65,783

)

Financing income

                                                    14,991  

Share in profits of investee companies accounted for using the equity method of accounting

                                                    9,079  
                                                       

Income before taxes on income

                                                    36,034  
                                                       
                                                       

Capital expenditures

    95,682     37,407         133,089     26,282     18,527     2,768         180,666  

Unallocated capital expenditures

                                                    15,569  
                                                       

Total capital expenditures

                                                    196,235  
                                                       
                                                       

Depreciation and amortization

    26,540     32,108         58,648     16,371     13,261     1,615         89,895  

Unallocated depreciation and amortization

                                                    1,348  
                                                       

Total depreciation and amortization

                                                    91,243  
                                                       
                                                       

F-132


Table of Contents

Notes to the condensed consolidated interim financial statements (Continued)

as at June 30, 2014 (Unaudited)

Note 4—Operating Segments (Continued)

B.    Operating segment data (Continued)

 
  Fertilizers    
   
   
   
   
 
 
  Industrial
products
  Performance
products
  Other
activities
   
   
 
 
  Potash   Phosphate   Eliminations   Total   Eliminations   Consolidated  
 
  US$ thousands
 

For the three-month period ended June 30, 2013

                                                       

Sales to external parties

    526,472     477,062         1,003,534     348,789     384,918     32,825         1,770,066  

Inter-segment sales

    66,461     40,109     (38,191 )   68,379     4,023     21,246     10,853     (104,501 )    
                                       

Total sales

    592,933     517,171     (38,191 )   1,071,913     352,812     406,164     43,678     (104,501 )   1,770,066  
                                       
                                       

Income from ordinary activities

    248,250     59,754     (1,667 )   306,337     49,655     51,945     (2,497 )         405,440  
                                           

Unallocated expenses and intercompany eliminations

                                                    (12,545 )
                                                       

Operating income

                                                    392,895  

Financing expenses

                                                   
(24,923

)

Financing income

                                                    8,837  

Share in profits of investee companies accounted for using the equity method of accounting

                                                    8,168  
                                                       

Income before taxes on income

                                                    384,977  
                                                       
                                                       

Capital expenditures

    140,330     37,363         177,693     40,010     9,491     2,439         229,633  

Unallocated capital expenditures

                                                    3,483  
                                                       

Total capital expenditures

                                                    233,116  
                                                       
                                                       

Depreciation and amortization

    25,197     26,979         52,176     15,675     11,679     1,608         81,138  

Unallocated depreciation and amortization

                                                    290  
                                                       

Total depreciation and amortization

                                                    81,428  
                                                       
                                                       

F-133


Table of Contents

Notes to the condensed consolidated interim financial statements (Continued)

as at June 30, 2014 (Unaudited)

Note 4—Operating Segments (Continued)

B.    Operating segment data (Continued)

 
  Fertilizers    
   
   
   
   
 
 
  Industrial
products
  Performance
products
  Other
activities
   
   
 
 
  Potash   Phosphate   Eliminations   Total   Eliminations   Consolidated  
 
  US$ thousands
 

For the year ended December 31, 2013

                                                       

Sales to external parties

    1,797,360     1,584,420         3,381,780     1,277,432     1,496,601     115,729         6,271,542  

Inter-segment sales

    229,237     169,815     (125,567 )   273,485     19,253     78,095     38,980     (409,813 )    
                                       

Total sales

    2,026,597     1,754,235     (125,567 )   3,655,265     1,296,685     1,574,696     154,709     (409,813 )   6,271,542  
                                       
                                       

Income from ordinary activities

    740,342     79,494     1,235     821,071     114,525     195,797     (16,574 )         1,114,819  
                                           

Unallocated expenses and intercompany eliminations

                                                    (13,453 )
                                                       

Operating income

                                                    1,101,366  

Financing expenses

                                                   
(158,403

)

Financing income

                                                    131,548  

Share in profits of investee companies accounted for using the equity method of accounting

                                                    25,685  
                                                       

Income before taxes on income

                                                    1,100,196  
                                                       
                                                       

Capital expenditures

    551,508     141,983         693,491     141,338     93,394     8,860         937,083  

Unallocated capital expenditures

                                                    10,180  
                                                       

Total capital expenditures

                                                    947,263  
                                                       
                                                       

Depreciation and amortization

    100,533     117,895         218,428     75,071     46,580     6,323         346,402  

Unallocated depreciation and amortization

                                                    1,339  
                                                       

Total depreciation and amortization

                                                    347,741  
                                                       
                                                       

F-134


Table of Contents


Notes to the condensed consolidated interim financial statements (Continued)

as at June 30, 2014 (Unaudited)

Note 5—Financial Instruments and Risk Management

A.    Fair value of financial instruments

        The Group's financial instruments mostly include non-derivative assets: cash and cash equivalents, investments, short-term deposits and loans, receivables and other current-receivable, long-term investments and receivables; non-derivative financial liabilities: short-term credit, payables and other current liabilities, long-term loans and other long-term liabilities; as well as derivative financial instruments.

        Due to their nature, the fair value of the financial instruments included in the working capital of the Group is generally identical or approximates their carrying value in the books. The fair value of the long-term deposits and receivables and the long-term liabilities also approximates their carrying value in the books, as these financial instruments bear interest at a rate which approximates the accepted interest market rate.

        The following table details the book value and the fair value of financial instrument groups presented in the financial statements not in accordance with their fair value

 
  As at June 30, 2014   As at June 30, 2013   As at December 31, 2013  
 
  Carrying
amount
  Fair
value
  Carrying
amount
  Fair
value
  Carrying
amount
  Fair
value
 
 
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
  US$ thousands
 

Debentures bearing fixed interest

                                     

Marketable

            345,506     352,051     147,848     148,711  

Non-marketable

    349,680     350,990     68,022     73,092     68,342     69,889  
                           

    349,680     350,990     413,528     425,143     216,190     218,600  
                           
                           

B.    Hierarchy of fair value

        The following table presents an analysis of the financial instruments measured by fair value, using the valuation method.

        The following levels were defined:

        Level 1: Quoted (unadjusted) prices in an active market for identical instruments

        Level 2: Observed data in the market (directly or indirectly) not included in Level 1 above.

 
  As at June 30, 2014  
 
  Level 1   Level 2   Total  
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Securities held for trading purposes

    29,233         29,233  

Derivatives used for hedging, net

        29,698     29,698  
               

    29,233     29,698     58,931  
               
               

F-135


Table of Contents


Notes to the condensed consolidated interim financial statements (Continued)

as at June 30, 2014 (Unaudited)

Note 5—Financial Instruments and Risk Management (Continued)

B.    Hierarchy of fair value (Continued)

 
  As at June 30, 2013  
 
  Level 1   Level 2   Total  
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Securities held for trading purposes

    36,364         36,364  

Derivatives used for hedging, net

        33,209     33,209  
               

    36,364     33,209     69,573  
               
               

 

 
  As at December 31, 2013  
 
  Level 1   Level 2   Total  
 
  US$ thousands
  US$ thousands
  US$ thousands
 

Securities held for trading purposes

    36,140         36,140  

Derivatives used for hedging, net

        51,491     51,491  
               

    36,140     51,491     87,631  
               
               

Note 6—Additional Information

        1.     On February 11, 2014, the Company's Board of Directors decided to distribute a one-time dividend in the amount of $500 million (the net dividend, less the share of a subsidiary, amounts to $499.1 million). The dividend was distributed on March 26, 2014.

        2.     On March 18, 2014, the Company's Board of Directors decided to distribute a dividend in the amount of $83 million (the net dividend, less the share of a subsidiary, amounts to $82.9 million). The dividend was distributed on May 27, 2014.

        3.     On May 14, 2014, the Company's Board of Directors decided to distribute a dividend, in the amount of $91.5 million (the net dividend, less the share of a subsidiary, is $91.3 million), about $0.07 per share. The dividend was distributed on June 25, 2014.

        4.     On August 6, 2014, the Company's Board of Directors decided to distribute a dividend, in the amount of $47 million (the net dividend, less the share of a subsidiary, is $46.9 million), about $0.04 per share. The dividend will be distributed on September 17, 2014.

        5.     Further to that stated in Note 17 to the annual financial statements, in January 2014, the Company received the proceeds from the private placement in the United States of unregistered debentures. The amount of the issuance is about $275 million, for a period of 7-12 years, as follows: the amount of about $84 million bearing fixed interest at an annual rate of 4.55% for a period of 7 years, the amount of about $145 million bearing fixed interest at an annual rate of 5.16% for a period of 10 years and the amount of about $46 million bearing fixed interest at an annual rate of 5.31% for a period of 12 years.

        6.     In the first quarter of 2014, the Company included a provision, in the amount of about $51 million, which was based on principles agreed to in of assessment hearings between subsidiaries in Europe and the relevant tax authorities. During the second quarter, an assessment agreement was signed, the results of which correspond with the principles used in calculating the said provision.

        7.     In May 2014, the Company signed an agreement with a European bank whereby the bank provided a credit framework, in the amount of €50 million. This credit framework is for a period of

F-136


Table of Contents


Notes to the condensed consolidated interim financial statements (Continued)

as at June 30, 2014 (Unaudited)

Note 6—Additional Information (Continued)

5 years and is to be repaid in full at the end of the period. This credit framework bears variable interest on the basis of the Euribor plus a margin of 0.95%-1.25%. A non-utilization commission will be charged at the rate of 0.35% per year. As at the date of the report, the credit framework had not been used. The financial covenants in respect of this credit framework are the same as the financial covenants detailed in Note 17 to the annual financial statements.

        8.     In June 2014, the Company signed loan agreements with a number of international institutional entities, in the aggregate amount of about €57 million and about $45 million. The proceeds of these loans were received subsequent to the period of the report, in July 2014. The loans are to be repaid in a period of between five to ten years, where some of the loans bear fixed interest in the range of 2.1%-3.75%, some of them bear variable interest on the basis of Libor + 1.55% and some of them bear variable interest on the basis of the Euribor plus a margin of 1.4%-1.7%. The financial covenants in respect of these loans are the same as the financial covenants detailed in Note 17 to the annual financial statements.

        9.     In the period of the report, the Company entered into an undertaking with a European bank whereby the bank provided a credit framework in the amount of €100 million and $100 million. This credit framework is for a period of six years and is to be repaid in full at the end of the period. The credit framework in euro replaces the credit framework provided by the bank to the Company in November 2011 which has not yet been utilized. For details – see Note 17 to the annual financial statements. The dollar framework bears variable interest on the basis of Libor + 0.9%-1.4%, the euro framework bears variable interest on the basis of Euribor + 0.9%-1.4%. A non-utilization commission will be charged at the rate of 0.35% per year. As at the date of the report, about $63 million had been utilized out of the dollar credit framework. The financial covenants in respect of this credit framework are the same as the financial covenants detailed in Note 17 to the annual financial statements. As at the date of the report, the Company was in compliance with the financial covenants.

        10.   Further to that stated in Note 23 to the annual financial statements, regarding receipt of phosphate mining permits in the Barir Field, on April 3, 2014, the Company was informed that the Minister of Health, Ms. Yael German, contacted the Head of the Planning Administration in the Ministry of the Interior, Ms. Binat Schwartz, and notified her that after reviewing the opinion of the expert appointed by the Ministry of Health, she had decided to oppose the possibility of mining in the Barir Field, including the test mining. The Company disagrees with the Minister of Health's interpretation of the opinion. In the Company's estimation and based on its understanding of the said opinion, this opinion does not contradict the Company's position that the mining activities in the Barir Field do not involve any risks to the environment or to the population.

        11.   Further to rejection by the Court of the petition of the Hotels Union for issuance of an Interim Order prohibiting raising of the dikes, and the hearing scheduled to be held on September 15, 2014, as stated in Note 23 to annual financial statements, on May 1, 2014, some of the hotels in the Dead Sea area filed a separate administrative petition and a request for issuance of an Interim Order (in the District Court for Jerusalem) against the Regional Planning Board and the Company for Protection of the Dead Sea (the respondents), instructing with respect to the issuance of Injunctive Orders prohibiting the Regional Planning Board from hearing the request for a building permit for raising the dikes in the area of Nevei Zohar and a prohibition against performance of the work on the Nevei Zohar beaches by the Company for Protection of the Dead Sea. On June 1, 2014, a hearing was held wherein the Court gave the force of a court decision to the compromise proposed as part of the separate petition, whereby the Company for Protection of the Dead Sea will be required to provide the

F-137


Table of Contents


Notes to the condensed consolidated interim financial statements (Continued)

as at June 30, 2014 (Unaudited)

Note 6—Additional Information (Continued)

petitioners documents and plans in connection with the request for a building permit, and the petitioners are to submit their responses to the plans, as stated, which will be restricted solely to the matter of the timetables and the manner of execution of the plan, and where no objections will be heard regarding the height of the dike and the height of the water level. No interim order was issued.

        12.   Further to that stated in Note 23 to the Company's annual financial statements, on March 18, 2014, the Company's subsidiary, Dead Sea Works ("DSW") notified the Government of Israel ("the State") with respect to filing of a statement of claim in the framework of an arbitration proceeding concerning violation of the concession agreement and the request of DSW to appoint an arbitrator on behalf of the State. On March 27, 2014, the Ministry of Finance rejected the request of DSW to appoint an arbitrator on behalf of the State. As a result, on April 30, 2014, DSW filed a request in the District Court in Jerusalem to exercise its authority pursuant to Section 8 of the Arbitration Law, 1968, and to order the appointment of an arbitrator on behalf of the State for purposes of conducting an arbitration proceeding between DSW and the State pursuant to the mandatory arbitration clause between the parties. Subsequent to the period of the report, on July 10, 2014, a court hearing was held, however the Court's decision has not yet been issued.

        13.   Further to that stated in Note 23 to the annual financial statements, on May 19, 2014, a partial arbitration decision was received regarding the royalties issue (hereafter – "the Arbitrators' Decision"). Based on the principles of the decision received, Dead Sea Works Ltd. ("DSW") is required to pay the State royalties on the sale of downstream products manufactured by companies that are controlled by ICL that have production plants located both in and outside the Dead Sea area, including outside Israel. The royalties are to be paid according to the value of the downstream products, which will be set according to the formula described in Section 15(a)(2) of the Concession Deed, based on the selling price of the downstream products to unrelated third parties less the deductions set forth in subsections (I), (II) and (III) of that Section. Regarding metal magnesium, it was decided that the State of Israel and DSW are to exhaust their discussions on the subject of the royalties to be paid by DSW on metal magnesium, and if no agreement is reached the matter is to be returned to arbitration.

        The Arbitrators' Decision was issued with respect to fundamental determinations with respect to the obligation to pay royalties on downstream products and does not include reference to the financial calculations arising from the decision. These financial calculations will be discussed in the next phase of the arbitration. In the second quarter of 2014, in accordance with the Company's estimate, based on its legal advisors, a provision was recorded in the amount of about $135 million due to implementation of the partial arbitration award for the prior periods for the years 2000 through 2013. The amount of this provision includes, among other things, interest and is net of the tax effect. In addition, as a result of the Arbitrators' Decision, the current expense in the period of the report in respect of royalties increased by about $6 million. The Arbitrators' Decision is partial and the financial calculations with respect to the manner of implementation of the Decision have not yet been provided. Therefore, the Company's estimation is based on various assumptions regarding the manner of calculating the royalties deriving from the partial Arbitrators' Decision and reflects the best estimate of the expenditure that will be required to settle the liability presently, at the end of the period of the report. The final amount that will be determined by the arbitrators at the end of the second stage of the arbitration after the arbitration panel determines the financial calculations, as noted, may differ, even materially, from the amount of the provision. In the second stage of the arbitration, which will deal with determination of the amounts of the royalties, the Company intends to claim that the correct amount of the royalties is significantly lower than the amount stated.

F-138


Table of Contents


Notes to the condensed consolidated interim financial statements (Continued)

as at June 30, 2014 (Unaudited)

Note 6—Additional Information (Continued)

        14.   Subsequent to the period of the report, on August 6, 2014, the Company's Board of Directors approved an issuance of up to about 4,384,540 non-marketable options, for no consideration, exercisable for about 4,384,540 of the Company's shares, and up to about 1,025,449 restricted shares, to about 450 ICL officers and senior employees. The issuance includes a private placement of 367,294 options and 85,907 restricted shares to the Company's CEO, which is subject to approval by the General Meeting of the Company's shareholders. This grant format of the options plan includes a "cap" for the value of a share where if as at the exercise date the closing price of a Company share is higher than twice the exercise price ("the Share Value Cap"), the number of the exercised shares will be reduced so that the product of the exercised shares actually issued to the offeree multiplied by the share closing price will equal the product of the number of exercised options multiplied by the Share Value Cap.

        The options and restricted shares will vest in three equal tranches: one third at the end of 24 months from December 1, 2014, one third at the end of 36 months from December 1, 2014 and one third at the end of 48 months from December 1, 2014. The expiration date of the options in the first tranche is at the end of 48 months from December 1, 2014, the expiration date of the options in the second tranche is at the end of 60 months from December 1, 2014 and the expiration date of the options in the third tranche is at the end of 72 months from December 1, 2014.

        Upon exercise, every option may be converted into one ordinary share of NIS 1 par value of the Company, subject to the adjustment set forth above. The ordinary shares issued as a result of exercise of the options have the same rights as the Company's ordinary shares, immediately upon their issuance. The options issued to the employees in Israel are covered by the provisions of Section 102 of the Israeli Income Tax Ordinance (New Version) and the regulations promulgated thereunder. The Company elected that the issuance will be made through a trustee, under the Capital Gains Track.

        The exercise price is about $8.4 for each option, linked to the CPI that is known as of the date of payment, which is the exercise date. In case of distribution of a dividend by the Company, the exercise price is reduced, on the ex dividend date, by the amount of the dividend per share (gross), based on the amount thereof in shekels on the effective date. The options are not marketable and may not be transferred.

        The fair value of the options was estimated by means of application of a binomial options pricing model and is about $8.4 million as of the approval date of the financial statements. The expected volatility for the first, second and third tranches is about 29.37%, 31.24% and 40.77%, respectively, which was determined on the basis of the historical volatility in the Company's share prices. The expected life of the options was determined on the basis of Management's estimate of the period the employees will hold the options, taking into consideration their position with the Company and the Company's past experience regarding the turnover of employees. The risk-free interest rate was determined on the basis of the yield to maturity of shekel-denominated Government debentures, with a remaining life equal to the anticipated life of the options.

        The fair value of the said restricted shares is $8.4 million. The value of the restricted shares offered to the offerees was determined based on the closing price on the stock market on the last trading day prior to the approval date of the Board of Directors.

        The cost of the benefit embedded in the above-mentioned plan will be recognized in the statement of income over the vesting period.

        In addition, a long-term remuneration plan was approved for about 11,800 non-management Company employees that are not included in the plan for issuance of options and restricted shares, as described above, in the aggregate scope of up to about $17 million.

F-139


Table of Contents

 

ISRAEL CHEMICALS LTD.

Ordinary Shares



PROSPECTUS



            , 2014

   


Table of Contents


PART II
INFORMATION NOT REQUIRED IN PROSPECTUS

Item 6.     Indemnification of Directors and Officers .

        General.     Our Articles of Association set forth the following provisions regarding the grant of insurance coverage, indemnification and an exemption from liability to any of our directors or officers, all subject to the provisions of applicable law. In accordance with such provisions and pursuant to the requisite corporate approvals, we have obtained liability insurance covering our directors and officers, have granted indemnification undertakings to our directors and officers and have agreed to exempt our directors and officers from liability for breach of the duty of care.

        Insurance.     We are entitled to insure the liability of any director or officer to the fullest extent permitted by law. Without derogating from the aforesaid, we may enter into a contract to insure the liability of a director or officer for an obligation imposed on him in consequence of an act done in his capacity as such, in any of the following cases:

    a breach of the duty of care toward us or a third party;

    a breach of the duty of loyalty toward us, provided that the director or officer acted in good faith and had reasonable basis to believe that the act would not harm us;

    a monetary obligation imposed on him in favor of a third party;

    reasonable litigation expenses, including attorney fees, incurred by the director or officer as a result of an administrative enforcement proceeding instituted against him; or

    a payment imposed on the director or officer in favor of an injured party as set forth in Section 52(54)(a)(1)(a) of the Israeli Securities Law, 5728-1968, as amended (the "Securities Law").

        In connection with this offering, we expect to update the terms of our insurance policy for directors and officers in accordance with the practice of companies listed in the United States, including with respect to the limit of liability, the premium and the apportioning of the insurance premium to be paid between us and Israel Corporation. The insurance policy would include a joint tier with Israel Corporation with a liability limit of up to $20 million and a separate tier that covers us alone for up to $350 million, with our directors and officers as beneficiaries of both tiers. Premiums on the joint tier will be paid 60% by us and 40% by Israel Corporation. The new insurance policy was approved by our shareholders, as a three year framework resolution, on May 8, 2014.

    Indemnification

        We are entitled to indemnify a director or officer to the fullest extent permitted by law, either retroactively or pursuant to an undertaking given in advance. Without derogating from the aforesaid, we may indemnify our directors or officers for liability or expense imposed on him in consequence of an action taken by him in his capacity as such, as follows:

    a financial liability incurred or imposed on him in favor of another person in accordance with a judgment, including a judgment given in a settlement or an award of an arbitrator that is approved by a court, provided that any undertaking in advance to indemnify is limited to events that, in the opinion of our Board of Directors, are foreseeable in light of our actual activity at the time of granting the undertaking and limited to a sum or criteria determined by our Board of Directors to be reasonable under the circumstances;

    reasonable litigation expenses, including legal fees, incurred in connection with an investigation or proceeding conducted against him by an authority authorized to conduct such an investigation or proceeding, and which concluded without an indictment against him and without a financial

II-1


Table of Contents

      sanction in lieu of a criminal proceeding (except for an offense that does not require proof of criminal intent), or in connection with a financial sanction;

    reasonable litigation expenses, including legal fees, incurred by the director or officer or which he was ordered to pay by a court, within the framework of proceedings filed against him by or on behalf of us, or by a third party, or in a criminal proceeding in which he was acquitted, or in a criminal proceeding in which he was convicted of an offense which does not require a criminal intent;

    reasonable litigation expenses, including attorney fees, incurred by the director or officer as a result of an administrative enforcement proceeding instituted against him; or

    a payment imposed on the director or officer in favor of an injured party as set forth in Section 52(54)(a)(1)(a) of the Securities Law.

        Exemption.     We are entitled to exempt a director or officer in advance from any or all of his liability for damage in consequence of a breach of the duty of care toward us, except in connection with illegal distributions to shareholders.

        Limitations.     The Companies Law provides that a company may not provide its directors or officers with insurance or indemnification or exempt its directors or officers from liability with respect to the following:

    a breach of the duty of loyalty toward the company, unless, with respect to insurance coverage or indemnification, the director or officer acted in good faith and had a reasonable basis to believe that the act would not harm us;

    an intentional or reckless breach of the duty of care;

    an act done with the intention of illegally deriving a personal profit; or

    a fine imposed on the director or officer.

        The proposed form of Underwriting Agreement filed as Exhibit 1.1 to this registration statement provides for indemnification of our directors and officers and persons who control us within the meaning of the Securities Act by the underwriters against certain liabilities.

Item 7.     Recent Sales of Unregistered Securities .

        Since January 1, 2011, we have issued securities without registration under the Securities Act of 1933, as amended (the "Securities Act"), as follows:

    On December 27, 2012, we issued 11,999,400 non-marketable options for no consideration to certain of our officers and senior employees. The issuance included a private placement of 1,190,000 options to our Chief Executive Officer. The issuance of these options was deemed to be exempt from registration under the Securities Act in reliance upon Section 4(a)(2) of the Securities Act, as a transaction by an issuer not involving any public offering, or Regulation S promulgated under the Securities Act, as a transaction involving offers and sales of securities outside the United States.

    In 2011, 2012 and 2013, 2,991,740, 2,159,929 and 6,633,574 options under our equity compensation plans were exercised, resulting in the sale to certain of our officers and senior employees at a weighted average exercise price of NIS 47.01, NIS 16.84 and NIS 18.61, respectively, of 2,991,740, 2,159,929 and 6,633,574 ordinary shares, respectively. The issuance of these ordinary shares was deemed to be exempt from registration under the Securities Act in reliance upon Section 4(a)(2) of the Securities Act, as a transaction by an issuer not involving any public offering, or Regulation S

II-2


Table of Contents

      promulgated under the Securities Act, as a transaction involving offers and sales of securities outside the United States.

    In November 2013, a wholly owned and controlled subsidiary of ours entered into an agreement with institutional and international investors to make a private offering in the United States of unregistered debentures in an amount of up to $275 million. Our subsidiary issued three series of debentures in an aggregate principal amount of $275 million, the proceeds of which were received in January 2014:

    $84 million of debentures with a repayment date of January 15, 2021 bearing interest at a fixed rate of 4.55%;

    $145 million of debentures with a repayment date of January 15, 2024 bearing interest at a fixed rate of 5.16%; and

    $46 million of debentures with a repayment date of January 15, 2026 bearing interest at a fixed rate of 5.31%.

      The issuance of these debentures was deemed to be exempt from registration under the Securities Act in reliance upon Section 4(a)(2) of the Securities Act, as a transaction by an issuer not involving any public offering.

        On August 6, 2014, our Board of Directors approved an issuance of up to approximately 4,384,540 non-marketable options, for no consideration, exercisable for approximately 4,384,540 of our ordinary shares, and up to 1,025,449 restricted shares, to approximately 450 of our officers and senior employees. The issuance includes a private placement of 367,294 options and 85,907 restricted shares to our Chief Executive Officer, which is subject to the approval by the general meeting of our shareholders scheduled for October 20, 2014. The issuance of these options and restricted shares will be deemed to be exempted from registration under the Securities Act in reliance upon Section 4(a)(2) of the Securities Act, as a transaction by an issuer not involving any public offering, or Regulation S promulgated under the Securities Act, as a transaction involving offers and sales of securities outside the United States.

Item 8.     Exhibits and Financial Statement Schedules.

    (a)
    The following exhibits are filed as part of this Prospectus:

  1.1*   Form of Underwriting Agreement.

 

3.1

 

Memorandum of Association of Israel Chemicals Ltd. (unofficial translation from original Hebrew).

 

3.2

 

Articles of Association of Israel Chemicals Ltd. (unofficial translation from original Hebrew).

 

5.1

 

Opinion of Goldfarb Seligman & Co., Israeli counsel of Israel Chemical Ltd., as to the validity of the ordinary shares.

 

8.1

 

Tax Opinion of Davis Polk & Wardwell LLP

 

8.2

 

Tax Opinion of Goldfarb Seligman & Co.

 

10.1

 

Dead Sea Concession Law, 1961 (and the Deed of Concession, dated as of May 31, 1961, between the State of Israel and Dead Sea Works, Ltd. set out as a schedule thereto) (unofficial translation from original Hebrew).

 

10.2

 

Plan for the Private Allocation of Options for Shares of the Company to the CEO of the Company, to Office Holders and Employees of the Company and its Subsidiaries dated January 7, 2010 (unofficial translation from original Hebrew).

II-3


Table of Contents

  10.3   Plan for the Private Allocation of Options for Shares of the Company to the CEO of the Company, to Office Holders and Employees of the Company and its Subsidiaries dated November 27, 2012 (unofficial translation from original Hebrew).

 

10.4

 

Equity Compensation Plan (2014) dated August 20, 2014 (unofficial translation from original Hebrew).

 

10.5

 

Compensation Policy for Directors and Officers, as adopted in July 2013 and approved by shareholders in August 2013.

 

10.6

 

Agreement between the Israeli Ministry of Finance and Dead Sea Works Ltd. dated as of July 8, 2012 relating to salt harvesting at the Dead Sea.

 

10.7

 

2012 Controlling Shareholder Loan, as amended.

 

10.8

 

Form of Registration Rights Agreement by and between Israel Chemicals Ltd. and Israel Corporation Ltd.

 

21.1

 

List of subsidiaries of Israel Chemicals Ltd.

 

23.1

 

Consent of Somekh Chaikin, Certified Public Accountants (Israel), a member firm of KPMG International, independent registered public accounting firm.

 

23.2

 

Consent of Goldfarb Seligman & Co., Israeli counsel of Israel Chemical Ltd. (included in Exhibits 5.1 and 8.2).

 

23.3

 

Consent of DMT Consulting Limited (formerly known as IMC Group Consulting Limited)

 

23.4

 

Consent of Davis Polk & Wardwell LLP (included in Exhibit 8.1)

 

24.1

 

Powers of attorney (included on signature page to the registration statement)

*
To be filed by amendment.

        Instruments defining the rights of holders of certain issues of long-term debt of Israel Chemicals Ltd. have not been filed as exhibits to this registration statement because the authorized principal amount of any one of such issues does not exceed 10% of the total assets of Israel Chemicals Ltd. and its subsidiaries on a consolidated basis. Israel Chemicals Ltd. hereby agrees to furnish a copy of each of such instrument to the Securities and Exchange Commission upon request.

    (b)
    Financial Statement Schedules

        No financial statement schedules are provided because the information called for is not required or is shown either in the financial statements or the notes thereto.

Item 9.     Undertakings

        The undersigned hereby undertakes:

            (a)   The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.

            (b)   Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the provisions referenced in this registration statement, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a

II-4


Table of Contents

    director, officer, or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered hereunder, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

            (c)   The undersigned Registrant hereby undertakes that:

              (1)   For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

              (2)   For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

II-5


Table of Contents


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Tel Aviv, Israel, on the 12 th day of September, 2014.

    ISRAEL CHEMICALS LTD.

 

 

By:

 

/s/ AVI DOITCHMAN

        Name:   Avi Doitchman
        Title:   Executive Vice President,
Chief Financial Officer & Strategy

    ISRAEL CHEMICALS LTD.

 

 

By:

 

/s/ LISA HAIMOVITZ

        Name:   Lisa Haimovitz
        Title:   Vice President, General Counsel and Corporate Secretary

        KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Avi Doitchman, Israel Dreyfuss and Lisa Haimovitz, and each of them, individually, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this prospectus and any and all additional prospectuses pursuant to Rule 462(b) of the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agents full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or either of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

        Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

Signature
 
Title
 
Date

 

 

 

 

 
/s/ STEFAN BORGAS

Stefan Borgas
  Chief Executive Officer
(principal executive officer)
  September 12, 2014

/s/ AVI DOITCHMAN

Avi Doitchman

 

Executive Vice President,
Chief Financial Officer & Strategy
(principal financial officer)

 

September 12, 2014

II-6


Table of Contents

Signature
 
Title
 
Date

 

 

 

 

 
/s/ ISRAEL DREYFUSS

Israel Dreyfuss
  Controller
(principal accounting officer)
  September 12, 2014

/s/ NIR GILAD

Nir Gilad

 

Chairman of the Board of Directors

 

September 12, 2014

/s/ YAACOV DIOR

Yaacov Dior

 

Director

 

September 12, 2014

/s/ OVADIA ELI

Ovadia Eli

 

Director

 

September 12, 2014

/s/ CHAIM EREZ

Chaim Erez

 

Director

 

September 12, 2014

/s/ DR. MIRIAM HARAN

Dr. Miriam Haran

 

Director

 

September 12, 2014

/s/ VICTOR MEDINA

Victor Medina

 

Director

 

September 12, 2014

/s/ PROF. YAIR ORGLER

Prof. Yair Orgler

 

Director

 

September 12, 2014

/s/ AVISAR PAZ

Avisar Paz

 

Director

 

September 12, 2014

/s/ ERAN SARIG

Eran Sarig

 

Director

 

September 12, 2014

/s/ AVRAHAM (BAIGA) SHOCHAT

Avraham (Baiga) Shochat

 

Director

 

September 12, 2014

/s/ AVIAD KAUFMAN

Aviad Kaufman

 

Director

 

September 12, 2014

/s/ DONALD J. PUGLISI

Donald J. Puglisi

 

Authorized U.S. Representative

 

September 12, 2014

II-7




Exhibit 3.1

 

Translation from the Hebrew. The binding version is in the Hebrew.

 

The Companies Ordinance

A Company Limited by Shares

 

MEMORANDUM OF ASSOCIATION

OF

ISRAEL CHEMICALS LTD.

 

1. The name of the company is —

 

In Hebrew:

 

and in English: ISRAEL CHEMICALS LTD.

 

2.  The objectives for which the Company was established are:

 

2.1.       To engage, establish, develop and manage operations of any kind and type which is in the field of mining, manufacturing, production, trade, conveying, marketing and distribution of quarries, minerals and materials or compounds of all kinds, including downstream products or products associated with them, alone or with others, and including to hold shares or other rights in corporations or businesses in those fields.

 

2.2.       To engage in any legal activity whatsoever. [Amended, January 2005]

 

3. The liability of the members is limited.

 

4. The share capital of the Company is: NIS 1,485,000,000 divided into 1,484,999,999 ordinary shares of NIS 1 nominal value each, and one registered Special State Share of NIS 1 nominal value. [Amended, May 2000]

 

The rights of the shares and their various classes are set out in the Articles of Association of the company, as shall be in force from time to time.

 

We the several persons whose names and addresses are set out below are desirous of being incorporated into a company in accordance with this Memorandum of Association and we hereby undertake to take the number of shares in the capital of the company set opposite our respective names, as set out below.

 



 

Name of Members

 

Addresses and Titles

 

No. of shares
taken by each
member

 

Signature

 

 

 

 

 

 

 

1. The state of Israel represented by the Minister of Development, Moshe Kol and P. Sapir

 

 

 

1,000,000

 

(-)

 

 

 

 

 

 

 

 

 

 

 

 

 

2. Pinchas Sapir

 

Minister of Finance,
The Treasury, Jerusalem

 

1

 

(-)

 

 

 

 

 

 

 

3. Moshe Kol

 

Minister of Development,

Ministry of Development,
Jerusalem

 

1

 

(-)

 

 

 

 

 

 

 

4. Ze’ev Sherf

 

Minister of Trade and Industry, Ministry of Trade and Industry, Jerusalem

 

1

 

(-)

 

 

 

 

 

 

 

5. Haim Givati

 

Minister of Agriculture
Ministry of Agriculture,
Jerusalem

 

1

 

(-)

 

 

 

 

 

 

 

6. Yehuda Sha’ ari

 

Deputy Minister of Development,

Ministry of Development,
Jerusalem

 

1

 

(-)

 

 

 

 

 

 

 

7. Jerry Sudarski

 

Engineer, Kfar Shmaryahu

 

1

 

(-)

 

 

 

 

 

 

 

8. Israel Gil’ad

 

Director-General of the Ministry of Development,
Ministry of Development, Jerusalem

 

1

 

(-)

 

 

 

 

 

 

 

 

 

Total number of shares taken: 1,000,007

 

 

 

 

 

2



 

Date: December 5, 1967

 

Witness to signatures: M. Firon

 

 

Address: 43 Rothschild Boulevard, Tel-Aviv.

 

(The founding shares, from number 2 to number 8, were transferred according to the following sequence to the following companies and institutions:

 

2. Timna Copper Ltd.

 

3. Export Industries Umbrella Company Ltd.

 

4. The Petroleum and Geophysics Research Institute.

 

5. The Israel Electric Corporation Ltd.

 

6. Industrial Research Center Ltd.

 

7. Israel Desalination Engineering (Zarhin Process) Ltd.

 

8. Negev Clay and Clear Sand Company Ltd.

 

Details of the transfers and the other movements in the share capital — in the register of the Company)

 

3




Exhibit 3.2

 

[CONVENIENCE TRANSLATION FROM THE HEBREW]
ARTICLES OF ASSOCIATION
OF
ISRAEL CHEMICALS LIMITED

 

Interpretation

 

1.                                       In these Articles of Association, unless the wording of the text requires otherwise:

 

Words

 

Meaning

 

 

 

“Person”

 

Including a company, cooperative association or any other group of Persons, whether associated or not associated.

 

 

 

“Director”

 

A member of the Board of Directors of the Company, including a substitute Director.

 

 

 

“the Board of Directors”

 

The Board of Directors of the Company serving at that time.

 

 

 

“the Company”

 

Israel Chemicals Ltd.

 

 

 

“the Seal”

 

The Company seal.

 

 

 

“the Stamp”

 

The Company stamp.

 

 

 

“the Office”

 

The registered office of the Company, as will be from time to time.

 

 

 

“the Special State Share”

 

As defined in these Articles of Association.

 

 

 

“the Law” or “the Companies Law”

 

The Companies Law, 5759-1999, including all the changes inserted therein from time to time, or any law which supersedes or replaces it.

 

 

 

“the Shareholders Register”

 

The register of shareholders to be maintained in accordance with Section 127 of the Law, and/or, if the Company elected to maintain an additional Shareholders Register as provided in Section 138 of the Law, any such additional Shareholders Register.

 

 

 

“the Material Shareholders Register”

 

The register of material shareholders to be maintained in accordance with Section 128 of the Law.

 



 

“Writing”

 

Print, lithograph, photograph and any other way of fixing or imprinting words in visible form or, subject to the provisions of the law permitting it — electronically.

 

 

 

“Officer”

 

As this term is defined in the Companies Law, as amended from time to time.

 

 

 

“Securities”

 

Including a share, debenture, or a right to purchase, convert or sell any of them, whether registered or bearer.

 

 

 

“Securities Law”

 

Securities Law, 5729-1968.

 

 

 

“Administrative proceeding”

 

A proceeding pursuant to Chapters H3 (Imposition of a financial sanction by the Securities Authority), H4 (Imposition of administrative means of enforcement by the Administrative Enforcement Committee) or I1 (Arrangement for refraining from proceedings or termination of proceedings, contingent upon conditions), of the Securities Law, as may be amended from time to time.

 

 

 

“these Articles” or “these Articles of Association”

 

These Articles of Association, as worded here or as changed from time to time.

 

Subject to the provisions of this Article, each term, word and expression in these Articles shall have the meaning given then in the Law, unless the written text necessitates another meaning.

 

Anything stated in the singular shall mean also the plural and vice versa, and anything stated in the masculine shall mean also the feminine, and vice versa.

 

The headings appearing in these Articles of Association are intended for convenience only, and shall not be used for the interpretation of these Articles of Association.

 

2.                                       The liability of the shareholders for the debts of the Company is limited to repayment of the consideration they undertook to pay in respect of their shares in the Company.

 

3.                                       The objectives of the Company are as listed in the Company’s Memorandum of Association.

 

4.                                       The ongoing management and the control of the Company’s business, and its principal place of business, shall be in Israel.

 

2



 

A change, amendment or cancellation of this Article 4 shall be deemed to be a change of the rights attaching to the Special State Share, and shall not be made except with the consent of the holder of the Special State Share. Any decision or action which contravenes or does not comply with the provisions of this Article 4, shall be void and invalid without receipt of the consent of the holder of the Special State Share. Any consent, waiver or approval of the holder of the Special State Share shall be given in Writing.

 

The Business

 

5.                                       The Company may engage in any service, sector or type of business which, under these Articles of Association, it is authorized to manage or engage in, whether expressly or by implication. The Board of Directors may decide to abandon or suspend the management of such sector or type of business, whether it actually started to manage them or not.

 

6.                                       The Company may donate a reasonable sum to a worthy cause, even if the donation is not part of its business considerations, the object of which is to generate profits.

 

The Share Capital and the Rights Attaching to the Shares

 

7.                                       The registered share capital of the Company is NIS 1,485,000,000, divided into 1,484,999,999 ordinary shares of a par value of NIS 1 each (hereinafter “the Ordinary Shares”) and one registered Special State share of a par value of NIS 1.

 

8.                                       (a)          (1)                      The Ordinary Shares shall be equal in their rights and shall grant their holders the right to receive notices concerning General Meetings of the Company, to participate and vote therein, to elect the members of the Board of Directors as set forth in these Articles of Association, as well as the right to participate in the distribution of the Company’s profits and the distribution of surplus assets upon liquidation.

 

(2)                                  In case of distribution of dividends — they shall be paid proportionally to the amounts paid up or credited as paid up on account of the par value of the shares, without taking into account the premium paid on them.

 

(3)                                  Ordinary Shares which have been paid up or credited as paid up, in full or partially, within any period with regard to which the dividends are paid, shall entitle their holders to the dividend so that, unless determined otherwise in the terms of their issue, it will be proportional to the amount paid up or credited as paid up on the par value of those shares as at the date of its payment.

 

(4)                                  In case of distribution of bonus shares — they shall be distributed among the holders of the Ordinary Shares in the same proportion as they are entitled to participate in the distribution of a dividend,

 

3



 

and shall be of the same class as the shares in respect of which they were distributed.

 

(5)                                  Upon liquidation of the Company, its surplus assets shall be distributed, including all its obligations, subject to rights granted for any class of shares which have been issued at that time, if any, among the holders of the Ordinary Shares, proportionally to the amount paid up or credited as paid up on the par value of those shares, without taking into account the premium paid on the shares.

 

(b)                                  The Special State Share cannot be sold or transferred from the name of the Government of Israel, and shall grant its holder, for the purpose of preserving the vital interests of the State, the following rights:

 

(1)                                  Sale or transfer of material assets of the Company or the granting of any other right in such assets (hereinafter: “Transfer”), not in the ordinary course of the Company’s business, shall be invalid without the consent of the holder of the Special State Share, which may oppose Transfer of a material asset as aforesaid only if it is likely, in its opinion, to harm one of the vital interests of the State as defined below.

 

In this Article 8(b)(1) — Transfer of material assets not in the ordinary course of the Company’s business, means — including simultaneously or in parts, whether in one transaction or in a series of transactions of each of these:

 

(a)                      Transfer of shares or other Securities in the Company, including Securities held by the Company in another corporation, as a result of which another will hold more than 25% of the voting rights in the Company or the other corporation, or as a result of which the control in the Company or in the other corporation will transfer or is likely to transfer to another holder (in this paragraph, Transfer — including an allotment of Securities).

 

(b)                      Assets that are vital to the existence and development or preservation of the production capabilities of the Company. These assets include: production lines, including production facilities, mining and quarrying rights, marketing arrays, know-how and technology — whether protected by patents or other intellectual property rights or not.

 

(2)                                  Decisions on voluntary liquidation, as well as decisions on settlement or arrangement pursuant to Section 350 of the Companies Law, or decisions on a change or reorganization of the structure of the Company, or on a merger (other than mergers of corporations controlled by the Company or controlled by a subsidiary, where

 

4



 

such mergers will not prejudice the rights or powers of the holder of the Special State Share) — shall be invalid without the consent of the holder of the Special State Share.

 

(3)                      (a)                      Any acquisition or holding of shares in the Company, of 14% or more of the issued share capital of the Company, shall not be valid vis-a-vis the Company unless the consent of the holder of the Special State Share was obtained.

 

(b)                      Any acquisition or holding of 25% or more of the issued share capital of the Company (including the making up of a holding to 25%), shall not be valid vis-a-vis the Company unless the consent of the holder of the Special State Share was obtained, even if such consent was obtained in the past for a holding of less than 25%.

 

(c)                       In addition to the aforesaid, the consent of the holder of the Special State Share shall be required for any percentage of holding of shares in the Company’s share capital which grants their holder the right, the ability or the practical possibility to appoint, directly or indirectly, a number of Directors in the Company which constitute half or more of the number of members of the Board of Directors of the Company, as it actually numbers from time to time. A holding of a percentage of the share capital for which the consent of the holder of the Special State Share is required as aforesaid, shall not be valid vis-a-vis the Company as long as such consent has not been obtained.

 

(d)                      The holder of the Special State Share may make its consent under this Article 8(b)(3) contingent on terms at its discretion, for the sake of securing the vital interests of the State. Furthermore, it may waive, on terms it stipulates, toward a certain shareholder, for a limited period or in perpetuity, any of the rights granted him under these Articles of Association. Any such waiver shall not be deemed to be a change or amendment of these Articles of Association or of the rights attaching to the Special State Share.

 

(e)                       Any lien and/or pledge transaction of shares in the Company in which, as a result of the enforcement or exercise of rights thereunder, the owner of the lien or pledge is likely to hold shares from the share capital of the Company in the percentages stated in Articles 8(b)(3)(a) to 8(b)(3)(c) inclusive of these Articles of Association, or to increase its holdings to those percentages, shall not be valid without the consent of the holder of the Special State Share, and everything stated in this Article 8(b)(3) concerning holding or acquisition of shares shall apply also to their lien or pledge.

 

5



 

(4)                                  The holder of the Special State Share shall be entitled to receive into its possession, upon its demand, from the Company, any information and documents which a holder of Ordinary Shares in the Company is entitled to receive, and in addition thereto shall be entitled to receive any information and documents which a Director and/or external Director is entitled to receive. Any information, which a General Meeting of the Company receives or is entitled to receive, shall be conveyed to the holder of the Special State Share prior to convening of the General Meeting. The holder of the Special State Share shall use this information only for the purpose of exercising its rights according to these Articles of Association, for preserving the vital interests of the State.

 

(5)                                  Whoever requests the consent of the holder of the Special State Share for any of the matters, for which its consent is required according to these Articles of Association, shall apply in Writing to the holder of the Special State Share, where the application includes the information needed for making the decision.

 

(5a)               The Company shall notify whoever reported to it that it is an interested party in the Company, that voting at its General Meetings by virtue of the shares held by the interested party shall be made conditional by the Company upon the submission of written confirmation, prior to the General Meeting, by whoever wishes to vote by virtue of those shares, that to the best of its knowledge, the voting is by virtue of shares, the holding of which does not require the consent of the holder of the Special State Share according to the Articles of Association of the Company, or that such consent was given.

 

The Company shall make such voting contingent also in relation to whoever wishes to vote at a General Meeting or to appoint Directors by virtue of the shares constituting 14% or more of the issued share capital of the Company.

 

(6)                                  The holder of the Special State Share shall be deemed to have given its consent for the actions mentioned in Articles 8(b)(1), 8(b)(2) and 8(b)(3)(e) of these Articles of Association, if within 90 days of the date it was requested, in Writing, to give its consent (where the request includes the information required for making the decision), it did not give a negative answer or did not give any answer — if one of the Ministers holding the Special State Share did not request that the matter be brought before the Government for discussion within that period.

 

(7)                                  Any consent, waiver or approval of the holder of the Special State Share shall be in Writing. The effect of any consent or waiver or

 

6



 

approval of the holder of the Special State Share shall be from the date it is given, unless expressly stated otherwise.

 

(8)                                  In these Articles of Association, “the vital interests of the State” means

 

(a)                      To preserve the character of the Company and its subsidiaries, Dead Sea Works Ltd., Rotem Amfert Negev Ltd., Dead Sea Bromine Ltd., Bromine Compounds Ltd. and Tami (E.M.I.) Research & Development Institute Ltd. (the Company and the above subsidiaries shall be referred to in this Article 8(b) below as “the Companies”), as Israeli companies, the center and management of whose business is in Israel.

 

(b)                      To supervise the control of quarries and natural resources for their development and efficient exploitation, including maximum implementation in Israel of the results of the investments, the research and the development.

 

(c)                       To prevent the acquisition of a position of influence in the Companies by hostile entities, or entities which are liable to harm the foreign and security interests of the State.

 

(d)                      To prevent the acquisition of a position of influence in the Companies or the management of the Companies, where such acquisition or management is liable to create a situation of conflict of material interests liable to harm one of the vital interests listed above.

 

(9)                                  In this Article 8(b) and in Article 38(a) of these Articles of Association: “holding” or “acquisition” of shares, “control” and “affiliated company” as these terms are defined in Section 1 of the Securities Law, and including holding by a holder or holders acting in coordination or as one, or in cooperation; however, in counting the holdings of a holder, its holdings by means of an affiliated company whose securities have been offered to the public shall not be taken into account, provided that the affiliated company is not in its control, alone or together with others who hold securities of the Company.

 

(10)                           The rights listed in this Article 8(b) and in Articles 4, 38(a), 68, 82(d), 83, 84, 92(c) and 117(c) of these Articles of Association, are the rights attaching to the Special State Share, and other than those, the Special State Share shall not grant its holder any voting rights or capital rights whatsoever.

 

A change, amendment or cancellation of this Article 8(b) shall be deemed to be a change of the rights attaching to the Special State Share,

 

7



 

and shall not be made without the consent of the holder of the Special State Share. Any decision or action, which is contrary to or not in compliance with the provisions of this Article 8(b), shall be void and invalid without receipt of the consent of the holder of the Special State Share.

 

Any change of these Articles of Association in a way liable to prejudice, directly or indirectly, the rights attaching to the Special State Share, shall be deemed to be a change of the rights attaching to the Special State Share. Any decision or action which is liable to prejudice, directly or indirectly, the rights attaching to the Special State Share, shall not be done without the consent of the holder of the Special State Share, and shall be void and invalid without receipt of the consent of the holder of the Special State Share.

 

Shares

 

9.                                       Taking into consideration the provisions of the Law and the provisions on this matter in these Articles of Association, where they exist, the Company can create shares with privileges or with deferred rights or with rights of redemption or with other special restricted rights or restrictions in connection with the distribution of the dividends, a right of opinion, payment of principal capital, or in connection with other matters, as may be determined by the Company from time to time, and to issue them from time to time, in accordance with a resolution of the Board of Directors.

 

10.                                (a)          A change in the rights attaching to a class of shares shall be made in a resolution of the holders of shares of that class and in a resolution of meetings of those classes of shares whose rights will be prejudiced by the change by a simple majority of those present and who vote at such meetings.

 

(b)                                  The provisions of these Articles of Association concerning General Meetings shall apply, mutatis mutandis , to any Special General Meetings as aforesaid, but the quorum required shall be constituted when there are present, in person or by proxy, two members who together hold more than 50% of the issued shares of the same class, and at such a Special General Meeting which was adjourned for lack of a quorum, the quorum required shall be — at least two members with a voting right who are present in person or by proxy, who hold at least one third of the issued shares of the same class.

 

11.                                A.             Subject to the provisions of the Law, any law and these Articles of Association, the Board of Directors may issue or allot shares and other securities, convertible to or exercisable for shares, up to the limit of the registered share capital of the Company (and for this matter, securities convertible to or exercisable for shares shall be seen as if converted or exercised on the date of the issue).

 

8



 

B.             The authority of the Board of Directors as provided in sub-article (A) can be delegated as provided in paragraphs (1) or (2), as the Board of Directors decides:

 

(1)                                  To a committee of the Board of Directors — Upon the issue or allotment of securities as part of an employee compensation plan or employment or salary agreements between the Company and its employees, or between the Company and employees of a related company whose board of directors consented to it in advance, provided that the issue or allotment is according to a plan that includes detailed criteria outlined and approved by the Board of Directors.

 

(2)                                  To a committee of the Board of Directors, the CEO or similar office-holder (in this Article — the CEO), or to another person recommended by the CEO — Upon an allotment of shares due to exercise or conversion of securities of the Company.

 

12.                                If under the terms of any allotment of a share, payment of the share, in full or in part, is in installments, then each such installment shall be paid to the Company on its due date by the Person who is the registered owner of the shares at that time, or by his legal guardian.

 

13.                                Upon the allotment of shares, the Board of Directors may introduce differences among those shareholders in relation to the amounts of the calls and/or their payment schedule.

 

14.                                Unless stipulated otherwise in these Articles of Association, the Company shall see whoever is registered in the Shareholders Register as the owner of a share or whoever holds a bearer share instrument or to whomever a share is credited with a member of a stock exchange and that share is included among the shares registered in the Shareholders Register in the name of a nominees company, as the outright owner of that share, and accordingly, it shall not be bound to recognize any claim on the basis of equitable title or a right contingent upon conditions or a future right or a partial right in the share, or on another basis in relation to such a share, or in relation to a benefit therein on the part of any other Person

 

15.                                Where two or more Persons are registered as joint holders of a share, each of them may give binding receipts for any dividend or other moneys in connection with that share.

 

Share Certificates

 

16.                                A certificate of possession of shares shall be issued with the Stamp of the Company and signed by two Directors together, or by one Director and the Company Secretary, or by any other Person appointed by the Board of Directors, all subject to the provisions of the Law and its concomitant Regulations.

 

9


 

17.                                Any shareholder may accept from the Company, free of charge, within a period of two months after the allotment or registration of the transfer (unless the terms of the issue determine a longer period), one certificate in respect of all the shares registered in his name, which sets out the number of shares in respect of which it is issued, and the amount paid for them, and any other detail which the Board of Directors considers important.

 

18.                                (a)                                  A share certificate registered in the names of two or more Persons shall be delivered to the Person whose name appears first in the Shareholders Register among the names of the joint owners.

 

(b)                                  If a share certificate is lost or disfigured, the Company may issue another certificate in its place, for payment, if imposed, and on such terms relating to proof of loss or disfigurement and relating to a guarantee for damages, as the Board of Directors sees fit.

 

Call for Payment

 

19.                                The Board of Directors may, from time to time, at its discretion, issue calls for payment to the shareholders for all the moneys not yet paid up in respect of the shares which are held by each of the shareholders, and which, under the terms of allotment of the shares, need not be paid on fixed dates, and each shareholder must pay the Company the amount of the call, at the time and in the place determined by the Board of Directors. A call can be by dividing the payment into installments.

 

20.                                For every call, at least 14 days’ notice shall be given, stating the amount of the payment and the place for its payment. The Board of Directors may, by giving written notice to the shareholders, cancel the call or postpone its date of payment. The Board of Directors may introduce differences among the shareholders in relation to the amounts of the calls and/or their dates of payment.

 

21.                                A call shall be deemed to have been made on the date on which the Board of Directors decided on the call.

 

22.                                Joint owners of a share shall be jointly and severally responsible for payment of all the payment installments and the call arriving in respect of such a share.

 

23.                                If a call or an installment due on account of a share is not paid on the date designated for payment or prior thereto, the Person who at that time is a shareholder must pay interest on the amount of the call or the installment, at the rate determined by the Board of Directors according to market credit conditions from time to time, starting from the date designated for payment and ending on the date of actual payment. However, the Board of Directors may waive payment of all the interest or part thereof.

 

24.                                Any sum which, under the terms of allotment of a share, must be paid at the time of the allotment or on a fixed date, whether on account of the par value of the

 

10



 

share or as a premium, shall be considered, with regard to these Articles of Association, as a call duly made by the Board of Directors and for which notice was duly given, and the date of payment is the date fixed for payment. In case of non-payment, all the Articles of these Articles of Association, which deal with payment of interest and expenses, forfeiture of shares, and all the other Articles relating to calls, shall apply.

 

25.                                A shareholder shall not be entitled to receive a dividend or to exercise any right as a shareholder unless he has paid all the calls which are paid from time to time which apply to his shares, whether he holds them alone or together with another Person, plus linkage differentials and interest and expenses, if any.

 

26.                                The Board of Directors may, if it sees fit, accept from a shareholder to pay in advance all or part of the moneys due on account of his he amounts actually called, and it may pay him interest, at a rate to be agreed upon between the Board of Directors and the shareholder, on amounts paid in advance as aforesaid, or on that part thereof which exceeds the amount which at that time had been called on account of the shares in relation to which the advance payment was made, or it may come to another arrangement with him, which will compensate him for the advance payment. The Board of Directors may, at any time, as long as its due date has not arrived, reimburse the amount paid in advance as aforesaid, by giving the shareholder three months’ notice in Writing.

 

Forfeiture and Lien

 

27.                                If a shareholder does not pay any or all calls or any payment installments on or before the date set for its payment, the Board of Directors may, at any time thereafter, as long as the call or the payment installment remains unpaid, deliver notice to such shareholder and demand that he pay them plus linkage differentials and accrued interest, as well as any expenses which the Company has incurred by reason of such non-payment.

 

28.                                The notice shall name a day (which shall be at least 14 days after the date of the notice) and a place, on which and in which the above call or installment should be paid, plus linkage differentials and interest and expenses as aforesaid. The notice shall also state that in the event of non-payment on or before time and in the place appointed in the notice, the shares in respect of which the call was made or the installment was due, shall be liable to forfeit.

 

29.                                If the requirements of the above notice are not met, then at any time thereafter and before payment of the call or installment, the linkage differentials, the interest and the expenses demanded in the notice has been made, any share in relation to which the above notice was given may, by a resolution of the Board of Directors to that effect, be forfeited. Forfeiture of the shares shall include all the dividends of those shares, which were not paid before the forfeiture, even if announced but not actually paid before the forfeiture.

 

11



 

30.                                Any share forfeited as aforesaid shall be considered a dormant share, and the Board of Directors may sell it, as it decides, taking into consideration these Articles of Association and subject to the provisions of any law.

 

31.                                The Board of Directors may, at any time prior to the sale of any share forfeited as aforesaid, cancel the forfeiture on such terms as it sees fit.

 

32.                                A shareholder whose shares were forfeited shall cease to be a shareholder in respect of the forfeited shares; nevertheless, he shall be required to pay the Company the entire call, payment installments, linkage differentials and interest and the expenses due on account of or for those shares at the time of the forfeiture, plus the interest on those amounts at the maximum rate permitted at that time by law, from the date of the forfeiture to the date of the payment. The shareholder shall be required to fulfill all the claims and demands which the Company could have made in relation to the shares up to the date of the forfeiture, without deduction or discount for the value of the shares on the date of forfeiture. His obligation will be discharged after the Company receives the full consideration, which the shareholder undertook to pay, plus the expenses involved in the sale. If the consideration received from the sale of the forfeited shares exceeds the consideration which the debtor undertook to pay, the debtor shall be entitled to recoup the partial consideration he gave for them, if any, provided that the consideration remaining in the hands of the Company shall be not less than the full consideration which the debtor undertook to pay plus the expenses involved in the sale.

 

The Board of Directors may, but is not obligated to, require the shareholder to pay some or all of these sums of money, if it sees fit to do so. Forfeiture of a share shall bring with it, at the time of forfeiture, cancellation of any right in the Company and any claim or demand against it in relation to the share, except for those rights and obligations which are excluded from this rule by virtue of these Articles of Association or which the law vests in or imposes upon a former shareholder.

 

33.                                The provisions of these Articles of Association concerning forfeiture of shares shall apply also to cases of non-payment of a known amount which, under the terms of issue of the share or under the terms of allotment of the share, falls due on an appointed ate, whether it is on account of the par value of the share or as a premium, as if that amount were due for payment by virtue of a call duly made and delivered.

 

34.                                The Company shall have a first right of lien on all the shares registered in the name of any holder of a share, whether alone or jointly with others, except for shares which are fully paid up, and on consideration of their sale, to secure the debts and obligations of that shareholder to the Company, whether himself or with others, whether the date of payment of those debts or the date of discharge of those obligations has arrived or not arrived, whatever the source of those debts,

 

12



 

and no equitable rights shall be created on any share except as provided in Article 14 of these Articles of Association.

 

The above lien shall apply to all the dividends announced from time to time on those shares.

 

35.                                In order to enforce the above lien, the Board of Directors may sell the forfeited shares as it sees fit, at its discretion, but no share may be sold unless the period referred to in Article 28 above has elapsed and written notice was delivered to the shareholder, his heirs, the executors of his will or the managers of his estate, that the Company is considering selling the share, and the shareholder, his heirs or the executors of his will or managers of his estate have not paid the above debts or have not fulfilled or discharged the above obligations within 7 days of the date of sending the notice.

 

36.                                The net consideration from any such sale, after payment of the sale expenses, shall be used to pay the debts and discharge the obligations of that shareholder (including the debts, obligations and contracts for which the date of payment has not yet arrived), and the surplus (if remaining) shall be paid to him, his heirs, the executors of his will or the manages of his estate, or to whomever the shareholder transfers the right thereto.

 

37.                                If a sale was made after forfeiture or for enforcement of a lien, by way of prima facie exercise of the powers granted above, the Board of Directors may register those shares in the Shareholders Register in the name of the buyer, and the buyer shall not be required to ascertain the propriety of the actions or the manner of disposition of the proceeds of the sale, and after those shares are registered in his name, no Person shall appeal the validity of the sale.

 

38.                                (a)          (1)                      A Person who intends to buy shares or to contract in a transaction that will lead to a holding of shares in percentages that require the consent of the holder of the Special State Share, or a Person who holds shares in the Company in such percentages as a result of certain events, shall give immediate notice thereof to the company Secretary and shall deliver to the Company a power of attorney, whereby the Company shall be authorized to sell the shares held by him and of the holding of which he requires a permit or an additional permit, as the case may be, pursuant to the provisions of these Articles of association.  If the Company Secretary learns of a Person who ostensibly holds Company shares in such percentages, he shall notify that Person accordingly and demand that he submit a declaration of the percentages of his holdings in the Company, whether by himself or through others, and deliver to the Company a power of attorney as aforesaid.

 

(2)                                  Immediately after a Person has notified the Company Secretary as aforesaid, the Company Secretary shall request from the holder of the Special State Share, its consent to the holding. The Secretary shall attach to his request all the documents and information

 

13



 

relevant to the matter, as well as any additional information required by the holder of the Special State Share.

 

(3)                                  As long as the consent of the holder of the Special State Share to the holding of shares in the above percentages, as the case may be, has not been received in Writing, or if the holder of the Special State Share does not consent to approve such holding, a Person cannot receive or exercise, with regard to the Company, any right vested in a shareholder who holds shares in a percentage that exceeds the percentage for which the consent of the holder of the Special State Share is required. Without derogating from the aforesaid, a Person shall not appoint Directors in the Company in a number exceeding the number of Directors he would have been authorized to appoint according to the shares he holds and for the holding of which no permit or additional permit is required, as the case may be, and in General Meetings his vote shall be according to a vote count as per the percentage of the quantity of shares for the holding of which he does not require a permit or additional permit, as the case may be.

 

(4)                                  Having received the response of the holder of the Special State Share to the request for a permit for a holding as aforesaid, the Company shall act as follows:

 

(a)                      If the reply was positive — the holding or voting agreement shall be registered in the Company’s books, noting the granting of the permit and the terms stipulated therein.

 

(b)                      If the reply was negative — the Board of Directors or the Company Secretary shall inform whoever requested the permit of the reply, and demand of him to reduce the percentage of his holdings in the Company within a period to be set in the notice and which shall not exceed 30 days, to a lower percentage than that not permitted him. If within that period the shares were not transferred as aforesaid, the Board of Directors shall be required to sell the shares through the stock exchange or in an off-the-floor transaction, at such price and on such terms as it sees fit. Any decision or action made by the Board of Directors as aforesaid in this Article shall be final and absolute, and any transfer or sale of shares carried out in accordance with this Article shall be acceptable towards any third party.

 

Without derogating from the aforesaid, no allegation shall be entertained concerning the rights of the transferee may demand that the Company’s books be altered accordingly.

 

The provisions of these Articles of Association concerning forfeiture and lien of shares shall apply, mutatis mutandis , to a sale

 

14



 

of shares pursuant to this Article insofar as they do not contradict the aforesaid.

 

(5)                                  The registration of shareholders in the Shareholders Register or in the Material Shareholders Register can be done only after receipt of the consent of the holder of the Special State Share, insofar as it is required pursuant to these Articles of Association.

 

(6)                                  The Directors are not required to give reasons for their decisions on the mattes referred to in this Article. Any such decision shall be conveyed to a shareholder at his address as written in the Shareholder Register, and if there is no such address, it shall be published in at least two daily newspapers, and its publication shall constitute, in all matters and respects, notice delivered to the shareholder himself.

 

A change, amendment or cancellation of this Article 38(a) shall be deemed to be a change of the rights attaching to the Special State Share, and shall not be made without the consent of the holder of the Special State Share. Any decision or action which contravenes or does not comply with the provisions of this Article 38(a), shall be void and invalid without receipt of the consent of the holder of the Special State Share.

 

Any consent or waiver or approval of the holder of the Special State Share shall be given in Writing.

 

(b)                                  Subject to the aforesaid, fully paid up shares can be transferred without need for the approval of the Board of Directors.

 

The aforesaid notwithstanding, the Special State Share cannot be transferred.

 

39.                                No transfer of securities shall be registered unless a suitable deed of transfer is submitted to the Company. A deed of transfer of a Company security shall be signed by the transferor and the transferee, and the transferor shall be considered as the holder of the transferred security until registration of the name of the transferee in the Shareholders Register or in other registers maintained by the Company, as the case may be, in respect of the transferred security.

 

40.                                The deed of transfer of a security, in the form below or in as similar form as possible, or in any normal or acceptable form as approved by the Board of Directors or by the Company Secretary:

 

I,                         , of                                 , in consideration of NIS                      which was paid to me by                               of                                                    (hereinafter called “the Transferee”), hereby transfer to the Transferee          shares of NIS                  each, which are marked with the numbers                    to

 

15



 

                                      inclusive, of Israel Chemicals Ltd., to be held by the Transferee, the managers of his estate, his guardians and legal representatives, in accordance with the terms under which I held them prior to signing this deed, and I, the Transferee, hereby agree to accept the above shares on those terms.

 

In witness whereof we have affixed our signatures this            day of the month of           , in the year               .

 

The Transferor

 

The Transferee

Witness to the Transferor’s signature

 

Witness to the Transferee’s signature

 

41.                                Every deed of transfer of securities shall be submitted to the Office for registration, together with the certificates of the shares which are to be transferred if the deed is for a transfer of shares, and any other proof which the Company may demand concerning the proprietary right of the transferor or his right to transfer the securities. All deed of transfer, which are registered, shall remain in the hands of the Company.

 

42.                                The Company may demand payment of a fee for registration of the transfer, in an amount, which shall be determined by the Board of Directors from time to time.

 

Assignment of Securities (Transfer by Virtue of the Law)

 

43.                                Subject to the provisions of Article 8(b)(3) of these Articles of Association, upon the death of a holder of Company securities, the Company shall recognize the executors of the will or managers of the estate of a single holder of securities who died, and where there are no executors of a will or manages of an estate, Persons who have a benefit as the heirs of a single holder of securities who died, as the sole Persons having rights to the securities of the deceased. With regard to a security, which is registered in the names of two or more holders, the Company shall recognize as those with rights to the security only those who are still alive, but nothing aforesaid shall exempt the estate of the deceased joint holder of a security from any obligation in respect of any security that he jointly owned.

 

44.                                The Company may, subject to the provisions of Article 8(b)(3) of these Articles of Association, recognize a receiver or liquidator of a holder of a Company security which is a corporation in liquidation or winding down, or a trustee in bankruptcies or any receiver of a bankrupt holder of securities of the Company, as being entitled to a security registered in the name of such a holder of securities of the Company.

 

45.                                Whoever becomes entitled to a security due to his being a guardian or executor of an estate or the heir of a holder of securities of the Company or a receiver or liquidator or trustee in bankruptcies of a holder of securities of the Company or according to another provision of law, may, subject to the provisions of Article 8(b)(3) of these Articles of Association, upon presenting proof of his right — as the Board of Directors may demand — be registered as the owner of the security or

 

16



 

transfer it, subject to the provisions included in these Articles of Association in relation to transfer, to another Person.

 

46.                                Subject to the provisions of Article 8(b)(3) of these Articles of Association, anyone becoming entitled to a security as a result of the death or bankruptcy of its holder, or other transfer by virtue of the Law, shall be entitled to the same dividends and other rights as those to which he would have been entitled were he the registered holder of the security, except he shall not be entitled to exercise thereby any right which is granted to a holder of a security in the Company with regard to Company Meetings, before he is registered in relation to that security in the Shareholders Register or in other registers maintained by the Company, as the case may be.

 

Bearer Share Instrument

 

47.                                The Company may issue a bearer share instrument for a fully paid up share, subject to the provisions of the Law and its concomitant Regulations.

 

Redeemable Securities

 

48.                                The Company may, taking into consideration the provisions of the Law, issue redeemable securities and redeem them on terms which it stipulates. In redeeming such shares, the Company shall act in accordance with the provisions of the Law.

 

Conversion of shares to stock

 

49.                                With the prior approval of the Company at a General Meeting, the Board of Directors may convert fully paid up shares to stock, and it may also, with similar approval, reconvert the stock to paid up shares of any mount whatsoever.

 

50.                                Stockholders may transfer the stock, in whole or in part, in the same manner and in accordance with the same Articles to the extent possible, just as they could have transferred, before the conversion, the shares from which the stock was created; in addition, the Board of Directors may determine, from time to time, the minimum quantity of the stock which can be transferred, and may limit or forbid quantities smaller than that minimum, but the minimum shall not exceed the nominal sum of all the shares from which the stock was created.

 

51.                                Stockholders shall have, according to the percentage of stock they hold, the same rights and discounts relating to dividends and other matters as if they held the shares from which the stock was created. These rights and discounts, apart from the right to share in dividends and in the profits of the Company, shall not be acquired by a part of stock which, were it in shares, would not entitle its holder to that right or that discount.

 

52.                                Those Articles in these Articles of Association which apply to fully paid up shares shall apply also to stock, and the words “shares” and “shareholder” mentioned therein shall include also “stock” and “stockholder”.

 

17



 

Change of Capital

 

53.                                The Company may, from time to time, subject to the provisions of the Law, increase the registered share capital by creating new shares, whether all the shares whose issue has been decided upon have been issued by that time or not, and whether all the shares issued up to that time were fully called or not.

 

54.                                The increase referred to in Article 53 of these Articles of Association shall be of such amount and divided into shares of such par value, and shall be issued with such stipulations and terms and with such rights and additional rights attaching to them, as the resolution of creation of the shares shall provide, and in particular, the shares can be issued with a preferred or qualified right to dividends or distribution of assets and with a special right to vote or without any right to vote — all subject to the provisions of Article 10 of these Articles of Association.

 

55.                                Unless stated otherwise in the resolution on increasing the share capital, the new shares shall be subject to the exact same provisions concerning payment of calls, right of lien, forfeiture, transfer, delivery and all other provisions applicable to the shares of the original share capital.

 

56.                                The Company may:

 

(a)                                  consolidate and redivide its share capital into shares of a larger sum than the existing shares;

 

(b)                                  divide, by redistribution of all or some of its existing shares, its share capital, in whole or in part, into shares of a smaller sum that the sum stated in these Articles of Association;

 

(c)                                   cancel registered share capital that has not yet been allotted, provided that there is no Company undertaking, including a conditional undertaking to allot the shares;

 

(d)                                  reduce its share capital in the same way and on the same terms, to the extent required, as the Law requires.

 

57.                                The shareholders have no priority to buy new shares in the Company.

 

Authority to Borrow Money

 

58.                                Without derogating from the generality of the provisions of Article 107 of these Articles of Association, the Board of Directors may, from time to time, as it sees fit:

 

(a)                                  give approval for the Company to borrow money in any amount and ensure its repayment in any way to sees fit;

 

18



 

(b)                                  give approval for the Company to give guarantees, collateral and security of any kind whatsoever, which in the opinion of the Board of Directors can be given to the Company’s benefit, and this shall include the Company being authorized to issue bonds, stock of bonds, promissory notes and bills of exchange, capital notes and deposit certificates of any kind whatsoever, and other securities of any kind which are convertible into other securities of any kind, and also to pledge and place a lien on the assets and/or property of the Company, in whole or in part, whether in the present or in the future (including share capital not yet called, or called and not yet paid), whether a floating lien or a fixed lien.

 

(c)                                   Debentures and all types of deeds of commitment or other securities can be issued with a discount, at a premium or in any other way, and with privileges or deferred rights or other rights, all as the Board of Directors shall decide.

 

59.                                In cases where a Director or any Person is held personally liable for the payment of any amount of money which is firstly due from the Company, the Board of Directors may draw up or cause to be drawn up any mortgage, lien or security on the Company’s assets or any part thereof, as indemnity to secure the Directors or the Persons held liable as aforesaid, against any loss due to that liability.

 

General Meetings

 

60.                                60.1                         An Annual General Meeting shall convene once a year, not later than 15 months after the last Annual General Meeting, at the time and in the place determined by the Board of Directors. Such General Meetings shall be called “Annual Meetings”, and all the other meetings of the Company shall be called “Special Meetings”. The term “General Meeting”, insofar as it appears in these Articles of Association, shall relate to both types of meeting together.

 

60.2                         The agenda of an Annual Meeting shall include discussion of the financial statements, the Board of Directors’ report, the appointment of Directors and the appointment of an auditor (including reporting on the fees and other engagement with it); the agenda can include additional subjects decided upon by the Board of Directors, including a subject requested in advance of the Board of Directors by one or more shareholders who have at least one percent of the voting rights in the General Meeting, provided that the subject is appropriate for discussion in the General Meeting.

 

60.3                         The agenda at a Special Meeting shall be decided by the Board of Directors and shall include subjects for which the Special Meeting is required to be convened, and a subject requested in advance of the Board of Directors by one or more shareholders who has at least one percent of the voting rights in the General Meeting provided that the subject is appropriate for discussion in the General Meeting.

 

19


 

61.                                The Board of Directors may call a Special Meeting whenever it sees fit to do so. A Special Meeting can be convened upon the demand of a Director/s or shareholder/s as prescribed in Section 63 of the Law, and if the Board of Directors did not convene it upon such demand, those demanding it may convene it in accordance with Section 64 of the Law or may apply to the Court with a request that it convene it as provided in Section 65 of the Law.

 

62.                                62.1                               Notice of a General Meeting shall be published as required by the Law and state the type of meeting, the place and date of its convening, the subjects on the agenda, a summary of the proposed resolutions, the majority required for adoption of the resolutions, the record date for the shareholders to vote in the General Meeting, whether it has been determined that an adjourned Meeting will take place on a date later than that prescribed in the Law — that date, the telephone number and address of the registered Office of the Company, the dates on which the full text of the proposed resolutions can be viewed, whether there are subjects on the agenda of the Meeting which can be voted upon by written ballots — the quantity of shares constituting the percentage of all the voting rights, if any such percentage has been determined in regulations or in these Articles of Association, and all the details which the Law, its concomitant Regulations and any law requires to be provided.

 

62.2                         Notice of a General Meeting shall be submitted to the shareholders as required by law. Notice of a General Meeting shall be published in at least two daily Hebrew-language newspapers of wide circulation and on the Company’s website.

 

Discussions at General Meetings

 

63.                                No discussion shall be opened at a General Meeting unless a quorum is present at the opening of the Meeting. A quorum shall be constituted when there are present, in person or by proxy, two shareholders who together hold more than 50% of the issued shares granting voting rights in the Company.

 

64.                                If after the elapse of half an hour from the time set for the Meeting a quorum is not present, the Meeting shall be adjourned to the same day the following week, at the same time and in the same place, or to any other date and/or time and/or place, as the Board of Directors shall state in a notice to the shareholders; and if at the adjourned Meeting no quorum is present after the elapse of half an hour from the time set for the Meeting, then two shareholders with voting rights who hold at least one third of the issued share capital of the Company, who are present in person or by proxy, shall constitute a quorum, and may discuss and resolve the matters for which the Meeting was called.

 

65.                                The Chairman of the Board of Directors, and in his absence — the Vice-Chairman, if there is a Vice-Chairman, shall chair every General Meeting of the Company; if there is no Chairman or Vice-Chairman as aforesaid or he is not present after the

 

20



 

elapse of 15 minutes from the time set for the Meeting, or if either of them does not wish to chair the Meeting, the shareholders who are present at the Meeting shall elect one of themselves to chair the Meeting.

 

66.                                All resolutions of the General Meeting shall be adopted by a simple majority of the shareholders who are present at the Meeting and who vote on the resolutions, unless stated otherwise in the Law or in these Articles of Association.

 

67.                                The chairman of a General Meeting shall have an additional or casting vote.

 

68.                                Any proposed resolution which is submitted to the Meeting shall be resolved by a court of votes.

 

A change, amendment to cancellation of this Article 68 shall be deemed to be a change in the rights attaching to the Special State Share, and shall not be made except with the consent of the holder of the Special State Share. Any decision or action which contravenes or does not comply with the provisions of this Article 68 shall be void and invalid without receipt of the consent of the holder of the Special State Share.

 

Any consent, waiver or approval of the holder of the Special State Share shall be given in Writing.

 

69.                                A dispute concerning the acceptance or rejection of a vote shall be resolved by the chairman, and his decision shall be final and absolute.

 

70.                                The announcement by the chairman of the General Meeting that a resolution has been passed unanimously or by a certain majority or has been rejected, shall serve as prima facie evidence of that fact, and there shall be no need to prove the number of votes or the quota of votes which were cast in favor of the resolution or against it.

 

71.                                A General Meeting at which a quorum is present may resolve to adjourn the Meeting, the discussion or a decision on a resolution which appeared in the agenda, to another time or another place, but at the adjourned Meeting, the discussion shall be only of the subjects of which discussion was not completed at the Meeting that decided on the adjournment. Notice of the adjournment and of the subjects on the agenda of the Meeting that was adjourned, shall be given to all the shareholders in the way determined in Article 62 of these Articles of Association.

 

If a General Meeting is adjourned without changing its agenda, to a date which does not exceed 21 days, notices and invitations relating to the new date will be given as early as possible, and no later than seventy-two hours before the General Meeting.

 

72.                               The General Meeting may assume powers vested in another organ, and may decide that the powers vested in the CEO should be transferred to the authority of

 

21



 

the Board of Directors (or to the Chairman of the Board, to the extent permitted by law), all for a particular matter or for a certain period of time that does not exceed the time required under the circumstances.

 

Voting of the Shareholders

 

73.                                Subject to all the special terms, privileges and limitations concerning the voting of shareholders, which are attached at that time to any shares, in a vote by vote count, each shareholder who is present in person or by proxy or who is voting by means of a written ballot, shall have one vote for every share he owns that grants a voting right.

 

74.                                A corporation that holds shares in the Company may empower, by a resolution duly adopted by it, the Person it deems suitable to be its representative at any Meeting of the Company. A Person so empowered may exercise on behalf of the corporation he represents such powers as the corporation itself could exercise. A resolution shall be proven by the minutes or by another document, all in accordance with the organizational documents of the empowering company.

 

75.                                In a case of joint owners of a share, the vote of the first of the joint owners shall be accepted, as cast by him or his proxy, and the votes of the other joint owners shall not be accepted, and for this purpose, the question of who is the first of the joint owners shall be resolved according to the order in which the names appear in the Shareholders Register.

 

76.                                The shareholders may vote in person or by proxy or by means of a written ballot, or in the case of a corporation, by a representative as provided in Article 74 of these Articles of Association, or by a proxy or by means of a written ballot if the vote at that Meeting is by written ballots.

 

77.                                Any letter of appointment of a legal representative shall be signed by the appointer or by his legal representative who has written authority to do so, or, if the appointer is a corporation, the appointment shall be made in Writing, duly signed by the corporation or with the signature of its authorized legal representative.

 

78.                                No shareholder may vote at a General Meeting unless he has paid the calls and all the moneys due from him at that time for his shares.

 

79.                                Every letter of appointment of a legal representative, whether for a Meeting specifically referred to or otherwise, shall be, as far as circumstances allow, in the following form or in any other form approved from time to time by the Board of Directors or the Company Secretary:

 

I,                                  of                                   , as owner of                                 shares in Israel Chemicals Ltd., hereby appoint Mr./Mrs./Ms.                                   of                                     , or in his/her absence, Mr./Mrs./Ms.                                    of                                     , to vote for me at the (Annual /

 

22



 

Special) General Meeting of the Company which will be held on the          of                   ,              — and at any adjourned Meeting of that Meeting.

 

In witness whereof I have affixed my signature on the          day of                     ,           .

 

80.                                A vote according to the provisions of the document appointing a legal representative shall be valid despite the death of the appointer or cancellation of the power of attorney or transfer of the share in respect of which such vote was cast, unless written notice of the death, cancellation or transfer was received at the Company’s Office or by the chairman of the Meeting prior to the vote, and in case of cancellation of a power of attorney or a share transfer, if it was received at least 48 hours before the Meeting.

 

81.                                The shareholders may vote at a General Meeting and at a specific type of Meeting by means of a written ballot in any manner permitted by law, on which the shareholder shall write his vote, in resolutions on subjects prescribed in the Law, and including on any subject which is determined by the Board of Directors, all on the terms and dates prescribed in law.

 

Board of Directors

 

82.                                (a)                                  The number of members of the Board of Directors shall be decided by the General Meeting, and as long as not decided otherwise, shall not be less than 7 and not more than 20. The external Directors of the Company shall be included in the number of members of the Board of Directors.

 

(b)                                  The members of the Board of Directors shall be elected:

 

(i)                                      by the General Meeting; or

 

(ii)                                   by the Board of Directors of the Company as provided in Article 86 below.

 

(c)                                   All members of the Board of Directors shall hold office from the date of their election and/or appointment or from a later date if so decided in the appointment decision, until the subsequent General Meeting and subject to Article 87 of these Articles of Association.

 

(d)                                  The majority of the members of the Board of Directors shall be Israeli citizens and residents.

 

A change, amendment to cancellation of this Article 82(d) shall be deemed to be a change in the rights attaching to the Special State Share, and shall not be made except with the consent of the holder of the Special State Share. Any decision or action which contravenes or does not comply with the provisions of this Article 82(d), shall be void and invalid without receipt of the consent of the holder of the Special State Share.

 

23



 

Any consent, waiver or approval of the holder of the Special State Share shall be given in Writing.

 

(e)                                   At least two external Directors shall hold office in the Company. The provisions of the Law and its regulations shall apply to their appointment, qualifications, tenure and authority.

 

83.                                Notwithstanding everything prescribed in these Articles of Association, a Person who is not an Israeli citizen and resident shall not be elected and/or appointed a Director if, as a result of his appointment, the majority of the members of the Board of Directors will not be Israeli citizens and residents, and the election and/or appointment of such a Director shall not be valid and shall be seen as if it were never made.

 

A change, amendment to cancellation of this Article 83 shall be deemed to be a change in the rights attaching to the Special State Share, and shall not be made except with the consent of the holder of the Special State Share. Any decision or action which contravenes or does not comply with the provisions of this Article 83, shall be void and invalid without receipt of the consent of the holder of the Special State Share.

 

Any consent, waiver or approval of the holder of the Special State Share shall be given in Writing.

 

84.                                If a Director ceased to serve in his office for any reason whatsoever, and as a result thereof the majority of the members of the Board of Directors are not citizens and residents of Israel, in contravention of Articles 82(d) and 83, then the remaining Directors may act in any matter, subject to the provisions of Article 88 below, for 30 days only. If after the elapse of 30 days the composition of the Board of Directors has not changed so that most of its members are citizens and residents of Israel, the remaining Directors may act to convene a General Meeting of the Company, and only to the extent necessary.

 

A change, amendment to cancellation of this Article 84 shall be deemed to be a change in the rights attaching to the Special State Share, and shall not be made except with the consent of the holder of the Special State Share. Any decision or action, which contravenes or does not comply with the provisions of this Article 84, shall be void and invalid without receipt of the consent of the holder of the Special State Share.

 

Any consent, waiver or approval of the holder of the Special State Share shall be given in Writing.

 

85.                                A Director who has ceased to hold office can be re-elected subject to any law.

 

86.                               The Board of Directors may, from time to time, appoint an additional Director or Directors to the Company, whether in order to fill the office of a Director that has fallen vacant for any reason or as an additional Director or Directors, provided

 

24



 

that the total number of Directors does not exceed the maximum number stated Article 82 above. A Director appointed in this way shall end his term of office on the date of the Annual General Meeting held after his appointment.

 

87.                                A Director shall cease to hold office in each of these:

 

(a)                                  Upon his death.

 

(b)                                  If he is found to be legally incompetent.

 

(c)                                   If he goes bankrupt or has come to an arrangement with his creditors in bankruptcy proceedings.

 

(d)                                  If he gave notice of his resignation by written notice to the Company, to the Board of Directors or to the Chairman of the Board.

 

(e)                                   If his tenure was terminated by the General Meeting.

 

(f)                                    At the end of his term of office, unless he is appointed for an additional term.

 

(g)                                   If the Board of Directors adopted a resolution on the termination of his office, as provided in Section 231 of the Law.

 

(h)                                  If he was convicted of an offense, as prescribed in Section 232 of the Law.

 

(i)                                      In accordance with a decision of a court of law, as prescribed in Section 233 of the Law.

 

(j)                                     If there exists with respect to him one of the circumstances that disqualifies a Person from serving as a Director according to any law.

 

88.                                If no Director is elected or if the office of a Director falls vacant and no other Director is elected and/or appointed in his place, the remaining Directors may act in any matter as long as the minimum number of Directors as provided in Article 82 remains. If the number of Directors falls below that minimum, the remaining Directors shall act to convene a General Meeting of the Company as soon as possible to elect Directors, and until the convening of that Meeting, the remaining Directors may take essential actions only.

 

89.                                (a)                                  Subject to the provisions of these Articles of Association and the Law, a Director may hold paid office or position in the Company and/or in another company which holds shares in the Company and/or in which the Company holds shares and/or in which the Company has a benefit.

 

(b)                                  A transaction of the Company with one of its Officers that is not about his terms of service and employment, and a transaction of the Company with another Person in which an Officer of the Company has a

 

25



 

personal interest, and which is not an extraordinary transaction, shall be approved by the Board of Directors or whoever was appointed for that purpose by the Board of Directors or by the Audit Committee or by an Officer in the Company who has no personal interest in the transaction; however, an Officer in the Company and in a subsidiary controlled by the Company shall not be considered as having a personal interest in a transaction between the Company and the subsidiary due to his being an Officer in both companies or due to his being a shareholder or holder of securities exercisable for shares of the Company. An Officer of several subsidiaries of the Company that are controlled by the Company, shall not be considered as having a personal interest in a transaction between the said subsidiaries, due to his being an Officer in the transacting parties.

 

(c)                                   A transaction of the Company with one of its Officers and transaction of the Company with another Person in which the Company Officer has a personal interest, which is an extraordinary transaction, shall be approved by the Audit Committee and then by the Board of Directors of the Company.

 

(d)                                  An Officer owes a duty of loyalty to the Company, shall act in good faith and in its interests, including —

 

a.                                       he shall refrain from any action constituting a conflict of interests between fulfilling his function in the Company and fulfilling another of his functions or personal interests;

 

b.                                       he shall refrain from any action constituting competition with the business of the Company;

 

c.                                        he shall refrain from exploiting a business opportunity of the Company with the object of personal gain for himself or another;

 

d.                                       he shall disclose to the Company any item of information and shall convey to it any document relating to its affairs, which comes into his possession in his capacity in the Company.

 

(e)                                   The Company may approve any of the actions listed in Article 89(d) above, provided that the Officer acted in good faith and the action or its approval does not harm the good of the Company, and provided that the Officer disclosed to the Company, a reasonable time prior to the date of discussion of the approval, the nature of his personal interest in the action, including any material document or fact.

 

(f)                                    In this Article 89:

 

“extraordinary transaction” means — a transaction which is not in the ordinary course of the Company’s business, or a transaction which is not on

 

26



 

market terms, or a transaction liable to have a material effect on the profitability, assets or liabilities of the Company.

 

90.                                Subject to the provisions of any law, the Company may approve payment to any Director, of any amount which the Company deems appropriate as remuneration for his service as a Director and/or for his participation in meetings of the Board of Directors and/or meetings of the boards of directors of companies held by the Company and/or meetings of Board of Directors’ committees and/or as reimbursement for expenses incurred for participation in the aforementioned meetings and/or for additional services requested by the Board of Directors or management.

 

Chairman of the Board and Vice-Chairman of the Board

 

91.                                (a)                                  The Board of Directors shall elect one of its members to serve as Chairman of the Board, and it may terminate his office.

 

(b)                                  The Board of Directors may elect one of its members to serve as Vice-Chairman of the Board, whether permanently or for a particular meeting, and it may terminate his office if he was appointed.

 

(c)                                   If a Director ceases to serve as a Director in the Company and that Director is Chairman of the Board or Vice-Chairman of the Board, his office as Chairman of the Board or as Vice-Chairman of the Board, as the case may be, shall cease automatically.

 

(d)                                  In the absence of the Chairman of the Board, the Vice-Chairman of the Board shall serve as Chairman of the Board, and he shall have all the powers and authority granted to the Chairman of the Board in these Articles of Association.

 

The Work of the Board of Directors

 

92.                                (a) The Chairman of the Board shall call the meetings of the Board of Directors according to the needs of the Company.

 

(b)                                  The Board of Directors shall convene for meetings according to the needs of the Company and as required by law. The Chairman of the Board shall call the meetings of the Board of Directors and shall determine their time, place and agenda. The agenda of the Board of Directors meetings shall include subjects determined by the Chairman of the Board, subjects determined as provided in Article 92(e) below, and any subject which a Director or the CEO has requested a reasonable time prior to the convening of the Board of Directors that the Chairman of the Board include on the agenda.

 

(c)                                   The meetings of the Board of Directors shall be held generally in Israel.

 

27



 

A change, amendment to cancellation of this Article 92(c) shall be deemed to be a change in the rights attaching to the Special State Share, and shall not be made except with the consent of the holder of the Special State Share. Any decision or action, which contravenes or does not comply with the provisions of this Article 92(c), shall be void and invalid without receipt of the consent of the holder of the Special State Share.

 

Any consent, waiver or approval of the holder of the Special State Share shall be given in Writing.

 

(d)                                  The Chairman of the Board may convene a meeting of the Board of Directors at any time.

 

(e)                                   The Chairman of the Board shall convene a meeting, on a subject which will be described, upon the demand of one Director, or where notice or a report of the CEO requires an action of the Board of Directors, or where the auditor of the Company notifies the Chairman of the Board of material faults in the audit of the Company’s books.

 

If a meeting of the Board of Directors is not convened within 14 days of the date of the demand or from the date of the notice or report of the CEO or from the date of the notice of the auditor, each of those listed above may convene a meeting of the Board of Directors to discuss the subject described in the demand, notice or report, as the case may be.

 

93.                                (a)                                  An invitation to a meeting of the Board of Directors shall be made in Writing, by telephone, by facsimile or by email and shall be delivered to the Directors at least 48 hours prior to the date set for the meeting, unless the Chairman of the Board, and in his absence the Vice-Chairman of the Board, determines that an urgent meeting of the Board of Directors must be held, in which case the invitation to the Board of Directors can be upon shorter notice before the meeting, as the Chairman of the Board or the Vice-Chairman decides, as the case may be. The invitation to a meeting of the Board of Directors shall state the date and time of the meeting, the place where it will convene, and give reasonable detail of the subjects on the agenda.

 

(b)                                  A Director who is an Israeli resident, who is out of the country at any time, shall not be entitled, during his absence, to receive an invitation to a meeting of the Board of Directors, but his substitute shall be notified if, subject to the provisions of Article 97 of these Articles of Association, the Director is entitled to appoint a substitute.

 

94.                                The Chairman of the Board, and in his absence the Vice-Chairman of the Board, shall chair every meeting of the Board of Directors. If there is no such chairman or if he is not present after the elapse of 15 minutes from the time set for the meeting, or if he does not wish to chair the meeting, the members of the Board of

 

28



 

Directors who are present at the meeting shall elect one of themselves to chair that meeting.

 

95.                                The quorum for meetings of the Board of Directors is a majority of the members of the Board of Directors.

 

96.                                Resolutions of the Board of Directors shall be adopted by a majority of those participating in the vote. If the vote is tied — the Chairman of the Board shall have a casting vote.

 

97.                                (a)                                  Subject to the provisions of this Article, a Director can appoint another Person who is qualified to be appointed as a Director and who is not serving as a Director or as a substitute Director in the Company, and who shall be approved by the Board of Directors, as a substitute Director, and he may cancel his appointment, all in compliance with the provisions of Article 82(d) of these Articles of Association. The Board of Directors, at its exclusive discretion, can at any time cancel the appointment of a substitute Director. The appointment of a substitute Director and the cancellation of his appointment shall be effected by giving notice thereof to the Company, in Writing or in another way, as the Board of Directors shall decide.

 

Unless determined otherwise in these Articles of Association, a substitute Director shall be considered as a Director in all matters and respects, except in the matter of appointing a substitute Director and he shall bear responsibility for his actions as a substitute Director. The appointment of a substitute Director shall not negate the responsibility of the Director for whom he substitutes, and it shall apply with consideration of the circumstances of the matter, including the circumstances of the appointment of the substitute Director and the duration of his tenure.

 

(b)                                  Notwithstanding the provisions of Articles 97(a), a serving Director can appoint a substitute Director as a member of a committee of the Board of Directors, provided that the candidate to serve as substitute Director for the committee member does not serve as a member of the same committee, and if he is a substitute Director for an external Director, the candidate shall be an external Director with accounting and financial expertise or professional qualification equivalent to that of the substituted Director.

 

(c)                                   Subject to the provisions of his letter of appointment, a substitute Director shall have the same authority as that of the Director whose substitute he is, except for the authority to appoint a substitute Director.

 

(d)                                  A substitute Director shall cease to serve as such if the office of the Director for whom he serves as substitute falls vacant for any reason.

 

29


 

(e)                                   A substitute cannot be appointed for an external Director other than as provided in Article 97(b) of these Articles of Association.

 

98.                                Any meeting of the Board of Directors at which a quorum is present shall be empowered to exercise all the authority, powers of attorney and discretion vested at that time, according to the directives of the Company, in the Board of Directors or which are usually exercised by it.

 

99.                                Subject to the provisions of the Law and these Articles of Association, including the provisions of Article 100, any actions taken by or pursuant to a resolution of the Board of Directors, or by a committee of the Board of Directors, or by any Person serving as a Director, shall be valid even if it is found thereafter that there was a fault in the appointment of those Directors (except for a fault relating to appointment of a Director who is not a citizen or resident of Israel, as a result of which the majority of the members of the Board of Directors are not citizens and residents of Israel, in contravention of Articles 82(d) and 83 of these Articles of Association) or that committee, or that all or one of them were disqualified, as if each of them was duly appointed and as if they had the qualifications required to be a Director or as if that committee was duly appointed.

 

100.                         Any organ of the Company may approve any action within its purview and which was carried out without authorization by another organ of the Company or in excess of its authority, and from the time of approval, the approved actions shall be seen as if they were carried out from the outset within the purview of the organ authorized to carry it out, all as the case may be, and provided that decisions which were approved as aforesaid received the approvals required by the provisions of the Law (insofar as it applies to the Company) and subject to the provisions of the Law.

 

The aforesaid notwithstanding, approval of the General Meeting for an action carried out by the Board of Directors, if at the time it was carried out a majority of the members of the Board of Directors were not citizens and residents of Israel, shall be subject also to the approval of the holder of the Special State Share.

 

101.                         The Board of Directors may hold a meeting both by actually convening for discussion and by telephone conference call and/or video conference call for holding a discussion, or by any other reasonable means for holding a discussion which is decided upon by the Board of Directors, provided that all the participating Directors can hear each other simultaneously. The Company Secretary or a person acting on his behalf, shall take minutes at the meeting and the minutes shall be signed by the Chairman of the Board.

 

102.                         The Board of Directors may adopt resolutions even without actually convening, provided that all the Directors who are entitled to participate in the discussion and vote on the matter brought for a decision have agreed not to convene to discuss that matter. A resolution adopted without actually convening and to which all the Directors have agreed in Writing, by telephone or by facsimile, or by telegram, or

 

30



 

by electronic mail, or by any other reasonable means as the Board of Directors may decide from time to time, shall have the same effect for any purposes whatsoever as if it were adopted at a meeting of Board of Directors formally convened, provided that the Company Secretary or a person acting on his behalf records minutes of the resolutions (including the resolutions not to convene) and the minutes shall be signed by the Chairman of the Board.

 

103.                         (a)                                  The Board of Directors may establish from among its members permanent or ad hoc committees, and it may delegate of its powers to such committees, except for the matters listed in Section 112(a) of the Law, with respect to which it may delegate of its power to Board of Directors committees for the purpose of recommendation only, or to the General Manager as it sees fit and subject to the provisions of the Law. A Person who is not a member of the Board of Directors can serve also on a committee of the Board of Directors whose function is to advise the Board of Directors or to make recommendations only.

 

(b)                                  The Board of Directors may cancel a resolution of a committee which it appointed, but such rescission shall not prejudice the validity of a resolution pursuant to which the Company acted towards another Person who did not know of its cancellation.

 

104.                         The Board of Directors may cancel or change, from time to time, the delegation of authority it made pursuant to these Articles of Association.

 

105.                         The Board of Directors shall appoint an audit committee from among its members, the number of whose members shall be not less than three, and the provisions of the Law shall apply to its appointment, its members, its powers, attendance of its meetings and discussions, and its functions.

 

106.                         The provisions of these Articles of Association regulating the meetings and discussions of the Board of Directors shall apply also, mutatis mutandis, to meetings and actions of the Board of Directors committees and their discussions, unless determined otherwise in accordance with any law.

 

Without derogating from the generality of the aforesaid, and subject to any law, the quorum required for conducting the affairs of a Board of Directors committee shall be a majority of the members of the committee. The Board of Directors shall appoint a chairman for each Board of Directors committee. The Chairman of the Audit Committee shall be one of the Company’s external directors. Every resolution shall be adopted by a majority vote, and in the event of a tied vote, the chairman of the committee shall not have an additional or casting vote.

 

The Powers of the Board of Directors

 

107.                         The Board of Directors shall outline the policy of the Company and oversee the performance and actions of the CEO, all as prescribed in the Law. The Board of Directors shall have all the authority and powers and shall be competent to take

 

31



 

all the actions which the Company may exercise and take pursuant to these Articles of Association or the Law, and which these Articles of Association or the Law do not direct or require to be exercised or taken by another organ of the Company, all subject to the provisions of the Companies Law, these Articles of Association and any resolutions which do not conflict with the above provisions and articles, and as determined by the Company at the General Meeting, provided that no such resolution shall cancel the legal validity of an action taken prior thereto or by the Board of Directors or in accordance with its directives and which would have been legally valid if not for that resolution.

 

108.                         Without prejudice to the general powers vested in the Board of Directors in Article 197 of these Articles of Association, and the other powers granted it by law and these Articles of Association, and without thereby limiting or narrowing in any way whatsoever those powers or any of them, it is hereby expressly declared that the Board of Directors shall have the following powers:

 

(a)                                  To open, manage, defend, settle or abandon any legal proceedings for or against the Company or against its staff or relating in another way to its affairs, including arbitration proceedings, and to settle and extend the time for repayment or satisfaction of any debt payable, or claims or demands by the Company or against it, all where the matter concerns legal proceedings which are material to the Company.

 

(b)                                  To determine, from time to time, the signatory rights in the Company, including who shall be entitled to sign in the name of the Company on bills of exchange, promissory notes, receipts, takings, assigns, checks, dividend certificates, releases, contracts and other documents of any kind and type.

 

(c)                                   Subject to the provisions of the Law and these Articles of Association, to appoint and also, at its discretion, to remove, dismiss or suspend Officers, excluding Directors, as the Board of Directors sees fit from time to time, and to define their authority and duties and to set their salaries and demand security, in such cases and in such amounts as the Board of Directors deems appropriate.

 

(d)                                  At any time and from time to time, to appoint, under powers of attorney, any Person or Persons to be the legal representative or legal representatives of the Company for such purposes and with such authority and discretion (which shall not exceed those vested in or exercisable by the Board of Directors under these Articles of Association), and for such period and subject to such terms as the Board of Directors sees fit from time to time, and any such appointment can be given (if the Board of Directors sees fit) to any company or its shareholders, members of its board of directors, the representatives or managers of any company or firm or to whomever is named by any company or firm, or in another way

 

32



 

to any varying group of Persons, whether appointed directly or indirectly by the Board of Directors.

 

Any power of attorney as aforesaid can contain the same powers for the defense or convenience of Persons who come into contact with such legal representatives, as the Board of Directors deems appropriate.

 

(e)                                   The Board of Directors may appoint on behalf of the Company the legal counsel of the Company, to represent the Company before any court of law, legal bodies and quasi-legal bodies, governmental, municipal or other bodies or ministries in or outside Israel, and it may vest in the legal counsel of the Company those powers which the Board of Directors deems appropriate, including the authority to delegate all or some of its powers to another or others.

 

109.                         Without derogating from its other functions, the Board of Directors —

 

(1)                                  shall determine the plan of action of the Company, the principles for financing them and the order of priority among them;

 

(2)                                  shall review the financial condition of the Company and determine the credit framework that the Company is permitted to take upon itself;

 

(3)                                  shall decide on the organizational structure and the salary policy;

 

(4)                                  may decide on an issue of series of debentures;

 

(5)                                  is responsible for the preparation and approval of the financial statements;

 

(6)                                  shall report to the Annual Meeting on the state of the Company’s affairs and on its business results;

 

(7)                                  shall hire and fire the CEO;

 

(8)                                  shall decide on actions and transactions requiring its approval according to the Articles of Association or according to the provisions of Sections 255 and 268 — 275 of the Companies Law;

 

(9)                                  may allot shares and securities convertible to shares up to a limit of the registered share capital of the Company;

 

(10)                           may decide on a distribution as provided in Sections 307 and 308 of the Companies Law;

 

(11)                           shall give its opinion on a special tender offer;

 

33



 

(12)                           Subject to the provisions of the Companies Law and its regulations, the Board of Directors shall determine the minimum number of Directors required on the Board of Directors who must have accounting and financial expertise, taking into consideration, inter alia, the type of Company, its size, the scope and complexity of its operations, and subject to the number of Directors prescribed in the Articles of Association.

 

110.                         The Board of Directors shall ensure that the financial statements of the Company are drawn up each year, as well as any other report which the Company is required to update pursuant to the provisions of any law.

 

111.                         The Board of Directors may, at any time it deems necessary, demand of the Chairman of the Board and/or the CEO of any company in the ICL concern, a report and information in their possession on any matter, which in the opinion of the Board of Directors, relates to the affairs of the ICL concern.

 

Internal Auditor

 

112.                         (a)                                  The Board of Directors shall appoint to the Company, according to the proposal of the Audit Committee of the Company, an internal auditor. The appointment, powers and responsibility of the Internal Auditor shall be as prescribed in the Law.

 

(b)                                  The organizational superior of the Internal Auditor shall be the Chairman of the Board and/or the CEO, as the Board of Directors shall decide.

 

(c)                                   The Internal Auditor shall submit an annual or periodic work plan for the approval of the Audit Committee, and the Audit Committee shall approve it with any changes it considers appropriate.

 

CEO

 

113.                         The Board of Directors shall appoint a CEO of the Company.

 

114.                         The CEO is responsible for the day-to-day management of the Company’s affairs in the framework of the policy set by the Board of Directors and subject to its directives.

 

115.                         (a)                                  The CEO shall have the executive and managerial powers not vested in the Law or the Articles of Association in another organ of the Company, and he shall be under the supervision of the Board of Directors.

 

(b)                                  The CEO may, with the approval of the Board of Directors, delegate of his powers to another, who is subordinate to him.

 

116.                        The salary, social benefits, benefits, grants and other terms of employment of the CEO shall be determined by the Board of Directors.

 

34



 

117.                         (a)                                  The CEO shall answer to the Board of Directors in every matter, and he must notify the Chairman of the Board without delay, of any extraordinary matter which is material to the Company. If the Company has no Chairman of the Board or if he is prevented from fulfilling his function, the CEO shall give such notice to any of the members of the Board of Directors.

 

(b)                                  The CEO must report to the Board of Directors on subjects, at times and in a scope determined therefor by the Board of Directors. The Chairman of the Board may, at any time, on his own initiative or pursuant to a resolution of the Board of Directors, demand reports from the CEO on matters relating to the business of the Company.

 

(c)                                   The CEO shall deliver, once every three months, to the holder of the Special State Share, a report on all the transaction in assets which were approved by the Board of Directors in the three months preceding the date of the report, on changes in the holdings in the share capital and on voting agreements which he knows to have been signed, if signed, in that period among the shareholders of the Company.

 

A change, amendment to cancellation of this Article 117(c) shall be deemed to be a change in the rights attaching to the Special State Share, and shall not be made except with the consent of the holder of the Special State Share. Any decision or action, which contravenes or does not comply with the provisions of this Article 117(c), shall be void and invalid without receipt of the consent of the holder of the Special State Share.

 

Any consent, waiver or approval of the holder of the Special State Share shall be given in Writing.

 

118.                         (a)                                  The CEO shall cease to serve in any one of these:

 

(1)                                  the resigned by delivering a letter of resignation to the Chairman of the Board;

 

(2)                                  the Board of Directors removed him from his office in a resolution adopted by a majority of those participating in the vote;

 

(3)                                  the was disqualified from serving according to the Companies Law or another law; and

 

(4)                                  the Company went into liquidation.

 

(b)                                  The tenure of the CEO having expired, the Board of Directors may appoint an Acting CEO until a CEO is appointed in accordance with Article 113 of these Articles of Association.

 

35



 

119.                         (a)                                  The Board of Directors may suspend the CEO if it has grounds for suspecting that he has committed a criminal offense which caused the Company damage.

 

(b)                                  If the CEO was suspended, the Board of Directors may appoint an Acting CEO for the period of his suspension.

 

Shareholders Register

 

120.                         The Company shall prepare and maintain a Shareholders Register, and shall record therein the following details:

 

(a)                                  For registered shares —

 

(1)                                  the name, ID number and address of each shareholder, all as conveyed to the Company;

 

(2)                                  the quantity of shares and the class of shares owned by each shareholder, noting their par value, if any, and if any sum has not yet been paid on account of the consideration determined for the share — the sum not paid;

 

(3)                                  the date of allotment of the shares or the date of their transfer to the shareholder, as the case may be;

 

(4)                                  if the shares are marked with serial numbers, the Company shall note alongside the name of each shareholder the numbers of the shares registered in his name;

 

(5)                                  if the share was registered in the name of a nominees company or a trustee, the name of the nominees company or the trustee shall be noted.

 

(b)                                  For dormant shares as defined in the Law — also their number and the date on which they became dormant shares, as known to the Company.

 

121.                         The Company shall prepare and maintain, in addition to the Shareholders Register, the Material Shareholders Register, and shall keep therein the reports it received in accordance with the Securities Law, concerning the holdings of material shareholders in the Company.

 

122.                         The Shareholders Register and the Material Shareholders Register shall be kept in the head Office of the Company, and other than at times when they are closed pursuant to the provisions of the Companies Law, they shall be open during normal working hours and can be viewed by any Person.

 

36



 

Additional Shareholders Register outside Israel

 

123.                         The Company may maintain an additional shareholders register outside Israel.

 

124.                         The Company shall note in the Shareholders Register the number of shares registered in the additional shareholders register and their numbers, if they are marked with numbers.

 

Minutes

 

125.                         (a)                                  The Board of Directors shall ensure that minutes are properly taken in books prepared for this purpose, concerning:

 

(1)                                  the names of the Directors who are present at each meeting of the Board of Directors and at each meeting of a Board of Directors committee.

 

(2)                                  The names of the shareholders participating in each General Meeting.

 

(3)                                  The directives issued by the Board of Directors to the Board of Directors committees.

 

(4)                                  The resolutions and summary of the discussions at General Meetings, Board of Directors meetings and the meetings of Board of Directors committees.

 

Every such minutes from a Board of Directors meeting or from a meeting of a Board of Directors committee or from a General Meeting of the Company, if seen to be signed by the Director who conducted the meeting or by the chairman of that meeting, shall be accepted as prima facie evidence of the matters recorded therein.

 

(b)                                  The books of minutes of the General Meeting shall be kept in the head Office, and shall be available for viewing by the shareholders, free of charge.

 

Rights of Action and Signature in the name of the Company

 

126.                         The Board of Directors may empower any Person, even if not a Director, to act and to sign in the name of the Company, and any actions and signatures of such Person shall bind the Company if and to the extent that he acted and signed within his aforementioned purview.

 

Stamp

 

127.                        The Company can make a Stamp or rubber stamp for imprinting on documents.

 

37



 

Company Secretary

 

128.                         The Board of Directors may appoint a Person from time to time to be the Company Secretary, dismiss him and appoint another in his stead, and determine his functions and authority.

 

Dividends and Bonus Shares

 

129.                         The Board of Directors and the Company shall decide on the distribution of dividends and on the issue of bonus shares, all in accordance with the provisions of the Law.

 

130.                         The Board of Directors may, but is not required to, as it deems useful and appropriate, appoint trustees for those registered shareholders who have not fulfilled their duty to notify the Company of change of address and who have not approached the Company for receipt of dividends, shares or bonds from capital or other rights of benefit during the aforesaid period. These trustees shall be appointed for the realization, collection or receipt of dividends, shares or bonds, but may not transfer the original shares in respect of which they were appointed and may not vote by virtue thereof. Every condition of the trusteeship shall be made contingent by the Company that upon first demand by a shareholder in respect of whom the trustees serve, the trustees shall be bound to return to that shareholder the share in question or all the rights held by them for him (all as the case may be). Any action and arrangement made by these trustees and any agreement between the Board of Directors and these trustees shall be valid and binding upon all those concerned. If trustees are appointed as aforesaid, the Company shall publish notice in two Israeli daily newspapers of wide circulation concerning the appointment.

 

131.                         The Board of Directors may determine, from time to time, the method of payment of the dividends or distribution of the bonus shares and the arrangements in connection therewith, to registered shareholders. Without derogating from the generality of the aforesaid, the Board of Directors may pay any dividend or moneys in respect of shares by sending a check by registered mail to the address of the shareholder as written in the Shareholders Register. Any such dispatch of a check as aforesaid shall be done at the shareholder’s risk. The Board of Directors may also determine that the payment shall be made at the Office or anywhere else it may decide upon.

 

132.                         The Board of Directors may deduct from any dividend, grant or other moneys payable in connection with shares held by a member which are not yet fully paid up, whether he is their sole owner or a joint owner with another, any sum of money payable by him which he must pay, alone or jointly with any other Person, to the Company on account of payment, etc.

 

38


 

Financial Statements and Appointment of an Auditor

 

133.                         The Company shall keep accounts and draw up financial statements in accordance with the provisions of the Law.

 

134.                         The Company shall appoint, at each Annual Meeting, an auditor who shall serve in that capacity until the next Annual Meeting. The General Meeting may appoint an auditor to serve for a longer period which shall not extent beyond the Annual Meeting after the one at which it is appointed. The Company may appoint a number of auditors to carry out the auditing work jointly. The appointment, termination, authority, rights, and functions of the auditor shall be determined according to that prescribed in the Law. The fees of the auditor for the auditing and for additional services shall be set by the Board of Directors at its discretion.

 

135.                         The auditor shall receive an invitation to every Annual General Meeting of the Company, and may express his opinion there on everything connected with the fulfillment of his function.

 

136.                         The auditor is required to deliver to the Board of Directors upon its demand, information about the affairs of the Company, to carry out a special audit in the Company and to deliver a report on its results.

 

Office

 

137.                         The Office shall be in Israel, at a location decided from time to time by the Board of Directors.

 

Notices

 

138.                         The giving of notices or the delivery of documents in accordance with the provisions of any law or pursuant to these Articles of Association shall be carried out in the ways mentioned in this section hereunder, at the discretion of the Board of Directors and subject to any law.

 

The aforesaid notwithstanding, notices to the holder of the Special State Share shall be in Writing, sent by registered mail, and in accordance with the provisions of these Articles of Association.

 

139.                         The Company may deliver a notice or document, except for notice of the convening of a General Meeting (hereinafter in this chapter: the “ Notice ”), to a shareholder, whether by delivery by hand or by mail to his address as written in the Shareholders Register, or if no such address is written, to the address he gave to the Company for delivery of a Notice to him. If a Notice is sent by mail, it shall be deemed to have been properly delivered if the above address is written, stamps are affixed as required and the letter containing the Notice is sent by mail. Delivery shall be deemed made when the letter was delivered in the normal way by mail, and in any case, for an address in Israel, not more than three days, and for a letter to outside Israel, not more than fourteen days, from the date on which

 

39



 

the letter containing the Notice was sent by mail. Notice of a General Meeting shall be sent as prescribed in the Law and in its concomitant Regulations.

 

The aforesaid notwithstanding, a Notice to the holders of the Special State Share shall be sent by registered mail.

 

140.                         The Company may deliver any Notice to the shareholders, including a Notice concerning the convening of a General Meeting, by publishing the Notice in two daily Israeli Hebrew-language newspapers of wide circulation, and the date of publication in the newspaper shall be considered the date on which the Notice was received by the shareholders.

 

141.                         For joint owners of a share, the Company may deliver a Notice or document by sending them to the joint owner listed first in the Shareholders Register for that share.

 

142.                         As long as a Notice must be given several days in advance or for a Notice which remains in effect for a certain period, the date of delivery shall be counted in the number of days or the period unless determined otherwise. If a Notice is given in more than one of the ways mentioned above, it shall be deemed to have been received on the earliest date.

 

143.                         Delivery of a Notice or document to one of the family members living with the Person for whom it is intended, shall be deemed to be delivery into the hands of that Person.

 

144.                         Subject to the provisions of any law, a shareholder, Director, CEO or other Person who is entitled to receive a Notice pursuant to these Articles of Association or the Law, may waive its receipt, whether in advance or retroactively, whether in a specific instance or in general, and having done so, he shall be considered as having duly received the Notice, and any proceeding or action in respect of which the Notice was to have been given shall be deemed as valid and abiding.

 

145.                         A Person who became entitled to any share by virtue of law, transfer or in any other way, shall be related in any Notice in respect of such share, which was properly delivered before his name was registered in the Shareholders Register, to the Person from whom his right to the share derives.

 

146.                         Any Notice which is sent by mail to a shareholder or which is left at his registered address as prescribed in these Articles of Association, or which was published in the newspaper in accordance with Article 140 of these Articles of Association, and any Notice of a General Meeting which was delivered as prescribed in the Law and in its concomitant Regulations, then even if that shareholder has died — and it is immaterial whether the Company knew of his death or not — the Notice shall be considered as having been properly delivered at its destination in relation to all registered shares, whether they were held by that shareholder separately or jointly with other Persons, until another Person is registered in his stead as the owner or joint owner thereof, and such delivery shall be considered, for all the

 

40



 

purposes of these Articles of Association, as sufficient delivery of the Notice or the Notice of a General Meeting to his personal representative and to all Persons, if any, who have a joint interest with him in those shares.

 

Liquidation

 

147.                         In the matter of Article 8(a)(5) of these Articles of Association, anyone who submitted an application for shares and the shares have not yet been allotted to him, shall be considered, prior to liquidation, as if the shares included in his application had been allotted to him and the sum payable on account of the par value of those shares had been paid up.

 

148.                         Subject to the provisions of the Law and the provisions of the Companies Ordinance (New Version), 5743-1983 (as long as it remains in effect or any law that supersedes it), the liquidator, upon a resolution of the General Meeting, may distribute the surplus assets in kind among the shareholders, in whole or in part, and the liquidator may also, upon a resolution of the Company as aforesaid, deposit any part of the surplus assets in the hands of the trustees, who will hold them in trust for the shareholders as the liquidator sees fit. For the distribution of surplus assets in kind, the liquidator may determine the fair value of the assets to be distributed, and decide how the distribution will be carried out among the shareholders, taking into consideration the rights attaching to the various classes of shares in the Company which they hold.

 

Merger

 

149.                         Approval of a merger in accordance with Chapter One of Part Eight of the Companies Law shall require the approval of the General Meeting by a simple majority of those present and voting.

 

Indemnification, Exemption and Insurance of Officers

 

150.                         Subject to the provisions of the Companies Law and the Securities Law, the Company may provide an undertaking to indemnify an Officer in the Company for a liability or expense as described below, which was imposed upon him or which he incurred due to an action he took in his capacity as an Officer of the Company, in each of the following instances:

 

(a)                                  A monetary liability imposed upon him in favor of another Person in a court decision, including a decision given in a settlement or in an arbitrator’s award approved by a court of law.

 

(b)                                  Reasonable litigation expenses, including attorney’s fees, incurred by an Officer due to an investigation or proceeding conducted against him by an authority competent to conduct an investigation or proceeding, and which ended without an indictment being filed against him and without any financial penalty being imposed upon him in lieu of a criminal proceeding, or which ended without an indictment being filed against him but with the

 

41



 

imposition of a financial liability in lieu of a criminal proceeding that does not require proof of criminal intent or in connection with a financial sanction. In this clause — “a proceeding which ended without an indictment being filed against him on a matter for which a criminal investigation was opened” and “financial penalty in lieu of a criminal proceeding” — as referred to in Section 260(a)(1a) of the Companies Law, as may be amended from time to time.

 

(c)                                   Reasonable litigation expenses, including attorney’s fees, incurred by an Officer or which he was ordered to pay by a court of law, in a proceeding filed against him by the Company or in its name or by another Person, or in a criminal indictment of which he was acquitted, or in a criminal indictment in which he was convicted of an offense which does not require proof of criminal intent.

 

(d)                                  Expenses that he incurred in connection with an administrative proceeding conducted against him, including reasonable litigation expenses, including lawyers’ fees.

 

(e)                                   Payment to a victim of breach in connection with an administrative proceeding as provided in Section 52(54)(A)(1)(a) of the Securities Law, as may be amended from time to time (“Payment to a Breach Victim”).

 

(f)                                    Indemnification, as mentioned above in this in Article 150, may be given by way of an undertaking in advance to indemnify, as follows: (1) as stipulated in subsection (a) above, provided that the undertaking to indemnify is limited to events that in the opinion of the Board of Directors can be foreseen at the time of granting the undertaking to indemnify, and to a sum or criterion determined by the Board of Directors as reasonable in the circumstances of the case, and that the undertaking to indemnify lists the events that in the opinion of the Board of Directors can be foreseen at the time of granting the undertaking in view of the Company’s actual activity, and the sum or criteria specified by the Board of Directors as reasonable under the circumstances; (2) in respect of the events specified in sub-sections (b)-(e) above (inclusive); or by way of indemnification ex post facto, and all as stipulated in Section 260(b) of the Companies Law and Section 56H(b) of the Securities Law, as may be amended from time to time.

 

(g)                                   Any other expense or liability permitted for indemnification according to the Companies Law.

 

151.                         Subject to the provisions of the Law, the Company may exempt an Officer in advance from his liability, in whole or in part, for damage due to infringement of the duty of care toward it, except due to breach of the duty of care in a distribution.

 

42



 

152.                         Subject to the provisions of the Law, the Company may enter into a contract for insurance of the liability of one of its Officers due to a duty imposed upon him for an action he took in his capacity as an Officer, in each of these:

 

(a)                                  breach of the duty of care toward the Company or toward another Person;

 

(b)                                  breach of the duty of loyalty toward it, provided that the Officer acted in good faith and had reasonable grounds for assuming that the action would not harm the interests of the Company;

 

(c)                                   a monetary liability imposed upon him in favor of another Person;

 

(d)                                  expenses that an Officer incurred in connection with an administrative proceeding conducted against him, including reasonable litigation expenses, including lawyers’ fees;

 

(e)                                   payment to a breach victim.

 

153.                         The Company may not enter into a contract for insurance of the liability of one of its Officers, or adopt a resolution concerning indemnification of an Officer or adopt a resolution exempting an Officer from his liability toward the Company, for each of these:

 

(a)                                  breach of duty of loyalty, except for the matter of indemnity and insurance for duty of loyalty, as prescribed in Article 152(b) above;

 

(b)                                  deliberate or reckless breach of the duty of care, except if done negligently only;

 

(c)                                   an action taken with the intention of making unlawful personal gain;

 

(d)                                  a penalty or fine imposed upon him.

 

Change of the Articles of Association

 

154.                         The Company may change the Articles of Association by a resolution passed at the General Meeting by a simple majority of the shareholders who attend and vote, excluding abstentions. A change in the rights attaching to the Special State Share requires the consent of its holder, all as provided in Article 8|(b) above.

 

* * * * * *

 

43




Exhibit 5.1

FORM OF OPINION OF COUNSEL

Goldfarb Seligman & Co.
Electra Tower
98 Yigal Alon Street
Tel Aviv 6789141, Israel

September 12, 2014                        

Israel Chemicals Ltd.
Millennium Tower
23 Aranha Street
Tel Aviv, 61202 Israel

Ladies and Gentlemen:

        We refer to the Registration Statement on Form F-1, as amended (the "Registration Statement") to be filed on or about the date hereof with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the "Securities Act"), on behalf of Israel Chemicals Ltd., an Israeli company (the "Company"), relating to the sale of up to 77,000,000 of the Company's ordinary shares, par value NIS 1.00 per share (the "Shares"), held by Israel Corporation Ltd.

        We are members of the Israeli bar and we express no opinion as to any matter relating to the laws of any jurisdiction other than the laws of Israel.

        In connection with this opinion, we have examined such corporate records, other documents and such questions of Israeli law as we have considered necessary or appropriate for the purposes of this opinion. In such examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all copies submitted to us, the authenticity of the originals of such copies and, as to matters of fact, the accuracy of all statements and representations made by officers of the Company.

        Based on the foregoing and subject to the qualifications stated herein, we advise you, that in our opinion, the Shares are duly authorized, validly issued, fully paid and non-assessable.

        This opinion is rendered as of the date hereof, and we undertake no obligation to advise you of any changes in applicable law or any other matters that may come to our attention after the date hereof that may affect this opinion.

        We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us in the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act, or the rules and regulations promulgated thereunder, nor do we thereby admit that we are experts with respect to any part of the Registration Statement within the meaning of the term "experts" as used in the Securities Act or the rules and regulations promulgated thereunder.

    Sincerely yours,

 

 

/s/ Goldfarb Seligman & Co.



Exhibit 8.1

 

September 12, 2014

 

Israel Chemicals Ltd.

Millennium Tower

23 Aranha Street

P.O. Box 20245

Tel Aviv, 61202 Israel

 

We are acting as United States counsel to Israel Chemicals Ltd., a company incorporated in Israel (the “Company”), in connection with the preparation of the registration statement on Form F-1 (the “Registration Statement”) and the related prospectus (the “Prospectus”) with respect to  the Company’s  public offering of its ordinary shares. The Company is filing the Registration Statement with the Securities and Exchange Commission under the Securities Act of 1933, as amended.

 

We have examined such matters of fact and law as we have deemed necessary or advisable for the purpose of our opinion.

 

We hereby confirm that the statements with respect to U.S. federal income tax law included under the caption “Tax Considerations—Material U.S. Federal Income Tax Considerations for U.S. Holders” constitute our opinion as to the material U.S. federal income tax consequences to “U.S. Holders” described therein of an investment in the Company’s ordinary shares.

 

We are members of the Bar of the State of New York, and we express no opinion as to the laws of any jurisdiction other than the laws of the State of New York and the federal laws of the United States.

 

We hereby consent to the use of our name under the caption “Tax Considerations” in the Prospectus included in the Registration Statement and to the filing, as an exhibit to the Registration Statement, of this letter.

 

In giving such consent we do not admit that we come within the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended.

 

Very truly yours,

 

/s/ Davis Polk & Wardwell LLP

 


 



Exhibit 8.2

 

Goldfarb Seligman & Co.

Electra Tower

98 Yigal Alon Street

Tel Aviv 6789141, Israel

 

 

September 12, 2014

 

Israel Chemicals Ltd.

 

Millennium Tower

 

23 Aranha Street

 

Tel Aviv, 61202 Israel

 

 

Ladies and Gentlemen:

 

In connection with the registration under the Securities Act of 1933, as amended (the “Securities Act”), of the resale of ordinary shares, par value NIS 1.00 per share (the “Ordinary Shares”), of Israel Chemicals Ltd., a company organized under the laws of the State of Israel (the “Company”), we, as your counsel, have examined such corporate records, certificates and other documents, and such questions of law, as we have considered necessary or appropriate for the purposes of this opinion.

 

Upon the basis of such examination, we advise you that, in our opinion, the discussion included in the Company’s Registration Statement on Form F-1 relating to the Ordinary Shares filed on or about the date hereof (the “Registration Statement”) under the caption “Tax Considerations—Israeli Tax Considerations—Taxation of Investors”, insofar as it relates to statements of law and legal conclusions, describes the material Israeli income tax consequences to the investors described therein of owning and disposing of Ordinary Shares, subject to the limitations and qualifications set forth therein.

 

The foregoing opinion is limited to the laws of the State of Israel and we are expressing no opinion as to the effect of the laws of any other jurisdiction.

 

This opinion addresses only matters set forth herein. This opinion does not address any other Israeli tax consequences or any state, local or foreign tax consequences that may result from the owning and disposing of Ordinary Shares. Our opinion is not binding on the Israel Tax Authority, and a court or the Israel Tax Authority may disagree with our opinion. This opinion is based upon current provisions of the Israeli Income Tax Ordinance [New Version], 1961, as amended, and the rules and regulations promulgated thereunder, and existing administrative and judicial interpretations thereof, all of which are subject to change, potentially with retroactive effect, which could adversely affect this opinion. We do not undertake to advise you as to any changes after the date hereof in applicable law or administrative or judicial rulings that may affect this opinion .

 

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to us in the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act, or the rules and regulations promulgated thereunder, nor do we thereby admit that we are experts with respect to any part of the Registration Statement within the meaning of the term “experts” as used in the Securities Act or the rules and regulations promulgated thereunder .

 

 

Very truly yours,

 

 

 

/s/ Goldfarb Seligman & Co.

 

Goldfarb Seligman & Co.

 




Exhibit 10.1

 

DEAD SEA CONCESSION LAW, 1961(1)

 

1.                    Concession

 

The Deed of Concession in the Schedule to this Law, made between the State and the Concession-holder named in it, is seen as valid for all its purposes notwithstanding the provisions of any law.

 

2.                    Subconcessions

 

Any subconcession granted in accordance with the provisions of section 5 of the Deed of Concession shall be published in the Official Gazette, and once published, shall be seen as valid for all its purposes notwithstanding the provisions of any law.

 

3.                    Implementation

 

The Ministers of Finance and of Development are responsible for the implementation of this Law.

 

SCHEDULE

 

This Deed of Concession was made on May 30, 1961 between the State of Israel, represented by the Government of Israel, acting through the Minister of Finance and the Minister of Development (“the Government”), of the first part;

 

And Dead Sea Works Ltd., a company incorporated under the laws of Israel, whose registered office is in Beit Ha’ashlag in Be’er Sheva (“the Concession-holder”), of the second part; since —

 

(a)               Minerals from the Dead Sea and the areas in its vicinity are part of the natural resources of the State of Israel, and their exploitation should be regulated in the economic interests of the State;

 

(b)               the Concession-holder was incorporated with the aim, inter alia, of examining, researching and developing the natural mineral resources of the Dead Sea and the areas in its vicinity;

 

(c)                the Concession-holder, since its incorporation, has developed and exploited some of these natural mining resources, and in the same context has purchased and built, in the southern section of the Dead Sea and in its vicinity, certain plants and facilities;

 

(d)               the Concession-holder has applied to the Government for the concession written below, and the Government is ready to grant it to the Concession-holder on the terms and stipulations set forth below; therefore, this Deed of Concessions attests and it is hereby agreed and declared as follows:

 


(1)  Enacted by the Knesset on May 31, 1961. See Dead Sea Concession Law, 1961.

 



 

1.                    Definitions

 

The words and expressions below shall have the meanings alongside them unless the context requires otherwise; and they are: Local Taxes — any municipal or other tax imposed at any time by a local authority in connection with the plant’s business, property or income (excluding government taxes, local taxes, levies and mandatory government payments);

 

the Concession-holder — Dead Sea Works Ltd. and its substitutes according to this Deed of Concession;

 

the Concession — The Concession awarded in this Deed of Concession;

 

the Plant — The business of extracting mineral salts, minerals and chemicals, their preparation for marketing, their sale and dealing in them and all those businesses, property and things required for or associated with them, all according to this Concession;

 

the Minister — The Ministers of Finance and Development;

 

Month — A Gregorian calendar month;

 

Ton — a metric ton of 1000 kilograms;

 

the Dead Sea — (a) The waters and bed of that part of the Dead Sea within the borders of the State of Israel and shown on Map “A” attached to this Deed of Concession, signed by the parties to it and an integral part thereof, and (b) the evaporation area shown on that Map “A”, and delineated by a dotted black line, and (c) the coastal strip enclosed by: to the north — coordinate line 100, to the south — the aforementioned evaporation area, to the east — the water line shown on Map “A”, and to the west — the imaginary line parallel to the aforementioned water line and 150 meters from it.

 

Fixed Tangible Assets — land, buildings, factories, machinery, dams, embankments, evaporation ponds, culverts, water barriers, pumping stations, anti-flood installations, fixed pipes and other equipment of any kind, which are part of the Plant and are in the leased land, in the reserved land or in the Dead Sea.

 

Land — Including any right, benefit or right of use of or lien in or on the Land;

 

Leased Land — The land leased at the time to the Concession-holder pursuant to section 6 of this Deed;

 

Reserved Land — The land shown on the aforementioned Map “A” and marked by a pattern of thick crossing black lines;

 

Auditor — Whoever serves at the time as auditor or auditors of the Concession-holder;

 

Local Authority — Including municipality, local council, regional council and any other local body entitled to impose municipal taxes;

 

Year — 12 consecutive months;

 

Start Date — The day on which the Law approving the Concession comes into force.

 

2



 

2.                    Grant of Concession

 

The Government hereby grants to the Concession-holder the following Concession:

 

(a)               the exclusive right to extract by way of evaporation (solar or artificial), cooling, mining, quarrying or in any other way, the mineral salts, minerals and chemicals, whether in solution or in solid form, which are in and beneath the Dead Sea, and to prepare them for marketing, to sell them and to deal in them;

 

(b)               the exclusive right — subject to all the rights existing on the date of this Deed, and subject to the provisions of section 3(3) below — to make, expand, modify, maintain and demolish, in and beneath the Dead Sea, any works, including — but without derogating from the generality of the aforesaid — embankments, evaporation ponds, culverts, water barriers, pumping stations, canals, pipes, electricity lines and electricity cables, roads, anti-flood installations, wells and bores and other installations, together with the exclusive right of access to and use of those works;

 

(c)                the right to sail vessels in the Dead Sea for the purposes of the Plant, subject to the laws applicable at the time;

 

(d)               the right — with the approval of the competent authority and subject to the rights existing on the date of this Deed — and subject to any right that may be granted after that date as in section 1(9)(b) of this Deed — to take all or some of the following actions in the Leased Land and in the Reserved Land;

 

(1)              to extract, by way of quarrying, mining or by any other production method, Dolomite rock and other rocks and mineral salts, minerals and chemicals as are required from time to time by the Concession-holder for any process that uses mineral salts, minerals and chemicals that are extracted or extractable from the Dead Sea, and to dig for the production of rock-salt at Mount Sdom or in its vicinity; and

 

(2)              to dig for the production of the materials required for the construction, expansion and maintenance of the Plant;

 

the competent authority shall not refuse its approval according to this sub-section, and it shall be granted within 30 days of the date of application for it;

 

(e)                the right, subject to the approval of the competent water authority — and that approval shall not be delayed or suspended unreasonably — to obtain sweet or semi-sweet water required for the production of the mineral salts, minerals and chemicals, for drinking, bathing or sanitation needs and for the general purposes of the Plant and of the workers of the Concession-holder, from streams or springs that flow through the Leased Lands and the Reserved Lands or rise from them or from wells in them or from any tributaries that flow to the Dead Sea, and to drill for discovery of sweet or semi-sweet water in the Leased Land and in the Reserved Land, and in that context to dig wells, to lay pipes, to build pumping stations and to do other works required for or associated with the aforesaid.

 

3



 

3.                    Exceptions and restrictions

 

(1)               Excluded from the grants described above and reserved to the Government —

 

(a)               Gold, silver or other precious metals and their dusts, precious stones, copper and iron dust, antiquities and oil — as defined in the Oil Law, 1952 (all of the foregoing are hereinafter together called the “Materials Outside the Confines of the Concession”) in or beneath the Dead Sea and in the Leased Land or the Reserved Land or beneath them;

 

(b)               the right to enter any facility and property of the Concession-holder in or beneath the Dead Sea, in the Leased Land, the Reserved Land and beneath them, for the purpose of examination or audit in connection with sub-section (1)(a) of this section.

 

(2)               Immediately upon discovery of a material from the Materials Outside the Confines of the Concession, the Concession-holder shall deliver notice to the Government of such discovery, and shall permit the Government or any person authorized by the Government to enter any location mentioned in sub-section 1(b) to search for and extract the Materials Outside the Confines of the Concession, and the Government shall pay the Concession-holder compensation for any damage caused to it in so doing.

 

(3)               The Government may permit any person to erect on the Coastal Strip mentioned in sub- section (c) of the definition of the Dead Sea, works which are not relevant to the Plant, provided that those works do not disturb or compete with the Plant or its development.

 

Before permitting such works, the Government shall deliver to the Concession-holder written notice, not less than four months in advance, of its intention, and shall describe in that notice the location and area of the Coastal Strip where the Government proposes to grant such a permit and the nature of the work that will be done there, and the Concession-holder may, within four months from the date of receipt of that notice, notify the Government in writing that it opposes grant of the proposed permit and the reasons for its opposition. If the Government rejects the opposition, the matter shall be referred to arbitration in accordance with section 26 below, and shall be resolved by it before such a permit is granted. If within four months of the date of receipt of the aforementioned notice the Concession-holder fails to give notice of its opposition to grant of the permit, the Concession-holder shall be seen as agreeing to grant of the permit.

 

4.                    Term of Concession

 

The term of the Concession shall be for the period starting on the date on which the law approving the Concession comes into force and ending March 31, 1999.

 

5.                    Subconcessions

 

(a)               The Concession-holder shall be entitled, with the consent of the Government and the approval of the Knesset Finance Committee, to grant subconcessions by virtue of the Concession.

 

(b)               The Concession-holder having granted a subconcession in accordance with the terms of this Deed of Concession, the subconcession-holder shall have, subject to the provisions of the subconcession, all the rights, privileges, authority and immunities, the duties and the obligations of the Concession-holder if those were granted to the subconcession-holder or imposed upon it in that subconcession, all as part of this Deed of Concession.

 

4



 

6.                    Land

 

(a)               The Government hereby leases to the Concession-holder for the term of the Concession, the Land shown on Map “A” in black, on the terms and under the guidelines set forth below.

 

(b)               The rent to be paid for the Land mentioned in sub-section (a) of this section, for the first ten Years of the lease, is IS 10, which will be paid upon the Government’s demand, and thereafter the rent shall be fair, based on the value of that Land, irrespective of any rise in its value owing to the actions or needs of the Concession-holder.

 

The rent for the period after the end of the first ten years of the lease shall be paid once a year in advance on the anniversary of the date of the Concession.

 

(c)                Whenever so required by the Concession-holder, the Government shall lease, or shall ensure that the Development Authority or Israel Lands Administration leases, to the Concession- holder for the remainder of the term of the Concession, any part of the Reserved Land granted to the State or to the Development Authority that is required by the Plant. For the first ten years from the Start Date the rent to be paid for that Land shall be symbolic, and thereafter the rent shall be fair, based on the value of that Land, irrespective of any rise in the value of the Land owing to the actions or needs of the Concession-holder and on the terms applicable to the Land mentioned in sub-section (a) of this section, mutatis mutandis.

 

(d)               The Concession-holder shall use the Leased Land only for the Plant’s purposes.

 

(e)                All the public roads passing through the Leased Land are excluded from any lease under this section.

 

(f)                 If at the end of the first ten years from the Start Date it transpires that reasonably, the Concession-holder does not need all the Land included in the lease granted under sub-section (c) of this section for the Plant’s purposes, taking into account the output capacity of the Plant at that time, the Government shall be entitled at any time thereafter to demand of the Concession-holder, by delivery of written notice at least 12 months in advance, that it return the part it does not require. However, no such return shall prevent the Concession-holder from thereafter demanding that the Government lease that same Land to it or ensure its lease to it in accordance with sub-section (c) of this section.

 

(g)                Land required by the Plant within the area of the Reserved Land which is not Land granted to the Government or to the Development Authority, shall be acquired through negotiation between the Concession-holder and the persons entitled to that Land, and if they cannot reach agreement, that Land shall be expropriated by the Minister of Finance in accordance with the provisions of the Lands (Acquisition for public purposes) Ordinance, 1943.

 

(h)               Where Land is acquired by way of negotiation or expropriation, as provided in sub-section (g) of this section, its price or the compensation for it shall be paid by the Concession-holder, and ownership of that Land shall be granted to the Concession-holder.

 

(i)                   The Concession-holder shall be entitled to grant sub-leases or licenses for any of the Lands leased to it under this Deed of Concession, to any subconcession-holder according to section 5 above or — with the consent of the Government — to others.

 

5



 

7.                    Registration of Government Lands

 

The Government shall ensure that the leases of Lands leased at the time according to section 5 above are registered as quickly as possible in the name of the Concession-holder at the competent Lands Registry office, but it is hereby declared that any such lease shall be valid even if no registration was made as aforesaid, provided that within 30 days of receipt of notice thereof from the Government, the Concession-holder appears at the competent Lands Registry office and signs all the documents required for such registration. This registration and the issue of registration certificates to the Concession-holder in respect of those Lands, shall be without payment of a registration fee or any other levy.

 

8.                    Pledge

 

For Lands leased without the prior written consent of the Minister, the Concession-holder shall not be entitled to create any mortgage or fixed lien on the right of lease on the Leased Land. Any such consensual mortgage or fixed lien for the Leased Land which is not registered at the Lands Registry office, shall be valid despite non-registration, provided that the mortgage was duly registered in accordance with section 127 of the Companies Ordinance and provided also that the holder of that mortgage or of that lien applies to the competent Lands Registry office to register the mortgage or the lien within three months of receipt of the Government’s notice of registration of the Land at the competent Lands Registry office.

 

9.                    Reserved Land

 

(1)               Throughout the term of the Concession, the Government —

 

(a)               shall not grant to any person other than the Concession-holder any lease, possession or license in the Reserved Land without first offering them to the Concession-holder on the terns prescribed in section 6(c) of this Deed of Concession; and

 

(b)               shall not grant to any person other than the Concession-holder any right, license or concession in or on the Reserved Land, for mining or for exploration by other means, of any mineral salts, minerals and chemicals that can be extracted from the Dead Sea, without first offering that right, license or concession to the Concession-holder. If the Concession-holder does not accept the offer within 18 months of the offer being delivered to it, the Government may grant the right, license or concession to that other person on terms no better than those offered to the Concession-holder, provided that no such right, license or concession is granted by the Government to that other person if such grant will have a negative effect on or is contrary to the interests or business of the Plant or of those of a subconcession-holder of the Concession-holder in connection with the Concession or the subconcession; and

 

(c)                shall not grant to any person other than the Concession-holder any right, license or concession for the production of a mineral salt in the Leased Land and in the Reserved Land, other than those persons who were entitled to do so on the date of the Concession, and together for such persons the Government may renew their licenses, concessions or rights or grant them other licenses, concessions or rights in their stead without first offering that right, license or concession to the Concession-holder, and in that case the provisions included in sub-paragraph (b) of this sub-section shall apply, including the term at its end, mutatis mutandis.

 

6



 

(2)               The Concession-holder shall be entitled, with the Government’s consent, to transfer to a suitable location in the Reserved Land, any waste products generated in the course of operation of the Plant.

 

10.             Quiet enjoyment during the term of the Concession

 

During the term of the Concession, the Concession-holder shall have absolute and undisturbed possession of the Plant, and the Plant shall not be forcibly acquired or confiscated nor shall possession be taken in any other forcible manner.

 

11.             Public works

 

The provisions of this Deed of Concession shall not prevent the Government or a Local Authority from carrying out and shall not prevent the Government from permitting any other competent entity to carry out such works, to carry out in, on or beneath the Leased Land or the Reserved Land, any public works, including public roads, railway tracks, electricity lines or cables, bridges, pipes and pipelines, provided that —

 

(i)                   the public works do not unreasonably disturb performance of works required by the Plant or for its proper operation; and

 

(ii)                all necessary means of care are employed by whoever carries out the public works, so as to prevent damage to the Plant or to any property owned by the Concession-holder or which is in its possession or under its supervision; and

 

(iii)             the Government or the Local Authority or whoever carries out the public works, as the case may be, indemnifies the Concession-holder for any loss or expense incurred by the Concession-holder as a result of or in connection with the performance of those public works.

 

Before carrying out such works or permitting them to be carried out, the Government or the Local Authority shall deliver to the Concession-holder, at least 90 days in advance, written notice of its intention, together with the plans of those works; the notice will describe the location of the works and the way in which it is proposed to comply with the terms noted in sub-paragraphs (i) and (ii) of this section; the Concession-holder shall notify the Government in writing, within 90 days of delivery of that notice, if it opposes performance of the public works and the reasons for its opposition, and if the Government rejects that opposition, the matter shall be referred to arbitration pursuant to section 26 below and shall be decided there before any such works are carried out. If the Concession-holder does not give notice of its opposition to grant of the permit within 90 days of the date of receipt of the notice, it shall be deemed to have agreed to performance of the works or to grant of the permit for carrying out the works.

 

12.             Concession-holder’s duty to work

 

Throughout the term of the Concession the Concession-holder shall work diligently to produce the mineral salts, minerals and chemicals mentioned above and to extract them, transport them and market them in accordance with the provisions of this Concession, and to increase within a reasonable time the capacity of the Plant and the output of potassium chloride to an additional four hundred thousand tons or thereabouts per year, above its current output of 165,000 tons per year.

 

7



 

Taking into consideration the Concession-holder’s ability to raise the requisite amounts from funds accrued in the Plant and in other ways, on reasonable terms, it shall use its best efforts at a later stage to continue to increase the Plant’s capacity to an additional annual output of approximately 200,000 — 300,000 tons of potassium chloride.

 

13.             Products not manufactured by the Concession-holder

 

(a)               If at any time after the first three years from the Start Date the Government wishes the Concession-holder to start manufacture of a product in which one or several of the components are mineral salts, minerals or chemicals extractable from the Dead Sea, which is not a product manufactured then by the Concession-holder or by a subconcession-holder of the Concession-holder, the Government shall be entitled, by written notice, to request that the Concession-holder notify the Government within 6 months of the date of receipt of such notice (“the Response Period”), whether the Concession-holder is ready to manufacture that product.

 

During the Response Period, the Concession-holder may oppose in writing the Government’s notice, explaining that the product referred to in the notice is not a product such as that referred to in this sub-section or that the manufacture of such a product would have a negative impact on or would oppose the interests or business of the Plant or of a subconcession-holder of the Concession-holder in connection with the subconcession, or that the provisions of this sub-section were not met in another way. In the event of a dispute, the matter shall be referred to arbitration and decided there in accordance with the provisions of section 26 below.

 

(b)               Any notice from the Government pursuant to this section should contain a detailed description of the product to be manufactured and the process by which it should be manufactured, as well as an undertaking by the Government to provide the Concession-holder or to ensure that it is provided with, upon demand, sufficient know-how on reasonable terms, enabling the Concession-holder to manufacture the product in commercial quantities according to the process mentioned in the notice, and it shall grant the Concession-holder or ensure that it is granted such licenses under patents relating to the product and the process so that the Concession-holder will be protected against any claims of breach whatsoever.

 

The notice should set out the name and address of the owner of the know-how or of the patent, as the case may be, and attach a copy of the details of the patent’s claims and point out the terns on which the owner of that know-how or of that patent is ready to provide the Concession-holder with the know-how or to grant the Concession-holder a license under the patent, as the case may be. The company shall not deliver to others any know-how or patent it receives as described above.

 

(c)                If during the Response Period the Concession-holder notifies the Government in writing that it is ready to manufacture the product in commercial quantities on which the parties will agree, the Concession-holder shall start carrying out the works required for such manufacture and shall complete them within a time agreed to by the Government and the Concession-holder. If the parties cannot agree on the quantities of the product, the period to the start of the works or the period to their completion, the matter shall be referred to arbitration and shall be decided in accordance with the provisions of section 26 below.

 

(d)              If during the Response Period the Concession-holder notifies the Government in writing that it is not ready to manufacture the product but has no objection to the Government granting

 

8



 

another person the right to manufacture the product, or if the Concession-holder does not reply in writing within the Response Period, the Government shall be entitled to grant to another person the right to manufacture the product, on terms that are not better than those stipulated in the notice, and thereafter the Concession-holder will be obliged to supply that person, on reasonable terms, with the end water-salt solution reasonably needed for the manufacture, subject to that end solution being in excess of the needs of the Concession- holder and the subconcession-holders of the Concession-holder.

 

(e)                If within 3 months of a final arbitration award denying the opposition of the Concession-holder as noted in sub-section (a) the Government and the Concession-holder are unable to reach agreement as to the quantities to be manufactured, the date of starting the works required for manufacture of the product and the date of their completion, the matter shall be referred to arbitration and shall be decided there in accordance with the provisions of section 26 below.

 

(f)                 If the Concession-holder has not started the works required or has not completed them within the dates agreed upon by the Government and the Concession-holder, or they were decided upon by the arbitrators, as the case may be, the Government shall be entitled to grant to another person the right to manufacture the product on terms that are no better than those stipulated in the aforementioned notice, and thereafter the Concession-holder will be obliged to supply that person, on reasonable terms, with the final water-salt solution reasonably needed for the manufacture, subject to that solution being in excess of the needs of the Concession-holder and the subconcession-holders of the Concession-holder.

 

14.             No contract / arrangement to limit output

 

The Concession-holder and the subconcession-holders of the Concession-holder shall not make — without the prior written consent of the Government — any contract or arrangement with any person whatsoever for limiting output of the products of the Concession-holder or for raising or maintaining prices in a way that limited the output. The provisions of this section replace the Antitrust Law, 1959, whose provisions shall not apply to the Concession-holder and the subconcession-holders of the Concession-holder in connection with the subconcession.

 

15.             Royalties

 

(a)               In consideration of any rights and privileges granted to the Concession-holder in this Deed of Concession, except for the leases mentioned in section 6 above (for which rent will be paid as provided in that section 6), the Concession-holder shall pay the Government the following royalties, commencing from the year starting April 1, 1964 and every Year thereafter:

 

(1)               Royalties equal to 5% of the value of the potassium chloride, bromine and magnesium chloride produced by the Plant and which is sold that Year, and that value shall be ascertained in the manner described below.

 

The value of each product mentioned in this sub-section shall be ascertained at the end of each Year and shall be its value at the Plant, unpacked. This value shall be determined by taking the price of its sales (including any bonus, if given), during that Year and by deduction of the following amounts from that price:

 

9



 

(i)                  the appropriate expenses of packing, sales commission and transportation and insurance from the Concession-holder’s Plant to the destination agreed upon with the customer, and

 

(ii)               10% of the amount obtained by deduction of all the appropriate expenses mentioned in sub-paragraph (i) of this sub-section from the selling price.

 

If the production and sale of potassium chloride in a particular Year exceed 1,000,000 tons, the Government can demand a new discussion of the rate of the royalties to be paid for the quantity in excess of the 1,000,000 tons of potassium chloride sold in that Year, provided that the royalties on that surplus in no circumstances exceed 10% of the selling price calculated as above.

 

(2)               Royalties equal to 5% of the value of products, except for the products mentioned in sub- section (1) above, of the Plant which are sold that Year and comprise or contain mineral salts, minerals and chemicals extracted from the Dead Sea, and that value should be ascertained in the manner described above; the value of each product mentioned in this sub-section shall be ascertained at the end of each Year and will be its value at the Plant, unpacked. This value will be determined by taking its selling price (including any grant if given) during that Year, and by deduction of the following amounts from that price:

 

(i)                  the appropriate expenses of raw materials (which are not mineral salts, minerals or chemicals extracted from the Dead Sea) which are in the sold product, plus 15% of those appropriate expenses; and

 

(ii)               the appropriate expenses of packing, sales commission and transportation and insurance from the Concession-holder’s Plant to the destination agreed upon with the customer, and

 

(iii)            10% of the amount obtained after deduction of all the appropriate expenses mentioned in sub-paragraph (ii) of this sub-section from the selling price.

 

(b)               The Government may — with the approval of the Knesset Finance Committee — reduce the royalties paid for the products mentioned in sub-section (a) of this section.

 

(c)                The amount of the royalties for each Year shall be ascertained and approved by an auditor. The amount due will be paid by the Concession-holder to the Government within 120 days of the end of the Year for which the royalties are paid.

 

(d)               The royalties paid by the Concession-holder to the Government pursuant to this Deed of Concession shall be seen, for the matter of the Income Tax Ordinance, as if they were an expense incurred entirely and only in generating the income of the Concession-holder.

 

(e)               For the matter of this section, the term “Year” means a year commencing April 1 and ending March 31 of the following year.

 

10


 

16.             Accounts and reports

 

(a)               The Concession-holder shall maintain at all times, at its head office, all normal and appropriate books of account and these shall be open at any reasonable time, by appointment, to the audit of Government representatives.

 

(b)               The Concession-holder shall submit to the Government every Year, a duly audited balance sheet and profit / loss report, and a detailed report approved by an auditor, providing all the details required for calculation of the royalties payable to the Government that Year in accordance with section 15 above.

 

17.             Transport facilities

 

The Government shall provide and maintain during the term of the Concession, roads or railway tracks and suitable and sufficient port facilities to enable transportation of the Concession-holder’s products and their shipment by sea from ports in Israel.

 

18.             Communication

 

The Government shall permit the Concession-holder, subject to the Postal Ordinance, to set up and operate, at its own expense, a long-distance communication system (and this term includes a telegraph and telephone network, whether above ground or underground, teleprinters, telecommunications and wireless) that provide communication between the various stations of the Plant, but such a communication system shall serve only the purposes of the Plant and shall be under Government supervision, and shall not be built or operated in a way that disturbs the actions of any competent authority whatsoever.

 

19.             Public health

 

The Concession-holder shall comply with all the laws relating to public health and safety and all the provisions of the Mines Ordinance and the Factories Ordinance, 1947, and their concomitant regulations which relate to the health and safety of workers.

 

20.             Payment in lieu of local taxes

 

(a)               The Minister of Finance and the Minister of the Interior may instruct, in an order, that the Concession-holder shall pay the Government throughout part or all of the term of the Concession, a fixed amount of tax to be agreed upon by the Minister of Finance, the Minister of the Interior and the Concession-holder, and this tax shall be in lieu of local taxes.

 

(b)               Upon execution of such an order, no local authority may impose upon or collect from the Concession-holder any local taxes, and the Minister of the Interior shall divide among the relevant local authorities, in such manner and in such proportionate percentages as he sees fit from time to time, all the monies received by the Government according to this section in lieu of any local taxes which, if not for the provisions of this section and the order referred to above, would have been paid by the Concession-holder.

 

(c)                This section or any order as referred to above shall not derogate from any relief or exemption from local taxes to which the Concession-holder was or will be entitled at any time by virtue of the provisions of the Capital Investment Encouragement Law, 1959, or any other law, and

 

11



 

in giving such an order, the Minister of Finance and the Minister of the Interior validate such relief or exemption.

 

21.             No transfer

 

Without the prior written consent of the Government and the approval of the Knesset Finance Committee, the Concession-holder shall not be entitled to assign, pledge or remove from its possession the Concession or any part thereof.

 

22.             Force majeure

 

Non-fulfillment or non-performance — or their breach whether on the part of the Concession-holder or of the Government — of any stipulation, agreement or term of the stipulations, agreements or terms included in this Concession that one party or the other has a duty to fulfill or perform, shall not serve as cause of any claim or demand by one party against the other and they shall not act in any way that is detrimental to the other party and shall not be seen as a breach of this Concession, if it is reasonably proven that the non-fulfillment or the non-performance stemmed from one or several of the following causes: acts of God, acts by foreign rulers or nations, acts of infiltration, war, quasi-war campaigns, quarantine, embargo, uprising, rebellion, riots, strikes and slow-downs or labor disputes, fire, storm, tempest, explosion, earthquake, floods or other causes beyond the control of the parties.

 

23.             Reliefs

 

(a)               If one of the parties to this Concession does not fulfill or does not perform a stipulation, agreement or term of the stipulations, the agreement and the terms included in this Concession which that party is required to fulfill or perform, the non-fulfilling party (“the Party in Breach”) shall pay the other party (“the Injured Party”) damages in an amount sufficient to indemnify the Injured Party for any loss or damage it suffered owing to that non-fulfillment.

 

(b)               If the Injured Party alleges that the non-fulfillment or the non-performance by the Party in Breach is so severe in nature that it touches on the very foundation of the Concession, the Injured Party may demand of the Party in Breach, in a written notice, that it correct the non- fulfillment within a time that seems reasonable in the circumstances.

 

If the Party in Breach does not meet that demand, the Injured Party shall be entitled to bring to arbitration a claim to see the Concession as having come to an end. If the arbitration finds that the breach was in its nature as alleged by the Injured Party as aforesaid, the arbitration may decide to bring the Concession to an end, commencing from a date it deems justified in the circumstances and subject to the provisions of section 24 below, it may decide on severance of the relations between the parties on such terms as it deems justified and on the matters involved therein. The arbitration may also, in addition to bringing the Concession to an end or instead of bringing it to an end, rule payment of damages or compensation or any other remedy or remedies it deems justified in the circumstances, and where the Concession is brought to an end the Government shall be entitled to set off the amount of those damages or compensation ruled in its favor, against any payment due from it to the Concession-holder pursuant to section 24 below.

 

If the non-fulfillment was reflected in non-grant of a lease on any Land according to section 6 above, the arbitration may, in addition to any other remedy, order the Government to lease

 

12



 

that Land to the Concession-holder or to ensure that it is leased to it, on terms that the arbitration lays down and which correspond to section 6 above.

 

(c)                If an order was given or a valid decision made for liquidation of the Concession-holder (not for the purpose of merger or reorganization with the consent of the Government and the approval of the Knesset Finance Committee), the arbitration shall see such order and such decision as a breach by the Concession-holder of its duties under this Deed of Concession, entitling the Government to see the Concession as ended.

 

24.             Handling the assets upon expiration of the Concession

 

(a)               At the end of the term of this Concession or upon it being brought to an end on an earlier date (““the End Date”), all the Fixed Tangible Assets belonging to the Concession-holder shall become the property of the Government and the Government shall pay the Concession- holder, in consideration of those Fixed Tangible Assets, their depreciated replacement value as is on the End Date. Any other assets of any kind belonging to the Concession-holder on the End Date shall remain the property of the Concession-holder.

 

The term “depreciated replacement value” when referring to the Fixed Tangible Assets means the purchase price of similar assets when new at market prices on the End Date, less the depreciation for the period of use of each of the assets, and this depreciation shall be based on the technical life of such an asset, taking into account the condition of its maintenance by the Concession-holder and the conditions prevailing in the Dead Sea area.

 

If on the End Date the Fixed Tangible Assets or any part of them are mortgaged or encumbered by a lien, the mortgage or the lien shall continue in place on those assets but their depreciated replacement value shall not be reduced because of the mortgage or the lien and the following provisions shall apply:

 

(i)                   The Government shall be entitled to withhold from that depreciated replacement value an amount sufficient to repay the principal and interest secured by the mortgage or the lien when they fall due, or a sum equal to the depreciated replacement value of the asset, whichever is the lower amount.

 

(ii)                If the Government withholds such an amount, it shall use it to settle the principal and interest of the debt secured by the mortgage or the lien or shall compensate the Concession-holder in the amount of the sum it withheld for that mortgage or lien against any claims and demands by the mortgagee or the lien-holder, in relation to the aforementioned principal and interest, and the balance, if any, shall be returned to the Concession-holder.

 

(b)               During the ten years prior to the end of the term of the Concession, the Concession-holder shall not invest new capital in the Plant without the prior written consent of the Government, unless the Income Tax Ordinance allows deduction of the entire investment during those ten years; however, the Government’s consent to any basic investment that could be essential for the proper operation of the Plant, shall not be unreasonably delayed or withheld.

 

25.             Priority for new concession

 

If after expiration of the Concession the Government wishes to offer a new concession for the production of mineral salts, minerals and chemicals from the Dead Sea to any person who is not

 

13



 

the Concession-holder, the Government shall first offer a new concession to the Concession- holder, on terms that are not inferior to those it intends to offer to such other person.

 

26.             Arbitration

 

If at any time within the term of the Concession or thereafter, any doubt, disagreement or dispute arises between the parties concerning the meaning or performance of this Concession or of anything related to it or concerning the rights and obligations of the parties to it, and if the doubt, disagreement or dispute cannot be resolved in other ways, and irrespective of whether there are specific provisions for referring the matter to arbitration in any of the sections of this Deed of Concession, they shall be brought to the arbitration of three persons, two of whom shall be appointed one each by the parties to the arbitration and the third shall be appointed in writing signed by the two persons appointed as aforesaid before the arbitration commences. If those two appointed persons are unable to agree on the third arbitrator, the third arbitrator shall be appointed by whoever is serving at that time as President of the Jerusalem District Court.

 

If the arbitration involves a matter of assessment or any other technical matter, the third arbitrator to be appointed as aforesaid shall be a technical expert who is competent to deal with that special matter.

 

The award of the three arbitrators shall be final and binding upon the parties. If the award is not unanimous, the ruling of the majority shall be final and binding.

 

The venue of the arbitration shall be as agreed between the parties, and if they cannot agree — the venue shall be Jerusalem. If not stipulated otherwise in this Deed of Concession, the provisions of the Arbitration Ordinance shall apply to arbitration pursuant to this section.

 

This section does not release the Government from the need for approval from the Knesset Finance Committee in those matters where such approval is required under the terms of this Deed of Concession.

 

27.             Notices

 

Whenever according to this Concession notices, consents, requests or information (“Notices”) must be delivered, the Notices shall be in writing and shall be seen as if duly delivered if sent by registered and prepaid mail to the parties at the following addresses:

 

The Government — Ministry of Finance and Ministry of Development, Jerusalem,

 

The Concession-holder — Beit Ha’ashlag, Be’er Sheva,

 

or to any other address within the State of Israel, as each party notifies the other in a similar Notice.

 

Every notice sent as aforesaid shall be seen as a Notice that was delivered seventy-two hours after the properly addressed letter containing the Notice was mailed.

 

28.             Waiver

 

(a)               If the Government accepted any payment from the Concession-holder pursuant to this Concession, whether to the royalties account or another account, such acceptance shall not

 

14



 

be seen as implying a waiver by the Government of any of its rights concerning any prior breach of any of the provisions of this Concession.

 

(b)               Waiver by one party of a breach of any of the provisions of this Concession shall not be seen as a waiver of any breach thereafter of the same provision or any other provision, whether similar or different in its nature.

 

29.             Footnotes

 

Footnotes in the Concession shall not be relied upon in the interpretation of the provisions of this Concession.

 

30.             Waiver of notarized notice

 

The parties to this Concession hereby waive the need for notarized notice or other official endorsement for any breach or non-fulfillment of any of its provisions.

 

31.             Government action

 

Any thing which under this Concession the Government is permitted to do or perform and any consent that must be given by the Government under this Concession, shall be duly done, performed or given by the Minister or by whoever is appointed under his signature for that purpose. In witness whereof the parties hereby affix their signatures and stamp on the date noted at the head of this Deed of Concession.

 

Minister of Finance Minister of Development - for and in the name of the State of Israel

 

Israel Hillman and Emmanuel Shachar — for and in the name of Dead Sea Works Ltd.

 

David Ben-Gurion

Prime Minister

Levi Eshkol

Minister of Finance

Mordechai Bentov

Minister of Development

 

 

 

Yitzchak Ben-Zvi

President

 

 

 

15



 

Dead Sea Concession (Amendment No. 2) Law, 1986(1)

 

1.                    Amendment of Concession

 

Deed of Amendment No. 2 of the Concession in the Schedule to this Law, made between the State and the Concession-holder named in it, is seen as valid for all its purposes notwithstanding the provisions of any law.

 

Schedule

 

The Deed of Concession Amendment made on April 2, 1986 between the State of Israel , represented by the Government of Israel, acting through the Minister of Finance and Minister of Industry and Trade of the first part, and Dead Sea Works Ltd., a company incorporated under the laws of Israel and whose registered office is in Beit Ha’ashlag in Be’er Sheva of the second part, hereby attests and it is hereby declared as follows:

 

1.                    This Deed is Amendment No. 2 to the Deed of Concession made between the above- named parties on May 30, 1961,(2) as amended on July 17, 1968(3) (“the Deed of Concession”).

 

2.                    In section 4 of the Deed of Concession, the words “March 31, 1999” shall be replaced by “March 31, 2030”.

 

3.                    In section 15 of the Deed of Concession, sub-sections (d) and (e) shall be marked (e) and (f), and the following shall be inserted before them:

 

“(d)         Notwithstanding the provisions of sub-section (c), commencing in the financial year starting April 1, 1999, the following provisions shall apply:

 

(1)              Any sum constituting a component in calculation of the annual royalties shall be linked. For this matter —

 

‘the base representative exchange rate’ — the representative exchange rate published for the following days:

 

(a)               for the matter of the selling price of a product — the date of receipt of the selling price by the Concession-holder;

 

(b)               for the matter of an expense — the date of incurring the expense;

 

‘the new representative exchange rate’ — the representative exchange rate published on the third day before the actual date of payment of the amount of the annual royalties.

 


(1)  No footnote or endnote in Hebrew doc.

 

(2)  “

 

(3)  “

 

16



 

(2)              Within one hundred and twenty days from the end of each of the first three quarters of the Year, a payment shall be made on account of the royalties (“Quarterly Payment”), in an amount equal to 75% of a quarter of the amount of

 

the annual royalties for the previous year; each Quarterly Payment shall be linked; For this matter —

 

‘the base representative exchange rate’ — the representative exchange rate published on the third day before the date of actual payment of the amount of the annual royalties for the previous year;

 

‘the new representative exchange rate’ — the representative exchange rate published on the third day before the date of actual payment of the Quarterly Payment.

 

(3)              From the amount of the annual royalties paid as provided in sub-section (c), the Quarterly Payments made for that year, linked, shall be deducted; for this matter —

 

‘the base representative exchange rate’ — the representative exchange rate published on the third day before the date of actual payment of the Quarterly Payment;

 

‘the new representative exchange rate’ — the representative exchange rate published on the third day before the date of actual payment of the annual royalties.

 

(4)              Should it transpire that the amount of the linked quarterly royalties for that year as provided in paragraph (3) exceeds the amount of the annual royalties for the same year as calculated in paragraph (1), the surplus amount shall be credited on account of the royalties in the year thereafter and will be deducted, linked, from the next Quarterly Payment or Quarterly Payments or from the amount of the annual royalties for the next year, as the case may be; for this matter —

 

‘the base representative exchange rate’ — the representative exchange rate published on the third day before the date of actual payment of the amount of the annual royalties for the year for which the surplus was generated;

 

‘the new representative exchange rate’ — the representative exchange rate published on the third day before the date of actual payment of the amount from which the surplus is deducted.

 

(5)              Calculation of the amount of the deduction which is to be made in percentages as provided in sub-sections (a)(1) (ii) and (a)(2)(iii), shall be based on the sum obtained after deduction of all the linked expenses as provided in paragraph (1) from the total linked selling prices as provided in paragraph (1); calculation of the amount of the deduction which is to be made in percentages as provided in sub-section (a)(2) (i) shall be based on the total expenses referred to in that section, linked as provided in paragraph (1).

 

17



 

(6)              In this sub-section —

 

‘linked’ — linked to the representative exchange rate, so that if a change occurs in the base representative exchange rate compared with the new representative exchange rate, the amount concerned will increase or decrease according to the rate of rise or fall;

 

‘representative exchange rate’ — the representative exchange rate of the US dollar published by the Bank of Israel; in a period when the Bank of Israel does not customarily publish exchange rates, the Governor of the Bank of Israel shall determine the representative exchange rate for the matter of this Deed of Concession;

 

‘quarter’ — a period of three months commencing April 1, July 1, October 1 and January 1.

 

4.                    Amendment of this Deed of Concession shall come into force on the start date of the law approving it.

 

In witness whereof the parties hereby affix their signatures and stamp on the date noted at the head of this Deed.

 

Yitzchak Moda’i

Ariel Sharon

Yoram Ziv

Aryeh Shachar

Minister of Finance

Minister of Industry and Trade

For and on behalf of Dead Sea Works Ltd.

 

Shimon Peres
Prime Minister

Moshe Nissim
Minister of Finance

Ariel Sharon
Minister of Industry and Trade

 

 

 

Haim Herzog
President

 

 

 

18


 

[Emblem of the State of Israel]

 

Jerusalem, January 11, 1995
95-9363.T

 

Dead Sea Works Ltd.
Beit Ha’ashlag, Be’er Shava

 

Re: Dead Sea Deed of Concession - Section 15(a)(1) — Potassium chloride royalties

 

I hereby notify you in the name of the Government of Israel (“the Government”), which is represented by us in accordance with section 31 of the Dead Sea Concession Deed dated May 30, 1961, (“the Deed of Concession”), that subject to section 17 of the Deed of Concession not being activated and exercise of any right under that section not being required, the Government will not demand re-discussion of the amount of the royalties to be paid in respect of the surplus quantity of one million (1,000,000) tons of potassium chloride that was or will be produced during any year as noted in the last paragraph of section 15(a)(1) of the Deed of Concession, for the period preceding the date of this letter, and for the period from the date of this letter to the end of the term of the Concession which is the subject of the Deed of Concession as has been or will be amended.

 

However, commencing 2010, the Government will be able to demand re-discussion of the amount of the royalties in accordance with and subject to the provisions of the aforementioned paragraph in the Deed of Concession, with reference to the quantity in excess of three million (3,000,000) toms of potassium chloride produced in any year from that year onwards, without it granting the company any right in connection with section 17 of the Deed of Concession.

 

For the removal of doubt, we note Government Decision No. 48/34 on January 27,1992 in the matter of certain amendments to the Deed of Concession, which declared section 17 of the Deed of Concession to be void.

 

The response of Dead Sea Works to that decision, as reflected in the prospectus of Israel Chemicals Ltd. dated February, 1992, was that implementation of that Government decision would not harm the proper functioning of Dead Sea Works.

 

Yours sincerely,

 

Signed:

/s/ Avraham (Baiga) Shochat

 

Signed:

/s/ Micha Harish

 

Avraham (Baiga) Shochat
Minister of Finance

 

 

Micha Harish
Minister of Industry & Trade

 

1 Kaplan St., Jerusalem 91131

P.O.B. 13195

Tel: 317377

Fax: 635769

 



 

Dead Sea Concession Law, 1961

 

Subconcession for Dead Sea Bromine Limited

 

Pursuant to section 2 of the Dead Sea Concession Law, 1961,(1) a subconcession is hereby published, granted in accordance with the provisions of section 5 of the Deed of Concession in the Schedule to the Law by the Concession-holder named in that Deed of Concession, to Dead Sea Bromine Limited in this wording:

 

This Deed of Subconcession was made on November 11, 1962

 

Between

 

Dead Sea Works Limited , a company incorporated under the laws of Israel and whose registered office is in Beit Ha’ashlag in Be’er Sheva (“the Primary Concession-holder”) of the first part;

 

And

 

Dead Sea Bromine Limited , a company incorporated under the laws of Israel and whose registered office is in Beit Ha’ashlag in Be’er Sheva (“the Subconcession-holder”) of the second part;

 

Whereas —

 

(a)               Under a deed of concession (“the Primary Concession”) made on May 30, 1961 between the State of Israel (“the Government”) of the first part and the Primary Concession-holder of the second part, the Government granted the Primary Concession-holder the exclusive right to extract by way of evaporation (solar or artificial), cooling, mining, quarrying, or in any other way, mineral salts and minerals and chemicals, whether in solution or in solid form, which are in and beneath the Dead Sea and to prepare them for marketing, to sell them and deal with them and all the other rights and privileges, subject to all the undertakings and terms and stipulations set forth in the Primary Concession; and

 

(b)               Section 5 of the Primary Concession authorizes the Primary Concession-holder, with the consent of the Government and the approval of the Knesset Finance Committee, to grant subconcessions by virtue of the Primary Concession; and

 

(c)                The Primary Concession-holder fully controls the Subconcession-holder; and

 

(d)               The Primary Concession-holder agreed to grant to the Subconcession-holder — subject to restrictions, terms and stipulations set forth below — a subconcession for the extraction of

 


(1)  Sefer Hahukkim 342, 1961, p. 130.

 

20



 

bromine and bromine compounds from minerals salts, minerals and chemicals, whether in solution or in solid form, which are in and beneath the Dead Sea, and to prepare them for marketing, to sell them and deal in them, as well as the other rights set forth below, and the Subconcession-holder is ready to accept such a subconcession, subject to those restrictions, terms and stipulations; and

 

(e)                In a letter dated November 11, 1962 signed by the Minister of Finance and by the Minister of Development, the Government agreed to grant of the subconcession to the Subconcession-holder as aforesaid.

 

It is hereby agreed and declared as follows:

 

1.                    (a)               In the subconcession, the following words and expressions shall have the meaning alongside them unless the context requires otherwise, and they are:

bromine compounds — compounds in which bromine is an element or descendant of such compounds, excluding compounds in which bromine is a trace-element only, or compounds which, despite the presence of bromine in them, are not usually described in the trade or industry as bromine compounds.

 

Solution concentrate — a solution originating in the Dead Sea and which has been evaporated or otherwise treated by the Primary Concession-holder and which is in one of the stages of production of potash or of other products from mineral salts, minerals and chemicals which are in the Dead Sea, by the Primary Concession-holder.

 

Solution from the Dead Sea — a solution from the Dead Sea which has not been evaporated or otherwise treated by the Primary Concession-holder.

 

The Plant — in relation to the Subconcession-holder — the business of extracting bromine and bromine compounds, their preparation for marketing, their sale and dealing in them, and all those businesses, property and things of the Subconcession-holder which are required or associated with such business, all in accordance with the subconcession.

 

(b)               Words and expressions whose meaning is defined in the Primary Concession shall have the same meaning in the subconcession provided the context does not require otherwise.

 

2.                    (a)               The Primary Concession-holder herby grants to the Subconcession-holder:

 

(1)              The exclusive right to extract bromine and bromine compounds from mineral salts, minerals and chemicals, whether in solution or in solid form, which are in or beneath the Dead Sea, and to prepare bromine and bromine compounds for marketing, to sell them and to deal in them.

 

(2)              The right, subject to the provisions of section 2(d) of the Primary Concession, to do all or some of the following in the Leased Land and in the Reserved Land:

 

(a)               To extract by way of quarrying, mining or by any other production method, mineral salts, minerals and chemicals as required from time to time by the

 

21



 

Subconcession-holder for any process in the manufacture of bromine or bromine compounds that use mineral salts, minerals and chemicals extracted or extractable from the Dead Sea.

 

(b)               To quarry for the production of the materials required for the construction, expansion and maintenance of the Plant.

 

(b)               In order to exercise the rights granted it in sub-section (a) of this section, the Subconcession-holder may enter the areas of the Dead Sea, the Leased Land and the Reserved Land, at points and on terms to be set from time to time in writing by the Primary Concession-holder (and those points, when used for the matter of a solution concentrate, are hereinafter called “Delivery Points”) for the extraction of a solution, a solution concentrate and other mineral salts, minerals and chemicals from the Dead Sea, from which bromine and bromine compounds will be manufactured, and to extract all of these in the quantities, by the means, in the manner and for the purpose as aforesaid, and to lay pipes and install pumping facilities and other facilities in or above the areas referred to above, as will be determined in writing from time to time by the Primary Concession-holder.

 

3.                    The subconcession is granted for the period commencing on the date of the subconcession or on the date on which the subconcession is approved by the Knesset Finance Committee, whichever is the later date, and ending one day before the end of the Primary Concession or one day before the Primary Concession is brought to an end, unless the subconcession ends earlier, as described below.

 

4.                    (a)               The Primary Concession-holder hereby leases to the Subconcession-holder in a sub- lease, for the term of the subconcession, the Land marked on Map “A” attached to the subconcession, which are within the Land leased by the Primary Concession-holder and marked with dense diagonal dotted lines, for the rent and on the terms set forth below.

 

(b)               The rent to be paid by the Subconcession-holder to the Primary Concession-holder for the sub-lease hereby granted, shall be IS 1 (one Israeli lira) for the period commencing on the date on which the subconcession comes into force and ending 10 (ten) years after the start of the Primary Concession; thereafter the rent shall be a sum equal to the rent paid by the Primary Concession-holder to the Government under the Primary Concession for the Land hereby leased in a sub-lease, and shall be paid each year in advance, one week before the anniversary of the date of the Primary Concession.

 

(c)                If the Subconcession-holder needs, for its Plant or its expansion, additional Land which is part of the Leased Land or of the Reserved Land, the Primary Concession-holder shall lease them to the Subconcession-holder, on its request, in a sub-lease for the remainder of the term of the subconcession, but the Primary Concession-holder is not obliged to lease any additional Land if it is needed for the Plant of the Primary Concession-holder or of another of its subconcession-holders, or additional Land from the Reserved Land, if it cannot obtain lease of such additional Land by virtue of section 6(b) of the Primary Concession.

 

22



 

(d)               During the period commencing on the date on which the subconcession comes into force and ending 10 (ten) years after the start of the Primary Concession, the rent to be paid for the additional Land shall be symbolic; thereafter, the rent will be a sum equal to the rent to be paid by the Primary Concession-holder to the Government under the Primary Concession for such additional land. The remaining terms of the subconcession shall be, mutatis mutandis, the same as the terms applicable to the Land hereby sub-leased.

 

(e)                If at the end of the first ten years from the date of the start of the Primary Concession it transpires that reasonably, the Subconcession-holder does not need for its Plant all the Land included in the lease granted under sub-section (c) of this section, taking into account the output capacity of the Plant at that time, the Primary Concession-holder is entitled at any time to demand, in a written notice delivered at least 12 months in advance, that the Subconcession-holder return to it the part not required; such return shall not prevent the Subconcession-holder from demanding of the Primary Concession-holder at a later date that it lease that Land to it again or ensure that it is leased to it in accordance with sub-section (c) of this section.

 

(f)                 The sub-lease hereby granted is subject to all the mortgages and liens that were and will be created in favor of any trustee under any deed of trust that is signed pursuant to the agreement made on July 11, 1961 between the International Restoration and Development Bank and the Primary Concession-holder.

 

(g)                The Subconcession-holder shall use the Land sub-leased to it only for the needs of the Plant.

 

(h)               All the public roads that pass through the Land leased according to the terms of the subconcession are excluded from any sub-lease under this section.

 

(i)                   Any sub-lease granted under this section shall be valid even if not registered at the competent Lands Registry office, provided that when the Government ensures the registration of lease of the Land referred to in section 7 of the Primary Concession, the Subconcession-holder appears, within 30 (thirty) days of having received notice thereof from the Primary Concession-holder, at the competent Lands Registry office and signs all the documents required for effecting registration of the sub-lease granted by virtue of this section, and that registration and the issue of registration certificates to the Subconcession-holder in respect of that Land shall be without payment of a registration fee or any other levy.

 

(j)                  Without the prior consent of the Minister and the Primary Concession-holder, the Subconcession-holder shall not be entitled to create any mortgage or fixed lien on the right of sub-lease. Any mortgage or lien created with such consent for the Land leased in the sub-lease, which was not registered at the Lands Registry office, shall be valid despite the non-registration provided that the mortgage was duly registered in accordance with section 127 of the Companies Ordinance and provided also that the holder of that mortgage or that lien applies to the competent Lands Registry to register the mortgage or the lien within three months from the date of receipt of notice from the

 

23



 

Primary Concession-holder concerning registration of the relevant Land at that Lands Registry office.

 

5.                    In any area of the Dead Sea and of the Leased Land or the Reserved Land on which part of the Plant of the Subconcession-holder operates or on which there are facilities or equipment of the Subconcession-holder, whether the area is sub-leased to the Subconcession-holder or not, the Primary Concession-holder shall be entitled at any time, notwithstanding the subconcession, to —

 

(a)               enter it for audit and for taking measurements, as it sees fit;

 

(b)               pass through it time and again, together with workers, contractors and vehicles or without them, for access to and exit from any part of the Plant of the Primary Concession-holder, and along routes determined by the Primary Concession-holder from time to time at its discretion;

 

(c)                lay pipes and cables in it and set up pumping facilities and other installations, build roads, railway tracks and other means of transportation, from one end to the other, above it or below it.

 

6.                    In consideration of expenses incurred by the Primary Concession-holder for pumping a solution concentrate to the Delivery Point and for the repair and maintenance of pipes, pumps, installations, dams and evaporation ponds of the Primary Concession-holder, the Subconcession-holder shall pay the Primary Concession-holder 20 (twenty) agorot for every cubic meter of solution concentrate received by the Subconcession-holder at the Delivery Point by virtue of the subconcession.

 

The payments under this section shall be annual, and shall be paid on January 1 of each year, the first of which is January 1, 1963.

 

If at any time one of the parties to the subconcession alleges that the amount of that payment should be changed, it can request of the other party that it agree to a change and the other amount will be paid from the date on which the parties agree to it, and if there is no agreement — as will be determined in arbitration according to the provisions of section 23 below. Until the arbitration award, the payment amount shall remain as was before the request for the change.

 

7.                    If the Primary Concession-holder carried out public works in or outside the Dead Sea, the Leased Land or the Reserved Land, including installations for flood prevention, railway tracks, roads, water, electricity, gas or fuel installations — and the public works are likely to benefit the Plant of the Subconcession-holder, the Subconcession-holder shall participate in the maintenance expenses to an extent deemed justified in the circumstances, and noting the scope of the benefit that will devolve to the Subconcession-holder from those works on the one hand, and the scope of the benefit from them for the Plant of the Primary Concession-holder and others, on the other hand, provided that nothing stated in this section applies to

 

24



 

the expenses of construction or maintenance of dams, evaporation ponds, pumps, installations, pipes and related installations.

 

Payments under this section shall be made on the dates and in the manner determined between the parties, and failing agreement, in arbitration in accordance with section 23 below.

 

Any dispute on the question of whether a particular public work constitutes a benefit to the Plant of the Subconcession-holder or concerning the amount of the participation of the Subconcession-holder in its performance and maintenance — failing agreement on its resolution — shall be decided in arbitration in accordance with section 23 below.

 

8.                    The Subconcession-holder undertakes to run its Plant in the manufacture of bromine and bromine compounds with appropriate diligence.

 

9.                    (a)               If at any time the Government delivers a notice to the Primary Concession-holder, by virtue of section 13 of the Primary Concession, demanding that the Primary Concession-holder start manufacture of a product as stated in that section and the product is bromine or a bromine compound, the Primary Concession-holder shall immediately send a copy of that notice to the Subconcession-holder, with a written request to notify the Primary Concession-holder in writing, within three months of the date of receipt of the copy of the notice, whether the Subconcession-holder is ready to manufacture that product.

 

(b)               If the Subconcession-holder wishes the Primary Concession-holder to exercise the powers granted it under section 13 of the Primary Concession to oppose the Government’s notice, it shall notify the Primary Concession-holder accordingly within the aforesaid three months, and shall present all the reasons and evidence required and desirable for preparation of the opposition.

 

(c)                Notice from the Subconcession-holder to the Primary Concession-holder under sub- section (a) of this section, of its readiness to manufacture the product, or notice under sub-section (b) of this section of its request that the Primary Concession-holder oppose the Government’s notice, shall not bind the Primary Concession-holder, but the Primary Concession-holder will consider it before notifying the Government that the Subconcession-holder is ready to manufacture the product or that the Subconcession-holder opposes the Government’s notice under the aforementioned section 13. Furthermore, before notifying the Government as aforesaid, the Primary Concession-holder may take into account each of the matters mentioned in that section 13 of the Primary Concession, whether they relate to the Subconcession- holder or were raised by it or not.

 

(d)               If the Subconcession-holder gave notice that it is ready to manufacture the product named in the Government’s notice, and the Primary Concession-holder confirmed this in accordance with sub-section (c) of this section, it shall notify the Subconcession-holder immediately, in writing, and the Subconcession-holder shall do everything necessary as

 

25



 

quickly as possible to ensure fulfillment of the undertakings of the Primary Concession-holder pursuant to section 13 of the Primary Concession in connection with that product.

 

(e)                If within the aforementioned period of three months the Subconcession-holder notified the Primary Concession-holder that it does not wish to manufacture the product, or does not notify it of its decision, the Primary Concession-holder may, at its discretion and without prejudice to any other remedy it has under the subconcession or under any law, oppose the Government’s notice or accept it and manufacture the product itself or using another subconcession-holder or another license-holder, or it may notify the Government that there is no objection to the Government granting the right to manufacture the product to another person.

 

MAP

 

(f)                 Unless stated otherwise in this section, the Subconcession-holder shall maintain, perform and fulfill all the undertakings of the Primary Concession-holder to the Government under the aforementioned section 13 concerning the manufacture of bromine and bromine compounds, including the undertakings of the Primary Concession-holder stemming from any arbitration award pursuant to the Primary Concession for the matter of bromine, bromine compounds or their manufacture.

 

(g)                The Subconcession-holder shall cooperate with the Primary Concession-holder in providing technical know-how, testimony and reasons before any arbitration between the Government and the Primary Concession-holder pursuant to the aforementioned section 13 of the Primary Concession, in the matter of the proposed manufacture of bromine or bromine compounds or everything stemming from it.

 

10.             The Subconcession-holder shall be entitled, with the approval of the Government and the Primary Concession-holder, to transfer to a suitable location in the Reserved Land any waste products generated in the course of operating the Plant.

 

11.             The Subconcession-holder hereby agrees — if there is no specific provision in the Subconcession (other than the undertaking of the Primary Concession-holder to pay royalties to the Government and to pay rent according to the Primary Concession) — to take upon itself all the undertakings of the Primary Concession-holder for the matter of extracting bromine and its compounds, their preparation for marketing, their sale and dealing in them, and to fulfill and uphold all the terms of the Primary Concession and to indemnify the Primary Concession-holder for any damages claims and expenses relating to them in any way.

 

12.             (1)               Excluded from any grants described in section 2 above and reserved to the Government —

 

26



 

(a)               Gold, silver or other precious metals and their dusts, precious stones, copper and iron dust, antiquities and oil — as defined in the Oil Law, 1952 (all of the foregoing are hereinafter together called the “Materials Outside the Confines of the Subconcession”) in or beneath the Dead Sea and in the Leased Land or the Reserved Land or beneath them;

 

(b)               the right to enter any facility and property of the Subconcession-holder in or beneath the Dead Sea, the Leased Land, the Reserved Land and beneath them, for the purpose of examination or audit in connection with sub-section (1)(a) of this section.

 

(2)               Immediately upon discovery of a material from the Materials Outside the Confines of the Subconcession, the Subconcession-holder shall deliver notice of such discovery to the Government and to the Primary Concession-holder, and shall permit the Government or any person authorized on behalf of the Government, to enter any location mentioned in sub-section 1(b) to search for and extract the Materials Outside the Confines of the Subconcession, and the Primary Concession-holder shall pay the Subconcession-holder compensation for any damage caused to it in so doing, within the limits of the compensation awarded to it by the Government under section 3(2) of the Primary Concession.

 

13.             The Subconcession-holder shall not make — without the prior written consent of the Government and the Primary Concession-holder — any contract or arrangement with any person whatsoever for limiting output of the products of the Subconcession-holder with the aim of raising or maintaining prices in a way that will limit the output. The provisions of this section replace the Antitrust Law, 1959, the provisions of which shall not apply to the Subconcession-holder in connection with the subconcession.

 

14.             The Subconcession-holder shall comply with all the laws relating to public health and safety and the provisions of the Mines Ordinance and the Factories Ordinance, 1947, and their concomitant regulations relating to the health and safety of the public.

 

15.             (a)               The Subconcession-holder may demand of the Primary Concession-holder that the Primary Concession-holder request of the Minister of Finance and the Minister of the Interior to issue an order or that the Subconcession-holder shall pay the Government during all or part of the term of the Subconcession, a fixed amount of tax that will be agreed upon between the Minister of Finance, the Minister of the Interior and the Subconcession-holder, and this tax shall be in lieu of local taxes.

 

(b)               Upon execution of such an order, no local authority may impose upon or collect from the Subconcession-holder any local taxes, and the Minister of the Interior shall divide among the relevant local authorities, in such manner and in such proportionate percentages as are deemed appropriate from time to time, all the monies received by the Government according to this section in lieu of any local taxes which, if not for the

 

27



 

provisions of this section and the order referred to above, would have been paid by the Subconcession-holder.

 

(c)                This section or any order as referred to above shall not derogate from any relief or exemption from local taxes to which the Subconcession-holder was or will be entitled at any time by virtue of the provisions of the Capital Investment Encouragement Law, 1959, or any other law, and in giving such an order, the Minister of Finance and the Minister of the Interior validate such relief or exemption.

 

16.             Non-execution or non-performance or the breach, whether on the part of the Primary Concession-holder or the Subconcession-holder, of any stipulation, agreement or term of the stipulations, agreements or terms included in the Subconcession and which one party or the other has a duty to fulfill or perform, shall not serve as cause of any claim or demand by one party against the other and they shall not act in any way that is detrimental to the other party and shall not be seen as breach of the Subconcession, if it is reasonably proven that the non-fulfillment or the non-performance stemmed from one or several of the following causes: acts of God, acts by foreign rulers or nations, acts of infiltration, war, quasi-war campaigns, quarantine, embargo, uprising, rebellion, riots, strikes and slow-downs or labor disputes, fire, storm, tempest, explosion, earthquake, floods or other causes beyond the control of the parties.

 

17.             (a)               In consideration of all the rights and privileges granted to the Subconcession-holder in the Subconcession, except for the sub-leases referred to in section 4 above and excluding the matters referred to in sections 6 and 7 above (in consideration of which payments shall be as provided in those sections), the Subconcession-holder shall pay the Primary Concession-holder each year of the Years commencing April 1, 1964, royalties equal to 5% (five percent) of the value of the bromine produced by the Subconcession-holder which is sold in the same Year, and that value shall be ascertained at the end of each Year and shall be the value at the Plant of the Subconcession-holder, unpacked. This value shall be determined by taking the price of its sales (including any bonus, if given), during that Year and by deduction of the following amounts from that price:

 

(i)                  Appropriate expenses of packing, sales commission and transportation and insurance from the Plant of the Subconcession-holder to the destination agreed upon with the customer; and —

 

(ii)               10% of the sum obtained by deduction of all the appropriate expenses referred to in paragraph (i) of this sub-section, from that selling price.

 

And royalties of 5% (five percent) of the value of the bromine compounds produced by the Subconcession-holder and sold in the same Year, and this value shall be ascertained at the end of each Year and shall be the value at the Plant of the Subconcession-holder, unpacked. This value shall be determined by taking the price of its sales (including any grant, if given), during that Year and by deduction of the following amounts from that price:

 

28


 

(i)                  Appropriate expenses of raw materials (which are not mineral salts, minerals and chemicals from the Dead Sea) which are in the product sold, plus 15% of those appropriate expenses, and —

 

(ii)               Appropriate expenses of packing, sales commission and transportation and insurance from the Plant of the Subconcession-holder to the destination agreed upon with the customer; and —

 

(iii)            10% of the sum obtained after deduction of all the appropriate expenses referred to in paragraph (ii) of this sub-section, from that selling price.

 

(b)               After the Government has deducted the Government royalties relating to bromine compounds in accordance with section 15(b) of the Primary Concession, the Government royalties relating to those bromine compounds shall be deducted by the royalties deducted as aforesaid.

 

(c)                The amount of the royalties for each Year shall be ascertained and confirmed by an auditor. The amount due shall be paid by the Subconcession-holder to the Primary Concession-holder within 90 (ninety) days of the end of the Year for which the royalties are paid.

 

(d)               Royalties paid by the Subconcession-holder to the Primary Concession-holder under the Subconcession shall be seen, for the matter of the Income Tax Ordinance, as if they were an expense incurred entirely and only in generating the income of the Subconcession-holder.

 

(e)                For the matter of this section, the word “Year” means a year commencing April and ending the following March 31.

 

18.             (a)               The Subconcession-holder shall hold at all times, at its head office, all normal and appropriate books of account and these shall be open at any reasonable time, by appointment, to the audit of Government representatives and the Primary Concession-holder.

 

(b)               The Subconcession-holder shall submit to the Government and to the Primary Concession-holder every Year, a duly audited balance sheet and profit / loss report, and a detailed report approved by an auditor, providing all the details required for calculation of the royalties payable to the Government and to the Primary Concession-holder that Year in accordance with section 17 above.

 

19.             The Subconcession shall expire if, without the prior consent of the Primary Concession- holder, the Government and the approval of the Knesset Finance Committee, the Subconcession-holder “pledges” a lien or removes from its possession in another way, the Subconcession or any part thereof, or grants subconcessions or licenses by virtue of the Subconcession.

 

29



 

20.             (a)               Notwithstanding the Subconcession, if the Subconcession-holder is in breach of or fails to fulfill its undertakings to the Primary Concession-holder according to the Subconcession and does not cure that breach or that non-fulfillment within a reasonable time after written notice from the Primary Concession-holder describing the breach or non-fulfillment and demanding that the Subconcession-holder cure them, the Primary Concession-holder may end at any time, in a written notice, without prejudice to any other right it has under the Subconcession or under any law, the Subconcession and all the rights and privileges granted under it to the Subconcession-holder, and take back possession of all the Land sub-leased to it under or by virtue of the Subconcession.

 

(b)               Notwithstanding the Subconcession, if an order was given or a decision was made to liquidate the Subconcession-holder, the Subconcession shall expire unless the Concession-holder, decides otherwise.

 

21.             (a)               At the end of the term of the Subconcession not by early termination pursuant to sections 19, 20 and 26 of the Subconcession (“the End Date”), all the Fixed Tangible Assets belonging to the Subconcession-holder shall become the property of the Primary Concession-holder and the Primary Concession-holder shall pay the Subconcession-holder the sum received by the Primary Concession-holder from the Government under section 24 of the Primary Concession in consideration of the depreciated replacement value of those Fixed Tangible Assets, and any other assets of any kind belonging to the Subconcession-holder on the End Date shall remain the property of the Subconcession-holder.

 

(b)               If on the End Date the Fixed Tangible Assets of the Subconcession-holder or any part of them are mortgaged or encumbered by a lien, the mortgage or the lien shall continue in place on those assets but their depreciated replacement value shall not be reduced because of the mortgage or the lien and the following provisions shall apply:

 

(i)                  The Primary Concession-holder shall be entitled to withhold from that depreciated replacement value an amount sufficient to repay the principal and interest secured by the mortgage or the lien when they fall due, or a sum equal to the depreciated replacement value of the assets, whichever is the lower amount.

 

(ii)               If the Primary Concession-holder withholds such an amount, it shall use it or shall agree that the Government use it to settle the principal and interest of the debt secured by the mortgage or the lien or — if the Government compensates the Primary Concession-holder pursuant to section 24(a)(ii) of the Primary Concession — the Primary Concession-holder shall compensate the Subconcession-holder in the amount of the sum given by the Government, for any claims and demands by the mortgagee or the lien-holder in relation to the aforementioned principal and interest; the balance of the amount of the compensation given to the Primary Concession-holder by the Government for the Fixed Tangible Assets of the Subconcession-holder, shall be returned to the Subconcession-holder.

 

30



 

(c)                During the ten years prior to the end of the term of the Subconcession, the Subconcession-holder shall not invest new capital in the Plant without the prior written consent of the Government and the Primary Concession-holder, unless the Income Tax Ordinance allows deduction of the entire investment during those ten years; however, the consent of the Government and the Primary Concession-holder to any basic investment that could be essential for the proper operation of the Subconcession-holder’s Plant, shall not be unreasonably delayed or withheld. Delay or withholding of that consent owing to the refusal of the Government to agree or owing to non-consent to investment according to the provisions of the Primary Concession, shall not be seen as a breach of this section and shall not constitute cause of any claim of the Subconcession-holder against the Primary Concession-holder.

 

22.             (a)               Upon early termination of the Subconcession by the Primary Concession-holder by virtue of section 20(a) above, and in the event of its expiration according to section 19, 20(c) or 26 of the Subconcession (“the Cancellation Date”), the Primary Concession-holder shall receive back all the Lands leased to the Subconcession-holder under or by virtue of the Subconcession and the all the Fixed Tangible Assets belonging to the Subconcession-holder shall become the property of the Primary Concession-holder and the Primary Concession-holder shall pay the Subconcession-holder, on the dates and in the manner and subject to the following exceptions: the depreciated replacement value of those Fixed Tangible Assets, and any other assets of any kind belonging to the Subconcession-holder on the Cancellation Date shall remain the property of the Subconcession-holder.

 

(b)               The depreciated replacement amount that will be paid by the Primary Concession- holder to the Subconcession-holder under this section shall be paid in 10 (ten) equal annual installments, the first of which shall be paid six months after the Cancellation Date and the subsequent payments shall be made each year thereafter on the same date as the first of those payments.

 

(c)                If on the Cancellation Date the Fixed Tangible Assets of the Subconcession-holder or any part of them are mortgaged or encumbered by a lien, the mortgage or the lien shall continue to encumber those assets but their depreciated replacement value shall not be reduced because of the mortgage or the lien, and the following provisions shall apply:

 

(i)                  The Primary Concession-holder shall be entitled to withhold from a depreciated replacement value such amount as is sufficient to repay the principal and interest secured by that mortgage or that lien when they fall due, or a sum equal to the depreciated replacement value of the assets, whichever is the lower amount;

 

(ii)               If the Primary Concession-holder withheld such an amount, it shall use it to settle the principal and interest secured by the mortgage or the lien, or, if it sees fit, it shall compensate the Subconcession-holder within the limits of the amount so withheld, for any claims and demands from the mortgagee or the lien-holder relating to that principal or interest; the balance of the amount withheld by the Primary Concession-holder relating to the Fixed Tangible Assets of the

 

31



 

Subconcession-holder shall be returned to the Subconcession-holder on the dates and in the manner described in sub-section (b) of this section.

 

23.             If at any time within the term of the Subconcession or thereafter, any doubt or dispute arises between the parties concerning the meaning or performance of the Subconcession or of anything related to it or concerning the rights and obligations of the parties to it, and if the doubt or dispute cannot be resolved in other ways, and irrespective of whether there are specific provisions for referring the matter to arbitration in any other section of the Subconcession, they shall be brought to the arbitration of two persons, where each party to the arbitration appoints one of them. The venue of the arbitration shall be as agreed between the parties, and failing agreement, the venue shall be Jerusalem.

 

This section shall not release the parties from the need for the approval of the Knesset Finance Committee in matters where such approval is required under the Subconcession.

 

24.             Nothing in the Subconcession derogates from the duties of the Primary Concession-holder towards the Government under the Primary Concession or grants the Subconcession-holder rights that were not granted to the Primary Concession-holder in the Primary Concession or releases the parties from obtaining the approval of the Knesset Finance Committee in any matter requiring such approval according to the Primary Concession or the Subconcession.

 

25.             Nothing in the Subconcession shall be construed as granting the Subconcession-holder the right to extract mineral salts, minerals and chemicals from the Dead Sea, from the Leased Land or from the Reserved Land except for the purpose of the production of bromine or bromine compounds, nor shall it prejudice or restrict in any way whatsoever the rights of the Primary Concession-holder under the Primary Concession to extract mineral salts, minerals and chemicals from the Dead Sea, from the Leased Land or from the Reserved Land for any purpose approved under the Primary Concession and which is not the production of bromine and bromine compounds.

 

26.             (a) The Primary Concession-holder shall not —

 

(1)              transfer more than 49% of the issued share capital of the company that holds the Subconcession it owns;

 

(2)              transfer more than 49% of its voting power in the company that holds the Subconcession;

 

(3)              waive the right to appoint most of the board of directors of the company that holds the Subconcession.

 

(b)               If the Primary Concession-holder is in breach of one of the provisions of sub-section (a) above, the Subconcession shall expire unless the Government gave its consent in advance and the Knesset Finance Committee gave its approval.

 

32



 

27.             The Subconcession shall be binding upon the parties, their legal representatives and their substitutes.

 

28.             (a)               If the Primary Concession-holder received royalties, rent or other payment under the Subconcession, such payment shall not be seen as implying a waiver of the Primary Concession-holder of any of its rights relating to any prior breach of one of the provisions of the Subconcession,

 

(b)               Waiver by one of the parties of a breach of one of the provisions of the Subconcession shall not be seen as a waiver of any breach thereafter of the same provision or of another provision, whether similar or different in its nature.

 

29.             Whenever according to the Subconcession notices, consents, requests demands or information (“Notices”) must be delivered, the Notices shall be in writing and shall be following addresses:

 

The Primary Concession-holder — Beit Ha’ashlag, Be’er Sheva;

 

The Subconcession-holder — Beit Ha’ashlag, Be’er Sheva;

 

or to any other address within the State of Israel, as each party notifies the other in a similar Notice.

 

Every notice sent as aforesaid shall be seen as a Notice that was delivered seventy-two hours after the properly addressed letter containing the Notice was mailed.

 

30.             The parties to the Subconcession hereby waive the need for notarized Notice of any breach or non-fulfillment of any of its provisions.

 

In witness whereof the parties hereby affix their signatures and stamps on the day and year noted at the head of this Subconcession.

 

 

For and in the name of
Dead Sea Works Ltd.

 

For and in the name of
Dead Sea Bromine Ltd.

 

33


 

Urban Building Ordinance, 1936

 

Urban Building Area, Tel Aviv Yafo

 

Notice of authorization to validate amendment of the detailed plan and notice of deposit of amendment of a detailed plan and drawing

 

Notice is hereby delivered, in accordance with section 19 of the Urban Building Ordinance, 1936, that the Regional Urban Building and Planning Committee, Tel Aviv District, has permitted validation — fifteen days after publication of this notice in the records — for amendment of a published plan called “Detailed Urban Building Plan No. 82 — and its amendments — in Lot 6966 — Hilton Hotel”, notice of the deposit of which with its attached drawing, at the office of the Local Urban Building and Planning Committee of Tel Aviv-Yafo, was published in Official Gazette 953, 1962, p. 1968.

 

Notice is also delivered, in accordance with section 19 of the Urban Building Ordinance, 1936, that copies of the aforementioned plan and of the drawing attached to it, in the form in which they were approved by that Local Committee — were deposited in the office of that Local Committee and can be reviewed there by any person.

 

December 5, 1962

 

Y. Cooperman

 

Chairman, Regional Urban Building
and Planning Committee
Tel Aviv District

 

Urban Building Area, Herzliya

 

Notice of deposit of amendment to
outline plan

 

Notice is hereby delivered, in accordance with section 19 of the Urban Building Ordinance, 1936, that a copy of an amendment to an outline plan called “Urban Building Plan No. 533, Amendment to Herzliya Outline Plan — in Lot 6531 Parcels 2, 7-14, 16, 31, 32, 36, 38, 55-60, 73-76, 93-98, 110-112; in Lot 6532 Parcels 1-3, 5, 6, 8, 9, 11, 32.37, 50-56, 59, 80, 99-106, 110-113, 118,119, 148-160, 165-177”, was deposited at the office of the Local Urban Building and Planning Committee of Herzliya, together with the drawing attached to it.

 

And these are the borders of the plan:

North: Lot 6531 Parcels 33-35, Lot 6532 Parcel 30; East: Lot 6532 the border of the Lot;

South: Lot 6531 Parcel 30, Lot 6532 Parcel 29; West: Lot 6531 the border of the Lot.

 

Whoever wishes to review copies of the above- mentioned plan and drawing, without payment, and whoever has an interest — as owner or from another aspect — in land, buildings or other assets which the plan affects, may submit opposition to the plan at the office of the aforementioned Local Committee during the two months from publication of a notice in the records.

 

November, 1982

 

Y. Cooperman

 

Chairman, Regional Urban Building
and Planning Committee
Tel Aviv District

 

34




Exhibit 10.2

 

Translation from the Hebrew. The Hebrew version is the binding version.

 

Outline

 

Pursuant to section 15B(1)(a) of the Securities Law, 5728-1968 and the
Securities Regulations (Details of Outline of an Offer of Securities to
Employees) 5760-2000

 

Together with

 

Report regarding a substantial private offering

 

pursuant to the Securities Regulations (Private Offering of Securities in a Listed Company), 5760-2000

 

An offer of

 

Up to 11,000,000 unlisted options, offered for no consideration to officers and other senior management employees at Israel Chemicals Ltd. (“the Company” or “ICL”) and subsidiaries, including for the chairman of the board of directors and CEO of the Company, exercisable for up to 11,000,000 registered ordinary shares of NIS 1.00 par value each in the Company.

 

Outline date: January 7, 2010

 

1



 

Contents

 

PART A — INTRODUCTION

4

 

 

 

1.

General

4

 

 

 

2.

Objective of the Plan

4

 

 

 

3.

Permits and approvals

4

 

 

 

PART B — DETAILS AND CONDITIONS OF THE OFFERING

5

 

 

 

4.

The offerees

5

 

 

 

5.

Description and rates of the offered securities

5

 

 

 

6.

Deposit of options with a trustee

8

 

 

 

7.

Right of exercise, lock-up and method of exercise of options

8

 

 

 

8.

Rights attaching to the underlying shares

9

 

 

 

9.

Restrictions applicable to activities in the options and underlying shares

9

 

 

 

10.

Conditions of the Plan in the event of termination of employment

10

 

 

 

11.

Change in control

11

 

 

 

12.

Restructure or merger

11

 

 

 

13.

Tax implications and issue to the trustee

12

 

 

 

14.

Adjustments for distribution of bonus shares and/or issue by way of rights and/or splitting or merging capital and/or distribution of a dividend

13

 

 

 

15.

Obligations of the offerees

14

 

 

 

16.

Applicable law

14

 

 

 

17.

The financial value of the options

14

 

 

 

18.

Information based on the sixth Addendum to the Securities Regulations (Periodic and Immediate Reports), 5730-1970

14

 

 

 

 

Organs of the Company which approved and issued the options to Akiva Mozes and Nir Gilad and officeholders and dates of approval

15

 

 

 

 

Method for determining compensation

15

 

 

 

 

Summary of the explanations of the audit committee and board of directors

16

 

 

 

19.

The issued share capital of the Company, quantity and rate of holdings of offerees and interested parties in the Company

17

 

 

 

20.

Consideration and method of determination thereof

18

 

 

 

21.

Personal interest in the approval of the Substantial Private Offering

19

 

 

 

22.

Required approvals

19

 

 

 

23.

Details of agreements pertaining to rights in the shares of the Company

19

 

 

 

24.

Restraints and restrictions applicable to the offerees with respect to operations that may be carried out with the options

19

 

 

 

25.

Term of grant of securities

19

 

 

 

26.

Powers of the board of directors of the Company

19

 

 

 

27.

No undertaking of continued employment

20

 

 

 

PART C — RIGHTS ATTACHING TO THE COMPANY’S SHARES

20

 

 

 

28.

Below is a summary description of the rights attaching of the Company’s shares as prescribed in the Company’s articles of association

20

 

2



 

PART D — ADDITIONAL DETAILS

21

 

 

 

29.

Details of the price of the Company’s shares on the Stock Exchange

21

 

 

 

30.

Notice of Outline

22

 

 

 

31.

Reference to periodic reports and interim financial statements

22

 

 

 

32.

Powers of the Israel Securities Authority

22

 

 

 

33.

Company representative

22

 

3



 

PART A — INTRODUCTION

 

1.                                       General

 

Israel Chemicals Ltd. (“the Company” or “ICL”) hereby reports, pursuant to the Securities Regulations (Details of an Outline of an Offer of Securities to Employees) 5760-2000 and the Securities Regulations (Private Offering of Securities in a Listed Company), 5760-2000 (“the Private Offering Regulations”) that on January 7, 2010, the Company’s board of directors approved a plan for a private offering of options exercisable for shares of the Company to approximately 300 offerees, including 14 officers and other senior management employees in the Company and subsidiaries (“the Private Offer”), including a substantial private offering of such options to the chairman of the board of directors and the CEO of the Company (“the Substantial Private Offer”), as set out below (“the Plan”). In respect of the offer to the chairman of the board of directors and CEO of the Company, this Outline also includes details as required by the Private Offering Regulations. Moreover, in respect of the offer for the chairman of the board of directors, an immediate report and notice regarding the convening of a special general meeting are attached to this Outline, pursuant to the Securities Regulations (Transaction between a Company and its Controlling Shareholder), 5761-2001 and the Securities Regulations (Periodic and Immediate Reports), 5730-1970.

 

The options shall be offered to the offerees under this Outline in accordance with section 15B(1)(a) of the Securities Law, 5728-1968 (“the Securities Law”) and the Outline Regulations and Private Offering Regulations (as the case may be).

 

2.                                       Objective of the Plan

 

The objective of the Plan is to provide an incentive to the offerees under the Plan to continue contributing to the Company and to its success in the future as well. This success is expected to be reflected, inter alia, in the long-term business results and in the price of the Company’s shares on the Tel Aviv Stock Exchange and as such, to promote the interests of the Company and increase its profits in the long term. The Plan will also create an incentive for the continued long-term employment of talented and skilled managers in the Company. This Plan is a continuation of the previous incentive plans of 1999, 2003 and 2007, ensuring the continuation of the incentive for the offerees and reflects the Company’s interest in expanding the circle of managers it wishes to motivate and retain.

 

3.                                       Permits and approvals

 

The offer of options under this Immediate Report is subject to obtaining the approvals set out below:

 

3.1                                The approval of the Tel Aviv Stock Exchange Ltd. (TASE) to list the shares underlying the exercise of the options (“the underlying shares”) that are the subject of this immediate report. Immediately after this Outline is issued, the Company intends to apply to the TASE to list the underlying shares for trading.

 

3.2                                Since, as set out in section 13 below, the options for the Company’s employees (with the exception of the offerees as set out in section 13.6 below), are to be issued in a capital gain track under section 102 of the Income Tax Ordinance (New Version) (“the Income Tax Ordinance”), the Plan requires the approval of the tax assessor and of a trustee to be appointed by the Company. The Company shall apply to the tax assessor close to the publication date of this Outline, requesting approval of the Plan and the trustee, and may issue the options 30 days after the submission date of the Plan to the tax assessor.

 

3.3                                Approvals from the relevant organs in the Company as required by law. The audit committee discussed the Plan in its meetings held on December 20, 2009 and December 28, 2009 and approved the private offering for officers, including the Substantial Private Offering, in its meeting on January 4, 2010. The board of directors’ human resource committee discussed the Plan on December 8, December 14 and December 24, 2009 and recommended that the board of directors approves the Plan and the offering to senior officers, including the Substantial Private Offering, in its meeting held on January 3, 2010.

 

4



 

The board of directors discussed the principles of the Plan in its meeting held on January 6, 2010 and discussed the Plan and the Private Offering for the officers in its meeting held on January 7, 2010.

 

The offering to the chairman of the board of director is also subject to the approval of the general meeting convened under an immediate report and notice regarding the convening of a special general meeting pursuant to the Securities Regulations (Transaction between a Company and its Controlling Shareholder), 5761-2001 and the Securities Regulations (Periodic and Immediate Reports), 5730-1970 together with this Outline.

 

The Company may offer options to offerees under the conditions of the Plan and this Outline, after receiving all the approvals required for the offering as set out in this section 3 above and subject to the provisions in section 25 below.

 

PART B — DETAILS AND CONDITIONS OF THE OFFERING

 

4.                                       The offerees

 

4.1                                The offerees of the Private Offering are, or shall be at the time of the offering, as the case may be, officers or other senior management employees at the Company and subsidiaries, in Israel and other countries, as defined in this section 4.1 below (these offerees, with the exception of the offerees set out in section 4.2 below, shall be referred to hereunder as: the “employees”).

 

Under the Private Offering, up to 11,000,000 options shall be issued to a trustee for approximately 300 employees (including 14 officers and including the CEO and chairman of the board of directors of the Company as set out in section 4.2 below) (for this matter, see also section 26 below).

 

4.2                                The offerees under the Substantial Private Offering are Mr. Akiva Mozes (“Akiva Mozes”), who is CEO of the Company, and Mr. Nir Gilad (“Nir Gilad”), who is the chairman of the board of Directors, and who are considered to have an interest in the Company by virtue of their positions. The options offered to Akiva Mozes and Nir Gilad are described in section 5.1 below.

 

4.3                                According to information provided to the Company, at the date of this immediate report:

 

4.3.1                                  Akiva Mozes holds 433,231 ordinary shares of NIS 1 par value each (“the shares”), representing 0.03% of the issued share capital of the Company and 2,200,000 options exercisable for up to 2,200,000 ordinary shares of the Company of NIS 1 par value each, under the Company’s 2007 options plan.

 

4.3.2                                  Nir Gilad does not hold Company shares or options that are exercisable into Company shares.

 

4.3.3                                  To the best of the Company’s knowledge, none of the employees is an interested party in ICL.

 

4.3.4                                  Akiva Mozes, Nir Gilad and the employees (hereinafter together: the “offerees”) are not an interested party, as such term is defined in section 270(5) of the Companies Law, 5759-1999 (“the Companies Law”).

 

5.                                       Description and rates of the offered securities

 

5.1                                The offerees — the employees (including 12 officers), Akiva Mozes and Nir Gilad shall be offered, for no consideration, 11,000,000 non-negotiable options, exercisable into up to 11,000,000 ordinary shares of the Company of NIS 1 par value each, subject to the adjustments set out in section 14 below and all the other conditions of the Plan as set out below. It is noted that the number of underlying shares that will be offered in practice when exercising the options are likely to be lower if the Company elects to exercise its right as

 

5



 

set out in section 5.3 below, and in this event, the offerees’ holdings will be lower that the rates set out below.

 

Below is the division of the options between the offerees:

 

 

 

 

 

 

 

Percentage after the
issue and exercise(1)

 

Percentage after the
issue and exercise
(fully diluted)(2)

 

Financial value of
the options

 

Offeree

 

Position

 

Number of options

 

In capital

 

In voting

 

In capital

 

In voting

 

(NIS thousands)(3)

 

Employees (including 8 officers)

 

 

7,700,000

 

0.6

 

0.6

 

0.6

 

0.6

 

142,450

 

 

 

 

(including 8 officers, offered a total of 725,000 options)

 

 

 

 

 

 

 

 

 

 

 

Akiva Mozes

 

CEO

 

1,100,000

 

0.086

%

0.086

%

0.085

%

0.085

%

20,350

 

Nir Gilad

 

Chairman of the board

 

800,000

 

0.063

%

0.063

%

0.062

%

0.062

%

14,800

 

Asher Grinbaum

 

Executive VP

 

350,000

 

0.027

%

0.027

%

0.027

%

0.027

%

6,475

 

Yossi Shahar

 

Executive VP

 

350,000

 

0.027

%

0.027

%

0.027

%

0.027

%

6,475

 

Dani Chen

 

CEO, ICL Fertilizers

 

350,000

 

0.027

%

0.027

%

0.027

%

0.027

%

6,475

 

Nissim Adar

 

CEO, ICL Industrial Products

 

350,000

 

0.027

%

0.027

%

0.027

%

0.027

%

6,475

 

All the offerees

 

 

 

11,000,000

 

0.861

%

0.861

%

0.855

%

0.855

%

203,500

 

 

Offer to offerees who are officers : The number of options offered to each offeree who is an officer was recommended for approval by the human resource committee of the board of directors, and approved by the audit committee and the board of directors. It is noted that the Private Offering for offerees who are officers and who are not directors was approved in accordance with the Company’s internal regulations and by the audit committee, notwithstanding the fact that the audit committee and board of directors believe that the Private Offering for officers does not constitute an extraordinary transaction under the circumstances, pursuant to the Companies Law.

 

It is further noted that the number of options that were approved for the offer to the CEO and chairman of the board and other officers were recommended by the human resource committee of the board of directors, and approved by the audit committee and board of directors, in view of the high appreciation of their activities and contribution to the Company, and out of a desire to ensure their continued tenure in the future, taking into account the size of the Company’s activities and its performance (for further details, see section 18.6 below). The issue of options to the chairman of the board of directors is also subject to the approval of the general meeting, convened under an immediate report and notice regarding the convening of a special general meeting pursuant to the Securities Regulations (Transaction between a Company and its Controlling Shareholder), 5761-2001

 


(1)          Presuming the theoretic exercise of all of the options for shares by the offerees under this Outline, without exercising the Company’s right to offer shares in an amount equivalent to the financial benefit under section 5.3 below, and without taking into account shares held by the Company.

(2)          The calculation, fully diluted, is based on the assumption in footnote 1 above, and assuming exercise of all of the balance of the Company’s securities that are convertible or exercisable for shares of the Company.

(3)          Calculated according to the economic opinion of external consultants based on the Black and Scholes model and according to the assumptions set out in section 17 below.

 

6



 

and the Securities Regulations (Periodic and Immediate Reports), 5730-1970, together with this Outline.

 

Offer to offerees who are not officers : The human resource committee of the board of directors shall approve the number of options offered to offerees who are not interested parties, subsequent to the date of this Outline, according to the authority delegated by the board of directors to this committee as set out in section 26 below.

 

5.2                                Each option confers the right to receive from the Company or its representative, by way of issue or transfer (as set out in section 5.3 below), one ordinary share of the Company, of NIS 1 par value, against payment of an exercise price of NIS 53.1, equivalent to the closing price of the Company’s share on the TASE on January 6, 2010 (the last known closing price at the date of the board of directors’ resolution), subject to adjustments as set out in section 14 below. The exercise price shall be linked to the CPI and the base index shall be the index for November 2009, published on December 15, 2009 (105.2 points). The exercise price will be increased or decreased according to the ratio between the known index at the exercise date and the base index (the linked exercise price shall be referred to hereunder as: “the exercise increment”). Notwithstanding the aforesaid, the exercise price for offerees who are residents of the United States and/or are subject to the tax laws in the United States, shall not be linked to the CPI as aforesaid, and accordingly the exercise increment for these offerees will be the same as the exercise price.

 

5.3                                Alternately, and at the sole discretion of the Company, the Company may, upon exercise of the options, issue share to the offerees, or transfer shares that are held or that will be held by the Company or a subsidiary, at the value of the benefit only, as set out below:

 

5.3.1                                  The number of underlying shares to which each offeree would be entitled at the exercise date of the options (as set out in section 7.5 below) shall be calculated according to the difference between:

 

5.3.1.1.                                 The closing price of the Company’s shares on the TASE on the trading day preceding the exercise date (“the effective price”) multiplied by the number of shares underlying the options tor which the exercise notice has been given (adjusted as set out in section 14 below).

 

And between:

 

5.3.1.2.                                 The exercise increment (adjusted as set out in section 14 below), multiplied by the number of options for which the exercise notice has been given.

 

This difference shall constitute the sum of the monetary bonus for the offeree on the date of the exercise (“the sum of the monetary bonus”).

 

5.3.2                                  The Company shall issue to the offerees, or transfer the shares that are held or that will be held by the Company or a company under its control, the number of shares with a market value, at the effective price, is equal to the sum of the monetary bonus only. Fraction of shares obtained as a result of this calculation shall be rounded up to the nearest full share.

 

The following conditions shall apply in the event of an issue of shares under this section: The Company shall convert part of its profits from share premiums or any other source included in its equity set out in its financial statements, into share capital, in the sum equal to the nominal value of the underlying shares, as set out in section 304 of the Companies Law. If this is not possible, the offeree shall be paid the nominal value of the underlying shares only. In this case, the Company will issue additional shares to the offeree, equivalent to the nominal value of the issued shares. It is clarified that in any event of issue of shares under this section, the exercise shall be effected in such a manner that the nominal value of the shares will be paid (or, as the case may be, capitalized), by the

 

7



 

Company or by the offeree, under any law, including the Companies Law, regarding distributions.

 

6.                                       Deposit of options with a trustee

 

The options shall be issued to a trustee according to the terms of the capital gains track, through a trustee as set out in section 13.4 below (“the trustee”), for the offerees, following and subject to receipt of all the approvals set out in section 3 above.

 

The effective date for implementing the Plan is the date of approval of the Plan by the board of directors of the Company, as set out in the introduction to this report, in other words, on January 7, 2010.(4)

 

7.                                       Right of exercise, lock-up and method of exercise of options

 

7.1                                All of the options granted to employees, Nir Gilad and Akiva Mozes are valid from the effective date (subject to the fulfillment of all the conditions set out in section 3 above). Unless otherwise determined by the board of directors, the options shall vest in three equal lots, as set out below:

 

7.1.1                                  One third of the options issued to each of the offerees shall vest 12 months after the effective date. The options or underlying shares shall be locked up for a minimum period as defined in section 13.4 below.

 

7.1.2                                  A second third of the options issued to each of the offerees shall vest 24 months after the effective date.

 

7.1.3                                  The last third of the options issued to each of the offerees shall vest 36 months after the effective date.

 

7.2                                Each of the offerees may exercise the options, in accordance with the conditions of the Plan (including section 10 below), in each lot that vests, in whole or in part, as follows: For the first and second lots — from the end of the minimum lock-up period as defined in section 13.4 below and up to 36 months after the date the options were issued (“the exercise date of the first lot” and the “exercise date of the second lot”, respectively). For the third lot, from the vesting date of that lot up to 48 months after the date the options were issued (“the exercise date of the third lot”). Should the exercise date of the first, second or third lots fall on a day other than a banking day in Israel or a trading day on the TASE, the final exercise date shall be deferred to the next business day thereafter, which is also a trading day on the TASE.

 

7.3                                An offeree wishing to exercise the options, under all the conditions of the Plan, shall submit a written and signed notice to the Company and the trustee, in the text prescribed by the Company (“the exercise notice”). The exercise notice shall include the identity of the offeree and the number of options he wishes to exercise. The offeree, and not the trustee, shall decide whether or not to exercise and shall pay the exercise price.

 

7.4                                The offeree shall pay the Company the consideration for the underlying shares issued to the offeree in accordance with the exercise notice as determined by the Company, unless the Company chooses to exercise its right under section 5.3 above.

 

7.5                                On the first trading day following the day the Company receives the exercise notice, completed and signed by the offeree, after having paid the consideration as set out in section 7.4 above (“the exercise date”), the Company shall issue the underlying shares to the trustee, and should the Company elect to exercise its right as set out in section 5.3 above, the provisions in section 5.3 shall apply.

 


(4)          Note that lock-up under section 102 shall apply to Israeli offerees, for 24 months subsequent to the date of issue to the trustee as set out in section 13.4 below.

 

8



 

7.6                                Options that are unexercised at the exercise date set for their relevant lot (as set out in section 7.2 above), shall expire and shall not afford any right to compensation or indemnification and shall not be valid.

 

8.                                       Rights attaching to the underlying shares

 

8.1                                The underlying shares shall be equal in their rights, to all intents and purposes, to the ordinary shares in the Company’s share capital at the date of this Outline, and shall confer, inter alia, the same rights to receive notice and to participate in the Company’s general meeting, receive dividends or any other distribution and receive surplus assets upon winding up.

 

8.2                                In any event where, according to the provisions of the Plan, the offeree is entitled to rights and/or bonus shares and/or any other right afforded to the offeree by virtue of the options and/or underlying shares (“the rights”), and at the date of record for distribution of the rights, the options and/or underlying shares were held by the trustee, the rights shall be transferred to the trustee, and the trustee shall deduct tax at source in accordance with the law, insofar as it applies. All the rights shall be issued to the trustee in favor of the offerees and shall be held by the trustee until the end of the lock up period of the options for which the rights were issued. The conditions of the tax track shall apply to these additional rights.

 

8.3                                In any event where the Company distributes a cash dividend and at the date of record for distribution of the dividend the trustee held underlying shares for any of the offerees, the Company shall transfer to the trustee the sum of the dividends for the underlying shares held by the trustee for each offeree. The trustee shall deduct tax at source according to the law, insofar as this is required, before transferring the sum of the dividend (net of the tax) to the offeree.

 

8.4                                Notwithstanding the aforesaid in section 8.1 above, if, in accordance with the provisions of the Plan, the trustee holds the underlying shares in favor of the offeree and these shares are yet to be transferred to the offerees, the shares shall not afford rights to receive notices and to participate in the Company’s general meetings.

 

9.                                       Restrictions applicable to activities in the options and underlying shares

 

9.1                                The options are a personal right that may not be transferred, endorsed or pledged, whether voluntarily or otherwise (except to the heirs of a deceased offeree according to a will or inheritance laws, provided they confirm their consent to the conditions). The options shall not be listed on the TASE. The shares underlying the exercise of the options (“the underlying shares”) shall be listed on the TASE.

 

9.2                                The options for offerees in Israel shall be issued to the trustee under section 102 of the Income Tax Ordinance. Accordingly the options or the underlying shares, as the case may be, shall be held by the trustee, under section 102 of the Income Tax Ordinance, for the minimum lock up period, as set out in section 13 below.

 

9.3                                The trustee may not transfer the options that were issued in accordance with the Plan to a third party, including an offeree, unless instructed by the Company.

 

9.4                                Transfer of rights to options and/or underlying shares under a will or inheritance laws shall be valid and shall bind the Company, only after the Company is furnished with the following notarized approvals:

 

A.             A written request for the transfer and a copy of a legal document confirming the right of the person to act in respect of the offeree’s estate or confirming the right of the transferee

 

9


 

B.             Written consent from the transferee to pay any amount in respect of the options under the Plan and any amount required under the provisions of the Plan as well as consent to comply with all the provisions of the Plan

 

C.             Any other evidence required by the board of directors to establish the right to transfer the options and/or underlying shares and the validity of the transfer.

 

9.5                                The underlying shares are subject to restrictions under the provisions in the Company’s articles of association.

 

9.6                                The options under this Outline are issued in accordance with section 15B(1)(a) of the Securities Law, and therefore restrictions on the buyback as set out in section 15C of the Securities Law will not apply to the underlying shares (except as set out below).

 

Section 15C of the Securities Law and the Securities Regulations (Details Regarding Sections 15A to 15C of the Law) 5760-2000 (“the Further Details Regulations”) apply to the shares underlying the options issued to the chairman of the board under the Private Offering Regulations and the shares underlying the options issued to offerees in countries other than Israel, as follows:

 

9.6.1                                  The offerees may not offer the underlying shares prior to the lapse of six months following the issue date of the options.

 

9.6.2                                  In six consecutive quarters, starting from the end of the period set out in section 9.6.1 above, each of the offerees may offer a number of shares on any trading day, which is no more than the daily average of the volume of trading of the Company’s shares on the TASE over the eight week period preceding the date of the offer, provided that the total number of shares offered in any quarter does not exceed one percent of the Company’s issued and paid up share capital, as set out in the further details regulations.

 

10.                                Conditions of the Plan in the event of termination of employment

 

10.1                         In the event of termination of employer-employee relations between the Company and the offeree following voluntary retirement of the offeree, and not as a result of disability due to health problems (“disability”), the offeree may exercise only those options included in the lots that have vested and are unexercised and unexpired by the termination date of employment, and they shall be exercisable for up to 90 days from the date of termination of employment (or, if the lock up period under section 102 of the Income Tax Ordinance has not yet ended, up to 90 days after the end of this period, whichever is the later). The rest of the options shall expire on the date of termination of employment.

 

10.2                         In the event of termination of employment due to disability or death, the offeree (or his heirs) may exercise the options in the lots that have already vested but which have not yet been exercised for shares, and a proportionate part of the next lot that has not yet vested, if any, to be calculated according to the proportion of the number of months that have lapsed since the date of vesting of the previous lot to have vested (or since the effective date, as the case may be), and up to termination of the offeree’s employment, and 12 months, and they shall be exercisable until the final date or dates of exercise (as set out in section 7.2 above), of each of the vested lots that are exercisable as set out in this section. The rest of the options shall expire on the date of termination of employment.

 

10.3                         In the event of termination of employment due to dismissal under circumstances which, in the Company’s opinion, afford the Company the right under law to dismiss the employee without severance pay, all the options offered to the offeree under this Plan shall expire immediately at the dismissal date, including those which have already vested but have not yet in fact been exercised.

 

10.4                         In the event of termination of employment for any reason which is not described in subsections 10.1-10.3, the offeree may exercise only the options that have vested by the

 

10



 

date of termination of employment, and which are unexercised and unexpired at the exercise date of the lot or the exercise dates of each of the shares (as the case may be), which vested and are exercisable as set out in this section. The rest of the options shall expire on the date of termination of employment.

 

10.5                         The offeree’s right to the options offered under the Plan or their exercise shall not be ended or expire or be accelerated solely as a result of the fact that the offeree was transferred from the Company to a subsidiary, or vice versa, as an employee or officer.

 

10.6                         The board of directors may amend the provisions of this section 10 (and/or any of them), in general or specifically, at its own absolute discretion.

 

10.7                         In this section 10, the severance date is the date of termination of employee-employer relations between the offeree and the Company, or the end of the notice period (or the adjustment period, if any), whichever is the later.

 

11.                                Change in control

 

In the event of change in control in the Company, on completion of the change in control, the rights to receive all the options issued to 14 offerees who are officers in the Company, will vest immediately, including those which, according to the dates set out in section 7.1 above, have not yet vested and they will be exercisable commencing from that date (subject to the minimum lock up period as set out in section 13.4 below) and up to the exercise date of each of the lots as set out in section 7.2 above.

 

In this section:

 

“Transfer of control” — including by way of the sale of shares (including a share swap), distribution of a dividend in kind or issue of shares to a third party

 

“Control” in this section — as defined in the Securities Law

 

12.                                Restructure or merger

 

In the event of merger of the Company with or into another Company, whether by way of a share swap, cash purchase or in any other manner, or sale of all (or the vast majority) of the Company’s assets or issued capital or any event with a similar corporate nature and any related action (hereinafter together: “restructure” or “merger”) and subject to any law, the board of directors may prescribe the following:

 

12.1                         Every option is replaced or converted into an option of equal value in the new company following the merger or sale and the exercise price is amended for such purpose, insofar as this is required, all at the discretion of the board of directors, or;

 

12.2                         Every option shall be adopted by the new company such that it shall be exercisable into a share of the new company subject to adjustments and amendments as may be prescribed by the board of directors, or;

 

12.3                         Every option shall be cancelled or returned to the Company and the Company shall pay the entitled employee monetary compensation for the cancellation or return of the option, provided that the value of the benefit in such compensation shall be no less than the value in the options that were cancelled or returned to the Company, as measured on the date of cancellation or return, as the case may be, and;

 

12.4                         To perform any action and/or adjustment in respect of the options and their conditions, as may be required, at its discretion.

 

For the purposes of the provisions of this clause, the term “new company” shall refer to the company with which a merger may take place, with which a sale transaction may be effected or which may stand in place of the Company following a restructuring or any related transaction. To

 

11



 

remove all doubt, it is clarified that if control in the Company is transferred as a result of restructure or merger, the provisions in section 11 above shall apply.

 

13.                                Tax implications and issue to the trustee

 

The following are details of certain tax-related provisions regarding the issue and exercise of the options:

 

13.1                         The offerees shall bear any tax obligation regarding issue of the options to offerees (including income tax, capital gains tax, national insurance and health tax) and any other mandatory payment owing on account of the grant or exercise of the options or the sale of the underlying shares. The trustee and the Company may deduct any amount required to be deducted at source by law.

 

13.2                         The provisions of section 102 of the Income Tax Ordinance (New Version) and the regulations promulgated thereunder (jointly: “section 102”) shall apply to the options issued to the offerees in Israel. The Company has decided that the issue shall be through a trustee, in the capital gains track.

 

13.3                         At the date of this report, the provisions of section 102 regarding the capital gains track provide, inter alia, the following :

 

·                         The options and underlying shares shall be locked up with the trustee until two years after the date of issue and designation of the issue for the employee.

 

·                         The offeree’s income from issue of the options shall not be taxed on the date of the issue.

 

·                         The employee’s tax liabilities for “part of the value of the benefit” on the date of the issue of the options shall be calculated in accordance with the marginal tax rate that applies to the employee. For this purpose, the “part of the value of the benefit” shall be calculated in accordance with the average value of the Company’s shares on the TASE at the end of the 30 trading days which preceded the issue of the options, less the cost of exercising the options.

 

·                         The balance of the value of the benefit shall be subject to tax at a rate of 25%.

 

·                         When issuing the options as aforesaid, the company employing the offeree shall be allowed a salary expense in the sum of the employee’s income, taxable at the marginal tax rate. In respect of the value of the benefit for the employee, taxable at a rate of 25%, the Company shall not be allowed an expense for tax purposes.

 

The aforesaid should not be considered as tax advice and offerees should examine the tax situation applicable to them and decide whether and how to act under their own specific circumstances.

 

13.4                         Accordingly

 

·                         The issue to the offerees shall only be effected after the approval of the tax assessor under section 102 and in accordance with the terms of the approval.

 

·                         Prior to the issue of the options to the offerees, the Company shall enter into an agreement with the trustee, which shall hold the options in trust for the offerees pending exercise (or expiration, as the case may be), and shall hold the underlying shares for at least 24 months subsequent to the date of issue to the trustee (“the minimum lock up period”)

 

13.5                         Notwithstanding any other provision in this clause, it is clarified that transfer of the underlying shares from the trustee to an Israeli offeree or from an Israeli offeree to any

 

12



 

third party (including sale thereof), is only be permitted after the minimum lock up period, after payment or deduction of the tax owing, if any, and shall be effected in accordance with the provisions, conditions and arrangements as may be agreed upon between the Company and the trustee, and subject to the provisions of section 102 or the provisions of any law and any agreement with the tax authorities.

 

13.6                         Notwithstanding the provisions above or below, the offerees under this Outline may include offerees whose place of residence or employment is outside of Israel, and therefore the provisions of section 102 are not applicable in their respect. The options of these offerees shall be deposited with the trustee on the date of their issue and shall be exercised through the trustee in the manner set out in this Outline, without the lock up restrictions under section 102.

 

The aforesaid in this section 13 above does not purport to be a certified interpretation of the provisions of the laws relating to issue of the options to the offerees, and is does not replace legal and professional advice on the matter. As is accepted in investments in securities, each of the offerees (including offerees as set out in section 13.6 above), should consider the various tax options and the implications of the tax applicable to the investment and should consult with professional advisors, including legal and tax consultants, taking into account their specific circumstances.

 

14.                                Adjustments for distribution of bonus shares and/or issue by way of rights and/or splitting or merging capital and/or distribution of a dividend

 

14.1                         If the Company distributes bonus shares after issuing options under this Outline, then on the date of record for distribution of the bonus shares, the number of underlying shares for exercising options that are unexercised and unexpired on the date of record for the bonus shares shall be increased by adding the appropriate number of shares, without consideration, to which the offeree would have been entitled had he exercised the unexercised options for shares on the date of record for the right to receive bonus shares, immediately prior to the date of distribution of the bonus shares. It is clarified that the exercise price of the options shall not change if bonus shares are distributed, however the payment for each share shall be decreased accordingly, in view of the increase in the number of underlying shares from each option.

 

14.2                         Should the Company offer its shareholders securities of any type whatsoever by way of a rights issue, the exercise price of the warrants shall not be adjusted, however the number of underlying shares for the exercise of the options not yet exercised by the date of record regarding the right to purchase rights under the rights issue shall be adjusted according to the benefit component embodied in the rights, to be calculated in accordance with the TASE guidelines in effect on the date of record.

 

14.3                         In any event of a split or merge of the Company’s share capital, or any corporate equity event that is materially similar in nature, the Company shall effect the amendments or adjustments that are required to prevent dilution or increase the offeree’s rights under the Plan in relation to the number and class of underlying shares for the unexercised options and/or in respect of the exercise price of each option.

 

14.4                         If the Company pays a cash dividend, and the date of record for its distribution falls after the options are issued under this Outline, then on the date of record, the exercise increment of the unexercised and unexpired options as of that date shall be reduced by the gross amount of the dividend per share, in its sum in Israeli shekels at the date of record. To remove all doubt, the exercise price shall not fall below the par value of the share. It is clarified that the provisions of this section shall not apply to offerees who are residents of the United States and/or subject to the tax laws in the United States.

 

14.5                         If the adjustments set out in this section result in share fractions, the Company shall not issue share fractions, and the number of shares issued to the offeree shall be rounded up to the next full share.

 

13



 

14.6                         It is clarified that the offeree’s right to additional underlying shares as a result of the adjustments under the provisions of this section shall only apply on the exercise date of the options.

 

15.                                Obligations of the offerees

 

When issuing the options, the Company shall deliver to each offeree a letter of offer in respect of the number of options that each offeree is entitled to receive under the Plan. When receiving the options under the Plan, the offeree shall undertake and declare the following: (1) To agree and confirm that he received and read the Plan and the letter of offer and accepts all of the conditions therein, including and without derogating from the generality of the aforesaid, his consent to bear all of the tax liabilities and other mandatory payments resulting from the offering and issue of the options, the exercise or sale of the underlying shares, and that he agrees and authorized the Company to deduct any tax at source that may apply (including, if required, from the number of options and/or underlying shares); (2) To fulfill all the conditions set out in section 102 (including provisions relating to the tax track), the provisions of section 102, the Plan, letter of offer and trustee agreement; (3) Subject to the provisions and conditions of section 102 and the rules, not to sell or remove the underlying shares from the trustee before the end of the lock up period; (4) To comply with the procedures for exercising the options and selling the underlying shares, as will be agreed upon between the Company and the trustee.

 

16.                                Applicable law

 

The Plan, this Outline and all the attached documents that were submitted or signed by the Company or subsidiaries in respect of the Plan and Outline, are subject to the laws of the State of Israel.

 

17.                                The financial value of the options

 

17.1                         The options will be offered to the offerees for no consideration.

 

17.2                         The financial value of each option at January 6, 2010, immediately prior to the date of record, is as follows: first and second lots: NIS 18.10; third lot: NIS 19.30. The total financial value of all of the options for the offerees is NIS 203.5 million. For further details, see paragraph 5.1 above.

 

17.3                         The financial value was calculated according to the financial opinion of external consultants and based on the Black and Scholes model, according to the calculation formula set out in the TASE guidelines for determining the value of options. The annual standard deviation of the share is 54.98% for the first and second lots and 48.45%, for the third lot. The annual capitalization rate is 0.59% for the first and second lots and 1.29% for the third lot. The life of the options is two and a half years for the first and second lots (taking into account, inter alia, the minimum lock-up period as set out in section 13.4 above) and three and a half years for the third lot. The exercise price set out in section 5.2 above and the closing price of the share on the TASE immediately prior to the date of record is NIS 53.10.

 

18.                               Information based on the sixth Addendum to the Securities Regulations (Periodic and Immediate Reports), 5730-1970

 

This section 18 presents information based on the sixth Addendum to the Securities Regulations (Periodic and Immediate Reports), 5730-1970, (“the Addendum”).

 

18.1                         For details of the options issued to Akiva Mozes and Nir Gilad and other officers under this Plan and Outline, and the percentage of their voting rights and the issued and paid-up share capital subsequent to their issue and exercise, at full dilution, and their financial value, see section 5 above.

 

18.2                         For details of all the compensation components for Akiva Mozes and the other four officers, who are the five highest-paid senior officers in 2009, among all the senior officers

 

14



 

in the Company and its subsidiaries, pursuant to Part C of the Addendum, see section 8.1 of the Shelf Prospectus (Ref. No.: 2009-01-190410) published by the Company on August 9, 2008. It should be noted that as from the second quarter of 2009 through to the date of this report, no changes have occurred in the terms and conditions of the tenure of the offerees as noted in this section 18.2.

 

18.3                         At the date of this report, Nir Gilad does not hold Company shares or options that are exercisable into Company shares. Furthermore, pursuant to the resolution adopted by the general meeting of the Company’s shareholders on July 20, 2009 pertaining to approval of the contract engaged by the Company to receive management services from Israel Corp. and/or H.L. Management Consulting (1986) Ltd., which is a wholly controlled subsidiary of Israel Corp., commencing January 1, 2009 through December 31, 2011, Mr. Gilad is not entitled to directors’ compensation for serving on the board of directors of the company and its committees. For further information see the Company’s Immediate Report dated June 16, 2009 (Ref. No.: 2009-01-143919). Likewise, as of the date of this report, Nir Gilad has no other compensation components with respect to his tenure with the Company or any of the Company’s subsidiaries.

 

18.4                         Organs of the Company which approved and issued the options to Akiva Mozes and Nir Gilad and officeholders and dates of approval

 

Further to the recommendations of the board of directors’ human resource committee (see details in section 3.3 above), the issue of options to Akiva Mozes and Nir Gilad and to the other officers, under this Outline, were approved by:

 

The Company’s audit committee deliberated the Plan and Private Offering, including the Substantial Private Offer to Akiva Mozes and Nir Gilad, in its meetings of December 20 and December 28, 2009, and approved them on January 3, 2010.

 

The Company’s board of directors deliberated the Plan at its meeting on January 6, 2010 and discussed the Plan and Private Offer to officers, including the Substantial Private Offer to Akiva Mozes and Nir Gilad, and approved them at its meeting on January 7, 2010.

 

In addition to the foregoing approvals, the issue of options to Nir Gilad is also subject to the approval of the general meeting of the Company’s shareholders which will be convened pursuant to an immediate report, and notice of the convening of a special general meeting, in accordance with the Securities Regulations (Transaction between a Company and its Controlling Shareholder), 5761-2001 and the Securities Regulations (Immediate and Periodic Reports), 5730-1970, published simultaneously and together with this Outline.

 

18.5                         Method for determining compensation

 

For the purpose of determining compensation, the audit committee and board of directors examined and took into account, in their deliberations concerning these matters, inter alia, the following parameters:

 

(a)          Assessment of the activities and contributions of Akiva Mozes and Nir Gilad and other officers to the Company’s performance and the achievement of its long-term goals;

 

(b)          The Company’s desire to ensure the continuation of their tenure in the Company in the upcoming years and to provide them with an incentive to continue to act to achieve the Company’s profits and its long-term goals;

 

(c)           The scope and complexity of the Company’s operations and its financial results;

 

(d)          Figures pertaining to the scope of the total compensation for Nir Gilad and Akiva Mozes and other officers (as well as details of the various compensation components, including options);

 

15



 

(e)           The terms for issuing the options and ratio between the inherent value of the benefit and the scope of the total compensation for Nir Gilad and Akiva Mozes and other officers.

 

(f)            Economic opinion prepared by external advisors with respect to the financial value of the benefit inherent in the options (see section 17.3 above);

 

(g)           Detailed review of the generally accepted methods of compensation for executives in Israel and other countries. As part of the review, the organizational, financial and accounting significance of these compensation methods were presented. The review included benchmarks for all the compensation components (including salary, bonus and equity compensation) for officers in public companies, the majority of which are included in the TASE TA-25 index and similar foreign companies which are public companies trading on stock exchanges abroad and operating in the sector in which the Company operates and which the Company deems to be a reference group for its business (in this connection, it is noted that the Company employs numerous employees abroad, some of whom are offerees in the Private Offer and for this reason emphasis was placed on benchmarks for similar compensation in competitive international companies. For further information see section 18.6.2 below). The benchmarks were gathered and prepared by external advisors, based on public information published by said companies.

 

(h)          Figures pertaining to the scope of compensation in securities for officers under the Company’s previous options plan of 2007.

 

18.6                         Summary of the explanations of the audit committee and board of directors

 

The audit committee and board of directors of the Company examined the terms and conditions of the issue of options with attention paid to all the parameters specified in section 18.5 above and resolved to approve the issue of options to Nir Gilad and Akiva Mozes and officers, based on the following considerations:

 

18.6.1                           The audit committee and board of directors resolved, while taking into account the terms and conditions of the issue of options and the total scope of the compensation for Nir Gilad and Akiva Mozes and other officers, the complexity of their positions, their skills and extensive experience and benchmarks for officers in similar positions among public companies in Israel, the majority of which are included in the TASE TA-25 index, as well as among similar foreign companies which are public companies trading on stock exchanges abroad and operating in the sector in which the Company operates, that: (a) the scope of compensation in securities and the total scope of compensation for Akiva Mozes and Nir Gilad and other officers, are reasonable under the circumstances and do not deviate from the conventional level of compensation for officers in these companies, including in respect of the percentage of the capital and voting rights underlying the exercise of the options; (b) the compensation is also reasonable in respect of the number of options offered under the plan.

 

18.6.2                           Without derogating from the stipulations in section 18.6.1 above, the audit committee and board of directors are of the opinion that, since ICL is a multinational company and its primary sales are carried out outside of Israel, and that a significant number of its employees operate and are employed abroad, and due to the relatively minor number of Israeli companies operating in ICL’s areas of operations, it is difficult to find similar relevant companies in Israel. Therefore, it is proper that, for the sake of analyzing information of similar companies and similar compensation in the sector in which ICL operates, an appropriate and relevant benchmark group is chosen of foreign public companies trading on foreign stock exchanges and that the Company deems them to be a reference group for the management of its business.

 

16



 

18.6.3                           The number of options approved for issue to Nir Gilad and Akiva Mozes and the other officers, was determined by the audit committee and the board of directors of the Company, in view of high appreciation for their activities and contribution to the Company and the outstanding achievements of the Company’s management (headed by the Company CEO, Akiva Mazes), in managing and navigating the Company through the recent global economic crisis, and by comparison with the business results of the competitors worldwide.

 

18.6.4                           Members of the audit committee and board of directors consider preservation of managerial stability of the Company and the continued activity of Nir Gilad. Akiva Mozes and other officers to be highly important, and in their decision to approve the number of issued options, they took into account the importance of ensuring their continued tenure in the Company in the upcoming years and the scope of the Company’s business operations, complexity of its operations and its performance in the long term.

 

18.6.5                           The scope of compensation for Nir Gilad and Akiva Mozes and the other officers is also reasonable compared to the scope of compensation in securities granted to officers under the Company’s previous options plan of 2007.

 

18.6.6                           Taking into account all the parameters that were examined and the above explanations, members of the audit committee and board of directors believe that the compensation in securities for Akiva Mozes and Nir Gilad and the other officers (including the ratio between them and their total compensation) is reasonable and appropriate and is an important and central part of the mix of compensation factors designed to provide an optimum incentive to act to achieve profits for the Company and its long-term goals, and that the options plan and issue of the options is designed to serve the benefit of the Company.

 

For further information pertaining to the method of determining the compensation and the considerations taken into account by the audit committee and the board of directors for the Private Offer to the chairman of the board, Mr. Nir Gilad, see immediate report and notice of the convening of a special general meeting, in accordance with the Securities Regulations (Transaction between a Company and its Controlling Shareholder), 5761-2001 and the Securities Regulations (Immediate and Periodic Reports), 5730-1970, published simultaneously and together with this Outline.

 

19.                                The issued share capital of the Company, quantity and rate of holdings of offerees and interested parties in the Company

 

19.1                         At the date of this report, the issued and paid-up share capital of the company is NIS 1,288,232,191 par value, divided into 1,288,232,190 ordinary shares of NIS 1.00 par value each and one special State share.

 

19.2                         At the date of this report, the amount of 2,216,131 shares of the Company are held by Ferson Chemical Materials Ltd., a wholly owned and controlled subsidiary of ICL. The Company holds 22,373,500 shares of the Company.

 

19.3                         Subsequent to the issue under this report and on the assumption of full exercise of all the options offered under this report, the shareholders’ equity(5) shall amount to NIS 1,276,853,788 par value (disregarding the shares held by the subsidiary, Ferson Chemical Materials Ltd. — see above).

 


(5)          Presuming full exercise by the offerees, without exercise of the Company’s right under section 5.3 of the plan, and without taking into account shares held by the Company, and without taking into account the exercise of the balance of the securities of the Company that are convertible or exercisable for shares of the Company.

 

17



 

19.4                         To the best of the Company’s knowledge, the holdings of Akiva Mozes and Nir Gilad, both of whom are interested parties by virtue of their positions in the Company, and the rest of the holders of issued and paid-up shares of the Company are, at the date of this report, and will be subsequent to the private offering, as follows:

 

 

 

 

 

Immediately prior to the private
offering

 

Subsequent to the private offering and presuming that
the offerees will exercise all of the options issued to
them under this Outline Plan.

 

 

 

 

 

 

 

 

 

 

 

Capital,

 

 

 

Voting
rights,

 

Company’s shareholders

 

Quantity

 

Capital

 

Voting
rights

 

Number

 

Capital(6)

 

fully
diluted(7)

 

Voting
rights(8)

 

fully
diluted(9)

 

Interested parties

 

Israel Corp. Ltd.

 

671,767,522

 

53.07

%

53.07

%

671,767,522

 

52.61

%

52.21

%

52.61

%

52.21

%

 

 

PCS

 

143,648,630

 

11.35

%

11.35

%

143,648,630

 

11.25

%

11.16

%

11.25

%

11.16

%

 

 

Ferson Chemical Materials Ltd.

 

2.216,131

 

0.18

%

0.18

%

2,216,131

 

0.17

%

0.17

%

0.17

%

0.17

%

 

 

Akiva Mozes

 

433,231

 

0.03

%

0.03

%

1,533,231

 

0.12

%

0.29

%

0.12

%

0.29

%

 

 

IDE Technologies

 

205

 

0.00

%

0.00

%

205

 

0.00

%

0.00

%

0.00

%

0.00

%

 

 

Rotem Amfert Negev Ltd.

 

205

 

0.00

%

0.00

%

205

 

0.00

%

0.00

%

0.00

%

0.00

%

 

 

Nir Gilad

 

 

0.00

%

0.00

%

800,000

 

0.06

%

0.06

%

0.06

%

0.06

%

 

 

Amnon Sadeh

 

27,500

 

0.00

%

0.00

%

27,500

 

0.00

%

0.00

%

0.00

%

0.00

%

 

 

Yair Orgler

 

1,600

 

0.00

%

0.00

%

1,600

 

0.00

%

0.00

%

0.00

%

0.00

%

 

 

Avraham (Baiga) Shochat:

 

2,000

 

0.00

%

0.00

%

2,000

 

0.00

%

0.00

%

0.00

%

0.00

%

 

 

Moshe Vidman:

 

6,100

 

0.00

%

0.00

%

6,100

 

0.00

%

0.00

%

0.00

%

0.00

%

 

 

Yossi Rosen

 

3,500

 

0.00

%

0.00

%

3,500

 

0.00

%

0.00

%

0.00

%

0.00

%

 

 

Ofer Holdings Group Ltd.

 

377,662

 

0.03

%

0.03

%

377,662

 

0.03

%

0.03

%

0.03

%

0.03

%

 

 

Israel Chemicals Ltd.

 

22,373,500

 

 

 

22,373,500

 

 

 

 

 

Balance of shareholders

 

Public

 

447,369,502

 

35.34

%

35.34

%

456,469,502

 

35.75

%

36.07

%

35.75

%

36.07

%

 

20.                                Consideration and method of determination thereof

 

20.1                         The options are offered to the offerees for no consideration.

 

20.2                         If all the options offered are exercised for shares(10), the Company should receive the sum of approximately NIS 584,100 thousands by the final date of exercise, inclusive.

 

20.3                         The Company intends to use the consideration obtained from the exercise of the options, if obtained, (see footnote 10), as may be resolved by the management or the board of directors of the Company, from time to time.

 

20.4                         The exercise price of the options is set by the audit committee and the board of directors in accordance with section 5.2 above, and it is identical for all the offerees under this Outline, including Akiva Mozes and Nir Gilad.

 


(6)           Presuming the theoretic exercise of all of the option warrants into shares by the offerees under this outline, without exercising the Company’s right to issue shares in an amount equivalent to the financial benefit under section 5.3 below, and without taking into account shares held by the Company.

(7)           The calculation of the fully diluted percentage is made on the basis of the assumption in footnote 6 above and assuming the exercise of all the balance of the securities of the Company that are convertible and exercisable for shares in the Company.

(8)           Cf. footnote 6 above

(9)           Cf. footnote 7 above

(10)     Without exercising the Company’s rights under section 5.3 above

 

18


 

21.                                Personal interest in the approval of the Substantial Private Offering

 

The Israel Corporation Ltd, the controlling shareholder in the Company. (“Israel Corp.”), is liable to have a personal interest in the approval of the Substantial Private Offering with respect to Nir Gilad due to his position as CEO of Israel Corp. To the best of the Company’s knowledge, none of the officers of the Company have a personal interest in the approval of the Substantial Private Offering, with the exception of the following officers who are offerees under the placement: Mr. Mozes and Mr. Gilad; and who may be deemed parties with personal interest with respect to the Substantial Private Offer to Nir Gilad — Mr. Moshe Vidman and Mr. Yossi Rosen, due to their tenure as directors in Israel Corp. (due the personal interest that Israel Corp. could have); and Mr. Avisar Paz and Mrs. Noga Yatziv, who may be deemed as parties with personal interest due to their tenure as officers in Israel Corp. who are, in the framework of their positions; subordinate to Mr. Nir Gilad, in his position as CEO of Israel Corp.

 

22.                                Required approvals

 

For further information pertaining to the required approvals and permits, see section 3 above.

 

23.                                Details of agreements pertaining to rights in the shares of the Company

 

To the best of the Company’s knowledge, subsequent to the clarifications conducted with Akiva Mozes and Nir Gilad, there are no agreements, either written or oral, between any of the offerees of the Substantial Private Offer and any shareholder in the Company, or between the offerees, all or in part, between each other or between them and other persons, with respect to the acquisition or sale of securities of the Company or with respect to the voting rights in the Company.

 

24.                                Restraints and restrictions applicable to the offerees with respect to operations that may be carried out with the options

 

For further information in this regard, see section 9 above.

 

25.                                Term of grant of securities

 

The term of the grant of options to the offerees under this Outline shall be effected as of: (a) receipt of all the required approvals as set forth in section 3 above or (b) 14 business days after the date of publication of this Outline, whichever is the later; and shall terminate on: (a) the date of submission of the periodic report for 2009 or (b) March 31, 2010, whichever is the earlier.

 

26.                                Powers of the board of directors of the Company

 

The board of directors of the Company is authorized to interpret the provisions of the Outline and the Plan and to make any supplementary or clarifying provision with respect to the execution thereof, to the extent that the matter may be required, at its discretion.

 

Without derogating from the generality of the aforesaid, it is clarified that subject to any law, the board of directors of the Company is authorized, at its exclusive discretion, to exercise all of the powers required for the purpose of management of the Plan, including determining the identity of the offerees, determining the number of options to be issued to each of the offerees, determining the dates of such issue, determining the vesting period and in special cases in which the board of directors shall deem fit, to bring forward the vesting dates of the unvested options (all or in part), with respect to all the offerees or some of them.

 

Likewise, the board of directors of the Company is authorized, at its exclusive discretion, to amend the provisions of the Plan (and its ancillary documents), provided that the amendment of any of the terms and conditions of the Plan shall not contradict the provisions of section 102 and shall not harm the rights of the offerees under the Plan without obtaining the prior consent of the offerees to whom options have been issued under the Plan on the date of the proposed amendment.

 

19



 

The board of directors has delegated its authority to designate the shares issued to the Trustee to specific employees (who are not officers) to its human resources committee, all in accordance with the provisions of section 288(b) (1) of the Companies Law.

 

27.                                No undertaking of continued employment

 

The granting of options to offerees under this Plan and this Outline shall not be interpreted as imposing any obligation on the Company and/or its subsidiaries to continue the employment of any of the offerees and/or as restricting them from terminating the employment of any of the employees and/or as granting any right to an offeree to continue to be employed.

 

PART C — RIGHTS ATTACHING TO THE COMPANY’S SHARES

 

28.                                Below is a summary description of the rights attaching of the Company’s shares as prescribed in the Company’s articles of association.

 

The full version of the Company’s articles of association can be viewed on the distribution website of the Securities Authority at (www.magna.isa.gov.il) and at the registered office of the Company.

 

At the date of this report, all the shares in the issued and paid-up share capital of the Company and the shares to be obtained from exercise of the options under this Plan are registered ordinary shares, except for one special State share (“the Gold Share”) which is held by the State of Israel.

 

28.1                         Conditions and rates of participation in the distribution of dividends and bonus shares: The ordinary shares shall have equal rights and shall afford the holders of them the right to receive notices regarding shareholders’ meetings of the Company, to participate in and vote at such meetings, to elect members of the board of directors as set forth in these articles of association and the right to participate in the distribution of the Company’s profits and surplus assets upon winding up.

 

In the event of a payment of dividends, such shall be paid proportionally to the sums paid-up or credited as paid-up on account of the par value of the shares, without taking into account any premium paid thereupon.

 

In the event of distribution of bonus shares, such shall be divided up between the ordinary shareholders, in proportion to their entitlement to participate in the payment of dividends, and shall be of the same class as the shares in respect of which they were distributed.

 

28.2                         Rights to participate in the division of the Issuer’s property upon winding- up: Upon winding up of the Company, the surplus of the Company’s assets over all of its liabilities, subject to rights granted for any class of shares that may be issued at such time, if any, shall be distributed among the ordinary shareholders in proportion to the sum paid-up or credited as being paid-up on the par value of such shares, without taking into account any premium paid on the shares.

 

28.3                         Right to appoint directors: The members of the board of directors shall be elected by the shareholders’ meeting by ordinary majority. All of the members of the board of directors shall hold office from the date of their election and/or appointment, until the next annual shareholders’ meeting, and subject to the provisions of any law and of the articles of association. The majority of the members of the board of directors shall be citizens and residents of Israel. A person who is not a citizen or resident of Israel shall not be elected and/or appointed as a director, if as a result of such appointment, the majority of the board of directors shall not be citizens and residents of Israel and the election and/or appointment of a director as aforesaid shall not have any force and shall be deemed not to have been made from the outset.

 

The number of members of the board of directors shall be no fewer than 7 and no greater than 20. The external directors of the Company shall be included in counting of the members of the board of directors.

 

20



 

28.4                         Rights to receive notices of meetings of shareholders, rights to participation and vote, and quorum : As aforesaid, every regular shareholder has the right to receive notices of general meetings of the Company and to attend and vote at such meetings. Deliberations in a shareholders’ meeting shall not commence unless a quorum is present. A quorum shall be constituted by the presence in person or by proxy, of at least two members who together hold at least 50% of the issued shares of the Company conferring voting rights. If, within half an hour of the time set for the commencement of the meeting, there is no quorum, the meeting shall be adjourned to the same day, time and place, or on such other day and/or other time and/or other place, as the board of directors shall prescribe by notice to the shareholders; and if at such adjourned meeting there is no quorum after half an hour of the time fixed for the meeting, then two members with voting rights, present in person or by proxy, holding at least one third of the Company’s issued share capital, shall be entitled to discuss and resolve matters in respect of which the meeting was convened.

 

28.5                         Restriction on transfer of shares : Fully paid up shares may be transferred without the need for the consent of the board of directors. The special State share shall not be transferable. The articles of association contain provisions restricting the purchase or holding of shares in rates exceeding 14%, 25% and any number affording the right, ability or practical possibility to appoint most of the directors of the Company, alone or jointly with others. Any such purchase shall require the consent of the person holding the special State share, in accordance with the proceedings and conditions set forth in the articles of association.

 

28.6                         Conditions for amendment of rights attaching to shares

 

Ordinary shares : Amendments of rights attaching to any class of shares shall be prescribed in a resolution of the shareholders of such class, and in a resolution of a meeting of such classes of shares whose rights may be harmed as a result of the amendment, by a majority of those persons holding three quarters of the voting rights of shareholders present at such meetings, or if such amendment has the written consent of the holders of three quarters of the number of shares of such class issued and of those classes whose rights shall be harmed as a result of the amendment.

 

The special State share : Any amendment of the articles of association which might directly or indirectly harm the rights attaching to the special State share, shall be deemed to be an amendment of the rights attaching to the special State share. Any resolution or act which might directly or indirectly harm the rights attaching to the special State share shall only be effected with the consent of the holder of the special State share, and shall be void and of no effect in the absence of the consent of the holder of the special State share.

 

PART D — ADDITIONAL DETAILS

 

29.                                Details of the price of the Company’s shares on the Stock Exchange

 

Below are details of the highest and lowest share prices (in agorot) on the dates on which the Company’s shares were traded during each of the two calendar years preceding the date of this Outline, and during the period from January 1, 2010 through shortly prior to the date of the publication of this Outline.

 

 

 

High price*

 

Low price*

 

Period

 

Date

 

Price

 

Date

 

Price

 

2008

 

June 18, 2008

 

7,296

 

November 23, 2008

 

1,781

 

2009

 

December 14, 2009

 

5,510

 

January 22, 2009

 

2,527

 

2010 (through to January 6, 2010)

 

January 6, 2010

 

5,310

 

January 3, 2010

 

5,020

 

 


* The closing prices of the shares subsequent to their adjustment for the purpose of the distribution of a dividend, as carried out by the Tel Aviv Stock Exchange Ltd.

 

21



 

30.                                Notice of Outline

 

Within 21 days from the date of the publication of this Outline, the Company shall provide a copy of the Outline, together with reference to the reports to which it refers, to each offeree at their place of employment or at their addresses as recorded by the Company. Each offeree shall receive a page setting out reference to links on the distribution website of the Securities Authority, with respect to each of the reports to which this Outline refers. In addition, a printed copy of the aforesaid reports shall be deposited with the Company’s secretariat and with segment secretariats, and each offeree will be able to view such and may obtain a copy thereof upon request.

 

Any notice from the Company to the offerees shall be given by way of written notice to be delivered to each of the offerees at their place of employment, or at their address as recorded by the Company, or at their email address.

 

31.                                Reference to periodic reports and interim financial statements

 

Attention is hereby drawn to the periodic report for 2008, which was published by the Company on March 30, 2009 (Ref. No.: 2009-01-071403) and to the interim financial statements for the period ended March 31, 2009, which was published by the Company on May 25, 2009 (Ref. No.: 2009-01-115038), to interim financial statements for the period ended June 30, 2009, which was published by the Company on August 24, 2009 (Ref. No.: 2009-01-206604) and to interim financial statements for the period ended September 30, 2009, which was published by the Company on November 24, 2009 (Ref. No.: 209-01-294039) and to the immediate reports published by the Company subsequent to the periodic report. These documents may be perused on the distribution website of the Securities Authority at: www.magna.isa.gov.il and at the website of the TASE at www.tase.co.il and at the registered office of the Company (at the office of the general counsel and company secretary), during regular business hours and with prior appointment, at Tel: 03-6844412.

 

32.                                Powers of the Israel Securities Authority

 

The Securities Authority, including an employee of the Authority so authorized, may instruct the Company, within 14 business days of the date of submission of the Outline, to provide any explanation, details, information or documents pertaining to the Outline and may instruct the Company to amend the Outline within such time as it may prescribe. Should the Authority instruct to amend this Outline, it may order a postponement of the effective date of the commencement of the term of granting of securities to a date which may fall no earlier than three business days and no later than 14 business days from the date on which the amendment to this Outline is published. The amendment of the Outline and the postponement of the commencement of the term of granting of the securities under these instructions shall be effected in accordance with the provisions of the Outline Regulations.

 

33.                                Company representative

 

The representative of the Company for the purpose of handling the report and this Outline is the Company’s general counsel and the company secretary, Adv. Liza Haimovitz, at telephone 972-3-6844412 and fax 972-3-6844427.

 

Israel Chemicals Ltd.

 

/s/ Lisa Haimovitz

 

Lisa Haimovitz

 

 

General Consul and Company Secretary

 

22




Exhibit 10.3

 

 

Translation from the Hebrew. The Hebrew version is the binding version

 

Outline

 

Pursuant to section 15B(1)(a) of the Securities Law, 5728-1968, the Securities Regulations (Periodic and Immediate Reports), 5730 — 1970 and the Securities Regulations (Outline Details of an Offer of Securities to Employees), 5760-2000

 

Along with

 

A Report regarding a substantial private offering

 

According to the Securities Regulations (Private offering of Securities in a Listed Company), 5760-2000 and to Regulations 37A(3) and 37A3 of the Securities Regulations (Periodic and Immediate Reports), 5730 — 1970

 

An offer of

 

Up to 12,000,000 unlisted options, offered, for no consideration, to officers and other senior employees in management positions at Israel Chemicals Ltd. (“ the Company ” or “ ICL ”) and companies under its control, including for the CEO of the Company, exercisable for up to 12,000,000 registered ordinary shares(1) of NIS 1.00 par value each, of the Company (“ the Option Warrants ” or “ the Options ”).

 

Outline date: November 27, 2012

 


(1)                    Assuming that all the Options are exercised into shares, the quantity of shares obtained may be less that indicated above, due to the exercise mechanisms as set forth hereafter in sub-Sections 5.2 and 5.3 of the Outline and this Immediate Report.

 



 

Table of Contents

 

Section

 

Page

 

 

 

 

Part A - Introduction

 

3

 

 

 

1.

General

3

 

 

 

2.

Objective of the Plan

3

 

 

 

3.

Permits and approvals

3

 

 

 

Part B — The details of the offer and its terms

4

 

 

 

4.

The Offerees

4

 

 

 

5.

Description and rates of the offered securities

4

 

 

 

6.

Deposit of options with a trustee

6

 

 

 

7.

Right of exercise, lock up and manner of exercising options

6

 

 

 

8.

Rights related to the underlying shares

7

 

 

 

9.

Restrictions applicable to activities in the options and the underlying shares

8

 

 

 

10.

Conditions of the Plan in the event of termination of employment

9

 

 

 

11.

Change in control

10

 

 

 

12.

Restructure or merger

10

 

 

 

13.

Tax implications and allocation to the trustee

10

 

 

 

14.

Adjustments for distribution of bonus shares and/or allocation by way of rights and/or splitting or merging of capital and/or distribution of a dividend

12

 

 

 

15.

Obligations of the Offerees

13

 

 

 

16.

Applicable law

13

 

 

 

17.

The financial value of the option warrants

13

 

 

 

18.

Information based on the Sixth Addendum to the Securities Regulations (Periodic and Immediate Reports), 5730-1970

14

 

 

 

19.

The issued share capital of the Company, quantity and rate of the Offerees holdings and interested parties in the Company

16

 

 

 

20.

Consideration and the manner of its determination

18

 

 

 

21.

Personal interest in the approval of the substantial private offering

18

 

 

 

22.

Required approvals

18

 

 

 

23.

Details of agreements pertaining to rights in the shares of the Company

18

 

 

 

24.

Restraints and restrictions applicable to the Offerees with respect to operations that may be carried out with the options

18

 

 

 

25.

Term of grant of securities

18

 

 

 

26.

Powers of the board of directors of the Company

19

 

 

 

27.

No undertaking of continued employment

19

 

 

 

Part C - Rights Attaching to the Company’s Shares

19

 

 

 

28.

Conditions and participation rates in the distribution of a dividend and bonus shares

19

 

 

 

 

Rights to participate in the division of the Issuer’s property upon winding-up

20

 

 

 

 

Right to appoint directors

20

 

 

 

 

Rights to receive notices of meetings of shareholders, right of participation and voting and legal quorum

20

 

1



 

 

Restriction on transfer of shares

20

 

 

 

 

Conditions for amendment of rights attaching to shares

20

 

 

 

Part D - Additional Details

21

 

 

 

29.

Details of the price of the Company’s shares on the Stock Exchange

21

 

 

 

30.

Notice of Outline

21

 

 

 

31.

Reference to periodic reports and interim financial statements

21

 

 

 

32.

Powers of the Israel Securities Authority

22

 

 

 

33.

Company representative

22

 

2



 

PART A - INTRODUCTION

 

1.                                       General

 

Israel Chemicals Ltd. hereby reports, according to the Securities Regulations (Details of an Outline of an Offer of Securities to Employees) 5760-2000 (“the Outline Regulations”), the Securities Regulations (Periodic and Immediate Reports), 5730 — 1970 (“The Report Regulations”), the Securities Regulations (Private placement of Securities in a Listed Company), 5760-2000 (“the Private placement Regulations”), that on November 26, 2012, the Company’s board of directors has approved a private placement of options exercisable for ordinary shares of NIS 1.00 par value each, of the Company (“ the Shares ” or “ the Company’s shares ”) to up to 500 offerees, including 14 officers and other senior employees in management positions in the Company and companies under its control (“ the Private Offering ”), including a substantial private placement of such options to the CEO of the Company (“ the Substantial Private Offering” ), in accordance with the “Plan for the Private Allocation of Options for Shares of the Company to the CEO of the Company, to Office Holders and Employees of The Company and Companies Under its Control (2012)”, which was adopted by the Board of Directors of the Company on November 26, 2012 (“ the Plan ”) and all as set forth below in this Outline and Report (“ The Outline and the Immediate Report ”). In respect of the allocation to the CEO of the Company, this Outline also includes details as required by the Private Placement Regulations and the Reports Regulations.

 

The options shall be allocated to the offerees under this Outline in accordance with section 15B(1)(a) of the Securities Law, 5728-1968 (“ the Securities Law ”) and the Outline Regulations and Private Placement Regulations (as the case may be).

 

2.                                       Object of the Plan

 

The objective of the Plan is to provide an incentive to the offerees according to the Plan to continue contributing to the Company and to its success in the future as well. This success is expected to be reflected, inter alia, in the long-term business results and in the price of the Company’s share on the Tel Aviv Stock Exchange (“ the TASE ”) and thereby to promote the interests of the Company and increase its profits in the long term. In addition, the Plan will create an incentive for the continued long-term employment of talented and skilled managers in the Company. This Plan is a continuation of the previous incentive plans from the years 1999, 2003, 2007 and 2010, ensuring the continuation of the incentive for the offerees and reflects the Company’s interest in expanding the circle of managers it wishes to motivate and retain.

 

3.                                       Permits and approvals

 

The allocation of options under the outline and this Immediate Report is subject to obtaining the cumulative approvals set out below:

 

3.1                                The approval of the Israeli stock exchange to list the shares which will be yielded by the exercise of the options (“ the Underlying Shares ”) that are the subject of this outline and immediate report. Immediately after this Outline is issued, the Company intends to apply to the TASE to list the underlying shares for trading.

 

3.2                                Since, as set forth in section 13 below, the options for the Company’s employees (with the exception of the offerees as set forth in section 13.6 below), are to be allocated in a capital gains track under section 102 of the Income Tax Ordinance (New Version) (“ the Income Tax Ordinance ”), the Plan requires the approval of the tax assessor and of a trustee to be appointed by the Company. The Company shall apply to the tax assessor close to the publication date of this Outline, requesting approval of the Plan and the trustee, and may allocate the options 30 days after the submission date of the Plan to the tax assessor.

 

3.3                                The allocation of the options is subject to obtaining all approvals required by law, including the approval of the organs of the Company and companies under its control, all as required by the Companies Law, 5759 — 1999 (“ the Companies Law ”). The Company’s board of directors’ human resources discussed the Plan in its meetings on November 15, 2012 and November 18, 2012 and recommended that the board of directors approve the Plan and the offering to senior officers, including the Substantial Private Offering. The

 

3



 

Company’s audit committee discussed the Plan in its meetings on November 15, 2012, November 18, 2012 and November 20, 2012, and approved the private placement for officers, including the Substantial Private Offering. The board of directors discussed the Plan and the Private placement for the officers including the Substantial Private Offering in its meetings on November 20, 2012 and November 26, 2012 and approved it, in its meeting held on November 26, 2012.

 

The Company may offer options to offerees under the conditions of the Plan and this Outline and immediate report, after receiving all the approvals required for the allocating as set forth in this section 3 above and subject to the provisions in section 25 below.

 

PART B - DETAILS AND CONDITIONS OF THE OFFERING

 

4.                                       The offerees

 

4.1                                The offerees of the Private placement are officers or other senior management employees at the Company and subsidiaries in its control, in Israel and outside of Israel, as defined in this section 4.1 below (these offerees, with the exception of the offerees set out in section 4.2 below, shall be referred to hereunder as: the “employees”).

 

Under the Private Offering, up to 12,000,000 options shall be allocated to a trustee for up to 500 employees (including 14 officers and including the CEO as set forth in section 4.2 below) (for this matter, see also section 26 below).

 

4.2                                The offeree under the Substantial Private placement is Mr. Stefan Bargas, who serves as the CEO of the Company (“ the CEO ”), and who is considered to have an interest in the Company by the virtue of his position. Tile options offered to the CEO are described in section 5.1 below.

 

4.3                                According to information provided to the Company, at the date of this immediate report:

 

4.3.1                      The CEO does not hold Company shares or options that are exercisable into Company shares.

 

4.3.2                      The CEO and the employees (hereinafter together “ the Offerees ”) are not an interested party, as such term is defined in section 270(5) of the Companies Law, 5759-1999 (“ the Companies Law ”). Also, to the best of the Company’s knowledge, none of the employees is an interested party in ICL.

 

5.                                       Description and rates of the offered securities

 

5.1                                The offerees - the employees (including 13 officers) and the CEO shall be offered, for no consideration, up to 12,000,000 non-negotiable options, exercisable into up to 12,000,000 ordinary shares of the Company of NIS 1.00 par value each, subject to the adjustments set out in section 14 below and all the other conditions of the Plan as set forth below, of which the CEO shall be allocated 1,190,000 options. It is noted, that the number of underlying shares that will be offered in practice when exercising the options may be lower due to the Maximum Share Value specified in Section 5.2 below, and if the company will choose to exercise its right under section 5.3 below, and in such a case the Offerees holding rates will be lower than the rates listed below.

 

The shares that shall be derived from the exercise of the options allocated to the Offerees shall constitute, as at the date of this report, 0.93% of the Company’s issued and paid-up share capital and 0.93% of its voting rights(2) (0.93% of the Company’s issued and paid-up

 


(2)                    Under the theoretical assumption of the exercise of all the options into shares by the offerees according to this outline, regardless of the maximum value of the share as described in Section 5.2 below, and without running the right of the Company to allocate shares in the value of the benefit under Section 5.3 below, and without considering the shares held by the Company and its subsidiary. The actual number of shares allotted may be lower than specified section 5.1 above, because of the Maximum Share Value specified in Section 5.2 below or because of the operation of a “net exercise” mechanism, as described in Section 5.3 below.

 

4



 

share capital and 0.93% of its voting rights, in full dilution(3)), Of which, the number of shares deriving from the exercise of the options allotted to the CEO shall constitute, as of this report, about 0.09% of the issued and paid-up capital of the Company and 0.09% of the voting rights(4) (0.09% of the Company’s issued and paid-up share capital and 0.09% of its voting rights, in full dilution(5)). The economic value of the options offered to the Offerees is NIS 146,040 thousand, of which the economic value of the options offered to the CEO is NIS 14,492 thousand(6).

 

Allocation to Offerees who are officers : The number of options offered to each offeree who is an officer was recommended for approval by the human resources committee of the board of directors, and approved by the audit committee and the board of directors.

 

Allocation to Offerees who are not officers : The human resources committee of the board of directors shall approve the number of options offered to Offerees who are not office holders, according to the authority delegated by the board of directors to that committee as set forth in section 26 below.

 

5.2                                Each option confers the right to receive from the Company or its representative by way of allocation or transfer (as set forth in sections 5.2 and 5.3 below) one ordinary registered share of the Company, of NIS 1.00 par value, against payment of an exercise price of NIS 46.6, equivalent to the average closing price of the Company’s share on the TASE for 30 days precedent to the date of the board of directors’ resolution, subject to adjustments as set forth in section 14 below. The exercise price shall be linked to the CPI and the base index shall be the index of October 2012 which was published on November 15, 2012 (106 points) (“ Base Index ”). The exercise price will be increased or decreased according to the ratio between the known index at the exercise date and the base index (the linked and adjusted exercise price as set forth in section 14.4 below, shall be referred to hereunder as: “ the Exercise Increment ”). Notwithstanding the aforesaid, the exercise price for Offerees who are residents of the United States and/or are subject to the tax laws in the United States shall not be linked to the CPI as aforesaid, and accordingly the exercise increment for these Offerees will be the same as the exercise price.

 

Notwithstanding the aforesaid, if on date of exercise (as defined below) the closing rate of the Company’s share on the trading date precedent to the exercise date (“ the Share Value ”) is higher than the exercise increment multiplied by 2 (“ the Maximum Share Value ”), then the quantity of underlying shares shall be adjusted in such a way that that the underlying shares that are actually allocated to an offeree multiplied by the share value shall be equal to the quantity of exercised options by the maximum share value. If the events set forth in sub-section 14.1 and 14.3 below take place, then the necessary adjustments shall be made. A fraction or a share obtained from the foregoing calculation will be rounded up to a whole share. Forthwith on exercise, the entire quantity of exercised options shall expire.

 

The Company shall take steps to preserve, in its registered capital, a sufficient number of shares for the purpose of the allocation of options in accordance with this Outline.

 

5.3                                Alternately, and at the sole discretion of the Company, the Company may, upon exercise of the options, allocate shares to the Offerees, or transfer shares that are held or that will be held by the Company or a company under its control, in the value of the benefit only, as set forth below:

 


(3)                    The computation of the full diluted share was based on the assumptions in footnote 2 above in relation to exercising the options by all offerees according to this outline, and under the assumption of the execution of all other securities of the Company which are convertible or exercisable for shares of the company.

 

(4)                    See footnote 2 above.

 

(5)                    See footnote 3 above.

 

(6)                    Calculated based on an opinion of external consultants on the basis of binomial model, depending on the assumptions specified in Section 17 below and considering the maximum value of the share as described in sections 5.2 and 5.3 below.

 

5



 

5.3.1                      The number of underlying shares to which each offeree will be entitled at the exercise date of the options (as defined in section 7.5 below) shall be calculated in accordance with the difference between:

 

5.3.1.1            The closing price of the Company’s shares on the TASE on the trading day preceding the exercise date and not more than the a sum equal to the exercise increment multiplied by 2 (“ the Determining Rate ”) multiplied by the option warrants for which the exercise notice has been given.

 

And:

 

5.3.1.2            The exercise increment multiplied by the number of options for which the exercise notice has been given.

 

In case of occurrence of the events set forth in sub-sections 14.1 to 14.3 below, the requisite adjustments shall be made.

 

This difference shall constitute the sum of the monetary bonus for the offeree on the date of the exercise (“ the Monetary Bonus Amount ”).

 

5.3.2                      The Company shall allocate to the Offerees, or transfer the shares that are held or that will be held by the Company or a company under its control, the number of shares with a market value at the effective price (less the par value of the company share, as far as paid by the Offerees in effect) equal to the sum of the Monetary bonus only. Fraction of share obtained as a result of this calculation shall be rounded up to the nearest full share.

 

The following conditions shall apply in the event of an allocation of shares under this section: The Company shall convert part of its profits from share premiums or any other source included in its equity set out in its financial statements, into share capital, in the sum equal to the nominal value of the underlying shares, as set forth in section 304 of the Companies Law. If this is not possible, the offeree shall pay only the nominal value of the underlying shares. It is clarified that if any event of the allocation of shares under this section, the exercise shall be effected in such a way that the nominal value of the shares will be paid (or, as the case may be, capitalized), by the Company or by the offeree, under any law, including the provisions of the Companies Law, for the purpose of distribution.

 

6.                                       Deposit of options with the trustee

 

The options shall be allocated to a trustee according to the terms of the capital gains track, through a trustee as set forth in section 13.4 below (“ the Trustee ”), for the Offerees, following and subject to receiving of all the approvals set out in section 3 above.

 

The determining date for implementing the Plan is the date of the approval of the Plan by the board of directors of the Company, as set forth in the introduction to this report, i.e., November 26, 2012 (“ the Determining Date ”)(7).

 

7.                                       Right of exercise, lock up and manner of exercising options

 

7.1                                All of the options will be granted to the CEO and the employees only after the fulfillment of all the conditions set out in section 3 above. The option shall vest in three equal lots, as set forth below:

 

7.1.1                      One third of the options allocated to each of the Offerees shall vest 12 months after the determining date. The options or the shares obtained from the exercise

 


(7)                    Note that in respect of Israeli offerees, lock-up will apply by virtue of Section 102 for a period of 24 months as from the date of allocation to the trustee as per sub-section PART B -13.4 below.

 

6



 

thereof (if exercised) shall be locked up for a minimum period as defined in section 13.4 below.

 

7.1.2                      A second third of the options allocated to each of the Offerees shall vest 24 months after the determining date.

 

7.1.3                      The last third of the options allocated to each of the Offerees shall vest 36 months after the determining date.

 

7.2                                Each of the Offerees may exercise the options, in accordance with the conditions of the Plan (including as set forth in section 10 below), in each and every lot that vests, in whole or in part, as follows: For the first and second lots — commencing as from the end of the minimum lock-up period as defined in section 13.4 below and up to 48 months after the date the options were allocated (“ the Exercise Date of the First Lot ” and “ the Exercise Date of the Second Lot ”, respectively). For the third lot, commending as from the vesting date of that lot up to 60 months after the date the options were allocated (“ The Exercise Date of the Third Lot ”). Should the exercise date of the first, second or third lots fall on a day other than a banking day in Israel or a trading day on the TASE, the final exercise date shall be deferred to the next business day thereafter, which is also a trading day on the TASE.

 

7.3                                An offeree wishing to exercise the options to which he is entitled, under all the conditions of the Plan, shall submit a written and signed notice to the Company and the trustee, in the wording prescribed by the Company (“ the Exercise Notice ”). The exercise notice shall include, inter alia , the identity of the offeree and the number of options he wishes to exercise. Each and every offeree, and not the trustee, shall decide whether or not to exercise and shall pay the exercise price

 

7.4                                The offeree shall pay the Company the consideration due to the Company for the underlying shares that shall be allocated to the offeree in accordance with the exercise notice in a manner determined by the Company, unless the Company chooses to exercise its right under section 5.3 above.

 

7.5                                On the first trading day following the day the Company receives the exercise notice, completed and signed by the offeree, after having paid the consideration as set forth in section 7.4 above (heretofore and hereafter: “ the Exercise Date ”), the Company shall allocate the underlying shares to the trustee(8) , and should the Company elect to exercise its right as set forth in section 5.3 above, the provisions of section 5.3 shall apply.

 

7.6                                Options that are unexercised at the exercise date set for their relevant lot (as set forth in section 7.2 above), shall expire and shall not afford any right to compensation or indemnification and shall not be valid.

 

7.7                                Notwithstanding the aforesaid, it is stated that in compliance with the TASE regulations, no options will be exercised into shares on the determining date for the distribution of bonus shares, for an offering by way of rights, for the distribution of a dividend, for consolidation of equity, or for the split or reduction of capital (each of the aforesaid shall be referred to hereafter in this section as a: “ corporate event ”), and such exercise shall be deferred until the next trading day. In addition, if the X-date of a corporate event falls prior to the determining date of the corporate event (within the definition of those terms in the TASE regulations), no exercise of options shall be made on such X date and the exercise shall be deferred until the next trading day.

 


(8)                    It is stated that wherever there exists, in the Plan and the Outline, a reference to the grant of the exercise shares to an offeree or to the trustee on his behalf, as the case may be, the meaning is registration of the shares in favour of the offeree or the trustee, as the case may be, with a TASE member, in such a way that

 

7



 

8.                                       Rights related to the underlying shares

 

8.1                                Forthwith upon allocation, the underlying shares shall be equal in their rights, to all intents and purposes, to the ordinary shares in the Company’s share capital at the date of this Outline, and shall confer, inter alia , the same rights to receive notice of and to participate in the Company’s general meeting, receive dividends or any other distribution and receive surplus assets upon winding up.

 

8.2                                In any event where, according to the provisions of the Plan, the offeree is entitled to rights and/or bonus shares and/or any other right vesting in the offeree by virtue of the options and/or underlying shares (hereafter: “ the Rights ”), and on the determining date for distribution of the rights, the options and/or underlying shares are held by the trustee, the rights shall be transferred to the trustee, and the trustee shall withhold tax at source in accordance with any law, insofar as it applies, and all the rights shall be allocated to the trustee in favor of the Offerees and shall be held by the trustee until the end of the minimal lock up period of the options for which the rights were allocated. The conditions of the tax track shall apply to these additional rights.

 

8.3                                In any event where the Company distributes a cash dividend and at the determining date for distribution of the dividend the trustee held underlying shares for any of the Offerees, the Company shall transfer to the trustee the dividend amounts for the underlying shares held by the trustee as stated for each offeree. The trustee shall withhold tax at source according to the law, insofar as it is required, before transferring the dividend amounts (net of the tax) to the offeree.

 

8.4                                Notwithstanding the aforesaid in section 8.1 above, as long as, in accordance with the provisions of the Plan, the trustee holds the underlying shares in favor of the Offerees and these shares are yet to be transferred to the Offerees, the shares shall not confer rights to receive notices and to participate in the Company’s general meetings.

 

9.                                       Restrictions on the making of transactions in options and in the underlying shares

 

9.1                                The options are a personal right that may not be transferred, endorsed or pledged, whether voluntarily or otherwise (except to the heirs of a deceased offeree according to a will or inheritance laws, provided they confirm their consent to the conditions). The options shall not be listed on the TASE. The shares underlying the exercise of the options to the Offerees shall be listed on the TASE.

 

9.2                                The options for Offerees in Israel shall be allocated to the trustee under section 102 of the Income Tax Ordinance. Accordingly the options or the underlying shares, as the case may be, shall be held by the trustee, under section 102 of the Income Tax Ordinance, for the minimum lock up period, as set forth in section 13 below.

 

9.3                                The trustee may not transfer the options that were granted in accordance with the Plan to a third party, including an offeree, unless instructed by the Company and subject to the applicable law.

 

9.4                                Transfer of rights to options and/or underlying shares under a will or inheritance laws shall be valid and shall bind the Company, only after the Company is furnished with the following notarized approvals:

 

A.             A written request for the transfer and a copy of a legal document creating and confirming the right of such person to act in respect of the Offeree’s estate and creating or confirming the right of the transferee

 

B.             Written consent from the transferee to pay any amount in respect of the options under the Plan and any amount required under the provisions of the Plan as well as consent to comply with all the provisions of the Plan

 

C.             Any other evidence required by the board of directors to establish the right to transfer the options and/or underlying shares and the validity of the transfer.

 

8


 

9.5                                The underlying shares are subject to restrictions under the provisions in the Company’s articles of association.

 

9.6                                The options under this Outline are allocated in accordance with section 15B(1)(A) of the Securities Law, and therefore restrictions on the buyback as set out in section 15C of the Securities Law will not apply to the underlying shares (except as set out below).

 

Section 15C of the Securities Law and the Securities Regulations (Details Regarding Sections 15A to 15C of the Law) 5760-2000 (“ the Further Details Regulations ”) apply to the shares underlying the options allocated to Offerees in countries other than Israel, as follows:

 

9.6.1                      The Offerees may not offer the underlying shares prior to the lapse of six months following the allocation date of the options.

 

9.6.2                      In six consecutive quarters, starting from the end of the period set out in section 9.6.1 above, each of the Offerees may offer a number of shares on any trading day, which is no more than the daily average of the volume of trading of the Company’s shares on the TASE over the eight week period preceding the date of the offer, provided that the total number of shares offered in any quarter does not exceed one percent of the Company’s issued and paid-up share capital, as set out in the further details regulations.

 

10.                                Conditions of the Plan in case of termination of labor relations

 

10.1                         In the event of termination of labor relations between the Company and the offeree following voluntary retirement of the offeree, and not as a result of disability due to health problems (“ Disability ”), the offeree may exercise only the options included in the lots that have vested and are unexercised and unexpired by the severance date of employment, and they shall be exercisable for up to 90 days from this day (or, if the lock up period under section 102 of the Income Tax Ordinance has not yet ended, up to 90 days after the end of this period, whichever is the later). The rest of the options shall expire on the date of termination of employment.

 

10.2                         In the event of termination of labor relations due to disability or death, the offeree (or his heirs) may exercise the options in the lots that have already vested but which have not yet been exercised for shares, and a proportionate part of the next lot that has not yet vested, if any, to be calculated according to the ratio of the number of months that have lapsed since the date of vesting of the previous lot to have vested (or since the determining date, as the case may be), and up to termination of the Offeree’s employment, and 12 months, and they shall be exercisable until the final date or dates of exercise (as set out in section 7.2 above), of each of the vested lots that are exercisable as set out in this section. The rest of the options shall expire on the date of termination of employment.

 

10.3                         In the event of termination of employment due to dismissal under circumstances which, in the Company’s opinion, confer on the Company the right under law to dismiss the employee without severance pay, including carrying out criminal offenses and breach of trust, all the options offered to the offeree under this Plan shall expire immediately at the date of notification of termination of employment, including those which have already vested but have not yet in fact been exercised.

 

10.4                         In the event of termination of employment for any reason which is not described in subsections 10.1-10.3 above, the offeree may exercise only the options that have vested by the date of termination of employment, and which are unexercised and unexpired at the exercise date of the lot or the exercise dates of each of the shares (as the case may be), which vested and are exercisable as set out in this section. The rest of the options shall expire on the date of termination of employment.

 

10.5                         The Offeree’s right to the options offered under the Plan or their exercise shall not be ended or expired or be accelerated solely as a result of the fact that the offeree was

 

9



 

transferred from the Company to a company under its control, or vice versa, as an employee or officer.

 

10.6                         The board of directors may amend the provisions of this section 10 (and/or any of them), in general or specifically, at its own absolute discretion.

 

10.7                         In this section 10, the severance date is the date of termination of employee employer relations between the offeree and the Company, or the end of the notice period (or the adaptation period, if any), whichever is the later.

 

11.                                Change of control

 

In the event of change in control in the Company, there will immediately vest, shortly before the date of completion of the transfer of control as stated, the entitlement of the Offerees to exercise all the options allocated to them including those which, according to the dates stipulated in sub-section 7.1 above has not yet vested, and these shall be exercisable by them commencing from that date (subject to the minimal lock up period as set forth in sub-section 13.4 below) and until the date of exercise of each of the lots as stated pin sub-section 7.2 above

 

Transfer of control ” - including by way of the sale of shares (including a share swap), distribution of a specific dividend or allocation of shares to a third party.

 

Control ” in this section - as defined in the Securities Law

 

12.                                Restructure or merger

 

In the event of merger of the Company with or into another Company, whether by way of a share swap, cash purchase or in any other manner, or the sale of all (or the vast majority) of the Company’s assets, activity, or issued capital or any event with a similar corporate nature and any related action (hereinafter jointly: “ Restructure or Merger ”) and subject to any law, the board of directors will prescribe one of the following alternatives:

 

12.1                         Every option shall be replaced or converted into an option of equal value in the new company following the merger or sale and the board of directors may amend the exercise price for such purpose, insofar as this is required, all at the discretion of the board of directors; or

 

12.2                         Every option shall be adopted by the new company such that it shall be exercisable into a share of the new company subject to adjustments and amendments as may be prescribed by the board of directors; or

 

12.3                         Every option shall be cancelled or returned to the Company and the Company shall pay the entitled employee monetary compensation for the cancellation or return of the option, provided that the value of the benefit inherent in such compensation shall be no less than the value inherent in the options that were cancelled or returned to the Company, as measured on the date of cancellation or return, as the case may be; and

 

12.4                         Any action and/or adjustment in respect of the options and their conditions, as may be required, at its discretion.

 

12.5                         Upon completion of the restructure or merger the options for the Company shares shall expire.

 

For the purposes of the provisions of this section, the term “ New Company ” shall refer to the company with which a merger may take place, with which a sale transaction may be effected or which may stand in place of the Company following a restructuring or any related transaction. To dispel any doubt, it is stated that if as a result of restructure or merger, control in the Company is transferred, the provisions in section 11 above shall apply.

 

10



 

13.                                Tax implications and allocation to the trustee

 

The following is an itemization of certain provisions relating to tax in respect of the allocation and exercise of the options:

 

13.1                         The Offerees shall bear any tax obligation regarding allocation of the options to Offerees (including income tax, capital gains tax, national insurance and health tax) and any other mandatory payment owing on account of the grant or exercise of the options. The trustee and the Company shall be entitled to deduct any amount that is lawfully subject to withholding at source.

 

13.2                         The provisions of section 102 of the Income Tax Ordinance (New Version) and the regulations promulgated thereunder (jointly: “ section 102 ”) shall apply to the options allocated to the Offerees in Israel. The Company has elected that the allocation to the Offerees who are Israeli residents shall be made through a trustee, in the capital gains track.

 

13.3                         At the date of this report, the provisions of section 102 regarding the capital gains track stipulate, inter alia, as follows:

 

·             The options and underlying shares that are obtained from the exercise of the options shall be locked up with the trustee until two years after the date being allocated and designated for the employee;

 

·             The Offeree’s income from allocation of the options shall not be taxed on the date of the allocation.

 

·             The employee’s tax liability for “part of the value of the benefit” on the date of the allocation of the options shall be calculated in accordance with the marginal tax rate that applies to the employee. For this purpose, the “part of the value of the benefit” shall be calculated in accordance with the average value of the Company’s shares on the TASE at the end of the 30 trading days which preceded the allocation of the options, less the cost of exercising the options.

 

·             The balance of the value of the benefit shall be subject to tax at a rate of 25%.

 

·             When allocating the options as aforesaid, the company employing the offeree shall be allowed a payroll expense in the sum of the employee’s income, taxable at the marginal tax rate. In respect of the value of the benefit to the employee, taxable at a rate of 25%, the Company shall not be allowed an expense for tax purposes.

 

The aforesaid should not be considered as tax advice and Offerees should examine the tax situation applicable to them and decide whether and how to act under their own specific circumstances.

 

13.4                         Accordingly

 

·             The allocation to the Offerees shall take place only after the fulfillment of the conditions required in the provisions of the capital gains track in Section 102 of the Income Tax Ordinance.

 

·             Prior to the allocation of the options to the Offerees, the Company shall enter into an agreement with the trustee (“ the Trustee ”), which shall hold the options in trust for the Offerees pending exercise (or expiration, as the case may be) and shall hold the underlying shares for at least 24 months subsequent to the date of allocation to the trustee (“ the Minimum Lock Up Period ”)

 

13.5                         Notwithstanding any other provision in this clause, it is stated that transfer of the underlying shares from the trustee to an Israeli offeree or from an Israeli offeree to any third party (including sale thereof), is only be permitted after the minimum lock up period, and payment of the applicable tax. Despite the aforementioned, it will be possible to transfer the underlying shares before the end of the minimum lock up period, after

 

11



 

payment or deduction of the tax owing, if any, and shall be effected in accordance with the provisions, conditions and arrangements as may be agreed upon between the Company and the trustee, and subject to the provisions of section 102 or the provisions of any law and any agreement with the tax authorities.

 

13.6                         Notwithstanding the provisions heretofore and hereafter, the Offerees under this Outline include Offerees whose place of residence or employment is outside of Israel, and therefore the provisions of section 102 may not be applicable in their respect. The options of these Offerees shall be deposited with the trustee on the date of their allocation and shall be exercised through the trustee in the manner set out in this Outline, without the lock up restrictions under section 102.

 

The foregoing of this Section 13 does not purport to be an authorized interpretation of the legal provisions pertaining to the taxes that may apply in connection with the grant of the options being offered to the Offerees, and cannot substitute for professional legal advice on the matter. As is customary in investment in securities, each of the Offerees (including Offerees as per sub-section 13.6 above) must consider the various tax aspects and the tax implications that will attach to their investment and should consult their professional advisers, including legal and taxation advice having regard to their particular data.

 

14.                                Adjustments in respect of the distribution of bonus shares and/or allocation by way of rights and/or capital split or consolidation and/or distribution of a dividend

 

14.1                         If the Company distributes bonus shares after allocating options according to this Outline, then the number of underlying shares for exercising options that are unexercised and unexpired by the determining date for the bonus shares shall be increased by adding the appropriate number of shares, without additional payment, to which the offeree would have been entitled as bonus shares had he exercised the unexercised options for shares by the determining date for the right to receive bonus shares, immediately prior to the determining date of distribution of the bonus shares. It is stated that the exercise price of the options shall not change if bonus shares are distributed, however the payment for each share shall be decreased accordingly, in view of the increase in the number of underlying shares deriving from each option.

 

14.2                         Should the Company offer its shareholder securities of any type whatsoever by way of a rights issue, the exercise price of the warrants shall not be adjusted, however the number of underlying shares for the exercise of the options not yet exercised by the determining date regarding the right to purchase rights under the rights issue shall be adjusted according to the benefit component embodied in the rights, to be calculated in accordance with the TASE guidelines in effect on the determining date.

 

14.3                         In any event of a split or consolidation of the Company’s share capital or any corporate equity event that is materially similar in nature, the Company shall effect the amendments or adjustments that are required to prevent dilution or increase of the Offeree’s rights under the Plan in relation to the number and class of underlying shares for the unexercised options and/or in respect of the exercise price of each option.

 

14.4                         If the Company pays a cash dividend and the determining date for its distribution falls after the options are allocated according to this Outline, then on the determining date, the exercise increment of the unexercised and unexpired options as of that date shall be reduced by the gross amount of the dividend per share, in its amount in Israeli shekels. To dispel any doubt, the exercise price shall not fall below the part value of the share. It is stated that the provisions of this section 14.4 shall not apply to Offerees who are residents of the United States and/or subject to the tax laws in the United States.

 

14.5                         If the adjustments set out in this section result in share fractions, the Company shall not allocate share fractions and the number of shares issued to the offeree shall be rounded up to the next full share.

 

12



 

14.6                         It is stated that the Offeree’s right to additional underlying shares as a result of the adjustments under the provisions of this section 14 shall only apply on the exercise date of the options.

 

15.                                The Offerees’ obligations

 

When allocating the options, the Company shall deliver to each offeree a letter of offer in respect of the number of options that each offeree is entitled to receive under the Plan. When receiving the options under the Plan, the offeree shall undertake and declare the following: (1) To agree and confirm that he received and read the Plan and the letter of offer and accepts all of the conditions therein, including and without derogating from the generality of the aforesaid, his consent to bear all of the tax liabilities and other mandatory payments resulting from the offering and allocation of the options, the exercise or sale of the underlying shares, and that he agrees and authorizes the Company to withhold at source any tax that may apply (including, if required, from the number of options and/or underlying shares); (2) To fulfill all the conditions set out in section 102 (including provisions relating to the tax track), the provisions of section 102, the Plan, letter of offer and trustee agreement; (3) Subject to the provisions and conditions of section 102 and the rules, not to sell or remote the underlying shares from the trustee before the end of the minimum lock-up period; (4) To comply with the procedures for exercising the options and selling the underlying shares, as will be agreed upon between the Company and the trustee.

 

16.                                The applicable law

 

The Plan, this Outline and all the attached documents that were submitted or signed by the Company or companies under its control in respect of the Plan and this Outline, will be Interpreted, conducted and subject to the laws of the State of Israel.

 

17.                                The financial value of the options

 

17.1                         The options will be offered to the Offerees for no consideration.

 

17.2                         The company is implementing the international financial reporting standard number 2 “share based payment.” The main provisions of the standard concern the recording of expenses in respect of share based payment transactions in the financial statements of the company in accordance with the economic value at the time of the allocation as defined in the abovementioned standard. The expenses shall be recorded in the financial statements of the company on the vesting period of the options and in accordance with the quantity of options expected to be vested.

 

17.3                         The financial value of each option at November 25, 2012, immediately prior to the determining date, is as follows: first and second lots: about NIS11.9 each; third lot: about NIS 12.4. For further details, see Paragraph 5.1 above.

 

17.4                         The stated financial value was calculated according to the financial opinion of external consultants and based on the binomic model which is suited for the calculation of economic value in cases where an upper limit is defined for the level of the benefit derived from the exercise of the options (“CAP”). The annual standard deviation of the share which is calculated for the first lot and the second lot is 36.70% and for the third lot is 44.20%. The capitalization rate that is taken into account in relation to the first and second lots is 0.22%, and in relation to the third lot is 0.54%. The lifetime of the options for the first and second lots is 48 months with a vesting period and limit of 24 months, while the lifetime of options for the third lot is 60 months with a vesting period of 36 months. (As set out in section 7 above the exercise price of the option is NIS 46.6, and the closing price of the share on the TASE immediately prior to the determining date is NIS 46.6. In accordance with the terms of the options, an upper limit for the level of the benefit derived from the exercise of the option (CAP) was taken into consideration — of twice the exercise increment (see sections 5.2 and 5.3 above)

 

17.5                         Accordingly, the cumulative economic value of the options that will be allotted to the Offerees for the period of 60 months is approximately NIS146,040 thousand, of which the

 

13



 

economic value of the options allotted to the CEO for a period of 60 months is about NIS14,492 thousand as at the date of the approval of the board of directors.

 

17.6                         The calculation of the fair value does not reflect the fact that the options will not be listed for trade on the stock market, and also does not reflect the tax that is likely to apply at the time of exercise of the options or sale of the underlying shares. Nonetheless, since that in the understanding of the Company this model calculates and reflects the fair value of the options in the best manner out of the currently existing models, the Company chose to implement it with regard to calculation of the fair value of options allocated by it.

 

17.7                         The time of approval of the allocation by the Company’s board of directors shall be the time of measuring the accounting expense with regard to the options that shall be allocated to the Offerees.

 

17.8                         Recording of the expense shall extend from the period of the board of directors’ approval to the termination of the vesting period of each of the option lots.

 

18.                                Information based on the Sixth Addendum to the Reports Regulations

 

This section 18 presents information based on the Sixth Addendum to the Reports Regulations concerning a Substantial private offering to the CEO.

 

18.1                         For details on the options allocated to the CEO in accordance with this Plan and Outline and their ratio out of the voting rights and the issued and paid-up share capital following allocation and exercise, and in full dilution and their financial value, see Section 5 above.

 

18.2                         For details of all the compensation components for the CEO, see the Immediate Report published by the Company on September 24, 2012 (ref. 2012-01-244113).

 

18.3                         Organs of the Company which approved and allocated the options to the CEO and dates of approval

 

Further to the recommendations of the Board of Directors’ human resources committee (see details in section 3.3 above), the allocation of options to the CEO under this Outline, were approved by:

 

The Company’s audit committee deliberated the Plan and the Private Offering, including the Substantial Private Offer to the CEO, in its meetings of November 15, 2012, November 18, 2012 and November 20, 2012, and approved them on November 20, 2012.

 

The Company’s Board of Directors deliberated the Plan and the Private Offer for officers, including the Substantial Private Offer to the CEO in its meetings of November 20, 2012 and November 25, 2012, and approved them at its meeting on November 25, 2012.

 

18.4                         Method for determining compensation

 

For the purpose of determining compensation, the audit committee and Board of Directors examined and took into account, in their deliberations concerning these matters, inter alia, the following parameters:

 

(A)                    The Company’s desire to incentivize the CEO such that he will act for the continued success of the Company, to achieve its long-term goals and raising its long-terms profits.

 

(B)                    The setting of a ceiling within the plan for the value of the bonus inhering in the exercise of the options in such a way that the bonus shall not exceed twice the amount of the exercise increment, as set forth in sub-sections 5.2 and 5.3 above.

 

14



 

(C)                    The scope and complexity of the Company’s operations and its financial results.

 

(D)                    Figures pertaining to the scope of the total compensation for the CEO (as well as details of the various compensation components, including options);

 

(E)                     The terms for allocating the options and the ratio between the inherent value of the benefit and the scope of the total compensation for the CEO.

 

(F)                      Economic opinion prepared by external advisors with respect to the financial value of the benefit inherent in the options (see section 17.3 above).

 

(G)                    Detailed review of the generally accepted methods of compensation for executives in Israel and other countries. As part of the review, the financial and accounting significance of these compensation methods were presented. The review included benchmarks for all the compensation components (including salary, bonus and equity compensation) for officers in public companies, the majority of which are included in the TASE TA-25 index and similar foreign companies which are public companies trading on Stock Exchanges abroad and operating in the sector in which the Company operates and which the Company deems to be a reference group for its business. The benchmarks were gathered and prepared by external advisors, based on public information published by said companies.

 

(H)                   Figures pertaining to the scope of compensation in securities for officers under the Company’s previous options plan of 2010.

 

18.5                         Summary of the explanations of the human resources committee, the audit committee and the Board of Directors

 

The human resources committee, the audit committee and the Board of Directors examined the terms and conditions of the issue of options with attention paid to all the parameters specified in sub-section 18.4 above, and the audit committee and the Board of Directors resolved to approve the allocation of options to the CEO, based on the following considerations:

 

18.5.1               In the employment contract of the CEO which was approved by the Company’s board of directors on September 24, 2012, (“the Employment Contract ”), after the approval of the audit committee, it was determined that the CEO shall be entitled to allocation of options within the plan, as elaborated in the Immediate Report published by the Company on September 24, 2012 (ref. 2012-01-244113). The audit committee and Board of Directors made a decision to approve the allocation of options for the CEO as elaborated in this Outline, at the maximal value set in the employment contract, this while taking into account (1) the terms and conditions of the allocation of options which include, inter alia, a ceiling at the date of exercise for the value of the benefit that is latent in the exercise of the options; (2) the complexity of the CEO’s position, his skills, his expertise, his proven managerial abilities in companies in the chemical industry worldwide and his vast professional experience; (3) the expected achievements of the CEO and the satisfaction generated by the manner of his entry into his position; (4) the scope and the complexity of the operation of the ICL group and its widespread global dispersion; (5) the total scope of the compensation for the CEO as set forth in the employment contract; (6) Members of the audit committee and Board of Directors ascribe great importance to incentivizing the CEO to bring about the ongoing success of the Company, to achieve its long term goals, and increase profitability over the long term, to preserving managerial stability of the Company and the continued leadership of its activity by the CEO, and in their decision to approve the number of allocated options, they took into account the importance of ensuring his continued tenure in the Company in the upcoming years and to create a connection between the Company’s performance and the compensation that will be derived from the options; and (7)

 

15



 

benchmarks for CEO positions among public companies in Israel, the majority of which are included in the TASE TA-25 index, as well as among similar foreign companies which are public companies trading on Stock Exchanges abroad and operating in the sector in which the Company operates.

 

18.5.2               Without derogating from the stipulation in sub-section 18.5.1 above, the audit committee and Board of Directors are of the opinion that, since ICL is a multinational company and its primary sales are carried out outside of Israel, and that significant number of its employees operates and are employed abroad, and due to the relatively minor number of Israeli companies operating in ICL’s area of operations, it is difficult to find similar relevant companies in Israel. Therefore, it is proper that, for the sake of analyzing information of similar companies and similar compensation in the sector in which ICL operates, an appropriate and relevant benchmark group is chosen of foreign public companies trading on foreign Stock Exchanges and that the Company deems them to be a reference group for the management of its business.

 

18.5.3               It was further determined by the audit committee and the Board of Directors that the scope of compensation for the CEO is also reasonable compared to the scope of compensation in securities granted to officers under the Company’s previous option plan of 2010. Furthermore, the allocation of options to the CEO as set forth in this Outline has enabled maintaining the ratio between the equity based compensation of the CEO and the equity based compensation of the rest of the officers as was the case in the Company’s previous option plan.

 

18.5.4               Taking into account all the parameters that were examined and the above explanations, members of the audit committee and Board of Directors have determined that (A) the scope of the compensation in securities and the scope of the total compensation for the CEO is reasonable and appropriate in the circumstances of the matter, and do not deviate from the level of compensation customary among CEOs in similar companies as elaborated above, including in relation to the rate of the equity and voting rights in the Company, which will be granted by the shares derived from exercise of the options; (B) the equity based compensation is reasonable also in relation to the total amount of options offered in accordance with the plan; (C) the equity based compensation is reasonable also when taking into account the ratio between the offered options and the other components of the CEO’s compensation; (D) the equity based compensation constitutes an important and central part of the mix of compensation factors designed to provide an optimum incentive to the CEO to act to achieve profits for the Company and its long-term goals, and that the compensation is designed to serve the benefit of the Company.

 

19.                                The issued share capital of the Company, quantity and rate of the Offerees holdings and interested parties in the Company

 

19.1                         Correct to the date of this report, the Company’s issued and paid-up share capital stands at NIS1,294,703,010 par value, divided into 1,294,703,009 ordinary shares of NIS 1.00 par value each and one special State share.

 

19.2                         At the date of this report, the amount of 2,216,131 shares of the Company is held by Ferson Chemical Materials Ltd., a wholly owned and controlled subsidiary of ICL. The Company holds 22,375,500 shares of that company.

 

19.3                         At the date of this report, officers and other employees hold the amount of 10,930,500 options allocated under an outline from January 7, 2010.

 

16


 

19.4                         Subsequent to the allocation under this report and on the assumption of full exercise of all the options offered under this report, the shareholders’ equity(9) shall amount to NIS 1,284,329,510 par value (disregarding the shares held by the Company — see above).

 

19.5                         To the best of the Company’s knowledge, the holdings of the CEO who is an interested party by virtue of his positions in the Company, other interested parties and the rest of the holders of issued and paid-up share capital of the Company are, at the date of this report, and will be subsequent to the private offering, as follows:

 

The Company’s
shareholders(**)

 

Immediately prior to the private
offering

 

Subsequent to the private offering and assuming that the
Offerees will exercise all of the options allocated to them under
this Outline Plan

 

Classification

 

Name

 

Quantity

 

Capital

 

Voting
rights

 

Quantity

 

Ratio in
equity(10)

 

Ratio in fully
diluted
equity(11)

 

Voting
ratio(12)

 

Voting
ratio fully
diluted(13)

 

CEO offeree in a substantial private offering

 

Stefan Borgas

 

0

 

0.00

%

0.00

%

1,190,000

 

0.09

%

0.09

%

0.09

%

0.09

%

 

 

Israel Corp. Ltd

 

665,485,881

 

52.30

%

52.30

%

665,485,881

 

51.82

%

51.38

%

51.82

%

51.38

%

 

 

PCS

 

176,088,630

 

13.84

%

13.84

%

176,088,630

 

13.71

%

13.59

%

13.71

%

13.59

%

 

 

Ferson Chemical Materials Ltd.

 

2,216,131

 

0.17

%

0.17

%

2,216,131

 

0.17

%

0.17

%

0.17

%

0.17

%

 

 

IDE Technologies

 

205

 

0.00

%

0.00

%

205

 

0.00

%

0.00

%

0.00

%

0.00

%

 

 

Rotem Amfert Negev Ltd.

 

205

 

0.00

%

0.00

%

205

 

0.00

%

0.00

%

0.00

%

0.00

%

 

 

Nir Gilad

 

800,000

(14)

0.00

%

0.00

%

800,000

(15)

0.00

%

0.06

%

0.00

%

0.06

%

 

 

Yair Orgeler

 

1,600

 

0.00

%

0.00

%

1,600

 

0.00

%

0.00

%

0.00

%

0.00

%

 

 

Avraham (Baiga) Shochat

 

2,000

 

0.00

%

0.00

%

2,000

 

0.00

%

0.00

%

0.00

%

0.00

%

 

 

Moshe Vidman

 

6,100

 

0.00

%

0.00

%

6,100

 

0.00

%

0.00

%

0.00

%

0.00

%

 

 

Yossi Rosen

 

6,500

 

0.00

%

0.00

%

6,500

 

0.00

%

0.00

%

0.00

%

0.00

%

 

 

Chaim Erez

 

2,595

 

0.00

%

0.00

%

2,595

 

0.00

%

0.00

%

0.00

%

0.00

%

 

 

Yaacov Dior

 

8,960

 

0.00

%

0.00

%

8,960

 

0.00

%

0.00

%

0.00

%

0.00

%

 

 

Ofer Holdings Group Ltd.

 

377,662

 

0.03

%

0.03

%

377,662

 

0.03

%

0.03

%

0.03

%

0.03

%

 

 

Israel Chemicals Ltd.

 

22,373,500

 

 

 

22,373,500

 

 

 

 

 

Other share-holders

 

Public(*)

 

428,133,039

 

33.65

%

33.65

%.

438,943,039

 

33.24

%

33.74

%

33.24

%

33.74

%

 


(9)         Assuming full exercise by the Offerees, without having regard to the maximum share value as per sub-sections 5.2 and 5.3 above, without exercising of the right of the Company as elaborated in section 5.3 above, and without taking into account shares held by the Company and by its subsidiary, and without taking into account the exercise of the balance of the securities of the Company that are convertible or exercisable for shares of the Company. The issued capital may be lower due to allocation of a lower amount of shares because of the maximum share value as elaborated in section 5.2 above or due to exercising of the right of the company for net exercise as elaborated in section 5.3 above.

 

(10)       On the theoretical assumption of the exercise of all the options into shares by the offerees under this outline, without taking into account the maximum share value as elaborated in sub-sections 5.2 and 5.3, without exercising the Company’s right to issue shares in an amount equivalent to the financial benefit, as set forth in subsection 5.3 above, and without taking into account shares held by the Company and its subsidiary. The amount of shares allocated in effect may be lower than indicated in sub-section 5.1 above, due to the maximum share value as elaborated in sub-section 5.2 above or due to exercising of the “net exercise” mechanism, as elaborated in sub-section 5.3 above.

 

(11)       The calculation of the fully diluted percentage is made on the basis of the assumption in footnote 10 above and assuming the exercise of all the balance of the securities of the Company that are convertible and exercisable for shares in the Company.

 

(12)       Cf. note 10 above

 

(13)       The computation of the fully diluted ratio was based on the assumptions in footnote 8 above, and on the theoretical assumption of the exercise of all the securities of the Company which are convertible or exercisable for shares of the company.

 

(14)       Options allocated under an outline from January 7, 2010.

 

(15)       Options allocated under an outline from January 7, 2010.

 

(*) Public, including the allocation to officers and employees who are Offerees according to this outline and report and with the exception of the allocation for the CEO according to this report and outline.

 

(**)For more information about the interested parties in the company, see the last list of Holdings, interested parties and senior officers that has been recently published by the Company on November 20, 2012 (Ref. 2012-01-240681)

 

17



 

20.                                Consideration and the manner of its determination

 

20.1                         The options are offered to the Offerees for no consideration.

 

20.2                         If all the options offered are exercised into shares(16), the Company should receive the sum of approximately NIS 559,200,000 by the final date of exercise, inclusive.

 

20.3                         The Company intends to use the proceeds obtained from the exercise of the options, if obtained (see Note 13), as may be resolved by the management or the Board of Directors of the Company, from time to time.

 

20.4                         The exercise price of the options is set by the audit committee and the Board of Directors in accordance with sub-section 5.2 above, and it is identical for all the Offerees under this Outline, including the CEO.

 

21.                                Personal interest in the approval of the Substantial Private Offering

 

To the best of the Company’s knowledge, none of the officers of the Company have a personal interest in the approval of the Substantial Private Offering, with the exception of the CEO.

 

22.                                Required approvals

 

For further information pertaining to the required approvals and permits, see section 3 above.

 

23.                                Details of agreements pertaining to rights in the share of the Company

 

To the best of the Company’s knowledge, subsequent to clarifications conducted with the CEO, there are no agreements, either written or oral, between the CEO and any shareholder in the Company, or between the Offerees, all or in part, between each other or between them and other persons with respect to the acquisition or sale of securities of the Company or with respect to the voting rights in the Company.

 

24.                               Restraints and restrictions applicable to the Offerees with respect to operations that may be carried out with the options

 

For further information in this regard, see section 9 above.

 

25.                                Term of grant of securities

 

The term of grant of options to the Offerees under this Outline shall be effected on the later of: (A) receipt of all the required approvals as set forth in section 3 above or (B) 14 business days after the date of publication of this Outline; and shall terminate on the earlier of: (A) the date of submission of the period report for 2012 or (B) March 31, 2013.

 


(16)  Without exercise of the Company’s right under sub-section 5.3 above

 

18



 

26.                                Powers of the Company’s Board of Directors

 

The Board of Directors of the Company is authorized to interpret the provisions of the Outline and the Plan and to make any supplementary of clarifying provision concerning execution thereof, insofar as necessary, at its discretion.

 

Without derogating from the generality of the aforesaid, it is clarified that subject to any law, the Board of Directors of the Company is authorized, at its exclusive discretion, to exercise all of the powers required for the purpose of management of the Plan, including determining the identity of the Offerees, determining the number of options to be allocated to each of the Offerees, determining the dates of such allocation, determining the exercise price, determining the vesting periods, and in special cases as the Board of Directors sees fit — to accelerate the vesting periods of options not yet vested (in whole or in part) and all in relation to all or any of the Offerees. The Board of Directors is also authorized to establish any other resolution required by or related to the Plan, whether or not indicated in the Plan.

 

Likewise, the Board of Directors of the Company is authorized, subject to any law and at its exclusive discretion, to amend the provisions of the Plan (and its ancillary documents), provided that any amendment of any of the terms and conditions of the Plan shall not contradict the provisions of section 102 and shall not harm the rights of the Offerees under the Plan without obtaining the prior consent of the Offerees to whom as yet unexercised and unexpired options have been allocated under the Plan.

 

The Board of Directors has delegated to the human resources committee its power to designate to specific employees (not being office holders) the options that shall be allocated to the trustee, all in accordance with and subject to matters set forth in section 288 (B) (1) of the Companies Law and the applicable provisions.

 

27.                                No undertaking of continued employment

 

The grant of options to Offerees under this Plan and this outline shall not be construed as imposing any obligation on the Company and/or its subsidiaries to continue the employment of any of the Offerees and/or as restricting them from terminating the employment of any of the employees and/or as granting any right to an offeree to continue to be employed.

 

PART C - The rights attaching to the Company’s shares

 

28.                                The following is a concise description of the rights attaching to the Company’s shares as prescribed in the Company’s Articles of Association. The full version of Company’s Articles of Association may be viewed on the distribution website of the Securities Authority at (www.magna.isa.gov.il) and at the registered office of the Company.

 

As of the date of this report, all the shares in the issued and paid-up share capital of the Company and the shares to be obtained from exercise of the options under this Plan are registered ordinary shares, of NIS1.00 par value each (“ordinary shares”), except for one special registered State share of NIS 1.00 par value (“ the Gold Share ”) which is held by the State of Israel.

 

28.1                         The conditions and rates of participation in the distribution of dividends and bonus shares : The ordinary shares shall be of equal rights and shall confer on the holders the right to receive notices regarding general meetings of the Company, to participate in and vote at such meetings, to elect members of the Board of Directors (in the manner set forth in these Articles of Association of the Company) and the right to participate in the distribution of the Company’s profits and the distribution of surplus assets upon winding up.

 

In the event of payment of dividends, such shall be paid proportionately to the sums paid-up or credited as paid-up on account of the par value of the shares, without taking into account any premium paid thereupon

 

19



 

In the event of distribution of bonus shares, such shall be distributed among the ordinary shareholders, in proportion to their entitlement to participate in the distribution of dividends, and shall be of the same class as the shares in respect of which they were distributed.

 

28.2                         Rights to participate in the division of the Issuer’s property upon winding-up : Upon winding up of the Company, the surplus of the Company’s assets over all of its liabilities, subject to rights granted for any class of shares that may be issued at such time, in any, shall be distributed among the ordinary shareholders in proportion to the sum paid-up or credited as being paid-up on the par value of such shares, without taking into account any premium paid on the shares.

 

28.3                         Right to appoint directors : the members of the Board of Directors shall be elected by the shareholders’ meeting or by the Company’s board of directors (in accordance with the provisions of the Company’s Articles of Association). All of the members of the Board of Directors shall hold office from the date of their election and/or appointment or from a later date, if so determined in the decision regarding the appointment, until the next annual shareholders’ meeting, and subject to the provisions of any law and the Company’s articles of association. The majority of the members of the board of directors shall be citizens and residents of Israel. A person who is not a citizen or resident of Israel shall not be elected and/or appointed as a director if, as a result of such appointment, the majority of the board of directors shall not be citizens and residents of Israel and the election and/or appointment of a director as aforesaid shall be invalid and shall be deemed not to have been made from the beginning.

 

The number of members of the Board of Directors shall be no fewer than 7 and not more than 20. The external directors of the Company shall be counted among the members of the Board of Directors.

 

28.4                         Rights to receive notices of meetings of shareholders, rights to participate and vote, and legal quorum : as set forth above, every regular shareholder has the right to receive notices of general meetings of the Company and to attend and vote at such meetings. Deliberations in a shareholders’ meeting shall not commence unless a quorum is present. A quorum shall be constituted by the presence, in person or by proxy, or at least two members who together hold more than 50% of the issued shares of the Company conferring voting rights. If, within half an hour of the time set for the inauguration of the meeting, there is no quorum, the meeting shall be adjourned to the same day, time and place, or to such other day and/or other time and/or other place as the Board of Directors shall prescribe by notice to the shareholders; if at such adjourned meeting there is no quorum after half an hour of the time fixed for the meeting, then two members with voting rights, being present in person or by proxy, and holding at least one third of the Company’s issued share capital, shall be entitled to discuss and resolve matters in respect of which the meeting was convened.

 

28.5                         Restriction on transfer of shares : Subject to what is stated in the Company’s Articles of Association, fully paid up shares may be transferred without need for the consent of the Board of Directors. The special /state share shall not be transferable. The Articles of Association contain provisions restricting the purchase or holding of shares in rates of 14% or more, of 25% or more, and the dominant rate of the shares in the share capital of the Company which confers on the holder the right, ability or practical possibility to appoint, either directly or indirectly, a number of directors of the Company constituting half or more of the number of members of the Company’s board of directors, as actually appointed, from time to time. Any such purchase or holding shall require the consent of the person holding the special State share, in according with the proceedings and conditions set forth in the Articles of Association.

 

28.6                         Conditions for the change of rights attaching to the shares

 

Ordinary shares : Change of rights attaching to any class of shares shall be prescribed in a resolution of the shareholders of such class, and in a resolution of meetings of such

 

20



 

classes of shares whose rights may be prejudiced as a result of the change, by an ordinary majority among those present and voting at those meetings.

 

Special State share : Any amendment of the Articles of Association which might directly or indirectly prejudice the rights attaching to the special State share shall be deemed to be a change of the rights attaching to the special State share. Any resolution or act which might directly or indirectly prejudice the rights attaching to the special State share shall only be made with the consent of the holder of the special State share and shall be null and void in the absence of the consent of the holder of the special State share.

 

PART D - ADDITIONAL DETAILS

 

29.                                Details of the price of the Company’s shares on the Stock Exchange

 

The closing price of the Company’s share on the Stock Exchange on November 25, 2012 (the last trading day prior to the date of the resolution of the Board of Directors concerning the grant of the options) was NIS 46.6.

 

The following are the details of the highest and lowest share prices (in Agorot) on the dates on which the Company’s shares were traded during each of the two calendar years preceding the date of this Outline, and during the period from January 1, 2012, through shortly prior to the date publication of this outline.

 

 

 

High quotation*

 

Low quotation*

 

Period

 

Date

 

Quotation
(Ag.)

 

Date

 

Quotation
(Ag.)

 

2010

 

December 21, 2010

 

5,485.41

 

June 1, 2010

 

3,467.99

 

2011

 

February 17, 2011

 

5,698.83

 

December 13, 2011

 

3,244.05

 

2012 (to November 25, 2012)

 

October 2, 2012

 

4,910.00

 

February 1, 2012

 

3,686.64

 

 


* The closing prices of the shares subsequent to their adjustment in respect of the distribution of a dividend, as implemented by the Tel Aviv Stock Exchange Ltd.

 

30.                                Notice of outline

 

Within 21 days of date of publication of this Outline, the Company shall provide a copy of the Outline, together with reference to the reports to which it refers, to each offeree at their place of employment or at their addresses as recorded by the Company. Each offeree shall receive a page setting forth references to links on the distribution website of the Securities Authority, with respect to each of the reports to which this Outline refers. In addition, a printed copy of the aforesaid reports shall be deposited with the Company’s secretariat and with segment secretariats, and each offeree will be able to view such and may obtain a copy thereof upon request.

 

Any notice from the Company to Offerees shall be served by means of written notice that shall be delivered to each of the Offerees at his place or work or his address registered with the Company or at his e-mail address.

 

31.                                Referral to periodic reports and interim financial statements

 

Attention is hereby drawn to the periodic report for 2011 which was published by the Company on March 27, 2012 (reference number 2012-01-080490) and to the interim financial statements for the period ended March 31, 2012, which were published by the Company on May 23, 2012 (Ref. No. 2012-01-132552) and to the interim financial statements for the period ended June 30, 2012, which was published by the Company on August 15, 2012 (Ref. No. 2012-01-210696), and to the interim financial statements for the period ended September 30, 2012, which were published by the Company on date November 21, 2012 (Ref. No. 2012-01-284880) and also to the Immediate

 

21



 

Reports published by the Company since the periodic report. These documents may be perused at the distribution website of the Securities Authority at: www.magna.isa.gov.il and at the website of the TASE at www.tase.co.il and at the registered office of the Company (at the office of the legal adviser and the company secretary), during ordinary office hours and by prior appointment, at Tel: 972-3-68444121.

 

32.                                Powers of the Israel Securities Authority

 

The Securities Authority, including an employee of the Authority so authorized, may instruct the Company, within 14 business days of the date of submission of the Outline, to provide any explanation, details, information or documents pertaining to the Outline, and may instruct the Company to amend the Outline within such time as it may prescribe. Should the Authority instruct to amend this Outline, it may order a postponement of the effective date of the commencement of the term of grant of securities to a date which may fall no earlier than three business days and no later than 14 business days from the date on which the amendment to this Outline is published. The amendment of the Outline and the postponement of the commencement of the term of grant of the securities under these instructions shall be effected in accordance with the provisions of the Outline Regulations.

 

33.                                Company representative

 

The representative of the Company for the purpose of dealing with the report and this Outline is the Company’s Vice-President, legal advisor and company secretary, Lisa Haimovitz, Adv, at Tel: 972-3-6844412 and fax 972-3-6844427.

 

Israel Chemicals Ltd.

 

/s/ Lisa Haimovitz

 

By: Lisa Haimovitz, Adv.

 

 

VP, Legal Advisor and Company Secretary

 

Signature date: November 27, 2012

 

22




Exhibit 10.4

 

 

Translated from the Hebrew - The Hebrew version is the binding version

 

Outline

 

Pursuant to section 15B (1) (a) of the Securities Law, 5728- 1968, the Securities Regulations (Periodic and Immediate Reports), 5730-1970, and the Securities Regulations (Details of an Outline of an Offer of Securities to Employees), 5760-2000

 

Together with

 

A substantial private offering report

 

In accordance with the Securities Regulations (Private Offering of Securities in a Listed Company), 5760-2000 and Regulations 37A (3) and 37 A3 of the Securities Regulations (Periodic and Immediate Reports), 5730-1970

 

An offer of

 

Up to 4,384,540 non-listed options, which are offered, for no consideration, to officers (who are not Directors of the Company) and other senior employees in management positions at Israel Chemicals Ltd. (the “ Company ” or “ ICL ”) and companies under its control, including the CEO of the Company, which are exercisable up to 4,384,540 ordinary shares(1) registered by name, of NIS 1.00 par value each of the Company (“ Option Warrants ” or “ Options ”).

 

Up to 1,025,449 ordinary restricted shares of NIS 1.00 par value each of the Company, which are offered for no consideration, to officers (who are not Directors of the Company) and other senior employees in management positions of the Company and companies under its control, including the CEO of the Company, as well as to Directors in the Company (the “ Restricted Shares ”).

 

Outline Date: August 20, 2014

 


(1)                                 Assuming the exercise of all share options - however, a lower number of shares than that stated above may be received due to the exercise mechanisms as set forth in Sections 4.3 and 4.4 of this Outline and Immediate Report below.

 

1



 

Table of Contents

 

Section

 

Page

 

 

 

 

Part A

Introduction

 

 

 

 

 

 

1

General

 

5

 

 

 

 

2

Permits and approvals

 

6

 

 

 

 

Part B

The details of the offer and its terms

 

 

 

 

 

 

3

The Offerees

 

7

 

 

 

 

Part B (1)

Option Warrants and conditions

 

 

 

 

 

 

4

Details, conditions and rates of Option Warrants

 

7

 

 

 

 

5

Exercise rights, lock-up and exercise method of Option Warrants

 

10

 

 

 

 

6

Rights associated with the Exercise Shares

 

12

 

 

 

 

7

Option conditions in the event of termination of employment

 

13

 

 

 

 

8

Option Warrant adjustments in respect of distribution and/or allocation of Bonus Shares due to of rights and/or split or consolidation of capital and/or dividend distribution

 

14

 

 

 

 

Part B (2)

Restricted Shares and conditions

 

15

 

 

 

 

9

Details conditions and rates of Restricted Shares

 

15

 

 

 

 

10

Vesting period of Restricted Shares

 

17

 

 

 

 

11

Rights associated with the Restricted Shares

 

17

 

 

 

 

12

Deposit of Options and Restricted Shares with the Trustee

 

18

 

 

 

 

13

Restrictions on Option Warrant, Exercise Share and Restricted Share transactions

 

18

 

 

 

 

14

Change of control

 

20

 

 

 

 

15

Restructuring or merger

 

20

 

 

 

 

16

Tax implications and allocation to the Trustee

 

21

 

 

 

 

17

The Offerees obligations

 

23

 

2



 

18

Applicable law

 

24

 

 

 

 

19

The economic value of the Option Warrants

 

24

 

 

 

 

20

The economic value of the Restricted Shares

 

25

 

 

 

 

21

Information based on the Sixth Addendum to the Reports Regulations

 

26

 

 

 

 

22

The issued share capital of the Company, the amount and the holding percentage of Offerees and Interested Parties in the Company

 

30

 

 

 

 

23

Consideration and manner of determination

 

32

 

 

 

 

24

Personal interest in the approval of the Material Private Offering

 

33

 

 

 

 

25

Required approvals

 

33

 

 

 

 

26

Details of agreements pertaining to rights in the shares of the Company

 

33

 

 

 

 

27

Restraints or Restrictions applicable to the Offerees with respect to transactions with the Option Warrants and Restricted Shares

 

33

 

 

 

 

28

Term for granting of securities

 

33

 

 

 

 

29

Powers of the Company’s Board of Directors

 

33

 

 

 

 

30

No undertaking for continued employment

 

34

 

 

 

 

Part C

Rights associated with the Company’s Shares

 

 

 

 

 

 

31

The conditions and rates of participation in the distribution of dividends and bonus shares

 

34

 

 

 

 

 

Rights to participate in the division of the Issuer’s property upon liquidation

 

35

 

 

 

 

 

Right to appoint Directors

 

35

 

 

 

 

 

Rights to receive notices of meetings of shareholders, right of participation and voting and legal quorum

 

36

 

 

 

 

 

Restriction on transfer of shares

 

36

 

 

 

 

 

Conditions for amendment of rights associated with the shares

 

36

 

 

 

 

Part D

Additional Details

 

 

 

 

 

 

32

Details of the price of the Company’s shares on the Stock Exchange

 

37

 

3



 

33

Notice of this Outline and Immediate Report

 

37

 

 

 

 

34

Referral to the periodic report, the interim financial statements and the immediate reports

 

38

 

 

 

 

35

Powers of the Israel Securities Authority

 

38

 

 

 

 

36

Company representative

 

38

 

4



 

Part A.                     Introduction

 

1.                 General

 

Israel Chemicals Ltd. hereby reports, according to the Securities Regulations (Details of an Outline of an Offer of Securities to Employees), 5760-2000 (the “ Outline Regulations ”), the Securities Regulations (Periodic and Immediate Reports), 5730 — 1970, (the “ Reports Regulations ”) and the Securities Regulations (Private offering of Securities in a Listed Company), 5760-2000 (the “ Private Offering Regulations ”), that on August 6, 2014, after approval by the HR and Compensation Committee (the “ Compensation Committee ”) on August 4, 2014, the Company’s Board of Directors approved a private offering (the “ Private Offering ”) of:

 

(a)          Up to 4,384,540 Option Warrants exercisable as ordinary shares of NIS 1.00 par value each, of the Company, (the “ Shares ” or the “ Shares of the Company ”) to up to about 450 Offerees including 18 officers (who are not Directors of the Company) and other senior employees in management positions of the Company and companies under its control, of which 367,294 of the said Option Warrants are for the CEO of the Company; and

 

(b)          Up To 1,025,449 Restricted Shares (as defined below) to up to about 450 Offerees, including 18 officers (who are not Directors in the Company) and other senior employees in management positions in the Company and companies under its control, of which 85,907 of the said Restricted Shares are for the CEO of the Company.

 

The Private Offering to the CEO of the Company shall henceforth be referred to as - the “Material Private Offering ”).

 

The Private Offering and the Material Private Offering are in accordance with the “Equity Compensation Plan (2014)”, which was adopted by the Board of Directors on August 6, 2014 and which also includes an option for the grant of compensation to the Directors of the Company(2) (the “ Plan ”), all as described below in this Outline and report (the “ Outline and the Immediate Report ”). In respect of the offering to the CEO, this Outline and Immediate Report also includes details as required by the Private Placement Regulations and the Reports Regulations.

 

The allocation of the Option Warrants and the Restricted Shares to the Offerees pursuant to this Outline and Immediate Report shall be performed in accordance with section 15B(1)(a) 

 


(2)                                 The Plan enables allocation of equity-based compensation in accordance therewith to the Directors of the Company. Such allocation will be made subject to receipt of the required approvals of the applicable organs as well as the required approval from the Tel Aviv Stock Exchange Ltd. Furthermore, the Company will publish the necessary reports associated with such allocation.

 

5



 

of the Securities Law, 5728-1968 (the “ Securities Law ”) and in accordance with the Outline Regulations and Private Placement Regulations (as the case may be).

 

2.                 Permits and approvals

 

The allocation of the Option Warrants and the Restricted Shares pursuant to the Outline and this Immediate Report is subject to the obtaining of the cumulative approvals set out below:

 

2.1                           The approval of the Tel Aviv Stock Exchange Ltd. (the “ Stock Exchange ”) to list for trading the Restricted Shares and the Shares that shall be derived from exercising the Option Warrants (the “ Exercise Shares ”) that are the subject of this Outline and Immediate Report. Immediately after this Outline and Immediate Report is published, the Company intends to apply to the TASE to list the Exercise Shares for trading.

 

2.2                           Since, as set forth in Section 16 below, the Option Warrants and the Restricted Shares for the Offerees (with the exception of the Offerees as set forth in Section 16.6 below), are to be allocated in a capital gains track under Section 102 of the Income Tax Ordinance (New Version) 5721-1961 (the “ Income Tax Ordinance ”), the Plan requires the approval of the tax assessor and of a trustee to be appointed by the Company. The Company applied to the tax assessor soon after the approval of the Private Offering by the Board of Directors, requesting approval of the Plan and the trustee, and may allocate the Restricted Shares 30 days after the submission date of the Plan to the tax assessor.

 

2.3                           The allocation of the Option Warrants and the Restricted Shares is subject to obtaining all of the approvals required by law, including the approval of the organs of the Company and companies under its control, all as required by the Companies Law, 5759—1999 (the “ Companies Law ”), and according to any other law that applies to companies controlled by the Company that have incorporated outside Israel. The Compensation Committee discussed the Plan and the Private Offering to the Offerees, including the Material Private Offering and recommended to the Board of Directors of the Company that they approve the plan, and the Board of Directors approved the offering to the Offerees, including the Material Private Offering, on August 4, 2014. The Board of Directors discussed the Plan and the Private Offering to the Offerees, including the Material Private Offering, and approved them in its meeting held on August 6, 2014.

 

2.4                           The allocation of the Option Warrants and the Restricted Shares offered to the CEO is subject to approval by the General Meeting of the shareholders of the Company in accordance with Section 272(c1)(1) oh the Companies Law.

 

2.5                           Allocations to Offerees who are not officers - the number and terms of the Restricted

 

6



 

Shares allocated to each Offeree that is not an officer shall be approved by the Compensation Committee, in accordance with the delegation of the Board of Directors’ powers to this Board of Directors committee, as stated in Section 29 below.

 

2.6                           The Company shall be entitled to allocate Option Warrants and Restricted Shares to Offerees pursuant to this Plan, Outline and Immediate Report, after obtaining all the necessary approvals for the said allocation as stated in this Section 2 above, and subject to the provisions of Section 28 below.

 

Part B. The Details of the offer and its terms

 

3.                 The Offerees

 

3.1                           The Offerees of the Private Offering are officers or other senior employees in management positions of the Company and subsidiaries under its control, in Israel and outside of Israel (the “ Employees ”).

 

3.2                           The Offeree under the Material Private Offering is Mr. Stefan Borgas, who serves as the CEO of the Company (the “ CEO ”), who is considered to be an interested party in the Company by virtue of his position. The Option Warrants and the Restricted Shares offered to the CEO are described in Sections 4.1 and 9.7 below.

 

3.3                           According to the information provided to the Company as of the date of this Immediate Report:

 

3.3.1                              The CEO holds shares and/or options of the Company that can be exercised into shares of the Company (see Section 22 below for more information).

 

3.3.2                              The CEO and the Employees (collectively: the “ Offerees ”) are not an ‘interested party’, as such term is defined in section 270(5) of the Companies Law. In addition, to the best of the knowledge of the Company and its managers, there are no interested parties among the Employees in ICL.

 

Part B(1)  Option Warrants and Conditions

 

4.                 Details, conditions and rates of the Option Warrants

 

4.1                           The Offerees (including 18 officers who are not Directors) shall be allocated, for no consideration, up to 4,384,540 non-marketable Option Warrants exercisable to up to 4,384,540 ordinary shares of NIS 1.00 par value each, of the Company, subject to the adjustments specified in Section 8 below and all the other conditions of the Plan

 

7



 

specified below, of which 367,294 Option Warrants shall be allocated to the CEO. It should be noted that the number of the actual Exercise Shares allocated at the time of the exercise of the Option Warrants may be less due to the Maximum Share Value as specified in section 4.3 below, and if the Company selects to exercise its right as provided in section 4.4 below, in such a case, the number of the Offerees holdings shall be less than the amounts specified below.

 

4.2                          The number of Shares that shall be derived from the exercise of the Option Warrants that shall be allocated to the Offerees shall constitute, as of the date of this report, about 0.34% of the issued and paid up capital of the Company and about 0.35% of the voting rights in the Company(3) (about 0.33% of the issued and paid up capital of the Company and about 0.34% of the voting rights of the Company, on a fully diluted basis)(4), of which, the amount of shares resulting from the exercise of options to be allotted to the CEO shall constitute, as of the date of this report, about 0.03% of the issued and paid up capital of the Company and about 0.03% of the voting rights in the Company(5) (about 0.03% of the issued and paid up capital of the Company and about 0.03% of the voting rights of the Company, on a fully diluted basis)(6). The economic value of the Option Warrants offered to the Offerees is approximately NIS28,806 thousand, of which the economic value of the Option Warrants offered to the CEO is approximately NIS2,413 thousand.(7)

 

4.3                           Each Option Warrant entitles the holder to receive from the Company or from its representative, by way of allocation, or transfer (as specified in Sections 4.4 and 4.5 below) one Ordinary Share of NIS 1.00 par value each of the Company against payment of the Exercise Price of NIS28.71 equal to the average closing prices on the Stock Exchange of the share of the Company on the 30 trading days preceding the

 


(3)                                 Assuming, theoretically, the exercise of all option warrants into shares by the Offerees under this Outline, regardless of the Maximum Share Value specified in Section 4.3 below, and without the Company exercising its right to allocate shares in the value of the benefit amount as per Section 4.4 below, and without considering the shares held by the Company and by its subsidiary. The actual number of shares allocated may be lower than that specified in Section 4.1 above due to the Maximum Share Value as specified in Section 4.3 below or due to the activating of the “net exercise” mechanism as described in section 4.4 below.

(4)                                 The calculation of the full dilution rate was carried out on the basis of the assumptions in footnote 3 above with regard to the exercise of options by all the Offerees under this Outline, and assuming the exercise of all the other securities of the Company that are convertible or exercisable for shares of the Company and the allocation of the restricted shares.

(5)                                 See Footnote 3 above.

(6)                                 See Footnote 4 above.

(7)                                 Calculated based on the economic opinions of eternal advisors on the basis of a binomial model, in accordance with the assumptions set forth in Section 19 below and considering the Maximum Share Value as described in Sections 4.3 and 4.4 below. The economic value to the US Offerees may be lower than the economic value to the other Offerees as the Exercise Price of the Option Warrants that are allocated to them is not adjusted to dividend and/or consumer index.

 

8


 

date of the decision of the Board of Directors, subject to the adjustments as provided in Section 8 below. The Exercise Price per share subject to the Option Warrant shall be linked to the CPI, with the base index being the index for the month of July published on the 15 th  of August 2014 (102.4 points) (the “ Base Index ”), with the Exercise Price increasing or decreasing in accordance with the ratio between the known index on the date of exercise and the Base Index. Notwithstanding the foregoing, the Exercise Price for the Offerees who are residents of the United States and/or subject to U.S. tax law shall not be linked to the CPI as above. The Exercise Price determined above, including the abovementioned CPI linkage with regard to the Option Warrants shall hereafter be termed, the “ Exercise Price ”.

 

Notwithstanding the above, if on the Exercise Date (as defined below) the closing price of the share of the Company on the day preceding the Exercise Date (the “ Share Value ”) is more than 2 times the Exercise Price (the “ Maximum Share Value ”), the number of Exercise Shares shall be adjusted so that the multiple of the number of Exercise Shares that will actually be allocated to the Offeree at the Share Value shall be equal to the multiple of the number of options exercised at the Maximum Share Value. In the case of the events set out in Sections 8.1 to 8.3 below, the necessary adjustments shall be made. A share fraction resulting from the above calculation shall be rounded upwards to a full share. Immediately following the exercise, the total amount of the exercise options shall expire.

 

The Company shall preserve a sufficient number of shares in its registered capital for the allocation of options in accordance with this Outline and Immediate Report.

 

4.4                           Alternatively, and according to the Company’s sole discretion, the Company shall be entitled at the time of exercise of the options to allocate shares to the Offerees, or transfer to them shares held or that shall be held by the Company or by a company under its control, at the value of the benefit only, as follows:

 

4.4.1                              The number of Exercise Shares to which each Offeree shall be entitled on the date of the exercise of the Option Warrants (as defined in Section 5.5 below) shall be calculated according to the difference between:

 

4.4.1.1                     The Stock Exchange closing price of the Company’s shares on the trading day preceding the Exercise Date and not more than a total equal to a 2 multiple of the Exercise Price per share (the “ Effective Rate ”), multiplied by the number of shares subject to the Option Warrants in respect of which the Exercise Notice is given,

 

9



 

And:

 

4.4.1.2                     The Exercise Price multiplied by the number of shares subject to the Option Warrants in respect of which the Exercise Notice is given.

 

In the case of the events set out in Sections 8.1 to 8.3 below, the necessary adjustments shall be made.

 

This difference shall constitute the amount of the benefit for the Offeree stemming from the Exercise Date (the “ Benefit Amount ”).

 

4.5                           The Company shall allocate to the Offerees, or transfer to them shares held or that shall be held by the Company or by a company under its control, such amount of shares, the market value of which according to the closing price of the shares of the Company on the stock exchange on the trading day preceding the Exercise Date (minus the par value of the share of the Company, if actually paid by the Offeree), shall be equal to the Benefit Amount, only. A share fraction resulting from this calculation shall be rounded upwards to a whole share.

 

4.6                          In the event of share allocation in accordance with this Section, the following conditions shall apply: The Company shall convert to share capital a portion of its profits or premium on shares or from any other source included in its equity capital according to its financial statements, for the nominal value of the Exercise Shares, and all as provided in Section 304 of the Companies Law. If this is not possible, the Offeree shall pay the par value of the Exercise Shares only. It is hereby clarified, that in every event of the allocation of shares pursuant to this Section the exercise shall be carried out in a manner in which the nominal value of the shares shall be paid (or, as applicable, shall be capitalized) by the Company or by the Offeree, subject to any applicable law, including the provisions of the Companies Law, regarding distribution.

 

5.                 Exercise rights, lock-up and exercise method for Option Warrants

 

5.1                          All of the Option Warrants shall be issued to the Offerees following compliance with all of the conditions specified in Section 2 above. The Options Warrants will be exercisable (“released”) in three (3) equal installments as follows:

 

5.1.1                              One-third (1/3) of the amount of Option Warrants allocated to each of the Offerees shall be “released” at the end of 24 months following December 1, 2014 (the “ Commencement Date ”);

 

5.1.2                              One-third (1/3) of the amount of Option Warrants allocated to each of the Offerees shall be “released” at the end of 36 months following the

 

10



 

Commencement Date;

 

5.1.3                              The remaining one-third (1/3) of the amount of Option Warrants allocated to each of the Offerees shall be “released” at the end of 48 months following the Commencement Date.

 

5.2                           Each of the Offerees shall be entitled to exercise the Option Warrants, pursuant to the conditions of the Plan (including as set out in Section 7 below), in whole or in part, starting from the date of each installment being “released” until the end of 24 months from this date (the “ Final Exercise Date ”). If the last day of the exercise falls on a non-business day for banks in Israeli and for trading on the stock exchange - the Final Exercise Date shall be postponed to a business day which is also a stock trading day.

 

5.3                           An Offeree who is interested in exercising the Option Warrants, to which he is entitled into shares, under the conditions of the Plan, shall provide the Company and the Trustee with a written notice, signed by him, in a format determined by the Company (the “ Exercise Notice ”). The Exercise Notice shall include, inter alia , the identity of the Offeree and the number of the Option Warrants he is interested in exercising. The discretion as to whether or not to exercise and the obligation to pay the Exercise Price is that of each individual Offeree and not that of the Trustee.

 

5.4                           The Offeree shall pay the Company the consideration owed to the Company for the Exercise Shares that shall be allocated to the Offeree in accordance with the Exercise Notice and as determined by the Company, unless the Company elects to exercise its right under Section 4.4 above.

 

5.5                           On the first trading day after the day on which the Company shall receive the Exercise Notice, fully completed and signed by the Offeree, with the consideration having been paid by it, as specified in section 5.4 above (hereinafter and hereinabove: the “ Exercise Date ”), the Company shall issue the Exercise Shares to the Trustee,(8) in the event that the Company elects to exercise its right as provided in Section 4.4 above the provisions of Section 4.4 above shall apply.

 

5.6                           Option Warrants that are not exercised by the Final Exercise Date (as per Section 5.2 above) shall expire and shall not grant any right to compensation or indemnity and shall not have any effect.

 


(8)                                 It is hereby clarified, that wherever there is a reference to the Plan and the Outline to award the exercise shares or the restricted shares to the Offeree or to the Trustee on his behalf, respectively, the intention is to register those shares in favor of the Offeree or the Trustee, as applicable, with a member of the stock exchange in a manner in which the shares shall be recorded in the register of shareholders of the Company in the name of the registration company.

 

11



 

5.7                           Notwithstanding the foregoing, it is hereby clarified that in accordance with the Stock Exchange Regulations, exercise of options to shares shall not be carried out on the effective date for the distribution of bonus shares, an offer by way of rights, distribution of dividends, consolidation of capital, split of capital, or reduction of capital (all of the above hereafter in this Section, a “ Company Event ”), and the said exercise shall be postponed to the following trading day. In addition, if the X day of a Company event falls prior to the Effective Date of the Company Event (as these terms are defined in the Stock Exchange Regulations), the exercise of options to shares shall not be performed on the said X date and the exercise shall be postponed to the following trading day.

 

6.                 Rights associated with the Exercise Shares

 

6.1                           The Exercise Shares shall, immediately upon their issuance, have equal rights for all intents and purposes, to ordinary shares in the share capital of the Company as of the date of this Outline and Immediate Report, and shall have, inter alia , the same rights to receive notice and to attend General Meetings of the Company, receive dividends or any other distributions and to receive surplus assets upon liquidation.

 

6.2                           In every case in which in accordance with the provisions of the Plan the Offeree shall be entitled to receive rights and/or bonus shares and/or any other right granted to the Offeree by virtue of the Option Warrants and/or Exercise Shares (hereinafter: the “ Rights ”), and if on the Effective Date of the distribution of the Rights the Option Warrants and/or the Exercise Shares were held by the Trustee, the Rights shall be transferred to the Trustee, which will deduct withholding tax according to any applicable law, if and to the extent applicable, and all the Rights shall be allocated to the Trustee in favor of the Offerees, and shall be held by the Trustee until the end of the Minimal Trust Period (as defined in Section 16.4 below) of the options for which the Rights were allocated and the conditions of the tax track shall apply to these additional Rights.

 

6.3                           In every case in which the Company shall distribute a dividend in cash and if on the Effective Date for the distribution of the dividend the Trustee is holding Exercise Shares for any Offeree, the Company shall transfer to the Trustee the amounts of the dividend for the Exercise Shares held by the Trustee as mentioned above for each Offeree. The Trustee shall deduct withholding tax, if and to the extent required, and shall then transfer the dividend amounts (after deduction of tax) to the Offeree.

 

6.4                           Notwithstanding Section 6.1 above, as long as with accordance with the Plan, during the period that the Exercise Shares are held in favor of the Offeree by the Trustee and have not yet been transferred to the Offerees, these shares shall not grant the

 

12



 

right to receive notice and to participate in the General Meeting of the Company.

 

7.                 Option conditions in the event of termination of employment

 

7.1                           In the event of termination of the employment relationship between the Company and the Offeree due to the voluntary retirement of the Offeree and not as a result of disability due to health problems (“ Disability ”), the Offeree shall be entitled to exercise only those Option Warrants that have been released and that have not yet been realized as shares, and that have not expired by the Date of Termination of Employment, and they shall be exercisable over a period of 90 days from that date (or, if the lock-up period has not yet expired under section 102 of the Income Tax Ordinance - up to 90 days from the end of this period, according to the latter of these periods). The remainder of the Option Warrants shall expire upon the termination of employment.

 

7.2                           In the event of termination of employment due to Disability or death — the Offeree (or his heirs) shall be entitled to exercise the Option Warrants that have been released and not yet realized for a period of twelve (12) months from the Date of Termination of Employment.

 

7.3                           In the event of termination of employment due to dismissal under circumstances which, in the Company’s opinion, confers on the Company the right, under law, to dismiss the Offeree without severance pay, including the carrying out of criminal offenses and breach of trust, all of the Option Warrants offered to the Offeree according to the plan, including those that are released that have not actually been realized, shall immediately expire on the date of notice of termination.

 

7.4                           In the event of termination of employment for any reason not described in Sections 7.1 to 7.3 above, the Offeree shall be entitled to exercise only those Option Warrants that have been released up to the Date of Termination of Employment and which have not yet been exercised as shares, and which have not yet expired and which are excisable up to their exercise date. The remainder of the Option Warrants shall expire upon termination of employment.

 

7.5                           The Offeree’s right to Option Warrants granted to him under the Plan or their realization shall not end or expire or be accelerated as a consequence of the fact that the Offeree moved from the Company to work as an employee or an officer of a company under its control, or vice-versa.

 

7.6                           The Board of Directors is entitled to amend the provisions of this Section 7 (and/or any one of them), at its absolute discretion.

 

13



 

7.7                           For purposes of this Outline and Immediate Report, the “Date of Termination of Employment” is the date of the termination of the employee-employer relationship between the Offeree and the Company, or the termination of the Notice Period (or period of adjustment, if any), whichever is later.

 

8.             Option Warrant adjustments in respect of distribution and/or allocation of bonus shares due to rights and/or split or consolidation of capital and/or dividend distribution

 

8.1                           If the Company distributes Bonus Shares after the allocation of Option Warrants according to this Outline and Immediate Report, then there shall be an increase in the number of Exercise Shares with respect to the exercise of the Option Warrants that have not been exercised into shares and have not expired by the date determining the right to receive Bonus Shares by adding the appropriate number, at no charge, of shares to which the Offeree would have been entitled as bonus shares if he had exercised the options not yet exercised into shares up to the effective date of the right to receive Bonus Shares, immediately prior to the date determining the date of the distribution of Bonus Shares. It is clarified that the Exercise Price of the options shall not change in the event of the distribution of Bonus Shares — however, the payment for each share shall be reduced accordingly due to the number of shares stemming from each option.

 

8.2                           If the Company offers its shareholders securities of any kind in way of issuance of rights, the Exercise Price of the Option Warrants shall not be adjusted, however, the number of Exercise Shares in respect of the exercise of Option Warrants that have not yet been exercised into shares on the date determining the right to acquire rights in the rights offering shall be adjusted in accordance with the inherent bonus component in the rights to be calculated in accordance with the instructions of the stock exchange as shall be on the Effective Date.

 

8.3                           In any event of split or consolidation of share capital of the Company, or any corporate equity event of a fundamentally similar nature, the Company shall perform the necessary changes or adjustments to prevent a dilution or increase of the rights of an Offeree under the plan with respect to the number and type of Exercise Shares in respect of options not yet exercised by the Offeree and/or in respect to the Exercise Price of each option.

 

8.4                           If the Company distributes a cash dividend in which the effective date for its distribution falls after the allocation of Option Warrants according to this Outline and Immediate Report, then on the X day the Exercise Price of the Option Warrants not yet exercised and not yet expired by that date shall be reduced by the amount of the

 

14



 

dividend per share (gross), according to its amount in NIS. For the avoidance of doubt, in any event, the Exercise Price shall not be less than the par value per share. It is clarified that the provisions of this Section 8.4 shall not apply to Offerees who are residents of the United States and/or are subject to U.S. tax law.

 

8.5                           In any case in which as a result of the adjustments specified in this Section, the Company is required to allocate a share fraction, the Company shall not allocate the abovementioned share fraction, and the number of shares allocated to the Offeree shall be rounded upwards to the nearest share.

 

8.6                           It is hereby clarified, that the Offeree’s right to additional Exercise Shares resulting from adjustments under the provisions of this Section 8, shall only apply on the Exercise Date of the Option Warrants.

 

Part B(2)  Restricted Shares and conditions

 

9.                 Details, conditions and rates of Restricted Shares

 

9.1                           The Restricted Shares shall be granted for no consideration. The Company shall capitalize a portion of its profits to share capital or behave in any other manner permitted by law in the event of a share issuance for an amount lower than the nominal value, all in accordance with the applicable law, including pursuant to Section 304 of the Companies Law.

 

9.2                           Restricted shares - are shares that are subject to transfer restrictions and are not able to be transferred or sold up to the end of their vesting period and the removal of the constraints imposed thereon. At the end of the vesting period of each Restricted Share, the lock up imposed on this share shall be released automatically and the share shall become a share released from all restrictions (the “ Restricted Shares ”).

 

9.3                           The Restricted Shares shall, immediately upon their issuance have, for all intents and purposes, equal rights to ordinary shares in the share capital of the Company as of the date of the Plan, this Outline and Immediate Report, and shall grant, inter alia , the same rights to receive notice and to attend General Meetings of the Company (subject to Section 9.5 below), to receive dividends or bonus shares (subject to Section 9.4 below) or any other distribution and receive surplus assets upon liquidation. In the event of issuance of Rights, the Rights will be deposited with the Trustee which shall act in accordance with the instructions of the Offeree and will ensure application of withholding tax for the Rights, as the case may be.

 

9.4                           Notwithstanding the above, a dividend or bonus shares that were distributed for

 

15



 

Restricted Shares that have not vested yet, shall be held by the Trustee until the Restricted Shares for which the dividend or bonus shares were distributed are vested and following their vesting shall be transferred to the Offeree, by the Trustee and following deduction of withholding tax, in accordance with applicable law, by the Trustee. A dividend or bonus shares that were distributed in respect of vested Restricted Shares shall be transferred directly to the Offeree by the Trustee after deduction of withholding tax, in accordance with applicable law.

 

9.5                           Voting rights — As long as the Restricted Shares have not vested in accordance with the instructions of the Plan, this Outline and Immediate Report, and the limitations placed on them have not been removed, their voting rights shall be that of the Trustee (as defined below) only. The Trustee shall not be obliged to activate his voting tights. Following the vesting of the shares, the provisions of Section 11 below will apply.

 

9.6                           Termination of Work

 

9.6.1                              Upon termination of the employment relationship, all of the unvested Restricted Shares allocated to the Offeree according to this Outline and Immediate Report shall be transferred to the Company for no consideration. In addition, dividends distributed in respect of unvested Restricted Shares that are held by the Trustee, shall also be returned to the Company. The vested Restricted Shares shall be transferred to the Offeree (shall not be returned to the Company), and, accordingly, the dividend distributed in respect of these shares shall be transferred to the Offeree.

 

9.6.2                              In the event of termination of employment under circumstances which the Company believes grant the Company the right by law to dismiss the Offeree without severance pay, including criminal offenses and breach of trust, the vested Restricted Shares that are not yet sold or transferred and the dividend in respect thereof shall also be returned to the Company immediately and for no consideration.

 

9.7                           For the Offerees - employees (including 18 officers who are not Directors of the Company) and the CEO shall be allocated, for no consideration, up to 1,025,449 Restricted Shares, subject to all the other terms of the Plan listed below, of which 85,907 Restricted Shares shall be allocated to the CEO.

 

9.8                           The number of Restricted Shares that shall be allocated to the Offerees shall constitute, as of the date of this report, approximately 0.08 % of the issued and outstanding capital of the Company and approximately 0.08 % of the voting rights of

 

16



 

the Company(9) (approximately 0.08% of the issued and outstanding capital of the Company and approximately 0.08% of the voting rights in the Company, on a fully diluted basis)(10), of which, the amount of restricted shares to be allotted to the CEO shall constitute, as of the date of this report, approximately 0.007% of the issued and outstanding capital of the Company and approximately 0.007% of the voting rights in the Company (approximately 0.007% of the issued and outstanding capital of the Company and about 0.007% of the voting rights in the Company, at full dilution)(11). The value of the Restricted Shares offered to the Offerees according to the closing price on the Stock Exchange on the day preceding the date of approval by the Board is approximately NIS28,806 thousand, of which the value of the Restricted Shares offered to the CEO is approximately NIS2,413 thousand.(12)

 

10.          Vesting period of the Restricted Shares

 

10.1                    The Restricted Shares that will be allocated to the Offerees after fulfillment of all the conditions specified in Section 2 above, shall be exercisable (“released”) in three (3) equal installments, as follows:

 

10.1.1                       One-thirds (1/3) of the number of restricted shares allocated to each of the Offerees shall be “released” at the end of 24 months following December 1, 2014 (the “ Commencement Date ”);

 

10.1.2                       One-thirds (1/3) of the number of restricted shares allocated to each of the Offerees shall be “released” at the end of 36 months following the Commencement Date;

 

10.1.3                       The remaining one-third (1/3) of the number of restricted shares allocated to each of the Offerees shall be “released” at the end of 48 months following the Commencement Date.

 

11.          Rights associated with the Restricted Shares

 

11.1                    At the end of the vesting period the restrictions on the Restricted Shares shall be removed and they shall become ordinary shares of the Company (the “ Released Shares ”).

 


(9)                                  Without considering the shares held by the Company and by its subsidiary.

(10)                          The calculation of the full dilution rate was performed assuming the exercise of all other securities of the Company that are convertible or exercisable for shares of the Company and the allocation of the restricted shares

(11)                           See footnote 10 above.

(12)                          Calculated in accordance with an economic opinion of external advisors, on the basis of a binomial model, in accordance with the assumptions set forth in Section 20 below.

 

17



 

11.2                    In any event in which, pursuant to the Plan, the Offeree will be entitled to receive rights and/or Bonus Shares and/or any other right, insofar as it is granted to the Offeree by virtue of the Released Shares (hereinafter: the “ Rights ”), and on the Effective Date of the distribution of the Rights, the Released Shares are held by the Trustee, the Rights shall be transferred to the Trustee, who shall deduct withholding tax, in accordance with any applicable law, if and to the extent it is applicable, and all the Rights shall be allocated to the Trustee in favor of the Offerees, and shall be held by the Trustee until the end of the Minimal Trust Period of the Restricted Shares (as defined in Section 10.4 below), in respect of which the Rights were allocated and the conditions of the tax track shall apply to these additional Rights.

 

12.          Deposit of Options and Restricted Shares with the Trustee

 

The Option Warrants and the Restricted Shares shall be allocated to a Trustee according to the terms of the capital gains track, through a Trustee as set forth in Section 16.4 below (the “ Trustee ”), for the Offerees, following and subject to receiving of all the approvals set out in Section 2 above. The Effective Date is the date the Board of Directors approved the allocation of the Option Warrants and the Restricted Shares to the Offeree, namely August 6, 2014 (the “ Effective Date ”). Regarding the CEO, since the approval of the General Meeting of the Shareholders of the Company is required to allocate Option Warrants and Restricted Shares to the CEO of the Company, the Effective Date regarding the CEO shall be the approval date of the abovementioned meeting.

 

13.          Restrictions on Option Warrant, Exercise Share and Restricted Share transactions

 

13.1                    The Option Warrants and the Restricted Shares are a non-transferrable personal right, endorsed or pledged, whether voluntarily or otherwise (except to the heirs of a deceased Offeree according to a will or inheritance laws, provided they convey acceptance to their conditions). The Restricted Shares shall be registered for trade on the stock exchange.

 

13.2                    The Option Warrants and the Restricted Shares awarded to the Offerees resident in Israel shall be allocated to the Trustee under Section 102 of the Income Tax Ordinance. Consequently, the Option Warrants or Exercise Shares or Restricted Shares, respectively, shall be held by the Trustee, under Section 102 of the Income Tax Ordinance, for the Minimal Trust Period, as set forth in Section 16 below.

 

13.3                    The Trustee may not transfer the Option Warrants and the Restricted Shares that were granted in accordance with this Outline and Immediate Report to any third party, including an Offeree, unless so instructed by the Company and subject to any applicable law.

 

18


 

13.4                    Transfer of Option Warrants and/or Exercise Shares and/or Restricted Shares in accordance with a will or inheritance laws shall be valid and shall bind the Company, only after the Company is furnished with the following notarized approvals:

 

a.                   A written request for the transfer and a copy of a legal document creating and confirming the right of such person to act in respect of the Offeree’s estate and creating or confirming the right of the transferee;

 

b.                   Written consent from the transferee to pay any amount in respect of the option warrants and the restricted shares under this Outline and Immediate Report, and agreement to pay any amount required under the provisions of this Outline and Immediate Report as well as consent to comply with all the provisions of this Plan, Outline and Immediate Report;

 

c.                    Any other evidence required by the Board of Directors to establish the right to transfer the option warrants and/or the exercise shares and/or the restricted shares and the validity of the transfer.

 

13.5                    The Option Warrants and the Restricted Shares are subject to the restrictions under the provisions in the Company’s articles of association.

 

13.6                    The allocation of the options and the Restricted Shares pursuant to this Outline and Immediate Report is made in accordance with section 15B(1)(A) of the Securities Law, and therefore the restrictions set out in Section 15C of the Securities Law with respect to reversed sale, shall not apply to the Exercise Shares, the Restricted Shares and the Released Shares (except as set out below), .

 

Section 15C of the Securities Law and the Securities Regulations (Details Regarding Sections 15A to 15C of the Law) 5760-2000 (the “ Additional Details Regulations ”) shall apply to the Exercise Shares that will be derived from the exercise of the Option Warrants, the Restricted Shares and the Released Shares that will be derived from the Restricted Shares that shall be allocated to Offerees in countries other than Israel, as follows:

 

13.6.1                       For a period of six months from the date of issuance, the said Offerees shall be prohibited from offering the Exercise Shares, the Restricted Shares or the Released Shares for trading on the stock exchange without publishing a prospectus which the Israeli Securities Authority has approved for publication.

 

13.6.2                       For a period of six consecutive quarters, commencing on the end of the period set out in Section 13.6.1 above, each of the said Offerees may offer

 

19



 

a number of shares on any trading day which is no more than the daily average of the volume of trading of the Company’s Exercise Shares, Restricted Shares or Released Shares on the stock exchange over the eight week period preceding the date of the offer, provided that the total number of shares offered in any quarter does not exceed one percent of the Company’s issued and outstanding capital, as set out in the Additional Details Regulations.

 

14.          Change of control

 

In the event of provision of notice of termination of the employment relationship for any reason, except for the event set forth in Section 7.3 above, during the 180 days following the completion of the change of control in the Company, the right of the Offerees to exercise all the Option Warrants allocated to them including those not yet “released” shall be formulated immediately prior to the Date of Termination of the Employment and all the Option Warrants shall be exercisable by them from that date until the date of their exercise as provided in Section 5.2 above. In addition, in the case specified in this Section above, the Restricted Shares shall become vested immediately prior to the Date of Termination of the Employment.

 

Change of control ” — includes by way of the sale of shares (including a share swap), distribution of a specific dividend or allocation of shares to a third party.

 

Control ” in this section - as defined in the Securities Law.

 

15.          Restructuring or merger

 

In the event of merger of the Company with or into another company, whether by way of exchange of shares, cash purchase or otherwise, or by the sale of all (or the majority of) the assets of the Company or its operations or its issued share capital or any other similar corporate event (collectively: “ Restructuring or Merger ”) and subject to any applicable law, the Board of Directors shall determine one of the following alternatives:

 

15.1                    Each option shall be replaced or converted to an equivalent option in the New Company after the merger or sale and the Board of Directors shall be entitled to make such modifications to the Exercise Price for this purpose, if and to the extent required, all subject to the discretion of the Board; OR

 

15.2                   Each option shall be adopted by the New Company so that it will be exchangeable for a share of the New Company, subject to adjustments and changes that will be determined by the Board of Directors; OR

 

15.3                   Each option shall be canceled or returned to the Company and the Company shall

 

20



 

pay the eligible employee monetary compensation for the cancellation or return of the option stated above, provided that the inherent value of the benefit in the compensation shall not be less than the inherent value of the options that were canceled or returned to the Company, as measured at the date of cancellation or return, as the case may be; AND

 

15.4                    Any resulting action and/or adjustment related to the options and their conditions, as required at their discretion.

 

15.5                    Upon completion of the Restructuring or Merger the options exercisable to shares of the Company shall expire.

 

15.6                    In the event of a Restructuring or a Merger, the treatment of the Restricted Shares shall be in accordance with the treatment of ordinary shares of the Company, subject to the Vesting Period of the Restricted Shares.

 

For purposes of this Section, the term, the “ New Company ” shall relate to the company with which the merger is to be performed, with which a sale transaction will be implemented or that shall take the place of the Company after the Restructuring or Merger or any resulting transaction. For the avoidance of any doubt, it is clarified that in the event that control of the Company is transferred as a result of the Restructuring or Merger, the provisions of Section 14 above shall apply.

 

16.          Tax implications and allocation to the Trustee

 

The following is an itemization of certain provisions relating to tax in respect of the allocation and exercise of the Option Warrants and/or the Restricted Shares:

 

16.1                    The Offerees shall bear any tax obligation regarding allocation of the Option Warrants and/or the Restricted Shares to the Offerees (including income tax, capital gains tax, national insurance and health tax) and any other mandatory payment with respect to the awarding of the Option Warrants and/or the Restricted Shares and the exercise or sale of the Exercise Shares and/or the Restricted Shares and/or the Released Shares. The Trustee and the Company shall be entitled to deduct any amount that is subject to withholding tax, in accordance with any applicable law.

 

16.2                    The provisions of Section 102 of the Income Tax Ordinance (New Version) and the regulations promulgated thereunder (collectively, heretofore and hereafter: “ Section 102 ”) shall apply to the Option Warrants and/or the Restricted Shares allocated to the Offerees in Israel. The Company has elected that the allocation to the Offerees who are Israeli residents shall be made through a Trustee, in a capital gains track.

 

21



 

16.3                    At the date of this report, the provisions of Section 102 regarding the capital gains track stipulate, inter alia , as follows:

 

·              The Options Warrants and/or Exercise Shares and/or Restricted Shares shall be held with the Trustee until two years have followed from the date of allocation;

 

·              The Offeree’s income from allocation of the Options Warrants and/or Restricted Shares shall not be taxed on the date of the allocation;

 

·              The Employee’s tax liability for “part of the value of the benefit” on the date of the allocation of the Option Warrants and/or the Restricted Shares shall be calculated in accordance with the marginal tax rate that applies to the Employee. For this purpose, the “part of the value of the benefit” shall be calculated in accordance with the average value of the Company’s shares on the TASE at the end of the 30 trading days which preceded the allocation of the Option Warrants and/or Restricted Shares, less the cost of exercising the Option Warrants.

 

·              The balance of the value of the benefit shall be subject to tax at the rate applicable to capital gain according to Section 102 (currently 25%).

 

·              When allocating the Option Warrants and/or Restricted Shares, the Company employing the Offeree shall be allowed a salary expense at the level of the Employee’s income, on which a tax at the marginal tax rate shall apply. The value of the benefit to the Employee shall be subject to the fixed tax rate applicable to capital gains according to Section 102 (currently 25%) - the Company shall not be allowed an expense for tax purposes.

 

The abovementioned should not be considered as tax advice and each Offeree should review the tax situation applicable to it and decide whether and how to act according to its own specific circumstances.

 

16.4          Accordingly

 

·              The allocation to the Offerees shall take place only after the fulfillment of the conditions required in the provisions of the capital gains track in Section 102 of the Income Tax Ordinance.

 

·              Prior to the allocation of the Option Warrants and/or the Restricted Shares to the Offerees, the Company shall enter into an agreement with the Trustee (the “ Trustee ”), which shall hold the Option Warrants and/or the Restricted Shares in trust for the Offerees pending exercise of the Option Warrants (or their expiry, as the case may be) or until the end of the expiration of the restriction on the Restricted Shares, as the case may be, and shall hold the Exercise Shares that

 

22



 

shall be derived from the exercise of the Option Warrants and/or the Released Shares for at least 24 months subsequent to the date of allocation to the Trustee (the “ Minimal Trust Period ”).

 

16.5                    Notwithstanding any other provision in this Section, it is stated that transfer of the Exercise Shares and/or Restricted Shares and/or Released Shares from the Trustee to an Israeli Offeree or from an Israeli Offeree to any third party (including sale thereof), shall only be permitted after the Minimal Trust Period, and payment of the applicable tax. Despite the aforementioned, it will be possible to transfer the Exercise Shares and/or the Restricted Shares and/or the Released Shares before the end of the Minimal Trust Period, after payment or deduction of the owed tax, if any, and shall be made in accordance with the provisions, conditions and arrangements as may be agreed upon between the Company and the Trustee, and subject to the provisions of Section 102 or the provisions of any applicable law and any agreement with the tax authorities.

 

16.6                    Notwithstanding the provisions heretofore and hereafter, the Offerees under this Outline and Immediate Report include Offerees whose place of residence or employment is outside of Israel, and therefore the provisions of Section 102 may not be applicable in their respect. The Option Warrants and/or the Restricted Shares of these Offerees shall be deposited with the Trustee on the date of their allocation and shall be exercised through the Trustee in the manner set out in this Outline and Immediate Report, without the lock up restrictions under Section 102.

 

The foregoing of this Section 16 above does not purport to be an authorized interpretation of the legal provisions pertaining to the taxes that may apply in connection with the grant of the Options Warrants and the Restricted Shares being offered to the Offerees, and cannot substitute for professional legal advice on the matter. As is customary in investment in securities, each of the Offerees (including Offerees as per sub-section 16.6 above) must consider the various tax aspects and the tax implications that will be associated with their investment and should consult with their professional advisers, including legal and taxation advice having regard to their particular circumstances .

 

17.      The Offerees obligations

 

Upon the allocating the Option Warrants or the Restricted Shares, the Company shall deliver to each Offeree a letter of offer in respect of the number of Option Warrants or Restricted Shares that each Offeree is entitled to receive under this Outline and the Immediate Report. Upon receipt of the Option Warrants or the Restricted Shares pursuant to this Outline and Immediate Report, the Offeree shall undertake and declare the following:

 

23



 

(1) to agree and confirm that he received and read the Plan and the letter of offer and accepts all of the conditions therein, including and without derogating from the generality of the aforesaid, his consent to bear all of the tax liabilities and other mandatory payments resulting from the offering and allocation of the Option Warrants and the Restricted Shares, the exercise of the Option Warrants or the sale of the Exercise Shares or of the Released Shares, as the case may be, and that he agrees and authorizes the Company to withhold any tax that may apply (including, if required, from the number of Option Warrants and/or Exercise Shares and/or Released Shares, as the case may be); (2) to fulfill all the conditions set out in Section 102 (including provisions relating to the tax track), the provisions of Section 102, the Plan, letter of offer and trust agreement; (3) subject to the provisions and conditions of Section 102 and the rules, not to sell or remove the Exercise Shares and/or the Restricted Shares and/or the Released Shares from the trust prior to the end of the Minimal Trust Period; (4) to comply with the procedures for exercising the Option Warrants and the sale of the Exercise Shares and/or the Released Shares, as the case may be, as will be agreed upon between the Company and the Trustee.

 

18.          Applicable law

 

The Plan, this Outline and Immediate Report as well as all of the ancillary documents thereto that were submitted or signed by the Company or companies under its control in respect of the Plan, this Outline and Immediate Report, shall be interpreted, conducted and subject to the laws of the State of Israel.

 

19.      The economic value of the Option Warrants

 

19.1                    The Option Warrants shall be allocated to the Offerees for no consideration.

 

19.2                    The Company is implementing International Financial Reporting Standard Number 2 “share based payment.” The main provisions of the standard are the recording of expenses in respect of share based payment transactions in the financial statements of the Company in accordance with the economic value at the time of the allocation as defined in the abovementioned standard. The expense shall be recorded in the financial statements of the Company over the Vesting Period of the Option Warrants and in accordance with the number of Option Warrants expected to be vested.

 

19.3                    The average economic value of an Option Warrant as of August 6, 2014, is NIS6.57. For additional details see Section 4 above.

 

19.4                    The aforesaid economic value calculation was performed according to the economic opinion of external consultants and is based on the binomial model, which is the appropriate model to calculate the economic value of an event in which a maximum limit is defined at the level of the benefit resulting from the exercise of the Option

 

24



 

Warrant (“CAP”). The annual standard deviation of the share that was calculated is 29%, 31%, 41% for the first, second and third portion, respectively. The risk free interest rate that was taken into account is 0.17%, 0.05%, 0.24% for the first, second and third portion, respectively. The duration of the Option Warrant for the first portion is 52 months with a vesting and lock up period of 28 months. The duration of the Option Warrant for the second portion is 64 months with a vesting and lock up period of 40 months. The duration of the Option Warrant for the third portion is 76 months with a vesting and lock up period of 52 months. As stated in Section 4.3 above, the Exercise Price of the Option Warrants is NIS28.71, and the closing price of the share on the Stock Exchange on the day preceding the date of approval of the Board of Directors is NIS28.09. Under the terms of the Option Warrants, a maximum limit of 2 times the Exercise Price was taken into account at the level of the benefit resulting from the exercise of the Option Warrant (CAP) (see Sections 4.3 and 4.4 above).

 

19.5                    Accordingly, the cumulative economic value of the Option Warrants that will be allocated to the Offerees is about NIS28,806 thousand, of which the economic value of the Option Warrants that will be allocated to the CEO is about NIS2,413 thousand, as of the date of approval of the Board of Directors.

 

19.6                    The fair value calculation does not take into account the fact that the Option Warrants will not be listed on the stock exchange, and does not take into account the tax that may be applicable at the time of exercise of the Option Warrants or the sale of the Exercise Shares. However, since the Company is of the understanding that this model calculates and reflects the fair value of the Option Warrants in the best manner among the currently available models, the Company has chosen to implement this model with regard to the calculation of the fair value of the Option Warrants allocated by the Company.

 

19.7                    The measurement date for the accounting expense for the Option Warrants allocated to the Offerees is the date of approval of the allocation by the Board of Directors of the Company, and with respect to the offer to the CEO — the date of approval of the general meeting.

 

19.8                    The registration of the expense shall be deployed over the period from the date of the approval of the Board of Directors until the end of the Vesting Period of the Option Warrants.

 

20.          The economic value of the Restricted Shares

 

20.1                    The Restricted Shares shall be allocated to the Offerees for no consideration.

 

20.2                    The Company applies the IFRS standard no. 2 “share based payment”. The main

 

25



 

provision of the standard is the recording of expenses for share based payment transactions in the financial statements of the Company according to their economic value on the date of allocation as defined in the aforementioned standard. The expense shall be recorded in the financial statements of the Company during the Vesting Period of the Restricted Shares in accordance with the number of Restricted Shares that are expected to be vested.

 

20.3                    The economic value of each Restricted Share is equal to the closing price of the Company’s share at the end of the trading day preceding the Effective Date.

 

20.4                    Accordingly, the economic value of each restricted share proposed to be allocated to the Offerees is NIS28.09, as per the date of approval of the Board of Directors of this Outline and Immediate Report (August 6, 2014).

 

20.5                    This value may vary, since the measurement date of the accounting expense for the award of the Restricted Shares shall be the actual date of the award of the Restricted Shares and not the day of publication of this Outline and Immediate Report.

 

20.6                    The registration of the expense shall be deployed over the period from the date of the award (as defined in the aforementioned IFRS No. 2) until the end of the Vesting Period of the Restricted Shares .

 

21.          Information based on the Sixth Addendum to the Reports Regulations

 

The following section 21 presents information based on the Sixth Addendum to the Reports Regulations concerning a material private offering to the CEO.

 

21.1                    For details regarding the Option Warrants and the Restricted Shares allocated to the CEO in accordance with the this Outline and Immediate Report, and their proportion of the voting rights and the issued and outstanding capital following allocation and exercise, as the case may be, and on a fully diluted basis and their financial value, see Sections 4 and 9 above.

 

21.2                    For details regarding all the compensation components of the CEO, see regulation 21, section E of the Company’s 2013 annual reports, as published by the Company on March 19, 2014 (ref. 2014-01-017478).

 

21.3          The organs that approved the allocation of the Option Warrants and Restricted Shares to the CEO and dates of approval

 

The Compensation Committee discussed and approved the Plan and the private offering, including the material private offering to the CEO at its meeting of August 4, 2014, and approved them.

 

26



 

The Company’s Board of Directors discussed and approved the Plan and the private offering, including the material private offering to the CEO at its meeting of August 6, 2014, and approved them.

 

The allocation of Option Warrants and Restricted Shares to the CEO according to this Outline and Immediate Report is subject to the approval of the General Meeting of shareholders of the Company by a special majority, as stipulated in section 272(c1)(1) of the Companies Law.

 

21.4          Method for determining compensation

 

For the purpose of determining the compensation, the Compensation Committee and the Board of Directors examined and took into account, in their deliberations concerning these matters, inter alia , the following parameters:

 

a.               The Company’s desire to incentivize the Officers and the CEO such that they will act for the continued success of the Company, to achieve its long-term goals and maximize its long-terms profits;

 

b.               Determining an maximum limit in the Plan for the inherent value of the benefit from the exercise of the Option Warrants in a manner so that the benefit shall not exceed twice the Exercise Price, as described in Sections 4.3 and 4.4 above;

 

c.                The scope and complexity of the Company’s operations and its financial results;

 

d.               Data pertaining to the scope of the total compensation for Officers and the CEO (including details of the various compensation components including the Option Warrants and the Restricted Shares);

 

e.                The terms of the allocation of the Option Warrants and the Restricted Shares and the ratio between the inherent value of the benefit and the level of total compensation of the Officers and the CEO;

 

f.                 Economic opinion prepared by external advisors with respect to the financial value of the benefit inherent in the Option Warrants and the Restricted Shares (see sections 19 and 20 above).

 

g.                Reports prepared by external advisors that included comparative figures regarding all the compensation components (including salary, bonus and equity-based compensation) for Equivalent Officers in Comparative Companies (as defined in Section 6.1 of the Compensation Policy — “ Comparative Companies ”). The Compensation Committee and the Board believe, that in light of the fact that ICL is a multinational company having most of its sales outside of Israel and where a

 

27



 

significant portion of its employees operates and is employed abroad, and considering the small number of Israeli companies in the field of operations of ICL, there is a difficulty in location relevant Comparative Companies in Israel. It is therefore appropriate that for purposes of examining the comparative compensation data of companies that are similar to ICL and the customary compensation data in its field of operation, the comparative data of the foreign Comparative Companies will be examined; Figures pertaining to the scope of compensation in securities to Officers pursuant to the Company’s previous options plan of 2012;

 

h.               Amendments to the Compensation Policy were recommended by the Compensation Committee on August 4, 2014 and thereafter approved by the Board of Directors on August 6, 2014, subject to approval of the amendments to the Compensation Policy by the General Meeting of the shareholders of the Company which was summoned to October 20, 2014. The allocation of the Option Warrants and Restricted Shares to the CEO corresponds with the Compensation Policy of the Company as it is as of the date of this Outline and Immediate Report, and as shall be amended (see the immediate report regarding the convening the General Meeting published by the Company concurrent with the publication of this Outline and Immediate Report).

 

21.5          Summary of the arguments of the Compensation Committee and the Board of Directors

 

The Compensation Committee and the Company’s Board of Directors examined the terms and conditions of the allocation of the Option Warrants and the Restricted Shares with attention paid to all the parameters specified in Section 21.4 above, and the Compensation Committee and the Board resolved to approve the allocation of the Option Warrants and the Restricted Shares, based on the following considerations:

 

21.5.1          The Compensation Committee and the Board of Directors decided to approve the allocation of the Option Warrants and Restricted Shares to the CEO as set out in this Outline and Immediate Report, and this considering: (1) the conditions of the allocation of the Option Warrants that include, inter alia , a maximum limit on the Exercise Date of the inherent benefit in the exercise of the Option Warrants; (2) the complex role of the CEO, his skills, expertise, proven managerial ability in the Company and his vast professional experience; (3) the achievements of the CEO since the beginning of his tenure and the accomplishments expected of him; (4) the scope and complexity of the activity of the ICL Group and its extensive global deployment; (5) the scope of the aggregated compensation of the officers and the CEO; and (6) the members of the Compensation

 

28


 

Committee and the Board place great importance in incentivizing the CEO to achieve the Company’s strategic plan for growth as well as the efficiency and cost savings plans of the Company, to attain its long-term goals and maximize its long-term profits, preserve the stability of the Company management and the continued leadership, and in their decision to approve the amount of the Option Warrants and the Restricted Shares for allocation, took into account the desire to ensure the continued tenure of the CEO in the Company in the coming years, and to link between the performance of the Company and the compensation that will derive from the Option Warrants and the Restricted Shares. Creation of mix of Option Warrants and Restricted Shares will reduce the incentive to take risks by the CEO, which are not compensated in an appropriate yield or excessive risks beyond the risk level desired for the Company, in accordance with its risk taking policy and will create an alignment with the interests of the shareholders.

 

21.5.2                       It was further determined by the Compensation Committee and the Board that the scope of compensation of the CEO is reasonable, even in comparison to the scope of the compensation in securities granted to the CEO in accordance with the Company’s previous options plan of 2012. Furthermore, the compensation proposed in this Outline and Immediate Report for all of the Offerees complies with the provisions of the Compensation Policy with regard to equity-based compensation. It was noted, the relative value of the offered compensation to the CEO is about third (1/3) of the value of the equity-based compensation that was granted to the CEO pursuant to the 2012 plan, taking into consideration that to the extent the amendments to the Compensation Policy are approved by the general meeting of the shareholders of the Company, the Company intends to allocate equity-based compensation annually (as opposed to allocate equity-based compensation once in 3 years).

 

21.5.3                       Taking into account all of the parameters that were examined and the arguments listed above, the Compensation Committee and the Board have determined that: (a) the scope of the compensation in securities and the scope of the aggregated compensation of the CEO are reasonable and appropriate in the circumstances of the matter, and do not deviate from the levels of compensation customary among CEOs in the foreign Comparative Companies, including in relation to the rate from the issued and outstanding capital and voting rights of the Company, which will be granted by the

 

29



 

shares that shall be derived from the exercise of the Option Warrants and the Restricted Shares; (b) the equity based compensation is reasonable even in relation to the total amount of the Option Warrants and the Restricted Shares offered in accordance with the Plan; (c) the equity based compensation is reasonable even when taking into account the ratio between the Option Warrants and Restricted Shares offered and the other components of the CEO’s compensation; (d) the equity based compensation constitutes an important and integral part of the mix of compensation components and is designated to provide the CEO with an optimum incentive to act to maximize the Company’s profits and to attain its long-term goals, and that the compensation is designed to serve the best interests of the Company.

 

21.5.4                       Concurrently with the approval of the Plan, the Compensation Committee and the Board of Directors approved a compensation plan to 11,800 employees of the Company and of companies controlled by the Company, which are not managers and which are Offerees pursuant to the Plan, in an aggregated amount of up to about $17.5 million.

 

21.5.5                       The compensation granted to the CEO pursuant to this Outline and Immediate Report, complies with the provisions of the Compensation Policy.

 

22.          The Issued Share Capital of the Company, the amount and holding percentage of the Offerees and Interested Parties in the Company

 

22.1                    As of the date of this Outline and Immediate Report, the Company’s issued and outstanding share capital is NIS1,295,015,590 par value, divided into 1,295,015,589 ordinary shares of NIS1.00 par value each and one Special State Share.

 

22.2                    As of the date of this Outline and Immediate Report the Company holds 24,589,631 shares of that Company.

 

22.3                    As of the date of this Outline and Immediate Report, the officers and other employees in the Company hold an amount of 11,993,400 option warrants allocated pursuant to the Outline dated November 27, 2012.

 

22.4                    Following the allocation pursuant to this Outline and Immediate Report and assuming full exercise of all the Option Warrants and allocation of the Restricted Shares offered according to this report, the issued share capital(13) shall amount to NIS

 


(13)                          Assuming full exercise by the Offerees, regardless of the Maximum Share Value as described in Sections 4.3 and 4.4 above, without activating the right of the Company as described in Section 4.4 above, and

 

30



 

1,275,835,947 par value (disregarding the shares held by the Company — see above).

 

22.5                    To the best of the Company’s knowledge, the holdings of the CEO who is an interested party by virtue of its position in the Company, other interested parties and the rest of the holders of issued and outstanding share capital of the Company are, at the date of this report, and shall be subsequent to the private offering, as follows:

 

The Company’s
Shareholders (***)

 

Immediately prior to the private
offering

 

Subsequent to the private offering and assuming that the
Offerees shall exercise all the options granted to them pursuant
to this Outline and Immediate Report

 

Classification

 

Name

 

Quantity

 

Ratio
in
equity

 

Ratio in
voting
rights

 

Quantity

 

Ratio in
equity
(14)

 

Ratio in
equity on
a fully
diluted
basis(15)

 

Ratio in
Voting
Rights
(16)

 

Ratio in
Voting
Rights on a
fully diluted
basis(17)

 

CEO Offeree in a material private offering

 

Stefan Borgas

 

 

 

 

 

 

 

1,643,201

 

0.13

%

0.13

%

0.13

%

0.13

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interested Parties

 

Israel Corporation Ltd

 

 

 

52.38

%

52.38

%

 

 

52.16

%

51.68

%

52.16

%

51.68

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

PotashCorp Agricultural Cooperative Society Ltd.

 

 

 

13.86

%

13/86

%

 

 

13.8

%

13.67

%

13.8

%

13.67

%

 


irrespective of the shares held by the Company and irrespective of exercising of all other securities of the Company convertible into or exercisable into shares of the Company. The issued capital may be lower due to the allocation of a smaller amount of shares in respect of the Maximum Share Value specified in Section 4.3 above or due to the activation of the right of the Company to a net exercise as specified in Section 4.4 above.

(14)                          Assuming theoretically the exercise of all the Option Warrants into shares by the Offerees under this Outline and the allocation of Restricted Shares, irrespective of the Maximum Share Value as described in Sections 4.3 and 4.4, without activating the right of the Company to allocate shares in the amount of the monetary benefit as described in Section 4.4 above, irrespective of the shares held by the Company. The actual number of shares allotted may be lower than that specified in Section 4.1 above due to the Maximum Share Value as specified in Section 4.3 above or due to activations of the “net exercise” mechanism as described in Section 4.4 above.

(15)                          The calculation of the ratio on a fully diluted basis was made under the assumptions in footnote 3 above and assuming of all the other securities of the Company that are convertible and exercisable into shares in the Company.

(16)                           See footnote 3 above.

(17)                          The calculation of the full dilution percentage is made on the assumptions in footnote 3 above and assuming of all the other securities of the Company that are convertible and exercisable into shares in the Company.

 

31



 

The Company’s
Shareholders (***)

 

Immediately prior to the private
offering

 

Subsequent to the private offering and assuming that the
Offerees shall exercise all the options granted to them pursuant
to this Outline and Immediate Report

 

Classification

 

Name

 

Quantity

 

Ratio
in
equity

 

Ratio in
voting
rights

 

Quantity

 

Ratio in
equity
(14)

 

Ratio in
equity on
a fully
diluted
basis(15)

 

Ratio in
Voting
Rights
(16)

 

Ratio in
Voting
Rights on a
fully diluted
basis(17)

 

 

 

IDE Technologies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Rotem Amfert Negev Ltd.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Yair Orgler

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Avraham (Baiga) Shochat

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ofer Holdings Group Ltd.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Israel Chemicals Ltd.

 

24,589,631

 

 

 

24,589,631

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other share-holders

 

Public(*)

 

427,281,575

 

33.6

%

33.6

%

432,238,363

 

33.88

%

33.56

%

.88

%

33.56

%

 


(*)             Public, including the allocation to officers and employees who are Offerees according to this Outline and Immediate report, with the exception of the allocation for the CEO according to this Outline and Immediate Report and additional holdings of the CEO.

(**)      For additional information about the interested parties in the Company, see the most recent list of Holdings of interested parties and senior officers that was published by the Company on August 5, 2014 (Ref. No.  2014-01- 127263 ) .

 

23.          Consideration and manner of determination

 

23.1                    The Option Warrants and the Restricted Shares are offered to the Offerees with no consideration.

 

23.2                    If all of the offered Option Warrants are exercised into shares, the Company may receive up to and including the Final Exercise Date an amount equal to NIS130,000 thousand.

 

23.3                    The Company intends to use the proceeds it receives from the exercise of Option

 

32



 

Warrants, if received (see footnote 13), as shall be determined by the management or the Board of Directors of the Company, from time to time.

 

23.4                   The Exercise Price of the Option Warrants is determined by the Compensation Committee and the Board, and is identical for all the Offerees under this Outline and Immediate Report, including the CEO.

 

33



 

24.          Personal Interest in the approval of the Material Private Offering

 

To the best of the Company’s knowledge, none of the officers of the Company have a personal interest in the approval of the Material Private Offering, with the exception of the CEO.

 

25.          Required approvals

 

For further information pertaining to the required approvals and permits, see Section 2 above.

 

26.          Details of agreements pertaining to rights in the Shares of the Company

 

To the best of the Company’s knowledge, following to clarifications conducted with the CEO, there are no agreements, either written or oral, between the CEO and any shareholder of the Company, or between the Offerees, all or in part, between each other or between them and other persons with respect to the acquisition or sale of securities of the Company or with respect to the voting rights in the Company.

 

27.          Restraints or Restrictions applicable to the Offerees with respect to transactions with the Option Warrants and Restricted Shares

 

For further information in this regard, see Section 13 above.

 

28.          Term for granting of securities

 

The term for granting the Option Warrants and Restricted Shares to the Offerees pursuant to this Outline and Immediate Report shall be effected on the later date of: (A) receipt of all the required approvals as set forth in Section 2 above or (B) 14 business days after the date of publication of this Outline and Immediate Report; and shall terminate on the date of publication of the Periodic Report for 2014.

 

29.          Power of the Company’s Board of Directors

 

The Board of Directors of the Company is authorized to interpret the provisions of the Outline and the immediate Report and the Plan and to make any supplemental of clarifying instruction concerning the execution thereof, insofar as necessary, at its discretion.

 

Without derogating from the generality of the foregoing, it is clarified that subject to any applicable law,(18) the Board of Directors of the Company is authorized, at its sole discretion, to exercise all of the powers required for the purpose of managing the Plan, including determining the identity of the Offerees, determining the number of Option Warrants and Restricted Shares to be allocated to each of the Offerees, determining the dates of such allocation, determining the Exercise Price, determining the Vesting Periods, and on special

 


(18)                          The stated in this Section shall not derogate from the powers of the Compensation Committee according to law and according to Company procedures.

 

34


 

occasions as the Board of Directors deems fit— to accelerate the Vesting Periods of the Option Warrants and the Restricted Shares not yet vested (in whole or in part) and all in relation to all or any of the Offerees. The Board of Directors is also authorized to establish any other resolution required by or related to the Plan, whether or not indicated in the Plan.

 

Furthermore, the Board of Directors of the Company is authorized, subject to any applicable law and at its sole discretion, to amend the provisions of the Plan (and its ancillary documents), provided that any amendment of any of the terms and conditions of the Plan shall not contradict the provisions of Section 102 and shall not derogate from the rights of the Offerees pursuant to the Plan without obtaining the prior consent of the Offerees who, as of the date of the proposed amendment, have been granted Option Warrants that have yet to be exercised and have yet to expire according to the Plan, or Restricted Shares that the Restriction Period thereof has yet to pass.

 

The Board of Directors has delegated to the Compensation Committee its power to designate to specific Offerees (that are not officers) the Option Warrants and the Restricted Shares that shall be allocated to the Trustee, all in accordance with and subject to matters set forth in Section 288(B)(1) of the Companies Law and any applicable law.

 

30.          No undertaking for continued employment

 

The granting of the Option Warrants and the Restricted Shares to the Offerees pursuant to the Plan and this Outline and Immediate Report shall not be construed as imposing any obligation on the Company and/or its subsidiaries to continue the employment of any of the Offerees and/or as restricting them from terminating the employment of any of the employees and/or as granting any right to an Offeree to continue to be employed.

 

Part C. Rights associated with the Company’s Shares

 

31.                             The following is a concise description of the rights attached to the Company’s shares as prescribed in the Company’s Articles of Association. The full version of Company’s Articles of Association may be viewed on the distribution website of the Securities Authority at (www.magna.isa.gov.il) and at the registered office of the Company.

 

As of the date of this report, all the shares in the issued and outstanding share capital of the Company and the shares that shall be derived from the exercise of Option Warrants pursuant to the Plan and the Restricted Shares are registered ordinary shares, of NIS1.00 par value each (the “ Ordinary Shares ”), except for one special registered State share of NIS 1.00 par value (the “ Gold Share ”) which is held by the State of Israel.

 

31.1                    The conditions and rates of participation in the distribution of dividends and bonus shares : The Ordinary Shares shall be of equal rights and shall confer on the

 

35



 

holders the right to receive notices regarding General Meetings of the Company, to participate in and vote at such meetings, to elect members of the Board of Directors (in the manner set forth in the Articles of Association of the Company) and the right to participate in the distribution of the Company’s profits and the distribution of surplus assets upon liquidation.

 

In the event of payment of dividends, such shall be paid proportionately to the sums that have been paid or credited as paid on account of the par value of the shares, without taking into account any premium paid thereupon.

 

In the event of distribution of bonus shares, such shall be distributed among the ordinary shareholders, in proportion to their entitlement to participate in the distribution of dividends, and shall be of the same class as the shares in respect of which they were distributed.

 

31.2                    Rights to participate in the division of the Issuer’s property upon liquidation: Upon liquidation of the Company, the surplus of the Company’s assets over all of its liabilities, subject to rights granted for any class of shares that may be issued at such time, in any, shall be distributed among the ordinary shareholders in proportion to the sum that has been paid credited as being paid on the par value of such shares, without taking into account any premium paid on the shares.

 

31.3                    Right to appoint directors: The members of the Board of Directors shall be appointed by the shareholders’ meeting or by the Company’s Board of Directors (in accordance with the provisions of the Company’s Articles of Association). All of the members of the Board of Directors shall hold office from the date of their election and/or appointment or from a later date, if so determined in the decision regarding the appointment, until the next annual shareholders’ meeting, and subject to the provisions of any applicable law and the Company’s Articles of Association. The majority of the members of the Board of Directors shall be citizens and residents of Israel. A person who is not a citizen or resident of Israel shall not be elected and/or appointed as a director if, as a result of such appointment, the majority of the Board of Directors shall not be citizens and residents of Israel and the election and/or appointment of a director as aforesaid shall be invalid and shall be deemed not to have been made from the beginning.

 

The number of members of the Board of Directors shall be no less than 7 and no more than 20. The external Directors of the Company shall be counted among the members of the Board of Directors.

 

36



 

31.4                    Rights to receive notices of meetings of shareholders, rights to participate and vote, and legal quorum: As set forth above, every regular shareholder has the right to receive notices of general meetings of the Company and to attend and vote at such meetings. Deliberations in a shareholders’ meeting shall not commence unless a quorum is present. A quorum shall be constituted by the presence, in person or by proxy, of at least two members who together hold more than 50% of the issued shares of the Company conferring voting rights. If, within half an hour of the time set for the inauguration of the meeting, there is no quorum, the meeting shall be adjourned to the same day in the following week, at the same and place, or to any other day and/or other time and/or other place as the Board of Directors shall prescribe by notice to the shareholders; if at such adjourned meeting there is no quorum after half an hour of the time set for the meeting, then two members with voting rights, being present in person or by proxy, and holding at least one third of the Company’s issued share capital, shall be entitled to discuss and resolve matters in respect of which the meeting was convened.

 

31.5                    Restriction on transfer of shares: Subject to the Company’s Articles of Association, fully paid shares may be transferred without need for the consent of the Board of Directors. The Special State share shall not be transferable. The Articles of Association contain provisions restricting the purchase or holding of shares in rates of 14% or more, of 25% or more, and the dominant rate of the shares in the share capital of the Company which confers on the holder the right, ability or practical possibility to appoint, either directly or indirectly, a number of Directors of the Company constituting half or more of the number of members of the Company’s Board of Directors, as actually appointed, from time to time. Any such purchase or holding shall require the consent of the person holding the Special State share, in accordance with the proceedings and conditions set forth in the Articles of Association.

 

31.6          Conditions for amendment of rights associated with the ordinary shares : Amendment of rights associated with any class of shares shall be prescribed in a resolution of the shareholders of such class, and in a resolution of meetings of such classes of shares whose rights may be prejudiced as a result of the change, by an ordinary majority among those present and voting at those meetings. Special State share : Any amendment of the Articles of Association which might directly or indirectly prejudice the rights attached to the Special State share shall be deemed to be a change of the rights attached to the Special State share. Any resolution or act which might directly or indirectly prejudice the rights attached to the special State share shall only be made with the consent of the holder of the Special

 

37



 

State share and shall be invalid in the absence of the consent of the holder of the Special State share.

 

Part D. Additional Details

 

32.          Details of the price of the Company’s shares on the Stock Exchange

 

The closing price of the Company’s share on the Stock Exchange on August 4, 2014 (the last trading day preceding the date of the resolution of the Board of Directors concerning the granting of the Option Warrants and the Restricted Shares) was NIS28.09.

 

The following are the details of the highest and lowest share price (in Agorot) on the dates on which the Company’s shares were traded during each of the two calendar years preceding the date of this Outline and Immediate Report, and during the period from January 1, 2014, through shortly prior to the date publication of this Outline and Immediate Report.

 

 

 

High Quotation*

 

Low Quotation*

 

Period

 

Date

 

Quotation (Ag.)

 

Date

 

Quotation (Ag.)

 

 

 

02/10/2012

 

4307.61

 

01/02/2012

 

3234.34

 

 

 

23/01/2013

 

4511.17

 

08/09/2013

 

2324.5

 

2014 (to August 6, 2014)

 

25/05/2014

 

3105.39

 

07/01/2014

 

2599.88

 

 


*  The closing prices of the shares subsequent to their adjustment in respect of the distribution of a dividend, as implemented by the Tel Aviv Stock Exchange Ltd.

 

33.          Notice of this Outline and Immediate Report

 

Within 21 days of date of publication of this Outline and Immediate Report, the Company shall provide a copy of the Outline and Immediate Report, together with reference to the reports to which it refers, to each Offeree at their place of employment or at their addresses as recorded by the Company. Each Offeree shall receive a page setting forth references to links on the distribution website of the Securities Authority, with respect to each of the reports to which this Outline and Immediate Report refers. In addition, a printed copy of the aforementioned reports shall be deposited with the Company’s secretariat and with segment secretariats, and each Offeree shall be able to view such and may obtain a copy thereof upon request.

 

38



 

Any notice from the Company to Offerees shall be served by means of written notice that shall be delivered to each of the Offerees at his place or work or his address registered with the Company or at his e-mail address.

 

34.          Referral to the periodic report, the interim financial statements and the immediate reports

 

Attention is hereby drawn to the periodic report for 2012 which was published by the Company on March 13, 2012 (reference number 2013-01-003520) and to the periodic report for 2013 which was published by the Company on March 19 th , 2014 (Ref. No. 2014-01-017478) and to the 1 st  Quarter Report for 2014 which was published by the Company May 15, 2013 (reference number 2014-01-064320), 2 nd  Quarter Report for 2014 which was published by the Company on August 7, 2014 (reference number 2014-01-128733) as well as the Immediate Reports which were published by the Company since the last Periodic Report. These documents may be perused at the distribution website of the Securities Authority at www.magna.isa.gov.il and at the website of the TASE at www.tase.co.il and at the registered office of the Company (at the office of the Legal adviser and Company Secretary), during ordinary office hours and by prior appointment, at Tel: 03-6844440.

 

35.          Powers of the Israel Securities Authority

 

The Securities Authority, including an employee of the Authority so authorized, may instruct the Company, within 14 business days of the date of submission of this Outline and Immediate Report, to provide any explanation, details, information or documents pertaining to this Outline and Immediate Report, and may instruct the Company to amend this Outline and Immediate Report within such time as it may prescribe. Should the Authority instruct to amend this Outline and Immediate Report, it may order a postponement of the effective date of the commencement of the term of grant of securities to a date which may fall no earlier than three business days and no later than 14 business days from the date on which the amendment to this Outline and Immediate Report is published. The amendment of this Outline and Immediate Report and the postponement of the commencement of the term of grant of the securities under these instructions shall be effected in accordance with the provisions of the Outline Regulations.

 

36.          Company representative

 

The representative of the Company for the purpose of dealing with this Outline and Immediate Report is the Company’s Vice-President, Legal Advisor and Company Secretary, Lisa Haimovitz, Adv., at Tel: 972-3-6844440 and fax 972-3-6844427.

 

39



 

Israel Chemicals Ltd.

 

 

 

/s/ Lisa Haimovitz

 

By: Lisa Haimovitz, Adv.

 

 

 

VP, Legal Advisor and Company Secretary

 

 

 

Signature date: August 20, 2014

 

 

40




Exhibit 10.5

 

 

Israel Chemicals Ltd.

 

Compensation Policy for Executive Officers

 

1.               General

 

This document describes the compensation policy of Israel Chemical Ltd. (“ ICL ” or the “ Company ”) for its Office Holders, as this term is defined in the Companies Law, 1999 (“ Companies Law ”).

 

This policy does not grant legal rights to Executive Officers in the Company. Executive Officers in the Company shall be entitled only to the compensation granted to each of them specifically by the Compensation Committee and the Board of Directors of the Company (“ Board ”), and where required, subject to the approval of the shareholders of the Company. For purposes of this Policy, the term “Authorized Organs” shall refer to the relevant organs in the Company stated above, the approval of which is required under the Companies Law regarding the grant of relevant compensation.

 

In the event that an Executive Officer shall receive compensation which is less favorable than the compensation described under this Policy for an Executive Officer in the same position at the Company, this shall not constitute a deviation from the provisions of this Policy.

 

For purposes of this Policy, the term “ Executive Officers ” shall refer to Executive Officers that have an active role with the Company, including the (full or part time) executive chairman of the Board, if the Board appoints an executive chairman of the Board (“ Executive Chairman of the Board ”), and shall not refer to non-executive members of the Board, unless otherwise expressly indicated.

 

The Policy is phrased in the masculine for convenience only and is intended for both men and women alike.

 

With the adoption of this Compensation Policy, the bonus procedure which was in effect in the Company since 2005 and the updated version which was approved by the Board in 2008 shall be cancelled.

 

2.               Compensation Objectives and Principles

 

ICL is a multinational company which operates mainly in the fields of fertilizers and specialty chemicals through a segmented management structure that is comprised of a number of business segments (“ Segments ”), with a separate CEO (“ Segment CEO ”) at the head of each one. ICL has a central role in marketing potash, bromine, purified phosphoric acid, specialty phosphates, flame retardants based on bromine and chemicals to prevent the spread of fires. The Company’s production facilities are located in Israel and around the world, about 95% of

 



 

the sales turnover of the Company for 2012 was from outside of Israel and about 45.7% of the total sales of the Company generated from production outside of Israel.

 

This Policy is directed at enabling ICL to recruit and retain Executive Officers with the relevant experience and qualifications to manage large-scale, complex global operations, and to motivate them to achieve the Company’s long-term goals by structuring a compensation package that awards a significant weight to the variable components and makes use of a “profit sharing” mechanism.

 

Accordingly, the compensation package for Executive Officers will have the following characteristics:

 

·                   The compensation elements will be clear and transparent;

 

·                   The compensation elements will be aligned with ICL’s short-term and long-term goals;

 

·                   The compensation will be structured in way that aligns Executive Officers’ interests with shareholders’ interests;

 

·                   A significant portion of the compensation package will be conditional and based on corporate performance as well as the individual performance of the Executive Officer;

 

·                   Most of the variable cash compensation will be subject to minimum performance thresholds requirement that must be achieved as a condition for payment or grant of components of compensation.

 

In addition to the characteristics above, compensation will be structured so as to ensure balanced and effective risk management by encouraging excellence which does not promote risk-taking that exceeds the boundaries defined by the Board. The Company believes that the following factors may help to prevent inappropriate risk-taking:

 

·                   A balanced mix of compensation components: fixed component, short-term variable component and long-term variable component;

 

·                   Compensation goals that reflect a mix of quantitative and qualitative performance measures;

 

·                   Setting award limits on the variable compensation components;

 

·                   Determining claw-back provisions with respect to variable compensation;

 

·                   Deferring a payment of a portion of the annual bonus so that it will be affected by future performance.

 

3.               Compensation Components

 

The overall compensation of ICL’s Executive Officers shall be composed of various components, fixed and variable.

 

2



 

The ICL’s Executive Officers’ compensation package is composed of the following elements:

 

·                   Base salary

 

·                   Fringe benefits

 

·                   Annual cash bonus

 

·                   Equity-based compensation

 

·                   Retirement and termination arrangements

 

It should be noted that this Policy deals with, inter alia, the terms of service and employment of the Executive Chairman of the Board. As of the date of the adoption of this Policy, the compensation of the Chairman of the Board is included in the services the Company receives from its controlling shareholder, in accordance with a management agreement. It should be clarified that when an Executive Chairman of the Board is appointed in the Company, the aforementioned Chairman of the Board shall be compensated, in accordance with the principles of this Compensation Policy and subject to the approval of the Authorized Organs. The compensation to be paid to the Chairman of the Board shall be discussed together with the terms of said management agreement, including while examining the need to amend the provisions of the management agreement in accordance with the compensation determined for the Executive Chairman of the Board to be appointed. For the avoidance of doubt, it is hereby clarified that the terms of employment and service of the Executive Chairman of the Board discussed in this Policy are for if and when an Executive Chairman of the Board is appointed in the Company not within the framework of the existing management agreement and the amounts of the compensation - including the amounts of the caps for the compensation components, and such Executive Chairman of the Board’s position is of 100% capacity.

 

4.               Ratio between Fixed and Variable Components

 

Herein are the details regarding the ranges for the desirable ratios between the fixed and the variable components of the Executive Officers’ compensation:

 

Executive Officers

 

Fixed
Component
(Base Salary and
Fringe Benefits)

 

Variable Components
(Bonuses and Equity-
Based)

 

Executive Chairman of the Board, CEO

 

20% - 50%

 

50% - 80%

 

Executive Officers (other than Chairman of the Board, CEO)

 

20% - 50%

 

50% - 80%

 

Board Members

 

50% - 75%

 

25% - 50%

 

 

The ratios stated in the table above represent the optimal desired compensation mix; however the actual ratios may vary based on performance in a given year.  For example, in a year with

 

3



 

no or only a limited bonus was granted, the ratio between the fixed compensation and the total compensation may be higher than stated above.

 

5.               Internal Company Comparison

 

Upon approval of compensation for an Executive Officer, the Authorized Organs will examine, inter alia: the ratio between the salary of the Executive Officer and the average and median salary of the other employees of the Company (including contract workers employed with the Company); and the ratio between the total cost of employment of the Executive Officer and the average and median total cost of employment of the other employees of the Company (including contract workers employed with ICL); and the influence of such ratios on the working relations in the Company, taking into consideration the Company’s size, nature of operations and the market in which it operates.

 

The following table shows the current ratio, on the date of the adoption of this Policy, between the total cost of employment of ICL’s CEO and the average and median total cost of employment for all other ICL employees (i.e., only the employees of the public Company, including the contract workers), and the current ratio between the average cost of employment of serving Executive Officers (other than the CEO) and the average and median cost of employment for all other ICL employees, assuming payment of the Target Bonus (as defined below) for 2013 and assuming the value of the equity-based compensation for 2013 for one vesting annum as estimated at the date of grant, according to the latest stock option plan in effect):

 

Position

 

Ratio to average of other
employees’ Total Compensation

 

Ratio to median of other
employees’ Total Compensation

 

CEO

 

About 12.15

 

About 25.48

 

Executive Officers (other than CEO)

 

About 5.50

 

About 3.88

 

 

6.               Fixed Compensation

 

6.1                                Base Salary

 

Base Salary may vary between the Executive Officers in ICL and shall be determined individually for each Executive Officer according to some or all of the following considerations:

 

4



 

·                   The Executive Officer’s educational background, qualifications, skills, specializations, professional and business experience, performance and achievements;

 

·                   The Executive Officer’s position and scope of responsibility;

 

·                   The Executive Officer’s previous compensation agreements; and

 

·                   Comparable compensation agreements within the Company.

 

Competitive Market Analysis - In addition to the considerations above, and to ensure that the Company offers Executive Officers competitive compensation packages and so that it may recruit and retain professional and skilled Executive Officers, Company will seek to establish a base salary that is competitive with the base salaries paid to Executive Officers in similar positions in both foreign and local companies, as appropriate for each position (“ Peer Group Companies ”). To that end, the Company shall utilize comparative market data relating to compensation packages in Peer Group Companies.

 

Peer Group Companies will be selected according to some or all of the following criteria:

 

·                   Foreign Peer Group Companies :

 

·              Large and medium companies in the U.S. and Europe, with revenues and/or market capitalization within a reasonable range of ICL’s revenues and/or market capitalization;

 

·              Direct business competitors of ICL or companies which operate in similar markets in which ICL operates; and

 

·              Companies competing with ICL for executive candidates in relevant positions.

 

·                   Local Peer Group Companies:

 

·              Large local companies with similar revenues/market capitalization to that of ICL.

 

The base salary of the ICL Executive Officers (excluding the salary of the Executive Chairman of the Board) shall be reviewed in relation to the foreign peer group (the “ Benchmark ”), with the target for the base salary of such Executive Officers not exceeding the 75th percentile of the Benchmark.(1) As of the date of the adoption of this

 


(1)          It should be noted that the peer group companies included in the Benchmark do not include local peer group companies since, as of the date of this Policy, there are no local companies that have a similar business volume to that of the Company, according to the parameters listed above (turnover and market capitalization).

 

5



 

Policy, the 75th percentile of the Benchmark indicates the following amounts for an annual base salary:(2)

 

·                   CEO: about $1,244 thousand

 

·                   Other Executive Officers: about $749 thousand

 

Deviation from the aforementioned range may be possible under special circumstances with the approval of the Authorized Organs, and will not be considered to be a deviation from this Policy.

 

The maximum annual base salary of the Executive Chairman of the Board shall be up to $1,000 thousand. It should be noted that on the date of the adoption of the Policy, the base salary of the Executive Chairman of the Board was not reviewed in relation to the foreign peer companies since an equivalent role is unusual among these foreign peer group companies.

 

Annual Base Salary Review - The Authorized Organs are entitled to conduct an annual review of the base salary of Executive Officers. In the aforementioned annual review all or some of the following factors will be considered:

 

·                   The position of the Executive Officer;

 

·                   The scope of responsibility of the Executive Officer ;

 

·                   The relevant achievements of the Executive Officer;

 

·                   The professional and business experience of the Executive Officer;

 

·                   The previous salary agreements signed with the Executive Officer;

 

·                   Salary levels for comparable positions within the Company;

 

·                   The size of the Company and the nature of its operations;

 

·                   The macroeconomic environment in which the Company operates; and

 

·                   Competitive market analysis (as described above).

 

The base salary includes cash benefits (such as convalescence pay and welfare package) and it may be linked to the Israeli consumer price index or to other equivalent index.

 


(2)          It should be clarified that these amounts are for full time (100%) positions.

 

6



 

6.2                                Sign-on Bonus

 

For the purpose of recruiting qualified Executive Officers, the Authorized Organs are entitled to approve to grant an Executive Officer a sign-on bonus, as an incentive to join the Company. The sign-on bonus shall be granted, as long as the Compensation Committee and the Board believe that due to the specific circumstances, there is a special need for it to be granted in order to recruit the specific Executive Officer. The amount of the sign-on bonus shall be determined while considering, among others, the market conditions, the specific circumstances involved in the hiring of such Executive Officer, including circumstance with respect to a relocation from one country to another, and such other criteria as specified in Section 6.1 above with respect to base salary. In addition, consideration may be given to the compensation of the Executive Officer if it is likely that it was denied from the Executive Officer by his previous employer due to joining the Company. In the event the Executive Officer leaves the Company within twenty-four (24) months of joining the Company, the Executive Officer may be required to return such sign-on bonus to the Company.

 

6.3                                Fringe Benefits

 

Executive Officers in the Company may be entitled to fringe benefits as mandated or afforded by law or that are customary, and for which the Authorized Organs deem advisable to provide a competitive compensation package. Such benefits may include, inter alia:

 

·                   Annual vacation as is customary;

 

·                   Annual sick leave as is customary;

 

·                   Company contributions to pension funds and disability and life insurance policies;

 

·                   Contributions to an advance study fund or other savings plans.

 

Additional non-cash benefits may include, inter alia, the following benefits (“ Additional Benefits ”):

 

·                   The use of a Company car or a car allowance;

 

·                   Providing communication packages, including telephone and a computer with internet access;

 

·                   Subscriptions to relevant professional literature related to the Executive Officer’s position;

 

·                   Life insurance;

 

·                   Health insurance;

 

·                   Tax gross-ups. It should be clarified that a new Executive Officer or an Executive Officer whose employment agreement at the date of the adoption of the Policy

 

7



 

does not include eligibility for tax gross-ups for car and an advance study fund shall not be given tax gross-ups;

 

·                   Trade union membership fees (Bar Association, Institute of Certified Public Accountants etc.); and

 

·                   Financial/Tax planning in the event of relocation from one country to another.

 

The value of the aforementioned Additional Benefits shall not be higher than 30% of the base salary of the Executive Officer.

 

Executive Officers in the Company are also entitled to reimbursement of expenses related to the fulfillment of their duties, as is customary in the Company. When applicable, Company’s Executive Officers may be entitled to relocation expenses and benefits, and pension consulting expenses.

 

6.4                                In the event that the Executive Officer provides services to the Company as a contractor or via a personal management company, the fees paid to such Executive Officer or personal management company shall reflect the fixed compensation elements (plus applicable taxes such as Value Added Tax), in accordance with the principles of this Policy.

 

7.               Annual Cash Bonus

 

Executive Officers in the Company may be entitled to a cash bonus in accordance with an annual bonuses plan (the “ Annual Bonuses Plan ”). The Annual Bonuses Plan aims to align between the compensation of the Executive Officers and the Company’s annual long-term goals while focusing, inter alia, on the specific goals that shall be defined for each Executive Officer.

 

7.1                                Indicators and Targets for the Annual Bonuses Plan

 

Quantitative and qualitative performance indicators will be used to determine bonus eligibility. The indicators and targets by which Executive Officers’ performance will be measured , will consist of up to three measurable categories (the “ Measurable Categories ”), such that with respect to each category the objectives to be included in it and the weight of each category of the total bonus amount shall be determined and a qualitative category (the “ Qualitative Category ”), all as described below:

 

Measurable Categories :

 

·                   ICL’s Financial Measures (based on unified audited annual financial statements) - will include an element of net profit of ICL that shall be measured in comparison to the average net profit of ICL for the preceding 3 years, and an element of operating profit of ICL that shall be measured in comparison to the average operating profit of ICL for the preceding 3 years.

 

8



 

The relative weight of this category out of the Target Bonus (as defined below) will be as follows:

 

·                   Executive Chairman of the Board: 100%

 

·                   CEO: 50% - 70%

 

Under the specific annual bonus plan for the current ICL CEO, Mr. Stefan Borgas, for the years 2013 to 2015, the weight of the ICL Financial Measures shall constitute 60% of the Target Bonus, with half of the ICL Financial Measures constituting the ICL net profit element and the other half constituting the ICL operating profit element.(3)

 

·                   Executive Officers that are not a segment CEO: 50% - 70%

 

·                   Segment CEO: 25% - 40%

 

·                   Segment Financial Measures (based on audited annual financial statements) — the formula related to Executive Officers who are segment CEOs will also include an element of operating profit of the relevant segment which shall be measured in comparison to the average operating profit of such segment for the preceding 3 years.

 

The relative weight of this category out of the Target Bonus will be 25% - 40%.

 

In the event of a merger or acquisition of a company or activity (“ Transaction ”), which results in additional annual revenues that exceed 10% of the revenues of ICL or the relevant segment (as applicable), in the year of the Transaction, a one-time adjustment of the financial measures of ICL and the financial measures of the relevant segment shall be made in the four quarters that begin with the quarter in which the Transaction was closed, in a manner in which the financial results of the Transaction are not taken into account for the calculation of the bonus of the Executive Officers.

 

·                   Specific Personal and Measurable Key Performance Indicators (KPIs) - will be determined by the Compensation Committee and the Board at the beginning of each year for all Executive Officers on an annual basis. The KPIs will be defined so that they are objectively measurable, and will be determined according to the role and the specific areas of responsibilities of the Executive Officer. In addition,

 


(3)          It is clarified that in this Policy, where the specific condition of the annual bonus plan of ICL’s current CEO, Mr. Borgas, are detailed, then such specifics refer to his current annual bonus plan for the years 2013 to 2015. Such annual bonus plan may be changed within the framework of the provisions of this policy, pursuant to, if required, Authorized Organs’ approval.

 

9


 

the KPIs will be determined in accordance with the goals set in ICL’s strategic long-term plan. The KPIs may be financial or non-financial. For example, the KPIs may include strategic project delivery milestones, quantitative targets related to elements of working capital, cash flow, cost structure, safety and environmental performance, economic profit, new product development targets, human resources development targets, integration of acquired businesses, etc.

 

The relative weight of this category out of the Target Bonus will be as follows:

 

·                   CEO: 20% - 40%

 

Under the specific annual bonus plan for the current CEO of ICL, Mr. Borgas, the weight of the specific, personal and measurable KPIs will constitute 30% of the Target Bonus. These measures shall be determined by the Compensation Committee and the Board at the beginning of each year in accordance with the strategic plans of ICL, its business and financial situation as well as the financial circumstances in ICL’s business environment. The measures shall be selected from the following list: achieving strategic objectives selected from ICL’s strategic plan, completing strategic project milestones, achieving efficiency and improvement objectives as well as reducing costs, meeting objectives related to working capital, cash flow objectives, improving capital structure, meeting safety and environmental objectives, economic profit objectives, increasing sale volume objectives, budget objectives, compliance program objectives, human resources development objectives and merger, acquisition and integration objectives.

 

·                   Executive Officers who are not segment CEOs: 20% - 40%

 

·                   Executive Officers who are segment CEOs: 25% - 40%

 

·                   The bonus plan of the Executive Chairman of the Board shall not include KPIs.

 

Qualitative Category :

 

·                   Management Capabilities Evaluation - In addition to the measurable categories, a qualitative category that also includes performance indicators will be determined at the beginning of each year, for that year, and that are based on a number of parameters that measure the aforementioned personal management capabilities as shall be determined, and a qualitative evaluation by the Executive Officer’s superiors with regard to the measure of improvement of his management capabilities and performance regarding those same parameters (an evaluation that shall be submitted to the Compensation Committee and the Board for approval) (“ Management Capabilities Evaluation ”). The relative weight of the Management Capabilities Evaluation indicator of the Target Bonus shall be up to 10%. The bonus plan of the

 

10



 

Executive Chairman of the Board shall not include any Management Capabilities Evaluation indicators.

 

Under the specific annual bonus plan for the current ICL CEO, Mr. Borgas, the weight of the Management Capabilities Evaluation indicators shall constitute 10% of the Target Bonus.

 

Except in the case of the CEO, the Authorized Organs are entitled to adjust the targets determined for a given year, during the year, in the event of a significant and irregular change in the business environment of the Company or a significant statutory change.

 

7.2                                General Bonus Threshold

 

No bonuses will be paid with respect to the Measurable Categories, in a specific year, if the net profit of ICL for that year (after adjustments in respect of a Transaction, as described above) is not at least equal to 60% of the average net profit of ICL for the preceding 3 years (the “ General Threshold ”).

 

7.3                                Target Bonus

 

The target bonus (“ Target Bonus ”) for each year shall reflect the bonus amount for performance levels of 100% (i.e. achieving 100% of targets) in a given year, and will generally be calculated according to the average bonus paid to the Executive Officer for the 3 preceding years (prior to any deferral of bonus, as described in Section 7.7 below). In specific circumstances where such calculation is not possible, since the Executive Officer has not served in the Company for the preceding 3 calendar years or has served in a different position, the Target Bonus will be calculated according to the average bonus of the Executive Officer for a period that is less than the three preceding years (prior to any deferral of bonus). For the first year in which an Executive Officer is entitled to participate in the Annual Bonuses Plan (for a specific position), such Executive Officer’s Target Bonus shall be determined based on the average bonus of other equivalent Executive Officers in a similar position (or previous Executive Officers in the same position) during the previous calendar year (prior to any deferral of bonus).

 

In circumstances where the General Threshold is not met for one or more of the relevant preceding years mentioned above, applicable adjustment will be made by the Authorized Organs in order to calculate the Target Bonus.

 

With respect to the Target Bonus of the current ICL CEO, Mr. Borgas — since Mr. Borgas began serving as the ICL CEO in September 2012, it was not possible to calculate his Target Bonus based on the average bonus of the preceding 3 years.

 

11



 

Therefore, Mr. Borgas’s Target Bonus for 2013 was calculated based on the actual bonus granted to the former CEO of ICL in 2012 (NIS 4,788 thousand).(4) Mr. Borgas’s Target Bonus for 2014 will be determined according to the amount of the actual bonus granted to him for 2013.  Mr. Borgas’s Target Bonus for 2015 will be determined as an average of the bonuses actually granted to him for the years 2013 and 2014.

 

In addition, regarding the Target Bonus of the Executive Chairman of the Board, if appointed: Since as of the date of the adoption of this Policy there is no such Executive Chairman of the Board which serves in the Company other than via management services provided by a controlling shareholder of the Company, and until an Executive Chairman of the Board is appointed, it will not be possible to determine his Target Bonus based on the average of the three preceding calendar years. Therefore, the Target Bonus of the Executive Chairman of the Board for the first year of his term (or part thereof, as applicable and in a relative manner) shall be determined to be a maximum amount of up to $1,000 thousand. For each subsequent year, the target bonus will be calculated, in general, according to the average bonus paid to the Executive Chairman of the Board of Directors for the three preceding calendar years (prior to the deferral of any bonus, as described in section 7.7 below). As long as the period of employment of the Executive Chairman of the Board is less than three calendar years, the Target Bonus will be calculated according to the average bonus of the Executive Chairman of the Board for a period that is less than aforementioned period (prior to the deferral of any bonus) (similar to the manner in which the Target Bonus for Mr. Borgas was determined, as aforesaid).

 

7.4                                Maximum Bonus Payout

 

The maximum bonus payout for any given year shall not exceed the lesser amount between; (a) 150% of the Executive Officer’s Target Bonus for such year, or (b) 300% of the annual base salary of the relevant Executive Officer for such year.

 

7.5                                Calculation of the Annual Bonus

 

The annual bonus for each Executive Officer will be calculated separately for each Measurable Category and for the evaluation indicators by multiplying the performance level for each category of the Target Bonus and the relative weight of the category. The bonus payment for the Measurable Categories will be set by using 2-3 performance levels which may include a minimum threshold performance level, a

 


(4)          This Target Bonus is prior to effecting any deferral of any bonus, as described in Section 7.7 below. For the avoidance of doubt, in this Section, the calculation regarding bonuses to be paid to the current CEO in accordance with the annual bonus plan is prior to effecting any bonus deferral.

 

12



 

target performance level and a maximum performance level, with a linier gradient between each and every relevant performance levels.

 

The Annual Bonuses Plan for the current Executive Officers including Mr. Borgas includes, with respect to the ICL Financial Measurements category, a minimum threshold of 60% (under which no bonus shall be granted) and a maximum threshold of the lesser amount between (a) 150% of the Target Bonus or, (b) 300% of the annual base salary in the same year (above which the bonus shall no longer be increased and will be set as the maximum bonus to be paid). The eligibility between these two thresholds will be calculated with a linear rate.

 

7.6                                Discretion of the Board to Reduce the Bonus

 

The Board shall have the discretion to reduce the amount of the annual bonus of an Executive Officer in any given year, based on circumstances determined by the Board.

 

7.7                                Deferral of Bonus

 

The portion of the annual bonus for any Executive Officer which exceeds 120% of the Target Bonus (the “ Excess Bonus ”), will not be paid in cash but rather converted into restricted stock or restricted stock units (based on the average ICL share price for the previous 30 trading days prior to the Board’s approval of the bonus), and that will be subject to a two year restriction period during which they may not be exercised. Notwithstanding, if the Excess Bonus is less than $2,500, the aforesaid in the this Section shall not apply and the Excess Bonus shall be paid in cash.

 

Matching Bonus - In order to encourage Executive Officers to improve the alignment of their compensation with the interests of Company’s shareholders, the Company will offer Executive Officers to voluntarily defer a larger portion of their annual bonus (up to an additional 30% of the cash bonus amount), according to the average price of ICL’s share in the 30 trading says that precede the date of the approval of the grant by the Board, and to convert it into restricted stock or restricted stock units (the “ Additional Equity Award ”). The Additional Equity Award, will also be subject to a two year restriction period during which it may not be exercised. In this case the Company will grant an additional amount to the Executive Officers, which shall match the amount of the Additional Equity Award at a ratio of 1:0.5 (the Company will grant 0.5 additional restricted stock or restricted stock units for each unit of an Additional Equity Award) (“ Matching Equity Awards ”). The Matching Equity Awards shall be granted in the event that the Total Shareholder Return (“ TSR ”) for the two calendar-year period, starting from the end of the calendar year in which the annual bonus was granted, is equal to at least 80% of the average TSR of the Foreign Peer Group Companies for such period.

 

13



 

Any restricted stock or restricted stock units mentioned above in this Section 7.7, will be entitled to participate in dividend distributions by the Company (or will be entitled to dividend equivalent payment, if not eligible under law to participate in a dividend distribution), during the restriction period and until exercised. However, any such dividend or abovementioned dividend equivalent payment will be paid to the relevant Executive Officer only after the entire restriction period has lapsed.

 

7.8                                Compensation Recovery (“Claw-Back”)

 

Each Executive Officer will be required to refund any part of the annual bonus paid to him in excess based on financial results that were proved to be inaccurate and which were restated in the unified financial statements of the Company, during the 4 years following the approval of the annual bonus by the Authorized Organs. The Authorized Organs shall determine the timing, manner and terms of the repayment of the bonus amount. It should be clarified, that a restatement due to changes in applicable law, regulations or accounting standards shall not be deemed as a restatement pursuant to which the provisions of this Section apply.

 

8.               Equity-Based Compensation

 

The Company may, from time to time offer(5) to its Executive Officers to participate in an equity-based compensation plan which aim is to retain the Executive Officers in their positions for the long-term while creating compensation that aligns, for long term, the benefit of the Executive Officers with the benefit of the shareholders of the Company. The scope of the equity-based compensation granted to an Executive Officer shall be determined in accordance with each Executive Officer’s position, areas of responsibility, achievements and skills. Such equity-based compensation shall be subject to the following criteria:

 

·                   Equity-based compensation may be granted in the form of stock options, restricted stocks, restricted stock units or any other equity based compensation instruments (“ Equity-Based Awards ”). Vesting and/or release from restriction of restricted shares and restricted share units may be subject to the performance of the Company and/or of the Executive Officer.

 

·                   Each Equity-Based Award shall be subject to a minimum vesting period of three (3) years (in equal annual tranches) and subject to the continued service of the Executive Officer in the Company. The terms of the Equity-Based Awards may include provisions for acceleration of vesting in certain events and corporate transactions in the Company, such

 


(5)          As of the date of the adoption of this Policy, the Company grants equity-based compensation every 3-year period. However, the Company intends to move to an annual, or other frequency, grants mechanism.

 

14



 

as in the event of a merger, consolidation or acquisition of the Company or of its assets (as these terms shall be defined in the applicable equity-based compensation plan).

 

·                   The exercise price of any stock options will be determined according to the average closing price of ICL’s share on the Tel Aviv Stock Exchange Ltd. during 30 day trading period preceding the date of the approval of grant of options by the Board. The exercise price may be linked to the Israeli consumer price index. The exercise price may include an adjustment for dividend if paid by the Company.

 

·                   Equity-Based Awards shall have a maximum term of no more than seven (7) years from the date of grant.

 

·                   Company shares deriving from all effective Equity-Based Awards for executive Officers will constitute no more than 5% of the Company’s issued and paid-up share capital over a 10-year period.

 

·                   On the date of grant, the value of all Equity-Based Awards granted to an Executive Officer shall not exceed (based on accepted valuation methods), for one vesting annum the following amounts:

 

·                   Executive Chairman of the Board — 180% of annual base salary;

·                   CEO — 200% of annual base salary;

·                   Other Executive Officers — 150% of annual base salary.

 

The aforementioned restriction will not include the deferred portion of a cash bonus which was converted into restricted stock or restricted stock units, or any Additional Equity-Based Awards or Matching Equity Awards, as described in Section 7.7 above.

 

In addition, regarding any specific Equity-Based Award, the Authorized Organs are entitled to consider the determination of a cap for the exercise value of the Equity-Based Awards.

 

The Company’s policy, in Israel, is to provide Equity-Based Awards pursuant to the “capital gains” route, as defined in Section 102 of the Income Tax Ordinance.

 

9.               Retirement arrangements

 

9.1                                All Executive Officers shall be entitled to the release of funds accumulated in their favor and on their name in designated provident and pension funds. Additional funds shall be paid to certain Executive Officers in Israel, if there will be a difference between the amounts actually accumulated in such designated funds and an amount equal to the product of the last known base salary at the date of termination and the number of years of employment in the company.

 

15



 

9.2                                Retirement Compensation

 

Company’s Executive Officers shall be entitled to retirement compensation of up to one monthly base salary of the Executive Officer for each year of employment with the Company.

 

9.3                                Advance Notice

 

Company’s Executive Officers shall be entitled to an advance notice period upon termination of employment as specified in the table below (“ Advance Notice Period ”), and as shall be determined in the applicable employment agreement (or any amendment thereof).

 

Executive Officer

 

Advance Notice Period

Chairman of the Board, CEO

 

Up to 12 months

Other Executive Officers

 

Up to 6 months

 

During the Advance Notice Period, the Executive Officer may be required to continue his employment at the Company. During the Advance Notice Period, the employee-employer relations between the Company and the Executive Officer shall be in effect and therefore the Executive Officer may be entitled to all of his compensation terms, including the annual bonus (in such case, the bonus formula will not include specific, personnel and measurable KPIs and evaluation indicators which will not be relevant for measuring performance regarding a period during which the Executive Officer does not actually provide services to the Company; but will only include such ICL financial measures and/or segment measure, as applicable).

 

9.4                                Transition Period and Non Compete

 

In addition, Company’s Executive Officers may also be entitled to a transition period of up to 6 months (“ Transition Period ”) during which the Executive Officer may be entitled to a base salary and to fringe benefits. The Executive Officer may be subject to non-compete obligations during such Transition Period. The Transition Period may apply only to an Executive Officer that was employed by, or provided services to, the Company for at least five (5) years and that was not terminated for “cause” or under circumstances justifying, according to the Authorized Organs’ judgment, revocation of the Executive Officer’s severance rights. The Transition Period shall be determined based on the following considerations: the period of service or employment of the Executive Officer, the conditions of his term or employment during this period; Company’s performance during such period, the Executive Officer’s contribution to the achievement of Company’s objectives and performance and the particular circumstances of the termination of employment or service. The entitlement to a transition period as provided by this Section shall not be commonplace, and it will be included in Executive Officer’s terms of service pursuant to the provisions of this

 

16



 

Section only if the Authorized Organs see a special necessity under the specific circumstances in order to recruit or retain an Executive Officer.

 

9.5                                Termination Grant

 

In addition to the above, the Authorized Organs may determine that the Executive Officer is to be granted a termination bonus (the “ Termination Grant ”), provided the Executive Officer was employed by, or provided services to, the Company for at least one (1) year. Such Termination Grant shall be determined according to the following considerations: the period of service or employment of the Executive Officer, the employment or service terms during this period, Company’s performance during such period, the Executive Officer’s contribution to the achievement of Company’s objectives and its performance, and the particular circumstances of termination of employment or service. A Termination Grant to any Executive Officer will not exceed an amount equal to 50% of the Executive Officer’s annual base salary times the average ratio between the actual calculated bonus (prior to any deferral of bonus, as described in section 7.7 above) and the Target Bonus, during the three (3) years preceding termination of employment.

 

For example, if during the last 3 years of his employment with ICL, an Executive Officer was granted annual bonuses at a rate of 100%, 110% and 120% of his Target Bonus, and assuming that such Executive Officer’s annual base salary is 1,000, then, said Executive Officer’s Termination Grant shall not exceed 550, which is equal to 50% of the multiple of 110%, (the average ratio between the actual paid bonuses (prior to any deferral of aforementioned grant in section 7.7 above) and the Target Bonus during the three (3) years preceding termination) and 1,000 (his annual base salary).

 

An entitlement to a termination grant as provided by this Section shall not be commonplace, and it will be included in Executive Officer’s terms of service pursuant to the provisions of this Section only if the Authorized Organs see a special necessity under the specific circumstances in order to recruit or retain an Executive Officer.

 

9.6                                Termination Grant Resulting From a Change of Control

 

In addition, Executive Officer in the Company may be entitled to a one-time payment equal to a base salary of up to one year upon his termination of employment by the Company, or in the case of a tangible damage to the Executive Officer’s status and/or his terms of employment in the Company during a 24-month period following the consummation of a change in control of the Company (as defined by the Authorized Organs or in a relevant employment document or plan). The entitlement to such payment may be determined in the applicable Executive Officer’s employment agreement (or any amendment thereof). Such arrangement allows to retain the

 

17



 

Executive Officers and provide them with certainty in a manner which encourages their support of potential transactions that may be beneficial to the shareholders.

 

9.7                                Acceleration of Equity-Based Compensation

 

The terms of the equity-based compensation may include provisions for acceleration of vesting in certain circumstances of termination of employment by the Company or due to a change in control.

 

9.8                                The total amounts paid to Executive Officers according to Sections 9.2 to 9.5 shall not exceed an amount equal to twenty four (24) monthly base salaries, except with regard to few certain Executive Officers who serve in the Company for many years, which in accordance with Company’s previous commitments towards them, they are entitled to retirement compensation in amounts exceeding the aforementioned cap.

 

10.        Compensation of Board Members

 

The compensation of the Board Members (“ Directors ”), may comprise of remuneration for participation in meetings and/or annual compensation and/or equity-based compensation (as described below), all subject to the relevant laws.

 

In addition, the Company may reimburse or cover its Directors’ certain expenses (including travel expenses) incurred while attending meetings of the Board and its committees or for providing other services to the Company in their capacity as Directors.

 

Directors may be eligible to participate in the Company’s equity-based compensation plans. On the date of the grant, the value of Equity-Based Awards granted to a Director, shall not exceed (based on accepted valuation methods) per one vesting annum, the amount of $150 thousand. The terms of Equity-Based Awards for Directors may include a provision for acceleration of vesting upon termination, under certain circumstances.(6)

 

Directors that fill executive roles (for example, an Executive Chairman of the Board) will be subject to the provisions of this Policy that applies to Executive Officers (as defined above).

 

11.        Management Fee

 

Subject to approval by the Authorized Organs, the Company may pay its controlling shareholders (as such term is defined under Israeli law) annual management fees, which will include compensation for services provided to the Company by Executive Officers, including

 


(6)          It should be noted with respect to the aforesaid that the termination of service and re-appointment of a Director for an additional term shall not be viewed as termination of services.

 

18



 

members of the Board, that are employed by, or providing services to, such controlling shareholder. (7)

 

12.        Exculpation, Indemnification and Insurance

 

The Company may exculpate its Executive Officers (including its Directors) from a breach of duty of care, and may indemnify its Executive Officers (including its Directors) for any liability and expense that may be imposed on them, to the extent permitted by applicable law. The Company may provide coverage through liability insurance to its Executive Officers (including its Directors). The maximum aggregate coverage for any such insurance policy will not exceed $350 million; the premiums paid for such insurance policy shall not exceed the amount of $1.6 million per annum, and the deductibles shall be in accordance with acceptable market terms.

 


(7)               An agreement with the controlling shareholder of the Company for the provisions of management services for annual management fees was approved by the Company’s Authorized Organs (including its general meeting) in October 2011. The details of the agreement are included in a report published by the Company on September 15, 2011 (reference no. 2011-01-27698).

 

19




Exhibit 10.6

 

Agreement

 

Made and signed in Jerusalem on July 8, 2012

 

Between:                            The Government of Israel on behalf of the State of Israel

represented by Michal Abadi-Boiangiu, the accountant general

and Mr. Avi Gabay, senior deputy accountant general

of 1 Kaplan Street, Jerusalem

(hereinafter – the State )

 

of the first part

 

And:                                                    The Dead Sea Works Ltd.

represented by Mr. Dani Chen, CEO, Dead Sea Works, Ltd.

and Mr. Noam Goldstein, manager , Meshivim Division

(hereinafter — DSW )

 

Of the second part

 

Whereas                                on January 1, 2012 government resolution number 4060 was passed in the matter of “Implementing the permanent protection project at the Dead Sea and its financing and increasing the royalties paid to the state” (hereinafter — the Government Resolution ), which contains this solution agreed upon between the Ministry Finance and DSW; and

 

Whereas                                the Government Resolution states that further to the announcement of the prime minister, the minister of the interior and the minister of finance, in accordance with the powers vested in them under the Planning and Building Law, 5725-1965 (hereinafter the Planning and Building Law ), the project, including the new pumping station, is an infrastructure project of national importance which will be promoted in the Committee for National Infrastructures (hereinafter — CNI ) in accordance with the schedules in the Planning and Building Law; and

 

Whereas                                The Government Resolution, in accordance with section 76B(C) of the Planning and Building Law, empowers DSW to serve as the promoter for the purpose of advancing the planning processes of the full harvest component and the new pumping station in the CNI and it has instructed the CNI chairman and DSW to make every effort so that the plan required for implementing this resolution will become effective by June 30, 2013; and

 

Whereas                                in the Government Resolution, the government determined that it sees no need at present for making additional changes in its specific fiscal policy in connection with

 

[stamp]

 

[stamp]

Accountant General’s Division

 

Dead Sea Works Ltd.

Ministry of Finance

 

/s/ Noam Goldstein

/s/ Avi Gabai

 

 

 

1



 

mining the minerals at the Dead Sea, including their commercial exploitation and, therefore, for the present, it will not initiate, and it will oppose, as the case may be, bills in this matter; and

 

Whereas                                the Government Resolution has charged the accountant general at the Ministry of Finance with reaching a detailed agreement with DSW in accordance with the outline agreed upon between the parties;

 

The following has therefore been agreed and stipulated between the parties:

 

1.               Preamble and appendices

 

1.1              The preamble and appendices to this Agreement constitute an integral part hereof.

 

1.2              The section headings are designed solely for the sake of convenience and may not be used to interpret the Agreement.

 

2.               Appendices to this Agreement

 

2.1              Appendix A — the components of the full harvest project, which constitute both an investment in this project and the current expenses until the end of the franchise period.

 

2.2.           Appendix B — accompanying appendix.

 

2.3.           Appendix C — location and measurement method of the water level in pool 5.

 

3.               The project

 

3.1              The project is a project for the full harvest of the salt in pool no. 5, which includes the components specified in Appendix A to the Agreement (hereinafter — the Project ).

 

3.2              As a result of the Project, from the beginning of 2017, the water level in pool no. 5 will not rise above a height of +15.1 in the Dead Sea Works network.

 

3.3              it is agreed that the height of the embankments on the western shore will not rise, under any circumstances, above a height of +16.5 in the Dead Sea Works network, all in accordance with the decision of the relevant planning institution.

 

3.4              It is agreed that the initiation and promotion of the Project in the CNI or in any other

 

[stamp]

 

[stamp]

Accountant General’s Division

 

Dead Sea Works Ltd.

Ministry of Finance

 

/s/ Noam Goldstein

/s/ Avi Gabai

 

 

 

2



 

relevant planning institution, its planning and implementation in accordance with the provisions of this agreement, are in the sphere of responsibility and handling of DSW.

 

3.5              If there should be any substantive deviation from the schedules for implementing the Project as a result of non-approval of the Project plan in the planning institutions, which derived from planning requirements that deviate from that stated in Appendix A or as a result of judicial decisions that caused a delay of at least one year in making the Project plan effective in the planning institutions, notwithstanding the fact that DSW fulfilled all the obligations, the instructions and the rules specified and required by the CNI, the rise in the water level beyond that set forth in section 3.2 above, or the rise in the height of the embankments on the western shores as a result of this, beyond that stated in section 3.3 above, will not be deemed a breach of this Agreement, provided that these rises were given approval by the planning authorities and DSW will bear all the costs and damages that will be caused as a result of said rises. Nothing stated will constitute support for DSW’s demand to raise the level, to raise the height of the embankments or to prevent the State from opposing this in the relevant planning committee. DSW will not be given any compensation for deviating from the schedules for implementing the Project.

 

4.               Funding

 

4.1              In accordance with DSW’s calculation, the estimated comprehensive cost of the Project, as of October 2010, is NIS 3.8 billion, pursuant to a 7% rate of capitalization. This amount is linked to the index (October 2010). DSW will bear the amount of NIS 3.04 billion, linked to the index (October 2010) and bearing annual interest at the rate of 7% (as of January 1, 2012). The State will bear, at the most, the cost of NIS 0.76 billion, linked to the index (October 2010) and bearing annual interest of 7% (as of January 1, 2012). If the cost of the Project decreases in relation to the estimate, the State’s participation will decrease accordingly.

 

4.2              In the event of a joint infrastructure that is meant to serve the Project and an additional project (e.g., the pumping station) the division of costs between the two projects will be determined by consent between DSW and the State, and for this purpose each party will provide the relevant information in its possession. It is clarified that nothing in the aforementioned will increase the amount of the State’s participation in the Project.

 

4.3              The State’s participation in funding the Project will be as follows: DSW will submit to the State, up to 45 days from the end of each calendar year, a report audited by an outside accountant of DSW, itemizing the Project’s costs up to the end of the year that has passed, in accordance with the components of the Project specified in Appendix A. The payment per demand submitted to the State by DSW will not exceed 20% of the total cumulative expenses that were received for an invoice or billing order (including

 

[stamp]

 

[stamp]

Accountant General’s Division

 

Dead Sea Works Ltd.

Ministry of Finance

 

/s/ Noam Goldstein

/s/ Avi Gabai

 

 

 

3



 

internal billing orders) and have been registered in DSW’s account books by the end of the calendar year that passed, and for which no bill was submitted in the past. The State will pay to DSW an advance in the amount of 75% of the payment demand within 30 days from the date of the demand. Within 60 additional days, in which the approval of the Dead Sea Preservation Government Company Ltd. (hereinafter — DSPC ) and the accountant general will be given for the implementation of actions by DSW, the State will pay the balance of the payment demand. To the aforementioned payments will be added VAT, if transfer of the amount to DSW will be subject to VAT.

 

4.4              If it should transpire that a certain amount was paid by the State for an expense that does not belong to the Project, or that was not debited in DSW’s account books (including a debit for which a credit was later made), DSW will refund to the State the excess amounts paid by the State to DSW within 14 business days from the date of the demand, with the addition of accountant general’s interest. To preclude doubt, it is clarified that payments demands will be submitted by DSW after reduction of the amounts for which credit notes were received during the period of the payment demand, including credit notes relating to prior payments, if any.

 

5.               Deviations from the Project cost

 

5.1              An increase in the Project costs, as stated in section 4.1, which do not arise from decisions of the planning committee, as stated below in section 5.2, will be borne in full by DSW and paid thereby.

 

5.2              If the planning committees make a planning decision that constitutes a deviation from the cost of the Project, as stated in section 4.1, the State will participate in funding 20% of the additional cost beyond a deviation of NIS 100 million from the cost of the Project that was approved by the State (i.e., NIS 3.8 billion) up to a deviation of NIS 1,000 million. As stated, for a deviation of up to NIS 100 million no payment will be made, for a deviation of NIS 200 million the amount of NIS 20 million will be paid and for a deviation of NIS 1,000 and above the amount of NIS 180 million will be paid, and no more.

 

5.3              It is clarified that the provisions of section 5.2 will also apply with regard to planning deviations in the matter of the new pumping station, compared with the plan to be agreed with the DSPC, which affect the Project costs, and solely with regard to the effect on the Project costs.

 

[stamp]

 

[stamp]

Accountant General’s Division

 

Dead Sea Works Ltd.

Ministry of Finance

 

/s/ Noam Goldstein

/s/ Avi Gabai

 

 

 

4



 

6.               Monitoring implementation of the Project

 

6.1              Beginning on January 1, 2017, the level in pool 5 will be measured in accordance with that stated in Appendix C.

 

6.2              If, after the date set forth in section 6.1, the level in pool 5 has risen above +15.1 in the DSW network, the State will not pay the relative part of the current expenses connected with the Project for the period in which the level rose as stated, in accordance with the following calculation:

 

{X/365}*Y

 

X –           the number of days in a particular year in which the level in pool 5 rose above the height of +15.1 in the DSW network.

 

{ –              The cumulative amount of the current expenses of the Project in that particular year.

 

6.3              The accounting records of the Project will be implemented in separate dedicated accounts in a manner that enables full management and control of all the Project expenses and in accordance with the provisions of section 1 in Appendix B.

 

6.4              The DSPC will be allowed, in the way and in the manner set forth in Appendix B to this Agreement, to accompany and monitor implementation of the Project planning and engineering. It is agreed that the accompaniment and monitoring to be implemented by the DSPC or any other entity on behalf of the State will not serve to derogate from DSW’s undertakings by virtue of this Agreement or to impose any undertaking or liability whatsoever on the State, either directly or indirectly, beyond those undertaken expressly in this Agreement.

 

6.5              DSW will act in a fully transparent manner and in cooperation with an accountant or other professional examiner on behalf of the State, who will be entitled to conduct an examination of any financial transaction connected with implementation of the Project, including examining the reports submitted by DSW, in accordance with that stated in section 4.2.

 

7.               Royalties

 

7.1              DSW hereby agrees to raise the amount of the royalties to 10% for any quantity of Potassium chloride sold by the company in a given year in excess of 1,500,000 tons. A change in the royalties as stated will apply to a sale in excess of 3,000,000 tons a year, beginning on January 1, 2010, and in excess of 1,500,000 tons a year beginning on

 

[stamp]

 

[stamp]

Accountant General’s Division

 

Dead Sea Works Ltd.

Ministry of Finance

 

/s/ Noam Goldstein

/s/ Avi Gabai

 

 

 

5



 

January 1, 2012. The complaint in the arbitration that is currently underway in the matter of the royalties will be amended accordingly.

 

7.2              If legislation is passed that will change the specific fiscal policy in connection with profits or royalties arising from the mining of minerals at the Dead Sea, including their commercial exploitation (either directly by the State or as a result of the initiatives of others), after the law becomes effective, DSW’s agreement pursuant to section 7.1 of this Agreement will not apply with regard to the period in which additional tax is collected as stated in that legislation. If the aforementioned comes to pass, the subject of raising the royalties that was removed from arbitration due to this agreement will be returned to the arbitration process and will be deliberated in that framework and the two parties will be entitled, in this matter, to make any claim that they could make prior to the signing of the agreement.

 

8.               Miscellaneous

 

8.1              Is clarified that nothing in the aforementioned will serve to impair the discretion of the planning institutions in accordance with their powers pursuant to the provisions of the law and all matters requiring the approval of the planning institutions are subject to provision of the required approvals from the relevant planning institutions and pursuant to any law.

 

8.2              All the fixed tangible assets that will belong to DSW at the end of the franchise, which served it at the time stated for the purpose of implementing the salt harvest and for which the State participated in the funding in the framework of this Agreement, will be deemed fixed tangible assets that will come under the ownership of the State as stated in section 24 of the franchise deed, however, for these assets the Government will pay only 90% of the amount of the payment pursuant to said section.

 

8.3              For the duration of the entire period of implementing the work, DSW must take out and maintain insurance at its own expense, as follows:

 

“Third party legal liability” insurance with a limit of liability of at least NIS 100 million for one event and for the period of the insurance.

 

“Employers’ liability” insurance with a limit of liability of at least NIS 40 million for one employee, for one event and for the period of the insurance.

 

The name of the insured will be extended to include the State and those acting on its behalf, and the contractors and subcontractors.

 

[stamp]

 

[stamp]

Accountant General’s Division

 

Dead Sea Works Ltd.

Ministry of Finance

 

/s/ Noam Goldstein

/s/ Avi Gabai

 

 

 

6



 

The policy will include an explicit clause whereby the insurance will be primary and will proceed any other insurance taken out by the State or in its favor.

 

The policy will include an explicit clause whereby the insurance will not be canceled and will not be reduced unless the insurer gives the State, through DSW, written notification by registered mail 60 days in advance of the date of the cancellation or reduction.

 

It should be noted that taking out the insurance policies or part thereof will not serve to reduce DSW’s liability pursuant to this Agreement or pursuant to law.

 

DSW must fulfill the conditions of all the insurance policies taken out pursuant to this section 8.3, it must notify the insurer and the State in writing of the occurrence of a substantive damage event, cooperate with the State for the purpose of preserving and exercising the rights of the State thereunder, extend the insurance policies each time and as required, so that they will be in effect during the entire period of the work (including if they are extended).

 

8.4              DSW undertakes that the entire Project will be insured at its expense and the cost of the insurance will constitute part of the cost of the Project. The cost of the insurance appears as an expense component in the framework of Appendix A to this Agreement.

 

8.5              That stated in this Agreement does not cancel previous agreements between the parties, unless another specific arrangement in the same matter is set forth in this Agreement. In any conflict between this Agreement and previous agreements between the parties, the provisions of this Agreement will control.

 

In witness whereof we affix our signatures:

 

[stamp] Avi Gabai

 

[stamp] Dead Sea Works Ltd.

Senior deputy accountant general

 

 

/s/ Avi Gabai

 

/s/ Dani Chen

/s/ Michal Abadi-Boiangiu

 

/s/ Noam Goldstein

The Government

 

Dead Sea Works Ltd.

 

7


 

Appendix A to detailed agreement dated              between the Government of Israel and the Dead Sea Works (the Agreement)

 

Components of the full harvest

 

1.               The salt harvest Project set forth in sections 3.1 of the Agreement encompasses all the following components and any additional or other component that will enable the planning, establishment, operation and effective functioning of the Project, which includes both the investment and the current expenses up to the end of the franchise period.

 

2.               List of the components:

 

·                   System for excavating, mining, gathering, conveying and stacking the salt in a pool 5.

 

·                   System of infrastructures supporting pool 5.

 

·                   System for stacking the salt.

 

·                   Operational and emergency terminal for gathering and concentrating the salt.

 

·                   System for conveying the salt from pool 5 to the site of its final unloading in the northern lake.

 

·                   System for conveying, removing and burying the salt in the northern lake, including the supporting infrastructures.

 

·                   Accompanying infrastructures, including electricity and civil works.

 

·                   Monitoring and control systems.

 

·                   Area/s for operations, maintenance, support, command and control systems.

 

·                   Statutory matters.

 

3.               DSW, as the entity implementing the Project, may transfer amounts included in Appendix A of the Government’s resolution, from section to section, from investments to current and vice versa, it may replace items of equipment appearing in said appendix with other items and it may substitute equipment with the receipt of services, all on condition that the State’s participation in funding the Project as a result of these transfers or replacements will not exceed the amount of its participation required by the provisions of this Agreement.

 

[stamp]

 

[stamp]

Accountant General’s Division

 

Dead Sea Works Ltd.

Ministry of Finance

 

/s/ Noam Goldstein

/s/ Avi Gabai

 

 

 

8



 

Appendix B to detailed agreement dated              between the Government of Israel and the Dead Sea Works (the Agreement)

 

Accompaniment

 

1.               Separate bookkeeping by DSW

 

DSW will implement the bookkeeping for the Project as a separate operations center (profit and loss center). As a rule, bills or invoices from contractors or suppliers will refer only to the Project. If, in addition to the Project, a bill or invoice also refers to work that is not for the Project, DSW will make a distinction enables the identification of the expense that belongs to the Project.

 

2.               Periodic reports

 

During the period from the beginning of the Project until the time at which the level of the water in pool 5 is stabilized in the framework of the Project (hereinafter — the Establishment Period ), DSW will provide the DSPC, within 30 days from the end of each quarter, with a written report (hereinafter — the Periodic Report ), which will also include the following details: (the format of the Periodic Report will be agreed between the parties and will serve for the purpose of preparing and submitting the Periodic Report):

 

(a)                Schedules.

 

(b)                Monitoring of expenses (with regard to both investments and current expenses).

 

(c)                 A general review of the Project relating to the quarter for which the Periodic Report is submitted, including pivotal decisions made in connection with the Project during the period of the report, significant engagements, the state of the various aspects of the Project’s planning (engineering, statutory, techno-economic) at the end of the period and so forth.

 

3.               Annual reports

 

3.1              By October 31 st  of each year, and as long as the State is participating in the Project funding, DSW will submit to the State a forecast of expenses for the next calendar year.

 

3.2              In the period after the Establishment Period and as long as the State is participating in the Project funding, Periodic Reports will be submitted up to 45 days from the end of each calendar year, including the monitoring of current expenses and investments.

 

[stamp]

 

[stamp]

Accountant General’s Division

 

Dead Sea Works Ltd.

Ministry of Finance

 

/s/ Noam Goldstein

/s/ Avi Gabai

 

 

 

9



 

4.               Meetings

 

From time to time, at the request of the DSPC, or DSW and as agreed between them, and no less than once a quarter, meetings will be held between representatives of the DSPC and DSW in order to discuss various aspects connected with the Project and tangential projects which have common infrastructures or which affect each other on some level, including engineering and statutory. One of the goals of said meetings will be to discuss the Periodic Reports. Another goal will be to discuss common issues (such as, but not only, engineering, statutory and scheduling issues) in the various works in the framework of the Project, the interim preservation project and the shoreline preservation project, and to achieve maximum streamlining in the coordination that will be required between the various projects and also in order to prevent a situation in which a particular project delays the progress of another project.

 

5.               Perusal of documents

 

A representative of the DSPC will be entitled to peruse various documents located at the DSW offices, which relate to the Project. If, for the purpose of the accompaniment and monitoring set forth in this Agreement, the physical holding of documents will be required, the DSPC will be entitled to photocopy them and make use of them solely for the purpose of fulfilling its duties. The documents that will be photocopied or transferred on magnetic media will be deemed to be loaned to the DSPC and to belong to DSW, and will be returned to DSW after use. To preclude doubt, it is hereby clarified that the permission to photocopy as stated does not include permission for mass photocopying of all the documents.

 

When the DSPC representative arrives at the DSW offices for the purpose of perusing the documents, he will be allocated a work area with access to a computer, however, it is clarified that material from the Computer will not be transmitted to any entities.

 

6.               Visits to the work sites

 

After, and pursuant to, advance coordination with DSW, the DSPC may send representatives to visit the work sites of the Project in the franchise area and ascertain the existence of equipment that was purchased and the rate of progress of work that is connected with the Project and other aspects connected with the Project. DSW undertakes to enable visits as stated within 14 days of the date of such requests by the DSPC.

 

7.               DSW — DSPC interface with the planning institutions

 

7.1              Requests by DSW regarding additional costs due to requirements of planning institutions, which deviate from that stated in Appendix A, will be submitted to the DSPC by DSW together with the relevant material in support of the request.

 

[stamp]

 

[stamp]

Accountant General’s Division

 

Dead Sea Works Ltd.

Ministry of Finance

 

/s/ Noam Goldstein

/s/ Avi Gabai

 

 

 

10



 

7.2              DSW agrees that in accordance the request of the DSPC, a three-way meeting will be convened with the participation of DSW, the DSPC and the CNI.

 

8.               Questions and requests for explanations

 

Once each quarter, the DSPC may submit questions in writing to DSW in connection with the Project, including in connection with issues arising from other projects that are connected with, or affect, the Project, and DSW will respond to them in writing within 14 days. In urgent cases only, the explanation for the urgency of which will be submitted to DSW by the DSPC in a written notification, the DSPC can submit additional questions outside the times set forth above.

 

9.               Clarification

 

It is clarified that the DSPC does not have the authority to instruct, influence, intervene or give directions to DSW in connection with the planning or implementation of the Project, or any other matter connected thereto and the implementation thereof.

 

10.        Confidentiality

 

Information that the DSPC will receive from DSW with regard to the Project, and information with regard to the Project that the State or anyone on its behalf will receive, will be deemed confidential information (subject to that stated below) and it will be kept confidential by the party in possession of said information.

 

The provision of information as stated by the DSPC to outside parties engaged thereby in the context of the Project, if any (hereinafter — the Outside Entity ), is conditional upon the following: (I) that the DSPC has determined that its provision is necessary and it is not sufficient that the Outside Entity study it at the offices of the DSPC, and (II) that the Outside Entity sign an undertaking vis-à-vis DSW to maintain the confidentiality and not to use that information for any purpose other than the purpose for which it was given. The text of the aforementioned undertaking will be agreed in advance between DSW and the DSPC. Said text will contain a provision whereby the Outside Entity will return or transfer to DSW the means on which the information is stored (including documents) which contain the relevant information or any part thereof, immediately upon completion of its study thereof for the purpose for which it was given. In any case, it is clarified that the means on which the information is stored will be given to the Outside Entity as a loan for the purpose of a defined goal connected with the DSPC’s duties in the matter of the Project.

 

No information as stated will be given to an External Entity before DSW receives an undertaking, duly signed by the former, to maintain confidentiality and not to use the information, in the wording to be agreed as stated.

 

[stamp]

 

[stamp]

Accountant General’s Division

 

Dead Sea Works Ltd.

Ministry of Finance

 

/s/ Noam Goldstein

/s/ Avi Gabai

 

 

 

11



 

An undertaking to maintain confidentiality and not to use the information as stated will not apply to information that is public knowledge at the time of the signing of this Agreement or that will become so afterwards, not as a result of the action or inaction of the DSPC or anyone on its behalf, or of anyone for whom or on behalf of whom the DS PC is acting or anyone on its behalf.

 

11.        General — cooperation

 

In addition, and without derogating from that stated above, DSW and the DSPC will cooperate with one another in the way and in the manner on which they will decide from time to time, with the aim of advancing the Project in an efficient and continuous manner.

 

12.        Interpretations

 

For the purpose of that stated in this Appendix, a quarter means any period of 3 (three) months: January — March; April — June; July — September; October — December; of each calendar year.

 

A year means a calendar year.

 

That stated is subject to the following: that the first-quarter will begin on the date agreed between the parties and will end at the end of the period of the three relevant months, even if it is shorter than three months; that the first year will begin on the date to be agreed between the parties and will end on December 31                                                 afterwards, even if it involves a period of less than 12 months.

 

13.        General

 

To preclude doubt, it is clarified that everything stated in this Appendix (including documents that will be transferred in the framework of the harvest agreement and the subject of confidentiality) applies solely to the matter of the harvest agreement and nothing in these agreements will change the undertakings of DSW and the State in the framework of the franchise deed.

 

 

 

 

 

Date of signing

 

 

[stamp]

 

[stamp]

Accountant General’s Division

 

Dead Sea Works Ltd.

Ministry of Finance

 

/s/ Noam Goldstein

/s/ Avi Gabai

 

 

 

12



 

Appendix C to detailed agreement dated           between the Government of Israel and the Dead Sea Works (the Agreement)

 

Principles of Level Measurement

 

The method of measuring the level in the pool will be as follows:

 

1.               The level of the pool will be measured in a manner that will not include the effect of the waves and the flooding.

 

2.               The measurement point will be on the West Bank opposite the Crowne Plaza hotel. DSW has installed its a system for measuring and transmitting data at the site, which will be approved by the DSPC.

 

3.               The measurement will be continuous with an ultrasonic level gauge and continuous transmission of data.

 

4.               The measurement device will be calibrated at least twice a year, and at any time demanded by the DSPC, by a qualified surveyor to be agreed upon by DSW and the DSPC.

 

5.               The data will be transferred to the DSPC continuously.

 

6.               A deviation of up to 10 cm for a period of up to one week and up to three times a year will not be deemed a breach of the Agreement.

 

[stamp]

 

[stamp]

Accountant General’s Division

 

Dead Sea Works Ltd.

Ministry of Finance

 

/s/ Noam Goldstein

/s/ Avi Gabai

 

 

 

13




Exhibit 10.7

 

ICL — Israel Chemicals Ltd.

 

26.03.2014

 

Israel Corporation

 

Dear Sirs/Madams,

 

Subject: Providing a Loan of $50 million for 6 Months

 

With regard to the $50 million loan granted to Israel Chemicals Ltd. by the Israel Corporation Ltd. on 26.06.2012 :

 

We hereby confirm that on 26.03.2014 the loan was renewed for an additional 6 months until 26.09.2014, in accordance with the following conditions:

 

Amount: $50,000,000

0.77625% interest to be paid in one payment at the end of the period

 

The interest is calculated as follows:

 

1.0325%

Total interest Israel Chemicals Ltd. pays for a similar loan

0.52%

I nterest the Israel Corporation would receive for a deposit with similar conditions

0.77625%

Average interest to be paid

 

 

Yours sincerely,

 

 

/s/ Kobi Ilia

 

/s/ Eli Amit

 

Israel Chemicals Ltd.

 

 



 

ICL — Israel Chemicals Ltd.

 

30.09.2013

 

Israel Corporation

 

Dear Sirs/Madams,

 

Subject: Providing a Loan of $50 million for 6 Months

 

With regard to the $50 million loan granted to Israel Chemicals Ltd. by the Israel Corporation Ltd. on 26.06.2012 :

 

We hereby confirm that on 26.09.2013 the loan was renewed for an additional 6 months until 26.03.2014, in accordance with the following conditions:

 

Amount: $50,000,000

0.85975% interest to be paid in one payment at the end of the period

 

The interest is calculated as follows:

 

1.0695%

Total interest Israel Chemicals Ltd. pays for a similar loan

0.65%

I nterest the Israel Corporation would receive for a deposit with similar conditions

0.85975%

Average interest to be paid

 

 

Yours sincerely,

 

 

/s/ Kobi Ilia

 

/s/ Eli Amit

 

Israel Chemicals Ltd.

 

 



 

ICL — Israel Chemicals Ltd.

 

26.06.2013

 

Israel Corporation

 

Dear Sirs/Madams,

 

Subject: Providing a Loan of $50 million

 

With regard to the $50 million loan granted to Israel Chemicals Ltd. by the Israel Corporation Ltd. on 26.06.2012 :

 

We hereby confirm that on 26.06.2013 the loan was renewed for an additional 3 months until 26.09.2013, in accordance with the following conditions:

 

Amount: $50,000,000

0.97675% interest to be paid in one payment at the end of the period

 

The interest is calculated as follows:

 

0.27675%

LIBOR interest for three months from 24.06.2013

0.70%

Profit

0.97675%

Total interest

 

 

Yours sincerely,

 

 

/s/ Kobi Ilia

 

/s/ Herzel Bar Niv

 

Israel Chemicals Ltd.

 

 



 

ICL — Israel Chemicals Ltd.

 

25.03.2013

 

Israel Corporation

 

Dear Sirs/Madams,

 

Subject: Providing a Loan of $50 million

 

With regard to the $50 million loan granted to Israel Chemicals Ltd. by the Israel Corporation Ltd. on 26.06.2012 :

 

We hereby confirm that on 25.03.2013 the loan was renewed for an additional 3 months until 26.06.2013, in accordance with the following conditions:

 

Amount: $50,000,000

0.9841% interest to be paid in one payment at the end of the period

 

The interest is calculated as follows:

 

0.2841%

LIBOR interest for three months from 21.03.2013

0.70%

Profit

0.9841%

Total interest

 

 

Yours sincerely,

 

 

/s/ Michael Hazan

 

/s/ Osi Sessler

 

Israel Chemicals Ltd.

 

 



 

ICL — Israel Chemicals Ltd.

 

31.12.2012

 

Israel Corporation

 

Dear Sirs/Madams,

 

Subject: Providing a Loan of $50 million

 

With regard to the $50 million loan granted to Israel Chemicals Ltd. by the Israel Corporation Ltd. on 26.06.2012 :

 

We hereby confirm that on 26.12.2012 the loan was renewed for an additional 3 months until 25.03.2013, in accordance with the following conditions:

 

Amount: $50,000,000

1.01% interest to be paid in one payment at the end of the period

Therefore, the amount of USD 124,847.22 shall be paid on 25.03.2013.

 

The interest is calculated as follows:

 

0.31%

LIBOR interest for three months from 21.12.2012

0.70%

Profit

1.01%

Total interest

 

 

Yours sincerely,

 

 

/s/ Kobi Ilia

 

/s/ Herzel Bar Niv

 

Israel Chemicals Ltd.

 

 



 

ICL — Israel Chemicals Ltd.

 

24.09.2012

 

Israel Corporation

 

Dear Sirs/Madams,

 

Subject: Providing a Loan of $50 million

 

We hereby confirm that on 24.09.2012 the Israel Corporation provided Israel Chemicals Ltd. with a loan of $50 million in accordance with the following conditions:

 

Amount: $50,000,000

1.073% interest to be paid in one payment at the end of the period

Maturity date 26.12.2012

 

Therefore, the amount of USD 138,595.83 shall be paid on 26.12.2012

 

The interest is calculated as follows:

 

0.373%

LIBOR interest for three months from 20.09.2012

0.70%

Profit

1.073%

Total interest

 

 

Yours sincerely,

 

 

/s/ Kobi Ilia

 

/s/ Eli Amit

 

Israel Chemicals Ltd.

 

 



 

ICL — Israel Chemicals Ltd.

 

26.06.2012

 

Israel Corporation

 

Dear Sirs/Madams,

 

Subject: Providing a Loan of $50 million

 

On 26.06.2012, a short-term loan of $50 million was provided to Israel Chemicals Ltd. by the Israel Corporation Ltd. in accordance with the following conditions :

 

Amount: $50,000,000

Interest: 1.22%, to be paid in one payment at the end of the period

Maturity date: 24.09.2012

 

 

Yours sincerely,

 

 

/s/ Michael Hazan

 

/s/ Eli Amit

 

Israel Chemicals Ltd.

 

 




Exhibit 10.8

 

REGISTRATION RIGHTS AGREEMENT

 

This Registration Rights Agreement (this “ Agreement ”) was made on [    ], 2014 by and between Israel Chemicals Ltd. (the “ Company ”), a company incorporated with limited liability organized under the laws of the State of Israel, and Israel Corporation Ltd. , a corporation organized under the laws of the State of Israel (“ IC ”).

 

WHEREAS, the Company is a specialty minerals company whose ordinary shares, par value NIS 1.00 per share (the “ Ordinary Shares ”), are traded on the Tel-Aviv Stock Exchange (“ TASE ”) under the symbol “ICL”;

 

WHEREAS, the Company is considering the registration under the 1933 Act (as defined below) of a certain portion of its outstanding Ordinary Shares held by IC or its Affiliates (as defined below) for sale in connection with a forward sale (the “ Forward Sale Agreement ”) with one or more financial intermediaries (the “ Forward Counterparty ”) or an outright sale, or a combination thereof, as determined by IC in its sole discretion (the “ Initial Shares ”);

 

WHEREAS, the Company is considering listing the Initial Shares for trading on the New York Stock Exchange (“ NYSE ”) or another securities exchange outside Israel under the symbol “ICL”; and

 

WHEREAS, the parties intend that the registration rights set forth in this Agreement be applicable to all outstanding Ordinary Shares of the Company which are or may be owned by IC and by any of its Affiliates at any time during the term of this Agreement (and not be limited to the Initial Shares) and to all Ordinary Shares that may be issued or granted at any time in the future on account or by virtue of such outstanding Ordinary Shares, as set out in the definition of Registrable Securities below.

 

NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and IC hereby agree as follows:

 

1.                                       DEFINITIONS AND INTERPRETATION

 

As used in this Agreement, the following terms shall have the following meanings:

 

(a)                                  Affiliate ” means, with respect to any corporate entity, any person which controls, is controlled by or is under common control with such entity, whereas “ control ”, for purposes of this Agreement, means the ability to effectively direct the operations and policies of a corporate entity.

 

(b)                                  Business Day ” means any day except a Saturday, Sunday or other day on which commercial banks in Tel Aviv, Israel are authorized by law to close.

 

(c)                                   Demand Registration ” shall have the meaning set out in Section 2(a)  below.

 

(d)                                  Filing Deadline ” shall have the meaning set out in Section 2(a)  below.

 

(e)                                   Forward Counterparty ” shall have the meaning set out in the preamble.

 

(f)                                    Forward Sale Agreement ” shall have the meaning set out in the preamble.

 

(g)                                   Initial Shares ” shall have the meaning set out in the preamble.

 



 

(h)                                  IC ” means IC, any transferee or assignee to whom IC assigns its rights, in whole or in part, and any transferee or assignee thereof to whom a transferee or assignee assigns its rights, in accordance with Section 11 below.

 

(i)                                      1933 Act ” means the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute.

 

(j)                                     1934 Act ” means the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder, or any similar successor statute.

 

(k)                                  Marketed Takedown ” shall have the meaning set out in Section 4(c)  below.

 

(l)                                      Offered Shares ” shall have the meaning set out in Section 2(a)  below.

 

(m)                              Ordinary Shares ” shall have the meaning set out in the preamble.

 

(n)                                  Register ”, “ registered ”, and “ registration ” refer to a registration effected by preparing and filing a registration statement in compliance with the 1933 Act and the effectiveness of such registration statement in accordance with the 1933 Act or the equivalent actions under the laws of another jurisdiction.

 

(o)                                  Registrable Securities ” means (i) any Ordinary Shares owned by IC during the term of this Agreement, and (ii) any shares issued or issuable with respect to such Ordinary Shares as a result of any stock split, stock dividend, rights offering, recapitalization, merger, exchange or similar event or otherwise.

 

(p)                                  Registration Statement ” means any registration statement of the Company covering Registrable Securities filed with the SEC under the 1933 Act.

 

(q)                                  SEC ” means the United States Securities and Exchange Commission or any similar or successor agency of the United States administering the 1933 Act.

 

In this Agreement:

 

(a)                                  Words importing the singular shall include the plural and vice versa , words importing any gender shall include all other genders and references to persons shall include partnerships, corporations and unincorporated associations.

 

(b)                                  Any reference in this Agreement to a specific form or to any rule or regulation adopted by the SEC shall also include any successor form or amended or successor rule or regulation subsequently adopted by the SEC, all as the same may be in effect at the time.

 

(c)                                   Any reference in this Agreement to a statute, act or law shall be construed as a reference to such statute, act or law as the same may have been, or may from time to time be, amended or reenacted.

 

(d)                                  A “ person ” shall be construed as a reference to any person, firm, company, corporation, government, state or agency of a state or any association or partnership (whether or not having separate legal personality) or two or more of the foregoing.

 

(e)                                   Including ” and “ includes ” means, including, without limiting the generality of any description preceding such terms.

 

2



 

(f)                                    The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.

 

2.                                       DEMAND REGISTRATIONS

 

(a)                                  IC may request, on up to three (3) separate occasions but not more frequently than once every twelve (12) months, that the Company register under the 1933 Act all or any portion of the remaining Registrable Securities held by IC at that time (each such registration, a “ Demand Registration ”), provided that the Registrable Securities requested to be registered have an aggregate value of at least fifty million U.S. dollars ($50,000,000) based on their then-current market price, or a lower amount if the total value of the remainder of IC’s holdings of Registrable Securities at that time falls short of such threshold and such request covers all of IC’s remaining Registrable Securities.  A registration will not count as a Demand Registration until the Registration Statement relating to such registration has become effective and unless IC was able to register and sell all the Registrable Securities requested by it to be included in such registration, as reduced by Section 2(c)  below.

 

In furtherance of the foregoing, before or promptly following the date of this Agreement (the “ Filing Deadline ”), the Company shall prepare and file with the SEC a Registration Statement on Form F-1, covering the sale of the Initial Shares (the “ Offered Shares ”).  A draft of the Registration Statement (and each amendment or supplement thereto, and each request for acceleration of effectiveness thereof) shall be provided to IC and its counsel prior to its filing or other submission.  The Company shall use its commercially reasonable best efforts to have the Registration Statement declared effective by the SEC as soon as possible after such filing with the SEC.

 

The registration of the Offered Shares shall be deemed an exercise of one of IC’s Demand Registrations pursuant to this Section 2(a) .

 

(b)                                  Upon receiving a written request from IC as set out in Section 2(a)  above (other than with respect to the Offered Shares), the Company shall prepare and file, no later than 45 days after receipt of such request, a Registration Statement on Form F-1 (or F-3 if then eligible for use of such form) with the SEC covering the resale of all (or, at the request of IC, any portion of) the then Registrable Securities that are not already registered and that are covered by such request.  The Company shall use its commercially reasonable best efforts to have the Registration Statement become effective with the SEC as soon as possible after such filing with the SEC.

 

(c)                                   If the managing underwriter determines in connection with an offering pursuant to Section 2(a)  that the number of Ordinary Shares intended to be included in such registration exceeds the largest number of Ordinary Shares that can be sold without having an adverse effect on such offering, including the price at which such Ordinary Shares can be sold, the Company shall include in such registration only such largest number, with the Ordinary Shares to be sold to be (i) first, the

 

3



 

Registrable Securities held by IC and (ii) second, all other Ordinary Shares contemplated to be sold in such registration.

 

(d)                                  [Reserved]

 

(e)                                   Notwithstanding the above, the Company may defer the filing of any Registration Statement pursuant to Section 2(a)  above or suspend the offering of Registrable Securities under a Registration Statement filed pursuant to Section 2(b)   above for up to 45 days at any one time (but for no more than 90 days in the aggregate during any 365-day period) if the Company determines in its good faith judgment that any such filing or offering, as the case may be, would (a) impede, delay or otherwise interfere with any pending or contemplated material financing, acquisition, corporate reorganization or other similar transaction, or (b) require disclosure of material nonpublic information which, if disclosed at such time, would be materially harmful to the interests of the Company and its shareholders.   The Company shall give notice of such deferral or suspension (without having to specify the exact nature or details of its cause) to IC, and inform IC promptly upon such events or conditions ceasing to exist.

 

(f)                                    Furthermore, the Company shall not be required to honor any demand by IC to register its Registrable Securities pursuant to Section 2(b)   above if a shelf Registration Statement that had previously been demanded by IC pursuant to Section 4(a)  below is effective and available for use at that time and covers the full scope of the transaction contemplated by IC.  The Company shall nevertheless remain bound by all its obligations under Section 5 below with regard to IC’s takedown under such shelf Registration Statement, including the Company’s obligations to facilitate and assist the offering of the Registrable Securities by IC, subject to the limitation set forth in Section 4(c)  below.

 

3.                                       PIGGYBACK REGISTRATIONS

 

If at any time the Company shall determine to prepare and file with the SEC a registration statement relating to an underwritten offering for its own account or the account of others under the 1933 Act of any of its Ordinary Shares or other securities convertible or exercisable into its Ordinary Shares (other than on Form F-4 or Form S-8, each as promulgated under the 1933 Act, or their then equivalents relating to equity securities to be issued in connection with any acquisition of any entity or business, any exchange offer or merger, or any similar transaction, or equity securities issuable in connection with stock option or other employee benefit plans), then the Company shall send IC written notice of such determination and, if within five (5) Business Days after receipt of such notice IC shall so request in writing, the Company shall include in such registration statement all or any part of the Registrable Securities that IC requests to be so registered, provided that (A) if such registration involves an underwritten public offering, IC must sell its Registrable Securities to the underwriters selected as provided in Section 5(l)  on the same terms and conditions as apply to the Company and (B) if, at any time, after giving notice of its intention to register any securities pursuant to this Section 3 and prior to the effective date of the registration statement filed in connection with such registration, the Company shall determine for any reason not to register such securities, the Company shall give notice to IC and, thereupon, shall be relieved of its obligation to

 

4



 

register any Registrable Securities in connection with such registration.  However, if the managing underwriter determines in good faith in connection with an offering pursuant to this Section 3 that the number of Ordinary Shares intended to be included in such registration exceeds the largest number of Ordinary Shares that can be sold without having an adverse effect on such offering, including the price at which such Ordinary Shares can be sold, then the Company shall include in such registration only such largest number, with the Ordinary Shares to be sold to be (i) first, the Ordinary Shares held by the Company (or any other person who may be exercising a demand in such situation) and (ii) second, the Registrable Securities held by IC up to the amount determined in good faith by the managing underwriter as would not have such an effect.

 

4.                                       SHELF REGISTRATIONS

 

(a)                                  At IC’s written request, the Company shall use its best efforts to qualify and remain qualified to register securities on Form F-3 (or any successor form) under the 1933 Act.  So long as the Company is qualified to register securities on Form F-3 (or any successor form), IC shall have the right to request registration on Form F-3 (or any successor form) for the Registrable Securities held by IC at any time during the term of this Agreement, including registrations for the sale of such Registrable Securities on a delayed or continuous basis pursuant to Rule 415 under the 1933 Act, provided that the Registrable Securities requested by IC to be registered have an aggregate value of at least fifty million U.S. dollars ($50,000,000) based on their then-current market price , or a lower amount if the total value of the remainder of IC’s holdings of Registrable Securities at that time falls short of such threshold and such request covers all of IC’s remaining Registrable Securities .

 

(b)                                  Any such request shall be in writing and shall state the number of Registrable Securities to be disposed of and the intended method of disposition of such Registrable Securities by IC.  Upon receiving a written request from IC as aforesaid, the Company shall prepare and file, no later than forty-five (45) days after receipt of such request, a Registration Statement on Form F-3 (or any successor form) with the SEC covering the resale of all (or, at the request of IC, any portion of) the then Registrable Securities that are not already registered and that are covered by such request .  The Company shall use its commercially reasonable best efforts to have such Registration Statement become effective with the SEC as soon as possible after such filing with the SEC.

 

(c)                                   IC may effect takedowns under the shelf Registration Statement without limitation (other than as set out in Section 4(a)  above), whether alone or alongside the Company, provided, however , that the Company may, but shall not be required to, comply with its obligations under Sections 5(l) , 5(m)  and 5(n)  below with respect to more than one takedown (a “ Marketed Takedown ”) during any 365-day period.

 

(d)                                  Notwithstanding the above, the Company may defer the filing of, or suspend the offering of Registrable Securities under, a Registration Statement filed pursuant to

 

5



 

this Section 4 for up to 45 days at any one time (but for no more than 90 days in the aggregate during any 365-day period) if the Company determines in its good faith judgment, that any such filing or offering, as the case may be, would (a) impede, delay or otherwise interfere with any pending or contemplated material financing, acquisition, corporate reorganization or other similar transaction, or (b) require disclosure of material nonpublic information which, if disclosed at such time, would be materially harmful to the interests of the Company and its shareholders.  The Company shall give notice of such deferral or suspension (without having to specify the exact nature or details of its cause) to IC and shall inform IC promptly upon such events or conditions ceasing to exist.

 

5.                                       RELATED COMPANY REPRESENTATIONS AND OBLIGATIONS

 

(a)                                  The Company represents and warrants to IC that the Company is not a party to any agreement that conflicts in any manner with IC’s rights to cause the Company to register Registrable Shares pursuant to this Agreement, and the Company shall not enter into any such agreement during the term of this Agreement without IC’s consent (which shall not be unreasonably withheld).

 

(b)                                  Subject to Section 2(e)  and Section 4(d)  above, following the effectiveness of each Registration Statement with the SEC pursuant to Sections 2(a)  or 4(a)  above, the Company shall keep such Registration Statement effective under the 1933 Act at all times until the date on which IC shall have sold all the Registrable Securities covered by such Registration Statement (A) in accordance with such Registration Statement or (B) to the public pursuant to Rule 144 under the 1933 Act, as the case may be (the “ Registration Period ”), and during such Registration Period the Company shall ensure that such Registration Statement (including any amendments or supplements thereto and prospectuses contained therein) shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading, subject to Section 5(f)  below and except insofar as any such untrue statement or omission is made based upon information furnished by or on behalf of IC or its Affiliates (other than the Company) expressly for use therein.

 

(c)                                   The Company shall prepare and file with the SEC such amendments (including post-effective amendments) and supplements to each Registration Statement and the prospectus used in connection with such Registration Statement, which prospectus is to be filed pursuant to Rule 424 under the 1933 Act, as may be necessary to keep such Registration Statement effective at all times during the Registration Period with respect to such Registration Statement, and, during such period, the Company shall comply with the applicable provisions of the 1933 Act with respect to the disposition of all Registrable Securities of the Company covered by such Registration Statement until such time as all of such Registrable Securities (as reduced by Section 2(c)  or Section 3 , if applicable) shall have been disposed of in accordance with the intended methods of disposition by the seller or sellers thereof as set forth in such Registration Statement (subject to Section 5(q)  below).

 

6



 

(d)                                  The Company shall furnish IC, without charge, (i) promptly after the same is prepared and filed with the SEC, at least three (3) copies of each Registration Statement and any amendment(s) thereto, including financial statements and schedules, all documents incorporated therein by reference, all exhibits and each preliminary prospectus (or such other number of copies as IC may reasonably request), (ii) upon the effectiveness of any Registration Statement, at least ten (10) copies of the prospectus included in such Registration Statement and all amendments and supplements thereto (or such other number of copies as IC may reasonably request) and (iii) such other documents, including copies of any preliminary or final prospectus and of any Registration Statements, as IC may reasonably request from time to time in order to facilitate the disposition of the Registrable Securities owned by IC.

 

(e)                                   The Company shall use its commercially reasonable best efforts to (i) register and qualify, unless an exemption from registration and qualification applies, the resale by IC of the Registrable Securities covered by a Registration Statement under such other securities or “blue sky” laws of all the states of the United States, (ii) prepare and file in those jurisdictions such amendments (including post-effective amendments) and supplements to such registrations and qualifications as may be necessary to maintain the effectiveness thereof during the Registration Period, (iii) take such other actions as may be necessary to maintain such registrations and qualifications in effect at all times during the Registration Period, and (iv) take all other actions reasonably necessary or advisable to qualify the Registrable Securities for sale in such jurisdictions; provided, however , that the Company shall not be required in connection therewith or as a condition thereto to (x) qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section 5(e) , or (y) file a general consent to service of process in any such jurisdiction.  The Company shall promptly notify IC of the receipt by the Company of any notification with respect to the suspension of the registration or qualification of any of the Registrable Securities for sale under the securities or “blue sky” laws of any jurisdiction in the United States or its receipt of actual notice of the initiation or threatening of any proceeding for such purpose.

 

(f)                                    The Company shall notify IC in writing of the happening of any event, as promptly as practicable after becoming aware of such event, as a result of which the prospectus included in a Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.  Subject to Section 2(e)  and Section 4(d)  above, the Company shall use its commercially reasonable best efforts to minimize the period of time during which a Registration Statement includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, and the provisions of Section 2(e)  or Section 4(d)  shall apply, as applicable, to such occurrence.  The Company shall promptly notify IC in writing (i) when a prospectus or any prospectus supplement or post-effective amendment has been

 

7



 

filed so that the Registration Statement does not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, and when a Registration Statement or any post-effective amendment has become effective (notification of such effectiveness shall be delivered to IC by facsimile on the same day of such effectiveness and by overnight mail), (ii) of any comments by the SEC on any Registration Statement (and provide a copy of such comments and the proposed response thereto) and of any request by the SEC for amendments or supplements to a Registration Statement or related prospectus or related information, and (iii) of the Company’s reasonable determination that a post-effective amendment to a Registration Statement would be appropriate.

 

(g)                                   Subject to Section 2(e)  and Section 4(d)  above, the Company shall use its commercially reasonable best efforts to prevent the issuance of any stop order or other suspension of effectiveness of a Registration Statement, or the suspension of the qualification of any of the Registrable Securities for sale in any jurisdiction, and, if such an order or suspension is issued, to obtain the withdrawal of such order or suspension at the earliest possible moment and to notify IC of the issuance of such order and the resolution thereof or its receipt of actual notice of the initiation or threat of any proceeding for such purpose.

 

(h)                                  The Company shall cause all the Registrable Securities covered by a Registration Statement to be listed on each securities exchange on which securities of the same class or series issued by the Company are then listed, including the NYSE and the TASE.  The Company shall deliver to IC a copy of the approvals of the TASE and the NYSE (or any other exchange, if applicable) to the listing of the Registrable Securities covered by such Registration Statement on such exchange, in the case of the TASE, by not later than the date hereof, and in the case of the NYSE (or any other applicable exchange) not later than the effective date of such Registration Statement.

 

(i)                                      The Company shall cooperate with IC and, to the extent applicable, facilitate the timely preparation and delivery of certificates (not bearing any restrictive legend) representing the Registrable Securities to be offered pursuant to a Registration Statement and enable such certificates to be in such denominations or amounts, as the case may be, as IC may reasonably request and registered in such name or names as IC may request.

 

(j)                                     The Company shall provide a transfer agent and registrar of all Registrable Securities and a CUSIP number not later than the effective date of the applicable Registration Statement.

 

(k)                                  Subject to Section 2(e)  and Section 4(d)  above, if requested by IC, the Company shall (i) as soon as practicable incorporate in a prospectus supplement or post-effective amendment such information as IC requests to be included therein, information with respect to the number of Registrable Securities being offered or sold, the manner of distribution, the purchase price being paid therefor and any other terms of the offering of the Registrable Securities to be sold in such

 

8



 

offering; (ii) as soon as practicable make all required filings of such prospectus supplement or post-effective amendment after being notified of the matters to be incorporated in such prospectus supplement or post-effective amendment; and (iii) as soon as practicable, supplement or make amendments to any Registration Statement if reasonably requested by IC.

 

(l)                                      In the event of any underwritten public offering of the Registrable Securities, the Company shall enter into and perform its obligations under an underwriting agreement with usual and customary terms that are generally satisfactory to the managing underwriter of such offering, including management participation in road shows if so requested by the managing underwriter.  IC shall also enter into and perform its obligations under such an agreement (the terms of which must be satisfactory to IC if it is to participate in such offering).  If such offering is a Demand Registration or a takedown pursuant to Section 4(c)  above, IC shall be entitled to select the underwriters, provided that such underwriters are reasonably acceptable to the Company.

 

(m)                              The Company shall afford IC, any underwriters in connection with any underwritten public offering of the Registrable Securities and their representatives (including counsel) the opportunity at any time and from time to time during the Registration Period to make such examinations of the business affairs and other material financial and corporate documents of the Company and its subsidiaries as IC may reasonably deem necessary to satisfy itself as to the accuracy of the Registration Statement (subject to a reasonable confidentiality undertaking on the part of IC, such underwriters and their representatives).

 

(n)                                  The Company shall furnish, at the request of IC in connection with the registration of Registrable Shares pursuant to this Agreement, on the date that such Registrable Shares are delivered to the underwriters for sale, if such securities are being sold through underwriters: (i) an opinion and 10b-5 letter, each dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to IC and IC’s board of directors; and (ii) a letter, dated such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to IC and IC’s board of directors.

 

(o)                                  The Company shall comply with all applicable rules and regulations of the SEC and shall make generally available to its security holders an earnings statement satisfying the provisions of Section 11(a) of the 1933 Act as soon as practicable after the effective date of the Registration Statement and in any event no later than 45 days after the end of a 12-month period (or 90 days, if such period is a fiscal year) beginning with the Company’s first fiscal quarter commencing after the effective date of the Registration Statement.

 

(p)                                  IC shall not participate in any public offering hereunder unless IC completes and executes all questionnaires, powers of attorney, indemnities, underwriting

 

9



 

agreements and other documents reasonably required under the terms of such underwriting arrangements and the provisions of this Agreement in respect of registration rights.

 

(q)                                  The Company acknowledges and agrees that, subject to applicable U.S. securities laws, IC may dispose of its Registrable Securities in a sale transaction, but may also utilize this Agreement to facilitate any financing relating thereto, such as a collar, forward, secured loan and the sale by the counterparties thereto or by the lenders, as applicable, of the Registrable Securities in connection with entering into such transactions, hedging their rights and obligations, settling the transactions and exercising their rights thereunder; provided that such other financing shall not impose any material obligation on the Company beyond the obligations set forth in this Agreement that would apply to a normal sale, and that any use of a Registration Statement for such financing shall be deemed a usage for a sale transaction.

 

6.                                       OBLIGATIONS OF IC

 

IC agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in the first sentence of Section 5(f)  or the issuance of any stop order or suspension as referred to in Section 5(g)  or any suspension noticed pursuant to Section 2(e)  or Section 4(d) , IC shall immediately discontinue disposition of Registrable Securities pursuant to any Registration Statement(s) covering such Registrable Securities until IC’s receipt of the copies of the supplemented or amended prospectus contemplated by clause (i) of Section 5(f)  or receipt of notice that no supplement or amendment is required.

 

With respect to any registered offering of Registrable Securities, IC agrees not to use any free writing prospectus (as defined in Rule 405) other than an issuer free writing prospectus (as defined in Rule 433(h)) provided by the Company.

 

7.                                       EXPENSES OF REGISTRATION

 

All expenses, other than underwriting discounts and commissions, incurred in connection with registrations, filings or qualifications hereunder, including, without limitation, all registration, listing and qualifications fees, printing expenses, accounting fees, and fees and disbursements of counsel to the Company, shall be paid by the Company. Any underwriting discounts and commissions incurred in connection with the transactions registered pursuant to this Agreement shall be borne pro rata by the persons selling the applicable securities, so that if such underwritten offering is also in respect of securities being sold by the Company, IC shall only be responsible for its pro rata share.  Any fees and disbursements of separate counsel retained by IC in connection with any registration of its Registrable Securities, including for the purpose of carrying out the examinations described in Section 5(m)  above, shall be borne by IC and will not be reimbursable by the Company. The Company shall not be required to bear any fees and disbursements of separate counsel retained by the underwriters in connection with an underwritten offering of Registrable Securities.

 

10


 

8.                                       INDEMNIFICATION

 

In the event any Registrable Securities are included in a Registration Statement under this Agreement:

 

(a)                                  To the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend IC, the directors, officers, partners, employees, agents, representatives of, and each Person, if any, who controls IC within the meaning of the 1933 Act or 1934 Act (each, an “ Indemnified Person ”), against any losses, claims, damages, liabilities, judgments, fines, penalties, charges, costs, reasonable attorneys’ fees, amounts paid in settlement or expenses, joint or several, (collectively, “ Claims ”) incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory agency, body or the SEC, whether pending or threatened, whether or not a person to be indemnified is or may be a party thereto (“ Indemnified Damages ”), to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement of a material fact in a Registration Statement or any post-effective amendment thereto, or the omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading or (ii) any untrue statement or alleged untrue statement of a material fact contained in any preliminary prospectus, final prospectus or “issuer free writing prospectus” (as such term is defined in Rule 405 under the 1933 Act) or any amendment or supplement to any such prospectus or the omission or alleged omission to state therein any material fact necessary to make the statements made therein, in light of the circumstances under which the statements therein were made, not misleading (the matters in the foregoing clauses (i) through (ii) being, collectively, “ Violations ”).  Subject to Section 8(c) , the Company shall reimburse the Indemnified Persons promptly as such expenses are incurred and are due and payable, for any legal fees or other reasonable expenses incurred by them in connection with investigating or defending any such Claim.  Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section 8(a) : (i) shall not apply to a Claim by an Indemnified Person arising out of or based upon a Violation which occurs in reliance upon and in conformity with information furnished to the Company by an Indemnified Person expressly for inclusion in any such Registration Statement, preliminary prospectus, final prospectus or free writing prospectus or any such amendment thereof or supplement thereto and (ii) shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld.  Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person and shall survive the transfer of the Registrable Securities by IC pursuant to Section 8 .

 

(b)                                  In connection with any Registration Statement in which IC is participating, IC agrees to indemnify, hold harmless and defend, to the same extent and in the same

 

11



 

manner as is set forth in Section 8(a) , the Company, each of its directors, each of its officers who signs the Registration Statement, and each Person, if any, who controls the Company within the meaning of the 1933 Act or the 1934 Act (each an “ Indemnified Party ”), against any Claim or Indemnified Damages to which any of them may become subject, under the 1933 Act, the 1934 Act or otherwise, insofar as such Claim or Indemnified Damages arise out of or are based upon any Violation, in each case to the extent, and only to the extent, that such Violation occurs in reliance upon and in conformity with information furnished to the Company by IC expressly for inclusion in Registration Statement, preliminary prospectus, final prospectus or free writing prospectus and, subject to Section 8(c) , IC will reimburse any legal or other expenses reasonably incurred by an Indemnified Party in connection with investigating or defending any such Claim; provided, however , that the indemnity agreement contained in this Section 8(b)  and the agreement with respect to contribution contained in Section 9 shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of IC, which consent shall not be unreasonably withheld; provided, further, however , that IC shall be liable under this Section 8 for only that amount of a Claim or Indemnified Damages as does not exceed the net proceeds to IC yielded from the sale of Registrable Securities pursuant to such Registration Statement.  Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Indemnified Party and shall survive the transfer of the Registrable Securities by IC pursuant to Section 8 .

 

(c)                                   Promptly after receipt by an Indemnified Person or Indemnified Party under this Section 8 of notice of the commencement of any action or proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified Party shall, if a Claim in respect thereof is to be made against any indemnifying party under this Section 8 , deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof with counsel mutually satisfactory to the indemnifying party and the Indemnified Person or the Indemnified Party, as the case may be; provided, however , that an Indemnified Person or Indemnified Party shall have the right to retain its own counsel with the reasonable fees and expenses of not more than one counsel for such Indemnified Person or Indemnified Party to be paid by the indemnifying party if the representation by such counsel of the Indemnified Person or Indemnified Party and the indemnifying party would be inappropriate due to actual or potential differing interests between such Indemnified Person or Indemnified Party and any other party represented by such counsel in such proceeding.  In the case of an Indemnified Person under Section 8(a) , legal counsel referred to in the immediately preceding sentence shall be selected by IC and, in the case of an Indemnified Party under Section 8(b) , legal counsel referred to in the immediately preceding sentence shall be selected by the Company.  The Indemnified Party or Indemnified Person shall cooperate with the indemnifying party in connection

 

12



 

with any negotiation or defense of any such action or Claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Indemnified Party or Indemnified Person which relates to such action or Claim.  The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not relieve such indemnifying party of any liability to the Indemnified Person or Indemnified Party under this Section 8 , except to the extent that the indemnifying party is prejudiced in its ability to defend such action but the omission to so notify the indemnifying party will not relieve such indemnifying party of any liability that it may have to any Indemnified Person or Indemnified Party otherwise than under this Section 8(c) , including under Section 8(e) .

 

(d)                                  The indemnification required by this Section 8 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or Indemnified Damages are incurred.

 

(e)                                   The indemnity agreements contained herein shall be in addition to (i) any cause of action or similar right of the Indemnified Party or Indemnified Person against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject to pursuant to the law.

 

9.                                       CONTRIBUTION

 

To the extent any indemnification by an indemnifying party is prohibited or limited by law or insufficient to hold an Indemnified Person or an Indemnified Party, as the case may be, harmless, then the indemnifying party, in lieu of indemnifying such Indemnified Person or Indemnified Party hereunder, shall contribute to the amount paid or payable by such Indemnified Person or Indemnified Party as a result of such Claims and Indemnified Damages (each as defined in Section 8(a)  above) in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the Indemnified Person or Indemnified Party, as the case may be, on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable considerations. The relative fault of the indemnifying party and of the Indemnified Person or Indemnified Party, as the case may be, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the Indemnified Person or Indemnified Party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission.

 

Notwithstanding the foregoing, (i) no person involved in the sale of Registrable Securities, which person is guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the 1933 Act) in connection with such sale, shall be entitled to contribution from any person involved in such sale of Registrable Securities who was not guilty of fraudulent misrepresentation; and (ii) contribution by any seller of Registrable Securities shall be limited in amount to the net amount of proceeds received by such seller from the sale of such Registrable Securities pursuant to such Registration Statement.

 

13



 

10.                                REPORTS UNDER THE 1934 ACT

 

With a view to making available to IC the benefits of Rule 144 promulgated under the 1933 Act or any other similar rule or regulation of the SEC that may at any time permit IC to sell securities of the Company to the public without registration (“ Rule 144 ”), the Company agrees to use commercially reasonable best efforts to:

 

(a)                                  make and keep available current public information, as described and defined in Rule 144;

 

(b)                                  file or furnish with the SEC in a timely manner all reports and other documents required by the Company under the 1934 Act so long as the Company remains subject to such requirements and the filing of such reports and other documents is required for the applicable provisions of Rule 144; and

 

(c)                                   furnish to IC, so long as IC owns Registrable Securities, promptly upon request, (i) a written statement by the Company that it has complied with the reporting requirements of Rule 144 and the 1934 Act, (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed or furnished by the Company, and (iii) such other information as may be reasonably requested to permit IC to sell such securities pursuant to any rule or regulation of the SEC allowing IC to sell any securities without registration.

 

11.                                ASSIGNMENT OF REGISTRATION RIGHTS

 

(a)                                  The rights under this Agreement shall be freely assignable by IC, in whole or in part at any time and from time to time during each Registration Period, to any transferee of all or any portion (in excess of 10% of the Company’s outstanding share capital) of IC’s Registrable Securities if: (i) the transferee is, or will become immediately following the transfer from IC, the holder of at least ten percent (10%) of the Company’s issued and outstanding share capital at that time, (ii) IC

 

14



 

agrees in writing with the transferee to assign such rights, and a copy of such agreement is furnished to the Company within a reasonable time after such transfer or assignment; and (iii) within a reasonable period of time after such transfer or assignment, the transferee agrees in writing with the Company to be bound by all of the provisions contained herein.

 

(b)                                  Any assignment of rights by IC to a transferee shall reduce IC’s rights correspondingly, so that the overall rights held by IC and its transferee together shall not exceed those held by IC immediately prior to such assignment.  Any right that cannot practically and readily be divided or pro-rated (for example, the right to initiate a single remaining Demand Registration) shall either be assigned in its entirety to the transferee or retained in its entirety by IC.

 

At the transferee’s request, the Company shall promptly prepare and file any required prospectus supplement under Rule 424(b) of the 1933 Act or other applicable provision of the 1933 Act to appropriately amend the list of selling shareholders thereunder to include such transferee.

 

12.                                AMENDMENT OF REGISTRATION RIGHTS

 

Provisions of this Agreement may be amended and the observance thereof may be waived (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company and IC.  Any amendment or waiver effected in accordance with this Section 12 shall be binding upon IC and the Company.  No consideration shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of any of this Agreement unless the same consideration also is offered to all of the parties to this Agreement.

 

13.                                TERM

 

This Agreement shall become effective upon its signing by both parties and shall remain in effect until the earlier of (a) the date that is ten (10) years from the effective date of the Registration Statement on Form F-1 that is filed in connection with the Offered Shares and (b) the date when IC ceases to be an Affiliate of the Company.

 

14.                                MISCELLANEOUS

 

(a)                                  Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered:  (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party); or (iii) three (3) Business Days after deposit if deposited in the mail for mailing by certified mail, postage prepaid, in each case properly addressed to the party to receive the same.  The addresses and facsimile numbers for such communications shall be:

 

to the Company at:

 

Israel Chemicals Ltd.
23 Aranha St., Millennium Tower

 

15



 

P.O. Box 20245
Tel Aviv, Israel 61202
Facsimile:  972-3-684-4444
Attention:  Lisa Haimovitz, Adv.

 

to IC at:

 

Israel Corporation Ltd.
23 Aranha St., Millennium Tower
Tel Aviv, Israel 61070
Facsimile: 972-3-6844587
Attention:  Maya Alcheh Kaplan, Adv.

 

(b)                                  Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy, shall not operate as a waiver thereof.

 

(c)                                   To the extent that the Company lists its shares on any stock exchange outside of the United States in lieu of the NYSE, the provisions of this Agreement shall apply, mutatis mutandis , to such listing.

 

(d)                                  This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the choice of law principles thereof.  Each party hereby irrevocable submits to the exclusive jurisdiction of the courts of the State of New York located in New York County and the United States District Court for the Southern District of New York for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the Transactions contemplated hereunder.  EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT.

 

(e)                                   This Agreement constitutes the entire agreement among the parties hereto with respect to the subject matter hereof and thereof.  There are no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein and therein.  This Agreement supersedes all prior agreements and understandings among the parties hereto with respect to the subject matter hereof and thereof.

 

(f)                                    Neither this Agreement, nor any of the Company’s obligations hereunder, may be assigned by the Company, except with the prior written consent of IC.  Subject to the requirements of Section 11 , this Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the parties hereto.

 

(g)                                   The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.

 

(h)                                  This Agreement may be executed in identical counterparts, each of which shall be deemed an original but all of which shall constitute one and the same agreement.  This Agreement, once executed by a party, may be delivered to the other party hereto by facsimile transmission of a copy of this Agreement bearing the signature of the party so delivering this Agreement.

 

16



 

(i)                                      Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as another party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

(j)                                     The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent and no rules of strict construction will be applied against any party.

 

(k)                                  This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

[Remainder of page intentionally left blank]

 

17



 

IN WITNESS WHEREOF, the parties have caused this Registration Rights Agreement to be duly executed as of the day and year first above written.

 

 

 

ISRAEL CHEMICALS LTD.

 

 

 

 

 

 

By:

 

 

Name:

 

 

Title:

 

 

 

 

 

 

 

 

By:

 

 

Name:

 

 

Title:

 

 

 

 

 

 

 

ISRAEL CORPORATION LTD.

 

 

 

 

 

 

 

By:

 

 

Name:

 

 

Title:

 

 




Exhibit 21.1

 

SUBSIDIARIES OF THE REGISTRANT

 

Name

 

Jurisdiction of Organization

Absia SL

 

Spain

Adentatec GmbH Competence in Dental

 

Germany

ADOM Ashkelon desalination Ltd.

 

Israel

Agripo Management services Ltd.

 

Israel

Agrocallejas mediterranea, S.L Unipersonal

 

Spain

Agro-Vant

 

Israel

Ambient Technologies Inc.

 

USA — Virgin Islands

Amsterdam Fertilizers B.V.

 

The Netherlands

Angang BK Giulini Water Treatment Co Ltd.

 

China

Anti-Germ Austria GmbH

 

Austria

Anti-Germ CZ s.r.o

 

Czech Republic

Anti-Germ Deutschland GmbH

 

Germany

Anti-Germ Hungary

 

Hungary

Anti-Germ Slovakia s.r.o.

 

Slovakia

ARM Ltd.

 

Hong Kong

Ashli Chemicals (Holland) B.V.

 

Israel

AUB Storing and Services (Hong Kong) Ltd.

 

Hong Kong

B.K Giulini Argentina S.A

 

Argentina

B.K. Giulini GmbH

 

Germany

B.K. Mercosur S.A.

 

Uruguay

BK Giulini GmbH

 

Germany

BK Giulini Hong Kong Limited

 

Hong Kong

BK Giulini Hygiene Hong Kong Ltd.

 

Hong Kong

BK Giulini Iberica S.L

 

Spain

BK Giulini Kimya ve Sanayi Ticaret A.S

 

Turkey

BK Giulini Leather Chemistry Co. Ltd.

 

Hong Kong

BK Giulini Specialities Private Ltd.

 

India

BKG Finance Gmbh

 

Germany

BKG Finance NE BV

 

The Netherlands

BKG Finance Sup GmbH

 

Germany

BKG Performance Products Jiangyin Co. Ltd.

 

China

BKG Personal Care Co. Ltd.

 

Hong Kong

BKG Puriphos B.V

 

The Netherlands

BKG Puriphos C.V

 

The Netherlands

Bromine and Chemicals Ltd.

 

UK

Bromine Compounds Ltd.

 

Israel

Bromine Compounds Marketing (2002) Ltd.

 

Israel

Bromisa Industrial e Commercial Ltda

 

Brazil

Chemada Fine Chemicals Ltd.

 

Israel

Clearon Corp.

 

USA

Cleveland Potash Ltd (CPL)

 

U.K.

Constantine & Company (Export) Ltd.

 

U.K.

DDFR Corporation Ltd.

 

Hong Kong

Dead Sea Bromine Company Ltd.

 

Israel

Dead Sea Magnesium Inc.

 

USA

Dead Sea Magnesium Ltd.

 

Israel

Dead Sea Periclase Fused products Co.

 

Israel

Dead Sea Periclase Ltd.

 

Israel

Dead Sea Works Ltd.

 

Israel

Desalination Plants (Development of Zarchin Process) Ltd.

 

Israel

Detelca UTE

 

Spain

Eisenbacher Dentalwaren ED GmbH

 

Germany

 



 

Euro Clearon B.V.

 

The Netherlands

Eurocil Luxembourg SA

 

Luxembourg

Everris Australia Pty. Ltd.

 

Australia

Everris GmbH

 

Germany

Everris Iberica Fertilizers SL

 

Spain

Everris International B.V.

 

The Netherlands

Everris Italia S.r.l

 

Italy

Everris Kenya Ltd.

 

Kenya

Everris Ltd.

 

UK

Everris Malaysia Sdn. Bhd

 

Malaysia

Everris NA Inc.

 

USA

Ferson Chemicals Ltd.

 

Israel

Fertilizers and Chemicals Ltd.

 

Israel

Fibrisol Muscalla GmbH

 

Germany

Fibrisol Service Australia Pty. Ltd.

 

Australia

Fibrisol Service Ltd.

 

UK

Finacil EEIG (European Economic Interest Grouping)

 

The Netherlands

Flexotex GmbH

 

Germany

Fomento y Desarrollo Agrícola, S.L

 

Spain

Fosbrasil S.A.

 

Brazil

Fuentes Fertilizantes S.L.

 

Spain

Guangzhou Eclean Technology Co. Ltd.

 

China

Gurit Worbla GmbH

 

Germany

H2ID Ltd.

 

Israel

Hoyermann Chemie GmbH

 

Germany

I.D.E. Technologies Ltd.

 

Israel

I.D.E.S.B DESALINATION PARTNERSHIP

 

Israel

Iberpotash S.A.

 

Spain

ICL (Shanghai) Investment Co. Ltd.

 

China

ICL ASIA Ltd.

 

Hong Kong

ICL Brasil Ltda.

 

Brasil

ICL Fertilizers (India) Private Ltd.

 

India

ICL Fertilizers Deutschland GmbH

 

Germany

ICL Fertilizers Europe CV

 

The Netherlands

ICL Finance B.V.

 

The Netherlands

ICL Finance Belgium NV

 

Belgium

ICL Finance Inc.

 

USA

ICL Fine Chemicals Ltd.

 

Israel

ICL Fosfatos Y Adtivos Servicios De Mexico, S.A. DE C.V.

 

Mexico

ICL Fostfatos Y Aditivos Mexico, S.A. DE C.V

 

Mexico

ICL France S.A.S

 

France

ICL Holding beschränkt haftende OHG

 

Germany

ICL Holding Germany GmbH

 

Germany

ICL Holding The Netherlands Cooperatief U.A.

 

The Netherlands

ICL Iberia Ltd

 

UK

ICL Iberia SCS

 

Spain

ICL Innovation Ltd.

 

Israel

ICL IP America Inc.

 

USA

ICL IP Bitterfeld GmbH

 

Germany

ICL IP Europe B.V.

 

The Netherlands

ICL Japan Ltd

 

Japan

ICL Management & Trading India Private Limited

 

India

ICL North America Inc

 

USA

ICL Performance Products Canada Ltd.

 

Canada

ICL Performance Products Inc

 

USA

ICL Performance Products LLC

 

USA

ICL Performance Products LP

 

USA

 



 

ICL Polska Sp.z.o.o

 

Poland

ICL Trading (HK) Ltd.

 

Hong Kong

ICL-IP Bitterfeld Grundbesitz GmbH & Co KG

 

Germany

ICL-IP Terneuzen BV

 

The Netherlands

IDE Americas Inc.

 

USA

IDE Canaries S.A.

 

Spain

IDE Technologies India Private Ltd.

 

India

Idea Desalination Construction Partnership

 

Israel

IMI Tami Institute for R&D Ltd.

 

Israel

Incap B.V

 

The Netherlands

Indian Desalination Engineering PVT Ltd.

 

India

Industrial Chemical Equipment Ltd.

 

Israel

Intracap Insurance Ltd.

 

Switzerland

Israeli Light Metal Initiative Ltd.

 

Israel

Jiaxing ICL Chemical Co., Ltd.

 

China

Landchem Ltd.

 

South Africa

Larnaca Water Partners

 

Cyprus

Lianyungang Dead Sea Bromine Compounds Co. Ltd

 

China

Logística de Fertilizantes Fuentes, S.A.

 

Spain

M.M.M. Company United Landfill Industries (1998) Ltd.

 

Israel

M.R.I. Research & Development Ltd.

 

Israel

Magsens Ltd.

 

Israel

Medentech Limited

 

Ireland

Mifalei Tovala Ltd.

 

Israel

Novetide Ltd.

 

Israel

NU3 NV

 

Belgium

OMIS Water Ltd.

 

Israel

OTID desalination partnership

 

Israel

P.A.M.A (Energy Resources Development) Ltd.

 

Israel

P.M. Chemicals Srl

 

Italy

Patentwise Ltd.

 

Ireland

PCT Protective Coating Technologies Ltd.

 

Israel

Pekafert B.V.

 

The Netherlands

Pelagos Desalination Services

 

Cyprus

Phosphorus Derivatives Inc.

 

USA

Potassium Nitrate Ltd.

 

Israel

Revivim In The Bay Water and Environment Ltd.

 

Israel

Rhenoflex GmbH

 

Germany

Rotem Amfert Negev Ltd.

 

Israel

Rotem do Brasil Ltd.

 

Brazil

Rotem Holding G.M.B.H

 

Germany

Rotem Kimyevi Maddeler Sanayi ve Ticaret A.S

 

Turkey

Scora S.A.S

 

France

Shanghai Tari International Ltd.

 

China

Sherut Rail & Road Transportaion Services Registered Partnership

 

Israel

Sinobrom compounds Co. Ltd

 

China

Sorek Desalination Ltd.

 

Israel

Sorek Desalination Partnership

 

Israel

Sorek Operation and maintenance company Ltd.

 

Israel

Specialty Technologies Europe B.V

 

The Netherlands

Stodiek Dunger GmbH

 

Germany

Tari International N.Z Ltd.

 

New Zealand

Tetrabrom Technologies Ltd.

 

Israel

Tiami Vattenkemi AB

 

Sweden

Trafico de Mercancias S.A.

 

Spain

Turris Versicherungvermittlung GmbH

 

Germany

Twincap Försäkrings AB

 

Sweden

 



 

V.I.D Desalination Company Ltd.

 

Israel

West Galile Desalination Company Ltd.

 

Israel

Yunnan B.K Giulini Tianchuang Phosphate Co. Ltd.

 

China

Zhangjiagang FTZ ICL Trading Co. Ltd.

 

China

Zuari Rotem specialty fertilizers Ltd.

 

India

 


 



Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

The Board of Directors

Israel Chemicals Ltd.

 

We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” in the prospectus.

 

 

/s/ Somekh Chaikin

 

Somekh Chaikin

 

Certified Public Accountants (Isr.)

 

Member Firm of KPMG International

 

 

Tel Aviv, Israel

 

September 12, 2014

 




Exhibit 23.3

 

 

GRAPHIC

 

 

DMT Consulting Limited

International Mining Consultants

Pure Offices

Lake View Drive, Sherwood Park
Nottingham, NG15 0DT
United Kingdom

 

UK@dmt-group.com
www.dmt-group.com

 

 

Our/Your Reference

Contact

Direct Dial

Date

CCW/AC-H/B69C

 

 

12 th  September 2014

 

CONSENT OF DMT CONSULTING LIMITED (formerly IMC Group Consulting Limited)

 

We hereby consent to the reference to our firm in the Prospectus contained in the Registration Statement on Form F-1 of Israel Chemicals Ltd. and, subject to our prior review, any amendments thereto.  We hereby further consent to the use of the information contained in our respective Competent Persons Reports, dated 27 th  April, 2014 and 13 th  May, 2014, relating to estimates of reserves of Israel Chemicals Ltd. and its subsidiaries in the Registration Statement, and to the reference to us under the heading “Experts.”

 

DMT Consulting Limited

(formerly IMC Group Consulting Limited)

 

By:

/s/ Christopher Charles Wells

 

 

Name: Christopher Charles Wells

Title: Managing Director

 

Dated: 12 th  September, 2014

 

DMT Consulting Limited

 

Registered Office:

Pure Offices

Lake View Drive, Sherwood Park

Nottingham, NG15 0DT

 

Tel +44 1623 726166

Fax +44 1623 729359

 

UK@dmt-group.com

www.dmt-group.com

 

Registered in England

Company Number 430855

United Kingdom

 

Member of DMT Group

 

GRAPHIC